Secreted proteins and polynucleotides encoding them

ABSTRACT

Novel polynucleotides and the proteins encoded thereby are disclosed.

[0001] This application is a continuation-in-part of the followingapplications:

[0002] (1) Ser. No. 09/197,886 (GI 6055A), filed Nov. 23,1998; which isa continuation-in-part of provisional application Ser. No.60/126,425 (GI6055), filed Nov. 26,1997, now abandoned;

[0003] (2) Ser. No.09/203,106 (GI 6056A), filed Nov. 30,1998; which is acontinuation-in-part of provisional application Ser. No. 60/067,454 (GI6056), filed Dec. 4,1997, now abandoned;

[0004] (3) Ser. No.09/212,843 (GI 6057A), filed Dec. 16,1998; which is acontinuation-in-part of provisional application Ser. No. 60/068,379 (GI6057), filed Dec. 20, 1997, now abandoned;

[0005] (4) Ser. No.09/227,653 (GI 6058A), filed Dec. 30,1998; which is acontinuation-in-part of provisional application Ser. No. 60/070,346 (GI6058), filed Jan. 2, 1998, now abandoned;

[0006] (5) Ser. No. 09/225,049 (GI 6059A), filed Jan. 4,1999; which is acontinuation-in-part of provisional application Ser. No.60/070,643 (GI6059), filed Jan. 7,1998, now abandoned;

[0007] (6) Ser. No. 09/225,585 (GI 6060A), filed Jan. 6,1999; which is acontinuation-in-part of provisional application Ser. No.60/070,755 (GI6060), filed Jan. 8,1998, now abandoned;

[0008] (7) Ser. No. 09 /227,462 (GI 6061A), filed Jan. 8, 1999; which isa continuation-in-part of provisional application Ser. No. 60/071,304(GI 6061), filed Jan. 13, 1998, now abandoned;

[0009] (8) Ser. No.09/235,609 (GI 6062A), filed Jan. 20,1999; which is acontinuation-in-part of provisional application Ser. No. 60/072,134 (GI6062), filed Jan. 22, 1998, now abandoned;

[0010] (9) Ser. No.09/237,847 (GI 6063A), filed Jan. 27,1999; which is acontinuation-in-part of provisional application Ser. No. 60/073,095 (GI6063), filed Jan. 30, 1998, now abandoned;

[0011] (10) Ser. No. 09/251,600 (GI 6064A), filed Feb. 17,1999; which isa continuation-in-part of provisional application Ser. No.60/075,038 (GI6064), filed Feb. 18, 1998, now abandoned;

[0012] all of which are incorporated by reference herein.

FIELD OF THE INVENTION

[0013] The present invention provides novel polynucleotides and proteinsencoded by such polynucleotides, along with therapeutic, diagnostic andresearch utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION

[0014] Technology aimed at the discovery of protein factors (includinge.g., cytokines, such as lymphokines, interferons, CSFs andinterleukins) has matured rapidly over the past decade. The now routinehybridization cloning and expression cloning techniques clone novelpolynucleotides “directly” in the sense that they rely on informationdirectly related to the discovered protein (i.e., partial DNA/amino acidsequence of the protein in the case of hybridization cloning; activityof the protein in the case of expression cloning). More recent“indirect” cloning techniques such as signal sequence cloning, whichisolates DNA sequences based on the presence of a now well-recognizedsecretory leader sequence motif, as well as various PCR-based or lowstringency hybridization cloning techniques, have advanced the state ofthe art by making available large numbers of DNA/ amino acid sequencesfor proteins that are known to have biological activity by virtue oftheir secreted nature in the case of leader sequence cloning, or byvirtue of the cell or tissue source in the case of PCR-based techniques.It is to these proteins and the polynucleotides encoding them that thepresent invention is directed.

SUMMARY OF THE INVENTION

[0015] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0016] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:1;

[0017] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:1 from nucleotide 63 to nucleotide 1265;

[0018] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:1 from nucleotide 132 to nucleotide 1265;

[0019] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bd306_(—)7 deposited withthe ATCC under accession number 98599;

[0020] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bd306_(—)7 deposited with the ATCC underaccession number 98599;

[0021] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bd306_(—)7 deposited with theATCC under accession number 98599;

[0022] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bd306_(—)7 deposited with the ATCC under accessionnumber 98599;

[0023] (h) a polynucleotide encoding a protein comprising the arninoacid sequence of SEQ ID NO:2;

[0024] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:2 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:2;

[0025] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0026] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0027] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0028] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:1 from nucleotide 63 to nucleotide 1265; the nucleotidesequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265; thenucleotide sequence of the full-length protein coding sequence of clonebd306_(—)7 deposited with the ATCC under accession number 98599; or thenucleotide sequence of a mature protein coding sequence of clonebd306_(—)7 deposited with the ATCC under accession number 98599. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone bd306_(—)7deposited with the ATCC under accession number 98599. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:2from amino acid 148 to amino acid 189. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:2 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:2, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:2 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 195 to amino acid 204 of SEQ ID NO:2.

[0029] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:1.

[0030] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0031] (a) a process comprising the steps of:

[0032] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0033] (aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:1; and

[0034] (ab) the nucleotide sequence of the cDNA insert of clonebd306_(—)7 deposited with the ATCC under accession number 98599; and

[0035] (ii) hybridizing said probe(s) to human DNA; and

[0036] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0037] (b) a process comprising the steps of:

[0038] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0039] (ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:1; and

[0040] (bb) the nucleotide sequence of the cDNA insert of clonebd306_(—)7 deposited with the ATCC under accession number 98599; and

[0041] (ii) hybridizing said primer(s) to human DNA;

[0042] (iii) amplifying human DNA sequences; and

[0043] (iv) isolating the polynucleotide product of step (b)(iii).

[0044] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:1, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:1 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:1, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:1. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1from nucleotide 63 to nucleotide 1265, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:1 from nucleotide 63 to nucleotide 1265, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:1 fromnucleotide 63 to nucleotide 1265. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 132 tonucleotide 1265, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:1 fromnucleotide 132 to nucleotide 1265, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:1 fromnucleotide 132 to nucleotide 1265.

[0045] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0046] (a) the amino acid sequence of SEQ ID NO:2;

[0047] (b) the amino acid sequence of SEQ ID NO:2 from amino acid 148 toamino acid 189;

[0048] (c) fragments of the amino acid sequence of SEQ ID NO:2comprising eight consecutive amino acids of SEQ ID NO:2; and

[0049] (d) the amino acid sequence encoded by the cDNA insert of clonebd306_(—)7 deposited with the ATCC under accession number 98599;

[0050] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2 from amino acid148 to amino acid 189. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:2 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:2, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:2 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 195 to amino acid 204 of SEQ ID NO:2.

[0051] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0052] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:3;

[0053] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:3 from nucleotide 719 to nucleotide 1855;

[0054] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:3 from nucleotide 779 to nucleotide 1855;

[0055] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone fj283_(—)11 deposited withthe ATCC under accession number 98599;

[0056] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone fj283_(—)11 deposited with the ATCC underaccession number 98599;

[0057] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone fj28311 deposited with the ATCCunder accession number 98599;

[0058] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone fj283_(—)11 deposited with the ATCC under accessionnumber 98599;

[0059] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:4;

[0060] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:4 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:4;

[0061] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0062] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0063] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0064] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:3 from nucleotide 719 to nucleotide 1855; the nucleotidesequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855; thenucleotide sequence of the full-length protein coding sequence of clonefj283_(—)11 deposited with the ATCC under accession number 98599; or thenucleotide sequence of a mature protein coding sequence of clonefj283_(—)11 deposited with the ATCC under accession number 98599. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone fj283_(—)11deposited with the ATCC under accession number 98599. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:4from amino acid 1 to amino acid 27. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:4 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:4, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:4 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 184 to amino acid 193 of SEQ ID NO:4.

[0065] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:3.

[0066] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0067] (a) a process comprising the steps of:

[0068] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0069] (aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:3; and

[0070] (ab) the nucleotide sequence of the cDNA insert of clonef283_(—)11 deposited with the ATCC under accession number 98599; and

[0071] (ii) hybridizing said probe(s) to human DNA; and

[0072] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0073] (b) a process comprising the steps of:

[0074] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0075] (ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:3; and

[0076] (bb) the nucleotide sequence of the cDNA insert of clonefj283_(—)11 deposited with the ATCC under accession number 98599; and

[0077] (ii) hybridizing said primer(s) to human DNA;

[0078] (iii) amplifying human DNA sequences; and

[0079] (iv) isolating the polynucleotide product of step (b)(iii).

[0080] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:3, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:3 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:3 , but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:3. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3from nucleotide 719 to nucleotide 1855, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:3 from nucleotide 719 to nucleotide 1855, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:3from nucleotide 719 to nucleotide 1855. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3from nucleotide 779 to nucleotide 1855, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:3 from nucleotide 779 to nucleotide 1855, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:3from nucleotide 779 to nucleotide 1855.

[0081] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0082] (a) the amino acid sequence of SEQ ID NO:4;

[0083] (b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 toamino acid 27;

[0084] (c) fragments of the amino acid sequence of SEQ ID NO:4comprising eight consecutive amino acids of SEQ ID NO:4;

[0085] (d) the amino acid sequence encoded by the cDNA insert of clonefj283_(—)11 deposited with the ATCC under accession number 98599; and

[0086] (e) the amino acid sequence encoded by the cDNA insert of clonefj283_(—)6 deposited with the ATCC under accession number xxxxx;

[0087] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:4 or the amino acid sequence of SEQ ID NO:4 from amino acid 1to amino acid 27. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:4 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:4, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:4 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 184 to amino acid 193 of SEQ ID NO:4.

[0088] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0089] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:198;

[0090] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:198 from nucleotide 982 to nucleotide 2118;

[0091] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:198 from nucleotide 1042 to nucleotide 2118;

[0092] (d) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:198 from nucleotide 621 to nucleotide 1248;

[0093] (e) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone fj283_(—)6 deposited withthe ATCC under accession number 98988;

[0094] (f) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone fj283_(—)6 deposited with the ATCC underaccession number 98988;

[0095] (g) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone fj283_(—)6 deposited with theATCC under accession number 98988;

[0096] (h) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone fj283_(—)6 deposited with the ATCC under accessionnumber 98988;

[0097] (i) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:4;

[0098] (j) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:4 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:4;

[0099] (k) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(h) above;

[0100] (l) a polynucleotide which encodes a species homologue of theprotein of (i) or (j) above ; and

[0101] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(j).

[0102] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:198 from nucleotide 982 to nucleotide 2118; the nucleotidesequence of SEQ ID NO:198 from nucleotide 1042 to nucleotide 2118; thenucleotide sequence of SEQ ID NO: 198 from nucleotide 621 to nucleotide1248; the nucleotide sequence of the full-length protein coding sequenceof clone fj283_(—)6 deposited with the ATCC under accession number98988; or the nucleotide sequence of a mature protein coding sequence ofclone fj283_(—)6 deposited with the ATCC under accession number 98988.In other preferred embodiments, the polynucleotide encodes thefull-length or a mature protein encoded by the cDNA insert of clonefj283_(—)6 deposited with the ATCC under accession number 98988. Infurther preferred embodiments, the present invention provides apolynucleotide encoding a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:4 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:4 having biological activity, the fragment comprising theamino acid sequence from amino acid 184 to amino acid 193 of SEQ IDNO:4.

[0103] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:198.

[0104] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0105] (a) a process comprising the steps of:

[0106] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0107] (aa) SEQ ID NO:198, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:198; and

[0108] (ab) the nucleotide sequence of the cDNA insert of clonefj283_(—)6 deposited with the ATCC under accession number 98988; and

[0109] (ii) hybridizing said probe(s) to human DNA; and

[0110] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0111] (b) a process comprising the steps of:

[0112] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0113] (ba) SEQ ID NO:198, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:198; and

[0114] (bb) the nucleotide sequence of the cDNA insert of clonefj283_(—)6 deposited with the ATCC under accession number 98988; and

[0115] (ii) hybridizing said primer(s) to human DNA;

[0116] (iii) amplifying human DNA sequences; and

[0117] (iv) isolating the polynucleotide product of step (b)(iii).

[0118] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:198, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:198 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:198, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:198. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:198from nucleotide 982 to nucleotide 2118, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:198 from nucleotide 982 to nucleotide 2118, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:198from nucleotide 982 to nucleotide 2118. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:198from nucleotide 1042 to nucleotide 2118, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:198 from nucleotide 1042 to nucleotide 2118, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:198from nucleotide 1042 to nucleotide 2118. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:198from nucleotide 621 to nucleotide 1248, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:198 from nucleotide 621 to nucleotide 1248, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:198from nucleotide 621 to nucleotide 1248.

[0119] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0120] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:5;

[0121] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:5 from nucleotide 259 to nucleotide 624;

[0122] (c) a polvnucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone fk317_(—)3 deposited withthe ATCC under accession number 98599;

[0123] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone fk317_(—)3 deposited with the ATCC underaccession number 98599;

[0124] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone fk317_(—)3 deposited with theATCC under accession number 98599;

[0125] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone fk317_(—)3 deposited with the ATCC under accessionnumber 98599;

[0126] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:6;

[0127] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:6 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:6;

[0128] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[0129] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[0130] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[0131] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:5 from nucleotide 259 to nucleotide 624; the nucleotidesequence of the full-length protein coding sequence of clone fk317_(—)3deposited with the ATCC under accession number 98599; or the nucleotidesequence of a mature protein coding sequence of clone fk317_(—)3deposited with the ATCC under accession number 98599. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone fk317_(—)3 deposited withthe ATCC under accession number 98599. In yet other preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising the amino acid sequence of SEQ ID NO:6 from aminoacid 1 to amino acid 72. In further preferred embodiments, the presentinvention provides a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:6 having biologicalactivity, the fragment preferably comprising eight (more preferablytwenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6,or a polynucleotide encoding a protein comprising a fragment of theamino acid sequence of SEQ ID NO:6 having biological activity, thefragment comprising the amino acid sequence from amino acid 56 to aminoacid 65 of SEQ ID NO:6.

[0132] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:5.

[0133] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0134] (a) a process comprising the steps of:

[0135] (i) preparing one ormore polynucleotide probes thathybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0136] (aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:5; and

[0137] (ab) the nucleotide sequence of the cDNA insert of clonefk317_(—)3 deposited with the ATCC under accession number 98599; and

[0138] (ii) hybridizing said probe(s) to human DNA; and

[0139] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0140] (b) a process comprising the steps of:

[0141] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0142] (ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:5; and

[0143] (bb) the nucleotide sequence of the cDNA insert of clonefk317_(—)3 deposited with the ATCC under accession number 98599; and

[0144] (ii) hybridizing said primer(s) to human DNA;

[0145] (iii) amplifying human DNA sequences; and

[0146] (iv) isolating the polynucleotide product of step (b)(iii).

[0147] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:5, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:5 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:5, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:5. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5from nucleotide 259 to nucleotide 624, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:5 from nucleotide 259 to nucleotide 624, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:5 fromnucleotide 259 to nucleotide 624.

[0148] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0149] (a) the amino acid sequence of SEQ ID NO:6;

[0150] (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 toamino acid 72;

[0151] (c) fragments of the amino acid sequence of SEQ ID NO:6comprising eight consecutive amino acids of SEQ ID NO:6; and

[0152] (d) the amino acid sequence encoded by the cDNA insert of clonefk317_(—)3 deposited with the ATCC under accession number 98599;

[0153] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amnino acid sequence ofSEQ ID NO:6 or the amino acid sequence of SEQ ID NO:6 from amino acid 1to amino acid 72. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:6 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:6, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:6 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 56 to amino acid 65 of SEQ ID NO:6.

[0154] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0155] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:7;

[0156] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:7 from nucleotide 357 to nucleotide 578;

[0157] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:7 from nucleotide 471 to nucleotide 578;

[0158] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone k213_(—)2x deposited withthe ATCC under accession number 98599;

[0159] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone k213_(—)2x deposited with the ATCC underaccession number 98599;

[0160] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone k213_(—)2x deposited with theATCC under accession number 98599;

[0161] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone k213_(—)2x deposited with the ATCC under accessionnumber 98599;

[0162] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:8;

[0163] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:8 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:8;

[0164] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0165] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0166] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0167] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:7 from nucleotide 357 to nucleotide 578; the nucleotidesequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578; thenucleotide sequence of the full-length protein coding sequence of clonek213_(—)2x deposited with the ATCC under accession number 98599; or thenucleotide sequence of a mature protein coding sequence of clonek213_(—)2x deposited with the ATCC under accession number 98599. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone k213_(—)2xdeposited with the ATCC under accession number 98599. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:8 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:8, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:8having biological activity, the fragment comprising the amino acidsequence from amino acid 32 to amino acid 41 of SEQ ID NO:8.

[0168] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:7.

[0169] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0170] (a) a process comprising the steps of:

[0171] (i) preparing one or more polynudeotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0172] (aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:7; and

[0173] (ab) the nucleotide sequence of the cDNA insert of clonek213_(—)2x deposited with the ATCC under accession number 98599; and

[0174] (ii) hybridizing said probe(s) to human DNA; and

[0175] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0176] (b) a process comprising the steps of:

[0177] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0178] (ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:7; and

[0179] (bb) the nucleotide sequence of the cDNA insert of clonek213_(—)2x deposited with the ATCC under accession number 98599; and

[0180] (ii) hybridizing said primer(s) to human DNA;

[0181] (iii) amplifying human DNA sequences; and

[0182] (iv) isolating the polynucleotide product of step (b)(iii).

[0183] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:7, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:7 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:7, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:7. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7from nucleotide 357 to nucleotide 578, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:7 from nucleotide 357 to nucleotide 578, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:7 fromnucleotide 357 to nucleotide 578. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 471 tonucleotide 578, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:7 fromnucleotide 471 to nucleotide 578, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:7 from nucleotide 471 tonucleotide 578.

[0184] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0185] (a) the amino acid sequence of SEQ ID NO:8;

[0186] (b) fragments of the amino acid sequence of SEQ ID NO:8comprising eight consecutive amino acids of SEQ ID NO:8; and

[0187] (c) the amino acid sequence encoded by the cDNA insert of clonek213_(—)2x deposited with the ATCC under accession number 98599;

[0188] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:8. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:8 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:8, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:8 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 32 to amino acid 41 of SEQ ID NO:8.

[0189] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0190] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:9;

[0191] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:9 from nucleotide 332 to nucleotide 598;

[0192] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:9 from nucleotide 458 to nucleotide 598;

[0193] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone na316_(—)1 deposited withthe ATCC under accession number 98599;

[0194] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone na316_(—)1 deposited with the ATCC underaccession number 98599;

[0195] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone na316_(—)6deposited with theATCC under accession number 98599;

[0196] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone na316_(—)1 deposited with the ATCC under accessionnumber 98599;

[0197] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:10;

[0198] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:10 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:10;

[0199] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0200] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0201] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0202] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:9 from nucleotide 332 to nucleotide 598; the nucleotidesequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598; thenucleotide sequence of the full-length protein coding sequence of clonena316_(—)6 deposited with the ATCC under accession number 98599; or thenucleotide sequence of a mature protein coding sequence of clonena316_(—)1 deposited with the ATCC under accession number 98599. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone na316_(—)1deposited with the ATCC under accession number 98599. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:10 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:10, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:10having biological activity, the fragment comprising the amino acidsequence from amino acid 39 to amino acid 48 of SEQ ID NO:10.

[0203] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:9.

[0204] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0205] (a) a process comprising the steps of:

[0206] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0207] (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:9; and

[0208] (ab) the nucleotide sequence of the cDNA insert of clone na316⁻1deposited with the ATCC under accession number 98599; and

[0209] (ii) hybridizing said probe(s) to human DNA; and

[0210] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0211] (b) a process comprising the steps of:

[0212] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0213] (ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:9; and

[0214] (bb) the nucleotide sequence of the cDNA insert of clonena316_(—)1 deposited with the ATCC under accession number 98599; and

[0215] (ii) hybridizing said primer(s) to human DNA;

[0216] (iii) amplifying human DNA sequences; and

[0217] (iv) isolating the polynucleotide product of step (b)(iii).

[0218] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:9, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:9 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:9 , but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:9. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9from nucleotide 332 to nucleotide 598, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:9 from nucleotide 332 to nucleotide 598, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:9 fromnucleotide 332 to nucleotide 598. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 458 tonucleotide 598, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:9 fromnucleotide 458 to nucleotide 598, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:9 from nucleotide 458 tonucleotide 598.

[0219] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0220] (a) the amino acid sequence of SEQ ID NO:10;

[0221] (b) fragments of the amino acid sequence of SEQ ID NO: 10comprising eight consecutive amino acids of SEQ ID NO:10; and

[0222] (c) the amino acid sequence encoded by the cDNA insert of clonena316_(—)1 deposited with the ATCC under accession number 98599;

[0223] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:10. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO: 10 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:10, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:10 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 39 to amino acid 48 of SEQ ID NO:10.

[0224] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0225] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:11;

[0226] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:11 from nucleotide 354 to nucleotide 986;

[0227] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:11 from nucleotide 408 to nucleotide 986;

[0228] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nf93_(—)20 deposited withthe ATCC under accession number 98599;

[0229] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nf93_(—)20 deposited with the ATCC underaccession number 98599;

[0230] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nf93_(—)20 deposited with theATCC under accession number 98599;

[0231] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nf93_(—)20 deposited with the ATCC under accessionnumber 98599;

[0232] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:12;

[0233] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:12 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:12;

[0234] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0235] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0236] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0237] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:1l from nucleotide 354 to nucleotide 986; the nucleotidesequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986; thenucleotide sequence of the full-length protein coding sequence of clonenf93_(—)20 deposited with the ATCC under accession number 98599; or thenucleotide sequence of a mature protein coding sequence of clonenf93_(—)20 deposited with the ATCC under accession number 98599. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone nf93_(—)20deposited with the ATCC under accession number 98599. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:12 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:12, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:12having biological activity, the fragment comprising the amino acidsequence from amino acid 100 to amino acid 109 of SEQ ID NO:12.

[0238] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:11.

[0239] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0240] (a) a process comprising the steps of:

[0241] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0242] (aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:11; and

[0243] (ab) the nucleotide sequence of the cDNA insert of clonenf93_(—)20 deposited with the ATCC under accession number 98599; and

[0244] (ii) hybridizing said probe(s) to human DNA; and

[0245] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0246] (b) a process comprising the steps of:

[0247] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0248] (ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:11; and

[0249] (bb) the nucleotide sequence of the cDNA insert of clonenf93_(—)20 deposited with the ATCC under accession number 98599; and

[0250] (ii) hybridizing said primer(s) to human DNA;

[0251] (iii) amplifying human DNA sequences; and

[0252] (iv) isolating the polynucleotide product of step (b)(iii).

[0253] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:11, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:11 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:11, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:11. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11from nucleotide 354 to nucleotide 986, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:11 from nucleotide 354 to nucleotide 986, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:11 fromnucleotide 354 to nucleotide 986. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 408to nucleotide 986, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:11 fromnucleotide 408 to nucleotide 986, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:11 from nucleotide 408 tonucleotide 986.

[0254] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0255] (a) the amino acid sequence of SEQ ID NO:12;

[0256] (b) fragments of the amino acid sequence of SEQ ID NO: 12comprising eight consecutive amino acids of SEQ ID NO:12; and

[0257] (c) the amino acid sequence encoded by the cDNA insert of clonenf93_(—)20 deposited with the ATCC under accession number 98599;

[0258] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:12. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:12 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:12, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:12 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 100 to amino acid 109 of SEQ ID NO:12.

[0259] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0260] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:13;

[0261] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:13 from nucleotide 301 to nucleotide 1821;

[0262] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:13 from nucleotide 1381 to nucleotide 1821;

[0263] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone np164_(—)1 deposited withthe ATCC under accession number 98599;

[0264] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone np164_(—)1 deposited with the ATCC underaccession number 98599;

[0265] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone np164_(—)1 deposited with theATCC under accession number 98599;

[0266] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone np164_(—)1 deposited with the ATCC under accessionnumber 98599;

[0267] (h) a polynucleotide encoding a protein comprising the amninoacid sequence of SEQ ID NO:14;

[0268] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:14 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:14;

[0269] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0270] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0271] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0272] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:13 from nucleotide 301 to nucleotide 1821; the nucleotidesequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821; thenucleotide sequence of the full-length protein coding sequence of clonenp164_(—)1 deposited with the ATCC under accession number 98599; or thenucleotide sequence of a mature protein coding sequence of clonenp164_(—)1 deposited with the ATCC under accession number 98599. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone np164_(—)1deposited with the ATCC under accession number 98599. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:14 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:14, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:14having biological activity, the fragment comprising the amino acidsequence from amnino acid 248 to amino acid 257 of SEQ ID NO:14.

[0273] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:13.

[0274] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0275] (a) a process comprising the steps of:

[0276] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0277] (aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:13; and

[0278] (ab) the nucleotide sequence of the cDNA insert of clonenp164_(—)1 deposited with the ATCC under accession number 98599; and

[0279] (ii) hybridizing said probe(s) to human DNA; and

[0280] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0281] (b) a process comprising the steps of:

[0282] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0283] (ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:13; and

[0284] (bb) the nucleotide sequence of the cDNA insert of clonenp164_(—)1 deposited with the ATCC under accession number 98599; and

[0285] (ii) hybridizing said primer(s) to human DNA;

[0286] (iii) amplifying human DNA sequences; and

[0287] (iv) isolating the polynucleotide product of step (b)(iii).

[0288] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:13, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:13 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:13, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:13. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13from nucleotide 301 to nucleotide 1821, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:13 from nucleotide 301 to nucleotide 1821, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:13from nucleotide 301 to nucleotide 1821. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13from nucleotide 1381 to nucleotide 1821, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:13 from nucleotide 1381 to nucleotide 1821, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:13from nucleotide 1381 to nucleotide 1821.

[0289] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0290] (a) the amino acid sequence of SEQ ID NO:14;

[0291] (b) fragments of the amino acid sequence of SEQ ID NO: 14comprising eight consecutive amino acids of SEQ ID NO:14; and

[0292] (c) the amino acid sequence encoded by the cDNA insert of clonenp164_(—)1 deposited with the ATCC under accession number 98599;

[0293] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:14. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:14 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:14, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:14 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 248 to amino acid 257 of SEQ ID NO:14.

[0294] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0295] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:15;

[0296] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:15 from nucleotide 148 to nucleotide 537;

[0297] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pe204_(—)1 deposited withthe ATCC under accession number 98599;

[0298] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pe204_(—)1 deposited with the ATCC underaccession number 98599;

[0299] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pe204_(—)1 deposited with theATCC under accession number 98599;

[0300] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pe204_(—)1 deposited with the ATCC under accessionnumber 98599;

[0301] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:16;

[0302] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:16 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:16;

[0303] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(h) above;

[0304] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[0305] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[0306] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:15 from nucleotide 148 to nucleotide 537; the nucleotidesequence of the full-length protein coding sequence of clone pe204_(—)1deposited with the ATCC under accession number 98599; or the nucleotidesequence of a mature protein coding sequence of clone pe204_(—)1deposited with the ATCC under accession number 98599. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone pe204_(—)1 deposited withthe ATCC under accession number 98599. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:16 havingbiological activity, the fragmentpreferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:16, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:16 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 60 to amino acid 69 of SEQ ID NO: 16.

[0307] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:15.

[0308] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0309] (a) a process comprising the steps of:

[0310] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0311] (aa) SEQ ID NO: 15, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:15; and

[0312] (ab) the nucleotide sequence of the cDNA insert of clonepe204_(—)1 deposited with the ATCC under accession number 98599; and

[0313] (ii) hybridizing said probe(s) to human DNA; and

[0314] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0315] (b) a process comprising the steps of:

[0316] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0317] (ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:15; and

[0318] (bb) the nucleotide sequence of the cDNA insert of clonepe204_(—)1 deposited with the ATCC under accession number 98599; and

[0319] (ii) hybridizing said primer(s) to human DNA;

[0320] (iii) amplifying human DNA sequences; and

[0321] (iv) isolating the polynucleotide product of step (b)(iii).

[0322] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:15, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:15 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:15 , but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:15. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15from nucleotide 148 to nucleotide 537, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO: 15 from nucleotide 148 to nucleotide 537, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:15from nucleotide 148 to nucleotide 537.

[0323] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0324] (a) the amino acid sequence of SEQ ID NO:16;

[0325] (b) fragments of the amino acid sequence of SEQ IDNO:16comprising eight consecutive amino acids of SEQ ID NO:16; and

[0326] (c) the armino acid sequence encoded by the cDNA insert of clonepe204_(—)1 deposited with the ATCC under accession number 98599;

[0327] the protein being substantially free from other mamnmalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:16. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:16 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:16, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:16 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 60 to amino acid 69 of SEQ ID NO:16.

[0328] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0329] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:17;

[0330] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:17 from nucleotide 24 to nucleotide 1109;

[0331] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:17 from nucleotide 1050 to nucleotide 1109;

[0332] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ya1_(—)1 deposited with theATCC under accession number 98599;

[0333] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ya1_(—)1 deposited with the ATCC underaccession number 98599;

[0334] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ya1_(—)1 deposited with the ATCCunder accession number 98599;

[0335] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ya1_(—)1 deposited with the ATCC under accessionnumber 98599;

[0336] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:18;

[0337] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:18 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:18;

[0338] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0339] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0340] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0341] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:17 from nucleotide 24 to nucleotide 1109; the nucleotidesequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109; thenucleotide sequence of the full-length protein coding sequence of cloneya1_(—)1 deposited with the ATCC under accession number 98599; or thenucleotide sequence of a mature protein coding sequence of cloneya1_(—)1 deposited with the ATCC under accession number 98599. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone ya1_(—)1 depositedwith the ATCC under accession number 98599. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:18having biological activity, the fragment preferably comprising eight(more preferably twenty, most preferably thirty) consecutive amino acidsof SEQ ID NO:18, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:18 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 176 to amino acid 185 of SEQ ID NO:18.

[0342] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:17.

[0343] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0344] (a) a process comprising the steps of:

[0345] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0346] (aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:17; and

[0347] (ab) the nucleotide sequence of the cDNA insert of clone ya1_(—)1deposited with the ATCC under accession number 98599; and

[0348] (ii) hybridizing said probe(s) to human DNA; and

[0349] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0350] (b) a process comprising the steps of:

[0351] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0352] (ba) SEQ ID NO: 17, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:17; and

[0353] (bb) the nucleotide sequence of the cDNA insert of clone ya1_(—)1deposited with the ATCC under accession number 98599; and

[0354] (ii) hybridizing said primer(s) to human DNA;

[0355] (iii) amplifying human DNA sequences; and

[0356] (iv) isolating the polynucleotide product of step (b)(iii).

[0357] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:17, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:17 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:17, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:17. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17from nucleotide 24 to nucleotide 1109, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:17 from nucleotide 24 to nucleotide 1109, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:17 fromnucleotide 24 to nucleotide 1109. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 1050to nucleotide 1109, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of said sequence of SEQ ID NO:17from nucleotide 1050 to nucleotide 1109, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:17 fromnucleotide 1050 to nucleotide 1109.

[0358] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0359] (a) the amino acid sequence of SEQ ID NO:18;

[0360] (b) fragments of the amino acid sequence of SEQ ID NO:18comprising eight consecutive amino acids of SEQ ID NO:18; and

[0361] (c) the amino acid sequence encoded by the cDNA insert of cloneya1_(—)1 deposited with the ATCC under accession number 98599;

[0362] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:18. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:18 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:18, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:18 having biologicalactivity, the fragment comprising the amino acid sequence from amninoacid 176 to amino acid 185 of SEQ ID NO:18.

[0363] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0364] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:19;

[0365] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:19 from nucleotide 27 to nucleotide 734;

[0366] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:19 from nucleotide 270 to nucleotide 734;

[0367] (d) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:19 from nucleotide 85 to nucleotide 1604;

[0368] (e) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone yb8_(—)1 deposited with theATCC under accession number 98599;

[0369] (f) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone yb8_(—)1 deposited with the ATCC underaccession number 98599;

[0370] (g) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone yb8_(—)1 deposited with the ATCCunder accession number 98599;

[0371] (h) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone yb8_(—)1 deposited with the ATCC under accessionnumber 98599;

[0372] (i) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:20;

[0373] (j) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:20 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:20;

[0374] (k) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(h) above;

[0375] (l) a polynucleotide which encodes a species homologue of theprotein of (i) or (j) above; and

[0376] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(j).

[0377] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:19 from nucleotide 27 to nucleotide 734; the nucleotidesequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734; thenucleotide sequence of SEQ ID NO:19 from nucleotide 85 tonucleotide1604; the nucleotide sequence of the full-length protein coding sequenceof clone yb8_(—)1 deposited with the ATCC under accession number 98599;or the nucleotide sequence of a mature protein coding sequence of cloneyb8_(—)1 deposited with the ATCC under accession number 98599. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone yb8_(—)1 depositedwith the ATCC under accession number 98599. In yet other preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising the amino acid sequence of SEQ ID NO:20 from aminoacid 70 to amino acid 236. In further preferred embodiments, the presentinvention provides a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:20 having biologicalactivity, the fragment preferably comprising eight (more preferablytwenty, most preferably thirty) consecutive amino acids of SEQ ID NO:20,or a polynucleotide encoding a protein comprising a fragment of theamino acid sequence of SEQ ID NO:20 having biological activity, thefragment comprising the amino acid sequence from amino acid 113 to aminoacid 122 of SEQ ID NO:20.

[0378] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:19.

[0379] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0380] (a) a process comprising the steps of:

[0381] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0382] (aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:19; and

[0383] (ab) the nucleotide sequence of the cDNA insert of clone yb8_(—)1deposited with the ATCC under accession number 98599; and

[0384] (ii) hybridizing said probe(s) to human DNA; and

[0385] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0386] (b) a process comprising the steps of:

[0387] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0388] (ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:19; and

[0389] (bb) the nucleotide sequence of the cDNA insert of clone yb8_(—)1deposited with the ATCC under accession number 98599; and

[0390] (ii) hybridizing said primer(s) to human DNA;

[0391] (iii) amplifying human DNA sequences; and

[0392] (iv) isolating the polynucleotide product of step (b)(iii).

[0393] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:19, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:19 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:19, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:19. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19from nucleotide 27 to nucleotide 734, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:19 from nucleotide 27 to nucleotide 734, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:19 fromnucleotide 27 to nucleotide 734. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 270to nucleotide 734, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:19 fromnucleotide 270 to nucleotide 734, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:19 from nucleotide 270 tonucleotide 734. Also preferably the polynucleotide isolated according tothe above process comprises a nucleotide sequence corresponding to thecDNA sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604, andextending contiguously from a nucleotide sequence corresponding to the5′ end of said sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide1604, to a nucleotide sequence corresponding to the 3′ end of saidsequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604.

[0394] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0395] (a) the amino acid sequence of SEQ ID NO:20;

[0396] (b) the amino acid sequence of SEQ ID NO:20 from amino acid 70 toamino acid 236;

[0397] (c) fragments of the amino acid sequence of SEQ ID NO:20comprising eight consecutive amino acids of SEQ ID NO:20; and

[0398] (d) the amino acid sequence encoded by the cDNA insert of cloneyb8_(—)1 deposited with the ATCC under accession number 98599;

[0399] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:20 or the amino acid sequence of SEQ ID NO:20 from amino acid70 to amino acid 236. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:20 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:20, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:20 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 113 to amino acid 122 of SEQ ID NO:20.

[0400] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0401] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:21;

[0402] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:21 from nucleotide 469 to nucleotide 609;

[0403] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:21 from nucleotide 574 to nucleotide 609;

[0404] (d) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:21 from nucleotide 214 to nucleotide 369;

[0405] (e) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone am856_(—)3 deposited withthe ATCC under accession number 98600;

[0406] (f) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone am856_(—)3 deposited with the ATCC underaccession number 98600;

[0407] (g) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone am856_(—)3 deposited with theATCC under accession number 98600;

[0408] (h) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone am856_(—)3 deposited with the ATCC under accessionnumber 98600;

[0409] (i) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:22;

[0410] (j) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:22 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:22;

[0411] (k) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(h) above;

[0412] (l) a polynucleotide which encodes a species homologue of theprotein of (i) or (j) above; and

[0413] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(j).

[0414] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:21 from nucleotide 469 to nucleotide 609; the nucleotidesequence of SEQ ID NO:21 from nucleotide 574 to nucleotide 609; thenucleotide sequence of SEQ ID NO:21 from nucleotide 214 to nucleotide369; the nucleotide sequence of the full-length protein coding sequenceof clone am856_(—)3 deposited with the ATCC under accession number98600; or the nucleotide sequence of a mature protein coding sequence ofclone am856_(—)3 deposited with the ATCC under accession number 98600.In other preferred embodiments, the polynucleotide encodes thefull-length or a mature protein encoded by the cDNA insert of cloneam856_(—)3 deposited with the ATCC under accession number 98600. In yetother preferred embodiments, the present invention provides apolynucleotide encoding a protein comprising the amino acid sequence ofSEQ ID NO:22 from amino acid 1 to amino acid 38. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:22having biological activity, the fragment preferably comprising eight(more preferably twenty, most preferably thirty) consecutive amino acidsof SEQ ID NO:22, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:22 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 18 to amino acid 27 of SEQ ID NO:22.

[0415] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:21.

[0416] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0417] (a) a process comprising the steps of:

[0418] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0419] (aa) SEQ ID NO:21, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:21; and

[0420] (ab) the nucleotide sequence of the cDNA insert of cloneam856_(—)3 deposited with the ATCC under accession number 98600; and

[0421] (ii) hybridizing said probe(s) to human DNA; and

[0422] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0423] (b) a process comprising the steps of:

[0424] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0425] (ba) SEQ ID NO:21, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:21; and

[0426] (bb) the nucleotide sequence of the cDNA insert of cloneam856_(—)3 deposited with the ATCC under accession number 98600; and

[0427] (ii) hybridizing said primer(s) to human DNA;

[0428] (iii) amplifying human DNA sequences; and

[0429] (iv) isolating the polynucleotide product of step (b)(iii).

[0430] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:21, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:21 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:21, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:21. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21from nucleotide 469 to nucleotide 609, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:21 from nucleotide 469 to nucleotide 609, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:21 fromnucleotide 469 to nucleotide 609. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 574to nucleotide 609, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:21 fromnucleotide 574 to nucleotide 609, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:21 from nucleotide 574 tonucleotide 609. Also preferably the polynucleotide isolated according tothe above process comprises a nucleotide sequence corresponding to thecDNA sequence of SEQ ID NO:21 from nucleotide 214 to nucleotide 369, andextending contiguously from a nucleotide sequence corresponding to the5′ end of said sequence of SEQ ID NO:21 from nucleotide 214 tonucleotide 369, to a nucleotide sequence corresponding to the 3′ end ofsaid sequence of SEQ ID NO:21 from nucleotide 214 to nucleotide 369.

[0431] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0432] (a) the amino acid sequence of SEQ ID NO:22;

[0433] (b) the amino acid sequence of SEQ ID NO:22 from amino acid 1 toamino acid 38;

[0434] (c) fragments of the amino acid sequence of SEQ ID NO:22comprising eight consecutive amino acids of SEQ ID NO:22; and

[0435] (d) the amino acid sequence encoded by the cDNA insert of cloneam856_(—)3 deposited with the ATCC under accession number 98600;

[0436] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:22 or the amino acid sequence of SEQ ID NO:22 from amino acid1 to amino acid 38. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:22 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:22, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:22 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 18 to amino acid 27 of SEQ ID NO:22.

[0437] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0438] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:23;

[0439] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:23 from nucleotide 442 to nucleotide 735;

[0440] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:23 from nucleotide 520 to nucleotide 735;

[0441] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone am996_(—)12 deposited withthe ATCC under accession number 98600;

[0442] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone am996_(—)12 deposited with the ATCC underaccession number 98600;

[0443] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone am996_(—)12 deposited with theATCC under accession number 98600;

[0444] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone am996_(—)12 deposited with the ATCC under accessionnumber 98600;

[0445] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:24;

[0446] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:24 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:24;

[0447] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0448] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0449] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0450] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:23 from nucleotide 442 to nucleotide 735; the nucleotidesequence of SEQ ID NO:23 from nucleotide 520 to nucleotide 735; thenucleotide sequence of the full-length protein coding sequence of cloneam996_(—)12 deposited with the ATCC under accession number 98600; or thenucleotide sequence of a mature protein coding sequence of cloneam996_(—)12 deposited with the ATCC under accession number 98600. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone am996_(—)12deposited with the ATCC under accession number 98600. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:24from amino acid 1 to amino acid 90. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:24 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:24, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:24 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 44 to amino acid 53 of SEQ ID NO:24.

[0451] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:23.

[0452] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0453] (a) a process comprising the steps of:

[0454] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0455] (aa) SEQ ID NO:23, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:23; and

[0456] (ab) the nucleotide sequence of the cDNA insert of cloneam996_(—)12 deposited with the ATCC under accession number 98600;and

[0457] (ii) hybridizing said probe(s) to human DNA; and

[0458] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0459] (b) a process comprising the steps of:

[0460] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0461] (ba) SEQ ID NO:23, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:23; and

[0462] (bb) the nucleotide sequence of the cDNA insert of cloneam996_(—)12 deposited with the ATCC under accession number 98600; and

[0463] (ii) hybridizing said primer(s) to human DNA;

[0464] (iii) amplifying human DNA sequences; and

[0465] (iv) isolating the polynucleotide product of step (b)(iii).

[0466] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:23, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:23 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:23 , but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:23. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23from nucleotide 442 to nucleotide 735, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:23 from nucleotide 442 to nucleotide 735, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:23 fromnucleotide 442 to nucleotide 735. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 520to nucleotide 735, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:23 fromnucleotide 520 to nucleotide 735, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:23 from nucleotide 520 tonucleotide 735.

[0467] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0468] (a) the amino acid sequence of SEQ ID NO:24;

[0469] (b) the amino acid sequence of SEQ ID NO:24 from amino acid 1 toamino acid 90;

[0470] (c) fragments of the amino acid sequence of SEQ ID NO:24comprising eight consecutive amino acids of SEQ ID NO:24; and

[0471] (d) the amino acid sequence encoded by the cDNA insert of cloneam996_(—)12 deposited with the ATCC under accession number 98600;

[0472] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:24 or the amino acid sequence of SEQ ID NO:24 from amino acid1 to amino acid 90. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:24 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:24, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:24 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 44 to amino acid 53 of SEQ ID NO:24.

[0473] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0474] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:25;

[0475] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:25 from nucleotide 127 to nucleotide 240;

[0476] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone cc69_(—)1 deposited withthe ATCC under accession number 98600;

[0477] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone cc69_(—)1 deposited with the ATCC underaccession number 98600;

[0478] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone cc69_(—)1 deposited with theATCC under accession number 98600;

[0479] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone cc69_(—)1 deposited with the ATCC under accessionnumber 98600;

[0480] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:26;

[0481] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:26 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:26;

[0482] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[0483] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[0484] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[0485] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:25 from nucleotide 127 to nucleotide 240; the nucleotidesequence of the full-length protein coding sequence of clone cc69_(—)1deposited with the ATCC under accession number 98600; or the nucleotidesequence of a mature protein coding sequence of clone cc69_(—)1deposited with the ATCC under accession number 98600. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone cc69_(—)1 deposited with theATCC under accession number 98600.

[0486] In further preferred embodiments, the present invention providesa polynucleotide encoding a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:26 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:26, or a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:26 having biological activity, the fragment comprising theamino acid sequence from amino acid 14 to amino acid 23 of SEQ ID NO:26.

[0487] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:25.

[0488] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0489] (a) a process comprising the steps of:

[0490] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0491] (aa) SEQ ID NO:25, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:25; and

[0492] (ab) the nucleotide sequence of the cDNA insert of clonecc69_(—)1 deposited with the ATCC under accession number 98600; and

[0493] (ii) hybridizing said probe(s) to human DNA; and

[0494] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0495] (b) a process comprising the steps of:

[0496] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0497] (ba) SEQ ID NO:25, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:25; and

[0498] (bb) the nucleotide sequence of the cDNA insert of clonecc69_(—)1 deposited with the ATCC under accession number 98600; and

[0499] (ii) hybridizing said primer(s) to human DNA;

[0500] (iii) amplifying human DNA sequences; and

[0501] (iv) isolating the polynucleotide product of step (b)(iii).

[0502] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:25, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:25 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:25, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:25. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25from nucleotide 127 to nucleotide 240, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:25 from nucleotide 127 to nucleotide 240, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:25 fromnucleotide 127 to nucleotide 240.

[0503] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0504] (a) the amino acid sequence of SEQ ID NO:26;

[0505] (b) fragments of the amino acid sequence of SEQ ID NO:26comprising eight consecutive amino acids of SEQ ID NO:26; and

[0506] (c) the amino acid sequence encoded by the cDNA insert of clonecc69_(—)1 deposited with the ATCC under accession number 98600;

[0507] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:26. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:26 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:26, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:26 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 14 to amino acid 23 of SEQ ID NO:26.

[0508] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0509] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:27;

[0510] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:27 from nucleotide 156 to nucleotide 413;

[0511] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:27 from nucleotide 198 to nucleotide 413;

[0512] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone cc162_(—)1 deposited withthe ATCC under accession number 98600;

[0513] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone cc162_(—)1 deposited with the ATCC underaccession number 98600;

[0514] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone cc162_(—)1 deposited with theATCC under accession number 98600;

[0515] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone cc162_(—)1 deposited with the ATCC under accessionnumber 98600;

[0516] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:28;

[0517] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:28 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:28;

[0518] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0519] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0520] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0521] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:27 from nucleotide 156 to nucleotide 413; the nucleotidesequence of SEQ ID NO:27 from nucleotide 198 to nucleotide 413; thenucleotide sequence of the full-length protein coding sequence of clonecc162_(—)1 deposited with the ATCC under accession number 98600; or thenucleotide sequence of a mature protein coding sequence of clonecc162_(—)1 deposited with the ATCC under accession number 98600. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone cc162_(—)1deposited with the ATCC under accession number 98600. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:28from amino acid 1 to amino acid 66. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:28 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:28, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:28 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 38 to amino acid 47 of SEQ ID NO:28.

[0522] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:27.

[0523] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0524] (a) a process comprising the steps of:

[0525] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0526] (aa) SEQ ID NO:27, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:27; and

[0527] (ab) the nucleotide sequence of the cDNA insert of clonecc162_(—)1 deposited with the ATCC under accession number 98600; and

[0528] (ii) hybridizing said probe(s) to human DNA; and

[0529] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0530] (b) a process comprising the steps of:

[0531] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0532] (ba) SEQ ID NO:27, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:27; and

[0533] (bb) the nucleotide sequence of the cDNA insert of clonecc162_(—)1 deposited with the ATCC under accession number 98600; and

[0534] (ii) hybridizing said primer(s) to human DNA;

[0535] (iii) amplifying human DNA sequences; and

[0536] (iv) isolating the polynucleotide product of step (b)(iii).

[0537] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:27, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:27 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:27, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:27. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27from nucleotide 156 to nucleotide 413, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:27 from nucleotide 156 to nucleotide 413, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:27 fromnucleotide 156 to nucleotide 413. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 198to nucleotide 413, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:27 fromnucleotide 198 to nucleotide 413, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:27 from nucleotide 198 tonucleotide 413.

[0538] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0539] (a) the amino acid sequence of SEQ ID NO:28;

[0540] (b) the amino acid sequence of SEQ ID NO:28 from amino acid 1 toamino acid 66;

[0541] (c) fragments of the amino acid sequence of SEQ ID NO:28comprising eight consecutive amino acids of SEQ ID NO:28; and

[0542] (d) the amino acid sequence encoded by the cDNA insert of clonecc162_(—)1 deposited with the ATCC under accession number 98600;

[0543] the protein being substantially free from other manmalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:28 or the amino acid sequence of SEQ ID NO:28 from amino acid1 to amino acid 66. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:28 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:28, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:28 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 38 to amino acid 47 of SEQ ID NO:28.

[0544] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0545] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:29;

[0546] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:29 from nucleotide 180 to nucleotide 737;

[0547] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:29 from nucleotide 240 to nucleotide 737;

[0548] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone if87_(—)1 deposited withthe ATCC under accession number 98600;

[0549] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone if87_(—)1 deposited with the ATCC underaccession number 98600;

[0550] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone if87_(—)1 deposited with theATCC under accession number 98600;

[0551] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone if87_(—)1 deposited with the ATCC under accessionnumber 98600;

[0552] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:30;

[0553] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:30 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:30;

[0554] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0555] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0556] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0557] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:29 from nucleotide 180 to nucleotide 737; the nucleotidesequence of SEQ ID NO:29 from nucleotide 240 to nucleotide 737; thenucleotide sequence of the full-length protein coding sequence of cloneif87_(—)1 deposited with the ATCC under accession number 98600; or thenucleotide sequence of a mature protein coding sequence of cloneif87_(—)1 deposited with the ATCC under accession number 98600. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone if87_(—)1 depositedwith the ATCC under accession number 98600. In yet other preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising the amino acid sequence of SEQ ID NO:30 from aminoacid 1 to amino acid 88. In further preferred embodiments, the presentinvention provides a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:30 having biologicalactivity, the fragment preferably comprising eight (more preferablytwenty, most preferably thirty) consecutive amino acids of SEQ ID NO:30,or a polynucleotide encoding a protein comprising a fragment of theamnino acid sequence of SEQ ID NO:30 having biological activity, thefragment comprising the amino acid sequence from amino acid 88 to aminoacid 97 of SEQ ID NO:30.

[0558] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:29.

[0559] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0560] (a) a process comprising the steps of:

[0561] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0562] (aa) SEQ ID NO:29, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:29; and

[0563] (ab) the nucleotide sequence of the cDNA insert of cloneif87_(—)1 deposited with the ATCC under accession number 98600; and

[0564] (ii) hybridizing said probe(s) to human DNA; and

[0565] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0566] (b) a process comprising the steps of:

[0567] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0568] (ba) SEQ ID NO:29, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:29; and

[0569] (bb) the nucleotide sequence of the cDNA insert of cloneif87_(—)1 deposited with the ATCC under accession number 98600; and

[0570] (ii) hybridizing said primer(s) to human DNA;

[0571] (iii) amplifying human DNA sequences; and

[0572] (iv) isolating the polynucleotide product of step (b)(iii).

[0573] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:29, and extending contiguously from a nudeotidesequence corresponding to the 5′ end of SEQ ID NO:29 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:29, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:29. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29from nucleotide 180 to nucleotide 737, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:29 from nucleotide 180 to nucleotide 737, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:29 fromnucleotide 180 to nucleotide 737. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 240to nucleotide 737, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:29 fromnucleotide 240 to nucleotide 737, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:29 from nucleotide 240 tonucleotide 737.

[0574] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0575] (a) the amino acid sequence of SEQ ID NO:30;

[0576] (b) the amino acid sequence of SEQ ID NO:30 from amino acid 1 toamino acid 88;

[0577] (c) fragments of the amino acid sequence of SEQ ID NO:30comprising eight consecutive amino acids of SEQ ID NO:30; and

[0578] (d) the amino acid sequence encoded by the cDNA insert of cloneif87_(—)1 deposited with the ATCC under accession number 98600;

[0579] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:30 or the amino acid sequence of SEQ ID NO:30 from amino acid1 to amino acid 88. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:30 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:30, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:30 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 88 to amino acid 97 of SEQ ID NO:30.

[0580] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0581] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:31;

[0582] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:31 from nucleotide 2294 to nucleotide 2845;

[0583] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:31 from nucleotide 2387 to nucleotide 2845;

[0584] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nn103_(—)4 deposited withthe ATCC under accession number 98600;

[0585] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nn103_(—)4 deposited with the ATCC underaccession number 98600;

[0586] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nn103_(—)4 deposited with theATCC under accession number 98600;

[0587] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nn103_(—)4 deposited with the ATCC under accessionnumber 98600;

[0588] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:32;

[0589] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:32 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:32;

[0590] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0591] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0592] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0593] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:31 from nucleotide 2294 to nucleotide 2845; the nucleotidesequence of SEQ ID NO:31 from nucleotide 2387 to nucleotide 2845; thenucleotide sequence of the full-length protein coding sequence of clonenn103_(—)4 deposited with the ATCC under accession number 98600; or thenucleotide sequence of a mature protein coding sequence of clonenn103_(—)4 deposited with the ATCC under accession number 98600. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone nn103_(—)4deposited with the ATCC under accession number 98600. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:32from amino acid 12 to amino acid 137. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:32 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:32, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:32 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 87 to amino acid 96 of SEQ ID NO:32.

[0594] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:31.

[0595] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0596] (a) a process comprising the steps of:

[0597] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0598] (aa) SEQ ID NO:31, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:31; and

[0599] (ab) the nucleotide sequence of the cDNA insert of clonenn103_(—)4 deposited with the ATCC under accession number 98600; and

[0600] (ii) hybridizing said probe(s) to human DNA; and

[0601] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0602] (b) a process comprising the steps of:

[0603] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0604] (ba) SEQ ID NO:31, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:31; and

[0605] (bb) the nucleotide sequence of the cDNA insert of clonenn103_(—)4 deposited with the ATCC under accession number 98600; and

[0606] (ii) hybridizing said primer(s) to human DNA;

[0607] (iii) amplifying human DNA sequences; and

[0608] (iv) isolating the polynucleotide product of step (b)(iii).

[0609] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:31, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:31 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:31 , but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:31. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31from nucleotide 2294 to nucleotide 2845, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:31 from nucleotide 2294 to nucleotide 2845, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:31from nucleotide 2294 to nucleotide 2845. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31from nucleotide 2387 to nucleotide 2845, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:31 from nucleotide 2387 to nucleotide 2845, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:31from nucleotide 2387 to nucleotide 2845.

[0610] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0611] (a) the amino acid sequence of SEQ ID NO:32;

[0612] (b) the amino acid sequence of SEQ ID NO:32 from amino acid 12 toamino acid 137;

[0613] (c) fragments of the amino acid sequence of SEQ ID NO:32comprising eight consecutive amino acids of SEQ ID NO:32; and

[0614] (d) the amino acid sequence encoded by the cDNA insert of clonenn103_(—)4 deposited with the ATCC under accession number 98600;

[0615] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:32 or the amino acid sequence of SEQ ID NO:32 from amino acid12 to amino acid 137. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:32 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:32, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:32 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 87 to amino acid 96 of SEQ ID NO:32.

[0616] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0617] (a) a polvnucleotide comprising the nucleotide sequence of SEQ IDNO:33;

[0618] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:33 from nucleotide 1280 to nucleotide 1504;

[0619] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone np206_(—)8 deposited withthe ATCC under accession number 98600;

[0620] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone np206_(—)8 deposited with the ATCC underaccession number 98600;

[0621] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone np206_(—)8 deposited with theATCC under accession number 98600;

[0622] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone np206_(—)8 deposited with the ATCC under accessionnumber 98600;

[0623] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:34;

[0624] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:34 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:34;

[0625] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[0626] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[0627] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[0628] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:33 from nucleotide 1280 to nucleotide 1504; the nucleotidesequence of the full-length protein coding sequence of clone np206_(—)8deposited with the ATCC under accession number 98600; or the nucleotidesequence of a mature protein coding sequence of clone np206_(—)8deposited with the ATCC under accession number 98600. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone np206_(—)8 deposited withthe ATCC under accession number 98600. In yet other preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising the amino acid sequence of SEQ ID NO:34 from aminoacid 1 to amino acid 26. In further preferred embodiments, the presentinvention provides a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:34 having biologicalactivity, the fragment preferably comprising eight (more preferablytwenty, most preferably thirty) consecutive amino acids of SEQ ID NO:34,or a polynucleotide encoding a protein comprising a fragment of theamino acid sequence of SEQ ID NO:34 having biological activity, thefragment comprising the amino acid sequence from amino acid 32 to aminoacid 41 of SEQ ID NO:34.

[0629] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:33.

[0630] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0631] (a) a process comprising the steps of:

[0632] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0633] (aa) SEQ ID NO:33, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:33; and

[0634] (ab) the nucleotide sequence of the cDNA insert of clonenp206_(—8) deposited with the ATCC under accession number 98600; and

[0635] (ii) hybridizing said probe(s) to human DNA; and

[0636] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0637] (b) a process comprising the steps of:

[0638] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0639] (ba) SEQ ID NO:33, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:33; and

[0640] (bb) the nucleotide sequence of the cDNA insert of clonenp206_(—)8 deposited with the ATCC under accession number 98600; and

[0641] (ii) hybridizing said primer(s) to human DNA;

[0642] (iii) amplifying human DNA sequences; and

[0643] (iv) isolating the polynucleotide product of step (b)(iii).

[0644] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:33, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:33 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:33, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:33. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDN=A sequence of SEQ ID NO:33from nucleotide 1280 to nucleotide 1504, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:33 from nucleotide 1280 to nucleotide 1504, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:33from nucleotide 1280 to nucleotide 1504.

[0645] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0646] (a) the amino acid sequence of SEQ ID NO:34;

[0647] (b) the amino acid sequence of SEQ ID NO:34 from amino acid 1 toamino acid 26;

[0648] (c) fragments of the amino acid sequence of SEQ ID NO:34comprising eight consecutive amino acids of SEQ ID NO:34; and

[0649] (d) the amino acid sequence encoded by the cDNA insert of clonenp206_(—)8 deposited with the ATCC under accession number 98600;

[0650] the protein being substantially free from other mammalianproteins. Preferably such a protein comprises the amino acid sequence ofSEQ ID NO:34 or the amino acid sequence of SEQ ID NO:34 from amino acid1 to amino acid 26. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:34 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:34, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:34 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 32 to amino acid 41 of SEQ ID NO:34.

[0651] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0652] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:35;

[0653] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:35 from nucleotide 133 to nucleotide 432;

[0654] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nt746_(—)4 deposited withthe ATCC under accession number 98600;

[0655] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nt746_(—)4 deposited with the ATCC underaccession number 98600;

[0656] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nt746_(—)4 deposited with theATCC under accession number 98600;

[0657] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nt746_(—)4 deposited with the ATCC under accessionnumber 98600;

[0658] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:36;

[0659] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:36 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:36;

[0660] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[0661] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[0662] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[0663] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:35 from nucleotide 133 to nucleotide 432; the nucleotidesequence of the full-length protein coding sequence of clone nt746_(—)4deposited with the ATCC under accession number 98600; or the nucleotidesequence of a mature protein coding sequence of clone nt746_(—)4deposited with the ATCC under accession number 98600. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone nt746_(—)4 deposited withthe ATCC under accession number 98600. In yet other preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising the amino acid sequence of SEQ ID NO:36 from aminoacid 1 to amino acid 70. In further preferred embodiments, the presentinvention provides a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:36 having biologicalactivity, the fragment preferably comprising eight (more preferablytwenty, most preferably thirty) consecutive amino acids of SEQ ID NO:36,or a polynucleotide encoding a protein comprising a fragment of theamino acid sequence of SEQ ID NO:36 having biological activity, thefragment comprising the amino acid sequence from amino acid 45 to aminoacid 54 of SEQ ID NO:36.

[0664] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:35.

[0665] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0666] (a) a process comprising the steps of:

[0667] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0668] (aa) SEQ ID NO:35, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:35; and

[0669] (ab) the nucleotide sequence of the cDNA insert of clonent746_(—)4 deposited with the ATCC under accession number 98600; and

[0670] (ii) hybridizing said probe(s) to human DNA; and

[0671] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0672] (b) a process comprising the steps of:

[0673] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0674] (ba) SEQ ID NO:35, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:35; and

[0675] (bb) the nucleotide sequence of the cDNA insert of clonent746_(—)4 deposited with the ATCC under accession number 98600; and

[0676] (ii) hybridizing said primer(s) to human DNA;

[0677] (iii) amplifying human DNA sequences; and

[0678] (iv) isolating the polynucleotide product of step (b)(iii).

[0679] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:35, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:35 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:35, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:35. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35from nucleotide 133 to nucleotide 432, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:35 from nucleotide 133 to nucleotide 432, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:35 fromnucleotide 133 to nucleotide 432.

[0680] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0681] (a) the amino acid sequence of SEQ ID NO:36;

[0682] (b) the amino acid sequence of SEQ ID NO:36 from amino acid 1 toamino acid 70;

[0683] (c) fragments of the amino acid sequence of SEQ ID NO:36comprising eight consecutive amino acids of SEQ ID NO:36; and

[0684] (d) the amino acid sequence encoded by the cDNA insert of clonent746_(—)4 deposited with the ATCC under accession number 98600;

[0685] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:36 or the amino acid sequence of SEQ ID NO:36 from amino acid1 to amino acid 70. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:36 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:36, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:36 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 45 to amino acid 54 of SEQ ID NO:36.

[0686] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0687] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:37;

[0688] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:37 from nucleotide 31 to nucleotide 201;

[0689] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pe286_(—)1 deposited withthe ATCC under accession number 98600;

[0690] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pe286_(—)1 deposited with the ATCC underaccession number 98600;

[0691] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pe286_(—)1 deposited with theATCC under accession number 98600;

[0692] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pe286_(—)1 deposited with the ATCC under accessionnumber 98600;

[0693] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:38;

[0694] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:38 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:38;

[0695] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[0696] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[0697] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[0698] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:37 from nucleotide 31 to nucleotide 201; the nucleotidesequence of the full-length protein coding sequence of clone pe286_(—)1deposited with the ATCC under accession number 98600; or the nucleotidesequence of a mature protein coding sequence of clone pe286_(—)1deposited with the ATCC under accession number 98600. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone pe286_(—)1 deposited withthe ATCC under accession number 98600. In yet other preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising the amino acid sequence of SEQ ID NO:38 from aminoacid 1 to amino acid 49. In further preferred embodiments, the presentinvention provides a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:38 having biologicalactivity, the fragment preferably comprising eight (more preferablytwenty, most preferably thirty) consecutive amino acids of SEQ ID NO:38,or a polynucleotide encoding a protein comprising a fragment of theamino acid sequence of SEQ ID NO:38 having biological activity, thefragment comprising the amino acid sequence from amino acid 23 to aminoacid 32 of SEQ ID NO:38.

[0699] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:37.

[0700] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0701] (a) a process comprising the steps of:

[0702] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0703] (aa) SEQ ID NO:37, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:37; and

[0704] (ab) the nucleotide sequence of the cDNA insert of clonepe286_(—)1 deposited with the ATCC under accession number 98600; and

[0705] (ii) hybridizing said probe(s) to human DNA; and

[0706] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0707] (b) a process comprising the steps of:

[0708] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0709] (ba) SEQ ID NO:37, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:37; and

[0710] (bb) the nucleotide sequence of the cDNA insert of clonepe286_(—)1 deposited with the ATCC under accession number 98600; and

[0711] (ii) hybridizing said primer(s) to human DNA;

[0712] (iii) amplifying human DNA sequences; and

[0713] (iv) isolating the polynucleotide product of step (b)(iii).

[0714] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:37, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:37 to a-nucleotidesequence corresponding to the 3′ end of SEQ ID NO:37, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:37. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37from nucleotide 31 to nucleotide 201, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:37 from nucleotide 31 to nucleotide 201, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:37 fromnucleotide 31 to nucleotide 201.

[0715] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0716] (a) the amino acid sequence of SEQ ID NO:38;

[0717] (b) the amino acid sequence of SEQ ID NO:38 from amino acid 1 toamino acid 49;

[0718] (c) fragments of the amino acid sequence of SEQ ID NO:38comprising eight consecutive amino acids of SEQ ID NO:38; and

[0719] (d) the amino acid sequence encoded by the cDNA insert of clonepe286_(—)1 deposited with the ATCC under accession number 98600;

[0720] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:38 or the amino acid sequence of SEQ ID NO:38 from amino acid1 to amino acid 49. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:38 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:38, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:38 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 23 to amino acid 32 of SEQ ID NO:38.

[0721] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0722] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:39;

[0723] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:39 from nucleotide 843 to nucleotide 1004;

[0724] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone yb7_(—)1 deposited with theATCC under accession number 98600;

[0725] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone yb7_(—)1 deposited with the ATCC underaccession number 98600;

[0726] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone yb7_(—)1 deposited with the ATCCunder accession number 98600;

[0727] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone yb7_(—)1 deposited with the ATCC under accessionnumber 98600;

[0728] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:40;

[0729] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:40 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:40;

[0730] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[0731] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[0732] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[0733] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:39 from nucleotide 843 to nucleotide 1004; the nucleotidesequence of the full-length protein coding sequence of clone yb7_(—)1deposited with the ATCC under accession number 98600; or the nucleotidesequence of a mature protein coding sequence of clone yb7_(—)1 depositedwith the ATCC under accession number 98600. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone yb7_(—)1 deposited with theATCC under accession number 98600.

[0734] In further preferred embodiments, the present invention providesa polynucleotide encoding a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:40 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:40, or a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:40 having biological activity, the fragment comprising theamino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:40.

[0735] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:39.

[0736] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0737] (a) a process comprising the steps of:

[0738] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0739] (aa) SEQ ID NO:39, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:39; and

[0740] (ab) the nucleotide sequence of the cDNA insert of clone yb7_(—)1deposited with the ATCC under accession number 98600; and

[0741] (ii) hybridizing said probe(s) to human DNA; and

[0742] (iii) isolating the DNA polynucleotide detected with theprobe(s); and

[0743] (b) a process comprising the steps of:

[0744] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0745] (ba) SEQ ID NO:39, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:39; and

[0746] (bb) the nucleotide sequence of the cDNA insert of clone yb7_(—)1deposited with the ATCC under accession number 98600; and

[0747] (ii) hybridizing said primer(s) to human DNA;

[0748] (iii) amplifying human DNA sequences; and

[0749] (iv) isolating the polynucleotide product of step (b)(iii).

[0750] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:39, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:39 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:39, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:39. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39from nucleotide 843 to nucleotide 1004, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:39 from nucleotide 843 to nucleotide 1004, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:39from nucleotide 843 to nucleotide 1004.

[0751] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0752] (a) the amino acid sequence of SEQ ID NO:40;

[0753] (b) fragments of the amnino acid sequence of SEQ ID NO:40comprising eight consecutive amino acids of SEQ ID NO:40; and

[0754] (c) the amino acid sequence encoded by the cDNA insert of cloneyb7_(—)1 deposited with the ATCC under accession number 98600; theprotein being substantially free from other mammalian proteins.Preferably such protein comprises the amino acid sequence of SEQ IDNO:40. In further preferred embodiments, the present invention providesa protein comprising a fragment of the amnino acid sequence of SEQ IDNO:40 having biological activity, the fragment preferably comprisingeight (more preferably twenty, most preferably thirty) consecutive aminoacids of SEQ ID NO:40, or a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:40 having biological activity, the fragmentcomprising the arnino acid sequence from amino acid 22 to amino acid 31of SEQ ID NO:40.

[0755] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0756] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:41;

[0757] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:41 from nucleotide 179 to nucleotide 4285;

[0758] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone am728_(—)60 deposited withthe ATCC under accession number 98621;

[0759] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone am728_(—)60 deposited with the ATCC underaccession number 98621;

[0760] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone am728_(—)60 deposited with theATCC under accession number 98621;

[0761] (e) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone am728_(—)60 depositedwiththeATCCunderaccessionnumber98621;

[0762] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:42;

[0763] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:42 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:42;

[0764] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[0765] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[0766] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[0767] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:41 from nucleotide 179 to nucleotide 4285; the nucleotidesequence of the full-length protein coding sequence of clone am728_(—)60deposited with the ATCC under accession number 98621; or the nucleotidesequence of a mature protein coding sequence of clone am728_(—)60deposited with the ATCC under accession number 98621. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone am728_(—)60 deposited withthe ATCC under accession number 98621. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:42 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:42, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:42 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 679 to amino acid 688 of SEQ ID NO:42.

[0768] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:41.

[0769] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0770] (a) a process comprising the steps of:

[0771] (i) preparing one or more polynucleotide probes that hvbridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0772] (aa) SEQ ID NO:41; and

[0773] (ab) the nucleotide sequence of the cDNA insert of cloneam728_(—)60 deposited with the ATCC under accession number 98621;

[0774] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[0775] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[0776] (b) a process comprising the steps of:

[0777] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0778] (ba) SEQ ID NO:41; and

[0779] (bb) the nucleotide sequence of the cDNA insert of cloneam728_(—)60 deposited with the ATCC under accession number 98621;

[0780] (ii) hybridizing said primer(s) to human genornic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[0781] (iii) amplifying human DNA sequences; and

[0782] (iv) isolating the polynucleotide products of step (b)(iii).

[0783] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:41, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:41 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:41 . Also preferablythe polynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41from nucleotide 179 to nucleotide 4285, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:41 from nucleotide 179 to nucleotide 4285, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:41from nucleotide 179 to nucleotide 4285.

[0784] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamnino acid sequence selected from the group consisting of:

[0785] (a) the amino acid sequence of SEQ ID NO:42;

[0786] (b) fragments of the amino acid sequence of SEQ ID NO:42, eachfragment comprising eight consecutive amino acids of SEQ ID NO:42; and

[0787] (c) the amino acid sequence encoded by the cDNA insert of cloneam728_(—)60 deposited with the ATCC under accession number 98621;

[0788] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:42. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:42 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:42, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:42 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 679 to arnino acid 688 of SEQ ID NO:42.

[0789] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0790] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:43;

[0791] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:43 from nucleotide 108 to nucleotide 254;

[0792] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:43 from nucleotide 225 to nucleotide 254;

[0793] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bf377_(—)1 deposited withthe ATCC under accession number 98621;

[0794] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bf377_(—)1 deposited with the ATCC underaccession number 98621;

[0795] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bf377_(—)1 deposited with theATCC under accession number 98621;

[0796] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bf377_(—)1 deposited with the ATCC under accessionnumber 98621;

[0797] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:44;

[0798] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:44 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:44;

[0799] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0800] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0801] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0802] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:43 from nucleotide 108 to nucleotide 254; the nucleotidesequence of SEQ ID NO:43 from nucleotide 225 to nucleotide 254; thenucleotide sequence of the full-length protein coding sequence of clonebf377_(—)1 deposited with the ATCC under accession number 98621; or thenucleotide sequence of a mature protein coding sequence of clonebf377_(—)1 deposited with the ATCC under accession number 98621. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone bf377_(—)1deposited with the ATCC under accession number 98621. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:44 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:44, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:44having biological activity, the fragment comprising the amino acidsequence from amino acid 19 to amino acid 28 of SEQ ID NO:44.

[0803] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:43.

[0804] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0805] (a) a process comprising the steps of:

[0806] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0807] (aa) SEQ ID NO:43, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:43; and

[0808] (ab) the nucleotide sequence of the cDNA insert of clonebf377_(—)1 deposited with the ATCC under accession number 98621;

[0809] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[0810] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[0811] (b) a process comprising the steps of:

[0812] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0813] (ba) SEQ ID NO:43, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:43; and

[0814] (bb) the nucleotide sequence of the cDNA insert of clonebf377_(—)1 deposited with the ATCC under accession number 98621;

[0815] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[0816] (iii) amplifying human DNA sequences; and

[0817] (iv) isolating the polynucleotide products of step (b)(iii).

[0818] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:43, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:43 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:43, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:43. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43from nucleotide 108 to nucleotide 254, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:43 from nucleotide 108 to nucleotide 254, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:43 fromnucleotide 108 to nucleotide 254. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 225to nucleotide 254, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:43 fromnucleotide 225 to nucleotide 254, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:43 from nucleotide 225 tonucleotide 254.

[0819] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0820] (a) the amino acid sequence of SEQ ID NO:44;

[0821] (b) fragments of the amino acid sequence of SEQ ID NO:44, eachfragment comprising eight consecutive amino acids of SEQ ID NO:44; and

[0822] (c) the amino acid sequence encoded by the cDNA insert of clonebf377_(—)1 deposited with the ATCC under accession number 98621;

[0823] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:44. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:44 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:44, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:44 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 19 to amino acid 28 of SEQ ID NO:44.

[0824] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0825] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:45;

[0826] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:45 from nucleotide 426 to nucleotide 569;

[0827] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:45 from nucleotide 546 to nucleotide 569;

[0828] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone cw354_(—)1 deposited withthe ATCC under accession number 98621;

[0829] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone cw354_(—)1 deposited with the ATCC underaccession number 98621;

[0830] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone cw354_(—)1 deposited with theATCC under accession number 98621;

[0831] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone cw354_(—)1 deposited with the ATCC under accessionnumber 98621;

[0832] (h) a polynucleotide encoding a protein comprising the arninoacid sequence of SEQ ID NO:46;

[0833] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:46 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:46;

[0834] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0835] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0836] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0837] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:45 from nucleotide 426 to nucleotide 569; the nucleotidesequence of SEQ ID NO:45 from nucleotide 546 to nucleotide 569; thenucleotide sequence of the full-length protein coding sequence of clonecw354_(—)1 deposited with the ATCC under accession number 98621; or thenucleotide sequence of a mature protein coding sequence of clonecw354_(—)1 deposited with the ATCC under accession number 98621. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone cw354_(—)1deposited with the ATCC under accession number 98621. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:46 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:46, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:46having biological activity, the fragment comprising the amino acidsequence from amino acid 19 to amino acid 28 of SEQ ID NO:46.

[0838] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:45.

[0839] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0840] (a) a process comprising the steps of:

[0841] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0842] (aa) SEQ ID NO:45, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:45; and

[0843] (ab) the nucleotide sequence of the cDNA insert of clonecw354_(—)1 deposited with the ATCC under accession number 98621;

[0844] (ii) hybridizing said probe(s) to human genorric DNA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[0845] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[0846] (b) a process comprising the steps of:

[0847] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0848] (ba) SEQ ID NO:45, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:45; and

[0849] (bb) the nucleotide sequence of the cDNA insert of clonecw354_(—)1 deposited with the ATCC under accession number 98621;

[0850] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[0851] (iii) amplifying human DNA sequences; and

[0852] (iv) isolating the polynucleotide products of step (b)(iii).

[0853] Preferably the polynucleotide isolated according to the aboveprocess comprises a 9nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:45, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:45 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:45, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:45. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45from nucleotide 426 to nucleotide 569, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:45 from nucleotide 426 to nucleotide 569, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:45 fromnucleotide 426 to nucleotide 569. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 546to nucleotide 569, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:45 fromnucleotide 546 to nucleotide 569, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:45 from nucleotide 546 tonucleotide 569.

[0854] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0855] (a) the amino acid sequence of SEQ ID NO:46;

[0856] (b) fragments of the amino acid sequence of SEQ ID NO:46, eachfragment comprising eight consecutive amino acids of SEQ ID NO:46; and

[0857] (c) the amino acid sequence encoded by the cDNA insert of clonecw354_(—)1 deposited with the ATCC under accession number 98621;

[0858] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:46. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:46 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:46, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:46 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 19 to amino acid 28 of SEQ ID NO:46.

[0859] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0860] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:47;

[0861] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:47 from nucleotide 151 to nucleotide 891;

[0862] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:47 from nucleotide 595 to nucleotide 891;

[0863] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nm134_(—)4 deposited withthe ATCC under accession number 98621;

[0864] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nm134_(—)4 deposited with the ATCC underaccession number 98621;

[0865] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nm134_(—)4 deposited with theATCC under accession number 98621;

[0866] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nm134_(—)4 deposited with the ATCC under accessionnumber 98621;

[0867] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:48;

[0868] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:48 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:48;

[0869] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0870] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0871] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0872] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:47 from nucleotide 151 to nucleotide 891; the nucleotidesequence of SEQ ID NO:47 from nucleotide 595 to nucleotide 891; thenucleotide sequence of the full-length protein coding sequence of clonenm134_(—)4 deposited with the ATCC under accession number 98621; or thenucleotide sequence of a mature protein coding sequence of clonenm134_(—)4 deposited with the ATCC under accession number 98621. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone nm134_(—)4deposited with the ATCC under accession number 98621. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:48from amino acid 104 to amino acid 163. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:48 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:48, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:48 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 118 to amino acid 127 of SEQ ID NO:48.

[0873] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:47.

[0874] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0875] (a) a process comprising the steps of:

[0876] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0877] (aa) SEQ ID NO:47, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:47; and

[0878] (ab) the nucleotide sequence of the cDNA insert of clonenm134_(—)4 deposited with the ATCC under accession number 98621;

[0879] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[0880] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[0881] (b) a process comprising the steps of:

[0882] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0883] (ba) SEQ ID NO:47, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:47; and

[0884] (bb) the nucleotide sequence of the cDNA insert of clonenm134_(—)4 deposited with the ATCC under accession number 98621;

[0885] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[0886] (iii) amplifying human DNA sequences; and

[0887] (iv) isolating the polynucleotide products of step (b)(iii).

[0888] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:47, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:47 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:47, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:47. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47from nucleotide 151 to nucleotide 891, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:47 from nucleotide 151 to nucleotide 891, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:47 fromnucleotide 151 to nucleotide 891. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 595to nucleotide 891, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:47 fromnucleotide 595 to nucleotide 891, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:47 from nucleotide 595 tonucleotide 891.

[0889] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0890] (a) the amino acid sequence of SEQ ID NO:48;

[0891] (b) the amino acid sequence of SEQ ID NO:48 from amino acid 104to amino acid 163;

[0892] (c) fragments of the amino acid sequence of SEQ ID NO:48, eachfragment comprising eight consecutive amino acids of SEQ ID NO:48; and

[0893] (d) the amnino acid sequence encoded by the cDNA insert of clonenm134_(—)4 deposited with the ATCC under accession number 98621;

[0894] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:48 or the amino acid sequence of SEQ ID NO:48 from amino acid104 to amino acid 163. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:48 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:48, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:48 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 118 to amino acid 127 of SEQ ID NO:48.

[0895] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0896] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:49;

[0897] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:49 from nucleotide 1909 to nucleotide 2127;

[0898] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:49 from nucleotide 2074 to nucleotide 2127;

[0899] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone yb11_(—)1 deposited withthe ATCC under accession number 98621;

[0900] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone yb11_(—)1 deposited with the ATCC underaccession number 98621;

[0901] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone yb11_(—)1 deposited with theATCC under accession number 98621;

[0902] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone yb11_(—)1 deposited with the ATCC under accessionnumber 98621;

[0903] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:50;

[0904] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:50 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:50;

[0905] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0906] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0907] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0908] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:49 from nucleotide 1909 to nucleotide 2127; the nucleotidesequence of SEQ ID NO:49 from nucleotide 2074 to nucleotide 2127; thenucleotide sequence of the full-length protein coding sequence of cloneyb11_(—)1 deposited with the ATCC under accession number 98621; or thenucleotide sequence of a mature protein coding sequence of cloneyb11_(—)1 deposited with the ATCC under accession number 98621. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone yb11_(—)1 depositedwith the ATCC under accession number 98621. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:50having biological activity, the fragment preferably comprising eight(more preferably twenty, most preferably thirty) consecutive amino acidsof SEQ ID NO:50, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:50 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 31 to amino acid 40 of SEQ ID NO:50.

[0909] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:49.

[0910] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0911] (a) a process comprising the steps of:

[0912] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0913] (aa) SEQ ID NO:49, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:49; and

[0914] (ab) the nucleotide sequence of the cDNA insert of cloneyb11_(—)1 deposited with the ATCC under accession number 98621;

[0915] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[0916] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[0917] (b) a process comprising the steps of:

[0918] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0919] (ba) SEQ ID NO:49, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:49; and

[0920] (bb) the nucleotide sequence of the cDNA insert of cloneybll_(—)1 deposited with the ATCC under accession number 98621;

[0921] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[0922] (iii) amplifying human DNA sequences; and

[0923] (iv) isolating the polynucleotide products of step (b)(iii).

[0924] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:49, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:49 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:49, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:49. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49from nucleotide 1909 to nucleotide 2127, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:49 from nucleotide 1909 to nucleotide 2127, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:49from nucleotide 1909 to nucleotide 2127. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49from nucleotide 2074 to nucleotide 2127, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:49 from nucleotide 2074 to nucleotide 2127, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:49from nucleotide 2074 to nucleotide 2127.

[0925] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0926] (a) the amino acid sequence of SEQ ID NO:50;

[0927] (b) fragments of the amino acid sequence of SEQ ID NO:50, eachfragment comprising eight consecutive amino acids of SEQ ID NO:50; and

[0928] (c) the amino acid sequence encoded by the cDNA insert of cloneyb11_(—)1 deposited with the ATCC under accession number 98621;

[0929] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:50. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:50 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:50, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:50 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 31 to amino acid 40 of SEQ ID NO:50.

[0930] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0931] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:51;

[0932] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:51 from nucleotide 1077 to nucleotide 1733;

[0933] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:51 from nucleotide 1158 to nucleotide 1733;

[0934] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone yc2_(—)1 deposited with theATCC under accession number 98621;

[0935] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone yc2_(—)1 deposited with the ATCC underaccession number 98621;

[0936] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone yc2_(—)1 deposited with the ATCCunder accession number 98621;

[0937] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone yc2_(—)1 deposited with the ATCC under accessionnumber 98621;

[0938] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:52;

[0939] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:52 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:52;

[0940] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[0941] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[0942] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[0943] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:51 from nucleotide 1077 to nucleotide 1733; the nucleotidesequence of SEQ ID NO:51 from nucleotide 1158 to nucleotide 1733; thenucleotide sequence of the full-length protein coding sequence of cloneyc2_(—)1 deposited with the ATCC under accession number 98621; or thenucleotide sequence of a mature protein coding sequence of cloneyc2_(—)1 deposited with the ATCC under accession number 98621. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone yc2_(—)1 depositedwith the ATCC under accession number 98621.

[0944] In further preferred embodiments, the present invention providesa polynucleotide encoding a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:52 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:52, or a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:52 having biological activity, the fragment comprising theamino acid sequence from amino acid 104 to amino acid 113 of SEQ IDNO:52.

[0945] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:51.

[0946] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0947] (a) a process comprising the steps of:

[0948] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0949] (aa) SEQ ID NO:51, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:51; and

[0950] (ab) the nucleotide sequence of the cDNA insert of clone yc2_(—)1deposited with the ATCC under accession number 98621;

[0951] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[0952] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[0953] (b) a process comprising the steps of:

[0954] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0955] (ba) SEQ ID NO:51, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:51; and

[0956] (bb) the nucleotide sequence of the cDNA insert of clone yc2_(—)1deposited with the ATCC under accession number 98621;

[0957] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[0958] (iii) amplifying human DNA sequences; and

[0959] (iv) isolating the polynucleotide products of step (b)(iii).

[0960] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:51, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:51 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:51 , but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:51. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51from nucleotide 1077 to nucleotide 1733, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:51 from nucleotide 1077 to nucleotide 1733, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:51from nucleotide 1077 to nucleotide 1733. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51from nucleotide 1158 to nucleotide 1733, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:51 from nucleotide 1158 to nucleotide 1733, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:51from nucleotide 1158 to nucleotide 1733.

[0961] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0962] (a) the amino acid sequence of SEQ ID NO:52;

[0963] (b) fragments of the amino acid sequence of SEQ ID NO:52, eachfragment comprising eight consecutive amino acids of SEQ ID NO:52; and

[0964] (c) the amino acid sequence encoded by the cDNA insert of cloneyc2_(—)1 deposited with the ATCC under accession number 98621;

[0965] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:52. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:52 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:52, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:52 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 104 to amino acid 113 of SEQ ID NO:52.

[0966] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[0967] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:53;

[0968] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:53 from nucleotide 257 to nucleotide 622;

[0969] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ff168_(—)12 deposited withthe ATCC under accession number 98623;

[0970] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ff168_(—)12 deposited with the ATCC underaccession number 98623;

[0971] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ff168_(—)12 deposited with theATCC under accession number 98623;

[0972] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ff168_(—)12 deposited with the ATCC under accessionnumber 98623;

[0973] (g) a polynucleotide encoding a protein comprising the amninoacid sequence of SEQ ID NO:54;

[0974] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:54 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:54;

[0975] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[0976] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[0977] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[0978] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:53 from nucleotide 257 to nucleotide 622; the nucleotidesequence of the full-ength protein coding sequence of clone ff168_(—)12deposited with the ATCC under accession number 98623; or the nucleotidesequence of a mature protein coding sequence of clone ff168_(—)12deposited with the ATCC under accession number 98623. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone ff168_(—)12 deposited withthe ATCC under accession number 98623. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:54 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:54, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:54 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 56 to amino acid 65 of SEQ ID NO:54.

[0979] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:53.

[0980] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[0981] (a) a process comprising the steps of:

[0982] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[0983] (aa) SEQ ID NO:53, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:53; and

[0984] (ab) the nucleotide sequence of the cDNA insert of cloneff168_(—)12 deposited with the ATCC under accession number 98623;

[0985] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[0986] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[0987] (b) a process comprising the steps of:

[0988] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[0989] (ba) SEQ ID NO:53, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:53; and

[0990] (bb) the nucleotide sequence of the cDNA insert of cloneff168_(—)12 deposited with the ATCC under accession number 98623;

[0991] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[0992] (iii) amplifying human DNA sequences; and

[0993] (iv) isolating the polynucleotide products of step (b)(iii).

[0994] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:53, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:53 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:53, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:53. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53from nucleotide 257 to nucleotide 622, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:53 from nucleotide 257 to nucleotide 622, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:53 fromnucleotide 257 to nucleotide 622.

[0995] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[0996] (a) the amino acid sequence of SEQ ID NO:54;

[0997] (b) fragments of the amino acid sequence of SEQ ID NO:54, eachfragment comprising eight consecutive amino acids of SEQ ID NO:54; and

[0998] (c) the amino acid sequence encoded by the cDNA insert of cloneff168_(—)12 deposited with the ATCC under accession number 98623;

[0999] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:54. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:54 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:54, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:54 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 56 to amino acid 65 of SEQ ID NO:54.

[1000] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1001] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:55;

[1002] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:55 from nucleotide 1323 to nucleotide 1829;

[1003] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:55 from nucleotide 1539 to nucleotide 1829;

[1004] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ls9_(—)1 deposited with theATCC under accession number 98623;

[1005] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ls9_(—)1 deposited with the ATCC underaccession number 98623;

[1006] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ls9_(—)1 deposited with the ATCCunder accession number 98623;

[1007] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ls9_(—)1 deposited with the ATCC under accessionnumber 98623;

[1008] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:56;

[1009] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:56 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:56;

[1010] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1011] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1012] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1013] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:55 from nucleotide 1323 to nucleotide 1829; the nucleotidesequence of SEQ ID NO:55 from nucleotide 1539 to nucleotide 1829; thenucleotide sequence of the full-length protein coding sequence of clonels9_(—)1 deposited with the ATCC under accession number 98623; or thenucleotide sequence of a mature protein coding sequence of clonels9_(—)1 deposited with the ATCC under accession number 98623. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone ls9_(—)1 depositedwith the ATCC under accession number 98623.

[1014] In further preferred embodiments, the present invention providesa polynucleotide encoding a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:56 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:56, or a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:56 having biological activity, the fragment comprising theamino acid sequence from amino acid 79 to amino acid 88 of SEQ ID NO:56.

[1015] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:55.

[1016] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1017] (a) a process comprising the steps of:

[1018] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1019] (aa) SEQ ID NO:55, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:55; and

[1020] (ab) the nucleotide sequence of the cDNA insert of clone ls9_(—)1deposited with the ATCC under accession number 98623;

[1021] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1022] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1023] (b) a process comprising the steps of:

[1024] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1025] (ba) SEQ ID NO:55, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:55; and

[1026] (bb) the nucleotide sequence of the cDNA insert of clone ls9_(—)1deposited with the ATCC under accession number 98623;

[1027] (ii) hybridizing said primer(s) to human genomnic DNA inconditions at least as stringent as 4)(SSC at 65 degrees C;

[1028] (iii) amplifying human DNA sequences; and

[1029] (iv) isolating the polynucleotide products of step (b)(iii).

[1030] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:55, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:55 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:55, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:55. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55from nucleotide 1323 to nucleotide 1829, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:55 from nucleotide 1323 to nucleotide 1829, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:55from nucleotide 1323 to nucleotide 1829. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55from nucleotide 1539 to nucleotide 1829, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:55 from nucleotide 1539 to nucleotide 1829, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:55from nucleotide 1539 to nucleotide 1829.

[1031] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1032] (a) the amino acid sequence of SEQ ID NO:56;

[1033] (b) fragments of the amino acid sequence of SEQ ID NO:56, eachfragment comprising eight consecutive amino acids of SEQ ID NO:56; and

[1034] (c) the amino acid sequence encoded by the cDNA insert of clonels9_(—)1 deposited with the ATCC under accession number 98623;

[1035] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:56. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:56 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:56, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:56 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 79 to amino acid 88 of SEQ ID NO:56.

[1036] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1037] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:57;

[1038] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:57 from nucleotide 507 to nucleotide 722;

[1039] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:57 from nucleotide 615 to nucleotide 722;

[1040] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone na1010_(—)1 deposited withthe ATCC under accession number 98623;

[1041] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone na1010_(—)1 deposited with the ATCC underaccession number 98623;

[1042] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone na1010_(—)1 deposited with theATCC under accession number 98623;

[1043] (g) a poly-nucleotide encoding a mature protein encoded by thecDNA insert of clone na1010_(—)1 deposited with the ATCC under accessionnumber 98623;

[1044] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:58;

[1045] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:58 having biological activity, thefragment comprising eight consecutive arnino acids of SEQ ID NO:58;

[1046] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1047] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1048] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1049] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:57 from nucleotide 507 to nucleotide 722; the nucleotidesequence of SEQ ID NO:57 from nucleotide 615 to nucleotide 722; thenucleotide sequence of the full-length protein coding sequence of clonena1010_(—)1 deposited with the ATCC under accession number 98623; or thenucleotide sequence of a mature protein coding sequence of clonena1010_(—)1 deposited with the ATCC under accession number 98623. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone na1010_(—)1deposited with the ATCC under accession number 98623. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:58 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:58, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:58having biological activity, the fragment comprising the amino acidsequence from amino acid 31 to amino acid 40 of SEQ ID NO:58.

[1050] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:57.

[1051] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1052] (a) a process comprising the steps of:

[1053] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1054] (aa) SEQ ID NO:57, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:57; and

[1055] (ab) the nucleotide sequence of the cDNA insert of clonena1010_(—)1 deposited with the ATCC under accessionnumber 98623;

[1056] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1057] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1058] (b) a process comprising the steps of:

[1059] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1060] (ba) SEQ ID NO:57, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:57; and

[1061] (bb) the nucleotide sequence of the cDNA insert of clonena1010_(—)1 deposited with the ATCC under accession number 98623;

[1062] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1063] (iii) amplifying human DNA sequences; and

[1064] (iv) isolating the polynucleotide products of step (b)(iii).

[1065] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:57, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:57 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:57, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:57. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57from nucleotide 507 to nucleotide 722, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:57 from nucleotide 507 to nucleotide 722, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:57 fromnucleotide 507 to nucleotide 722. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 615to nucleotide 722, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:57 fromnucleotide 615 to nucleotide 722, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:57 from nucleotide 615 tonucleotide 722.

[1066] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1067] (a) the amino acid sequence of SEQ ID NO:58;

[1068] (b) fragments of the amino acid sequence of SEQ ID NO:58, eachfragment comprising eight consecutive amino acids of SEQ ID NO:58; and

[1069] (c) the amino acid sequence encoded by the cDNA insert of clonena1010_(—)1 deposited with the ATCC under accession number 98623;

[1070] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:58. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:58 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:58, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:58 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 31 to amino acid 40 of SEQ ID NO:58.

[1071] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1072] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:59;

[1073] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:59 from nucleotide 673 to nucleotide 987;

[1074] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:59 from nucleotide 868 to nucleotide 987;

[1075] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nf87_(—)1 deposited withthe ATCC under accession number 98623;

[1076] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nf87_(—)1 deposited with the ATCC underaccession number 98623;

[1077] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nf87_(—)1 deposited with theATCC under accession number 98623;

[1078] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nf87_(—)1 deposited with the ATCC under accessionnumber 98623;

[1079] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:60;

[1080] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:60 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:60;

[1081] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1082] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1083] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1084] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:59 from nucleotide 673 to nucleotide 987; the nucleotidesequence of SEQ ID NO:59 from nucleotide 868 to nucleotide 987; thenucleotide sequence of the full-length protein coding sequence of clonenf87_(—)1 deposited with the ATCC under accession number 98623; or thenucleotide sequence of a mature protein coding sequence of clonenf87_(—)1 deposited with the ATCC under accession number 98623. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone nf87_(—)1 depositedwith the ATCC under accession number 98623. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:60having biological activity, the fragment preferably comprising eight(more preferably twenty, most preferably thirty) consecutive amino acidsof SEQ ID NO:60, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:60 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 47 to amino acid 56 of SEQ ID NO:60.

[1085] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:59.

[1086] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1087] (a) a process comprising the steps of:

[1088] (i) preparing one ormore polynucleotideprobes thathybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1089] (aa) SEQ ID NO:59, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:59; and

[1090] (ab) the nucleotide sequence of the cDNA insert of clonenf87_(—)1 deposited with the ATCC under accession number 98623;

[1091] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1092] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1093] (b) a process comprising the steps of:

[1094] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1095] (ba) SEQ ID NO:59, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:59; and

[1096] (bb) the nucleotide sequence of the cDNA insert of clonenf87_(—)1 deposited with the ATCC under accession number 98623;

[1097] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1098] (iii) amplifying human DNA sequences; and

[1099] (iv) isolating the polynucleotide products of step (b)(iii).

[1100] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:59, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:59 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:59 , but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:59. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59from nucleotide 673 to nucleotide 987, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:59 from nucleotide 673 to nucleotide 987, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:59 fromnucleotide 673 to nucleotide 987. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 868to nucleotide 987, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:59 fromnucleotide 868 to nucleotide 987, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:59 from nucleotide 868 tonucleotide 987.

[1101] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1102] (a) the amino acid sequence of SEQ ID NO:60;

[1103] (b) fragments of the amino acid sequence of SEQ ID NO:60, eachfragment comprising eight consecutive amino acids of SEQ ID NO:60; and

[1104] (c) the amino acid sequence encoded by the cDNA insert of clonenf87_(—)1 deposited with the ATCC under accession number 98623;

[1105] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:60. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:60 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:60, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:60 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 47 to amino acid 56 of SEQ ID NO:60.

[1106] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1107] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:61;

[1108] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:61 from nucleotide 57 to nucleotide 824;

[1109] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:61 from nucleotide 114 to nucleotide 824;

[1110] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nh796_(—)1 deposited withthe ATCC under accession number 98623;

[1111] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nh796_(—)1 deposited with the ATCC underaccession number 98623;

[1112] (i) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nh796_(—)1 deposited with theATCC under accession number 98623;

[1113] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nh796_(—)1 deposited with the ATCC under accessionnumber 98623;

[1114] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:62;

[1115] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:62 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:62;

[1116] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1117] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1118] (1) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1119] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:61 from nucleotide 57 to nucleotide 824; the nucleotidesequence of SEQ ID NO:61 from nucleotide 114 to nucleotide 824; thenucleotide sequence of the full-length protein coding sequence of clonenh796_(—)1 deposited with the ATCC under accession number 98623; or thenucleotide sequence of a mature protein coding sequence of clonenh796_(—)1 deposited with the ATCC under accession number 98623. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone nh796_(—)1deposited with the ATCC under accession number 98623. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:62 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:62, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:62having biological activity, the fragment comprising the amino acidsequence from amino acid 123 to amino acid 132 of SEQ ID NO:62.

[1120] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:61.

[1121] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1122] (a) a process comprising the steps of:

[1123] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1124] (aa) SEQ ID NO:61, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:61; and

[1125] (ab) the nucleotide sequence of the cDNA insert of clonenh796_(—)1 deposited with the ATCC under accession number 98623;

[1126] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1127] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1128] (b) a process comprising the steps of:

[1129] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1130] (ba) SEQ ID NO:61, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:61; and

[1131] (bb) the nucleotide sequence of the cDNA insert of clonenh796_(—)1 deposited with the ATCC under accession number 98623;

[1132] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1133] (iii) amplifying human DNA sequences; and

[1134] (iv) isolating the polynucleotide products of step (b)(iii).

[1135] Preferably the polvnucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:61, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:61 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:61, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:61. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61from nucleotide 57 to nucleotide 824, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:61 from nucleotide 57 to nucleotide 824, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:61 fromnucleotide 57 to nucleotide 824. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 114to nucleotide 824, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:61 fromnucleotide 114 to nucleotide 824, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:61 from nucleotide 114 tonucleotide 824.

[1136] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1137] (a) the amino acid sequence of SEQ ID NO:62;

[1138] (b) fragments of the amino acid sequence of SEQ ID NO:62, eachfragment comprising eight consecutive amino acids of SEQ ID NO:62; and

[1139] (c) the amino acid sequence encoded by the cDNA insert of clonenh796_(—)1 deposited with the ATCC under accession number 98623;

[1140] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:62. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:62 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:62, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:62 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 123 to amino acid 132 of SEQ ID NO:62.

[1141] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1142] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:63;

[1143] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:63 from nucleotide 297 to nucleotide 542;

[1144] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:63 from nucleotide 510 to nucleotide 542;

[1145] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nn229_(—)1 deposited withthe ATCC under accession number 98623;

[1146] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nn229_(—)1 deposited with the ATCC underaccession number 98623;

[1147] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nn229_(—)1 deposited with theATCC under accession number 98623;

[1148] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nn229_(—)1 deposited with the ATCC under accessionnumber 98623;

[1149] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:64;

[1150] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:64 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:64;

[1151] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1152] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1153] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1154] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:63 from nucleotide 297 to nucleotide 542; the nucleotidesequence of SEQ ID NO:63 from nucleotide 510 to nucleotide 542; thenucleotide sequence of the full-length protein coding sequence of clonenn229_(—)1 deposited with the ATCC under accession number 98623; or thenucleotide sequence of a mature protein coding sequence of clonenn229_(—)1 deposited with the ATCC under accession number 98623. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone nn229_(—)1deposited with the ATCC under accession number 98623. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:64 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:64, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:64having biological activity, the fragment comprising the amino acidsequence from amino acid 36 to amino acid 45 of SEQ ID NO:64.

[1155] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:63.

[1156] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1157] (a) a process comprising the steps of:

[1158] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1159] (aa) SEQ ID NO:63, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:63; and

[1160] (ab) the nucleotide sequence of the cDNA insert of clonenn229_(—)1 deposited with the ATCC under accession number 98623;

[1161] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1162] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1163] (b) a process comprising the steps of:

[1164] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1165] (ba) SEQ ID NO:63, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:63; and

[1166] (bb) the nucleotide sequence of the cDNA insert of clonenn229_(—)1 deposited with the ATCC under accession number 98623;

[1167] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1168] (iii) amplifying human DNA sequences; and

[1169] (iv) isolating the polynucleotide products of step (b)(iii).

[1170] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:63, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:63 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:63, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:63. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63from nucleotide 297 to nucleotide 542, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:63 from nucleotide 297 to nucleotide 542, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:63 fromnucleotide 297 to nucleotide 542. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 510to nucleotide 542, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:63 fromnucleotide 510 to nucleotide 542, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:63 from nucleotide 510 tonucleotide 542.

[1171] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1172] (a) the amino acid sequence of SEQ ID NO:64;

[1173] (b) fragments of the amino acid sequence of SEQ ID NO:64, eachfragment comprising eight consecutive amino acids of SEQ ID NO:64; and

[1174] (c) the amino acid sequence encoded by the cDNA insert of clonenn229_(—)1 deposited with the ATCC under accession number 98623;

[1175] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:64. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:64 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:64, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:64 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 36 to amino acid 45 of SEQ ID NO:64.

[1176] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1177] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:65;

[1178] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:65 from nucleotide 547 to nucleotide 750;

[1179] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:65 from nucleotide 601 to nucleotide 750;

[1180] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone np156_(—)1 deposited withthe ATCC under accession number 98623;

[1181] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone np156_(—)1 deposited with the ATCC underaccession number 98623;

[1182] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone np156_(—)1 deposited with theATCC under accession number 98623;

[1183] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone np156_(—)1 deposited with the ATCC under accessionnumber 98623;

[1184] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:66;

[1185] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:66 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:66;

[1186] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1187] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1188] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1189] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:65 from nucleotide 547 to nucleotide 750; the nucleotidesequence of SEQ ID NO:65 from nucleotide 601 to nucleotide 750; thenucleotide sequence of the full-length protein coding sequence of clonenp156_(—)1 deposited with the ATCC under accession number 98623; or thenucleotide sequence of a mature protein coding sequence of clonenp156_(—)1 deposited with the ATCC under accession number 98623. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone np156_(—)1deposited with the ATCC under accession number 98623. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:66 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:66, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:66having biological activity, the fragment comprising the amino acidsequence from amino acid 29 to amino acid 38 of SEQ ID NO:66.

[1190] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:65.

[1191] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1192] (a) a process comprising the steps of:

[1193] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1194] (aa) SEQ ID NO:65, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:65; and

[1195] (ab) the nucleotide sequence of the cDNA insert of clonenp156_(—)1 deposited with the ATCC under accession number 98623;

[1196] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1197] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1198] (b) a process comprising the steps of:

[1199] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1200] (ba) SEQ ID NO:65, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:65; and

[1201] (bb) the nucleotide sequence of the cDNA insert of clonenp156_(—)1 deposited with the ATCC under accession number 98623;

[1202] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4(SSC at 65 degrees C;

[1203] (iii) amplifying human DNA sequences; and

[1204] (iv) isolating the polynucleotide products of step (b)(iii).

[1205] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:65, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:65 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:65, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:65. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65from nucleotide 547 to nucleotide 750, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:65 from nucleotide 547 to nucleotide 750, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:65 fromnucleotide 547 to nucleotide 750. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 601to nucleotide 750, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:65 fromnucleotide 601 to nucleotide 750, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:65 from nucleotide 601 tonucleotide 750.

[1206] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1207] (a) the amino acid sequence of SEQ ID NO:66;

[1208] (b) fragments of the amino acid sequence of SEQ ID NO:66, eachfragment comprising eight consecutive amino acids of SEQ ID NO:66; and

[1209] (c) the amino acid sequence encoded by the cDNA insert of clonenp156_(—)1 deposited with the ATCC under accession number 98623;

[1210] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:66. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:66 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:66, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:66 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 29 to amino acid 38 of SEQ ID NO:66.

[1211] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1212] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:67;

[1213] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:67 from nucleotide 310 to nucleotide 459;

[1214] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:67 from nucleotide 445 to nucleotide 459;

[1215] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bg570_(—)1 deposited withthe ATCC under accession number 98629;

[1216] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bg570_(—)1 deposited with the ATCC underaccession number 98629;

[1217] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bg570_(—)1 deposited with theATCC under accession number 98629;

[1218] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bg570_(—)1 deposited with the ATCC under accessionnumber 98629;

[1219] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:68;

[1220] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:68 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:68;

[1221] (j) a polynucleotide which is an allelic variant of apolynudeotide of (a)-(g) above;

[1222] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1223] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1224] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:67 from nucleotide 310 to nucleotide 459; the nucleotidesequence of SEQ ID NO:67 from nucleotide 445 to nucleotide 459; thenucleotide sequence of the full-length protein coding sequence of clonebg570_(—)1 deposited with the ATCC under accession number 98629; or thenucleotide sequence of a mature protein coding sequence of clonebg570_(—)1 deposited with the ATCC under accession number 98629. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone bg570_(—)1deposited with the ATCC under accession number 98629. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:68 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:68, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:68having biological activity, the fragment comprising the amino acidsequence from amino acid 20 to amino acid 29 of SEQ ID NO:68.

[1225] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:67.

[1226] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1227] (a) a process comprising the steps of:

[1228] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1229] (aa) SEQ ID NO:67, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:67; and

[1230] (ab) the nucleotide sequence of the cDNA insert of clonebg570_(—)1 deposited with the ATCC under accession number 98629;

[1231] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1232] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1233] (b) a process comprising the steps of:

[1234] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1235] (ba) SEQ ID NO:67, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:67; and

[1236] (bb) the nucleotide sequence of the cDNA insert of clonebg570_(—)1 deposited with the ATCC under accession number 98629;

[1237] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1238] (iii) amplifying human DNA sequences; and

[1239] (iv) isolating the polynucleotide products of step (b)(iii).

[1240] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:67, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:67 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NQ:67, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:67. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67from nucleotide 310 to nucleotide 459, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:67 from nucleotide 310 to nucleotide 459, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:67 fromnucleotide 310 to nucleotide 459. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 445to nucleotide 459, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:67 fromnucleotide 445 to nucleotide 459, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:67 from nucleotide 445 tonucleotide 459.

[1241] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamnino acid sequence selected from the group consisting of:

[1242] (a) the amino acid sequence of SEQ ID NO:68;

[1243] (b) fragments of the amino acid sequence of SEQ ID NO:68, eachfragment comprising eight consecutive amino acids of SEQ ID NO:68; and

[1244] (c) the amino acid sequence encoded by the cDNA insert of clonebg570_(—)1 deposited with the ATCC under accession number 98629;

[1245] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:68. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:68 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:68, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:68 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 20 to amino acid 29 of SEQ ID NO:68.

[1246] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1247] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:69;

[1248] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:69 from nucleotide 90 to nucleotide 1019;

[1249] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:69 from nucleotide 243 to nucleotide 1019;

[1250] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bi120_(—)2 deposited withthe ATCC under accession number 98629;

[1251] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bi120_(—)2 deposited with the ATCC underaccession number 98629;

[1252] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bi120_(—)2 deposited with theATCC under accession number 98629;

[1253] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bi120_(—)2 deposited with the ATCC under accessionnumber 98629;

[1254] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:70;

[1255] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:70 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:70;

[1256] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1257] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1258] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1259] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:69 from nucleotide 90 to nucleotide 1019; the nucleotidesequence of SEQ ID NO:69 from nucleotide 243 to nucleotide 1019; thenucleotide sequence of the full-length protein coding sequence of clonebi120_(—)2 deposited with the ATCC under accession number 98629; or thenucleotide sequence of a mature protein coding sequence of clonebi120_(—)2 deposited with the ATCC under accession number 98629. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone bi120_(—)2deposited with the ATCC under accession number 98629. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:70 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:70, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:70having biological activity, the fragment comprising the amino acidsequence from amino acid 149 to amino acid 158 of SEQ ID NO:70.

[1260] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:69.

[1261] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1262] (a) a process comprising the steps of:

[1263] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1264] (aa) SEQ ID NO:69, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:69; and

[1265] (ab) the nucleotide sequence of the cDNA insert of clonebi120_(—)2 deposited with the ATCC under accession number 98629;

[1266] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1267] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1268] (b) a process comprising the steps of:

[1269] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1270] (ba) SEQ ID NO:69, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:69; and

[1271] (bb) the nucleotide sequence of the cDNA insert of clonebi120_(—)2 deposited with the ATCC under accession number 98629;

[1272] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1273] (iii) amplifying human DNA sequences; and

[1274] (iv) isolating the polynucleotide products of step (b)(iii).

[1275] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:69, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:69 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:69, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:69. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69from nucleotide 90 to nucleotide 1019, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:69 from nucleotide 90 to nucleotide 1019, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:69 fromnucleotide 90 to nucleotide 1019. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:69 from nucleotide 243to nucleotide 1019, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of said sequence of SEQ ID NO:69from nucleotide 243 to nucleotide 1019, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:69 fromnucleotide 243 to nucleotide 1019.

[1276] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1277] (a) the amino acid sequence of SEQ ID NO:70;

[1278] (b) fragments of the amino acid sequence of SEQ ID NO:70, eachfragment comprising eight consecutive amino acids of SEQ ID NO:70; and

[1279] (c) the amino acid sequence encoded by the cDNA insert of clonebi120_(—)2 deposited with the ATCC under accession number 98629;

[1280] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:70. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:70 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:70, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:70 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 149 to amino acid 158 of SEQ ID NO:70.

[1281] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1282] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:71;

[1283] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:71 from nucleotide 682 to nucleotide 894;

[1284] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bn594_(—)1 deposited withthe ATCC under accession number 98629;

[1285] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bn594_(—)1 deposited with the ATCC underaccession number 98629;

[1286] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bn594_(—)1 deposited with theATCC under accession number 98629;

[1287] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bn594_(—)1 deposited with the ATCC under accessionnumber 98629;

[1288] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:72;

[1289] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:72 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:72;

[1290] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[1291] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[1292] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[1293] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:71 from nucleotide 682 to nucleotide 894; the nucleotidesequence of the full-length protein coding sequence of clone bn594_(—)1deposited with the ATCC under accession number 98629; or the nucleotidesequence of a mature protein coding sequence of clone bn594_(—)1deposited with the ATCC under accession number 98629. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone bn594_(—)1 deposited withthe ATCC under accession number 98629. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:72 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:72, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:72 having biologicalactivity, the fragment comprising the armino acid sequence from aminoacid 30 to amino acid 39 of SEQ ID NO:72.

[1294] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:71.

[1295] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1296] (a) a process comprising the steps of:

[1297] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1298] (aa) SEQ ID NO:71, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:71; and

[1299] (ab) the nucleotide sequence of the cDNA insert of clonebn594_(—)1 deposited with the ATCC under accession number 98629;

[1300] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1301] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1302] (b) a process comprising the steps of:

[1303] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1304] (ba) SEQ ID NO:71, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:71; and

[1305] (bb) the nucleotide sequence of the cDNA insert of clonebn594_(—)1 deposited with the ATCC under accession number 98629;

[1306] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1307] (iii) amplifying human DNA sequences; and

[1308] (iv) isolating the polynucleotide products of step (b)(iii).

[1309] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:71, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:71 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:71 , but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:71. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71from nucleotide 682 to nucleotide 894, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:71 from nucleotide 682 to nucleotide 894, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:71 fromnucleotide 682 to nucleotide 894.

[1310] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1311] (a) the amino acid sequence of SEQ ID NO:72;

[1312] (b) fragments of the amino acid sequence of SEQ ID NO:72, eachfragment comprising eight consecutive amino acids of SEQ ID NO:72; and

[1313] (c) the amino acid sequence encoded by the cDNA insert of clonebn594_(—)1 deposited with the ATCC under accession number 98629;

[1314] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:72. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:72 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:72, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:72 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 30 to amino acid 39 of SEQ ID NO:72.

[1315] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1316] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:73;

[1317] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:73 from nucleotide 1184 to nucleotide 1582;

[1318] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:73 from nucleotide 1265 to nucleotide 1582;

[1319] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone en554_(—)1 deposited withthe ATCC under accession number 98629;

[1320] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone en554_(—)1 deposited with the ATCC underaccession number 98629;

[1321] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone en554_(—)1 deposited with theATCC under accession number 98629;

[1322] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone en554_(—)1 deposited with the ATCC under accessionnumber 98629;

[1323] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:74;

[1324] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:74 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:74;

[1325] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1326] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1327] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1328] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:73 from nucleotide 1184 to nucleotide 1582; the nucleotidesequence of SEQ ID NO:73 from nucleotide 1265 to nucleotide 1582; thenucleotide sequence of the full-length protein coding sequence of cloneen554_(—)1 deposited with the ATCC under accession number 98629; or thenucleotide sequence of a mature protein coding sequence of cloneen554_(—)1 deposited with the ATCC under accession number 98629. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone en554_(—)1deposited with the ATCC under accession number 98629. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:74 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:74, or a polynucleotide encoding aprotein comprising a fragment of the amnino acid sequence of SEQ IDNO:74 having biological activity, the fragment comprising the amino acidsequence from amino acid 61 to amino acid 70 of SEQ ID NO:74.

[1329] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:73.

[1330] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1331] (a) a process comprising the steps of:

[1332] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1333] (aa) SEQ ID NO:73, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:73; and

[1334] (ab) the nucleotide sequence of the cDNA insert of cloneen554_(—)1 deposited with the ATCC under accession number 98629;

[1335] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1336] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1337] (b) a process comprising the steps of:

[1338] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1339] (ba) SEQ ID NO:73, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:73; and

[1340] (bb) the nucleotide sequence of the cDNA insert of clone en554 1deposited with the ATCC under accession number 98629;

[1341] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1342] (iii) amplifying human DNA sequences; and

[1343] (iv) isolating the polynucleotide products of step (b)(iii).

[1344] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:73, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:73 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:73, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:73. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73from nucleotide 1184 to nucleotide 1582, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:73 from nucleotide 1184 to nucleotide 1582, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:73from nucleotide 1184 to nucleotide 1582. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73from nucleotide 1265 to nucleotide 1582, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:73 from nucleotide 1265 to nucleotide 1582, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:73from nucleotide 1265 to nucleotide 1582.

[1345] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1346] (a) the amino acid sequence of SEQ ID NO:74;

[1347] (b) fragments of the amino acid sequence of SEQ ID NO:74, eachfragment comprising eight consecutive amino acids of SEQ ID NO:74; and

[1348] (c) the amino acid sequence encoded by the cDNA insert of cloneen554_(—)1 deposited with the ATCC under accession number 98629;

[1349] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:74. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:74 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:74, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:74 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 61 to amino acid 70 of SEQ ID NO:74.

[1350] In one embodiment, the present invention provides a compositioncomprising an isolated polvnucleotide selected from the group consistingof:

[1351] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:75;

[1352] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:75 from nucleotide 79 to nucleotide 504;

[1353] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:75 from nucleotide 322 to nucleotide 504;

[1354] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone na474_(—)10 deposited withthe ATCC under accession number 98629;

[1355] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone na474_(—)10 deposited with the ATCC underaccession number 98629;

[1356] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone na474_(—)10 deposited with theATCC under accession number 98629;

[1357] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone na474_(—)10 deposited with the ATCC under accessionnumber 98629;

[1358] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:76;

[1359] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:76 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:76;

[1360] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1361] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1362] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1363] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:75 from nucleotide 79 to nucleotide 504; the nucleotidesequence of SEQ ID NO:75 from nucleotide 322 to nucleotide 504; thenucleotide sequence of the full-length protein coding sequence of clonena474_(—)10 deposited with the ATCC under accession number 98629; or thenucleotide sequence of a mature protein coding sequence of clonena474_(—)10 deposited with the ATCC under accession number 98629. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone na474_(—)10deposited with the ATCC under accession number 98629. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:76 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:76, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:76having biological activity, the fragment comprising the amino acidsequence from amino acid 66 to amino acid 75 of SEQ ID NO:76.

[1364] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:75.

[1365] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1366] (a) a process comprising the steps of:

[1367] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1368] (aa) SEQ ID NO:75, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:75; and

[1369] (ab) the nucleotide sequence of the cDNA insert of clonena474_(—)10 deposited with the ATCC under accession number 98629;

[1370] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1371] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1372] (b) a process comprising the steps of:

[1373] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1374] (ba) SEQ ID NO:75, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:75; and

[1375] (bb) the nucleotide sequence of the cDNA insert of clonena474_(—)10 deposited with the ATCC under accession number 98629;

[1376] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1377] (iii) amplifying human DNA sequences; and

[1378] (iv) isolating the polynucleotide products of step (b)(iii).

[1379] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:75, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:75 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:75, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:75. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75from nucleotide 79 to nucleotide 504, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:75 from nucleotide 79 to nucleotide 504, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:75 fromnucleotide 79 to nucleotide 504. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 322to nucleotide 504, and extending contiguously from a a-nucleotidesequence corresponding to the 5′ end of said sequence of SEQ ID NO:75from nucleotide 322 to nucleotide 504, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:75 fromnucleotide 322 to nucleotide 504.

[1380] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1381] (a) the amino acid sequence of SEQ ID NO:76;

[1382] (b) fragments of the amino acid sequence of SEQ ID NO:76, eachfragment comprising eight consecutive amino acids of SEQ ID NO:76; and

[1383] (c) the amino acid sequence encoded by the cDNA insert of clonena474_(—)10 deposited with the ATCC under accession number 98629;

[1384] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:76. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:76 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:76, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:76 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 66 to amino acid 75 of SEQ ID NO:76.

[1385] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1386] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:77;

[1387] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:77 from nucleotide 92 to nucleotide 1435;

[1388] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:77 from nucleotide 170 to nucleotide 1435;

[1389] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nn16_(—)10 deposited withthe ATCC under accession number 98629;

[1390] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nn16_(—)10 deposited with the ATCC underaccession number 98629;

[1391] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nn16_(—)10 deposited with theATCC under accession number 98629;

[1392] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nn16_(—)10 deposited with the ATCC under accessionnumber 98629;

[1393] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:78;

[1394] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:78 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:78;

[1395] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1396] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1397] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1398] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:77 from nucleotide 92 to nucleotide 1435; the nucleotidesequence of SEQ ID NO:77 from nucleotide 170 to nucleotide 1435; thenucleotide sequence of the full-length protein coding sequence of clonenn16_(—)10 deposited with the ATCC under accession number 98629; or thenucleotide sequence of a mature protein coding sequence of clonenn16_(—)10 deposited with the ATCC under accession number 98629. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone nn16_(—)10deposited with the ATCC under accession number 98629. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:78 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:78, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:78having biological activity, the fragment comprising the amino acidsequence from amino acid 218 to amino acid 227 of SEQ ID NO:78.

[1399] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:77.

[1400] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1401] (a) a process comprising the steps of:

[1402] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1403] (aa) SEQ ID NO:77, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:77; and

[1404] (ab) the nucleotide sequence of the cDNA insert of clonenn16_(—)10 deposited with the ATCC under accession number 98629;

[1405] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1406] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1407] (b) a process comprising the steps of:

[1408] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1409] (ba) SEQ ID NO:77, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:77; and

[1410] (bb) the nucleotide sequence of the cDNA insert of clonenn16_(—)10 deposited with the ATCC under accession number 98629;

[1411] (ii) hybridizing said primer(s) to human genornic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1412] (iii) amplifying human DNA sequences; and

[1413] (iv) isolating the polynucleotide products of step (b)(iii).

[1414] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:77, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:77 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:77, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:77. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77from nucleotide 92 to nucleotide 1435, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:77 from nucleotide 92 to nucleotide 1435, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:77 fromnucleotide 92 to nucleotide 1435. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 170to nucleotide 1435, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of said sequence of SEQ ID NO:77from nucleotide 170 to nucleotide 1435, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:77 fromnucleotide 170 to nucleotide 1435.

[1415] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1416] (a) the amino acid sequence of SEQ ID NO:78;

[1417] (b) fragments of the amino acid sequence of SEQ ID NO:78, eachfragment comprising eight consecutive amino acids of SEQ ID NO:78; and

[1418] (c) the amino acid sequence encoded by the cDNA insert of clonenn16_(—)10 deposited with the ATCC under accession number 98629;

[1419] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:78. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:78 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:78, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:78 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 218 to amino acid 227 of SEQ ID NO:78.

[1420] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1421] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:79;

[1422] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:79 from nucleotide 1567 to nucleotide 1809;

[1423] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:79 from nucleotide 1726 to nucleotide 1809;

[1424] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone np189_(—)9 deposited withthe ATCC under accession number 98629;

[1425] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone np189_(—)9 deposited with the ATCC underaccession number 98629;

[1426] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone np189_(—)9 deposited with theATCC under accession number 98629;

[1427] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone np189_(—)9 deposited with the ATCC under accessionnumber 98629;

[1428] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:80;

[1429] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:80 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:80;

[1430] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1431] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1432] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1433] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:79 from nucleotide 1567 to nucleotide 1809; the nucleotidesequence of SEQ ID NO:79 from nucleotide 1726 to nucleotide 1809; thenucleotide sequence of the full-length protein coding sequence of clonenp189_(—)9 deposited with the ATCC under accession number 98629; or thenucleotide sequence of a mature protein coding sequence of clonenp189_(—)9 deposited with the ATCC under accession number 98629. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone np189_(—)9deposited with the ATCC under accession number 98629. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:80 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO: 80, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:80having biological activity, the fragment comprising the amino acidsequence from amino acid 35 to amino acid 44 of SEQ ID NO:80.

[1434] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:79.

[1435] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1436] (a) a process comprising the steps of:

[1437] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1438] (aa) SEQ ID NO:79, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:79; and

[1439] (ab) the nucleotide sequence of the cDNA insert of clonenp189_(—)9 deposited with the ATCC under accession number 98629;

[1440] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1441] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1442] (b) a process comprising the steps of:

[1443] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1444] (ba) SEQ ID NO:79, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:79; and

[1445] (bb) the nucleotide sequence of the cDNA insert of clonenp189_(—)9 deposited with the ATCC under accession number 98629;

[1446] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1447] (iii) amplifying human DNA sequences; and

[1448] (iv) isolating the polynucleotide products of step (b)(iii).

[1449] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:79, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:79 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:79, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:79. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79from nucleotide 1567 to nucleotide 1809, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:79 from nucleotide 1567 to nucleotide 1809, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:79from nucleotide 1567 to nucleotide 1809. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79from nucleotide 1726 to nucleotide 1809, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:79 from nucleotide 1726 to nucleotide 1809, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:79from nucleotide 1726 to nucleotide 1809.

[1450] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1451] (a) the amino acid sequence of SEQ ID NO:80;

[1452] (b) fragments of the amino acid sequence of SEQ ID NO:80, eachfragment comprising eight consecutive amino acids of SEQ ID NO:80; and

[1453] (c) the amino acid sequence encoded by the cDNA insert of clonenp189_(—)9 deposited with the ATCC under accession number 98629;

[1454] the protein being substantially free from other marunalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:80. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:80 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:80, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:80 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 35 to amino acid 44 of SEQ ID NO:80.

[1455] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1456] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:81;

[1457] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:81 from nucleotide 2054 to nucleotide 2206;

[1458] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ny226_(—)1 deposited withthe ATCC under accession number 98629;

[1459] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ny226_(—)1 deposited with the ATCC underaccession number 98629;

[1460] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ny226_(—)1 deposited with theATCC under accession number 98629;

[1461] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ny226_(—)1 deposited with the ATCC under accessionnumber 98629;

[1462] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:82;

[1463] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:82 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:82;

[1464] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[1465] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[1466] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[1467] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:81 from nucleotide 2054 to nucleotide 2206; the nucleotidesequence of the full-length protein coding sequence of clone ny226_(—)1deposited with the ATCC under accession number 98629; or the nucleotidesequence of a mature protein coding sequence of clone ny226_(—)1deposited with the ATCC under accession number 98629. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone ny226_(—)1 deposited withthe ATCC under accession number 98629. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:82 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:82, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:82 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 20 to amino acid 29 of SEQ ID NO:82.

[1468] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:81.

[1469] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1470] (a) a process comprising the steps of:

[1471] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1472] (aa) SEQ ID NO:81, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:81; and

[1473] (ab) the nucleotide sequence of the cDNA insert of cloneny226_(—)1 deposited with the ATCC under accession number 98629;

[1474] (ii) hybridizing said probe(s) to human genomnic DNA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[1475] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1476] (b) a process comprising the steps of:

[1477] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1478] (ba) SEQ ID NO:81, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:81; and

[1479] (bb) the nucleotide sequence of the cDNA insert of cloneny226_(—)1 deposited with the ATCC under accession number 98629;

[1480] (ii) hybridizing said primer(s) to human genornic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1481] (iii) amplifying human DNA sequences; and

[1482] (iv) isolating the polynucleotide products of step (b)(iii).

[1483] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:81, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:81 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:81, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:81. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81from nucleotide 2054 to nucleotide 2206, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:81 from nucleotide 2054 to nucleotide 2206, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:81from nucleotide 2054 to nucleotide 2206.

[1484] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1485] (a) the amino acid sequence of SEQ ID NO:82;

[1486] (b) fragments of the amino acid sequence of SEQ ID NO:82, eachfragment comprising eight consecutive amino acids of SEQ ID NO:82; and

[1487] (c) the amino acid sequence encoded by the cDNA insert of cloneny226_(—)1 deposited with the ATCC under accession number 98629;

[1488] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:82. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:82 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:82, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:82 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 20 to amino acid 29 of SEQ ID NO:82.

[1489] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1490] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:83;

[1491] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:83 from nucleotide 567 to nucleotide 701;

[1492] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pe159_(—)1 deposited withthe ATCC under accession number 98629;

[1493] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pe159_(—)1 deposited with the ATCC underaccession number 98629;

[1494] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pe159_(—)1 deposited with theATCC under accession number 98629;

[1495] (e) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pe159_(—)1 deposited with the ATCC under accessionnumber 98629;

[1496] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:84;

[1497] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:84 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:84;

[1498] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[1499] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[1500] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[1501] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:83 from nucleotide 567 to nucleotide 701; the nucleotidesequence of the full-length protein coding sequence of clone pe159_(—)1deposited with the ATCC under accession number 98629; or the nucleotidesequence of a mature protein coding sequence of clone pe159_(—)1deposited with the ATCC under accession number 98629. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone pe159_(—)1 deposited withthe ATCC under accession number 98629. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:84 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:84, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:84 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 17 to amino acid 26 of SEQ ID NO:84.

[1502] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:83.

[1503] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1504] (a) a process comprising the steps of:

[1505] (i) preparing one ormorepolynucleotide probes thathybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1506] (aa) SEQ ID NO:83, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:83; and

[1507] (ab) the nucleotide sequence of the cDNA insert of clonepe159_(—)1 deposited with the ATCC under accession number 98629;

[1508] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1509] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1510] (b) a process comprising the steps of:

[1511] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1512] (ba) SEQ ID NO:83, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:83; and

[1513] (bb) the nucleotide sequence of the cDNA insert of clonepe159_(—)1 deposited with the ATCC under accession number 98629;

[1514] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1515] (iii) amplifying human DNA sequences; and

[1516] (iv) isolating the polynucleotide products of step (b)(iii).

[1517] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:83, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:83 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:83, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:83. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83from nucleotide 567 to nucleotide 701, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:83 from nucleotide 567 to nucleotide 701, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:83 fromnucleotide 567 to nucleotide 701.

[1518] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1519] (a) the amino acid sequence of SEQ ID NO:84;

[1520] (b) fragments of the amino acid sequence of SEQ ID NO:84, eachfragment comprising eight consecutive amino acids of SEQ ID NO:84; and

[1521] (c) the amino acid sequence encoded by the cDNA insert of clonepe159_(—)1 deposited with the ATCC under accession number 98629;

[1522] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:84. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:84 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:84, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:84 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 17 to amino acid 26 of SEQ ID NO:84.

[1523] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1524] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:85;

[1525] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:85 from nucleotide 593 to nucleotide 784;

[1526] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:85 from nucleotide 698 to nucleotide 784;

[1527] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pj314_(—)8 deposited withthe ATCC under accession number 98629;

[1528] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pj314_(—)8 deposited with the ATCC underaccession number 98629;

[1529] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pj314_(—)8 deposited with theATCC under accession number 98629;

[1530] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pj314_(—)8 deposited with the ATCC under accessionnumber 98629;

[1531] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:86;

[1532] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:86 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:86;

[1533] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1534] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1535] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1536] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:85 from nucleotide 593 to nucleotide 784; the nucleotidesequence of SEQ ID NO:85 from nucleotide 698 to nucleotide 784; thenucleotide sequence of the full-length protein coding sequence of clonepj314_(—)8 deposited with the ATCC under accession number 98629; or thenucleotide sequence of a mature protein coding sequence of clonepj314_(—)8 deposited with the ATCC under accession number 98629. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone pj314_(—)8deposited with the ATCC under accession number 98629. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:86 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:86, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:86having biological activity, the fragment comprising the amino acidsequence from amino acid 27 to amino acid 36 of SEQ ID NO:86.

[1537] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:85.

[1538] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1539] (a) a process comprising the steps of:

[1540] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1541] (aa) SEQ ID NO:85, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:85; and

[1542] (ab) the nucleotide sequence of the cDNA insert of clonepj314_(—)8 deposited with the ATCC under accession number 98629;

[1543] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1544] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1545] (b) a process comprising the steps of:

[1546] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1547] (ba) SEQ ID NO:85, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:85; and

[1548] (bb) the nucleotide sequence of the cDNA insert of clonepj314_(—)8 deposited with the ATCC under accession number 98629;

[1549] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1550] (iii) amplifying human DNA sequences; and

[1551] (iv) isolating the polynucleotide products of step (b)(iii).

[1552] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:85, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:85 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:85, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:85. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:85fromnucleotide 593 tonucleotide 784, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:85 from nucleotide 593 to nucleotide 784, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:85 fromnucleotide 593 to nucleotide 784. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:85 from nucleotide 698to nucleotide 784, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:85 fromnucleotide 698 to nucleotide 784, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:85 from nucleotide 698 tonucleotide 784.

[1553] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1554] (a) the amino acid sequence of SEQ ID NO:86;

[1555] (b) fragments of the amino acid sequence of SEQ ID NO:86, eachfragment comprising eight consecutive amino acids of SEQ ID NO:86; and

[1556] (c) the amino acid sequence encoded by the cDNA insert of clonepj314_(—)8 deposited with the ATCC under accession number 98629;

[1557] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:86. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:86 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:86, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:86 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 27 to amino acid 36 of SEQ ID NO:86.

[1558] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1559] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:87;

[1560] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:87 from nucleotide 176 to nucleotide 328;

[1561] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:87 from nucleotide 239 to nucleotide 328;

[1562] (d) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:87 from nucleotide 1 to nucleotide 512;

[1563] (e) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bp870_(—)1 deposited withthe ATCC under accession number 98724;

[1564] (f) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bp870_(—)1 deposited with the ATCC underaccession number 98724;

[1565] (g) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bp870_(—)1 deposited with theATCC under accession number 98724;

[1566] (h) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bp870_(—)1 deposited with the ATCC under accessionnumber 98724;

[1567] (i) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:88;

[1568] (j) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:88 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:88;

[1569] (k) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(h) above;

[1570] (l) a polynucleotide which encodes a species homologue of theprotein of (i) or (j) above; and

[1571] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(j).

[1572] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:87 from nucleotide 176 to nucleotide 328; the nucleotidesequence of SEQ ID NO:87 from nucleotide 239 to nucleotide 328; thenucleotide sequence of SEQ ID NO:87 from nucleotide 1 to nucleotide 512;the nucleotide sequence of the full-length protein coding sequence ofclone bp870_(—)1 deposited with the ATCC under accession number 98724;or the nucleotide sequence of a mature protein coding sequence of clonebp870_(—)1 deposited with the ATCC under accession number 98724. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone bp870_(—)1deposited with the ATCC under accession number 98724. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:88 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:88, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:88having biological activity, the fragment comprising the amino acidsequence from amino acid 20 to amino acid 29 of SEQ ID NO:88.

[1573] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:87.

[1574] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1575] (a) a process comprising the steps of:

[1576] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1577] (aa) SEQ ID NO:87, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:87; and

[1578] (ab) the nucleotide sequence of the cDNA insert of clonebp870_(—)1 deposited with the ATCC under accession number 98724;

[1579] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1580] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1581] (b) a process comprising the steps of:

[1582] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1583] (ba) SEQ ID NO:87, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:87; and

[1584] (bb) the nucleotide sequence of the cDNA insert of clonebp870_(—)1 deposited with the ATCC under accession number 98724;

[1585] (ii) hybridizing said primer(s) to human genormic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1586] (iii) amplifying human DNA sequences; and

[1587] (iv) isolating the polynucleotide products of step (b)(iii).

[1588] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:87, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:87 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:87, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:87. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87from nucleotide 176 to nucleotide 328, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:87 from nucleotide 176 to nucleotide 328, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:87 fromnucleotide 176 to nucleotide 328. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:87 from nucleotide 239to nucleotide 328, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:87 fromnucleotide 239 to nucleotide 328, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:87 from nucleotide 239 tonucleotide 328. Also preferably the polynucleotide isolated according tothe above process comprises a nucleotide sequence corresponding to thecDNA sequence of SEQ ID NO:87 from nucleotide 1 to nucleotide 512, andextending contiguously from a nucleotide sequence corresponding to the5′ end of said sequence of SEQ ID NO:87 from nucleotide 1 to nucleotide512, to a nucleotide sequence corresponding to the 3′ end of saidsequence of SEQ ID NO:87 from nucleotide 1 to nucleotide 512.

[1589] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1590] (a) the amino acid sequence of SEQ ID NO:88;

[1591] (b) fragments of the amino acid sequence of SEQ ID NO:88, eachfragment comprising eight consecutive amino acids of SEQ ID NO:88; and

[1592] (c) the amino acid sequence encoded by the cDNA insert of clonebp870_(—)1 deposited with the ATCC under accession number 98724;

[1593] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:88. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:88 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:88, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:88 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 20 to amino acid 29 of SEQ ID NO:88.

[1594] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1595] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:89;

[1596] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:89 from nucleotide 15 to nucleotide 749;

[1597] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:89 from nucleotide 141 to nucleotide 749;

[1598] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bx141_(—)2 deposited withthe ATCC under accession number 98630;

[1599] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bx141_(—)2 deposited with the ATCC underaccession number 98630;

[1600] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bx141_(—)2 deposited with theATCC under accession number 98630;

[1601] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bx141_(—)2 deposited with the ATCC under accessionnumber 98630;

[1602] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:90;

[1603] (i) a polynucleotide encoding a protein comprising a fragment ofthe amnino acid sequence of SEQ ID NO:90 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:90;

[1604] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1605] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1606] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1607] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:89 from nucleotide 15 to nucleotide 749; the nucleotidesequence of SEQ ID NO:89 from nucleotide 141 to nucleotide 749; thenucleotide sequence of the full-length protein coding sequence of clonebx141_(—)2 deposited with the ATCC under accession number 98630; or thenucleotide sequence of a mature protein coding sequence of clonebx141_(—)2 deposited with the ATCC under accession number 98630. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone bx141_(—)2deposited with the ATCC under accession number 98630. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:90from amino acid 1 to amino acid 122. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:90 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:90, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:90 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 117 to amino acid 126 of SEQ ID NO:90.

[1608] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:89.

[1609] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1610] (a) a process comprising the steps of:

[1611] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1612] (aa) SEQ ID NO:89, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:89; and

[1613] (ab) the nucleotide sequence of the cDNA insert of clonebx141_(—)2 deposited with the ATCC under accession number 98630;

[1614] (ii) hybridizing said probe(s) to human genomiic DNA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[1615] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1616] (b) a process comprising the steps of:

[1617] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1618] (ba) SEQ ID NO:89, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:89; and

[1619] (bb) the nucleotide sequence of the cDNA insert of clonebx141_(—)2 deposited with the ATCC under accession number 98630;

[1620] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1621] (iii) amplifying human DNA sequences; and

[1622] (iv) isolating the polynucleotide products of step (b)(iii).

[1623] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:89, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:89 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:89, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:89. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89from nucleotide 15 to nucleotide 749, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:89 from nucleotide 15 to nucleotide 749, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:89 fromnucleotide to nucleotide 749. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:89 from nucleotide 141to nucleotide 749, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:89 fromnucleotide 141 to nucleotide 749, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:89 from nucleotide 141 tonucleotide 749.

[1624] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1625] (a) the amino acid sequence of SEQ ID NO:90;

[1626] (b) the amino acid sequence of SEQ ID NO:90 from amino acid 1 toamino acid 122;

[1627] (c) fragments of the amino acid sequence of SEQ ID NO:90, eachfragment comprising eight consecutive amino acids of SEQ ID NO:90; and

[1628] (d) the amino acid sequence encoded by the cDNA insert of clonebx141_(—)2 deposited with the ATCC under accession number 98630;

[1629] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:90 or the amino acid sequence of SEQ ID NO:90 from amino acid1 to amino acid 122. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:90 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:90, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:90 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 117 to amino acid 126 of SEQ ID NO:90.

[1630] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1631] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:91;

[1632] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:91 from nucleotide 100 to nucleotide 1767;

[1633] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:91 from nucleotide 280 to nucleotide 1767;

[1634] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone cw272_(—)7 deposited withthe ATCC under accession number 98630;

[1635] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone cw272_(—)7 deposited with the ATCC underaccession number 98630;

[1636] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone cw272_(—)7 deposited with theATCC under accession number 98630;

[1637] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone cw272_(—)7 deposited with the ATCC under accessionnumber 98630;

[1638] (h) a polynucleotide encoding a protein comprising the amninoacid sequence of SEQ ID NO:92;

[1639] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:92 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:92;

[1640] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1641] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1642] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1643] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:91 from nucleotide 100 to nucleotide 1767; the nucleotidesequence of SEQ ID NO:91 from nucleotide 280 to nucleotide 1767; thenucleotide sequence of the full-length protein coding sequence of clonecw272_(—)7 deposited with the ATCC under accession number 98630; or thenucleotide sequence of a mature protein coding sequence of clonecw272_(—)7 deposited with the ATCC under accession number 98630. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone cw272_(—)7deposited with the ATCC under accession number 98630. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:92 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:92, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ ID NO:92having biological activity, the fragment comprising the amino acidsequence from amino acid 273 to amino acid 282 of SEQ ID NO:92.

[1644] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:91.

[1645] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1646] (a) a process comprising the steps of:

[1647] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1648] (aa) SEQ ID NO:91, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:91; and

[1649] (ab) the nucleotide sequence of the cDNA insert of clonecw272_(—)7 deposited with the ATCC under accession number 98630;

[1650] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1651] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1652] (b) a process comprising the steps of:

[1653] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1654] (ba) SEQ ID NO:91, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:91; and

[1655] (bb) the nucleotide sequence of the cDNA insert of clonecw272_(—)7 deposited with the ATCC under accession number 98630;

[1656] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1657] (iii) amplifying human DNA sequences; and

[1658] (iv) isolating the polynucleotide products of step (b)(iii).

[1659] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:91, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:91 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:91, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:91. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:91from nucleotide 100 to nucleotide 1767, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:91 from nucleotide 100 to nucleotide 1767, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:91from nucleotide 100 to nucleotide 1767. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:91from nucleotide 280 to nucleotide 1767, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:91 from nucleotide 280 to nucleotide 1767, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:91from nucleotide 280 to nucleotide 1767.

[1660] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1661] (a) the amino acid sequence of SEQ ID NO:92;

[1662] (b) fragments of the amino acid sequence of SEQ ID NO:92, eachfragment comprising eight consecutive amino acids of SEQ ID NO:92; and

[1663] (c) the amino acid sequence encoded by the cDNA insert of clonecw272_(—)7 deposited with the ATCC under accession number 98630;

[1664] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:92. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:92 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:92, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:92 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 273 to amino acid 282 of SEQ ID NO:92.

[1665] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1666] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:93;

[1667] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:93 from nucleotide 49 to nucleotide 1245;

[1668] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:93 from nucleotide 265 to nucleotide 1245;

[1669] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nh328_(—)5 deposited withthe ATCC under accession number 98630;

[1670] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nh328_(—)5 deposited with the ATCC underaccession number 98630;

[1671] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nh328_(—)5 deposited with theATCC under accession number 98630;

[1672] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nh328_(—)5 deposited with the ATCC under accessionnumber 98630;

[1673] (h) a polynucleotide encoding a protein comprising the arninoacid sequence of SEQ ID NO:94;

[1674] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:94 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:94;

[1675] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1676] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1677] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1678] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:93 from nucleotide 49 to nucleotide 1245; the nucleotidesequence of SEQ ID NO:93 from nucleotide 265 to nucleotide 1245; thenucleotide sequence of the full-length protein coding sequence of clonenh328_(—)5 deposited with the ATCC under accession number 98630; or thenucleotide sequence of a mature protein coding sequence of clonenh328_(—)5 deposited with the ATCC under accession number 98630. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone nh328_(—)5deposited with the ATCC under accession number 98630. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:94from amino acid 229 to amino acid 387. in further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:94 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:94, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:94 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 194 to amino acid 203 of SEQ ID NO:94.

[1679] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:93.

[1680] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1681] (a) a process comprising the steps of:

[1682] (i) preparing one ormore polynucleotide probes thathybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1683] (aa) SEQ ID NO:93, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:93; and

[1684] (ab) the nucleotide sequence of the cDNA insert of clonenh328_(—)5 deposited with the ATCC under accession number 98630;

[1685] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1686] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1687] (b) a process comprising the steps of:

[1688] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1689] (ba) SEQ ID NO:93, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:93; and

[1690] (bb) the nucleotide sequence of the cDNA insert of clonenh328_(—)5 deposited with the ATCC under accession number 98630;

[1691] (ii) hybridizing said primer(s) to human genomnic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1692] (iii) amplifying human DNA sequences; and

[1693] (iv) isolating the polynucleotide products of step (b)(iii).

[1694] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:93, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:93 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:93, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:93. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93from nucleotide 49 to nucleotide 1245, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:93 from nucleotide 49 to nucleotide 1245, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:93 fromnucleotide 49 to nucleotide 1245. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 265to nucleotide 1245, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of said sequence of SEQ ID NO:93from nucleotide 265 to nucleotide 1245, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:93 fromnucleotide 265 to nucleotide 1245.

[1695] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1696] (a) the amino acid sequence of SEQ ID NO:94;

[1697] (b) the amino acid sequence of SEQ ID NO:94 from amino acid 229to amino acid 387;

[1698] (c) fragments of the amino acid sequence of SEQ ID NO:94, eachfragment comprising eight consecutive amino acids of SEQ ID NO:94; and

[1699] (d) the amino acid sequence encoded by the cDNA insert of clonenh328_(—)5 deposited with the ATCC under accession number 98630;

[1700] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:94 or the amino acid sequence of SEQ ID NO:94 from amino acid229 to amino acid 387. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:94 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:94, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:94 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 194 to amino acid 203 of SEQ ID NO:94.

[1701] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1702] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:95;

[1703] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:95 from nucleotide 166 to nucleotide 552;

[1704] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nm214_(—)3 deposited withthe ATCC under accession number 98630;

[1705] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nm214_(—)3 deposited with the ATCC underaccession number 98630;

[1706] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nm214_(—)3 deposited with theATCC under accession number 98630;

[1707] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nm214_(—)3 deposited with the ATCC under accessionnumber 98630;

[1708] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:96;

[1709] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:96 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:96;

[1710] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[1711] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[1712] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[1713] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:95 from nucleotide 166 to nucleotide 552; the nucleotidesequence of the full-length protein coding sequence of clone nm214_(—)3deposited with the ATCC under accession number 98630; or the nucleotidesequence of a mature protein coding sequence of clone nm214_(—)3deposited with the ATCC under accession number 98630. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone nm214_(—)3 deposited withthe ATCC under accession number 98630. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:96 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:96, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:96 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 59 to amino acid 68 of SEQ ID NO:96.

[1714] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:95.

[1715] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1716] (a) a process comprising the steps of:

[1717] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1718] (aa) SEQ ID NO:95, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:95; and

[1719] (ab) the nucleotide sequence of the cDNA insert of clonenm214_(—)3 deposited with the ATCC under accession number 98630;

[1720] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1721] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1722] (b) a process comprising the steps of:

[1723] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1724] (ba) SEQ ID NO:95, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:95; and

[1725] (bb) the nucleotide sequence of the cDNA insert of clonenm214_(—)3 deposited with the ATCC under accession number 98630;

[1726] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1727] (iii) amplifying human DNA sequences; and

[1728] (iv) isolating the polynucleotide products of step (b)(iii).

[1729] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:95, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:95 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:95, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:95. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95from nucleotide 166 to nucleotide 552, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:95 from nucleotide 166 to nucleotide 552, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:95 fromnucleotide 166 to nucleotide 552.

[1730] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1731] (a) the amino acid sequence of SEQ ID NO:96;

[1732] (b) fragments of the amino acid sequence of SEQ ID NO:96, eachfragment comprising eight consecutive amino acids of SEQ ID NO:96; and

[1733] (c) the amino acid sequence encoded by the cDNA insert of clonenm214_(—)3 deposited with the ATCC under accession number 98630;

[1734] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:96. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:96 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:96, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:96 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 59 to amino acid 68 of SEQ ID NO:96.

[1735] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1736] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:97;

[1737] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:97 from nucleotide 203 to nucleotide 1441;

[1738] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:97 from nucleotide 251 to nucleotide 1441;

[1739] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nn320_(—)2 deposited withthe ATCC under accession number 98630;

[1740] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nn320_(—)2 deposited with the ATCC underaccession number 98630;

[1741] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nn320_(—)2 deposited with theATCC under accession number 98630;

[1742] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nn320_(—)2 deposited with the ATCC under accessionnumber 98630;

[1743] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:98;

[1744] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:98 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:98;

[1745] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1746] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1747] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1748] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:97 from nucleotide 203 to nucleotide 1441; the nucleotidesequence of SEQ ID NO:97 from nucleotide 251 to nucleotide 1441; thenucleotide sequence of the full-length protein coding sequence of clonenn320_(—)2 deposited with the ATCC under accession number 98630; or thenucleotide sequence of a mature protein coding sequence of clonenn320_(—)2 deposited with the ATCC under accession number 98630. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone nn320_(—)2deposited with the ATCC under accession number 98630. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:98from amino acid 1 to amino acid 92. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:98 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:98, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:98 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 201 to amino acid 210 of SEQ ID NO:98.

[1749] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:97.

[1750] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1751] (a) a process comprising the steps of:

[1752] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1753] (aa) SEQ ID NO:97, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:97; and

[1754] (ab) the nucleotide sequence of the cDNA insert of clonenn320_(—)2 deposited with the ATCC under accession number 98630;

[1755] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1756] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1757] (b) a process comprising the steps of:

[1758] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1759] (ba) SEQ ID NO:97, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:97; and

[1760] (bb) the nucleotide sequence of the cDNA insert of clonenn320_(—)2 deposited with the ATCC under accession number 98630;

[1761] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1762] (iii) amplifying human DNA sequences; and

[1763] (iv) isolating the polynucleotide products of step (b)(iii).

[1764] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:97, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:97 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:97, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:97. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97from nucleotide 203 to nucleotide 1441, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:97 from nucleotide 203 to nucleotide 1441, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:97from nucleotide 203 to nucleotide 1441. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97from nucleotide 251 to nucleotide 1441, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:97 from nucleotide 251 to nucleotide 1441, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:97from nucleotide 251 to nucleotide 1441.

[1765] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1766] (a) the amino acid sequence of SEQ ID NO:98;

[1767] (b) the amino acid sequence of SEQ ID NO:98 from amino acid 1 toamino acid 92;

[1768] (c) fragments of the amino acid sequence of SEQ ID NO:98, eachfragment comprising eight consecutive amino acids of SEQ ID NO:98; and

[1769] (d) the amino acid sequence encoded by the cDNA insert of clonenn320_(—)2 deposited with the ATCC under accession number 98630;

[1770] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:98 or the amino acid sequence of SEQ ID NO:98 from amino acid1 to amino acid 92. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the armino acidsequence of SEQ ID NO:98 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:98, or a protein comprisinga fragment of the amino acid sequence of SEQ ID NO:98 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 201 to amino acid 210 of SEQ ID NO:98.

[1771] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1772] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:99;

[1773] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:99 from nucleotide 74 to nucleotide 1531;

[1774] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pp392_(—)3 deposited withthe ATCC under accession number 98630;

[1775] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pp392_(—)3 deposited with the ATCC underaccession number 98630;

[1776] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pp392_(—)3 deposited with theATCC under accession number 98630;

[1777] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pp392_(—)3 deposited with the ATCC under accessionnumber 98630;

[1778] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:100;

[1779] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:100 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:100;

[1780] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(fl above;

[1781] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[1782] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[1783] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:99 from nucleotide 74 to nucleotide 1531; the nucleotidesequence of the full-length protein coding sequence of clone pp392_(—)3deposited with the ATCC under accession number 98630; or the nucleotidesequence of a mature protein coding sequence of clone pp392_(—)3deposited with the ATCC under accession number 98630. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone pp392_(—)3 deposited withthe ATCC under accession number 98630. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:100 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:100, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:100 having biologicalactivity, the fragment comprising the amino acid sequence rrom aminoacid 237 to amino acid 246 of SEQ ID NO:100.

[1784] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:99.

[1785] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1786] (a) a process comprising the steps of:

[1787] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1788] (aa) SEQ ID NO:99, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:99; and

[1789] (ab) the nucleotide sequence of the cDNA insert of clonepp392_(—)3 deposited with the ATCC under accession number 98630;

[1790] (ii) hybridizing said probe(s) to human genomnic DNA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[1791] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1792] (b) a process comprising the steps of:

[1793] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1794] (ba) SEQ ID NO:99, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:99; and

[1795] (bb) the nucleotide sequence of the cDNA insert of clonepp392_(—)3 deposited with the ATCC under accession number 98630;

[1796] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1797] (iii) amplifying human DNA sequences; and

[1798] (iv) isolating the polynucleotide products of step (b)(iii).

[1799] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:99, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:99 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:99, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:99. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99from nucleotide 74 to nucleotide 1531, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:99 from nucleotide 74 to nucleotide 1531, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:99 fromnucleotide 74 to nucleotide 1531.

[1800] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1801] (a) the amino acid sequence of SEQ ID NO:100;

[1802] (b) fragments of the amino acid sequence of SEQ ID NO:100, eachfragment comprising eight consecutive amino acids of SEQ ID NO:100; and

[1803] (c) the amino acid sequence encoded by the cDNA insert of clonepp392_(—)3 deposited with the ATCC under accession number 98630;

[1804] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:100. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:100 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:100, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:100 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 237 to amino acid 246 of SEQ ID NO:100.

[1805] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1806] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:101;

[1807] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:101 from nucleotide 58 to nucleotide 474;

[1808] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:101 from nucleotide 310 to nucleotide 474;

[1809] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ya13_(—)1 deposited withthe ATCC under accession number 98630;

[1810] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ya13_(—)1 deposited with the ATCC underaccession number 98630;

[1811] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ya13_(—)1 deposited with theATCC under accession number 98630;

[1812] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ya13_(—)1 deposited with the ATCC under accessionnumber 98630;

[1813] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:102;

[1814] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:102 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:102;

[1815] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1816] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1817] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1818] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:101 from nucleotide 58 to nucleotide 474; the nucleotidesequence of SEQ ID NO:101 from nucleotide 310 to nucleotide 474; thenucleotide sequence of the full-length protein coding sequence of cloneya13_(—)1 deposited with the ATCC under accession number 98630; or thenucleotide sequence of a mature protein coding sequence of cloneya13_(—)1 deposited with the ATCC under accession number 98630. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone ya13_(—)1 depositedwith the ATCC under accession number 98630. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:102 having biological activity, the fragment preferably comprisingeight (more preferably twenty, most preferably thirty) consecutive aminoacids of SEQ ID NO:102, or a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:102 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 64 to amino acid 73 of SEQ ID NO:102.

[1819] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:101.

[1820] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1821] (a) a process comprising the steps of:

[1822] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1823] (aa) SEQ ID NO:101, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:101; and

[1824] (ab) the nucleotide sequence of the cDNA insert of cloneya13_(—)1 deposited with the ATCC under accession number 98630;

[1825] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1826] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1827] (b) a process comprising the steps of:

[1828] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1829] (ba) SEQ ID NO:101, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:101; and

[1830] (bb) the nucleotide sequence of the cDNA insert of cloneya13_(—)1 deposited with the ATCC under accession number 98630;

[1831] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1832] (iii) amplifying human DNA sequences; and

[1833] (iv) isolating the polynucleotide products of step (b)(iii).

[1834] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:101, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:101 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:101, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:101. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:101from nucleotide 58 to nucleotide 474, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:101 from nucleotide 58 to nucleotide 474, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:101 fromnucleotide 58 to nucleotide 474. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:101 from nucleotide 310to nucleotide 474, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:101 fromnucleotide 310 to nucleotide 474, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:101 from nucleotide 310 tonucleotide 474.

[1835] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1836] (a) the amino acid sequence of SEQ ID NO:102;

[1837] (b) fragments of the amino acid sequence of SEQ ID NO:102, eachfragment comprising eight consecutive amino acids of SEQ ID NO:102; and

[1838] (c) the amino acid sequence encoded by the cDNA insert of cloneya13_(—)1 deposited with the ATCC under accession number 98630;

[1839] the protein being substantially free from other marnmalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:102. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:102 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:102, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:102 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 64 to amino acid 73 of SEQ ID NO:102.

[1840] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1841] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:103;

[1842] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:103 from nucleotide 76 to nucleotide 540;

[1843] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:103 from nucleotide 196 to nucleotide 540;

[1844] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone yb37_(—)1 deposited withthe ATCC under accession number 98630;

[1845] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone yb37_(—)1 deposited with the ATCC underaccession number 98630;

[1846] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone yb37_(—)1 deposited with theATCC under accession number 98630;

[1847] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone yb37_(—)1 deposited with the ATCC under accessionnumber 98630;

[1848] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:104;

[1849] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:104 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:104;

[1850] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1851] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1852] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1853] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:103 from nucleotide 76 to nucleotide 540; the nucleotidesequence of SEQ ID NO:103 from nucleotide 196 to nucleotide 540; thenucleotide sequence of the full-length protein coding sequence of cloneyb37_(—)1 deposited with the ATCC under accession number 98630; or thenucleotide sequence of a mature protein coding sequence of cloneyb37_(—)1 deposited with the ATCC under accession number 98630. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone yb37_(—)1 depositedwith the ATCC under accession number 98630. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:104 having biological activity, the fragment preferably comprisingeight (more preferably twenty, most preferably thirty) consecutive aminoacids of SEQ ID NO:104, or a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:104 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 72 to amino acid 81 of SEQ ID NO:104.

[1854] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:103.

[1855] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1856] (a) a process comprising the steps of:

[1857] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1858] (aa) SEQ ID NO:103, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:103; and

[1859] (ab) the nucleotide sequence of the cDNA insert of cloneyb37_(—)1 deposited with the ATCC under accession number 98630;

[1860] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1861] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1862] (b) a process comprising the steps of:

[1863] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1864] (ba) SEQ ID NO:103, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:103; and

[1865] (bb) the nucleotide sequence of the cDNA insert of cloneyb37_(—)1 deposited with the ATCC under accession number 98630;

[1866] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1867] (iii) amplifying human DNA sequences; and

[1868] (iv) isolating the polynucleotide products of step (b)(iii).

[1869] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:103, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:103 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:103, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:103. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103fromnucleotide 76 to nucleotide 540, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:103 from nucleotide 76 to nucleotide 540, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:103 fromnucleotide 76 to nucleotide 540. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:103 from nucleotide 196to nucleotide 540, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:103 fromnucleotide 196 to nucleotide 540, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO:103 from nucleotide 196 tonucleotide 540.

[1870] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1871] (a) the amino acid sequence of SEQ ID NO:104;

[1872] (b) fragments of the amino acid sequence of SEQ ID NO:104, eachfragment comprising eight consecutive amino acids of SEQ ID NO:104; and

[1873] (c) the amino acid sequence encoded by the cDNA insert of cloneyb37_(—)1 deposited with the ATCC under accession number 98630;

[1874] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:104. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:104 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:104, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:104 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 72 to amino acid 81 of SEQ ID NO:104.

[1875] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1876] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:105;

[1877] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:105 from nucleotide 275 to nucleotide 415;

[1878] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:105 from nucleotide 374 to nucleotide 415;

[1879] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone yb39_(—)1 deposited withthe ATCC under accession number 98630;

[1880] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone yb39_(—)1 deposited with the ATCC underaccession number 98630;

[1881] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone yb39_(—)1 deposited with theATCC under accession number 98630;

[1882] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone yb39_(—)1 deposited with the ATCC under accessionnumber 98630;

[1883] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:106;

[1884] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:106 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:106;

[1885] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1886] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1887] (1) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1888] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:105 from nucleotide 275 to nucleotide 415; the nucleotidesequence of SEQ ID NO:105 from nucleotide 374 to nucleotide 415; thenucleotide sequence of the full-length protein coding sequence of cloneyb39_(—)1 deposited with the ATCC under accession number 98630; or thenucleotide sequence of a mature protein coding sequence of cloneyb39_(—)1 deposited with the ATCC under accession number 98630. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone yb39_(—)1 depositedwith the ATCC under accession number 98630. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:106 having biological activity, the fragment preferably comprisingeight (more preferably twenty, most preferably thirty) consecutive aminoacids of SEQ ID NO:106, or a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:106 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 15 to amino acid 24 of SEQ ID NO:106.

[1889] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:105.

[1890] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1891] (a) a process comprising the steps of:

[1892] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1893] (aa) SEQ ID NO: 105, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:105; and

[1894] (ab) the nucleotide sequence of the cDNA insert of cloneyb39_(—)1 deposited with the ATCC under accession number 98630;

[1895] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1896] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1897] (b) a process comprising the steps of:

[1898] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1899] (ba) SEQ ID NO:105,but excluding the poly(A) tail at the 3′ endof SEQ ID NO:105; and

[1900] (bb) the nucleotide sequence of the cDNA insert of cloneyb39_(—)1 deposited with the ATCC under accession number 98630;

[1901] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1902] (iii) amplifying human DNA sequences; and

[1903] (iv) isolating the polynucleotide products of step (b)(iii).

[1904] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:105, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:105 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:105 , but excludingthe poly(A) tail at the 3′ end of SEQ ID NO:105. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105from nucleotide 275 to nucleotide 415, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:105 from nucleotide 275 to nucleotide 415, to a nucleotidesequence corresponding to the 3′ end of said sequence or SEQ ID NO:105from nucleotide 275 to nucleotide 415. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105from nucleotide 374 to nucleotide 415, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:105 from nucleotide 374 to nucleotide 415, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:105from nucleotide 374 to nucleotide 415.

[1905] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1906] (a) the amino acid sequence of SEQ ID NO:106;

[1907] (b) fragments of the amino acid sequence of SEQ ID NO:106, eachfragment comprising eight consecutive amino acids of SEQ ID NO:106; and

[1908] (c) the amino acid sequence encoded by the cDNA insert of cloneyb39_(—)1 deposited with the ATCC under accession number 98630;

[1909] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:106. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:106 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:106, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:106 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 15 to amino acid 24 of SEQ ID NO:106.

[1910] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1911] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:107;

[1912] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:107 from nucleotide 427 to nucleotide 1146;

[1913] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:107 from nucleotide 589 to nucleotide 1146;

[1914] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bd577_(—)1 deposited withthe ATCC under accession number 98631;

[1915] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bd577_(—)1 deposited with the ATCC underaccession number 98631;

[1916] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bd577_(—)1 deposited with theATCC under accession number 98631;

[1917] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bd577_(—)1 deposited with the ATCC under accessionnumber 98631;

[1918] (h) a polynucleotide encoding a protein comprising the arninoacid sequence of SEQ ID NO:108;

[1919] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:108 having biological activity, thefragment comprising eight consecutive an-ino acids of SEQ ID NO:108;

[1920] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1921] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1922] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1923] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:107 from nucleotide 427 to nucleotide 1146; the nucleotidesequence of SEQ ID NO: 107 from nucleotide 589 to nucleotide 1146; thenucleotide sequence of the full-length protein coding sequence of clonebd577_(—)1 deposited with the ATCC under accession number 98631; or thenucleotide sequence of a mature protein coding sequence of clonebd577_(—)1 deposited with the ATCC under accession number 98631. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone bd577_(—)1deposited with the ATCC under accession number 98631. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:108 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:108, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:108 having biological activity, the fragment comprising the aminoacid sequence from amino acid 115 to amino acid 124 of SEQ ID NO:108.

[1924] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO: 107.

[1925] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1926] (a) a process comprising the steps of:

[1927] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1928] (aa) SEQ ID NO:107, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:107; and

[1929] (ab) the nucleotide sequence of the cDNA insert of clonebd577_(—)1 deposited with the ATCC under accession number 98631;

[1930] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1931] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1932] (b) a process comprising the steps of:

[1933] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1934] (ba) SEQ ID NO:107, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:107; and

[1935] (bb) the nucleotide sequence of the cDNA insert of clonebd577_(—)1 deposited with the ATCC under accession number 98631;

[1936] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1937] (iii) amplifying human DNA sequences; and

[1938] (iv) isolating the polynucleotide products of step (b)(iii).

[1939] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:107, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:107 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:107, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:107. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:107from nucleotide 427 to nucleotide 1146, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:107 from nucleotide 427 to nucleotide 1146, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:107from nucleotide 427 to nucleotide 1146. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:107from nucleotide 589 to nucleotide 1146, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:107 from nucleotide 589 to nucleotide 1146, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:107from nucleotide 589 to nucleotide 1146.

[1940] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1941] (a) the amino acid sequence of SEQ ID NO:108;

[1942] (b) fragments of the amino acid sequence of SEQ ID NO:108, eachfragment comprising eight consecutive amino acids of SEQ ID NO:108; and

[1943] (c) the amino acid sequence encoded by the cDNA insert of clonebd577_(—)1 deposited with the ATCC under accession number 98631;

[1944] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:108. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:108 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:108, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:108 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 115 to amino acid 124 of SEQ ID NO:108.

[1945] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1946] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:109;

[1947] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:109 from nucleotide 95 to nucleotide 1522;

[1948] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:109 from nucleotide 161 to nucleotide 1522;

[1949] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bv280_(—)3 deposited withthe ATCC under accession number 98631;

[1950] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bv280_(—)3 deposited with the ATCC underaccession number 98631;

[1951] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bv280_(—)3 deposited with theATCC under accession number 98631;

[1952] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bv280_(—)3 deposited with the ATCC under accessionnumber 98631;

[1953] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:110;

[1954] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:110 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:110;

[1955] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1956] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1957] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1958] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:109 from nucleotide 95 to nucleotide 1522; the nucleotidesequence of SEQ ID NO: 109 from nucleotide 161 to nucleotide 1522; thenucleotide sequence of the full-length protein coding sequence of clonebv280_(—)3 deposited with the ATCC under accession number 98631; or thenucleotide sequence of a mature protein coding sequence of clonebv280_(—)3 deposited with the ATCC under accession number 98631. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone bv280_(—)3deposited with the ATCC under accession number 98631. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:110 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:110, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:110 having biological activity, the fragment comprising the aminoacid sequence from amino acid 233 to amino acid 242 of SEQ ID NO:110.

[1959] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:109.

[1960] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1961] (a) a process comprising the steps of:

[1962] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1963] (aa) SEQ ID NO:109, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:109; and

[1964] (ab) the nucleotide sequence of the cDNA insert of clonebv280_(—)3 deposited with the ATCC under accession number 98631;

[1965] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[1966] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[1967] (b) a process comprising the steps of:

[1968] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[1969] (ba) SEQ ID NO: 109, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:109; and

[1970] (bb) the nucleotide sequence of the cDNA insert of clonebv280_(—)3 deposited with the ATCC under accession number 98631;

[1971] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[1972] (iii) amplifying human DNA sequences; and

[1973] (iv) isolating the polynucleotide products of step (b)(iii).

[1974] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:109, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:109 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:109, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:109. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:109from nucleotide 95 to nucleotide 1522, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:109 from nucleotide 95 to nucleotide 1522, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:109from nucleotide 95 to nucleotide 1522. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:109from nucleotide 161 to nucleotide 1522, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:109 from nucleotide 161 to nucleotide 1522, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:109from nucleotide 161 to nucleotide 1522.

[1975] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[1976] (a) the amino acid sequence of SEQ ID NO:110;

[1977] (b) fragments of the amino acid sequence of SEQ ID NO:110, eachfragment comprising eight consecutive amino acids of SEQ ID NO:110; and

[1978] (c) the amino acid sequence encoded by the cDNA insert of clonebv280_(—)3 deposited with the ATCC under accession number 98631;

[1979] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:110. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:110 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:110, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:110 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 233 to amino acid 242 of SEQ ID NO:110.

[1980] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[1981] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:111;

[1982] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:111 from nucleotide 286 to nucleotide 552;

[1983] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:111 from nucleotide 475 to nucleotide 552;

[1984] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone co315_(—)3 deposited withthe ATCC under accession number 98631;

[1985] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone co315_(—)3 deposited with the ATCC underaccession number 98631;

[1986] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone co315_(—)3 deposited with theATCC under accession number 98631;

[1987] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone co315_(—)3 deposited with the ATCC under accessionnumber 98631;

[1988] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:112;

[1989] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:112 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:112;

[1990] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[1991] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[1992] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[1993] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:111 fromnucleotide 286 to nucleotide 552; the nucleotidesequence of SEQ ID NO:111 from nucleotide 475 to nucleotide 552; thenucleotide sequence of the full-length protein coding sequence of cloneco315_(—)3 deposited with the ATCC under accession number 98631; or thenucleotide sequence of a mature protein coding sequence of cloneco315_(—)3 deposited with the ATCC under accession number 98631. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone co315_(—)3deposited with the ATCC under accession number 98631. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:112 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:112, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:112 having biological activity, the fragment comprising the aminoacid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:112.

[1994] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:111.

[1995] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[1996] (a) a process comprising the steps of:

[1997] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[1998] (aa) SEQIDNO:11,but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:111; and

[1999] (ab) the nucleotide sequence of the cDNA insert of cloneco315_(—)3 deposited with the ATCC under accession number 98631;

[2000] (ii) hybridizing said probe(s) to human genonic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2001] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2002] (b) a process comprising the steps of:

[2003] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2004] (ba) SEQ ID NO:111,but excluding the poly(A) tail at the 3′ endof SEQ ID NO:111; and

[2005] (bb) the nucleotide sequence of the cDNA insert of cloneco315_(—)3 deposited with the ATCC under accession number 98631;

[2006] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2007] (iii) amplifying human DNA sequences; and

[2008] (iv) isolating the polynucleotide products of step (b)(iii).

[2009] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:111, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:111 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:111, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:111. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:111from nucleotide 286 to nucleotide 552, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:111 from nucleotide 286 to nucleotide 552, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:111from nucleotide 286 to nucleotide 552. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:111from nucleotide 475 to nucleotide 552, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:111 from nucleotide 475 to nucleotide 552, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:111from nucleotide 475 to nucleotide 552.

[2010] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2011] (a) the amino acid sequence of SEQ ID NO:112;

[2012] (b) fragments of the amino acid sequence of SEQ ID NO:112, eachfragment comprising eight consecutive amino acids of SEQ ID NO:112; and

[2013] (c) the amino acid sequence encoded by the cDNA insert of cloneco315_(—)3 deposited with the ATCC under accession number 98631;

[2014] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:112. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:112 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:112, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:112 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 39 to amino acid 48 of SEQ ID NO:112.

[2015] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2016] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:113;

[2017] (b) a polynudeotide comprising the nucleotide sequence of SEQ IDNO:113 from nucleotide 1682 to nucleotide 1963;

[2018] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ij226_(—)6 deposited withthe ATCC under accession number 98631;

[2019] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ij226_(—)6 deposited with the ATCC underaccession number 98631;

[2020] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ij226_(—)6 deposited with theATCC under accession number 98631;

[2021] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ij226_(—)6 deposited with the ATCC under accessionnumber 98631;

[2022] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:114;

[2023] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:114 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:114;

[2024] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[2025] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[2026] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[2027] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:113 from nucleotide 1682 to nucleotide 1963; the nucleotidesequence of the full-length protein coding sequence of clone ij226_(—)6deposited with the ATCC under accession number 98631; or the nucleotidesequence of a mature protein coding sequence of clone ij226_(—)6deposited with the ATCC under accession number 98631. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone ij226_(—)6 deposited withthe ATCC under accession number 98631.

[2028] In further preferred embodiments, the present invention providesa polynucleotide encoding a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:114 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:114, or a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:114 having biological activity, the fragment comprising theamino acid sequence from amino acid 42 to amino acid 51 of SEQ IDNO:114.

[2029] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:113.

[2030] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2031] (a) a process comprising the steps of:

[2032] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2033] (aa) SEQ ID NO:113, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:113; and

[2034] (ab) the nucleotide sequence of the cDNA insert of cloneij226_(—)6 deposited with the ATCC under accession number 98631;

[2035] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2036] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2037] (b) a process comprising the steps of:

[2038] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2039] (ba) SEQ ID NO:1 13, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:113; and

[2040] (bb) the nucleotide sequence of the cDNA insert of cloneij226_(—)6 deposited with the ATCC under accession number 98631;

[2041] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2042] (iii) amplifying human DNA sequences; and

[2043] (iv) isolating the polynucleotide products of step (b)(iii).

[2044] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:113, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:113 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:113, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:113. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113from nucleotide 1682 to nucleotide 1963, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:113 from nucleotide 1682 to nucleotide 1963, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:113from nucleotide 1682 to nucleotide 1963.

[2045] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2046] (a) the amino acid sequence of SEQ ID NO:114;

[2047] (b) fragments of the amino acid sequence of SEQ ID NO:114, eachfragment comprising eight consecutive amino acids of SEQ ID NO:114; and

[2048] (c) the amino acid sequence encoded by the cDNA insert of cloneij226_(—)6 deposited with the ATCC under accession number 98631;

[2049] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:114. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:114 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:114, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:114 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 42 to amino acid 51 of SEQ ID NO:114.

[2050] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2051] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:115;

[2052] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:115 from nucleotide 1137 to nucleotide 1346;

[2053] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nf443_(—)1 deposited withthe ATCC under accession number 98631;

[2054] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nf443_(—)1 deposited with the ATCC underaccession number 98631;

[2055] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nf443_(—)1 deposited with theATCC under accession number 98631;

[2056] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nf443_(—)1 deposited with the ATCC under accessionnumber 98631;

[2057] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:116;

[2058] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:116 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:116;

[2059] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[2060] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[2061] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[2062] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:115 from nucleotide 1137 to nucleotide 1346; the nucleotidesequence of the full-length protein coding sequence of clone nf443_(—)1deposited with the ATCC under accession number 98631; or the nucleotidesequence of a mature protein coding sequence of clone nf443_(—)1deposited with the ATCC under accession number 98631. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone nf443_(—)1 deposited withthe ATCC under accession number 98631. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:116 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:116, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:116 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 30 to amino acid 39 of SEQ ID NO:116.

[2063] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:115.

[2064] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2065] (a) a process comprising the steps of:

[2066] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2067] (aa) SEQ ID NO:115, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:115; and

[2068] (ab) the nucleotide sequence of the cDNA insert of clonenf443_(—)1 deposited with the ATCC under accession number 98631;

[2069] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2070] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2071] (b) a process comprising the steps of:

[2072] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2073] (ba) SEQ ID NO:115, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:115; and

[2074] (bb) the nucleotide sequence of the cDNA insert of clonenf443_(—)1 deposited with the ATCC under accession number 98631;

[2075] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2076] (iii) amplifying human DNA sequences; and

[2077] (iv) isolating the polynucleotide products of step (b)(iii).

[2078] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:115, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:115 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:115, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:115. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:115from nucleotide 1137 to nucleotide 1346, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID jNO:115 from nucleotide 1137 to nucleotide 1346, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:115from nucleotide 1137 to nucleotide 1346.

[2079] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2080] (a) the amino acid sequence of SEQ ID NO:116;

[2081] (b) fragments of the amino acid sequence of SEQ ID NO:116, eachfragment comprising eight consecutive amino acids of SEQ ID NO:116; and

[2082] (c) the amino acid sequence encoded by the cDNA insert of clonenf443_(—)1 deposited with the ATCC under accession number 98631;

[2083] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:116. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:116 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:116, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:116 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 30 to amino acid 39 of SEQ ID NO:116.

[2084] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2085] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:117;

[2086] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:117 from nucleotide 308 to nucleotide 634;

[2087] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nt429_(—)1 deposited withthe ATCC under accession number 98631;

[2088] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nt429_(—)1 deposited with the ATCC underaccession number 98631;

[2089] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nt429_(—)1 deposited with theATCC under accession number 98631;

[2090] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nt429_(—)1 deposited with the ATCC under accessionnumber 98631;

[2091] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:118;

[2092] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:118 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:118;

[2093] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[2094] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[2095] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[2096] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:117 from nucleotide 308 to nucleotide 634; the nucleotidesequence of the full-length protein coding sequence of clone nt429_(—)1deposited with the ATCC under accession number 98631; or the nucleotidesequence of a mature protein coding sequence of clone nt429_(—)1deposited with the ATCC under accession number 98631. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone nt429_(—)1 deposited withthe ATCC under accession number 98631. In yet other preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising the amino acid sequence of SEQ ID NO:1 18 from aminoacid 1 to amino acid 47. In further preferred embodiments, the presentinvention provides a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:118 having biologicalactivity, the fragment preferably comprising eight (more preferablytwenty, most preferably thirty) consecutive amino acids of SEQ IDNO:118, or a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:118 having biological activity, thefragment comprising the amino acid sequence from amino acid 49 to aminoacid 58 of SEQ ID NO:118.

[2097] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:117.

[2098] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2099] (a) a process comprising the steps of:

[2100] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2101] (aa) SEQ ID NO:117, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:117; and

[2102] (ab) the nucleotide sequence of the cDNA insert of clonent429_(—)1 deposited with the ATCC under accession number 98631;

[2103] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2104] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2105] (b) a process comprising the steps of:

[2106] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2107] (ba) SEQ ID NO:117, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:117; and

[2108] (bb) the nucleotide sequence of the cDNA insert of clonent429_(—)1 deposited with the ATCC under accession number 98631;

[2109] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2110] (iii) amplifying human DNA sequences; and

[2111] (iv) isolating the polynucleotide products of step (b) (iii).

[2112] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:117, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:117 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:117, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:117. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:117from nucleotide 308 to nucleotide 634, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:117 from nucleotide 308 to nucleotide 634, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:117from nucleotide 308 to nucleotide 634.

[2113] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2114] (a) the amino acid sequence of SEQ ID NO:118;

[2115] (b) the amino acid sequence of SEQ ID NO:118 from amino acid 1 toamino acid 47;

[2116] (c) fragments of the amino acid sequence of SEQ ID NO:118, eachfragment comprising eight consecutive amino acids of SEQ ID NO:118; and

[2117] (d) the amino acid sequence encoded by the cDNA insert of clonent429_(—)1 deposited with the ATCC under accession number 98631;

[2118] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:118 or the amino acid sequence of SEQ ID NO:118 from aminoacid 1 to amino acid 47. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amnino acidsequence of SEQ ID NO:118 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:118, or a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:118 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 49 to amino acid 58 of SEQ ID NO:118.

[2119] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2120] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:119;

[2121] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:119 from nucleotide 104 to nucleotide 652;

[2122] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:119 from nucleotide 377 to nucleotide 652;

[2123] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pe503_(—)1 deposited withthe ATCC under accession number 98631;

[2124] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pe503_(—)1 deposited with the ATCC underaccession number 98631;

[2125] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pe503_(—)1 deposited with theATCC under accession number 98631;

[2126] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pe503_(—)1 deposited with the ATCC under accessionnumber 98631;

[2127] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:120;

[2128] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:120 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:120;

[2129] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2130] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2131] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2132] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:119 from nucleotide 104tonucleotide652;thenucleotidesequence ofSEQIDNO:119 from nucleotide 377 to nucleotide 652; thenucleotide sequence of the full-length protein coding sequence of clonepe503_(—)1 deposited with the ATCC under accession number 98631; or thenucleotide sequence of a mature protein coding sequence of clonepe503_(—)1 deposited with the ATCC under accession number 98631. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone pe503_(—)1deposited with the ATCC under accession number 98631. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:120from amino acid 69 to amino acid 125. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:120 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:120, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:120 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 86 to amino acid 95 of SEQ ID NO:120.

[2133] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:119.

[2134] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2135] (a) a process comprising the steps of:

[2136] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2137] (aa) SEQIDNO:119, butexcluding the poly(A) tail at the 3′ end ofSEQ ID NO:119; and

[2138] (ab) the nucleotide sequence of the cDNA insert of clonepe503_(—)1 deposited with the ATCC under accession number 98631;

[2139] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2140] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2141] (b) a process comprising the steps of:

[2142] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2143] (ba) SEQ ID NO:119, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:119; and

[2144] (bb) the nucleotide sequence of the cDNA insert of clonepe503_(—)1 deposited with the ATCC under accession number 98631;

[2145] (ii) hybridizing said primer(s) to human genonic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2146] (iii) amplifying human DNA sequences; and

[2147] (iv) isolating the polynucleotide products of step (b)(iii).

[2148] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:119, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:119 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:119, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:119. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119from nucleotide 104 to nucleotide 652, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:119 from nucleotide 104 to nucleotide 652, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:119from nucleotide 104 to nucleotide 652. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119from nucleotide 377 to nucleotide 652, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:119 from nucleotide 377 to nucleotide 652, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:119from nucleotide 377 to nucleotide 652.

[2149] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2150] (a) the anino acid sequence of SEQ ID NO:120;

[2151] (b) the amino acid sequence of SEQ ID NO:120 from amino acid 69to amino acid 125;

[2152] (c) fragments of the amino acid sequence of SEQ ID NO:120, eachfragment comprising eight consecutive amino acids of SEQ ID NO:120; and

[2153] (d) the amino acid sequence encoded by the cDNA insert of clonepe503_(—)1 deposited with the ATCC under accession number 98631;

[2154] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:120 or the amino acid sequence of SEQ ID NO:120 from aminoacid 69 to amino acid 125. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:120 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:120, or a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:120 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 86 to amino acid 95 of SEQ ID NO:120.

[2155] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2156] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:121;

[2157] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO: 121 from nucleotide 23 to nucleotide 442;

[2158] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:121 from nucleotide 224 to nucleotide 442;

[2159] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pe834_(—)6 deposited withthe ATCC under accession number 98631;

[2160] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pe834_(—)6 deposited with the ATCC underaccession number 98631;

[2161] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pe834_(—)6 deposited with theATCC under accession number 98631;

[2162] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pe834_(—)6 deposited with the ATCC under accessionnumber 98631;

[2163] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:122;

[2164] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:122 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO: 122;

[2165] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2166] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2167] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2168] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:121 fromnucleotide23 tonucleotide442; thenucleotidesequenceof SEQIDNO:121 from nucleotide 224 to nucleotide 442; the nucleotidesequence of the full-length protein coding sequence of clone pe834_(—)6deposited with the ATCC under accession number 98631; or the nucleotidesequence of a mature protein coding sequence of clone pe834_(—)6deposited with the ATCC under accession number 98631. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone pe834_(—)6 deposited withthe ATCC under accession number 98631. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amnino acid sequence of SEQ ID NO:122having biological activity, the fragment preferably comprising eight(more preferably twenty, most preferably thirty) consecutive amino acidsof SEQ ID NO:122, or a polynucleotide encoding a protein comprising afragment of the amiuno acid sequence of SEQ ID NO:122 having biologicalactivity, the fragment comprising the amnino acid sequence from aminoacid 65 to amino acid 74 of SEQ ID NO:122.

[2169] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:121.

[2170] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2171] (a) a process comprising the steps of:

[2172] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2173] (aa) SEQ ID NO:121, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:121; and

[2174] (ab) the nucleo tide sequence of the cDNA insert of clonepe834_(—)6 deposited with the ATCC under accession number 98631;

[2175] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2176] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2177] (b) a process comprising the steps of:

[2178] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2179] (ba) SEQIDNO:121,butexcludingthepoly(A)tailatthe 3′ end of SEQ IDNO:121; and

[2180] (bb) the nucleotide sequence of the cDNA insert of clonepe834_(—)6 deposited with the ATCC under accession number 98631;

[2181] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2182] (iii) amplifying human DNA sequences; and

[2183] (iv) isolating the polynucleotide products of step (b)(iii).

[2184] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:121, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:121 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:121, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:121. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 121from nucleotide 23 to nucleotide 442, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:121 from nucleotide 23 to nucleotide 442, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:121 fromnucleotide 23 to nucleotide 442.

[2185] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2186] (a) the amino acid sequence of SEQ ID NO:122;

[2187] (b) fragments of the amino acid sequence of SEQ ID NO:122, eachfragment comprising eight consecutive amino acids of SEQ ID NO:122; and

[2188] (c) the amino acid sequence encoded by the cDNA insert of clonepe834_(—)6 deposited with the ATCC under accession number 98631;

[2189] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:122. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:122 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:122, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:122 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 65 to amino acid 74 of SEQ ID NO:122.

[2190] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2191] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:123;

[2192] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO: 123 from nucleotide 98 to nucleotide 265;

[2193] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:123 from nucleotide 152 to nucleotide 265;

[2194] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ya10_(—)1 deposited withthe ATCC under accession number 98631;

[2195] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ya10_(—)1 deposited with the ATCC underaccession number 98631;

[2196] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ya10_(—)1 deposited with theATCC under accession number 98631;

[2197] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ya10_(—)1 deposited with the ATCC under accessionnumber 98631;

[2198] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:124;

[2199] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:124 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:124;

[2200] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2201] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2202] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2203] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:123 from nucleotide 98 to nucleotide 265; the nucleotidesequence of SEQ ID NO:123 from nucleotide 152 to nucleotide 265; thenucleotide sequence of the full-length protein coding sequence of cloneya10_(—)1 deposited with the ATCC under accession number 98631; or thenucleotide sequence of a mature protein coding sequence of cloneya10_(—)1 deposited with the ATCC under accession number 98631. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone ya10_(—)1 depositedwith the ATCC under accession number 98631.

[2204] In further preferred embodiments, the present invention providesa polynucleotide encoding a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:124 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:124, or a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:124 having biological activity, the fragment comprising theamino acid sequence from amino acid 22 to amino acid 31 of SEQ IDNO:124.

[2205] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:123.

[2206] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2207] (a) a process comprising the steps of:

[2208] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2209] (aa) SEQ ID NO:123, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:123; and

[2210] (ab) the nucleotide sequence of the cDNA insert of cloneya10_(—)1 deposited with the ATCC under accession number 98631;

[2211] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2212] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2213] (b) a process comprising the steps of:

[2214] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2215] (ba) SEQ ID NO: 123, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:123; and

[2216] (bb) the nucleotide sequence of the cDNA insert of cloneya10_(—)1 deposited with the ATCC under accession number 98631;

[2217] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2218] (iii) amplifying human DNA sequences; and

[2219] (iv) isolating the polynucleotide products of step (b)(iii).

[2220] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:123, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:123 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:123, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:123. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123from nucleotide 98 to nucleotide 265, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:123 from nucleotide 98 to nucleotide 265, to a nucleotide sequencecorresponding to the 3′ end of said sequence of SEQ ID NO:123 fromnucleotide 98 to nucleotide 265. Also preferably the polynucleotideisolated according to the above process comprises a nucleotide sequencecorresponding to the cDNA sequence of SEQ ID NO:123 from nucleotide 152to nucleotide 265, and extending contiguously from a nucleotide sequencecorresponding to the 5′ end of said sequence of SEQ ID NO:123 fromnucleotide 152 to nucleotide 265, to a nucleotide sequence correspondingto the 3′ end of said sequence of SEQ ID NO: 123 from nucleotide 152 tonucleotide 265.

[2221] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2222] (a) the amino acid sequence of SEQ ID NO:124;

[2223] (b) fragments of the amino acid sequence of SEQ ID NO:124, eachfragment comprising eight consecutive amino acids of SEQ ID NO:124; and

[2224] (c) the amino acid sequence encoded by the cDNA insert of cloneya10_(—)1 deposited with the ATCC under accession number 98631;

[2225] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:124. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:124 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:124, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:124 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 22 to amino acid 31 of SEQ ID NO:124.

[2226] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2227] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:125;

[2228] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO: 125 from nucleotide 176 to nucleotide 583;

[2229] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone yb40_(—)1 deposited withthe ATCC under accession number 98631;

[2230] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone yb40_(—)1 deposited with the ATCC underaccession number 98631;

[2231] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone yb40_(—)1 deposited with theATCC under accession number 98631;

[2232] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone yb40_(—)1 deposited with the ATCC under accessionnumber 98631;

[2233] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:126;

[2234] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:126 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:126;

[2235] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[2236] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[2237] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[2238] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:125 from nucleotide 176 to nucleotide 583; the nucleotidesequence of the full-length protein coding sequence of clone yb40_(—)1deposited with the ATCC under accession number 98631; or the nucleotidesequence of a mature protein coding sequence of clone yb40_(—)1deposited with the ATCC under accession number 98631. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone yb40_(—)1 deposited with theATCC under accession number 98631. In further preferred embodiments, thepresent invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:126 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:126, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:126 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 63 to amLino acid 72 of SEQ ID NO:126.

[2239] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:125.

[2240] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2241] (a) a process comprising the steps of:

[2242] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2243] (aa) SEQIDNO:125,but excluding the poly(A) tail at the 3′ end ofSEQ ID NO:125; and

[2244] (ab) the nucleotide sequence of the cDNA insert of cloneyb40_(—)1 deposited with the ATCC under accession number 98631;

[2245] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2246] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2247] (b) a process comprising the steps of:

[2248] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2249] (ba) SEQ ID NO:125, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:125; and

[2250] (bb) the nucleotide sequence of the cDNA insert of cloneyb40_(—)1 deposited with the ATCC under accession number 98631;

[2251] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2252] (iii) amplifying human DNA sequences; and

[2253] (iv) isolating the polynucleotide products of step (b)(iii).

[2254] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:125, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:125 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:125, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:125. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125from nucleotide 176 to nucleotide 583, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:125 from nucleotide 176 to nucleotide 583, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:125from nucleotide 176 to nucleotide 583.

[2255] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2256] (a) the amino acid sequence of SEQ ID NO:126;

[2257] (b) fragments of the amino acid sequence of SEQ ID NO:126, eachfragment comprising eight consecutive amino acids of SEQ ID NO:126; and

[2258] (c) the amino acid sequence encoded by the cDNA insert of cloneyb40_(—)1 deposited with the ATCC under accession number 98631;

[2259] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:126. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:126 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:126, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:126 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 63 to amino acid 72 of SEQ ID NO:126.

[2260] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2261] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:127;

[2262] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:127 from nucleotide 734 to nucleotide 1873;

[2263] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:127 from nucleotide 1403 to nucleotide 1873;

[2264] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone cs756_(—)2 deposited withthe ATCC under accession number 98636;

[2265] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone cs756_(—)2 deposited with the ATCC underaccession number 98636;

[2266] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone cs756_(—)2 deposited with theATCC under accession number 98636;

[2267] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone cs756_(—)2 deposited with the ATCC under accessionnumber 98636;

[2268] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:128;

[2269] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:128 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:128;

[2270] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2271] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2272] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2273] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:127 from nucleotide 734 to nucleotide 1873; the nucleotidesequence of SEQ ID NO:127 from nucleotide 1403 to nucleotide 1873; thenucleotide sequence of the full-length protein coding sequence of clonecs756_(—)2 deposited with the ATCC under accession number 98636; or thenucleotide sequence of a mature protein coding sequence of clonecs756_(—)2 deposited with the ATCC under accession number 98636. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone cs756_(—)2deposited with the ATCC under accession number 98636. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:128 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:128, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:128 having biological activity, the fragment comprising the aminoacid sequence from amino acid 185 to amino acid 194 of SEQ ID NO:128.

[2274] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:127.

[2275] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2276] (a) a process comprising the steps of:

[2277] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2278] (aa) SEQ ID NO:127, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:127; and

[2279] (ab) the nucleotide sequence of the cDNA insert of clonecs756_(—)2 deposited with the ATCC under accession number 98636;

[2280] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2281] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2282] (b) a process comprising the steps of:

[2283] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2284] (ba) SEQ ID NO:127, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:127; and

[2285] (bb) the nucleotide sequence of the cDNA insert of clonecs756_(—)2 deposited with the ATCC under accession number 98636;

[2286] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2287] (iii) amplifying human DNA sequences; and

[2288] (iv) isolating the polynucleotide products of step (b)(iii).

[2289] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:127, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:127 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:127, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:127. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127from nucleotide 734 to nucleotide 1873, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:127 from nucleotide 734 to nucleotide 1873, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:127from nucleotide 734 to nucleotide 1873. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127from nucleotide 1403 to nucleotide 1873, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:127 from nucleotide 1403 to nucleotide 1873, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:127from nucleotide 1403 to nucleotide 1873.

[2290] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2291] (a) the amino acid sequence of SEQ ID NO:128;

[2292] (b) fragments of the amino acid sequence of SEQ ID NO:128, eachfragment comprising eight consecutive amino acids of SEQ ID NO:128; and

[2293] (c) the amino acid sequence encoded by the cDNA insert of clonecs756_(—)2 deposited with the ATCC under accession number 98636;

[2294] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:128. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:128 having biological activity, the fragment preferablycomprising eight (more preferably twenty, mostpreferably thirty)consecutive amino acids of SEQ ID NO:128, or a protein comprising afragment of the arino acid sequence of SEQ ID NO:128 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 185 to amnino acid 194 of SEQ ID NO:128.

[2295] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2296] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:129;

[2297] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:129 from nucleotide 26 to nucleotide 1738;

[2298] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:129 from nucleotide 140 to nucleotide 1738;

[2299] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ew150_(—)1 deposited withthe ATCC under accession number 98636;

[2300] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ew150_(—)1 deposited with the ATCC underaccession number 98636;

[2301] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ew150_(—)1 deposited with theATCC under accession number 98636;

[2302] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ew150_(—)1 deposited with the ATCC under accessionnumber 98636;

[2303] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:130;

[2304] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:130 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:130;

[2305] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2306] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2307] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2308] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:129 from nucleotide 26 to nucleotide 1738; the nucleotidesequence of SEQ ID NO:129 from nucleotide 140to nucleotide 1738;thenucleotidesequence of the full length protein coding sequence ofclone ew150_(—)1 deposited with the ATCC under accession number 98636;or the nucleotide sequence of a mature protein coding sequence of cloneew150_(—)1 deposited with the ATCC under accession number 98636. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone ew150_(—)1deposited with the ATCC under accession number 98636. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:130from amino acid 108 to amino acid 166. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:130 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:130, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:130 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 280 to amino acid 289 of SEQ ID NO:130.

[2309] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:129.

[2310] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2311] (a) a process comprising the steps of:

[2312] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2313] (aa) SEQ IDNO:129, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:129; and

[2314] (ab) the nucleotide sequence of the cDNA insert of cloneew150_(—)1 deposited with the ATCC under accession number 98636;

[2315] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2316] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2317] (b) a process comprising the steps of:

[2318] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2319] (ba) SEQ ID NO:129, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:129; and

[2320] (bb) the nucleotide sequence of the cDNA insert of cloneew150_(—)1 deposited with the ATCC under accession number 98636;

[2321] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2322] (iii) amplifying human DNA sequences; and

[2323] (iv) isolating the polynucleotide products of step (b)(iii).

[2324] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:129, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:129 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:129, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:129. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129from nucleotide 26 to nucleotide 1738, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:129 from nucleotide 26 to nucleotide 1738, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:129from nucleotide 26 to nucleotide 1738. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129from nucleotide 140 to nucleotide 1738, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:129 from nucleotide 140 to nucleotide 1738, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:129from nucleotide 140 to nucleotide 1738.

[2325] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2326] (a) the amino acid sequence of SEQ ID NO:130;

[2327] (b) the amino acid sequence of SEQ ID NO:130 from amino acid 108to amino acid 166;

[2328] (c) fragments of the amino acid sequence of SEQ ID NO:130, eachfragment comprising eight consecutive amino acids of SEQ ID NO:130; and

[2329] (d) the amino acid sequence encoded by the cDNA insert of cloneew150_(—)1 deposited with the ATCC under accession number 98636;

[2330] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:130 or the amino acid sequence of SEQ ID NO:130 from aminoacid 108 to amino acid 166. In further preferred embodiments, thepresent invention provides a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:130 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:130, or a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:130 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 280 to amino acid 289 of SEQ ID NO:130.

[2331] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2332] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:131;

[2333] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:131 from nucleotide 1101 to nucleotide 1910;

[2334] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:131 from nucleotide 1260 to nucleotide 1910;

[2335] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone gg894_(—)13 deposited withthe ATCC under accession number 98636;

[2336] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone gg894_(—)13 deposited with the ATCC underaccession number 98636;

[2337] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone gg894_(—)13 deposited with theATCC under accession number 98636;

[2338] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone gg894_(—)13 deposited with the ATCC under accessionnumber 98636;

[2339] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:132;

[2340] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:132 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:132;

[2341] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2342] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2343] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2344] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:131 from nucleotide 1101 to nucleotide 1910; the nucleotidesequence of SEQ ID NO:131 from nucleotide 1260 to nucleotide 1910; thenucleotide sequence of the full-length protein coding sequence of clonegg894_(—)13 deposited with the ATCC under accession number 98636; or thenucleotide sequence of a mature protein coding sequence of clonegg894_(—)13 deposited with the ATCC under accession number 98636. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone gg894_(—)13deposited with the ATCC under accession number 98636. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:132 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:132, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:132 having biological activity, the fragment comprising the aminoacid sequence from amnino acid 130 to amino acid 139 of SEQ ID NO: 132.

[2345] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:131.

[2346] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2347] (a) a process comprising the steps of:

[2348] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2349] (aa) SEQ ID NO:131, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:131; and

[2350] (ab) the nucleotide sequence of the cDNA insert of clonegg894_(—)13 deposited with the ATCC under accession number 98636;

[2351] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2352] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2353] (b) a process comprising the steps of:

[2354] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2355] (ba) SEQ ID NO:131, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:131; and

[2356] (bb) the nucleotide sequence of the cDNA insert of clonegg894_(—)13 deposited with the ATCC under accession number 98636;

[2357] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2358] (iii) amplifying human DNA sequences; and

[2359] (iv) isolating the polynucleotide products of step (b)(iii).

[2360] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:131, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:131 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:131, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:131. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131from nucleotide 1101 to nucleotide 1910, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO: 131 from nucleotide 1101 to nucleotide 1910, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:131from nucleotide 1101 to nucleotide 1910. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131from nucleotide 1260 to nucleotide 1910, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:131 from nucleotide 1260 to nucleotide 1910, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:131from nucleotide 1260 to nucleotide 1910.

[2361] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2362] (a) the amino acid sequence of SEQ ID NO:132;

[2363] (b) fragments of the amino acid sequence of SEQ ID NO:132, eachfragment comprising eight consecutive amino acids of SEQ ID NO:132; and

[2364] (c) the amino acid sequence encoded by the cDNA insert of clonegg894_(—)13 deposited with the ATCC under accession number 98636;

[2365] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:132. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:132 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:132, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:132 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 130 to amino acid 139 of SEQ ID NO: 132.

[2366] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2367] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:133;

[2368] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:133 from nucleotide 452 to nucleotide 1102;

[2369] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone it217_(—)2 deposited withthe ATCC under accession number 98636;

[2370] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone it217_(—)2 deposited with the ATCC underaccession number 98636;

[2371] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone it217_(—)2 deposited with theATCC under accession number 98636;

[2372] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone it217_(—)2 deposited with the ATCC under accessionnumber 98636;

[2373] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:134;

[2374] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:134 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:134;

[2375] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[2376] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[2377] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[2378] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:133 from nucleotide 452 to nucleotide 1102; the nucleotidesequence of the full-length protein coding sequence of clone it217_(—)2deposited with the ATCC under accession number 98636; or the nucleotidesequence of a mature protein coding sequence of clone it217_(—)2deposited with the ATCC under accession number 98636. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone it217_(—)2 deposited withthe ATCC under accession number 98636. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:134 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:134, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:134 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 103 to amino acid 112 of SEQ ID NO:134.

[2379] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:133.

[2380] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2381] (a) a process comprising the steps of:

[2382] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2383] (aa) SEQ ID NO:133, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:133; and

[2384] (ab) the nucleotide sequence of the cDNA insert of cloneit217_(—)2 deposited with the ATCC under accession number 98636;

[2385] (ii) hybridizing said probe(s) to human genormic DNA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[2386] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2387] (b) a process comprising the steps of:

[2388] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2389] (ba) SEQ ID NO:133, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:133; and

[2390] (bb) the nucleotide sequence of the cDNA insert of cloneit217_(—)2 deposited with the ATCC under accession number 98636;

[2391] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2392] (iii) amplifying human DNA sequences; and

[2393] (iv) isolating the polynucleotide products of step (b)(iii).

[2394] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:133, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:133 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:133, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:133. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133from nucleotide 452 to nucleotide 1102, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:133 from nucleotide 452 to nucleotide 1102, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:133from nucleotide 452 to nucleotide 1102.

[2395] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2396] (a) the amnino acid sequence of SEQ ID NO:134;

[2397] (b) fragments of the amino acid sequence of SEQ ID NO:134, eachfragment comprising eight consecutive amino acids of SEQ ID NO:134; and

[2398] (c) the amino acid sequence encoded by the cDNA insert of cloneit217_(—)2 deposited with the ATCC under accession number 98636;

[2399] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:134. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:134 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:134, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:134 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 103 to amino acid 112 of SEQ ID NO:134.

[2400] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2401] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:135;

[2402] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:135 from nucleotide 127 to nucleotide 387;

[2403] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:135 from nucleotide 172 to nucleotide 387;

[2404] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ml235_(—)2 deposited withthe ATCC under accession number 98636;

[2405] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ml235_(—)2 deposited with the ATCC underaccession number 98636;

[2406] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ml235_(—)2 deposited with theATCC under accession number 98636;

[2407] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ml235_(—)2 deposited with the ATCC under accessionnumber 98636;

[2408] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:136;

[2409] (i) a polynucleotide encoding a protein comprising a fragment ofthe armino acid sequence of SEQ ID NO:136 having biological activity,the fragment comprising eight consecutive amino acids of SEQ ID NO:136;

[2410] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2411] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2412] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2413] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:135 from nucleotide 127 to nucleotide 387; the nucleotidesequence of SEQ ID NO:135 from nucleotide 172 to nucleotide 387; thenucleotide sequence of the full-length protein coding sequence of cloneml235_(—)2 deposited with the ATCC under accession number 98636; or thenucleotide sequence of a mature protein coding sequence of cloneml235_(—)2 deposited with the ATCC under accession number 98636. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone ml235_(—)2deposited with the ATCC under accession number 98636. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:136 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:136, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:136 having biological activity, the fragment comprising the aminoacid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:136.

[2414] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:135.

[2415] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2416] (a) a process comprising the steps of:

[2417] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2418] (aa) SEQ ID NO:135, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:135; and

[2419] (ab) the nucleotide sequence of the cDNA insert of cloneml235_(—)2 deposited with the ATCC under accession number 98636;

[2420] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2421] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2422] (b) a process comprising the steps of:

[2423] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2424] (ba) SEQ ID NO:135, but excluding thepoly(A) tail at the 3′ endof SEQ ID NO:135; and

[2425] (bb) the nucleotide sequence of the cDNA insert of cloneml235_(—)2 deposited with the ATCC under accession number 98636;

[2426] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2427] (iii) amplifying human DNA sequences; and

[2428] (iv) isolating the polynucleotide products of step (b)(iii).

[2429] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:135, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:135 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:135, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:135. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135from nucleotide 127 to nucleotide 387, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:135 from nucleotide 127 to nucleotide 387, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:135from nucleotide 127 to nucleotide 387. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135from nucleotide 172 to nucleotide 387, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:135 from nucleotide 172 to nucleotide 387, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:135from nucleotide 172 to nucleotide 387.

[2430] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2431] (a) the amino acid sequence of SEQ ID NO:136;

[2432] (b) fragments of the amino acid sequence of SEQ ID NO:136, eachfragment comprising eight consecutive amino acids of SEQ ID NO:136; and

[2433] (c) the amino acid sequence encoded by the cDNA insert of cloneml235_(—)2 deposited with the ATCC under accession number 98636;

[2434] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:136. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:136 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:136, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:136 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 38 to amino acid 47 of SEQ ID NO:136.

[2435] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2436] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:137;

[2437] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:137 from nucleotide 147 to nucleotide 1163;

[2438] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:137 from nucleotide 273 to nucleotide 1163;

[2439] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone mt24_(—)2 deposited withthe ATCC under accession number 98636;

[2440] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone mt24_(—)2 deposited with the ATCC underaccession number 98636;

[2441] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone mt24_(—)2 deposited with theATCC under accession number 98636;

[2442] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone mt24_(—)2 deposited with the ATCC under accessionnumber 98636;

[2443] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:138;

[2444] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:138 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:138;

[2445] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2446] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2447] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2448] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:137 from nucleotide 147 to nucleotide 1163; the nucleotidesequence of SEQ ID NO:137 from nucleotide 273 to nucleotide 1163; thenucleotide sequence of the full-length protein coding sequence of clonemt24_(—)2 deposited with the ATCC under accession number 98636; or thenucleotide sequence of a mature protein coding sequence of clonemt24_(—)2 deposited with the ATCC under accession number 98636. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone mt24_(—)2 depositedwith the ATCC under accession number 98636. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:138 having biological activity, the fragment preferably comprisingeight (more preferably twenty, most preferably thirty) consecutive aminoacids of SEQ ID NO:138, or a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:138 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 164 to amino acid 173 of SEQ ID NO:138.

[2449] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:137.

[2450] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2451] (a) a process comprising the steps of:

[2452] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2453] (aa) SEQ ID NO:137, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:137; and

[2454] (ab) the nucleotide sequence of the cDNA insert of clonemt24_(—)2 deposited with the ATCC under accession number 98636;

[2455] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2456] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2457] (b) a process comprising the steps of:

[2458] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2459] (ba) SEQ ID NO:137, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:137; and

[2460] (bb) the nucleotide sequence of the cDNA insert of clonemt24_(—)2 deposited with the ATCC under accession number 98636;

[2461] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2462] (iii) amplifying human DNA sequences; and

[2463] (iv) isolating the polynucleotide products of step (b)(iii).

[2464] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:137, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:137 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:137, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:137. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137from nucleotide 147 to nucleotide 1163, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:137 from nucleotide 147 to nucleotide 1163, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:137from nucleotide 147 to nucleotide 1163. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137from nucleotide 273 to nucleotide 1163, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:137 from nucleotide 273 to nucleotide 1163, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:137from nucleotide 273 to nucleotide 1163.

[2465] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2466] (a) the amino acid sequence of SEQ ID NO:138;

[2467] (b) fragments of the amino acid sequence of SEQ ID NO:138, eachfragment comprising eight consecutive amino acids of SEQ ID NO:138; and

[2468] (c) the amino acid sequence encoded by the cDNA insert of clonemt24_(—)2 deposited with the ATCC under accession number 98636;

[2469] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:138. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:138 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:138, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:138 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 164 to amino acid 173 of SEQ ID NO:138.

[2470] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2471] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:139;

[2472] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:139 from nucleotide 320 to nucleotide 1681;

[2473] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:139 from nucleotide 437 to nucleotide 1681;

[2474] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pe584_(—)2 deposited withthe ATCC under accession number 98636;

[2475] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pe584_(—)2 deposited with the ATCC underaccession number 98636;

[2476] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pe584_(—)2 deposited with theATCC under accession number 98636;

[2477] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pe584_(—)2 deposited with the ATCC under accessionnumber 98636;

[2478] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:140;

[2479] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:140 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:140;

[2480] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2481] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2482] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2483] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:139 from nucleotide 320 to nucleotide 1681; the nucleotidesequence of SEQ ID NO:139 from nucleotide 437 to nucleotide 1681; thenucleotide sequence of the full-length protein coding sequence of clonepe584_(—)2 deposited with the ATCC under accession number 98636; or thenucleotide sequence of a mature protein coding sequence of clonepe584_(—)2 deposited with the ATCC under accession number 98636. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone pe584_(—)2deposited with the ATCC under accession number 98636. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:140 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:140, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:140 having biological activity, the fragment comprising the aminoacid sequence from amino acid 222 to amino acid 231 of SEQ ID NO:140.

[2484] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:139.

[2485] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2486] (a) a process comprising the steps of:

[2487] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2488] (aa) SEQ ID NO: 139, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:139; and

[2489] (ab) the nucleotide sequence of the cDNA insert of clonepe584_(—)2 deposited with the ATCC under accession number 98636;

[2490] (ii) hybridizing said probe(s) to human genornic DNA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[2491] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2492] (b) a process comprising the steps of:

[2493] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2494] (ba) SEQ ID NO:139, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:139; and

[2495] (bb) the nucleotide sequence of the cDNA insert of clonepe584_(—)2 deposited with the ATCC under accession number 98636;

[2496] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2497] (iii) amplifying human DNA sequences; and

[2498] (iv) isolating the polynucleotide products of step (b)(iii).

[2499] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:139, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:139 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:139, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:139. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:139from nucleotide 320 to nucleotide 1681, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:139 from nucleotide 320 to nucleotide 1681, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:139from nucleotide 320 to nucleotide 1681. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:139from nucleotide 437 to nucleotide 1681, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:139 from nucleotide 437 to nucleotide 1681, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:139from nucleotide 437 to nucleotide 1681.

[2500] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2501] (a) the amino acid sequence of SEQ ID NO:140;

[2502] (b) fragments of the amino acid sequence of SEQ ID NO:140, eachfragment comprising eight consecutive amino acids of SEQ ID NO:140; and

[2503] (c) the amino acid sequence encoded by the cDNA insert of clonepe584_(—)2 deposited with the ATCC under accession number 98636;

[2504] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:140. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:140 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:140, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:140 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 222 to amino acid 231 of SEQ ID NO:140.

[2505] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2506] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:141;

[2507] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:141 from nucleotide 78 to nucleotide 1502;

[2508] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:141 from nucleotide 564 to nucleotide 1502;

[2509] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pj323_(—)2 deposited withthe ATCC under accession number 98636;

[2510] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pj323_(—)2 deposited with the ATCC underaccession number 98636;

[2511] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pj323_(—)2 deposited with theATCC under accession number 98636;

[2512] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pj323_(—)2 deposited with the ATCC under accessionnumber 98636;

[2513] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:142;

[2514] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:142 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:142;

[2515] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2516] (k) a polynucleotide which encodes a species homologue of theprotein of ) or (i) above; and

[2517] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2518] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:141 fromnucleotide 78 to nucleotide 1502; the nucleotidesequence of SEQ ID NO:141 from nucleotide 564 to nucleotide 1502; thenucleotide sequence of the full-length protein coding sequence of clonepj323_(—)2 deposited with the ATCC under accession number 98636; or thenucleotide sequence of a mature protein coding sequence of clonepj323_(—)2 deposited with the ATCC under accession number 98636. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone pj323_(—)2deposited with the ATCC under accession number 98636. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:142from amino acid 54 to amino acid 145. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:142 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:142, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:142 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 232 to amino acid 241 of SEQ ID NO: 142.

[2519] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:141.

[2520] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2521] (a) a process comprising the steps of:

[2522] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2523] (aa) SEQ ID NO:141, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:141; and

[2524] (ab) the nucleotide sequence of the cDNA insert of clonepj323_(—)2 deposited with the ATCC under accession number 98636;

[2525] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2526] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2527] (b) a process comprising the steps of:

[2528] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2529] (ba) SEQ ID NO:141, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:141; and

[2530] (bb) the nucleotide sequence of the cDNA insert of clonepj323_(—)2 deposited with the ATCC under accession number 98636;

[2531] (ii) hybridizing said primer(s) to human genonic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2532] (iii) amplifying human DNA sequences; and

[2533] (iv) isolating the polynucleotide products of step (b)(iii).

[2534] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:141, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:141 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:141, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:141. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:141from nucleotide 78 to nucleotide 1502, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:141 from nucleotide 78 to nucleotide 1502, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:141from nucleotide 78 to nucleotide 1502. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:141from nucleotide 564 to nucleotide 1502, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:141 from nucleotide 564 to nucleotide 1502, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:141from nucleotide 564 to nucleotide 1502.

[2535] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2536] (a) the amino acid sequence of SEQ ID NO:142;

[2537] (b) the amino acid sequence of SEQ ID NO:142 from amino acid 54to amino acid 145;

[2538] (c) fragments of the amino acid sequence of SEQ ID NO:142, eachfragment comprising eight consecutive amino acids of SEQ ID NO:142; and

[2539] (d) the amino acid sequence encoded by the cDNA insert of clonepj323_(—)2 deposited with the ATCC under accession number 98636;

[2540] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:142 or the amino acid sequence of SEQ ID NO:142 from aminoacid 54 to amino acid 145. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:142 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:142, or a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:142 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 232 to amino acid 241 of SEQ ID NO:142.

[2541] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2542] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:143;

[2543] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:143 from nucleotide 130 to nucleotide 294;

[2544] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:143 from nucleotide 241 to nucleotide 294;

[2545] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone yb24_(—)1 deposited withthe ATCC under accession number 98636;

[2546] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone yb24_(—)1 deposited with the ATCC underaccession number 98636;

[2547] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone yb24_(—)1 deposited with theATCC under accession numnber 98636;

[2548] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone yb24_(—)1 deposited with the ATCC under accessionnumber 98636;

[2549] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:144;

[2550] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:144 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:144;

[2551] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2552] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2553] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2554] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:143 from nucleotide 130 to nucleotide 294; the nucleotidesequence of SEQ ID NO:143 from nucleotide 241 to nucleotide 294; thenucleotide sequence of the full-length protein coding sequence of cloneyb24_(—)1 deposited with the ATCC under accession number 98636; or thenucleotide sequence of a mature protein coding sequence of cloneyb24_(—)1 deposited with the ATCC under accession number 98636. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone yb24_(—)1 depositedwith the ATCC under accession number 98636. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:144 having biological activity, the fragment preferably comprisingeight (more preferably twenty, most preferably thirty) consecutive aminoacids of SEQ ID NO:144, or a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:144 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 22 to amino acid 31 of SEQ ID NO:144.

[2555] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:143.

[2556] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2557] (a) a process comprising the steps of:

[2558] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2559] (aa) SEQ ID NO:143, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:143; and

[2560] (ab) the nucleotide sequence of the cDNA insert of cloneyb24_(—)1 deposited with the ATCC under accession number 98636;

[2561] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2562] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2563] (b) a process comprising the steps of:

[2564] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2565] (ba) SEQ ID NO:143, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:143; and

[2566] (bb) the nucleotide sequence of the cDNA insert of cloneyb24_(—)1 deposited with the ATCC under accession number 98636;

[2567] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2568] (iii) amplifying human DNA sequences; and

[2569] (iv) isolating the polynucleotide products of step (b)(iii).

[2570] Preferably the polynucleotide isolated according to the aboveprocess comprises a -nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:143, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:143 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:143, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:143. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143from nucleotide 130 to nucleotide 294, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:143 from nucleotide 130 to nucleotide 294, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:143from nucleotide 130 to nucleotide 294. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143from nucleotide 241 to nucleotide 294, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:143 from nucleotide 241 to nucleotide 294, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:143from nucleotide 241 to nucleotide 294.

[2571] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2572] (a) the amino acid sequence of SEQ ID NO:144;

[2573] (b) fragments of the amino acid sequence of SEQ ID NO:144, eachfragment comprising eight consecutive amino acids of SEQ ID NO:144; and

[2574] (c) the amino acid sequence encoded by the cDNA insert of cloneyb24_(—)1 deposited with the ATCC under accession number 98636;

[2575] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:144. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:144 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:144, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:144 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 22 to amino acid 31 of SEQ ID NO:144.

[2576] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2577] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:145;

[2578] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:145 from nucleotide 514 to nucleotide 1707;

[2579] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:145 from nucleotide 580 to nucleotide 1707;

[2580] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone yb44_(—)1 deposited withthe ATCC under accession number 98636;

[2581] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone yb44_(—)1 deposited with the ATCC underaccession number 98636;

[2582] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone yb44_(—)1 deposited with theATCC under accession number 98636;

[2583] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone yb44_(—)1 deposited with the ATCC under accessionnumber 98636;

[2584] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:146;

[2585] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:146 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:146;

[2586] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2587] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2588] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2589] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:145 from nucleotide 514 to nucleotide 1707; the nucleotidesequence of SEQ ID NO:145 from nucleotide 580 to nucleotide 1707; thenucleotide sequence of the full-length protein coding sequence of cloneyb44_(—)1 deposited with the ATCC under accession number 98636; or thenucleotide sequence of a mature protein coding sequence of cloneyb44_(—)1 deposited with the ATCC under accession number 98636. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone yb44_(—)1 depositedwith the ATCC under accession number 98636. In further preferredembodiments, the present invention provides a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:146 having biological activity, the fragment preferably comprisingeight (more preferably twenty, most preferably thirty) consecutive aminoacids of SEQ ID NO:146, or a polynucleotide encoding a proteincomprising a fragment of the amnino acid sequence of SEQ ID NO:146having biological activity, the fragment comprising the amino acidsequence from amino acid 194 to amino acid 203 of SEQ ID NO:146.

[2590] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:145.

[2591] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2592] (a) a process comprising the steps of:

[2593] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2594] (aa) SEQIDNO:145,butexcludingthepoly(A) tail atthe 3′ end of SEQID NO:145; and

[2595] (ab) the nucleotide sequence of the cDNA insert of cloneyb44_(—)1 deposited with the ATCC under accession number 98636;

[2596] (ii) hybridizing said probe(s) to human genomnic DNA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[2597] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2598] (b) a process comprising the steps of:

[2599] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2600] (ba) SEQ ID NO:145, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:145; and

[2601] (bb) the nucleotide sequence of the cDNA insert of cloneyb44_(—)1 deposited with the ATCC under accession number 98636;

[2602] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2603] (iii) amplifying human DNA sequences; and

[2604] (iv) isolating the polynucleotide products of step (b)(iii).

[2605] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:145, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:145 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:145, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:145. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145from nucleotide 514 to nucleotide 1707, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:145 from nucleotide 514 to nucleotide 1707, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:145from nucleotide 514 to nucleotide 1707. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145from nucleotide 580 to nucleotide 1707, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:145 from nucleotide 580 to nucleotide 1707, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:145from nucleotide 580 to nucleotide 1707.

[2606] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2607] (a) the amino acid sequence of SEQ ID NO:146;

[2608] (b) fragments of the amino acid sequence of SEQ ID NO:146, eachfragment comprising eight consecutive amino acids of SEQ ID NO:146; and

[2609] (c) the amino acid sequence encoded by the cDNA insert of cloneyb44_(—)1 deposited with the ATCC under accession number 98636;

[2610] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:146. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:146 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:146, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:146 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 194 to amino acid 203 of SEQ ID NO: 146.

[2611] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2612] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:147;

[2613] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:147 from nucleotide 1529 to nucleotide 1726;

[2614] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:147 from nucleotide 1706 to nucleotide 1726;

[2615] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone bn69_(—)15 deposited withthe ATCC under accession number 98647;

[2616] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone bn69_(—)15 deposited with the ATCC underaccession number 98647;

[2617] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone bn69_(—)15 deposited with theATCC under accession number 98647;

[2618] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone bn69_(—)15 deposited with the ATCC under accessionnumber 98647;

[2619] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:148;

[2620] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 148 having biological activity,the fragment comprising eight consecutive amino acids of SEQ ID NO:148;

[2621] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2622] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2623] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2624] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:147 from nucleotide 1529 to nucleotide 1726; the nucleotidesequence of SEQ ID NO:147 from nucleotide 1706 to nucleotide 1726; thenucleotide sequence of the full-length protein coding sequence of clonebn69_(—)15 deposited with the ATCC under accession number 98647; or thenucleotide sequence of a mature protein coding sequence of clonebn69_(—)15 deposited with the ATCC under accession number 98647. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone bn69_(—)15deposited with the ATCC under accession number 98647. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:148from amino acid 1 to amino acid 53. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:148 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:148, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:148 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 28 to amino acid 37 of SEQ ID NO:148.

[2625] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:147.

[2626] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2627] (a) a process comprising the steps of:

[2628] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2629] (aa) SEQ ID NO:147,but excluding the poly(A) tail at the 3′ endof SEQ ID NO:147; and

[2630] (ab) the nucleotide sequence of the cDNA insert of clonebn69_(—)15 deposited with the ATCC under accession number 98647;

[2631] (ii) hybridizing said probe(s) to human genomnic DNA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[2632] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2633] (b) a process comprising the steps of:

[2634] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2635] (ba) SEQ ID NO:147, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:147; and

[2636] (bb) the nucleotide sequence of the cDNA insert of clonebn69_(—)15 deposited with the ATCC under accession number 98647;

[2637] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2638] (iii) amplifying human DNA sequences; and

[2639] (iv) isolating the polynucleotide products of step (b)(iii).

[2640] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:147, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:147 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:147, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:147. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:147from nucleotide 1529 to nucleotide 1726, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:147 from nucleotide 1529 to nucleotide 1726, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:147from nucleotide 1529 to nucleotide 1726. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:147from nucleotide 1706 to nucleotide 1726, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:147 from nucleotide 1706 to nucleotide 1726, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO: 147from nucleotide 1706 to nucleotide 1726.

[2641] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2642] (a) the amino acid sequence of SEQ ID NO:148;

[2643] (b) the amino acid sequence of SEQ ID NO:148 from amino acid 1 toamino acid 53;

[2644] (c) fragments of the amino acid sequence of SEQ ID NO:148, eachfragment comprising eight consecutive amino acids of SEQ ID NO:148; and

[2645] (d) the amino acid sequence encoded by the cDNA insert of clonebn69_(—)15 deposited with the ATCC under accession number 98647;

[2646] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:148 or the amino acid sequence of SEQ ID NO:148 from aminoacid 1 to amino acid 53. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:148 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:148, or a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:148 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 28 to amino acid 37 of SEQ ID NO:148.

[2647] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2648] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:149;

[2649] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO: 149 from nucleotide 334 to nucleotide 597;

[2650] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:149 from nucleotide 478 to nucleotide 597;

[2651] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone cb110_(—)1 deposited withthe ATCC under accession number 98647;

[2652] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone cb110_(—)1 deposited with the ATCC underaccession number 98647;

[2653] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone cb110_(—)1 deposited with theATCC under accession number 98647;

[2654] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone cb110_(—)1 deposited with the ATCC under accessionnumber 98647;

[2655] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:150;

[2656] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:150 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:150;

[2657] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2658] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2659] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2660] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:149 from nucleotide 334 to nucleotide 597; the nucleotidesequence of SEQ ID NO:149 from nucleotide 478 to nucleotide 597; thenucleotide sequence of the full-length protein coding sequence of clonecb110_(—)1 deposited with the ATCC under accession number 98647; or thenucleotide sequence of a mature protein coding sequence of clonecbllO_(—)1 deposited with the ATCC under accession number 98647. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone cb110_(—)1deposited with the ATCC under accession number 98647. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:150 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:150, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:150 having biological activity, the fragment comprising the aminoacid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:150.

[2661] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:149.

[2662] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2663] (a) a process comprising the steps of:

[2664] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2665] (aa) SEQ ID NO:149, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:149; and

[2666] (ab) the nucleotide sequence of the cDNA insert of clonecb110_(—)1 deposited with the ATCC under accession number 98647;

[2667] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2668] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2669] (b) a process comprising the steps of:

[2670] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2671] (ba) SEQ ID NO: 149, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:149; and

[2672] (bb) the nucleotide sequence of the cDNA insert of clonecb110_(—)1 deposited with the ATCC under accession number 98647;

[2673] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2674] (iii) amplifying human DNA sequences; and

[2675] (iv) isolating the polynucleotide products of step (b)(iii).

[2676] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:149, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:149 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:149, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:149. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149from nucleotide 334 to nucleotide 597, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:149 from nucleotide 334 to nucleotide 597, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:149from nucleotide 334 to nucleotide 597. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 149from nucleotide 478 to nucleotide 597, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:149 from nucleotide 478 to nucleotide 597, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:149from nucleotide 478 to nucleotide 597.

[2677] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2678] (a) the amino acid sequence of SEQ ID NO:150;

[2679] (b) fragments of the amino acid sequence of SEQ ID NO:150, eachfragment comprising eight consecutive amino acids of SEQ ID NO:150; and

[2680] (c) the amino acid sequence encoded by the cDNA insert of clonecb110_(—)1 deposited with the ATCC under accession number 98647;

[2681] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:150. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:150 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:150, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:150 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 39 to amino acid 48 of SEQ ID NO:150.

[2682] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2683] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:151;

[2684] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO: 151 from nucleotide 191 to nucleotide 1132;

[2685] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:151 from nucleotide 290 to nucleotide 1132;

[2686] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone ch4_(—)11 deposited withthe ATCC under accession number 98647;

[2687] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone ch4_(—)11 deposited with the ATCC underaccession number 98647;

[2688] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone ch4_(—)11 deposited with theATCC under accession number 98647;

[2689] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone ch4_(—)11 deposited with the ATCC under accessionnumber 98647;

[2690] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:152;

[2691] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 152 having biological activity,the fragment comprising eight consecutive amino acids of SEQ ID NO: 152;

[2692] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2693] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2694] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2695] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:151 from nucleotide 191 to nucleotide 1132; the nucleotidesequence of SEQ ID NO:151 from nucleotide 290 to nucleotide 1132; thenucleotide sequenceof the full-length protein coding sequence of clonech4_(—)11 deposited with the ATCC under accession number 98647; or thenucleotide sequence of a mature protein coding sequence of clonech4_(—)11 deposited with the ATCC under accession number 98647. In otherpreferred embodiments, the polynucleotide encodes the full-length or amature protein encoded by the cDNA insert of clone ch4_(—)11 depositedwith the ATCC under accession number 98647.

[2696] In further preferred embodiments, the present invention providesa polynucleotide encoding a protein comprising a fragment of the aminoacid sequence of SEQ ID NO:152 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:152, or a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:152 having biological activity, the fragment comprising theamino acid sequence from amino acid 152 to amino acid 161 of SEQ IDNO:152.

[2697] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:151.

[2698] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2699] (a) a process comprising the steps of:

[2700] (i) preparing one or more polynucleotideprobes thathybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2701] (aa) SEQ IDNO:151, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:151; and

[2702] (ab) the nucleo tide sequence of the cDNA insert of clonech4_(—)11 deposited with the ATCC under accession number 98647;

[2703] (ii) hybridizing said probe(s) to human genomic DINA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[2704] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2705] (b) a process comprising the steps of:

[2706] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2707] (ba) SEQ ID NO:151,butexcludingthepoly(A) tail atthe 3′ end ofSEQ ID NO:151; and

[2708] (bb) the nucleotide sequence of the cDNA insert of clonech4_(—)11 deposited with the ATCC under accession number 98647;

[2709] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2710] (iii) amplifying human DNA sequences; and

[2711] (iv) isolating the polynucleotide products of step (b)(iii).

[2712] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:151, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:151 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:151, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:151. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151from nucleotide 191 to nucleotide 1132, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:151 from nucleotide 191 to nucleotide 1132, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:151from nucleotide 191 to nucleotide 1132. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151from nucleotide 290 to nucleotide 1132, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:151 from nucleotide 290 to nucleotide 1132, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:151from nucleotide 290 to nucleotide 1132.

[2713] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2714] (a) the amino acid sequence of SEQ ID NO:152;

[2715] (b) fragments of the amino acid sequence of SEQ ID NO:152, eachfragment comprising eight consecutive amino acids of SEQ ID NO:152; and

[2716] (c) the amino acid sequence encoded by the cDNA insert of clonech4_(—)11 deposited with the ATCC under accession number 98647;

[2717] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:152. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:152 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:152, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:152 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 152 to amino acid 161 of SEQ ID NO:152.

[2718] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2719] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:153;

[2720] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:153 from nucleotide 732 to nucleotide 1898;

[2721] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone cn621_(—)8 deposited withthe ATCC under accession number 98647;

[2722] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone cn621_(—)8 deposited with the ATCC underaccession number 98647;

[2723] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone cn621_(—)8 deposited with theATCC under accession number 98647;

[2724] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone cn621_(—)8 deposited with the ATCC under accessionnumber 98647;

[2725] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:154;

[2726] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:154 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:154;

[2727] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[2728] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[2729] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[2730] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:153 from nucleotide 732 to nucleotide 1898; the nucleotidesequence of the full-length protein coding sequence of clone cn621_(—)8deposited with the ATCC under accession number 98647; or the nucleotidesequence of a mature protein coding sequence of clone cn621_(—)8deposited with the ATCC under accession number 98647. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone cn621_(—)8 deposited withthe ATCC under accession number 98647. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:154 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:154, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:154 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 189 to amino acid 198 of SEQ ID NO:154.

[2731] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:153.

[2732] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2733] (a) a process comprising the steps of:

[2734] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2735] (aa) SEQ ID NO:153, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:153; and

[2736] (ab) the nucleotide sequence of the cDNA insert of clonecn621_(—)8 deposited with the ATCC under accession number 98647;

[2737] (ii) hybridizing said probe(s) to human genornic DNA inconditions at least as stringent as 4×SSC at 65 degrees C; and

[2738] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2739] (b) a process comprising the steps of:

[2740] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2741] (ba) SEQ ID NO: 153, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:153; and

[2742] (bb) the nucleotide sequence of the cDNA insert of clonecn621_(—)8 deposited with the ATCC under accession number 98647;

[2743] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2744] (iii) amplifying human DNA sequences; and

[2745] (iv) isolating the polynucleotide products of step (b)(iii).

[2746] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:153, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:153 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:153, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:153. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:153from nucleotide 732 to nucleotide 1898, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:153 from nucleotide 732 to nucleotide 1898, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:153from nucleotide 732 to nucleotide 1898.

[2747] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2748] (a) the amino acid sequence of SEQ ID NO:154;

[2749] (b) fragments of the amino acid sequence of SEQ ID NO:154, eachfragment comprising eight consecutive amino acids of SEQ ID NO:154; and

[2750] (c) the amino acid sequence encoded by the cDNA insert of clonecn621_(—)8 deposited with the ATCC under accession number 98647;

[2751] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:154. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:154 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:154, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:154 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 189 to amino acid 198 of SEQ ID NO:154.

[2752] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2753] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:155;

[2754] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:155 from nucleotide 308 to nucleotide 592;

[2755] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:155 from nucleotide 377 to nucleotide 592;

[2756] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone gy621_(—)1 deposited withthe ATCC under accession number 98647;

[2757] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone gy621_(—)1 deposited with the ATCC underaccession number 98647;

[2758] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone gy621_(—)1 deposited with theATCC under accession number 98647;

[2759] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone gy621_(—)1 deposited with the ATCC under accessionnumber 98647;

[2760] (h) a polynucleotide encoding a protein comprising the amninoacid sequence of SEQ ID NO:156;

[2761] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:156 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO: 156;

[2762] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2763] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2764] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2765] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:155 fromnucleotide 308 to nucleotide 592; the nucleotidesequence of SEQ ID NO:155 from nucleotide 377 to nucleotide 592; thenucleotide sequence of the full-length protein coding sequence of clonegy621_(—)1 deposited with the ATCC under accession number 98647; or thenucleotide sequence of a mature protein coding sequence of clonegy621_(—)1 deposited with the ATCC under accession number 98647. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone gy621_(—)1deposited with the ATCC under accession number 98647. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:156 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:156, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:156 having biological activity, the fragment comprising the aminoacid sequence from amino acid 42 to amino acid 51 of SEQ ID NO:156.

[2766] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:155.

[2767] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2768] (a) a process comprising the steps of:

[2769] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2770] (aa) SEQ ID NO: 155, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:155; and

[2771] (ab) the nucleotide sequence of the cDNA insert of clonegy621_(—)1 deposited with the ATCC under accession number 98647;

[2772] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2773] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2774] (b) a process comprising the steps of:

[2775] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2776] (ba) SEQ ID NO:155, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:155; and

[2777] (bb) the nucleotide sequence of the cDNA insert of clonegy621_(—)1 deposited with the ATCC under accession number 98647;

[2778] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2779] (iii) amplifying human DNA sequences; and

[2780] (iv) isolating the polynucleotide products of step (b)(iii).

[2781] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:155, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:155 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:155, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:155. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155from nucleotide 308 to nucleotide 592, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:155 from nucleotide 308 to nucleotide 592, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:155from nucleotide 308 to nucleotide 592. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155from nucleotide 377 to nucleotide 592, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:155 from nucleotide 377 to nucleotide 592, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:155from nucleotide 377 to nucleotide 592.

[2782] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2783] (a) the amino acid sequence of SEQ ID NO:156;

[2784] (b) fragments of the amino acid sequence of SEQ ID NO:156, eachfragment comprising eight consecutive amino acids of SEQ ID NO:156; and

[2785] (c) the amino acid sequence encoded by the cDNA insert of clonegy621_(—)1 deposited with the ATCC under accession number 98647;

[2786] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:156. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:156 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:156, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:156 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 42 to amino acid 51 of SEQ ID NO:156.

[2787] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2788] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:157;

[2789] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:157 from nucleotide 124 to nucleotide 1881;

[2790] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:157 from nucleotide 325 to nucleotide 1881;

[2791] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone hb1041_(—)2 deposited withthe ATCC under accession number 98647;

[2792] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone hb1041_(—)2 deposited with the ATCC underaccession number 98647;

[2793] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone hb1041_(—)2 deposited with theATCC under accession number 98647;

[2794] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone hb1041_(—)2 deposited with the ATCC under accessionnumber 98647;

[2795] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:158;

[2796] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO: 158 having biological activity,the fragment comprising eight consecutive amino acids of SEQ ID NO:158;

[2797] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2798] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2799] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2800] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:157 from nucleotide 124 to nucleotide 1881; the nucleotidesequence of SEQ ID NO:157 from nucleotide 325 to nucleotide 1881; thenucleotide sequence of the full-length protein coding sequence of clonehb1041_(—)2 deposited with the ATCC under accession number 98647; or thenucleotide sequence of a mature protein coding sequence of clonehb1041_(—)2 deposited with the ATCC under accession number 98647. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone hb1041_(—)2deposited with the ATCC under accession number 98647. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:158 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO: 158, or a polynucleotide encodinga protein comprising a fragment of the amino acid sequence of SEQ IDNO:158 having biological activity, the fragment comprising the aminoacid sequence from amino acid 288 to amino acid 297 of SEQ ID NO:158.

[2801] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:157.

[2802] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2803] (a) a process comprising the steps of:

[2804] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2805] (aa) SEQ ID NO:157, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:157; and

[2806] (ab) the nucleotide sequence of the cDNA insert of clonehb1041_(—)2 deposited with the ATCC under accession number 98647;

[2807] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2808] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2809] (b) a process comprising the steps of:

[2810] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2811] (ba) SEQ ID NO: 157, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:157; and

[2812] (bb) the nucleotide sequence of the cDNA insert of clonehb1041_(—)2 deposited with the ATCC under accession number 98647;

[2813] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2814] (iii) amplifying human DNA sequences; and

[2815] (iv) isolating the polynucleotide products of step (b)(iii).

[2816] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:157, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:157 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:157, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:157. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:157from nucleotide 124 to nucleotide 1881, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:157 from nucleotide 124 to nucleotide 1881, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:157from nucleotide 124 to nucleotide 1881. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:157from nucleotide 325 to nucleotide 1881, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:157 from nucleotide 325 to nucleotide 1881, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:157from nucleotide 325 to nucleotide 1881.

[2817] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2818] (a) the amino acid sequence of SEQ ID NO:158;

[2819] (b) fragments of the amino acid sequence of SEQ ID NO:158, eachfragment comprising eight consecutive amino acids of SEQ ID NO:158; and

[2820] (c) the amino acid sequence encoded by the cDNA insert of clonehb1041_(—)2 deposited with the ATCC under accession number 98647;

[2821] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:158. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:158 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:158, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:158 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 288 to amino acid 297 of SEQ ID NO:158.

[2822] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2823] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:159;

[2824] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:159 from nucleotide 163 to nucleotide 1431;

[2825] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone mh703_(—)1 deposited withthe ATCC under accession number 98647;

[2826] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone mh703_(—)1 deposited with the ATCC underaccession number 98647;

[2827] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone mh703_(—)1 deposited with theATCC under accession number 98647;

[2828] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone mh703_(—)1 deposited with the ATCC under accessionnumber 98647;

[2829] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:160;

[2830] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:160 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:160;

[2831] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[2832] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above; and

[2833] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h).

[2834] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:159fromnucleotide 163 tonucleotide 1431;thenucleotidesequence of the full-length protein coding sequence ofclone mh703_(—)1 deposited with the ATCC under accession number 98647;or the nucleotide sequence of a mature protein coding sequence of clonemh703_(—)1 deposited with the ATCC under accession number 98647. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone mh703_(—)1deposited with the ATCC under accession number 98647. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:160 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:160, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:160 having biological activity, the fragment comprising the aminoacid sequence from amino acid 206 to amino acid 215 of SEQ ID NO:160.

[2835] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:159.

[2836] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2837] (a) a process comprising the steps of:

[2838] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2839] (aa) SEQ ID NO:159, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:159; and

[2840] (ab) the nucleotide sequence of the cDNA insert of clonemh703_(—)1 deposited with the ATCC under accession number 98647;

[2841] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2842] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2843] (b) a process comprising the steps of:

[2844] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2845] (ba) SEQ ID NO: 159, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:159; and

[2846] (bb) the nucleotide sequence of the cDNA insert of clonemh703_(—)1 deposited with the ATCC under accession number 98647;

[2847] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2848] (iii) amplifying human DNA sequences; and

[2849] (iv) isolating the polynucleotide products of step (b)(iii).

[2850] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:159, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:159 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:159, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:159. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159from nucleotide 163 to nucleotide 1431, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:159 from nucleotide 163 to nucleotide 1431, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:159from nucleotide 163 to nucleotide 1431.

[2851] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2852] (a) the amino acid sequence of SEQ ID NO:160;

[2853] (b) fragments of the amino acid sequence of SEQ ID NO:160, eachfragment comprising eight consecutive amino acids of SEQ ID NO:160; and

[2854] (c) the amino acid sequence encoded by the cDNA insert of clonemh703_(—)1 deposited with the ATCC under accession number 98647;

[2855] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:160. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:160 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:160, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:160 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 206 to amino acid 215 of SEQ ID NO:160.

[2856] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2857] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:161;

[2858] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:161 from nucleotide 653 to nucleotide 934;

[2859] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:161 from nucleotide 878 to nucleotide 934;

[2860] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone na461_(—)19 deposited withthe ATCC under accession number 98647;

[2861] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone na461_(—)19 deposited with the ATCC underaccession number 98647;

[2862] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone na461_(—)19 deposited with theATCC under accession number 98647;

[2863] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone na461_(—)19 deposited with the ATCC under accessionnumber 98647;

[2864] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:162;

[2865] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:162 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:162;

[2866] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2867] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2868] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2869] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:161 fromnucleotide 653 to nucleotide 934; the nucleotidesequence of SEQ ID NO:161 from nucleotide 878 to nucleotide 934; thenucleotide sequence of the full-length protein coding sequence of clonena461_(—)19 deposited with the ATCC under accession number 98647; or thenucleotide sequence of a mature protein coding sequence of clonena461_(—)19 deposited with the ATCC under accession number 98647. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone na461_(—)19deposited with the ATCC under accession number 98647. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:162 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:162, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:162 having biological activity, the fragment comprising the aminoacid sequence from amino acid 42 to amino acid 51 of SEQ ID NO:162.

[2870] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:161.

[2871] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2872] (a) a process comprising the steps of:

[2873] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2874] (aa) SEQ ID NO:161, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:161; and

[2875] (ab) the nucleotide sequence of the cDNA insert of clonena461_(—)19 deposited with the ATCC under accession number 98647;

[2876] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2877] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2878] (b) a process comprising the steps of:

[2879] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2880] (ba) SEQ ID NO:161,but excluding the poly(A) tail at the 3′ endof SEQ ID NO:161; and

[2881] (bb) the nucleotide sequence of the cDNA insert of clonena461_(—)19 deposited with the ATCC under accession number 98647;

[2882] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2883] (iii) amplifying human DNA sequences; and

[2884] (iv) isolating the polynucleotide products of step (b)(iii).

[2885] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:161, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:161 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:161, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:161. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:161from nucleotide 653 to nucleotide 934, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:161 from nucleotide 653 to nucleotide 934, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:161from nucleotide 653 to nucleotide 934. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:161from nucleotide 878 to nucleotide 934, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:161 from nucleotide 878 to nucleotide 934, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:161from nucleotide 878 to nucleotide 934.

[2886] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2887] (a) the amino acid sequence of SEQ ID NO:162;

[2888] (b) fragments of the amino acid sequence of SEQ ID NO:162, eachfragment comprising eight consecutive amino acids of SEQ ID NO:162; and

[2889] (c) the amino acid sequence encoded by the cDNA insert of clonena461_(—)19 deposited with the ATCC under accession number 98647;

[2890] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:162. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:162 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:162, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:162 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 42 to amino acid 51 of SEQ ID NO: 162.

[2891] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2892] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:163;

[2893] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:163 from nucleotide 72 to nucleotide 1319;

[2894] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:163 from nucleotide 1071 to nucleotide 1319;

[2895] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone na492_(—)2 deposited withthe ATCC under accession number 98647;

[2896] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone na492_(—)2 deposited with the ATCC underaccession number 98647;

[2897] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone na492_(—)2 deposited with theATCC under accession number 98647;

[2898] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone na492_(—)2 deposited with the ATCC under accessionnumber 98647;

[2899] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:164;

[2900] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:164 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:164;

[2901] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2902] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2903] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2904] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:163 from nucleotide 72 to nucleotide 1319; the nucleotidesequence of SEQ ID NO:163 from nucleotide 1071 to nucleotide 1319; thenucleotide sequence of the full-length protein coding sequence of clonena492_(—)2 deposited with the ATCC under accession number 98647; or thenucleotide sequence of a mature protein coding sequence of clonena492_(—)2 deposited with the ATCC under accession number 98647. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone na492_(—)2deposited with the ATCC under accession number 98647. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:164 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:164, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:164 having biological activity, the fragment comprising the aminoacid sequence from amino acid 202 to amino acid 211 of SEQ ID NO:164.

[2905] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:163.

[2906] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2907] (a) a process comprising the steps of:

[2908] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2909] (aa) SEQ ID NO: 163, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:163; and

[2910] (ab) the nucleotide sequence of the cDNA insert of clonena492_(—)2 deposited with the ATCC under accession number 98647;

[2911] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2912] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2913] (b) a process comprising the steps of:

[2914] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2915] (ba) SEQ ID NO:163, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:163; and

[2916] (bb) the nucleotide sequence of the cDNA insert of clonena492_(—)2 deposited with the ATCC under accession number 98647;

[2917] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2918] (iii) amplifying human DNA sequences; and

[2919] (iv) isolating the polynucleotide products of step (b)(iii).

[2920] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:163, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:163 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:163, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:163. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:163from nucleotide 72 to nucleotide 1319, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:163 from nucleotide 72 to nucleotide 1319, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:163from nucleotide 72 to nucleotide 1319. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:163from nucleotide 1071 to nucleotide 1319, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:163 from nucleotide 1071 to nucleotide 1319, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:163from nucleotide 1071 to nucleotide 1319.

[2921] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2922] (a) the amino acid sequence of SEQ ID NO:164;

[2923] (b) fragments of the amino acid sequence of SEQ ID NO:164, eachfragment comprising eight consecutive amino acids of SEQ ID NO:164; and

[2924] (c) the amino acid sequence encoded by the cDNA insert of clonena492_(—)2 deposited with the ATCC under accession number 98647;

[2925] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:164. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:164 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)consecutive amino acids of SEQ ID NO:164, or a protein comprising afragment of the anino acid sequence of SEQ ID NO:164 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 202 to amino acid 211 of SEQ ID NO:164.

[2926] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2927] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:165;

[2928] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:165 from nucleotide 2848 to nucleotide 3048;

[2929] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:165 from nucleotide 3004 to nucleotide 3048;

[2930] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone na669_(—)10 deposited withthe ATCC under accession number 98647;

[2931] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone na669_(—)10 deposited with the ATCC underaccession number 98647;

[2932] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone na669_(—)10 deposited with theATCC under accession number 98647;

[2933] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone na669_(—)10 depositedwith the ATCC underaccessionnumber 98647;

[2934] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:166;

[2935] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:166 having biological activity, thefragment comprising eight consecutive amino acids of SEQ ID NO:166;

[2936] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2937] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above; and

[2938] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i).

[2939] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:165 from nucleotide 2848 to nucleotide 3048; the nucleotidesequence of SEQ ID NO:165 from nucleotide 3004 to nucleotide 3048; thenucleotide sequence of the full-length protein coding sequence of clonena669_(—)10 deposited with the ATCC under accession number 98647; or thenucleotide sequence of a mature protein coding sequence of clonena669_(—)10 deposited with the ATCC under accession number 98647. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone na669_(—)10deposited with the ATCC under accession number 98647. In yet otherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:166from amino acid 5 to amino acid 62. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:166 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) consecutive amino acids ofSEQ ID NO:166, or a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:166 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 28 to amino acid 37 of SEQ ID NO:166.

[2940] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:165.

[2941] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2942] (a) a process comprising the steps of:

[2943] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2944] (aa) SEQ ID NO: 165, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:165; and

[2945] (ab) the nucleotide sequence of the cDNA insert of clonena669_(—)10 deposited with the ATCC under accession number 98647;

[2946] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 65 degrees C; and

[2947] (iii) isolating the DNA polynucleotides detected wth theprobe(s); and

[2948] (b) a process comprising the steps of:

[2949] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2950] (ba) SEQ ID NO:165, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:165; and

[2951] (bb) the nucleotide sequence of the cDNA insert of clonena669_(—)10 deposited with the ATCC under accession number 98647;

[2952] (ii) hybridizing said primer(s) to human genornic DNA inconditions at least as stringent as 4×SSC at 65 degrees C;

[2953] (iii) amplifying human DNA sequences; and

[2954] (iv) isolating the polynucleotide products of step (b)(iii).

[2955] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:165, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:165 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:165, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:165. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:165from nucleotide 2848 to nucleotide 3048, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:165 from nucleotide 2848 to nucleotide 3048, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:165from nucleotide 2848 to nucleotide 3048. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:165from nucleotide 3004 to nucleotide 3048, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:165 from nucleotide 3004 to nucleotide 3048, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:165from nucleotide 3004 to nucleotide 3048.

[2956] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2957] (a) the amino acid sequence of SEQ ID NO:166;

[2958] (b) the amino acid sequence of SEQ ID NO:166 from amino acid 5 toamino acid 62;

[2959] (c) fragments of the amino acid sequence of SEQ ID NO:166, eachfragment comprising eight consecutive amino acids of SEQ ID NO:166; and

[2960] (d) the amino acid sequence encoded by the cDNA insert of clonena669_(—)10 deposited with the ATCC under accession number 98647;

[2961] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:166 or the amino acid sequence of SEQ ID NO:166 from aminoacid 5 to amino acid 62. In further preferred embodiments, the presentinvention provides a protein comprising a fragment of the amino acidsequence of SEQ ID NO:166 having biological activity, the fragmentpreferably comprising eight (more preferably twenty, most preferablythirty) consecutive amino acids of SEQ ID NO:166, or a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:166 havingbiological activity, the fragment comprising the amino acid sequencefrom amino acid 28 to amino acid 37 of SEQ ID NO:166.

[2962] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2963] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:167;

[2964] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:167 from nucleotide 185 to nucleotide 1678;

[2965] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:167 from nucleotide 482 to nucleotide 1678;

[2966] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone co821_(—)31 deposited withthe ATCC under accession number 98663;

[2967] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone co821_(—)31 deposited with the ATCC underaccession number 98663;

[2968] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone co821_(—)31 deposited with theATCC under accession number 98663;

[2969] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone co821_(—)31 deposited with the ATCC under accessionnumber 98663;

[2970] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:168;

[2971] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:168 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:168;

[2972] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[2973] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above;

[2974] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i); and

[2975] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i) and that has alength that is at least 25% of the length of SEQ ID NO:167.

[2976] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:167 from nucleotide 185 to nucleotide 1678; the nucleotidesequence of SEQ ID NO:167 from nucleotide 482 to nucleotide 1678; thenucleotide sequence of the fulllength protein coding sequence of cloneco821_(—)31 deposited with the ATCC under accession number 98663; or thenucleotide sequence of a mature protein coding sequence of cloneco821_(—)31 deposited with the ATCC under accession number 98663. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone co821_(—)31deposited with the ATCC under accession number 98663. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:168 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:168, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:168 having biological activity, the fragment comprising the aminoacid sequence from amino acid 244 to amino acid 253 of SEQ ID NO:168.

[2977] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:167.

[2978] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[2979] (a) a process comprising the steps of:

[2980] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[2981] (aa) SEQ ID NO:167, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:167; and

[2982] (ab) the nucleotide sequence of the cDNA insert of cloneco821_(—)31 deposited with the ATCC under accession number 98663;

[2983] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[2984] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[2985] (b) a process comprising the steps of:

[2986] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[2987] (ba) SEQ ID NO:167, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:167; and

[2988] (bb) the nucleotide sequence of the cDNA insert of cloneco821_(—)31 deposited with the ATCC under accession number 98663;

[2989] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[2990] (iii) amplifying human DNA sequences; and

[2991] (iv) isolating the polynucleotide products of step (b)(iii).

[2992] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:167, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:167 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:167, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:167. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:167from nucleotide 185 to nucleotide 1678, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:167 from nucleotide 185 to nucleotide 1678, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:167from nucleotide 185 to nucleotide 1678. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:167from nucleotide 482 to nucleotide 1678, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:167 from nucleotide 482 to nucleotide 1678, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:167from nucleotide 482 to nucleotide 1678.

[2993] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[2994] (a) the amino acid sequence of SEQ ID NO:168;

[2995] (b) a fragment of the amino acid sequence of SEQ ID NO:168, thefragment comprising eight contiguous amino acids of SEQ ID NO:168; and

[2996] (c) the amino acid sequence encoded by the cDNA insert of cloneco821_(—)31 deposited with the ATCC under accession number 98663;

[2997] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:168. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:168 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:168, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:168 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 244 to amino acid 253 of SEQ ID NO:168.

[2998] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[2999] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:169;

[3000] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:169 from nucleotide 176 to nucleotide 754;

[3001] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:169 from nucleotide 425 to nucleotide 754;

[3002] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone dk329_(—)1 deposited withthe ATCC under accession number 98663;

[3003] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone dk329_(—)1 deposited with the ATCC underaccession number 98663;

[3004] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone dk329_(—)1 deposited with theATCC under accession number 98663;

[3005] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone dk329_(—)1 deposited with the ATCC under accessionnumber 98663;

[3006] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:170;

[3007] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:170 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:170;

[3008] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[3009] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above;

[3010] (1) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i); and

[3011] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i) and that has alength that is at least 25% of the length of SEQ ID NO:169.

[3012] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:169 fromnucleotide 176 to nucleotide 754; the nucleotidesequence of SEQ ID NO:169 from nucleotide 425 to nucleotide 754; thenucleotide sequence of the full-length protein coding sequence of clonedk329_(—)1 deposited with the ATCC under accession number 98663; or thenucleotide sequence of a mature protein coding sequence of clonedk329_(—)1 deposited with the ATCC under accession number 98663. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone dk329_(—)1deposited with the ATCC under accession number 98663. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:170 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:170, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:170 having biological activity, the fragment comprising the aminoacid sequence from amino acid 91 to amino acid 100 of SEQ ID NO:170.

[3013] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:169.

[3014] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[3015] (a) a process comprising the steps of:

[3016] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[3017] (aa) SEQ ID NO:169, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:169; and

[3018] (ab) the nucleotide sequence of the cDNA insert of clonedk329_(—)1 deposited with the ATCC under accession number 98663;

[3019] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[3020] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[3021] (b) a process comprising the steps of:

[3022] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[3023] (ba) SEQ ID NO:169, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:169; and

[3024] (bb) the nucleotide sequence of the cDNA insert of clonedk329_(—)1 deposited with the ATCC under accession number 98663;

[3025] (ii) hybridizing said primer(s) to human genornic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[3026] (iii) amplifying human DNA sequences; and

[3027] (iv) isolating the polynucleotide products of step (b)(iii).

[3028] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:169, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:169 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:169, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:169. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:169from nucleotide 176 to nucleotide 754, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:169 from nucleotide 176 to nucleotide 754, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:169from nucleotide 176 to nucleotide 754. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:169from nucleotide 425 to nucleotide 754, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:169 from nucleotide 425 to nucleotide 754, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:169from nucleotide 425 to nucleotide 754.

[3029] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[3030] (a) the amino acid sequence of SEQ ID NO:170;

[3031] (b) a fragment of the amino acid sequence of SEQ ID NO:170, thefragment comprising eight contiguous amino acids of SEQ ID NO:170; and

[3032] (c) the amino acid sequence encoded by the cDNA insert of clonedk329_(—)1 deposited with the ATCC under accession number 98663;

[3033] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:170. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:170 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:170, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:170 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 91 to amino acid 100 of SEQ ID NO:170.

[3034] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[3035] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:171;

[3036] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:171 from nucleotide 190 to nucleotide 1449;

[3037] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:171 from nucleotide 913 to nucleotide 1449;

[3038] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone fx317_(—)11 deposited withthe ATCC under accession number 98663;

[3039] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone fx317_(—)11 deposited with the ATCC underaccession number 98663;

[3040] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone fx317_(—)11 deposited with theATCC under accession number 98663;

[3041] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone fx317_(—)11 deposited with the ATCC under accessionnumber 98663;

[3042] (h) a polynucleotide encoding a protein comprising the amninoacid sequence of SEQ ID NO:172;

[3043] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:172 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:172;

[3044] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[3045] (k) a pglynucleotide which encodes a species homologue of theprotein of (h) or (i) above;

[3046] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i); and

[3047] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i) and that has alength that is at least 25% of the length of SEQ ID NO:171.

[3048] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:171 from nucleotide 190 to nucleotide 1449; the nucleotidesequence of SEQ ID NO:171 from nucleotide 913 to nucleotide 1449; thenucleotide sequence of the full-length protein coding sequence of clonefx317_(—)11 deposited with the ATCC under accession number 98663; or thenucleotide sequence of a mature protein coding sequence of clonefx317_(—)11 deposited with the ATCC under accession number 98663. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone fx317_(—)11deposited with the ATCC under accession number 98663. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:172 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:172, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:172 having biological activity, the fragment comprising the aminoacid sequence from amino acid 205 to amino acid 214 of SEQ ID NO:172.

[3049] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:171.

[3050] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[3051] (a) a process comprising the steps of:

[3052] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[3053] (aa) SEQ ID NO:171,but excluding the poly(A) tail at the 3′ endof SEQ ID NO:171; and

[3054] (ab) the nucleotide sequence of the cDNA insert of clonefx317_(—)11 depositedwiththe ATCC underaccession number 98663;

[3055] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[3056] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[3057] (b) a process comprising the steps of:

[3058] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[3059] (ba) SEQ ID NO:171, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:171; and

[3060] (bb) the nucleotide sequence of the cDNA insert of clonefx317_(—)11 deposited with the ATCC under accession number 98663;

[3061] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[3062] (iii) amplifying human DNA sequences; and

[3063] (iv) isolating the polynucleotide products of step (b)(iii).

[3064] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:171, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:171 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:171, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:171. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:171from nucleotide 190 to nucleotide 1449, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:171 from nucleotide 190 to nucleotide 1449, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:171from nucleotide 190 to nucleotide 1449. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:171fromnucleotide 913 to nucleotide 1449, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:171 from nucleotide 913 to nucleotide 1449, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:171from nucleotide 913 to nucleotide 1449.

[3065] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[3066] (a) the amino acid sequence of SEQ ID NO:172;

[3067] (b) a fragment of the amino acid sequence of SEQ ID NO:172, thefragment comprising eight contiguous amino acids of SEQ ID NO:172; and

[3068] (c) the amino acid sequence encoded by the cDNA insert of clonefx317_(—)11 deposited with the ATCC under accession number 98663;

[3069] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:172. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:172 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:172, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:172 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 205 to amino acid 214 of SEQ ID NO:172.

[3070] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[3071] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:173;

[3072] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:173 from nucleotide 51 to nucleotide 1202;

[3073] (c) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone lp547_(—)4 deposited withthe ATCC under accession number 98663;

[3074] (d) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone lp547_(—)4 deposited with the ATCC underaccession number 98663;

[3075] (e) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone lp547_(—)4 deposited with theATCC under accession number 98663;

[3076] (f) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone lp547_(—)4 deposited with the ATCC under accessionnumber 98663;

[3077] (g) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:174;

[3078] (h) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:174 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:174;

[3079] (i) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(f) above;

[3080] (j) a polynucleotide which encodes a species homologue of theprotein of (g) or (h) above;

[3081] (k) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h); and

[3082] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(h) and that has alength that is at least 25% of the length of SEQ ID NO:173.

[3083] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:173 from nucleotide 51 to nucleotide 1202; the nucleotidesequence of the full-length protein coding sequence of clone lp547_(—)4deposited with the ATCC under accession number 98663; or the nucleotidesequence of a mature protein coding sequence of clone lp547_(—)4deposited with the ATCC under accession number 98663. In other preferredembodiments, the polynucleotide encodes the full-length or a matureprotein encoded by the cDNA insert of clone lp547_(—)4 deposited withthe ATCC under accession number 98663. In further preferred embodiments,the present invention provides a polynucleotide encoding a proteincomprising a fragment of the amino acid sequence of SEQ ID NO:174 havingbiological activity, the fragment preferably comprising eight (morepreferably twenty, most preferably thirty) contiguous amino acids of SEQID NO:174, or a polynucleotide encoding a protein comprising a fragmentof the amnino acid sequence of SEQ ID NO:174 having biological activity,the fragment comprising the amino acid sequence from amino acid 187 toamino acid 196 of SEQ ID NO:174.

[3084] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:173.

[3085] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[3086] (a) a process comprising the steps of:

[3087] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[3088] (aa) SEQ ID NO: 173, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:173; and

[3089] (ab) the nucleotide sequence of the cDNA insert of clonelp547_(—)4 deposited with the ATCC under accession number 98663;

[3090] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[3091] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[3092] (b) a process comprising the steps of:

[3093] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[3094] (ba) SEQ ID NO:173, but exluding the poly(A) tail at the 3′ endof SEQ ID NO:173; and

[3095] (bb) the nucleotide sequence of the cDNA insert of clonelp547_(—)4 deposited with the ATCC under accession number 98663;

[3096] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[3097] (iii) amplifying human DNA sequences; and

[3098] (iv) isolating the polynucleotide products of step (b)(iii).

[3099] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:173, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:173 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:173, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:173. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:173from nucleotide 51 to nucleotide 1202, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:173 from nucleotide 51 to nucleotide 1202, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:173from nucleotide 51 to nucleotide 1202.

[3100] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[3101] (a) the amino acid sequence of SEQ ID NO:174;

[3102] (b) a fragment of the amino acid sequence of SEQ ID NO:174, thefragment comprising eight contiguous amino acids of SEQ ID NO:174; and

[3103] (c) the amino acid sequence encoded by the cDNA insert of clonelp547_(—)4 deposited with the ATCC under accession number 98663;

[3104] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:174. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:174 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:174, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:174 having biologicalactivity, the fragment comprising the L amino acid sequence from aminoacid 187 to amino acid 196 of SEQ ID NO:174.

[3105] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[3106] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:175;

[3107] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:175 from nucleotide 61 to nucleotide 2559;

[3108] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:175 from nucleotide 904 to nucleotide 2559;

[3109] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone lv310_(—)7 deposited withthe ATCC under accession number 98663;

[3110] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone lv310_(—)7 deposited with the ATCC underaccession number 98663;

[3111] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone lv310_(—)7 deposited with theATCC under accession number 98663;

[3112] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone lv310_(—)7 deposited with the ATCC under accessionnumber 98663;

[3113] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:176;

[3114] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:176 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:176;

[3115] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[3116] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above;

[3117] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i); and

[3118] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i) and that has alength that is at least 25% of the length of SEQ ID NO:175.

[3119] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:175 from nucleotide 61 to nucleotide 2559; the nucleotidesequence of SEQ ID NO:175 from nudeotide 904 to nucleotide 2559; thenucleotide sequence of the full-length protein coding sequence of clonelv310_(—)7 deposited with the ATCC under accession number 98663; or thenucleotide sequence of a mature protein coding sequence of clonelv310_(—)7 deposited with the ATCC under accession number 98663. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone lv310_(—)7deposited with the ATCC under accession number 98663. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:176 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:176, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:176 having biological activity, the fragment comprising the aminoacid sequence from amino acid 411 to amino acid 420 of SEQ ID NO:176.

[3120] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:175.

[3121] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[3122] (a) a process comprising the steps of:

[3123] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[3124] (aa) SEQ ID NO:175, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:175; and

[3125] (ab) the nucleotide sequence of the cDNA insert of clonelv310_(—)7 deposited with the ATCC under accession number 98663;

[3126] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[3127] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[3128] (b) a process comprising the steps of:

[3129] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[3130] (ba) SEQ ID NO:175, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:175; and

[3131] (bb) the nucleotide sequence of the cDNA insert of clonelv310_(—)7 deposited with the ATCC under accession number 98663;

[3132] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[3133] (iii) amplifying human DNA sequences; and

[3134] (iv) isolating the polynucleotide products of step (b)(iii).

[3135] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:175, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:175 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:175, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:175. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 175from nucleotide 61 to nucleotide 2559, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:175 from nucleotide 61 to nucleotide 2559, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:175from nucleotide 61 to nucleotide 2559. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:175from nucleotide 904 to nucleotide 2559, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:175 from nucleotide 904 to nucleotide 2559, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:175from nucleotide 904 to nucleotide 2559.

[3136] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[3137] (a) the amino acid sequence of SEQ ID NO:176;

[3138] (b) a fragment of the amino acid sequence of SEQ ID NO:176, thefragment comprising eight contiguous amino acids of SEQ ID NO:176; and

[3139] (c) the amino acid sequence encoded by the cDNA insert of clonelv310_(—)7 deposited with the ATCC under accession number 98663;

[3140] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:176. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:176 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:176, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:176 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 411 to amino acid 420 of SEQ ID NO:176.

[3141] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[3142] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:177;

[3143] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:177 from nucleotide 389 to nucleotide 1330;

[3144] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:177 from nucleotide 1286 to nucleotide 1330;

[3145] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone nq34_(—)12 deposited withthe ATCC under accession number 98663;

[3146] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone nq34_(—)12 deposited with the ATCC underaccession number 98663;

[3147] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone nq34_(—)12 deposited with theATCC under accession number 98663;

[3148] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone nq34_(—)12 deposited with the ATCC under accessionnumber 98663;

[3149] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:178;

[3150] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:178 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:178;

[3151] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[3152] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above;

[3153] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i); and

[3154] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i) and that has alength that is at least 25% of the length of SEQ ID NO:177.

[3155] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:177 from nucleotide 389 to nucleotide 1330; the nucleotidesequence of SEQ ID NO:177 from nucleotide 1286 to nucleotide 1330; thenucleotide sequence of the full-length protein coding sequence of clonenq34_(—)12 deposited with the ATCC under accession number 98663; or thenucleotide sequence of a mature protein coding sequence of clonenq34_(—)12 deposited with the ATCC under accession number 98663. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone nq34_(—)12deposited with the ATCC under accession number 98663. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:178 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:178, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:178 having biological activity, the fragment comprising the aminoacid sequence from amino acid 152 to amino acid 161 of SEQ ID NO:178.

[3156] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:177.

[3157] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[3158] (a) a process comprising the steps of:

[3159] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[3160] (aa) SEQ ID NO:177, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:177; and

[3161] (ab) the nucleotide sequence of the cDNA insert of clonenq34_(—)12 deposited with the ATCC under accession number 98663;

[3162] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[3163] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[3164] (b) a process comprising the steps of:

[3165] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[3166] (ba) SEQ ID NO:177, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:177; and

[3167] (bb) the nucleotide sequence of the cDNA insert of clonenq34_(—)12 deposited with the ATCC under accession number 98663;

[3168] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[3169] (iii) amplifying human DNA sequences; and

[3170] (iv) isolating the polynucleotide products of step (b)(iii).

[3171] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:177, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:177 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:177, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:177. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:177from nucleotide 389 to nucleotide 1330, and extending contiguously froma nucleotide sequence corresponding to the 5 end of said sequence of SEQID NO:177 from nucleotide 389 to nucleotide 1330, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:177from nucleotide 389 to nucleotide 1330. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:177from nucleotide 1286 to nucleotide 1330, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:177 from nucleotide 1286 to nucleotide 1330, to a nucleotidesequence correspondingto the 3′ end of said sequence of SEQ IDNO:177from nucleotide 1286 to nucleotide 1330.

[3172] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[3173] (a) the amino acid sequence of SEQ ID NO:178;

[3174] (b) a fragment of the amino acid sequence of SEQ ID NO:178, thefragment comprising eight contiguous amino acids of SEQ ID NO:178; and

[3175] (c) the amino acid sequence encoded by the cDNA insert of clonenq34_(—b 12) deposited with the ATCC under accession number 98663;

[3176] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:178. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:178 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:178, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:178 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 152 to amino acid 161 of SEQ ID NO:178.

[3177] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[3178] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:179;

[3179] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:179 from nucleotide 1026 to nucleotide 1226;

[3180] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:179 from nucleotide 1101 to nucleotide 1226;

[3181] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pj154_(—)1 deposited withthe ATCC under accession number 98663;

[3182] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pj154_(—)1 deposited with the ATCC underaccession number 98663;

[3183] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pj154_(—)1 deposited with theATCC under accession number 98663;

[3184] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pj154_(—)1 deposited with the ATCC under accessionnumber 98663;

[3185] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:180;

[3186] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:180 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:180;

[3187] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[3188] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above;

[3189] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i); and

[3190] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i) and that has alength that is at least 25% of the length of SEQ ID NO:179.

[3191] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:179 from nucleotide 1026 to nucleotide 1226; the nucleotidesequence of SEQ ID NO:179 from nucleotide 1101 to nucleotide 1226; thenucleotide sequence of the full-length protein coding sequence of clonepj154_(—)1 deposited with the ATCC under accession number 98663; or thenucleotide sequence of a mature protein coding sequence of clonepj154_(—)1 deposited with the ATCC under accession number 98663. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone pj154_(—)1deposited with the ATCC under accession number 98663. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:180 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:180, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:180 having biological activity, the fragment comprising the aminoacid sequence from amino acid 28 to amino acid 37 of SEQ ID NO:180.

[3192] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:179.

[3193] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[3194] (a) a process comprising the steps of:

[3195] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[3196] (aa) SEQ ID NO:179, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:179; and

[3197] (ab) the nucleotide sequence of the cDNA insert of clonepj154_(—)1 deposited with the ATCC under accession number 98663;

[3198] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[3199] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[3200] (b) a process comprising the steps of:

[3201] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[3202] (ba) SEQ ID NO:179, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:179; and

[3203] (bb) the nucleotide sequence of the cDNA insert of clonepj154_(—)1 deposited with the ATCC under accession number 98663;

[3204] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[3205] (iii) amplifying human DNA sequences; and

[3206] (iv) isolating the polynucleotide products of step (b)(iii).

[3207] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:179, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:179 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:179, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:179. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:179from nucleotide 1026 to nucleotide 1226, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:179 from nucleotide 1026 to nucleotide 1226, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:179from nucleotide 1026 to nucleotide 1226. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:179from nucleotide 1101 to nucleotide 1226, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:179 from nucleotide 1101 to nucleotide 1226, to a nucleotidesequence correspondingto the 3′ end of said sequence of SEQIDNO:179fromnucleotide 1101 to nucleotide 1226.

[3208] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[3209] (a) the amino acid sequence of SEQ ID NO:180;

[3210] (b) a fragment of the amino acid sequence of SEQ ID NO:180, thefragment comprising eight contiguous amino acids of SEQ ID NO:180; and

[3211] (c) the amino acid sequence encoded by the cDNA insert of clonepj154_(—)1 deposited with the ATCC under accession number 98663;

[3212] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:180. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:180 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:180, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:180 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 28 to amino acid 37 of SEQ ID NO:180.

[3213] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[3214] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:181;

[3215] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:181 from nucleotide 478 to nucleotide 651;

[3216] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:181 from nucleotide 562 to nucleotide 651;

[3217] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pk147_(—)1 deposited withthe ATCC under accession number 98663;

[3218] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pk147_(—)1 deposited with the ATCC underaccession number 98663;

[3219] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pk147_(—)1 deposited with theATCC under accession number 98663;

[3220] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pk147_(—)1 deposited with the ATCC under accessionnumber 98663;

[3221] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:182;

[3222] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:182 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:182;

[3223] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[3224] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above;

[3225] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i); and

[3226] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i) and that has alength that is at least 25% of the length of SEQ ID NO:181.

[3227] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:181 fromnucleotide 478 to nucleotide 651; the nucleotidesequence of SEQ ID NO:181 from nucleotide 562 to nucleotide 651; thenucleotide sequence of the full-length protein coding sequence of clonepk147_(—)1 deposited with the ATCC under accession number 98663; or thenucleotide sequence of a mature protein coding sequence of clonepk147_(—)1 deposited with the ATCC under accession number 98663. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone pk147_(—)1deposited with the ATCC under accession number 98663. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:182 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:182, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:182 having biological activity, the fragment comprising the aminoacid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:182.

[3228] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:181.

[3229] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[3230] (a) a process comprising the steps of:

[3231] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[3232] (aa) SEQ ID NO:181,but excluding the poly(A) tail at the 3′ endof SEQ ID NO:181; and

[3233] (ab) the nucleotide sequence of the cDNA insert of clonepk147_(—)1 deposited with the ATCC under accession number 98663;

[3234] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[3235] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[3236] (b) a process comprising the steps of:

[3237] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[3238] (ba) SEQ ID NO:181, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:181; and

[3239] (bb) the nucleotide sequence of the cDNA insert of clonepk147_(—)1 deposited with the ATCC under accession number 98663;

[3240] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[3241] (iii) amplifying human DNA sequences; and

[3242] (iv) isolating the polynucleotide products of step (b)(iii).

[3243] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:181, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:181 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:181, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:181. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:181from nucleotide 478 to nucleotide 651, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:181 from nucleotide 478 to nucleotide 651, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:181from nucleotide 478 to nucleotide 651. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:181from nucleotide 562 to nucleotide 651, and extending contiguously from anucleotide sequence corresponding to the 5′ end of said sequence of SEQID NO:181 from nucleotide 562 to nucleotide 651, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:181from nucleotide 562 to nucleotide 651.

[3244] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[3245] (a) the amino acid sequence of SEQ ID NO:182;

[3246] (b) a fragment of the amino acid sequence of SEQ ID NO:182, thefragment comprising eight contiguous amino acids of SEQ ID NO:182; and

[3247] (c) the armino acid sequence encoded by the cDNA insert of clonepk147_(—)1 deposited with the ATCC under accession number 98663;

[3248] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:182. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:182 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:182, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:182 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 24 to amino acid 33 of SEQ ID NO:182.

[3249] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[3250] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:183;

[3251] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:183 from nucleotide 1129 to nucleotide 1896;

[3252] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:183 from nucleotide 1189 to nucleotide 1896;

[3253] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone pt127_(—)1 deposited withthe ATCC under accession number 98663;

[3254] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of clone pt127_(—)1 deposited with the ATCC underaccession number 98663;

[3255] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone pt127_(—)1 deposited with theATCC under accession number 98663;

[3256] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone pt127_(—)1 deposited with the ATCC under accessionnumber 98663;

[3257] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:184;

[3258] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:184 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:184;

[3259] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[3260] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above;

[3261] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i); and

[3262] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i) and that has alength that is at least 25% of the length of SEQ ID NO:183.

[3263] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:183 from nucleotide 1129 to nucleotide 1896; the nucleotidesequence of SEQ ID NO:183 from nucleotide 1189 to nucleotide 1896; thenucleotide sequence of the full-length protein coding sequence of clonept127_(—)1 deposited with the ATCC under accession number 98663; or thenucleotide sequence of a mature protein coding sequence of clonept127_(—)1 deposited with the ATCC under accession number 98663. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone pt127_(—)1deposited with the ATCC under accession number 98663. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:184 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:184, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:184 having biological activity, the fragment comprising the aminoacid sequence from amino acid 123 to amino acid 132 of SEQ ID NO:184.

[3264] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:183.

[3265] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[3266] (a) a process comprising the steps of:

[3267] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[3268] (aa) SEQ ID NO:183, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:183; and

[3269] (ab) the nucleotide sequence of the cDNA insert of clonept127_(—)1 deposited with the ATCC under accession number 98663;

[3270] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[3271] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[3272] (b) a process comprising the steps of:

[3273] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[3274] (ba) SEQ ID NO: 183, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:183; and

[3275] (bb) the nucleotide sequence of the cDNA insert of clonept127_(—)1 deposited with the ATCC under accession number 98663;

[3276] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[3277] (iii) amplifying human DNA sequences; and

[3278] (iv) isolating the polynucleotide products of step (b)(iii).

[3279] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:183, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:183 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:183, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:183. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:183from nucleotide 1129 to nucleotide 1896, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:183 from nucleotide 1129 to nucleotide 1896, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:183from nucleotide 1129 to nucleotide 1896. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:183from nucleotide 1189 to nucleotide 1896, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:183 from nucleotide 1189 to nucleotide 1896, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:183from nucleotide 1189 to nucleotide 1896.

[3280] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[3281] (a) the amino acid sequence of SEQ ID NO:184;

[3282] (b) a fragment of the amino acid sequence of SEQ ID NO:184, thefragment comprising eight contiguous amino acids of SEQ ID NO:184; and

[3283] (c) the amino acid sequence encoded by the cDNA insert of clonept127_(—)1 deposited with the ATCC under accession number 98663;

[3284] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:184. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:184 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:184, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:184 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 123 to amino acid 132 of SEQ ID NO:184.

[3285] In one embodiment, the present invention provides a compositioncomprising an isolated polynucleotide selected from the group consistingof:

[3286] (a) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:185;

[3287] (b) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:185 from nucleotide 172 to nucleotide 1041;

[3288] (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:185 from nucleotide 295 to nucleotide 1041;

[3289] (d) a polynucleotide comprising the nucleotide sequence of thefull-length protein coding sequence of clone qo115_(—)13 deposited withthe ATCC under accession number 98663;

[3290] (e) a polynucleotide encoding the full-length protein encoded bythe cDNA insert of done qo115_(—)13 deposited with the ATCC underaccession number 98663;

[3291] (f) a polynucleotide comprising the nucleotide sequence of amature protein coding sequence of clone qo115_(—)13 deposited with theATCC under accession number 98663;

[3292] (g) a polynucleotide encoding a mature protein encoded by thecDNA insert of clone qo115_(—)13 deposited with the ATCC under accessionnumber 98663;

[3293] (h) a polynucleotide encoding a protein comprising the amino acidsequence of SEQ ID NO:186;

[3294] (i) a polynucleotide encoding a protein comprising a fragment ofthe amino acid sequence of SEQ ID NO:186 having biological activity, thefragment comprising eight contiguous amino acids of SEQ ID NO:186;

[3295] (j) a polynucleotide which is an allelic variant of apolynucleotide of (a)-(g) above;

[3296] (k) a polynucleotide which encodes a species homologue of theprotein of (h) or (i) above;

[3297] (l) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i); and

[3298] (m) a polynucleotide that hybridizes under stringent conditionsto any one of the polynucleotides specified in (a)-(i) and that has alength that is at least 25% of the length of SEQ ID NO:185.

[3299] Preferably, such polynucleotide comprises the nucleotide sequenceof SEQ ID NO:185 from nucleotide 172 to nucleotide 1041; the nucleotidesequence of SEQ ID NO:185 fromnucleotide295 tonucleotide 1041; thenucleotide sequence of the full-length protein coding sequence of cloneqo115_(—)13 deposited with the ATCC under accession number 98663; or thenucleotide sequence of a mature protein coding sequence of cloneqo115_(—)13 deposited with the ATCC under accession number 98663. Inother preferred embodiments, the polynucleotide encodes the full-lengthor a mature protein encoded by the cDNA insert of clone qo115_(—)13deposited with the ATCC under accession number 98663. In furtherpreferred embodiments, the present invention provides a polynucleotideencoding a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:186 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:186, or a polynucleotide encoding aprotein comprising a fragment of the amino acid sequence of SEQ IDNO:186 having biological activity, the fragment comprising the aminoacid sequence from amino acid 140 to amino acid 149 of SEQ ID NO:186.

[3300] Other embodiments provide the gene corresponding to the cDNAsequence of SEQ ID NO:185.

[3301] Further embodiments of the invention provide isolatedpolynucleotides produced according to a process selected from the groupconsisting of:

[3302] (a) a process comprising the steps of:

[3303] (i) preparing one or more polynucleotide probes that hybridize in6×SSC at 65 degrees C to a nucleotide sequence selected from the groupconsisting of:

[3304] (aa) SEQ IDNO:185, but excluding the poly(A) tail atthe 3′ end ofSEQ ID NO:185; and

[3305] (ab) the nucleotide sequence of the cDNA insert of cloneqo115_(—)13 deposited with the ATCC under accession number 98663;

[3306] (ii) hybridizing said probe(s) to human genomic DNA in conditionsat least as stringent as 4×SSC at 50 degrees C; and

[3307] (iii) isolating the DNA polynucleotides detected with theprobe(s); and

[3308] (b) a process comprising the steps of:

[3309] (i) preparing one or more polynucleotide primers that hybridizein 6×SSC at 65 degrees C to a nucleotide sequence selected from thegroup consisting of:

[3310] (ba) SEQ ID NO:185, but excluding the poly(A) tail at the 3′ endof SEQ ID NO:185; and

[3311] (bb) the nucleotide sequence of the cDNA insert of cloneqo115_(—)13 deposited with the ATCC under accession number 98663;

[3312] (ii) hybridizing said primer(s) to human genomic DNA inconditions at least as stringent as 4×SSC at 50 degrees C;

[3313] (iii) amplifying human DNA sequences; and

[3314] (iv) isolating the polynucleotide products of step (b)(iii).

[3315] Preferably the polynucleotide isolated according to the aboveprocess comprises a nucleotide sequence corresponding to the cDNAsequence of SEQ ID NO:185, and extending contiguously from a nucleotidesequence corresponding to the 5′ end of SEQ ID NO:185 to a nucleotidesequence corresponding to the 3′ end of SEQ ID NO:185, but excluding thepoly(A) tail at the 3′ end of SEQ ID NO:185. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:185from nucleotide 172 to nucleotide 1041, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:185 from nucleotide 172 to nucleotide 1041, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:185from nucleotide 172 to nucleotide 1041. Also preferably thepolynucleotide isolated according to the above process comprises anucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:185from nucleotide 295 to nucleotide 1041, and extending contiguously froma nucleotide sequence corresponding to the 5′ end of said sequence ofSEQ ID NO:185 from nucleotide 295 to nucleotide 1041, to a nucleotidesequence corresponding to the 3′ end of said sequence of SEQ ID NO:185from nucleotide 295 to nucleotide 1041.

[3316] In other embodiments, the present invention provides acomposition comprising a protein, wherein said protein comprises anamino acid sequence selected from the group consisting of:

[3317] (a) the amino acid sequence of SEQ ID NO:186;

[3318] (b) a fragment of the amino acid sequence of SEQ ID NO:186, thefragment comprising eight contiguous amino acids of SEQ ID NO:186; and

[3319] (c) the amino acid sequence encoded by the cDNA insert of cloneqo115_(—)13 deposited with the ATCC under accession number 98663;

[3320] the protein being substantially free from other mammalianproteins. Preferably such protein comprises the amino acid sequence ofSEQ ID NO:186. In further preferred embodiments, the present inventionprovides a protein comprising a fragment of the amino acid sequence ofSEQ ID NO:186 having biological activity, the fragment preferablycomprising eight (more preferably twenty, most preferably thirty)contiguous amino acids of SEQ ID NO:186, or a protein comprising afragment of the amino acid sequence of SEQ ID NO:186 having biologicalactivity, the fragment comprising the amino acid sequence from aminoacid 140 to amino acid 149 of SEQ ID NO:186.

[3321] In certain preferred embodiments, the polynucleotide is operablylinked to an expression control sequence. The invention also provides ahost cell, including bacterial, yeast, insect and mammalian cells,transformed with such polynucleotide compositions. Also provided by thepresent invention are organisms that have enhanced, reduced, or modifiedexpression of the gene(s) corresponding to the polynucleotide sequencesdisclosed herein.

[3322] Processes are also provided for producing a protein, whichcomprise:

[3323] (a) growing a culture of the host cell transformed with suchpolynucleotide compositions in a suitable culture medium; and

[3324] (b) purifying the protein from the culture.

[3325] The protein produced according to such methods is also providedby the present invention.

[3326] Protein compositions of the present invention may furthercomprise a pharmaceutically acceptable carrier. Compositions comprisingan antibody which specifically reacts with such protein are alsoprovided by the present invention.

[3327] Methods are also provided for preventing, treating orameliorating a medical condition which comprises administering to amammalian subject a therapeutically effective amount of a compositioncomprising a protein of the present invention and a pharmaceuticallyacceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

[3328]FIGS. 1A and 1B are schematic representations of the pED6 andpNOTs vectors, respectively, used for deposit of clones disclosedherein.

DETAILED DESCRIPTION

[3329] Isolated Proteins and Polynucleotides

[3330] Nucleotide and amino acid sequences, as presently determined, arereported below for each clone and protein disclosed in the presentapplication. The nucleotide sequence of each clone can readily bedetermined by sequencing of the deposited clone in accordance with knownmethods. The predicted amino acid sequence (both full-length and matureforms) can then be determined from such nucleotide sequence. The aminoacid sequence of the protein encoded by a particular clone can also bedetermined by expression of the clone in a suitable host cell,collecting the protein and determining its sequence. For each disclosedprotein applicants have identified what they have determined to be thereading frame best identifiable with sequence information available atthe time of filing.

[3331] As used herein a “secreted” protein is one which, when expressedin a suitable host cell, is transported across or through a membrane,including transport as a result of signal sequences in its amino acidsequence. “Secreted” proteins include without limitation proteinssecreted wholly (e.g., soluble proteins) or partially (e.g., receptors)from the cell in which they are expressed. “Secreted” proteins alsoinclude without limitation proteins which are transported across themembrane of the endoplasmic reticulum.

[3332] Clone “bd306_(—)7”

[3333] A polynucleotide of the present invention has been identified asclone “bd306_(—)7”. bd306_(—)7 was isolated from a human fetal kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. bd306_(—)7is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “bd306_(—)7 protein”).

[3334] The nucleotide sequence of bd306_(—)7 as presently determined isreported in SEQ ID NO: 1, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bd306_(—)7 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:2. Amino acids 11 to 23 area predicted leader/signal sequence, with the predicted mature amino acidsequence beginning at amino acid 24. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the bd306_(—)7 protein.

[3335] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bd306_(—)7 should be approximately 3700 bp.

[3336] The nucleotide sequence disclosed herein for bd306_(—)7 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. bd306_(—)7 demonstratedat least some similarity with sequences identified as AA027096(zk04d03.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 4695413′), AA027135 (zk04d03.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 469541 5′), AA166312 (ms42g11.r1 Life Tech mouse embryo 135dpc10666014 Mus musculus cDNA clone 6142765′ similar to TR E238793 E238793DUALIN, AA535890 (nf94a03.s1 NCI_CGAP_Co3 Homo sapiens cDNA cloneIMAGE:927532), H14467 (yl25g07.r1 Homo sapiens cDNA clone 159324 5′similar to contains HGR repetitive element), T21281 (Human genesignature HUMGS02637), T61016 (Total DNA sequence from cosmid clonesLP(2)127 and LP(2)128), U47621 (Human nucleolar autoantigen No55 mRNA,complete cds), W51808 (zc48g04.r1 Soares senescent fibroblasts NbHSFHomo sapiens cDNA clone 325590 5′ similar to PIR:S20742 S20742synaptonemal complex protein Sc65-rat; contains Alu repetitive element;mRNA sequence), and X97607 (G.gallus mRNA for cartilage associatedprotein). The predicted amino acid sequence disclosed herein forbd306_(—)7 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictedbd306_(—)7 protein demonstrated at least some similarity to sequencesidentified as R95913 (Neural thread protein [Homo sapiens]), U47621(nucleolar autoantigen No55 [Homo sapiens]), and X97607 (cartilageassociated protein [Gallus gallus]). Two regions of bd306_(—)7 protein(amino acids 148_(—)217 and 298_(—)367 of SEQ ID NO:2) align with thesame region, amino acids 145_(—)214, of cartilage associated protein.The homology between bd306_(—)7 protein and nucleolar autoantigen No55is also good, but in this case it appears that bd306_(—)7 amino acids148_(—)189 is similar to two regions of No55 (amino acids 145_(—)186 and296_(—)337), and bd306_(—)7 amino acids 298_(—)367 are also similar tonearby the same two regions of No55 (amino acids 145_(—)214 and296_(—)365). This implies that two regions in bd306_(—)7 (roughly148_(—)189 and 298_(—)367) are similar to each other, and one copy ofthis region is found in cartilage associated protein, but both arepresent in No55. Cartilage associated protein is reported tobe localizedto the extracelluar matrix {J. Cell Sci 1997 110(Pt 12):1351_(—)1359},while No55 is found in the granular component of the nucleolus {Mol BiolCell 1996 7(7):1015_(—)1024}. Based upon sequence similarity, bd306_(—)7proteins and each similar protein or peptide may share at least someactivity. The nucleotide sequence of bd306_(—)7 also indicates that itmay contain an Alu repetitive element.

[3337] bd306_(—)7 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 52 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3338] Clone “fj283_(—)11” and Clone “fj283_(—)6”

[3339] Polynucleotides of the present invention have been identified asclone “fj283_(—)11” and clone “fj283_(—)6”. fj283_(—)11 and fj283_(—)6were isolated from a human adult lung carcinoma cDNA library usingmethods which are selective for cDNAs encoding secreted proteins (seeU.S. Pat. No. 5,536,637), or were identified as encoding a secreted ortransmembrane protein on the basis of computer analysis of the aminoacid sequence of the encoded protein. fj283_(—)11 and fj283_(—)6 arefull-length clones, including the entire coding sequence of a secretedprotein (also referred to herein as “fj283 protein”).

[3340] The nucleotide sequence of fj283_(—)11 as presently determined isreported in SEQ ID NO:3, and includes a poly(A) tail. The nucleotidesequence of fj283_(—)6 as presently determined is reported in SEQ IDNO:198, and includes a poly(A) tail. Although cDNA clones fj283_(—)11and fj283_(—)6 have different nucleotide sequences, perhaps as a resultof alternative splicing of a common primary MRNA transcript(particularly between nucleotide 402 and nucleotide 618 of SEQ IDNO:198), these clones are predicted to encode the same protein. Whatapplicants presently believe to be the proper reading frame and thepredicted amino acid sequence of the fj283 protein corresponding to theforegoing nucleotide sequences is reported in SEQ ID NO:4. Amino acids 8to 20 of SEQ ID NO:4 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 21. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of the fj283protein.

[3341] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone fj283_(—)11 should be approximately 3350 bp. TheEcoRI/NotI restriction fragment obtainable from the deposit containingclone fj283_(—)6 should be approximately 2700 bp.

[3342] The nucleotide sequences disclosed herein for fj283_(—)11 andfj283_(—)6 were searched against the GenBank and GeneSeq nucleotidesequence databases using BLASTN/BLASTX and FASTA search protocols.fj283_(—)11 and/or fj283_(—)6 demonstrated at least some similarity withsequences identified as AA052962 (zl70c02.s1 Stratagene colon (#937204)Homo sapiens cDNA clone 509954 3′ similar to gb D14531 60S RIBOSOMALPROTEIN L9 (HUMAN)), AA080949 (zn04d12.r1 Stratagene hNT), AA160948(zq40e12.r1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone632206 5′), AA195089 (zr34c02.r1 Soares NhHMPu S1 Homo sapiens cDNAclone 665282 5′, mRNA sequence), AA258887 (zs32b02.r1 NCI_CGAP_GCB1 Homosapiens cDNA clone IMAGE:686859 5′), H97993 (yw06e03.s1 Homo sapienscDNA clone 251452 3′), R19768 (yg40g06.r1 Homo sapiens cDNA clone 349515′), U09953 (Human ribosomal protein L9 mRNA, complete cds), Z73639(Human DNA sequence from cosmid V389H8 on chromosome X; Contains MRNAnear btk gene involved in a-gamma-globulinemia, ESTs, STS), and Z73901(Human DNA sequence from cosmid V389H8, between markers DXS366 and DXS87on chromosome X contains pseudogene, mRNA near btk gene involved ina-gamma-globulinemia, ESTs, STSs). The predicted amino acid sequencedisclosed herein for the fj283 protein was searched against the GenPeptand GeneSeq amino acid sequence databases using the BLASTX searchprotocol. The predicted fj283 protein demonstrated at least somesimilarity to sequences identified as AB011084 (KIAA0512 protein [Homosapiens]) and U09953 (ribosomal protein L9 [Homo sapiens]). Based uponsequence similarity, fj283 proteins and each similar protein or peptidemay share at least some activity. Profile hidden markov model analysishas revealed the presence of an Armadillo/beta-catenin-like domainwithin the predicted fj283 protein sequence. The armadillo multigenefamily comprises many proteins widely differing in sizes and functionswhich have in common a variable number of tandemly repeated armsequences of about 42 amino acids in length. Many, but not all,armadillo-repeat-containing proteins are nuclear in localization. Thepredicted fj283 protein does not appear to be of the nuclear variety,but rather appears to be an extracellular protein.

[3343] Clone “fk317_(—)3”

[3344] A polynucleotide of the present invention has been identified asclone “fk317_(—)3”. fk317_(—)3 was isolated from a human adult kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. fk317_(—)3is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “fk317_(—)3 protein”). Thenucleotide sequence of fk317_(—)3 as presently determined is reported inSEQ ID NO:5, and includes a poly(A) tail. What applicants presentlybelieve to be the proper reading frame and the predicted amino acidsequence of the fk317_(—)3 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:6.

[3345] The EcoRI/NotI restriction fragment obtainable fromthe depositcontainingclone fk317_(—)3 should be approximately 1400 bp.

[3346] The nucleotide sequence disclosed herein for fk317_(—)3 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. fk317_(—)3 demonstratedat least some similarity with sequences identified as AA568588(nm21b11.s1 NCI_CGAP_Co10 Homo sapiens cDNA clone IMAGE:1060797),AC002326 (Genomic sequence from Human 6, complete sequence), H48562(yq78g07.s1 Homo sapiens cDNA clone 201948 3′ similar to contains Alurepetitive element; contains MER30 repetitive element), T67164 (Humanalpha-N-acetylglucosaminidase gene), and Z46941 (H.sapiens DNA for alurepeats). The predicted amino acid sequence disclosed herein forfk317_(—)3 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictedfk317_(—)3 protein demonstrated at least some similarity to sequencesidentified as X55777 (put. ORF [Homo sapiens]). Based upon sequencesimilarity, fk317_(—)3 proteins and each similar protein or peptide mayshare at least some activity. The TopPredII computer program predicts apotential transmembrane domain within the fk317_(—)3 protein sequencecentered around amino acid 42 of SEQ ID NO:6. The nucleotide sequence offk317_(—)3 indicates that it may contain an Alu repetitive element.

[3347] Clone “k213_(—)2x”

[3348] A polynucleotide of the present invention has been identified asclone “k213_(—)2x”. Secreted cDNA clones were first isolated from amurine adult bone marrow (stromal cell line FCM-4) cDNA library usingmethods which are selective for cDNAs encoding secreted proteins (seeU.S. Pat. No. 5,536,637), or were identified as encoding a secreted ortransmembrane protein on the basis of computer analysis of the aminoacid sequence of the encoded protein. These murine cDNAs were then usedto isolate k213_(—)2x, a full-length human cDNA clone, including theentire coding sequence of a secreted protein (also referred to herein as“k213_(—)2x protein”).

[3349] The nucleotide sequence of k213_(—)2x as presently determined isreported in SEQ ID NO:7, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the k213_(—)2x protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:8. Amino acids 26 to 38 area predicted leader/signal sequence, with the predicted mature amino acidsequence beginning at amino acid 39. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the k213_(—)2x protein.

[3350] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone k213_(—)2x should be approximately 1900 bp.

[3351] The nucleotide sequence disclosed herein for k213_(—)2x wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. k213_(—)2x demonstratedat least some similarity with sequences identified as AA123852(mp96e08.r1 Soares 2NbMT Mus musculus cDNA clone 577094 5′), AA362005(EST71348 T-cell lymphoma Homo sapiens cDNA 5′ end), AA436477(zv08f05.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 753057 3′),AA436528 (zv08fOb 05.r1 Soares NhHMPu SI Homo sapiens cDNA clone 7530575′), AA643506 (nq86f04.s1 NCI_CGAP_Co9 Homo sapiens cDNA cloneIMAGE:1159231, mRNA sequence), F13485 (H. sapiens partial cDNA sequence;clone c-3dh08), and T19502 (Human gene signature HUMGS00560). Based uponsequence similarity, k213_(—)2x proteins and each similar protein orpeptide may share at least some activity.

[3352] k213_(—)2x protein was expressed in a COS cell expression system,and an expressed protein band of approximately 6 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3353] Clone “na316_(—)1”

[3354] A polynucleotide of the present invention has been identified asclone “na316_(—)1”. na316_(—)1 was isolated from a human adult brain(corpus callosum) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.na316_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “na316_(—)1 protein”).The nucleotide sequence of na316_(—)1 as presently determined isreported in SEQ ID NO:9, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the na316_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:10. Amino acids 30 to 42are a predicted leader/signal sequence, with the predicted mature aminoacid sequence beginning at amino acid 43. Due to the hydrophobic natureof the predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the na316_(—)1 protein.

[3355] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone na316_(—)1 should be approximately 900 bp.

[3356] The nucleotide sequence disclosed herein for na316_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. No hits were found inthe database. The TopPredII computer program predicts two potentialtransmembrane domains within the na316_(—)1 protein sequence, centeredaround amino acids 31 and 66 of SEQ ID NO:10, respectively.

[3357] Clone “nf93_(—20”)

[3358] A polynucleotide of the present invention has been identified asclone “nf93_(—)20”. nf93_(—)20 was isolated from a human adult brain(substantia nigra) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nf93_(—)20 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nf93_(—)20 protein”).

[3359] The nucleotide sequence of nf93_(—)20 as presently determined isreported in SEQ ID NO:11, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nf93_(—)20 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO: 12. Amino acids 6 to 18are a predicted leader/signal sequence, with the predicted mature aminoacid sequence beginning at amino acid 19. Due to the hydrophobic natureof the predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the nf93_(—)20 protein.

[3360] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nf93_(—)20 should be approximately 2000 bp.

[3361] The nucleotide sequence disclosed herein for nf93_(—)20 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nf93_(—)20 demonstratedat least some similarity with sequences identified as AA063620(ze87g07.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 3660123′), AA317410 (EST19337 Retina II Homo sapiens cDNA 5′ end), H29417(ym60e07.r1 Homo sapiens cDNA clone 526315′), and N41425 (yw93e08.r1Homo sapiens cDNA clone 259814 5′). Based upon sequence similarity,nf93_(—)20 proteins and each similar protein or peptide may share atleast some activity.

[3362] nf93_(—)20 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 29 kDa was detected inmembrane fractions using SDS polyacrylarnide gel electrophoresis.

[3363] Clone “np164_(—)1”

[3364] A polynucleotide of the present invention has been identified asclone “np164_(—)1 ”. np164_(—)1 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.np164_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “np164_(—)1 protein”).

[3365] The nucleotide sequence of np164_(—)1 as presently determined isreported in SEQ ID NO:13, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the np164_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:14. Amino acids 348 to 360are a predicted leader/signal sequence, with the predicted mature aminoacid sequence beginning at amino acid 361. Due to the hydrophobic natureof the predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence notbeseparated from the remainder of the np164_(—)1 protein.

[3366] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone np164_(—)1 should be approximately 2100 bp.

[3367] The nucleotide sequence disclosed herein for np164_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. np164_(—)1 demonstratedat least some similarity with sequences identified as N63143 (yz37c12.s1Homo sapiens cDNA clone 285238 3′), T19992 (Human gene signatureHUMGS01129), Z46676 (Caenorhabditis elegans cosmid C08B11, completesequence), and Z74910 (S.cerevisiae chromosome XV reading frame ORFYOR002w). The predicted amino acid sequence disclosed herein fornp164_(—)1 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictednp164_(—)1 protein demonstrated at least some similarity to sequencesidentified as Z46676 (C08B11.8 [Caenorhabditis elegans]) and Z74910 (ORFYOR002w [Saccharomyces cerevisiae]). Based upon sequence similarity,np164_(—)1 proteins and each similar protein or peptide may share atleast some activity. The TopPredlI computer program predicts tenpotential transmembrane domains within the np164_(—)1 protein sequence,centered around amino acids 4, 114, 165,229,293,322, 360,386,436, and465 of SEQ ID NO:14, respectively.

[3368] np164_(—)1 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 43 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3369] Clone “pe204_(—)1”

[3370] A polynucleotide of the present invention has been identified asclone “pe204_(—)1”. pe204_(—)1 was isolated from a human adult blood(chronic myelogenous leukemia K5) cDNA library using methods which areselective for cDNAs encoding secreted proteins (see U.S. Pat.No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. pe204_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“pe204_(—)1 protein”).

[3371] The nucleotide sequence of pe204_(—)1 as presently determined isreported in SEQ ID NO:15, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pe204_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:16. Amino acids 116 to 128are a predicted leader/signal sequence, with the predicted mature aminoacid sequence beginning at amino acid 129. Due to the hydrophobic natureof the predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the pe204_(—)1 protein.

[3372] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pe204_(—)1 should be approximately 1100 bp.

[3373] The nucleotide sequence disclosed herein for pe204_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. pe204_(—)1 demonstratedat least some similarity with sequences identified as AA279961(zs92h08.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone 70499] 3′), AA306911(EST178043 Colon carcinoma (HCC) cell line Homo sapiens cDNA 5′ end),AC002086 (Human PAC clone DJ525N14), AC002094 (Genomic sequence fromHuman 17, complete sequence), T97749 (ye58c04.s1 Homo sapiens cDNAclone), Z74696 (Human DNA sequence from cosmid 203C2, between markersDXS6791 and DXS8038 on chromosome X contains ESTs), Z80901 (Human DNAsequence from cosmid N119A7 on chromosome 22q12-qter), and Z82245 (HumanDNA sequence *** SEQUENCING IN PROGRESS *** from clone 799F10; HTGSphase 1). The predicted amino acid sequence disclosed herein forpe204_(—)1 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictedpe204_(—)1 protein demonstrated at least some similarity to sequencesidentified as K02113 (Gallus gallus vitellogenin [Callus gallus]). Basedupon sequence similarity, pe204_(—)1 proteins and each similar proteinor peptide may share at least some activity. The TopPredII computerprogram predicts two additional potential transmembrane domains withinthe pe204_(—)1 protein sequence, one centered around amino acid 50 andanother around amino acid 90 of SEQ ID NO:16.

[3374] pe204_(—)1 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 14 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3375] Clone “ya 1_(—)1 ”

[3376] A polynucleotide of the present invention has been identified asclone “ya1_(—)1 ”. ya1_(—)1 was isolated from a human adult testes cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. Ya1_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“ya1_(—)1 protein”).

[3377] The nucleotide sequence of ya1_(—)1 as presently determined isreported in SEQ ID NO:17, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the ya1_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:18. Amino acids 330 to 342are a predicted leader/signal sequence, with the predicted mature aminoacid sequence beginning at amino acid 343. Due to the hydrophobic natureof the predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the ya1_(—)1 protein.

[3378] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone ya1_(—)1 should be approximately 1400 bp.

[3379] The nucleotide sequence disclosed herein for yal1_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. Ya1_(—)1 demonstrated atleast some similarity with sequences identified as AA431507 (zw76e05.r1Soares testis NHT Homo sapiens cDNA clone 782144 5′) and F03332 (H.sapiens partial cDNA sequence; clone c-1tg07). Based upon sequencesimilarity, ya1_(—)1 proteins and each similar protein or peptide mayshare at least some activity. The TopPredII computer program predictstwo potential transmembrane domains within the yalI protein sequencecentered around amino acid 156 and around amino acid 332 of SEQ IDNO:18, respectively. The nucleotide sequence of yalJ indicates that itmay contain an Alu repetitive element.

[3380] ya1_(—)1 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 38 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3381] Clone “yb8_(—)1”

[3382] A polynucleotide of the present invention has been identified asclone “yb8_(—)1”. yb8_(—)1 was isolated from a human fetal brain cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. yb8_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“yb8_(—)1 protein”).

[3383] The nucleotide sequence of yb8_(—)1 as presently determined isreported in SEQ ID NO:19, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the yb8_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:20. Amino acids 69 to 81are a predicted leader/signal sequence, with the predicted mature aminoacid sequence beginning at amino acid 82. Due to the hydrophobic natureof the predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the yb8_(—)1 protein.

[3384] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone yb8_(—)1 should be approximately 1800 bp.

[3385] The nucleotide sequence disclosed herein for yb8_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. yb8_(—)1 demonstrated atleast some similarity with sequences identified as AA418057 (zv97a06.r1Soares iNhHMPu Si Homo sapiens cDNA clone 767698 5′ similar toTR:G1143719 G1143719 RS-REX-B), L10334 (Homo sapiensneuroendocrine-specific protein B (NSP) MRNA, complete cds), U17603(Rattus norvegicus rS-Rex-s mRNA, complete cds), and W19986 (zb38e09.r1Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 305896 5′ , mRNAsequence). The predicted amino acid sequence disclosed herein foryb8_(—)1 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictedyb8_(—)1 protein demonstrated at least some similarity to sequencesidentified as L10334 (neuroendocrine-specific proteins B and C [Homosapiens]) and U17603 (rS-Rex-s [Rattus norvegicus]). Based upon sequencesimilarity, yb8_(—)1 proteins and each similar protein or peptide mayshare at least some activity. The predicted yb8_(—)1 protein showssignificant (60% identity) amino acid similarity to the neuro-endocrinespecific protein (NSP) family of proteins. Roebroek et al. (1993, J.Biol Chem. 268: 13439, which is incoporated by reference herein) reportobserving three transcripts from this gene family: NSP-A (3.4 kb), -B(2.3 kb), and -C (1.8 kb); they encode proteins of 776, 356, and 208amino acids, respectively. Roebroek et al. also observe that these threetranscripts are identical at the 3′ end and only differ over a shortportion near their 5′ ends, and are thus possible splice variants. NSP-Aand NSP-C were found in neural and endocrine tissues while NSP-B wasfound only in a lung carcinoma cell line (Roebrek et al. state thatNSP-B is “aberrant” suggesting that it might be an artifact). TheC-teminal portions of the protein sequences from all three transcriptsare identical. The predicted yb8_(—)1 protein shows strong amino acidsimilarity within this region and is about as long as NSP-C. Thus thepredicted yb8_(—)1 protein appears to be related to NSP-C. The TopPredIIcomputer program predicts two potential transmembrane domains within theyb8_(—)1 protein sequence, centered around amino acids 82 and 174 of SEQID NO:20, respectively. yb8_(—)1 protein was expressed in a COS cellexpression system, and an expressed protein band of approximately 25 kDawas detected in membrane fractions and in comditioned medium using SDSpolyacrylamide gel electrophoresis.

[3386] Clone “am856_(—)3”

[3387] A polynucleotide of the present invention has been identified asclone “am856_(—)3”. am856_(—)3 was isolated from a human fetal kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. am856_(—)3is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “am856_(—)3 protein”).

[3388] The nucleotide sequence of am856_(—)3 as presently determined isreported in SEQ ID NO:21, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the am856_(—)3 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:22. Amino acids 23 to 35are a predicted leader/signal sequence, with the predicted mature aminoacid sequence beginning at amino acid 36. Due to the hydrophobic natureof the predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the am856_(—)3 protein. The amino acidsequence of another protein that could be encoded by basepairs 214 to369 of SEQ ID NO:21 is reported in SEQ ID NO:274.

[3389] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone am856_(—)3 should be approximately 2100 bp.

[3390] The nucleotide sequence disclosed herein for am856_(—)3 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. am856_(—)3 demonstratedat least some similarity with sequences identified as M26434 (Humanhypoxanthine phosphoribosyltransferase (HPRT) gene, complete cds),N71723 (yw52b09.r1 Homo sapiens cDNA clone 255833 5′ similar to gb|M87920| HUMALNE652 Human carcinoma cell-derived Alu RNA transcript,(rRNA);

[3391] gb X77738_mal BAND 3 ANION TRANSPORT PROTEIN), U41196 (Human(TTTC)5 short tandem repeat polymorphism UM69, D17S1339), and X89398(H.sapiens ung gene for uracil DNA-glycosylase). Based upon sequencesimilarity, am856_(—)3 proteins and each similar protein or peptide mayshare at least some activity. The TopPredII computer program predictsthe amino-terminal half of the am856_(—)3 protein sequence to be highlyhydrophobic. The nucleotide sequence of am856_(—)3 indicates that it maycontain one or more of the following types of repetitive elements:AT-like, (TTTC)5 short tandem repeat polymorphism UM69.

[3392] Clone “am996_(—)12”

[3393] A polynucleotide of the present invention has been identified asclone “am996_(—)12”. am996_(—)12 was isolated from a human fetal kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. am996_(—)12is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “am996_(—)12 protein”).

[3394] The nucleotide sequence of am996_(—)12 as presently determined isreported in SEQ ID NO:23, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the am996_(—)12 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:24. Amino acids 14 to 26are a predicted leader/signal sequence, with the predicted mature aminoacid sequence beginning at amino acid 27. Due to the hydrophobic natureof the predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the am996_(—)12 protein.

[3395] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone am996_(—)12 should be approximately 1000 bp.

[3396] The nucleotide sequence disclosed herein for am996_(—)12 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. No hits were found inthe database. The TopPredII computer program predicts two potentialtransmembrane domains within the am996_(—)12 protein sequence, centeredaround amino acids 18 and 62 of SEQ ID NO:24, respectively.

[3397] Clone “cc69_(—)1”

[3398] A polynucleotide of the present invention has been identified asclone “cc69_(—)1”. cc69_(—)1 was isolated from a human adult brain cDNAlibrary using methods which are selective for cDNAs encoding secretedproteins (see U.S. Pat. No. 5,536,637), or was identified as encoding asecreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. cc69_(—)1 is afull-length clone, including the entire coding sequence of a secretedprotein (also referred to herein as “cc69_(—)1 protein”).

[3399] The nucleotide sequence of cc69_(—)1 as presently determined isreported in SEQ ID NO:25, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the cc691 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:26.

[3400] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone cc69_(—)1 should be approximately 550 bp.

[3401] The nucleotide sequence disclosed herein for cc69_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. cc69_(—)1 demonstratedat least some similarity with sequences identified as AA280712(zs98h11.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:711717 5′),AA421250 (zu27b03.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone739181 3′), H28886 (yp03e09.s1 Homo sapiens cDNA clone 186376 3′), andH84171 (yv87c11.r1 Homo sapiens cDNA). Based upon sequence similarity,cc69_(—)1 proteins and each similar protein or peptide may share atleast some activity. The TopPredII computer program predicts a potentialtransmembrane domain within the cc69_(—)1 protein sequence centeredaround amino acid 15 of SEQ ID NO:26.

[3402] Clone “cc162_(—)1”

[3403] A polynucleotide of the present invention has been identified asclone “cc162_(—)1”. cc162_(—)1 was isolated from a human adult braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. cc162_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “cc162_(—)1 protein”).

[3404] The nucleotide sequence of cc162_(—)1 as presently determined isreported in SEQ ID NO:27, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the cc162_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:28. Amino acids 2 to 14 area predicted leader/signal sequence, with the predicted mature amino acidsequence beginning at amino acid 15. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the cc162_(—)1 protein.

[3405] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone cc162_(—)1 should be approximately 785 bp.

[3406] The nucleotide sequence disclosed herein for cc162_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. cc162_(—)1 demonstratedat least some similarity with sequences identified as AA369067 (EST80419Placenta II Homo sapiens cDNA 5′ end similar to EST containing Alurepeat), L05367 (Human oligodendrocyte myelin glycoprotein (OMG) exons),and R97898 (yq60b11.r1 Homo sapiens cDNA clone 200157 5′). Based uponsequence similarity, cc162_(—)1 proteins and each similar protein orpeptide may share at least some activity. The nucleotide sequence ofcc162_(—)1 indicates that it may contain one or more of the followingtypes of repetitive elements: ALU, LI.

[3407] Clone “if87_(—)1”

[3408] A polynucleotide of the present invention has been identified asclone “if87_(—)1”. if87_(—)1 was isolated from a human adult uterus cDNAlibrary using methods which are selective for cDNAs encoding secretedproteins (see U.S. Pat. No. 5,536,637), or was identified as encoding asecreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. if87_(—)1 is afull-length clone, including the entire coding sequence of a secretedprotein (also referred to herein as “if87_(—)1 protein”).

[3409] The nucleotide sequence of if87_(—)1 as presently determined isreported in SEQ ID NO:29, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the if87_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:30. Amino acids 8 to 20 area predicted leader/signal sequence, with the predicted mature amino acidsequence beginning at amino acid 21. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the if87_(—)1 protein.

[3410] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone if87_(—)1 should be approximately 900 bp.

[3411] The nucleotide sequence disclosed herein for if87_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. if87_(—)1 demonstratedat least some similarity with sequences identified as AA172949(ms20b07.r1 Stratagene mouse skin (#937313) Mus musculus cDNA clone607477 5′), AC002310 (Homo sapiens Chromosome 16 BAC cloneCIT987-SKA-635H12˜complete genomic sequence, complete sequence),AC003012 (Human PAC clone DJ0169K13, complete sequence), D59442 (Humanfetal brain cDNA 3′-end GEN-037G12), R72810 (y109f12.r1 Homo sapienscDNA clone 157775 5′ similar to contains MSR1 repetitive element), andX74358 (P.camea Pod-EPPT mRNA). The predicted amino acid sequencedisclosed herein for if87_(—)1 was searched against the GenPept andGeneSeq amino acid sequence databases using the BLASTX search protocol.The predicted if87_(—)1 protein demonstrated at least some similarity tosequences identified as Z46970 (secreted acid phosphatase 2 (SAP2)[Leishmania mexicana]). Based upon sequence similarity, if87_(—)1proteins and each similar protein or peptide may share at least someactivity. The TopPredII computer program predicts an additionalpotential transmembrane domain within the if87_(—)1 protein sequencecentered around arnino acid 58 of SEQ ID NO:30. The nucleotide sequenceof if87_(—)1 indicates that it may contain one or more of the followingrepetitive elements: ALU, LIMA. if87_(—)1 protein was expressed in a COScell expression system, and an expressed protein band of approximately35 kDa was detected in membrane fractions using SDS polyacrylamide gelelectrophoresis.

[3412] Clone “nn103_(—)4”

[3413] A polynucleotide of the present invention has been identified asclone “nn103_(—)4”. nn103_(—)4 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), orwasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nn103_(—)4 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nn103_(—)4 protein”).

[3414] The nucleotide sequence of nn103_(—)4 as presently determined isreported in SEQ ID NO:31, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nn103_(—)4 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:32. Amino acids 19 to 31are a predicted leader/signal sequence, with the predicted mature aminoacid sequence beginning at amino acid 32. Due to the hydrophobic natureof the predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the nn103_(—)4 protein.

[3415] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nn103_(—)4 should be approximately 3500 bp. Thenucleotide sequence disclosed herein for nn103_(—)4 was searched againstthe GenBank and GeneSeq nucleotide sequence databases usingBLASTN/BLASTX and FASTA search protocols. nn103_(—)4 demonstrated atleast some similarity with sequences identified as AA134609 (zn90e04.r1Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 565470 5′),AA584818 (no09e05.s1 NCI_CGAP_Phel Homo sapiens cDNA clone IMAGE 1100192simnilar to contains L1.t1 L1 repetitive element), AC002416 (***SEQUENCING IN PROGRESS *** Human Chromosome X; HTGS phase 1, 3 unorderedpieces), AC002456 (Human BAC clone RG013L03 from 7q21, completesequence), D25252 (Human randomly sequenced mRNA), Q05615 (Insert frompARC 1153), U95743 (Homo sapiens chromosome 16 BAC done CIT987-SK65D3,complete sequence), Z22970 (H.sapiens mRNA for M130 antigen cytoplasmicvariant 2), Z71182 (Human DNA sequence from pac 248J6, between markersDXS366 and DXS87 on chromosome X contains STS), Z81310 (Human DNAsequence from cosmid 019A on chromosome 6 Contains HLA DNA gene andSTS), Z82253 (Human DNA sequence *** SEQUENCING IN PROGRESS *** fromclone U151E3; HTGS phase 1), and Z92547 (Human DNA sequence from PAC863K). The predicted amino acid sequence disclosed herein for nn103_(—)4was searched against the GenPept and GeneSeq amino acid sequencedatabases using the BLASTX search protocol. The predicted nn103_(—)4protein demonstrated at least some similarity to sequences identified asX52235 (ORFII [Homo sapiens]). Based upon sequence similarity,nn103_(—)4 proteins and each similar protein or peptide may share atleast some activity. The TopPredII computer program predicts anadditional potential transmembrane domain within the nn103_(—)4 proteinsequence centered around amino acid 52 of SEQ ID NO:32. The nucleotidesequence of nn103_(—)4 indicates that it may contain one or more of thefollowing types of repetitive elements: Li, A, MER31.

[3416] Clone “np206_(—)8”

[3417] A polynucleotide of the present invention has been identified asclone “np206_(—)8”. np206_(—)8 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.np206_(—)8 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “np206_(—)8 protein”).The nucleotide sequence of np206_(—)8 as presently determined isreported in SEQ ID NO:33, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the np206_(—)8 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:34.

[3418] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone np206_(—)8 should be approximately 1900 bp.

[3419] The nucleotide sequence disclosed herein for np206_(—)8 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. np206_(—)8 demonstratedat least some similarity with sequences identified as AA126810(zn87a12.r1 Stratagene lung cDNA), AC000053 (*** SEQUENCING IN PROGRESS*** Human Cosmid Clone 81a12 and 70g8; HTGS phase 2), AC002094 (Genomicsequence from Human 17, complete sequence), AC002431 (Human BAC cloneRG180F08 from 7q31, complete sequence), F09069 (H. sapiens partial cDNAsequence; clone c-2we10), G33587 (human STS SHGC-50493), R37071(yf66a08.s1 Homo sapiens cDNA clone 27020 3′), U91321 (Human chromosome16p13 BAC clone), Z68746 (Human DNA sequence from cosmid Q27, chromosomeregion 11p15.5), and Z92846 (Human DNA sequence from cosmid U105G4,between markers DXS366 and DXS87 on chromosome X contains ESTs). Basedupon sequence similarity, np206_(—)8 proteins and each similar proteinor peptide may share at least some activity. The nucleotide sequence ofnp206_(—)8 indicates that it may contain one or more of the followingtypes of repetitive elements: Alu/SVA.

[3420] Clone “nt746_(—)4”

[3421] A polynucleotide of the present invention has been identified asclone “nt746_(—)4”. nt746_(—)4 was isolated from a human adult brain(corpus callosum) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nt746_(—)4 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nt746_(—)4 protein”).

[3422] The nucleotide sequence of nt746_(—)4 as presently determined isreported in SEQ ID NO:35, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nt746_(—)4 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:36.

[3423] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nt746_(—)4 should be approximately 1200 bp.

[3424] The nucleotide sequence disclosed herein for nt746_(—)4 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nt746_(—)4 demonstratedat least some similarity with sequences identified as AA489740(aa43c06.r1 Soares NhPu S1 Homo sapiens cDNA clone 823690 5′),J04989(Bovine alpha 1_(—)3 galactosyltransferase mRNA completed cds),M60263(Human alpha-1,3-galactosyltransferase (HGT-2) pseudogene), Q74712(Galactosyl transferase clone), R24770 (yg42c11.r1 Homo sapiens cDNAclone 35316 5′ similar to SP GATR_BOVIN P14769 N-ACETYLLACTOSAMINIDEALPHA-1,3-GALACTOSYL-TRANSFERASE), and S71333 (alpha 1,3galactosyltransferase [New Wor1 d monkeys, mermoset lymphoid cell lineB95.8, rRNA Partial, 1131 nt]). The predicted amino acid sequencedisclosed herein for nt746_(—)4 was searched against the GenPept andGeneSeq amino acid sequence databases using the BLASTX search protocol.The predicted nt746_(—)4 protein demonstrated at least some similarityto sequences identified as M26925 (galactosyltransferase (EC 2.4.1.151)[Mus musculus]), R80016 (Marmoset alpha-1,3-galactosyltransferase),S71333 (alpha 1,3 galactosyltransferase, alpha 1,3GT [New Wor1 dmonkeys, mermoset lymphoid cell line B95.8, Peptide, 376 aa][Platyrrhinil), and W13639 (Murine alpha(1,3)-galactosyltransferase).Based upon sequence similarity, nt746_(—)4 proteins and each similarprotein or peptide may share at least some activity. The TopPredIIcomputer program predicts a potential transmembrane domain within thent746_(—)4 protein sequence centered around amino acid 15 of SEQ IDNO:36. The nucleotide sequence of nt746_(—)4 indicates that it maycontain an LTR repetitive element.

[3425] nt746_(—)4 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 100 kDa was detected inconditioned medium using SDS polyacrylamide gel electrophoresis.

[3426] Clone “pe286_(—)1”

[3427] A polynucleotide of the present invention has been identified asclone “pe286_(—)1”. pe286_(—)1 was isolated from a human adult blood(chronic myelogenous leukemia K5) cDNA library using methods which areselective for cDNAs encoding secreted proteins (see U.S. Pat.No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. pe286_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“pe286_(—)1 protein”).

[3428] The nucleotide sequence of pe286_(—)1 as presently determined isreported in SEQ ID NO:37, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pe286_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:38.

[3429] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pe286_(—)1 should be approximately 300 bp.

[3430] The nucleotide sequence disclosed herein for pe286_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. pe286_(—)1 demonstratedat least some similarity with sequences identified as AA588854(no21h03.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE 1101365), L46897(Homo sapiens (subclone 3_d9 from P1 H13) DNA sequence), and N48057(yy99d09.s1 Homo sapiens cDNA clone 281681 3′ similar to containselement MER4 repetitive element). Based upon sequence similarity,pe286_(—)1 proteins and each similar protein or peptide may share atleast some activity.

[3431] Clone “yb7_(—)1”

[3432] A polynucleotide of the present invention has been identified asclone “yb7_(—)1”. yb7_(—)1 was isolated from a human fetal brain cDNAlibrary using methods which are selective for cDNAs encoding secretedproteins (see U.S. Pat. No. 5,536,637), or was identified as encoding asecreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. yb7_(—)1 is afull-length clone, including the entire coding sequence of a secretedprotein (also referred to herein as “yb7_(—)1 protein”).

[3433] The nucleotide sequence of yb7_(—)1 as presently determined isreported in SEQ ID NO:39, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the yb7_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:40.

[3434] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone yb7_(—)1 should be approximately 1150 bp.

[3435] The nucleotide sequence disclosed herein for yb7_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. yb7_(—)1 demonstrated atleast some similarity with sequences identified as N99344 (IMAGE:20090Homo sapiens cDNA clone 20090). Based upon sequence similarity, yb7_(—)1proteins and each similar protein or peptide may share at least someactivity. The TopPredII computer program predicts a potentialtransmembrane domain within the yb7_(—)1 protein sequence located aroundamino acid 52 of SEQ ID NO:40; this domain is also a potentialleader/signal sequence with the mature protein beginning at or nearamino acid 52 of SEQ ID NO:40.

[3436] Clone “am728_(—)60”

[3437] A polynucleotide of the present invention has been identified asclone “am728_(—)60”. am728_(—)60 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.am728_(—)60 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “am728_(—)60protein”).

[3438] The nucleotide sequence of am728_(—)60 as presently determined isreported in SEQ ID NO:41. What applicants presently believe to be theproper reading frame and the predicted amino acid sequence of theam728_(—)60 protein corresponding to the foregoing nucleotide sequenceis reported in SEQ ID NO:42.

[3439] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone am728_(—)60 should be approximately 4333 bp.

[3440] The nucleotide sequence disclosed herein for am728_(—)60 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. am728_(—)60 demonstratedat least some similarity with sequences identified as AA446039(zw66a08.r1 Soares testis NHT Homo sapiens cDNA clone 781142 5′) andU73682 (Human meningioma-expressed antigen 11 (MEA11) mRNA, partialcds). The predicted amino acid sequence disclosed herein for am728_(—)60was searched against the GenPept and GeneSeq amino acid sequencedatabases using the BLASTX search protocol. The predicted am728_(—)60protein demonstrated at least some similarity to sequences identified asU67884 (melanoma inhibitory activity/condrocyte-derived retinoic acidsensitive protein homolog [Rattus norvegicus]), U73682(meningioma-expressed antigen 11 [Homo sapiens]), U94780 (MEA6 [Homosapiens]), and X84707 (melanoma growth regulatory protein [Homosapiens]). Based upon sequence similarity, am728_(—)60 proteins and eachsimilar protein or peptide may share at least some activity. TheTopPredII computer program predicts three potential transmembranedomains within the am728_(—)60 protein sequence, centered around aminoadds 300, 370, and 670 of SEQ ID NO:42, respectively.

[3441] When expressed in COS cells, am728_(—)60 protein was detected ina membrane fraction from these cells as a band migrating atapproximately 200 kD on a denaturing SDS polyacrylamide gel.

[3442] Clone “bf377_(—)1”

[3443] A polynucleotide of the present invention has been identified asclone 'sf377_(—)1”. bf377_(—)1 was isolated from a human fetal braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. bf377_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “bf377_(—)1 protein”).

[3444] The nucleotide sequence of bf377_(—)1 as presently determined isreported in SEQ ID NO:43, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bf377_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:44. Amnino acids 27 to 39of SEQ ID NO:44 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 40. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thebf377_(—)1 protein.

[3445] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bf377_(—)1 should be approximately 450 bp.

[3446] The nucleotide sequence disclosed herein for bf377_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. bf377_(—)1 demonstratedat least some similarity with sequences identified as AA559859(nl48c05.s1 NCI_CGAP_Pr4 Homo sapiens cDNA clone IMAGE 1043912),AA657838 (nu08b11.s1 NCI_CGAP_Pr2 Homo sapiens cDNA clone IMAGE:1207389similar to gb:M15990 PROTO-ONCOGENE TYROSINE-PROTEIN KINASE YES(HIJAN)), and R49353 (yg67e07.s1 Homo sapiens cDNA clone 38126 3′similar to contains MER22 repetitive element). Based upon sequencesimilarity, bf377_(—)1 proteins and each similar protein or peptide mayshare at least some activity.

[3447] Clone “cw354_(—)1”

[3448] A polynucleotide of the present invention has been identified asclone “cw354_(—)1”. cw354_(—)1 was isolated from a human fetal braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. cw354_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “cw354_(—)1 protein”).

[3449] The nucleotide sequence of cw354_(—)1 as presently determined isreported in SEQ ID NO:45, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the cw354_protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:46. Amino acids 28 to 40 ofSEQ ID NO:46 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 41. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the cw354_(—)1 protein.

[3450] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone cw354_(—)1 should be approximately 1350 bp.

[3451] The nucleotide sequence disclosed herein for cw354_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. cw354_(—)1 demonstratedat least some similarity with sequences identified as D58859 (Humanplacenta cDNA 5′-end GEN-514B03), H07863 (yl86b05.s1 Homo sapiens cDNAclone 45017 3′), N32178 (yy25b09.s1 Homo sapiens cDNA clone 272249 3′),R81953 (yi98e11.r1 Homo sapiens cDNA clone 147308 5′), and W84437(zd89d06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 3566513′). The predicted amino acid sequence disclosed herein for cw354_(—)1was searched against the GenPept and GeneSeq amino acid sequencedatabases using the BLASTX search protocol. The predicted cw354_(—)1protein demonstrated at least some similarity to sequences identified asU39726 (adenosinetriphosphatase [Mycoplasma genitalium]). Based uponsequence similarity, cw354_(—)1 proteins and each similar protein orpeptide may share at least some activity.

[3452] Clone “nm134_(—)4”

[3453] A polynucleotide of the present invention has been identified asclone “nm134_(—)4”. nm134_(—)4 was isolated from a human adult blood(erythroleukemia TF-1) cDNA library using methods which are selectivefor cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), orwas identified as encoding a secreted or transmembrane protein on thebasis of computer analysis of the amino acid sequence of the encodedprotein. nm134_(—)4 is a full-length clone, including the entire codingsequence of a secreted protein (also referred to herein as “nm134_(—)4protein”).

[3454] The nucleotide sequence of nm134_(—)4 as presently determined isreported in SEQ ID NO:47, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nm134_(—)4 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:48. Amino acids 136 to 148of SEQ ID NO:48 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 149. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thenm134_(—)4 protein. The EcoRI/NotI restriction fragment obtainable fromthe deposit containing clone nm134_(—)4 should be approximately 1500 bp.

[3455] The nucleotide sequence disclosed herein for nm134_(—)4 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nm134_(—)4 demonstratedat least some similarity with sequences identified as AA205020(zq72a12.r1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone647134 5′), AA205286 (zq72a12.s1 Stratagene neuroepithelium (#937231)Homo sapiens cDNA clone 647134 3′), AA261864 (zs18h05.r1 Soares NbHTGBCHomo sapiens cDNA clone 685593 5′), and H63680 (yr55d03.r1 Homo sapienscDNA clone 209189 5′). Based upon sequence similarity, nm134_(—)4proteins and each similar protein or peptide may share at least someactivity. The TopPredII computer program predicts five potentialtransmembrane domains within the nm134_(—)4 protein sequence centeredaround amino acids 108, 132, 170, 195, and 226 of SEQ ID NO:48,respectively.

[3456] Clone “yb11_(—)1”

[3457] A polynucleotide of the present invention has been identified asclone “yb11_(—)1”. yb11_(—)1 was isolated from a human fetal brain cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. Yb11_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“yb11_(—)1 protein”). The nucleotide sequence of yb11_(—)1 as presentlydetermined is reported in SEQ ID NO:49, and includes a poly(A) tail.What applicants presently believe to be the proper reading frame and thepredicted amino acid sequence of the yb11_(—)1 protein corresponding tothe foregoing nucleotide sequence is reported in SEQ ID NO:50. Aminoacids 43 to 55 of SEQ ID NO:50 are a predicted leader/signal sequence,with the predicted mature amino acid sequence beginning at amino acid56. Due to the hydrophobic nature of the predicted leader/signalsequence, it is likely to act as a transmembrane domain should thepredicted leader/signal sequence not be separated from the remainder ofthe yb11_(—)1 protein.

[3458] The EcoRI/NotI restriction fragment obtainable from the depositcontaining done yb11_(—)1 should be approximately 2800 bp.

[3459] The nucleotide sequence disclosed herein for yb11_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. Yb11_(—)1 demonstratedat least some similarity with sequences identified as R55695 (yg88f12.s1Homo sapiens cDNA clone 40397 3′) and R85100 (yo43b05.s1 Homo sapienscDNA clone 180657 3′). Based upon sequence similarity, ybll I proteinsand each similar protein or peptide may share at least some activity.

[3460] Clone “yc2_(—)1”

[3461] A polynucleotide of the present invention has been identified asclone “yc2_(—)1”. yc2_(—)1 was isolated from a human fetal kidney (293cell line) cDNA library and was identified as encoding a secreted ortransmembrane protein on the basis of computer analysis of the aminoacid sequence of the encoded protein. yc2_(—)1 is a full-length clone,including the entire coding sequence of a secreted protein (alsoreferred to herein as “yc2_(—)1 protein”).

[3462] The nucleotide sequence of yc2_(—)1 as presently determined isreported in SEQ ID NO:51, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the yc2_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:52. Amino acids 15 to 27 ofSEQ ID NO:52 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 28. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the yc2_(—)1 protein.

[3463] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone yc2_(—)1 should be approximately 2900 bp.

[3464] The nucleotide sequence disclosed herein for yc2_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. yc2_(—)1 demonstrated atleast some similarity with sequences identified as AA618531 (np38a03.s1NCI_CGAP_Lul Homo sapiens cDNA clone IMAGE:1118572 similar to containsAlu repetitive element) and AA626937 (af84h07.s1 Soares testis NHT Homosapiens cDNA clone 1048765 3′). Based upon sequence similarity, yc2_(—)1proteins and each similar protein or peptide may share at least someactivity. The nucleotide sequence of yc2_(—)1 indicates that it maycontain one or more Alu repetitive elements.

[3465] Clone “ff168_(—)12”

[3466] A polynucleotide of the present invention has been identified asclone “ff168_(—)12”. ff168_(—)12 was isolated from a human adult testes(teratocarcinoma NCCIT) cDNA library using methods which are selectivefor cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), orwas identified as encoding a secreted or transmembrane protein on thebasis of computer analysis of the amino acid sequence of the encodedprotein. ff168_(—)12 is a full-length clone, including the entire codingsequence of a secreted protein (also referred to herein as “ff168_(—)12protein”).

[3467] The nucleotide sequence of ff168_(—)12 as presently determined isreported in SEQ ID NO:53, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the ff168_(—)12 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:54.

[3468] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone ff168_(—)12 should be approximately 1600 bp.

[3469] The nucleotide sequence disclosed herein for ff168_(—)12 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. ff168_(—)12 demonstratedat least some similarity with sequences identified as AA025945(ze9le02.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 3663625′), AA156237 (z150c09.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 505360 3′), AA420993 (zu08e09.s1 Soares testis NHT Homo sapienscDNA clone 731272 3′), N78486 (yz78e03.r1 Homo sapiens cDNA clone 2891805′), WO1843 (za80a01.r1 Soares fetal lung NbHL19W Homo sapiens cDNAclone 298824 5′), and W95777 (ze07e02.r1 Soares fetal heart NbHH19W Homosapiens cDNA clone 358298 5′). Based upon sequence similarity,ff168_(—)12 proteins and each similar protein or peptide may share atleast some activity.

[3470] Clone “ls9_(—)1”

[3471] A polynucleotide of the present invention has been identified asclone “ls9_(—)1”. ls9_(—)1 was isolated from a human adult brain(substantia nigra) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.ls9_(—)1 is a full-length clone, including the entire coding sequence ofa secreted protein (also referred to herein as “ls9_(—)1 protein”).

[3472] The nucleotide sequence of ls9_(—)1 as presently determined isreported in SEQ ID NO:55, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the ls9_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:56. Amino acids 60 to 72 ofSEQ ID NO:56 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 73. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the ls9_(—)1 protein.

[3473] The EcoRI/Noti restriction fragment obtainable from the depositcontaining done ls9_(—)1 should be approximately 2300 bp.

[3474] The nucleotide sequence disclosed herein for ls9_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. ls9_(—)1 demonstrated atleast some similarity with sequences identified as AA527586 (ng42d05.s1NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE:937449), AC000119 (Human BACclone RG104I04 from 7q21_(—)7q22, complete sequence), T18551 (Humanpolycystic kidney disease normal PKD1 gene), Y10196 (H.sapiens PEXgene), and Z94721 (Human DNA sequence *** SEQUENCING IN PROGRESS ***from clone 167A14; HTGS phase 1). The predicted amnino acid sequencedisclosed herein for ls9_(—)1 was searched against the GenPept andGeneSeq amnino acid sequence databases using the BLASTX search protocol.The predicted ls9_(—)1 protein demonstrated at least some similarity tosequences identified as AB(02375 (KIAA0377 [Homo sapiens]) and R95913(Neural thread protein). Based upon sequence similarity, ls9_(—)1proteins and each similar protein or peptide may share at least someactivity. The TopPredIl computer program predicts an additionalpotential transmembrane domain within the ls9_(—)1 protein sequencecentered around amino acid 40 of SEQ ID NO:56. The nucleotide sequenceof ls9_(—)1 indicates that it may contain an Alu /SVA repetitiveelement.

[3475] Clone “na1010_(—)1”

[3476] A polynucleotide of the presentinventionhas been identified asclone “na1010_(—)1”. na1010_(—)1 was isolated from a human adult braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. na1010_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “na1010_(—)1 protein”). Thenucleotide sequence of na1010_(—)1 as presently determined is reportedin SEQ ID NO:57, and includes a poly(A) tail. What applicants presentlybelieve to be the proper reading frame and the predicted amino acidsequence of the na1010_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:58. Amino acids 24 to 36 ofSEQ ID NO:58 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 37. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the na1010_(—)1 protein.

[3477] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone na1010_(—)1 should be approximately 1050 bp.

[3478] The nucleotide sequence disclosed herein for na1010_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. na1010_(—)1 demonstratedat least some similarity with sequences identified as AC002091 (Genomicsequence from Human 17, complete sequence), AC002382 (Human BAC cloneRG022J17 from 7q21, complete sequence), and M26434 (Human hypoxanthinephosphoribosyltransferase (HPRT) gene, complete cds). Based uponsequence similarity, na1010_(—)1 proteins and each similar protein orpeptide may share at least some activity. The nucleotide sequence ofna1010_(—)1 indicates that it may contain one or more of the followingrepetitive elements: L1/A/MIR/SVA/LTRII, Alu/SVA/A/GAA, or Alu/A/GAAAA.

[3479] Clone “nf87_(—)1”

[3480] A polynucleotide of the present invention has been identified asclone “nf87_(—)1”. nf87_(—)1 was isolated from a human adult brain(substantia nigra) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nf87_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nf87_(—)1 protein”).

[3481] The nucleotide sequence of nf87_(—)1 as presently determined isreported in SEQ ID NO:59, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nf87_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:60. Amino acids 53 to 65 ofSEQ ID NO:60 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 66. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the nf87_(—)1 protein.

[3482] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nf87_(—)1 should be approximately 1200 bp.

[3483] The nucleotide sequence disclosed herein for nf87_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nf87_(—)1 demonstratedat least some similarity with sequences identified as AA358277 (EST67398Fetal lung III Homo sapiens cDNA 5′ end similar to similar tointerferon-alpha-inducible gene p27), W52706 (zc55g02.r1 Soaressenescent fibroblasts NbHSF Homo sapiens cDNA clone 326258 5′ similar toSW INI7_HUMAN P40305 INTERFERON-ALPHA INDUCED 11.5 KD PROTEIN), andX67325 (H.sapiens p27 mRNA). The predicted amino acid sequence disclosedherein for nf87_(—)1 was searched against the GenPept and GeneSeq aminoacid sequence databases using the BLASTX search protocol. The predictednf87_(—)1 protein demonstrated at least some similarity to sequencesidentified as X67325 (p27 gene product [Homo sapiens]). Theinterferon-alpha-inducible gene is localized on human chromosome 14q32and expresses the highly hydrophobic p27 gene product in breastcarcinoma cells. Based upon sequence similarity, nf87_(—)1 proteins andeach similar protein or peptide may share at least some activity.nf87_(—)1 protein was expressed in a COS cell expression system, and anexpressed protein band of approximately 16 kDa was detected in membranefractions using SDS polyacrylamide gel electrophoresis.

[3484] Clone “nh796_(—)1”

[3485] A polynucleotide of the present invention has been identified asclone “nh796_(—)1”. nh796_(—)1 was isolated from a human adult brain(thalamus) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nh796_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nh796_(—)1 protein”).

[3486] The nucleotide sequence of nh796_(—)1 as presently determined isreported in SEQ ID NO:61, and includes a poly(A) tail. VVhat applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nh796_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:62. Amino acids 7 to 19 ofSEQ ID NO:62 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 20. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the nh796_(—)1 protein.

[3487] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nh796_(—)1 should be approximately 1050 bp.

[3488] The nucleotide sequence disclosed herein for nh796_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nh796_(—)1 demonstratedat least some similarity with sequences identified as AA315985 (EST18772Lung Homo sapiens cDNA 5′ end), N23239 (yw47b07.s1 Homo sapiens cDNAdone 255349 3′), N27741 (yw51c06.s1 Homo sapiens cDNA clone 255754 3′),U69172 (Mus musculus unknown protein mRNA, complete cds), and Z24371 (H.sapiens (D20S195) DNA segment containing (CA) repeat; clone AFM321xc1;single read). The predicted amino acid sequence disclosed herein fornh796_(—)1 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictednh796_(—)1 protein demonstrated at least some similarity to sequencesidentified as U69172 (unknown [Mus musculus]). The mouse protein ofunknown function (U69172) is expressed in late palate development. Basedupon sequence similarity, nh796_(—)1 proteins and each similar proteinor peptide may share at least some activity.

[3489] nh796_(—)1 protein was expressed in a COS cell expression system,and an expressed proteinband of approximately 25 kDa was detected inconditioned media and membrane fractions using SDS polyacrylamide gelelectrophoresis.

[3490] Clone “nn229_(—)1”

[3491] A polynucleotide of the present invention has been identified asclone “nn229_(—)1”. nn229_(—)1 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nn229_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nn229_(—)1 protein”).

[3492] The nucleotide sequence of nn229_(—)1 as presently determined isreported in SEQ ID NO: 63, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nn229_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:64. Amino acids 59 to 71 ofSEQ ID NO:64 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 72. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the nn229_(—)1 protein.

[3493] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nn229_(—)1 should be approximately 1050 bp.

[3494] The nucleotide sequence disclosed herein for nn229_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nn229_(—)1 demonstratedat least some similarity with sequences identified as H24014 (ym49f02.s1Homo sapiens cDNA clone 51480 3′), R08508 (ye95h01.r1 Homo sapiens cDNAclone 125521 5′ similar to gb |M87910| HUMALNE34 Human carcinomacell-derived Alu RNA transcript, (rRNA); gb J02931 TISSUE FACTORPRECURSOR (HUMAN)), and Z96508 (H.sapiens telomeric DNA sequence, clone22QTEL030, read 22QTELOO030.seq). Based upon sequence similarity,nn229_(—)1 proteins and each similar protein or peptide may share atleast some activity. The TopPredII computer program predicts a potentialtransmembrane domain within the nn229_(—)1 protein sequence centeredaround amino acid 20 of SEQ ID NO:64. The nucleotide sequence ofnn229_(—)1 indicates that it may contain a MER20 repetitive element.

[3495] Clone “np156_(—)1”

[3496] A polynucleotide of the present invention has been identified asclone “np156_(—)1”. np156_(—)1 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.np156_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “np156_(—)1 protein”).The nucleotide sequence of np156_(—)1 as presently determined isreported in SEQ ID NO:65, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the np156_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:66. Amino acids 6 to 18 ofSEQ ID NO:66 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 19. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the np156_(—)1 protein.

[3497] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone np156_(—)1 should be approximately 1200 bp.

[3498] The nucleotide sequence disclosed herein for np156_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. np156_(—)1 demonstratedat least some similarity with sequences identified as AA298580(EST114211 HSC172 cells I Homo sapiens cDNA 5′ end), AA447514(zw81a05.s1 Soares testis NHT Homo sapiens cDNA clone 782576 3′),AC002309 (*e* SEQUENCING IN PROGRESS *** Human Chromosome 22qll CosmidClone 63e9; HTGS phase 1, 3 unordered pieces), AF007269 (Arabidopsisthaliana BAC IG002N01), and N53641 (yz04g03.r1 Homo sapiens cDNA clone282100 5′). Based upon sequence similarity, np156_(—)1 proteins and eachsimilar protein or peptide may share at least some activity.

[3499] Clone “bg570_(—)1”

[3500] A polynucleotide of the present invention has been identified asclone “bg570_(—)1”. bg570_(—)1 was isolated from a human adult braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. bg570_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “bg570_(—)1 protein”).

[3501] The nucleotide sequence of bg570_(—)1 as presently determined isreported in SEQ ID NO:67, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bg570_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:68. Amino acids 33 to 45 ofSEQ ID NO:68 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 46. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the bg570_(—)1 protein.

[3502] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bg570_(—)1 should be approximately 900 bp.

[3503] The nucleotide sequence disclosed herein for bg570_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. bg570_(—)1 demonstratedat least some similarity with sequences identified as T03370 (IB1429Infant brain, Bento Soares Homo sapiens cDNA clone IB1429 3′ end). Basedupon sequence similarity, bg570_(—)1 proteins and each similar proteinor peptide may share at least some activity.

[3504] Clone “bi120_(—)2”

[3505] A polynucleotide of the present invention has been identified asclone “bi120_(—)2”. bi120_(—)2 was isolated from a human fetal kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. bi120_(—)2is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “bi120_(—)2 protein”).

[3506] The nucleotide sequence of bi120_(—)2 as presently determined isreported in SEQ ID NO:69, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bi120_(—)2 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:70. Amino acids 39 to 51 ofSEQ ID NO:70 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 52. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the bi120_(—)2 protein.

[3507] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bi120_(—)2 should be approximately 1800 bp. Thenucleotide sequence disclosed herein for bi120_(—)2 was searched againstthe GenBank and GeneSeq nucleotide sequence databases usingBLASTN/BLASTX and FASTA search protocols. bi120_(—)2 demonstrated atleast some similarity with sequences identified as AA232119 (zr24a12.r1Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone 6643185′ similar to WP:C11H1.2 CE05261), D20759 (Human HL60 3′ directed MboIcDNA, HUMGS01738, clone mp1051), N28753 (yx67h11.r1 Homo sapiens cDNAclone), N28806 (yx70g12.r1 Homo sapiens cDNA clone 267142 5′), N35232(yy21d02.s1 Homo sapiens cDNA clone 271875 3′), W73805 (zd50g02.r1Soares fetal heart NbHH19W Homo sapiens cDNA clone 344114 5′), Z61133(H.sapiens CpG island DNA genomic Msel fragment, clone 45gl, forwardread cpg45gl.ftla), and Z70205 (Caenorhabditis elegans cosmid C11H1,complete sequence). bi120_(—)2 also demonstrated at least somesimilarity with CpG island DNA. The predicted amino acid sequencedisclosed herein for bi120_(—)2 was searched against the GenPept andGeneSeq amino acid sequence databases using the BLASTX search protocol.The predicted bi120_(—)2 protein demonstrated at least some similarityto sequences identified as Z70205 (C11H1.2 [Caenorhabditis elegans]).Based upon sequence similarity, bi120_(—)2 proteins and each similarprotein or peptide may share at least some activity. The TopPredIIcomputer program predicts five additional potential transmembranedomains within the bi120_(—)2 protein sequence, centered around aminoacids 20,80,110,150, and 290 of SEQ ID NO:70, respectively. There may bea frameshift in the full-clone sequence (somewhere within base pairs99-1010 of SEQ ID NO:69). This frameshift from reading frame 3 toreading frame 1 would extend the open reading frame from 309 amino acidsto at least 460 amino acids and add three more potential transmembranedomains to the protein. There also appears to be another frameshiftoccuring around base pair 1450 of SEQ ID NO:69 which shifts the openreading frame back into frame 3, adding approximately 20 more codons tothe open reading frame sequence.

[3508] Clone “bn594_(—)1”

[3509] A polynucleotide of the present invention has been identified asclone “bn594_(—)1”. bn594_(—)1 was isolated from a human adult placentacDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. bn594_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “bn594 1 protein”).

[3510] The nucleotide sequence of bn594_(—)1 as presently determined isreported in SEQ ID NO:71, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bn594_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:72.

[3511] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bn594_(—)1 should be approximately 1400 bp.

[3512] The nucleotide sequence disclosed herein for bn594_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. bn594_(—)1 demonstratedat least some similarity with sequences identified as J03071 (Humangrowth hormone (GH-1 and GH-2) and chorionic somatomammotropin (CS-1,CS2 and CS-5) genes, complete cds). Based upon sequence similarity,bn594_(—)1 proteins and each similar protein or peptide may share atleast some activity. The TopPredil computer program predicts a potentialtransmembrane domain within the bn594_(—)1 protein sequence centeredaround amino acid 52 of SEQ ID NO:72; this region is also a potentialsignal sequence, with the mature protein starting at amino acid 53 ofSEQ ID NO:72. The nucleotide sequence of bn594_(—)1 indicates that itmay contain one or more of the following types of repetitive elements:ALU, GAAA.

[3513] Clone “en554_(—)1”

[3514] A polynucleotide of the present invention has been identified asclone “en554_(—)1”. en554_(—)1 was isolated from a human fetal braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. en554_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as en554_(—)1 protein”). Thenucleotide sequence of en554_(—)1 as presently determined is reported inSEQ ID NO:73, and includes a poly(A) tail. What applicants presentlybelieve to be the proper reading frame and the predicted amino acidsequence of the en554 1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:74. Amino acids 15 to 27 ofSEQ ID NO:74 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 28. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the en554_(—)1 protein.

[3515] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone en554_(—)1 should be approximately 1800 bp.

[3516] The nucleotide sequence disclosed herein for en554_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. en554_(—)1 demonstratedat least some similarity with sequences identified as AA625842(zv87d08.s1 Soares N MPu S1 Homo sapiens cDNA clone 766767 3′) andR54550 (yg75h06.r1 Homo sapiens cDNA clone 39297 5′). Based uponsequence similarity, en554_(—)1 proteins and each similar protein orpeptide may share at least some activity. The nucleotide sequence ofen554_(—)1 indicates that it may contain repetitive elements in theregion between base pairs 849 and 1023 of SEQ ID NO:73.

[3517] Clone “na474_(—)10”

[3518] A polynucleotide of the presentinvention hasbeen identified asclone “na474_(—)10”. na474_(—)10 was isolated from a human adult brain(corpus callosum) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.na474_(—)10 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “na474_(—)10protein”).

[3519] The nucleotide sequence of na474_(—)10 as presently determined isreported in SEQ ID NO:75, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the na474_(—)10 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:76. Amino acids 69 to 81 ofSEQ ID NO:76 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 82. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the na474_(—)10 protein.

[3520] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone na474_(—)10 should be approximately 1500 bp. Thenucleotide sequence disclosed herein for na474_(—)10 was searchedagainst the GenBank and GeneSeq nucleotide sequence databases usingBLASTN/BLASTX and FASTA search protocols. na474_(—)10 demonstrated atleast some similarity with sequences identified as AA262604 (zs23f01.s1NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:686041 3′ similar tocontains Alu repetitive element), AA450131 (zx42a02.r1 Soares totalfetus Nb2HF8 9w Homo sapiens cDNA clone 789098 5′), U72661 (Humanninjurinl mRNA, complete cds), and W38567 (zb20h04.r1 Soares fetal lungNbHL19W Homo sapiens cDNA clone 302647 5′). The predicted amino acidsequence disclosed herein for na474_(—)10 was searched against theGenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted na474_(—)10 protein demonstrated at leastsome similarity to sequences identified as U72661 (ninjurinl [Homosapiens]). Based upon sequence similarity, na474_(—)10 proteins and eachsimilar protein or peptide may share at least some activity. Ninjurin isa cell-surface protein and adhesion molecule which is induced by nerveinjury and promotes axonal growth.

[3521] Ninjurin is capable of mediating homophilic adhesion and canpromote neurite extension of dorsal root ganglion neurons in vitro. Itis thought to play a role in nerve regeneration and in the formation andfunction of other tissues (Araki et al., 1996, Neuron 17(2):353_(—)361,incorporated herein by reference). na474_(—)10 and ninjurin appear todefine a novel family of adhesion molecules. na474_(—)10 protein wasexpressed in a COS cell expression system, and an expressed protein bandof approximately 15 kDa was detected in membrane fractions using SDSpolyacrylamide gel electrophoresis.

[3522] Clone “nn16_(—)10”

[3523] A polynucleotide of the present invention has been identified asclone “nn16_(—)10”. nn16_(—)10 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nn16_(—)10 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nn16_(—)10 protein”).

[3524] The nucleotide sequence of nn16_(—)10 as presently determined isreported in SEQ ID NO:77, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nn16_(—)10 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:78. Amino acids 14 to 26 ofSEQ ID NO:78 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 27. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the nn16_(—)10 protein.

[3525] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nn16_(—)10 should be approximately 1600 bp.

[3526] The nucleotide sequence disclosed herein for nn6_(—)10 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nn16_(—)10 demonstratedat least some simnilarity with sequences identified as R46973 (Y224Rattus norvegicus cDNA clone Y224 5′ end), U43404 (Sus scrofaameloblastin mRNA, complete cds), W13000 (mb21d12.r1 Soares mousep3NMF19.5 Mus musculus cDNA clone 330071 5′), and W36463 (mb71c12.r1Soares mouse p3NMF19.5 Mus musculus cDNA clone 334870 5′). The predictedamino acid sequence disclosed herein for nn16_(—)10 was searched againstthe GenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted nn16_(—)10 protein demonstrated at leastsome similarity to sequences identified as U43404 (ameloblastin [Susscrofa]), and to the amelobalstin proteins of rat (and other species).

[3527] Ameloblastin is a unique ameloblast-specific gene product thatmay be important in enamel matrix formation and mineralization(Krebsbach et al., 1996, J. Biol. Chem. 271: 4431, incorporated hereinby reference). Rat ameloblastin is 442 amino acids and is atooth-specific enamel matrix protein. Immunohistochemical data showstaining of golgi and of secretory granules of the secretory ameloblast,in addition to the entire thickness of the enamel matrix. The ratameloblastin protein is synthesized as a 55 kDa core protein whichundergoes extensive post-translational modifications with O-linkedoligo-saccharides to become the 65 kDa secretory form (Uchida et al.,1997, J. Histochem. Cytochem. 45(10):1329-1340, incorporated herein byreference). Based upon sequence similarity, nn16_(—)10 proteins and eachsimilar protein or peptide may share at least some activity.

[3528] nn16_(—)10 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 84 kDa was detected inconditioned medium and membrane fractions using SDS polyacrylamide gelelectrophoresis.

[3529] Clone “np189_(—)9”

[3530] A polynucleotide of the present invention has been identified asclone “np189_(—)9”. np189_(—)9 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.np189_(—)9 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “np189_(—)9 protein”).The nucleotide sequence of npl89_(—)9 as presently determined isreported in SEQ ID NO:79, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the npl89_(—)9 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:80. Amino acids 41 to 53 ofSEQ ID NO:80 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 54. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the npl89 9 protein.

[3531] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone np189_(—)9 should be approximately 2100 bp.

[3532] The nucleotide sequence disclosed herein for np89_(—)9 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. np89_(—)9 demonstratedat least some similarity with sequences identified as AA035196(zk27f12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 4717913′), AA336568 (EST41447 Endometrial tumor Homo sapiens cDNA 5′ end),AA420972 (zt86a11.s1 Soares testis NHT Homo sapiens cDNA clone 7292123′), and H38460 (yp69h08.s1 Homo sapiens cDNA clone 192735 3′). Basedupon sequence similarity, np189_(—)9 proteins and each similar proteinor peptide may share at least some activity. The TopPredII computerprogram predicts an additional potential transmembrane domain within thenp189_(—)9 protein sequence centered around amino acid 38 of SEQ IDNO:80.

[3533] Clone “nv226_(—)1”

[3534] A polynucleotide of the present invention has been identified asclone “ny226_(—)1”. ny226_(—)1 was isolated from a human adult brain(substantia nigra) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.ny226_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “ny226_(—)1 protein”).

[3535] The nucleotide sequence of ny226_(—)1 as presently determined isreported in SEQ ID NO:81, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the ny226_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:82.

[3536] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone ny226_(—)1 should be approximately 3175 bp.

[3537] The nucleotide sequence disclosed herein for ny226_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. ny226_(—)1 demonstratedat least some similarity with sequences identified as AC002463 (HumanBAC clone RG302F04 from 7q31, complete sequence), R07637 (ye98e03.s1Homo sapiens cDNA clone 125788 3′), and Z78730 (H.sapiens flow-sortedchromosome 6 HindIII fragment, SC6pA15C3). Based upon sequencesimilarity, ny226_(—)1 proteins and each similar protein or peptide mayshare at least some activity. The TopPredII computer program predicts apotential transmembrane domain within the ny226_(—)1 protein sequencecentered around amino acid 22 of SEQ ID NO:82; this region is also aputative signal sequence, with the mature protein starting at amino acid23 of SEQ ID NO:82. The nucleotide sequence of ny226_(—)1 indicates thatit may contain one or more repetitive elements, including ALU repetitiveelements.

[3538] Clone “pe159_(—)1”

[3539] A polynucleotide of the present invention has been identified asclone “pe159_(—)1”. pe159_(—)1 was isolated from a human adult blood(chronic myelogenous leukemia K5) cDNA library using methods which areselective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. pe159_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“pe159_(—)1 protein”).

[3540] The nucleotide sequence of pe159_(—)1 as presently determined isreported in SEQ ID NO:83, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pe159_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:84.

[3541] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pe159_(—)1 should be approximately 1000 bp.

[3542] The nucleotide sequence disclosed herein for pe159_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. pe159_(—)1 demonstratedat least some similarity with sequences identified as AA372974 (EST84925Colon adenocarcinoma IV Homo sapiens cDNA 5′ end), AC002377 (Human PACclone DJ222H05), AC002519 (*** SEQUENCING IN PROGRESS *** Humanchromosome 16p11.2 BAC clone CIT987SK-A-355G7; HTGS phase 2, 1 orderedpieces), H45355 (yn99b01.r1 Homo sapiens cDNA clone 176521 5′), W39648(zc19c09.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone322768 5′), and Z84816 (Human DNA sequence from PAC 2A2 on chromosome Xcontains ESTs). The predicted amino acid sequence disclosed herein forpe159_(—)1 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictedpe159_(—)1 protein demonstrated at least some similarity to sequencesidentified as M84237 (integrin beta-i subunit [Homo sapiens]) and R96800(Human histiocyte-secreted factor HSF). Based upon sequence similarity,pel59_(—)1 proteins and each similar protein or peptide may share atleast some activity. The nucleotide sequence of pel59_(—)1 indicatesthat it may contain one or more of the following types of repetitiveelements: Alu, SVA, MER3.

[3543] Clone “pj314₈”

[3544] A polynucleotide of the present invention has been identified asclone “pj314_(—)8”. pj314_(—)8 was isolated from a human fetal carcinoma(cell type NTD2 treated with retinoic acid for 23 days) cDNA libraryusing methods which are selective for cDNAs encoding secreted proteins(see U.S. Pat. No.5,536,637), or was identified as encoding a secretedor transmembrane protein on the basis of computer analysis of the aminoacid sequence of the encoded protein. pj314_(—)8 is a full-length clone,including the entire coding sequence of a secreted protein (alsoreferred to herein as “pj314_(—)8 protein”).

[3545] The nucleotide sequence of pj314_(—)8 as presently determined isreported in SEQ ID NO:85, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pj314_(—)8 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:86. Amino acids 23 to 35 ofSEQ ID NO:86 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 36. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the pj314_(—)8 protein.

[3546] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pj314_(—)8 should be approximately 1200 bp.

[3547] The nucleotide sequence disclosed herein for pj314_(—)8 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. pj314_(—)8 demonstratedat least some simnilarity with sequences identified as H98510(yv90g02.r1 Homo sapiens cDNA clone), U03019 (Human melanoma growthstimulatory activity beta (MGSA beta) gene, partial cds), U25660(Dictyostelium discoideum actin gene, partial cds), W67504 (zd40f09.s1Soares fetal heart NbHH19W Homo sapiens cDNA clone 343145 3′), Z99358(Homo sapiens mRNA; expressed sequence tag; clone DKFZphamy1_(—a)3, 5′read), and Z99359 (Homo sapiens mRNA; expressed sequence tag; cloneDKFZphamy1_a3, 3′ read). The predicted amino acid sequence disclosedherein for pj314_(—)8 was searched against the GenPept and GeneSeq aminoacid sequence databases using the BLASTX search protocol. The predictedpj314_(—)8 protein demonstrated at least some similarity to sequencesidentified as U16359 (nitric oxide synthase [Rattus norvegicus]). Basedupon sequence similarity, pj314_(—)8 proteins and each similar proteinor peptide may share at least some activity. The nucleotide sequence ofpj314_(—)8 indicates that it may contain one or more of the followingtypes of repetitive elements: AC repeats, PAB repeats, CA repeats.

[3548] Clone “bp870_(—)1”

[3549] A polynucleotide of the present invention has been identified asclone “bp870_(—)1”. bp870_(—)1 was isolated from a human fetal kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. bp870_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “bp870_(—)1 protein”).

[3550] The nucleotide sequence of bp870_(—)1 as presently determined isreported in SEQ ID NO:87, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bp870_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:88. Amino acids 9 to 21 ofSEQ ID NO:88 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 22. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the bp870_(—)1 protein.

[3551] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bp870_(—)1 should be approximately 1000 bp.

[3552] The nucleotide sequence disclosed herein for bp870_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. bp870_(—)1 demonstratedat least some similarity with sequences identified as AA229935(nc51g10.r1 NCI_CGAP_Pr3 Homo sapiens cDNA clone IMAGE:1011714 similarto contains Alu repetitive element;contains element MER4 repetitiveelement), Hi2643 (yj13a04.r1 Homo sapiens cDNA clone 1485905′), andH12594 (yj13a04.s1 Homo sapiens cDNA clone 148590 3′ similar to containsAlu repetitive element). Based upon sequence similarity, bp870_(—)1proteins and each similar protein or peptide may share at least someactivity. The nucleotide sequence of bp870_(—)1 indicates that it maycontain a simple repeat region and at least one copy of an Alurepetitive element. bp870_(—)1 protein was expressed in a COS cellexpression system, and an expressed protein band of approximately 23 kDawas detected in conditioned medium and membrane fractions using SDSpolyacrylamide gel electrophoresis.

[3553] Clone “bx141_(—)2”

[3554] A polynucleotide of the present invention has been identified asclone “bx141_(—)2”. bx141_(—)2 was isolated from a human adult ovary(PA-1 teratocarcinoma, pool of retinoic-acid-treated, activin-treated,and untreated tissue) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.bx141_(—)2 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “bx141_(—)2 protein”).

[3555] The nucleotide sequence of bx141_(—)2 as presently determined isreported in SEQ ID NO:89, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bxi41_(—)2 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:90. Amino acids 30 to 42 ofSEQ ID NO:90 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 43. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the bx1412 protein.

[3556] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bx141_(—)2 should be approximately 1800 bp. Thenucleotide sequence disclosed herein for bx141_(—)2 was searched againstthe GenBank and GeneSeq nucleotide sequence databases usingBLASTN/BLASTX and FASTA search protocols. bx141_(—)2 demonstrated atleast some similarity with sequences identified as AA173353 (zp32b01.r1Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 611113 5′similar to SW:A15_(—HUMAN) P41732 CELL SURFACE GLYCOPROTEIN A15),AA375927 (EST88303 HSC172 cells IIHomo sapiens cDNA 5′ end similar tosimilar to cell surface glycoprotein), D10653 (Human mRNA for cellsurface glycoprotein, complete cds), H64050 (yr58c07.r1 Homo sapienscDNA clone 209484 5′ similar to SP:S39262 S39262 PLATELET CELL SURFACEGLYCOPROTEIN), and R41866 (yg12f04.s1 Homo sapiens cDNA clone 31854 3′).The predicted amino acid sequence disclosed herein for bx141_(—)2 wassearched against the GenPept and GeneSeq amino acid sequence databasesusing the BLASTX search protocol. The predicted bx141_(—)2 proteindemonstrated at least some similarity to sequences identified as D10653(HUMA15_(—)1 cell surface glycoprotein [Homo sapiens]) and D29808(HUMTALLA1_(—)1 TALLA_(—)1 [Homo sapiens]). The human cell surfaceglycoprotein (“D10653 protein”) is a protein of 244 amino acids whichcontains four potential transmembrane domains and four possible N-linkedglycosylation sites. A computer-aided comparison showed a markedsimilarity between D10653 protein and several other membrane proteins:CD9, CD37, CD53, TAPA-1, Sm23, CO-029, and ME491/CD63; also, D10653protein is similar to the ME491/CD63 protein superfamily. bx141_(—)2protein also shows some similarity to the human and mouse ME491 and CD63proteins. Based upon sequence similarity, bx141_(—)2 proteins and eachsimilar protein or peptide may share at least some activity. TheTopPredII computer program predicts four potential transmembrane domainswithin the bx141_(—)2 protein sequence centered around amino acids 31,70, 104, and 222 of SEQ ID NO:90, respectively. bx141_(—)2 protein wasexpressed in a COS cell expression system, and an expressed protein bandof approximately 24 kDa was detected in membrane fractions using SDSpolyacrylamide gel electrophoresis.

[3557] Clone “cw272_(—)7”

[3558] A polynucleotide of the present invention has been identified asclone “cw272_(—)7”. cw272_(—)7 was isolated from a human fetal braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. cw272_(—)7is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “cw272 7 protein”).

[3559] The nucleotide sequence of cw272_(—)7 as presently determined isreported in SEQ ID NO:91, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the cw272_(—)7 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:92. Amino acids 48 to 60 ofSEQ ID NO:92 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 61. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the cw272 7 protein.

[3560] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone cw272_(—)7 should be approximately 2300 bp.

[3561] The nucleotide sequence disclosed herein for cw272_(—)7 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. While no clear hits werefound in these databases, cw272_(—)7 protein does show some similarityto bone morphogenetic proteins and procollagens.

[3562] Clone “nh328_(—)5”

[3563] A polynucleotide of the present invention has been identified asclone “nh328_(—)5”. nh328_(—)5 was isolated from a human adult brain(thalamus) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nh328_(—)5 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nh328_(—)5 protein”).

[3564] The nucleotide sequence of nh328_(—)5 as presently deternined isreported in SEQ ID NO:93, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nh328_(—)5 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:94. Amino acids 60 to 72 ofSEQ ID NO:94 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 73. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the nh328 5 protein.

[3565] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nh328_(—)5 should be approximately 2200 bp.

[3566] The nucleotide sequence disclosed herein for nh328_(—)5 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nh328_(—)5 demonstratedat least some similarity with sequences identified as AA426157(zv83aO9.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 7602165′), D17160 (Human HepG2 3′ region MboI cDNA, clone hmd2d01m3), D56329(Human fetal brain cDNA 5′-end GEN-424F08), N62903 (yy67e09.s1 Homosapiens cDNA clone 278632 3′), R88485 (ym94e01.r1 Homo sapiens cDNAclone 166584 5′), and T26592 (AB329E6R Homo sapiens cDNA clone LLAB329E65′). Based upon sequence similarity, nh328 5 proteins and each similarprotein or peptide may share at least some activity. The nucleotidesequence of nh328_(—)5 indicates that it may contain some GAA/TIGGERrepeat sequences. nh328_(—)5 protein was expressed in a COS cellexpression system, and an expressed protein band of approximately 70 kDawas detected in membrane fractions using SDS polyacrylamide gelelectrophoresis.

[3567] Clone “nm214_(—)3”

[3568] A polynucleotide of the present invention has been identified asclone “n214_(—)3”. nm214_(—)3 was isolated from a human adult blood(erythroleukemia TF-1) cDNA library using methods which are selectivefor cDNAs encoding secreted proteins (see U.S. Pat.

[3569] No.5,536,637), or was identified as encoding a secreted ortransmembrane protein on the basis of computer analysis of the aminoacid sequence of the encoded protein. nrn214_(—)3 is a full-lengthclone, including the entire coding sequence of a secreted protein (alsoreferred to herein as “nrn214_(—)3 protein”).

[3570] The nucleotide sequence of nmn214_(—)3 as presently determined isreported in SEQ ID NO:95, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the n-nL214_(—)3 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:96.

[3571] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nm214_(—)3 should be approximately 1300 bp.

[3572] The nucleotide sequence disclosed herein for nm214_(—)3 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nm214_(—)3 demonstratedat least some similarity with sequences identified as D10083 (Human RGH1gene), D11078 (Human RGH2 gene), R68638 (yi06g11.s1 Homo sapiens cDNAclone 138500 3′), U88895 (Human endogenous retrovirus H Dl leaderregion/integrase-derived ORFI, ORF2, and putative envelope protein mRNA,complete cds), Z95327 (Human DNA sequence *** SEQUENCING IN PROGRESSfrom clone 347M6; HTGS phase 1), and Z97183 (Human DNA sequence ***SEQUENCING IN PROGRESS from clone ICB2046; HTGS phase 1). The predictedamino acid sequence disclosed herein for nm214_(—)3 was searched againstthe GenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted nm214_(—)3 protein demonstrated at leastsome similarity to sequences identified as U88895 (HERV-Hintegrase/envelope region [Homo sapiens]). Based upon sequencesimilarity, nm214_(—)3 proteins and each similar protein or peptide mayshare at least some activity. The nm214_(—)3 protein has a putativesignal sequence at amino acids 13 to 25 of SEQ ID NO:96, with the matureprotein starting at amino acid 26. The TopPredHI computer programpredicts a potential transmembrane domain within the nm214_(—)3 proteinsequence cewntered around amino acid 90 of SEQ ID NO:96. nrm214_(—)3protein was expressed in a COS cell expression system, and an expressedprotein band of approximately 13 kDa was detected in conditioned mediumand membrane fractions using SDS polyacrylamide gel electrophoresis.

[3573] Clone “nn320_(—)2”

[3574] A polynucleotide of the present invention has been identified asclone “nn320_(—)2”. nn320_(—)2 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nn320_(—)2 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nn320_(—)2 protein”).

[3575] The nucleotide sequence of nn320_(—)2 as presently determined isreported in SEQ ID NO:97, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nn320_(—)2 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:98. Amino acids 4 to 16 ofSEQ ID NO:98 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 17. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the nn320 2 protein.

[3576] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nn320_(—)2 should be approximately 2500 bp.

[3577] The nucleotide sequence disclosed herein for nn320_(—)2 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nn320_(—)2 demonstratedat least some similarity with sequences identified as AA423969(zv79h04.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 7598955′) and AA423988 (zv79h04.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 759895 3′). The predicted amino acid sequence disclosedherein for nn320_(—)2 was searched against the GenPept and GeneSeq aminoacid sequence databases using the BLASTX search protocol. The predictednn320_(—)2 protein demonstrated at least some similarity to sequencesidentified as M60351 (filamentous hemagglutinin [Bordetella pertussis])and R05041 (Filamentous haemagglutinin A). The predicted nn320_(—)2protein also demonstrated similarity to a variety of proteases andenzyme precursors such as trypsinogen precursor. Based upon sequencesimilarity, nn320_(—)2 proteins and each similar protein or peptide mayshare at least some activity.

[3578] nn320_(—)2 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 58 kDa was detected inconditioned medium and membrane fractions using SDS polyacrylamide gelelectrophoresis.

[3579] Clone “pp392_(—)3”

[3580] A polynucleotide of the present invention has been identified asclone “pp392_(—)3”. pp392_(—)3 was isolated from a human adult blood(lymphoblastic leukemia MOLT-4) cDNA library using methods which areselective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. pp392_(—)3 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“pp392_(—)3 protein”).

[3581] The nucleotide sequence of pp392_(—)3 as presently determined isreported in SEQ ID NO:99, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pp392_(—)3 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:100.

[3582] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pp392 3 should be approximately 2100 bp. The nucleotidesequence disclosed herein for pp392_(—)3 was searched against theGenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTXand FASTA search protocols. pp392_(—)3 demonstrated at least somesimilarity with sequences identified as AA117686 (mo64c07.r1 Stratagenemouse heart (#937316) Mus musculus cDNA clone 558348 5′) and AL008726(Human DNA sequence *** SEQUENCING IN PROGRESS from clone 337018; HTGSphase 1). Based upon sequence similarity, pp392_(—)3 proteins and eachsimilar protein or peptide may share at least some activity. Thepp392_(—)3 protein has a putative signal sequence at amino acids 196 to208 of SEQ ID NO:100, with the mature protein starting at amino acid209. The TopPredII computer program predicts three potentialtransmembrane domains within the pp392_(—)3 protein sequence centeredaround amino acids 20, 130, and 310 of SEQ ID NO: 100, respectively. Thenucleotide sequence of pp392_(—)3 indicates that it may contain a CArepetitive element.

[3583] pp392_(—)3 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 56 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3584] Clone “ya13_(—)1”

[3585] A polynucleotide of the present invention has been identified asclone “ya13_(—)1”. ya13_(—)1 was isolated from a human adult testes cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. ya13_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“ya13_(—)1 protein”).

[3586] The nucleotide sequence of ya13_(—)1 as presently determined isreported in SEQ ID NO:101, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the yal3_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:102. Amino acids 72 to 84of SEQ ID NO:102 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 85. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of theya13_(—)1 protein.

[3587] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone ya13_(—)1 should be approximately 750 bp.

[3588] The nucleotide sequence disclosed herein for ya13_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. ya13_(—)1 demonstratedat least some similarity with sequences identified as AA190721(zp88a07.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone627252 5′). Based upon sequence similarity, ya13_(—)1 proteins and eachsimilar protein or peptide may share at least some activity.

[3589] Clone “yb37_(—)1”

[3590] A polynucleotide of the present invention has been identified asclone “yb37_(—)1”. yb37_(—)1 was isolated from a human fetal brain cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. yb37_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“yb37_(—)1 protein”).

[3591] The nucleotide sequence of yb37_(—)1 as presently determined isreported in SEQ ID NO:103, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the yb37_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:104. Amino acids 28 to 40of SEQ ID NO:104 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 41. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of theyb37_(—)1 protein. The TopPredll computer program predicts an additionalpotential transmembrane domain within the yb37_(—)1 protein sequencecentered around amino acid 144 of SEQ ID NO:104.

[3592] Another possible reading frame and predicted amino acid sequenceencoded by yb37_(—)1 is reported in SEQ ID NO:275; amino acids 49 to 61of SEQ ID NO:275 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 62. Due tothe hydrophobic nature of this predicted leader/signal sequence, it islikely to act as a transmembrane domain should it not be separated fromthe remainder of the protein of SEQ ID NO:275.

[3593] The nucleotide sequence disclosed herein for yb37_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. No hits were found inthe database. The nucleotide sequence of yb37_(—)1 indicates that it maycontain one or more A/TAAA repetitive elements.

[3594] yb37_(—)1 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 33 kDa was detected inconditioned medium fractions using SDS polyacrylamide gelelectrophoresis.

[3595] Clone “yb39_(—)1”

[3596] A polynucleotide of the present invention has been identified asclone “yb39_(—)1”. yb39_(—)1 was isolated from a human fetal brain cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. yb39_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“yb39_(—)1 protein”).

[3597] The nucleotide sequence of yb39_(—)1 as presently determined isreported in SEQ ID NO:105, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the yb39_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:106. Amino acids 21 to 33of SEQ ID NO:106 are a predicted leader/signal sequence, with thepredicted mature amnino acid sequence beginning at amino acid 34. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of theyb39_(—)1 protein.

[3598] The EcoRI/Notl restriction fragment obtainable from the depositcontaining clone yb39_(—)1 should be approximately 825 bp.

[3599] The nucleotide sequence disclosed herein for yb39_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. No hits were found inthe database.

[3600] Clone “bd577_(—)1”

[3601] A polynucleotide of the present invention has been identified asclone “bd577_(—)1”. bd577_(—)1 was isolated from a human fetal kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. bd577_(—)1is a full-length ;clone, including the entire coding sequence of asecreted protein (also referred to herein 3as “bd577_(—)1 protein”).

[3602] The nucleotide sequence of bd577_(—)1 as presently determined isreported in SEQ ID NO:107, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bd577_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:108. Amnino acids 42 to 54of SEQ ID NO:108 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 55. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thebd577_(—)1 protein.

[3603] Another possible reading frame and predicted amino acid sequenceencoded by base pairs 23 to 412 of bd577_(—)1 SEQ ID NO:107 is reportedin SEQ ID NO:276; the amino acid sequence of SEQ ID NO:276 has apossible signal sequence from amino acids 57 to 69, with the predictedmature amino acid sequence beginning at amino acid 70. The open readingframes corresponding to SEQ ID NO:276 and SEQ ID NO:108 could be joinedif a frameshift were introduced into the nucleotide sequence of SEQ IDNO:107.

[3604] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bd577_(—)1 should be approximately 1800 bp.

[3605] The nucleotide sequence disclosed herein for bd577_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. bd577_(—)1 demonstratedat least some similarity with sequences identified as AA306618(EST177563 Jurkat T-cells VI Homo sapiens cDNA 5′ end) and R20055(yg39b06.r1 Homo sapiens cDNA clone 34805 5′). Based upon sequencesimilarity, bd577_(—)1 proteins and each similar protein or peptide mayshare at least some activity. The TopPredII computer program predictstwo potential transmembrane domains within the bd577_(—)1 proteinsequence centered around amino acids 42 and 230 of SEQ ID NO:108.

[3606] bd577_(—)1 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 56 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis. Clone“by280_(—)3”

[3607] A polynucleotide of the present invention has been identified asclone “bv280_(—)3”. bv280_(—)3 was isolated from a human adult braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. bv280_(—)3is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “bv280_(—)3 protein”).

[3608] The nucleotide sequence of bv280_(—)3 as presently determined isreported in SEQ ID NO:109, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bv280_(—)3 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:110. Amino acids 10 to 22of SEQ ID NO:110 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 23. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thebv280_(—)3 protein.

[3609] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bv280_(—)3 should be approximately 1900 bp.

[3610] The nucleotide sequence disclosed herein for bv280_(—)3 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. bv28O_(—)3 demonstratedat least some similarity with sequences identified as AA095665(15468.seq.F Fetal heart, Lambda ZAP Express Homo sapiens cDNA 5′),AA577430 (nm96g10.s1 NCI_CGAP_Co9 Homo sapiens cDNA clone IMAGE:1076130similar to TR:G945383 G945383 CARBOXYPEPTIDASE), F06654 (H. sapienspartial cDNA sequence; clone c-1gal2), F08501 (H. sapiens partial cDNA),and H10119 (ym03f03.r1 Homo sapiens cDNA clone 46734 5′ similar toSP:A41612 A41612 VITELLOGENIC CARBOXYPEPTIDASE). The predicted aminoacid sequence disclosed herein for bv280_(—)3 was searched against theGenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted bv280_(—)3 protein demonstrated at leastsome similarity to sequences identified as L46594 (carboxypeptidase[Aedes aegypti]) and R96737 (A. niger Bo-1 carboxypeptidase Y). Basedupon sequence similarity, bv280_(—)3 proteins and each similar proteinor peptide may share at least some activity. The bv280_(—)3 protein alsohas a serine carboxipeptidase active site motif (residues 195_(—)212).This motif is highly specific to serine carboxypeptidases and is notfound in any other type of protein in the Swiss-Prot database. Thebv280_(—)3 protein also has one copy of the crystallins beta and gamma‘Greek key’ motif signature. The TopPredII computer program predictsanother potential transmembrane domain within the bv280_(—)3 proteinsequence centered around amino acid 110 of SEQ ID NO:110. bv280_(—)3protein was expressed in a COS cell expression system, and an expressedprotein band of approximately 61 kDa was detected in conditioned mediumfractions using SDS polyacrylamide gel electrophoresis.

[3611] Clone “co315_(—)3”

[3612] A polynucleotide of the present invention has been identified asclone “co315_(—)3”. co315_(—)3 was isolated from a human adult braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. co315_(—)3is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “co315_(—)3 protein”).

[3613] The nucleotide sequence of co315_(—)3 as presently determined isreported in SEQ ID NO:111, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the co315 3 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:112. Amino acids 51 to 63of SEQ ID NO:112 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 64. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of theco315_(—)3 protein.

[3614] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone co315_(—)3 should be approximately 710 bp.

[3615] The nucleotide sequence disclosed herein for co315_(—)3 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. co315_(—)3 demonstratedat least some similarity with sequences identified as AA031371(zk15e11.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 4706363′), AA026051 (ze86aO7.s1 Soares fetal heart NbHH19W Homo sapiens),AA393961 (zt78b10.r1 Soares testis NHT Homo sapiens cDNA clone 7284435′), AA481047 (aa29c06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIVIAGE:814666 3′), H46323 (yo15c05.r1 Homo sapiens cDNA clone 1779925′), N23329 (yx78h09.s1 Homo sapiens cDNA clone 267905 3′), and R43942(yg22f02.s1 Homo sapiens cDNA clone 33080 3′ similar to gb:M14648VITRONECTIN RECEPTOR ALPHA SUBUNIT PRECURSOR (HUMAN)). Based uponsequence similarity, co315_(—)3 proteins and each similar protein orpeptide may share at least some activity.

[3616] Clone “ij226_(—)6”

[3617] A polynucleotide of the present invention has been identified asclone “ij226_(—)6”. ij226_(—)6 was isolated from a human adult blood(peripheral blood mononuclear cells treated with granulocyte-colonystimulating factor in vivo) cDNA library using methods which areselective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. ij226_(—)6 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“ij226_(—)6 protein”).

[3618] The nucleotide sequence of ij226_(—)6 as presently determined isreported in SEQ ID NO:113, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the ij226_(—)6 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:114.

[3619] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone ij226_(—)6 should be approximately 2300 bp.

[3620] The nucleotide sequence disclosed herein for ij226_(—)6 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. ij226_(—)6 demonstratedat least some similarity with sequences identified as AE000658 (Homosapiens T-cell receptor alpha delta locus from bases 1 to 250529(section 1 of 5) of the Complete Nucleotide Sequence), AF004231 (Homosapiens monocyte/macrophage Ig-related receptor MIR-10 (MIR cl-10) MRNA,complete cds), G35352 (STS h14a108 5), H54023 (yq88h01.s1 Homo sapienscDNA), H54181 (yq88h01.r1 Homo sapiens cDNA clone 202897 5′), T18551(Human polycystic kidney disease normal PKD1 gene), and Z82206 (HumanDNA sequence SEQUENCING IN PROGRESS from clone 370M22; HTGS phase 1).The predicted amino acid sequence disclosed herein for ij226_(—)6 wassearched against the GenPept and GeneSeq amino acid sequence databasesusing the BLASTX search protocol. The predicted ij226_(—)6 proteindemonstrated at least some similarity to sequences identified as M22334(unknown protein [Homo sapiens]). Based upon sequence similarity,ij226_(—)6 proteins and each similar protein or peptide may share atleast some activity. The TopPredHI computer program predicts twopotential transmembrane domains within the ij226_(—)6 protein sequencecentered around amino acids 37 and 62 of SEQ ID NO:114. The nucleotidesequence of ij226_(—)6 indicates that it may contain one or more of thefollowing repetitive elements: Li, Alu, SVA.

[3621] Clone “nf443_(—)1”

[3622] A polynucleotide of the present invention has been identified asclone “nf443_(—)1”. nf443_(—)1 was isolated from a human adult brain(substantia nigra) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nf443_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nf443_(—)1 protein”).

[3623] The nucleotide sequence of nf443_(—)1 as presently determined isreported in SEQ ID NO:115, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nf443_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:116. Amino acids 21 to 43of SEQ ID NO:116 are a possible leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 44. Due tothe hydrophobic nature of this possible leader/signal sequence, it islikely to act as a transmembrane domain should the leader/signalsequence not be separated from the remainder of the nf443_(—)1 protein.

[3624] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nf443_(—)1 should be approximately 3800 bp.

[3625] The nucleotide sequence disclosed herein for nf443_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nf443_(—)1 demonstratedat least some similarity with sequences identified as AA417092(zuO7al2.s1 Soares testis NHT Homo sapiens cDNA clone 731134 3′),AA421511 (zu07a12.r1 Soares testis NHT Homo sapiens cDNA clone 7311345′), T23707 (Human gene signature HUMGS05583), and U61233 (Bos taurustubulin-folding cofactor D mRNA, complete cds). The predicted amino acidsequence disclosed herein for nf443_(—)1 was searched against theGenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted nf443_(—)1 protein demonstrated at leastsome similarity to sequences identified as U61233 (cofactor D [Bostaurus]). Based upon sequence similarity, nf443_(—)1 proteins and eachsimilar protein or peptide may share at least some activity. Thenucleotide sequence of nf443_(—)1 indicates that it may contain an Alurepetitive element.

[3626] nf443_(—)1 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 10 kDa was detected inconditioned medium fractions using SDS polyacrylamide gelelectrophoresis.

[3627] Clone “nt429_(—)1”

[3628] A polynucleotide of the present invention has been identified asclone “nt429_(—)1”. nt429_(—)1 was isolated from a human adult brain(corpus callosum) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.nt429_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “nt429_(—)1 protein”).

[3629] The nucleotide sequence of nt429_(—)1 as presently determined isreported in SEQ ID NO:117, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nt429_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:118. Another possiblereading frame and predicted amino acid sequence, encoded by base pairs399 to 731 of nt429_(—)1 SEQ ID NO:117, is reported in SEQ ID NO:277;the amino acid sequence of SEQ ID NO:277 is hydrophobic in nature nearits carboxyl terminus. The overlapping open reading frames correspondingto SEQ ID NO:118 and SEQ ID NO:277 could be joined if a frameshift wereintroduced into the nucleotide sequence of SEQ ID NO:117.

[3630] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nt429_(—)1 should be approximnately 1800 bp.

[3631] The nucleotide sequence disclosed herein for nt429_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. No significant hits werefound in the database. The nucleotide sequence of nt429_(—)1 indicatesthat it may contain one or more of the following repetitive elements:Alu, SVA, A.

[3632] Clone “pe503_(—)1”

[3633] A polynucleotide of the present invention has been identified asclone “pe503_(—)1”. pe503_(—)1 was isolated from a human adult blood(chronic myelogenous leukemia K5) cDNA library using methods which areselective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. pe503_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“pe503_(—)1 protein”). The nucleotide sequence of pe503_(—)1 aspresently determined is reported in SEQ ID NO:119, and includes apoly(A) tail. What applicants presently believe to be the proper readingframe and the predicted amino acid sequence of the pe503_(—)1 proteincorresponding to the foregoing nucleotide sequence is reported in SEQ IDNO:120. Amino acids 79 to 91 of SEQ ID NO:120 are a predictedleader/signal sequence, with the predicted mature amino acid sequencebeginning at amino acid 92. Due to the hydrophobic nature of thepredicted leader/signal sequence, it is likely to act as a transmembranedomain should the predicted leader/signal sequence not be separated fromthe remainder of the pe503_(—)1 protein.

[3634] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pe503_(—)1 should be approximately 1300 bp.

[3635] The nucleotide sequence disclosed herein for pe503_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. pe503_(—)1 demonstratedat least some similarity with sequences identified as AA298572(EST114204 HSC172 cells I Homo sapiens cDNA 5′ end), AA595242(no33a12.s1 NCI_CGAP_Pr23 Homo sapiens cDNA clone IMAGE:1102462), H60941(yr14g06.r1 Homo sapiens cDNA clone 205306 5′), H75686 (yr77g08.r1 Homosapiens cDNA clone 2113585′), and R61206 (yhO6d11.r1 Homo sapiens cDNAclone 42649 5′). Based upon sequence similarity, pe503_(—)1 proteins andeach similar protein or peptide may share at least some activity. TheTopPredII computer program predicts four potential transmembrane domainswithin the pe503_(—)1 protein sequence centered around amino acids 50,84, 107, and 148 of SEQ ID NO:120, respectively.

[3636] pe503_(—)1 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 19 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3637] Clone “pe834_(—)6”

[3638] A polynucleotide of the present invention has been identified asclone “pe834_(—)6”. pe834_(—)6 was isolated from a human adult blood(chronic myelogenous leukemia K5) cDNA library using methods which areselective for cDNAs encoding secreted proteins (see U.S. Pat.No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. pe834_(—)6 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“pe834_(—)6 protein”).

[3639] The nucleotide sequence of pe834_(—)6 as presently determined isreported in SEQ ID NO:121, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pe834_(—)6 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:122.

[3640] Another possible reading frame and predicted amino acid sequence,encoded by base pairs 414 to 725 of pe834_(—)6 SEQ ID NO:121, isreported in SEQ ID NO:278; the amino acid sequence of SEQ ID NO:278 ishydrophobic in nature near its carboxyl terminus. The overlapping openreading frames corresponding to SEQ ID NO:122 and SEQ ID NO:278 could bejoined if a frameshift were introduced into the nucleotide sequence ofSEQ ID NO:121.

[3641] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pe834_(—)6 should be approximately 1300 bp. Thenucleotide sequence disclosed herein for pe834_(—)6 was searched againstthe GenBank and GeneSeq nucleotide sequence databases usingBLASTN/BLASTX and FASTA search protocols. pe834_(—)6 demonstrated atleast some similarity with sequences identified as AA054341 (z168f04.s1Stratagene colon (#937204) Homo sapiens cDNA clone 509791 3′), N21462(yx57c10.s1 Homo sapiens cDNA clone 265842 3′), N34010 (yx75g07.r1 Homosapiens cDNA clone 267612 5′), and T90232 (ye15c09.r1 Homo sapiens cDNAclone 1178085′). Based upon sequence similarity, pe834_(—)6 proteins andeach similar protein or peptide may share at least some activity.

[3642] pe834_(—)6 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 17 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3643] Clone “ya10_(—)1”

[3644] A polynucleotide of the present invention has been identified asclone “ya10_(—)1”. ya10_(—)1 was isolated from a human adult testes cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. Ya10_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“ya10_(—)1 protein”).

[3645] The nucleotide sequence of ya10_(—)1 as presently determined isreported in SEQ ID NO:123, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predictedamnino acid sequence of the ya10_(—)1 protein corresponding to theforegoing nucleotide sequence is reported in SEQ ID NO:124.

[3646] Amino acids 6 to 18 of SEQ ID NO:124 are a predictedleader/signal sequence, with the predicted mature amino acid sequencebeginning at amino acid 19. Due to the hydrophobic nature of thepredicted leader/signal sequence, it is likely to act as a transmembranedomain should the predicted leader/signal sequence not be separated fromthe remainder of the ya10_(—)1 protein.

[3647] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone ya10_(—)1 should be approximately 800 bp.

[3648] The nucleotide sequence disclosed herein for ya10_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. No clearly significanthits were found in these databases. BLASTX analysis of the ya10_(—)1protein sequence revealed some amino acid sequence similarity tocystatins (cysteine protease inhibitors) of various species. Based uponthis sequence similarity, ya10_(—)1 proteins and each similar protein orpeptide may share at least some activity.

[3649] Clone “yb40_(—)1”

[3650] A polynucleotide of the present invention has been identified asclone “yb40_(—)1”. yb40_(—)1 was isolated from a human fetal brain cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. yb40_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“yb40_(—)1 protein”). The nucleotide sequence of yb40_(—)1 as presentlydetermined is reported in SEQ ID NO: 125, and includes a poly(A) tail.What applicants presently believe to be the proper reading frame and thepredicted amino acid sequence of the yb40_(—)1 protein corresponding tothe foregoing nucleotide sequence is reported in SEQ ID NO:126. Aminoacids 29 to 41 of SEQ ID NO:126 are a possible leader/signal sequence,with the predicted mature amino acid sequence beginning at amino acid42. Due to the hydrophobic nature of this possible leader/signalsequence, it could act as a transmembrane domain should it not beseparated from the remainder of the yb40_(—)1 protein.

[3651] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone yb40_(—)1 should be approximately 1700 bp.

[3652] The nucleotide sequence disclosed herein for yb40_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. yb40_(—)1 demonstratedat least some similarity with sequences identified as AA595189(no32f03.s1 NCI_CGAP_Pr23 Homo sapiens cDNA clone IMAGE:1102397), R74575(yi58d04.r1 Homo sapiens cDNA clone 143431 5′), and T25773 (Human genesignature HUMGS08001). Based upon sequence similarity, yb40_(—)1proteins and each similar protein or peptide may share at least someactivity.

[3653] Clone “cs756_(—)2”

[3654] A polynucleotide of the present invention has been identified asclone “cs756_(—)2”. cs756_(—)2 was isolated from a human fetal braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. cs756_(—)2is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “cs756 2 protein”).

[3655] The nucleotide sequence of cs756_(—)2 as presently determined isreported in SEQ ID NO:127, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the cs756 2 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:128. Amino acids 211 to 223of SEQ ID NO:128 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 224. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thecs756_(—)2 protein. The TopPredII computer program predicts a potentialtransmembrane domain within the cs756_(—)2 protein sequence of SEQ IDNO:128, centered around amino acid 15 of SEQ ID NO: 128; amino acids 2to 14 of SEQ ID NO:128 are also a possible leader/signal sequence, withthe predicted mature amino acid sequence in that case beginning at aminoacid 15.

[3656] Another possible cs756_(—)2 reading frame and predicted aminoacid sequence, encoded by base pairs 385 to 825 of SEQ ID NO:127, isreported in SEQ ID NO:279; the TopPredII computer program predicts apotential transmembrane domain centered around amino acid 100 of SEQ IDNO:279. The open reading frames corresponding to SEQ ID NO:279 and SEQID NO:128 could be joined if a frameshift were introduced into thenucleotide sequence of SEQ ID NO:127.

[3657] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone cs756_(—)2 should be approximately 3000 bp.

[3658] The nucleotide sequence disclosed herein for cs756_(—)2 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. cs756_(—)2 demonstratedat least some similarity with sequences identified as AA398077(zt58c03.s1 Soares testis NHT Homo sapiens cDNA clone 726532 3′),AA541286 (nf97e03.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE:927868),W28620 (49c2 Human retina cDNA randomly primed sublibrary Homo sapienscDNA), and W47601 (zc35g08.r1 Soares senescent fibroblasts NbHSF Homosapiens cDNA clone 324350 5′). The predicted amino acid sequencedisclosed herein for SEQ ID NO:279 was searched against the GenPept andGeneSeq amino acid sequence databases using the BLASTX search protocol.The predicted SEQ ID NO:279 protein demonstrated at least somesimilarity to sequences identified as L76938 (Werner syndrome gene,complete cds [Homo sapiens]). “Wemer's syndrome (WS) is an inheriteddisease with clinical symptoms resembling premature aging . . . [the]predicted protein is 1432 amino acids in length and shows significantsimilarity to DNA helicases” (Yu et al., 1996, Science272(5259):258_(—)262, which is incorporated by reference herein). Basedupon sequence similarity, cs756_(—)2 proteins and each similar proteinor peptide may share at least some activity. The nucleotide sequence ofcs756_(—)2 indicates that it may contain one or more of the followingrepetitive elements: MIR, MER.

[3659] Clone “ew150_(—)1”

[3660] A polynucleotide of the present invention has been identified asclone “ew15O_(—)1”. ew150_(—)1 was isolated from a human adult placentacDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. ew150_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “ew150_(—)1 protein”).

[3661] The nucleotide sequence of ew150_(—)1 as presently determined isreported in SEQ ID NO:129, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the ew150_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:130. Amino acids 26 to 38of SEQ ID NO:130 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 39. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of theew150_(—)1 protein.

[3662] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone ew150_(—)1 should be approximately 2000 bp.

[3663] The nucleotide sequence disclosed herein for ew150_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. ew150_(—)1 demonstratedat least some similarity with sequences identified as AA563938(nk23b12.s1 NCI_CGAP_Coll Homo sapiens cDNA clone IMAGE 1014335), D63209(Human placenta cDNA 5′-end GEN-506F01), M90423 (Bacteriphage US3lytic-enzyme), W23461 (zb33c01.r1 Soares parathyroid tumor NbHPA Homosapiens cDNA clone 305376 5′), and Z56916 (H.sapiens CpG DNA, clone153b7, forward read cpg153b7.ft1a). In the region around position 1514of SEQ ID NO:129, ew150_(—)1 also demonstrated at least some similaritywith sequences encoding a mitochondrial energy-transfer proteinssignature motif which is found in mitochondrial and other membraneproteins. Based upon sequence similarity, ewl501 proteins and eachsimilar protein or peptide may share at least some activity. TheTopPrediH computer program predicts ten potential transmembrane domainswithin the ew150_(—)1 protein sequence, which are centered around aminoacids 70,106,133,200,314,349,387, 457,504, and 527 of SEQ ID NO:130,respectively.

[3664] Clone “gg894_(—)13”

[3665] A polynucleotide of the present invention has been identified asclone “gg894_(—)13”. gg894_(—)13 was isolated from a human fetal kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. gg894_(—)13is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “gg894 13 protein”).

[3666] The nucleotide sequence of gg894_(—)13 as presently determined isreported in SEQ ID NO:131, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the gg894_(—)13 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:132. Amino acids 41 to 53of SEQ ID NO:132 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 54. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thegg894_(—)13 protein. Another possible gg894_(—)13 reading frame andpredicted amino acid sequence, encoded by base pairs 602 to 1129 of SEQID NO:131, is reported in SEQ ID NO:280. The open reading framescorresponding to SEQ ID NO:280 and SEQ ID NO:132 could be joined if aframeshift were introduced into the nucleotide sequence of SEQ IDNO:131.

[3667] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone gg894_(—)13 should be approximately 2400 bp.

[3668] The nucleotide sequence disclosed herein for gg894_(—)13 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. gg894_(—)13 demonstratedat least some similarity with sequences identified as H57424 (yr13a10.s1Homo sapiens cDNA clone 205146 3′), T23885 (Human gene signatureHUMGS05820), and W80358 (zh49aO7.s1 Soares fetal liver spleen 1NFLS S1Homo sapiens cDNA clone 415380 3′). Based upon sequence similarity,gg894_(—)13 proteins and each similar protein or peptide may share atleast some activity. The TopPredII computer program predicts a potentialtransmembrane domain within the gg894_(—)13 protein sequence centeredaround amino acid 115 of SEQ ID NO:132. The nucleotide sequence ofgg894_(—)13 indicates that it may contain a RBMI repetitive element.

[3669] Clone “it217_(—)2”

[3670] A polynucleotide of the present invention has been identified asclone “it217_(—)2”. it217_(—)2 was isolated from a human adult brain(thalamus) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.it217_(—)2 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “it217_(—)2 protein”).

[3671] The nucleotide sequence of it217_(—)2 as presently determined isreported in SEQ ID NO:133, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the it217_(—)2 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:134. Another possibleit217_(—)2 reading frame and predicted amino acid sequence, encoded bybase pairs 45 to 311 of SEQ ID NO:133, is reported in SEQ ID NO:281.Amino acids 36 to 48 of SEQ ID NO:281 are a predicted leader/signalsequence, with the predicted mature amino acid sequence beginning atamino acid 49. Due to the hydrophobic nature of the predictedleader/signal sequence, it is likely to act as a transmembrane domainshould the predicted leader/signal sequence not be separated from theremainder of the it217_(—)2 protein. The open reading framescorresponding to SEQ ID NO:281 and SEQ ID NO:134 could be joined if atleast one frameshift were introduced into the nucleotide sequence of SEQID NO:133.

[3672] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone it217_(—)2 should be approximately 2250 bp.

[3673] The nucleotide sequence disclosed herein for it217_(—)2 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. it217_(—)2 demonstratedat least some similarity with sequences identified as AA242969(zr65h09.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 668321 5′ similarto SW SCC2_HUMAN P48594 SQUAMOUS CELL CARCINOMA ANTIGEN 2 ;contains Alurepetitive element), B44876 (HS-1060-A1-G06-MR.abi CIT Human GenomicSperm Library C Homo sapien genomic clone Plate CT 782 Col 11 Row M),H82168 (yv78d08.r1 Homo sapiens cDNA clone), S66896 (squamous cellcarcinoma antigen), U19556 (Human squamous cell carcinoma antigen 1(SCCA1) mRNA, complete cds), U19557 (Human squamous cell carcinomaantigen 2 (SCCA2) mRNA, complete cds), and U35459 (Human bomapin mRNA,complete cds). The predicted amino acid sequence disclosed herein forit217_(—)2 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictedit217_(—)2 protein demonstrated at least some similarity to sequencesidentified as L40377 (cytoplasmic antiproteinase 2 [Homo sapiens]),M34352 (ovalbumin [Gallus gallus]), M91161 (serpin [Equus caballus]),R25276 (SCC antigen), R48379 (Human megakaryocyte differentiationfactor), S66896 (squamous cell carcinoma antigen, SCC antigen serineprotease inhibitor [human, Peptide, 390 aa] [Homo sapiensl), Ul19568(squamous cell carcinoma antigen [Homo sapiens]), and U19576 (squamouscell carcinoma antigen [Homo sapiens]). Human bomapin may play a role inthe regulation of protease activities during hematopoiesis (Riewald etal., 1995, J. Biol. Chem. 270: 26754, which is incorporated by referenceherein). Serpins are SERine Proteinase JNltbitors and are consideredextracellular in localization. Human squamous cell carcinoma antigen(SSCA) is a member of the serpin family of proteinase inhibitors,purified from sera of cancer patients. Based upon sequence similarity,it217_(—)2 proteins and each similar protein or peptide may share atleast some activity.

[3674] Clone “ml235_(—)2”

[3675] A polynucleotide of the present invention has been identified asclone “ml235_(—)2”. ml235_(—)2 was isolated from a human adult brain(caudate nucleus) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 35,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.ml235_(—)2 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “ml235 2 protein”).

[3676] The nucleotide sequence of mnl235_(—)2 as presently determined isreported in SEQ ID NO:135, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the mnl235 2 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:136. Amino acids 3 to 15 ofSEQ ID NO:136 are a predicted leader/signal sequence, with the predictedmature amino acid sequence beginning at amino acid 16. Due to thehydrophobic nature of the predicted leader/signal sequence, it is likelyto act as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the ml235_(—)2 protein.

[3677] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone mnl235_(—)2 should be approximately 1400 bp.

[3678] The nucleotide sequence disclosed herein for mi235_(—)2 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. ml235_(—)2 demonstratedat least some similarity with sequences identified as AA160887(zo79b05.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 5930733′), R14349 (yf79f12.r1 Homo sapiens cDNA clone 28451 5′), and R54256(yg74f07.r1 Homo sapiens cDNA clone 39059 5′). Based upon sequencesimilarity, ml235_(—)2 proteins and each similar protein or peptide mayshare at least some activity. The TopPredII computer program predicts apotential transmembrane domain within the ml235_(—)2 protein sequencecentered around amino acid 25 of SEQ ID NO:136.

[3679] Clone “mt24_(—)2”

[3680] A polynucleotide of the present invention has been identified asclone “mt24_(—)2”. mt24_(—)2 was isolated from a human adult testes cDNAlibrary using methods which are selective for cDNAs encoding secretedproteins (see U.S. Pat. No. 5,536,637), or was identified as encoding asecreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. mt24_(—)2 is afull-length clone, including the entire coding sequence of a secretedprotein (also referred to herein as =“mt24_(—)2 protein”).

[3681] The nucleotide sequence of mt24 2 as presently determined isreported in SEQ ID NO:137, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the mt24_(—)2 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:138. Amino acids 30 to 42of SEQ ID NO:138 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 43. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of the mt24 2protein.

[3682] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone mt24_(—)2 should be approximately 1400 bp. Thenucleotide sequence disclosed herein for mt24_(—)2 was searched againstthe GenBank and GeneSeq nucleotide sequence databases usingBLASTN/BLASTX and FASTA search protocols. mt24_(—)2 demonstrated atleast some similarity with sequences identified as AA062589 (zf68f04.r1Soares pineal gland N3HPG Homo sapiens cDNA clone 382111 5′) and T19332(b08016t Testis 1 Homo sapiens cDNA clone bO8016 5′ end). Based uponsequence similarity, mt24_(—)2 proteins and each similar protein orpeptide may share at least some activity. The TopPredII computer programpredicts four potential transmembrane domains within the mt24_(—)2protein sequence centered around amino acids 38, 153, 167, and 232 ofSEQ ID NO:138, respectively.

[3683] Clone “pe584_(—)2”

[3684] A polynucleotide of the present invention has been identified asclone “pe584_(—)2”. pe584 2 was isolated from a human adult blood(chronic myelogenous leukemia K5) cDNA library using methods which areselective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. pe584_(—)2 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“pe584_(—)2 protein”).

[3685] The nucleotide sequence of pe584_(—)2 as presently determined isreported in SEQ ID NO:139, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pe584_(—)2 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:140. Amino acids 27 to 39of SEQ ID NO:140 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 40. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thepe584_(—)2 protein.

[3686] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pe584_(—)2 should be approximately 3000 bp. Thenucleotide sequence disclosed herein for pe584_(—)2 was searched againstthe GenBank and GeneSeq nucleotide sequence databases usingBLASTN/BLASTX and FASTA search protocols. pe584_(—)2 demonstrated atleast some similarity with sequences identified as AA303149 (EST13039Uterus tumor I), AA405004 (zt06e03.s1 NCI_CGAP_GCB1 Homo sapiens cDNAclone IMAGE 712348 3′), AA481230 (aa34g01.r1 NCI_CGAP_GCB1 Homo sapienscDNA clone 815184 5′ similar to SW TCR2_ECOLI P02981 TETRACYCLINERESISTANCE PROTEIN), D88315 (Mouse mRNA for tetracyclinetransporter-like protein, complete cds), and T10077 (seql295 Homosapiens cDNA clone b4HB3MA-COT8-HAP-Ft109 5′). The predicted amino acidsequence disclosed herein for pe584_(—)2 was searched against theGenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted pe584_(—)2 protein demonstrated at leastsome similarity to sequences identified as D88315 (tetracyclinetransporter-like protein [Mus musculus]). Mouse tetracyclinetransporter-like protein is a sugar transporter (Matsuo et aZ., 1997,Biochem. Biophys. Res. Comm. 238: 126_(—)192, which is incorporated byreference herein). Based upon sequence similarity, pe584_(—)2 proteinsand each similar protein or peptide may share at least some activity.The TopPredII computer program predicts eleven potential transmembranedomains within the pe584_(—)2 protein sequence, which are centeredaround amino acids 32, 55, 78, 114, 142, 196, 235, 264,287, 332, and 375of SEQ ID NO:140, respectively.

[3687] Clone “pj323_(—)2”

[3688] A polynucleotide of the present invention has been identified asclone “pj323_(—)2”. pj323_(—)2 was isolated from a human fetal carcinoma(NTD2 cells treated with retinoic acid for 23 days) cDNA library usingmethods which are selective for cDNAs encoding secreted proteins (seeU.S. Pat. No. 5,536,637), or was identified as encoding a secreted ortransmembrane protein on the basis of computer analysis of the aminoacid sequence of the encoded protein. pj323_(—)2 is a full-length clone,including the entire coding sequence of a secreted protein (alsoreferred to herein as “pj323 2 protein”). The nucleotide sequence ofpj323 2 as presently determined is reported in SEQ ID NO:141, andincludes a poly(A) tail. What applicants presently believe to be theproper reading frame and the predicted amino acid sequence of the pj3232 protein corresponding to the foregoing nucleotide sequence is reportedin SEQ ID NO:142. Amino acids 150 to 162 of SEQ ID NO:142 are apredicted leader/signal sequence, with the predicted mature amino acidsequence beginning at amino acid 163. Due to the hydrophobic nature ofthe predicted leader/signal sequence, it is likely to act as atransmembrane domain should the predicted leader/signal sequence not beseparated from the remainder of the pj323_(—)2 protein.

[3689] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pj323_(—)2 should be approximately 2500 bp.

[3690] The nucleotide sequence disclosed herein for pj323_(—)2 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. pj323_(—)2 demonstratedat least some similarity with sequences identified as AA160454(zo74g05.r1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 5926645′), AA398257 (zt60a08.s1 Soares testis NHT Homo sapiens cDNA clone726710 3′), and T47284 (yb64g11.s1 Homo sapiens cDNA clone 76004 3′).The predicted amino acid sequence disclosed herein for pj323_(—)2 wassearched against the Gen~ept and GeneSeq amino acid sequence databasesusing the BLASTX search protocol. The predicted pj323_(—)2 proteindemonstrated at least some similarity to human integral nuclear envelopeprotein, lamnin B receptors from several species, and sterol reductasesfrom several species. Lamin B receptors have hydrophobic carboxyterminal portions and hydrophilic amino terminal portions. Antibodies tolamin B receptors have been found in patients with primary biliarycirrhosis. Sterol reductases demonstrate sequence similarity to thehydrophobic portions of lamin B receptors. Based upon sequencesimilarity, pj323_(—)2 proteins and each similar protein or peptide mayshare at least some activity. The TopPredIU computer program predictssix potential transmembrane domains within the pj323_(—)2 proteinsequence, which are centered around amino acids 47, 106, 164, 187, 341,and 432 of SEQ ID NO:142, respectively.

[3691] pj323_(—)2 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 46 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3692] Clone “yb24_(—)1”

[3693] A polynucleotide of the present invention has been identified asclone “yb24_(—)1”. yb24_(—)1 was isolated from a human fetal brain cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. yb24_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“yb24_(—)1 protein”).

[3694] The nucleotide sequence of yb24_(—)1 as presently determined isreported in SEQ ID NO:143, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the yb24_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:144. Amino acids 25 to 37of SEQ ID NO:144 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 38. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of theyb24_(—)1 protein.

[3695] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone yb24_(—)1 should be approximately 1700 bp.

[3696] The nucleotide sequence disclosed herein for yb24_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. yb24_(—)1 demonstratedat least some similarity with sequences identified as AA149807(zl47c09.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 5050723′) and AB003515 (Rat mRNA for GEF-2, complete cds). Based upon sequencesimilarity, yb24_(—)1 proteins and each similar protein or peptide mayshare at least some activity.

[3697] Clone “yb44_(—)1”

[3698] A polynucleotide of the present invention has been identified asclone “yb44_(—)1”. yb44_(—)1 was isolated from a human fetal brain cDNAlibrary and was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. yb44_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“yb44_(—)1 protein”).

[3699] The nucleotide sequence of yb44_(—)1 as presently determined isreported in SEQ ID NO:145, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the yb44_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:146. Amino acids 10 to 22of SEQ ID NO:146 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 23. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of theyb44_protein.

[3700] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone yb44_(—)1 should be approximately 2000 bp.

[3701] The nucleotide sequence disclosed herein for yb44_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. yb44_(—)1 demonstratedat least some similarity with sequences identified as AC000016 (***SEQUENCING IN PROGRESS *** EPM1/APECED region of chromosome 21, BACclone B4P3; H-TGS phase 1, 10 unordered pieces). The predicted aminoacid sequence disclosed herein for yb44_(—)1 was searched against theGenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted yb44_(—)1 protein demonstrated at leastsome similarity to sequences identified as R72377 (Human auxillarycytochrome P450 species 2D6 variant 2 protein) and U44753 (cytochromeP450 [Drosophila melanogaster]). Based upon sequence similarity,yb44_(—)1 proteins and each similar protein or peptide may share atleast some activity. The TopPredil computerprogrampredicts threeadditional potential transmembrane domains within the yb44_(—)1 proteinsequence, which are centered around amino acids 82,128, and 361 of SEQID NO:146, respectively. The nucleotide sequence of yb44_(—)1 indicatesthat it may contain one or more of the following repetitive elements:Alu, AT, TATACA, MER44A, TACA.

[3702] Clone “bn69_(—)15”

[3703] A polynucleotide of the present invention has been identified asclone “bn69_(—)15”. bn69_(—)15 was isolated from a human adult placentacDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. bn69_(—)15is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “bn69 15 protein”).

[3704] The nucleotide sequence of bn69_(—)15 as presently determined isreported in SEQ ID NO:147, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the bn69_(—)15 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:148. Amino acids 47 to 59of SEQ ID NO:148 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 60. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thebn69_(—)15 protein. Another potential bn69_(—)15 reading frame andpredicted amino acid sequence is encoded by basepairs 1008 to 1352 ofSEQ ID NO:147 and is reported in SEQ ID NO:282.

[3705] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone bn69_(—)15 should be approximately 2800 bp.

[3706] The nucleotide sequence disclosed herein for bn69_(—)15 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. bn69_(—)15 demonstratedat least some similarity with sequences identified as H80692 (yv01b10.r1Homo sapiens cDNA clone 241435 5′), T64701 (yc48d02.r1 Homo sapiens cDNAclone 83907 5′), and W21368 (zb59c01.r1 Soares fetal lung NbHL19W Homosapiens cDNA clone 307872 5′ similar to gb:M83186 CYTOCHROME C OXIDASEPOLYPEPTIDE VIIA-HEART PRECURSOR (HUMAN)). Based upon sequencesimilarity, bn69_(—)15 proteins and each similar protein or peptide mayshare at least some activity. The TopPredII computer program predicts anadditional potential transmembrane domain within the bn69_(—)15 proteinsequence centered around amino acid 32 of SEQ ID NO:148.

[3707] Clone “cb110_(—)1”

[3708] A polynucleotide of the present invention has been identified asclone “cb110_(—)1”. cb110_(—)1 was isolated from a human fetal braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. Cb110_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “cb110_(—)1 protein”).

[3709] The nucleotide sequence of cb110_(—)1 as presently determined isreported in SEQ ID NO:149, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the cb110_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:150. Amino acids 36 to 48of SEQ ID NO:150 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 49. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thecb110_(—)1 protein.

[3710] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone cb110_(—)1 should be approximately 900 bp.

[3711] The nucleotide sequence disclosed herein for cbllO_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. Cb110_(—)1 demonstratedat least some similarity with sequences identified as AC001083 (Homosapiens (subdone 2_a6 from BAC H75) DNA sequence, complete sequence),D28485 (Human MSMB gene for beta-microseminoprotein (MSP), promoterregion and exonl), and Z98052 (Human DNA sequence *** SEQUENCING INPROGRESS *** from clone 505B13; HTGS phase 1). Based upon sequencesimilarity, Cb1101 proteins and each similar protein or peptide mayshare at least some activity.

[3712] Clone “ch4_(—)11”

[3713] A polynucleotide of the present invention has been identified asclone “ch4_(—)11”. ch4_(—)11 was isolated from a human fetal kidney cDNAlibrary using methods which are selective for cDNAs encoding secretedproteins (see U.S. Pat. No. 5,536,637), or was identified as encoding asecreted or transmembrane protein on the basis of computer analysis ofthe amino acid sequence of the encoded protein. ch4_(—)11 is afull-length clone, including the entire coding sequence of a secretedprotein (also referred to herein as “ch4_(—)11 protein”).

[3714] The nucleotide sequence of ch4_(—)11 as presently determined isreported in SEQ ID NO:151, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the ch4_(—)11 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:152. Amino acids 21 to 33of SEQ ID NO:152 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 34. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of the ch4 11protein.

[3715] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone ch4_(—)11 should be approximately 1600 bp.

[3716] The nucleotide sequence disclosed herein for ch4_(—)11 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. ch4_(—)1I demonstratedat least some similarity with sequences identified as AA318160 (EST20431Retina II Homo sapiens cDNA 5′ end), R94133 (yt74g06.r1 Soares fetalliver spleen 1NFLS Homo sapiens cDNA clone 276275 5′), and W27798 (37hlHuman retina cDNA randomly primed sublibrary Homo sapiens). Thepredicted amino acid sequence disclosed herein for ch4_(—)11 wassearched against the GenPept and GeneSeq amino acid sequence databasesusing the BLASTX search protocol. The predicted ch4_(—)1 proteindemonstrated at least some similarity to sequences identified as L28819(involucrin [Mus musculus]). The ch4_(—)1l protein is the humanhomologue of the mouse K483_(—)1 protein (see GenBank I80067 and I80068,GeneSeq V09119, V09120, and W42028, and U.S. Pat. No. 5,708,157). Basedupon sequence similarity, ch4_(—)11 proteins and each similar protein orpeptide may share at least some activity. The TopPredII computer programpredicts three potential transmembrane domains within the ch4_(—)11protein sequence centered around amino acids 28, 189, and 280 of SEQ IDNO:152, respectively.

[3717] Clone “cn621_(—)8”

[3718] A polynucleotide of the present invention has been identified asclone “cn621_(—)8”. cn621_(—)8 was isolated from a human fetal braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. cn621_(—)8is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “cn621_(—)8 protein”). Thenucleotide sequence of cn621_(—)8 as presently determined is reported inSEQ ID NO:153, and includes a poly(A) tail. What applicants presentlybelieve to be the proper reading frame and the predicted amino acidsequence of the cn621 8 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:154.

[3719] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone cn621_(—)8 should be approximately 3500 bp.

[3720] The nucleotide sequence disclosed herein for cn621_(—)8 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. cn621_(—)8 demonstratedat least some similarity with sequences identified as WI 8181(JMAGE:20099 Soares infant brain 1NIB Homo sapiens cDNA clone 20099),W60570 (zd26g04.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone341814 5′), W60661 (zd26g04.s1 Soares fetal heart NbHH19W Homo sapienscDNA clone), and Z84474 (Human DNA sequence from PAC 11lM5 on chromosome6. Contains BBC1, RFP finger protein, EST, STS, tRNAs and polymorphicrepeat). The predicted arnino acid sequence disclosed herein forcn621_(—)8 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictedcn621_(—)8 protein demonstrated at least some similarity to sequencesidentified as L35279 (BMP-1 [Homo sapiens]), U91963 (tolloid-like (TLL)[Homo sapiens]), and X64414 (low density lipoprotein receptor [Musmusculus]). Based upon sequence similarity, cn621_(—)8 proteins and eachsimilar protein or peptide may share at least some activity. TheTopPredII computer program predicts a potential transmembrane domainwithin the cn621_(—)8 protein sequence centered around amino acid 220 ofSEQ ID NO:154.

[3721] Clone “g621_(—)1”

[3722] A polynucleotide of the present invention has been identified asclone “gy621_(—)1”. gy621_(—)1 was isolated from a human adult testescDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. gy621_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “gy621_(—)1 protein”).

[3723] The nucleotide sequence of gy621_(—)1 as presently determined isreported in SEQ ID NO:155, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the gy621_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:156. Amino acids 11 to 23of SEQ ID NO:156 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 24. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of the gy6211 protein.

[3724] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone gy621_(—)1 should be approximately 3800 bp.

[3725] The nucleotide sequence disclosed herein for gy621_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. gy621_(—)1 demonstratedat least some similarity with sequences identified as AA166536(ms63h05.r1 Stratagene mouse embryonic carcinoma (#937317) Mus musculuscDNA clone 616281 5′), AA416723 (zuO8a04.s1 Soares testis NHT Homosapiens cDNA clone 731214 3′), and AA463756 (aa07a05.r1 Soares NhHMPu S1Homo sapiens cDNA clone 812528 5′). Based upon sequence similarity,gy621_(—)1 proteins and each similar protein or peptide may share atleast some activity. The TopPredII computer program predicts at leastone additional potential transmembrane domains within the gy621_(—)1protein sequence of SEQ ID NO:156. The nucleotide sequence of gy621_(—)1indicates that it may contain one or more ACI or AC2 repetitiveelements.

[3726] Clone “hb1041_(—)2”

[3727] A polynucleotide of thepresentinventionhas been identified asclone “hb1041_(—)2”. hb1041_(—)2 was isolated from a human fetal kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. hb1041_(—)2is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “hb1041_(—)2 protein”).

[3728] The nucleotide sequence of hb1041_(—)2 as presently determined isreported in SEQ ID NO:157, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the hb1041_(—)2 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:158. Amino acids 55 to 67of SEQ ID NO:158 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 68. Due tothe hydrophobic nature of the predicted leader/signal sequence, it mayact as a transmembrane domain should the predicted leader/signalsequence not be separated from the remainder of the hb1041_(—)2 protein.

[3729] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone hb1041_(—)2 should be approximately 2450 bp.

[3730] The nucleotide sequence disclosed herein for hb1040_(—)2 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. hb1041_(—)2 demonstratedat least some similarity with sequences identified as AA050445(mj21c12.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone476758 5′), AA087161 (mo11b05.r1 Life Tech mouse embryo 10 5dpc 10665016Mus musculus cDNA clone 553233 5′), and W84558 (zd89h10.s1 Soares fetalheart NbHH19W Homo sapiens cDNA clone 356707 3′). The predicted aminoacid sequence disclosed herein for hb1041_(—)2 was searched against theGenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted hb1041_(—)2 protein demonstrated at leastsome similarity to sequences identified as AB000459 (unnamed proteinproduct [Homo sapiens]). Based upon sequence similarity, hb1041_(—)2proteins and each similar protein or peptide may share at least someactivity.

[3731] Clone “mh703_(—)1”

[3732] A polynucleotide of the present invention has been identified asclone “mh703_(—)1”. mh703_(—)1 was isolated from a human adult brain(thalamus) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.mnh703_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “mh703_(—)1 protein”).

[3733] The nucleotide sequence of mh703_(—)1 as presently determined isreported in SEQ ID NO:159, and includes a poly(A) tail. What applicantspresently believe to be the —proper reading frame and the predictedamino acid sequence of the mh703 1 protein corresponding to theforegoing nucleotide sequence is reported in SEQ ID NO:160.

[3734] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone mnh703_(—)1 should be approximately 1700 bp.

[3735] The nucleotide sequence disclosed herein for mh703_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. mh703_(—)1 demonstratedat least some similarity with sequences identified as AA173536(zp04e07.r1 Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone595428 5′), AA173577 (zp04e07.s1 Stratagene ovarian cancer (#937219)Homo sapiens cDNA clone 595428 3′), AA278788 (zs79a09.r1 NCI_CGAP_GCB1Homo sapiens cDNA clone IMAGE 703672 5′ similar to TR E189399 E189399HYPOTHETICAL 51.4 KD PROTEIN), and T26646 (Human gene signatureHUMGS08893). The predicted amino acid sequence disclosed herein formh703_(—)1 was searched against the GenPept and GeneSeq amino acidsequence databases using the BLASTX search protocol. The predictedmh703_(—)1 protein demonstrated at least some similarity to sequencesidentified as R85881 (WD-40 domain-contg. YCW2 protein) and U80447(similar to the beta transducin family [Caenorhabditis elegans]).mh703_(—)1 protein contains at least two beta-transducin family Trp-Asprepeat signature motifs, and also contains the WD-40 motif ofG-proteins. Based upon sequence similarity, mh703_(—)1 proteins and eachsimilar protein or peptide may share at least some activity. mh703_(—)1protein was expressed in a COS cell expression system, and an expressedprotein band of approximately 51 kDa was detected in conditioned mediumusing SDS polyacrylamide gel electrophoresis.

[3736] Clone “na461_(—)19”

[3737] A polynucleotide of the present invention has been identified asclone “na461_(—)19”. na461_(—)19 was isolated from a human adult brain(corpus callosum) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.na461_(—)19 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “na461_(—)19protein”).

[3738] The nucleotide sequence of na461_(—)19 as presently determined isreported in SEQ ID NO:161, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the na461 19 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:162.

[3739] Amino acids 63 to 75 of SEQ ID NO:162 are a predictedleader/signal sequence, with the predicted mature amino acid sequencebeginning at amino acid 76. Due to the hydrophobic nature of thepredicted leader/signal sequence, it is likely to act as a transmembranedomain should the predicted leader/signal sequence not be separated fromthe remainder of the na461_(—)19 protein.

[3740] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone na461_(—)19 should be approximately 2300 bp.

[3741] The nucleotide sequence disclosed herein for na461_(—)19 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. na461_(—)19 demonstratedat least some similarity with sequences identified as AA032203(zf01d04.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 3756553′), AA203707 (zx52c12.r1 Soares fetal liver spleen 1NFLS S1 Homosapiens cDNA clone 446134 5′ similar to contains element MER2 repetitiveelement), AA262333 30 (zr70h11.s1 Soares NhHMPu S1 Homo sapiens cDNAclone 668805 3′), AA318276 (EST20340 Retina II Homo sapiens cDNA 5′end), AA436588 (zv08e12.r1 Soares NhHMPu S1 Homo sapiens cDNA clone753070 5′), and T21229 (Human gene signature HUMGS02545). Based uponsequence similarity, na461_(—)19 proteins and each similar protein orpeptide may share at least some activity.

[3742] Clone “na492_(—)2”

[3743] A polynucleotide of the present invention has been identified asclone “na492_(—)2”. na492_(—)2 was isolated from a human adult brain(corpus callosum) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.na492_(—)2 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “na492_(—)2 protein”).

[3744] The nucleotide sequence of na492_(—)2 as presently determined isreported in SEQ ID NO:163, and includes a poly(A) tail. What applicantspresently believe to be the —proper reading frame and the predictedamino acid sequence of the na492 2 protein corresponding to theforegoing nucleotide sequence is reported in SEQ ID NO:164. Amino acids321 to 333 of SEQ ID NO:164 are a predicted leader/signal sequence, withthe predicted mature amino acid sequence beginning at amino acid 334.Due to the hydrophobic nature of the predicted leader/signal sequence,it is likely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thena492_(—)2 protein.

[3745] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone na492_(—)2 should be approximately 1800 bp.

[3746] The nucleotide sequence disclosed herein for na492_(—)2 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. na492_(—)2 demonstratedat least some similarity with sequences identified as AA514389(nf57b05.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE:923985), H81154(yu60f02.r1 Homo sapiens cDNA clone 230523 5′), and R89359 (yq05c05.s1Homo sapiens cDNA clone 196040 3′). The predicted amino acid sequencedisclosed herein for na492_(—)2 was searched against the GenPept andGeneSeq amino acid sequence databases using the BLASTX search protocol.The predicted na492_(—)2 protein demonstrated at least some similarityto sequences identified as AB004534 (pi015 [Schizosaccharomyces pombe]).Based upon sequence similarity, na492_(—)2 proteins and each similarprotein or peptide may share at least some activity. The TopPredIlcomputer program predicts two potential transmembrane domains within thena492_(—)2 protein sequence, one centered around amino acid 350 andanother around amino acid 370 of SEQ ID NO:164.

[3747] Clone “na669_(—)10”

[3748] A polynucleotide of the present invention has been identified asclone “na669_(—)10”. na669_(—)10 was isolated from a human adult brain(corpus callosum) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.na669_(—)10 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “na669_(—)10protein”).

[3749] The nucleotide sequence of na669_(—)10 as presently determined isreported in SEQ ID NO:165, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the na669 10 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:166. Amino acids 40 to 52of SEQ ID NO:166 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 53. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thena669_(—)10 protein.

[3750] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone na669_(—)10 should be approximately 3300 bp.

[3751] The nucleotide sequence disclosed herein for na669_(—)10 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. na669_(—)10 demonstratedat least some similarity with sequences identified as AA035207(zk27h11.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 4718133′), AA429797 (zw57d10.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774163 5′), AA512946 (nh91d01.s1 NCI_CGAP_Br1.1 Homo sapiens cDNAclone JMAGE:965857), C20746 (HUMGS0004776, Human Gene Signature), andN33343 (yy08d08.s1 Homo sapiens cDNA clone 270639 3′). Based uponsequence similarity, na669_(—)10 proteins and each similar protein orpeptide may share at least some activity. The TopPredII computer programpredicts two potential transmembrane domains within the na669 10 proteinsequence, one centered around amino acid 11 and another around aminoacid 46 of SEQ ID NO:166.

[3752] Clone “co821_(—)31”

[3753] A polynucleotide of the present invention has been identified asclone “co821_(—)31”. co821_(—)31 was isolated from a human adult braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. co821_(—)31is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “co821_(—)31 protein”).

[3754] The nucleotide sequence of co821_(—)31 as presently determined isreported in SEQ ID NO:167, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the co821 31 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:168. Amino acids 87 to 99of SEQ ID NO:168 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 100. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of theco821_(—)31 protein.

[3755] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone co821_(—)31 should be approximately 2400 bp.

[3756] The nucleotide sequence disclosed herein for co821_(—)31 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. co821_(—)31 demonstratedat least some similarity with sequences identified as AA488906(aa55a02.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:824810 5′similar to TR:G607003 G607003 BETA TRANSDUCIN-LIKE PROTEIN), L26690 (Musmusculus expressed sequence tag EST F101), N30002 (yx82e02.s1 Homosapiens cDNA clone 268250 3′), R82926 (EST23j22 Clontech adult human fatcell library HL1108A Homo sapiens cDNA clone 23j22), T20673 (Human genesignature HUMGS01889), and W44749 (zb98b11.s1 Soares parathyroid tumorNbHPA Homo sapiens cDNA clone 320829 3′). The predicted amino acidsequence disclosed herein for co821_(—)31 was searched against theGenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted co821_(—)31 protein demonstrated at leastsome similarity to sequences identified as U51030 (Ydr267cp[Saccharomyces cerevisiael). The predicted co821_(—)31 protein alsodemonstrated at least some similarity to U92792 (general transcriptionalrepressor Tup1 [Schizosaccharomyces pombe]), L28125 (betatransducin-like protein (het-el) [Podospora anserina]), and otherproteins containing WD-40 motifs. Based upon sequence similarity,co821_(—)31 proteins and each similar protein or peptide may share atleast some activity.

[3757] Clone “dk329_(—)1”

[3758] A polynucleotide of the present invention has been identified asclone “dk329_(—)1”. dk329_(—)1 was isolated from a human fetal kidneycDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. dk329_(—)1is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “dk329_(—)1 protein”).

[3759] The nucleotide sequence of dk329_(—)1 as presently determined isreported in SEQ ID NO:169, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the dk329_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:170. Amino acids 71 to 83of SEQ ID NO:170 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at arnino acid 84. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thedk329_(—)1 protein.

[3760] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone dk329_(—)1 should be approximately 1300 bp.

[3761] The nucleotide sequence disclosed herein for dk329_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. dk329_(—)1 demonstratedat least some similarity with sequences identified as AA147429(zo39g07.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone589308 5′ similar to WP T14G10.6 CE06452 LEUCOCYTE SURFACE ANTIGEN CD53LINE), AA190572 (zp42h08.r1 Strata gene muscle 937209 Homo sapiens cDNAclone 612159 5′ similar to WP T14G10.6 CE06452 LEUCOCYTE SURFACE ANTIGENCD53 LINE), AA234042 (zr51a05.s1 SoaresNhHMPu S1 Homo sapiens cDNA clone666896 3′ similar to WP:T14G10.6 CE06452 LEUCOCYTE SURFACE ANTIGEN CD53LINE), AA236262 (zr51a05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone666896 5′ similar to WP:T14G10.6 CE06452 LEUCOCYTE SURFACE ANTIGEN CD53LINE), N72328 (yv31f12.r1 Homo sapiens cDNA clone 244367 5′ similar toSW A15_HUMANP41732 CELL SURFACE GLYCOPROTEINA15), and W50192 (mb08d07.r1Life Tech mouse brain Mus musculus cDNA clone 319597 5′ similar toSW:CD53_HUMAN P19397 LEUKOCYTE SURFACE ANTIGEN CD53). The predictedamino acid sequence disclosed herein for dk329_(—)1 was searched againstthe GenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted dk329_(—)1 protein demonstrated at leastsome similarity to sequences identified as Z68880 (T14G10.6[Caenorhabditis elegans]) and a variety of membrane proteins involved inimmune function. Based upon sequence similarity, dk329_(—)1 proteins andeach similar protein or peptide may share at least some activity. TheTopPredII computer program predicts three potential transmembranedomains within the dk329_(—)1 protein sequence, centered around aminoacids 31, 71, and 103 of SEQ ID NO:170, respectively.

[3762] dk329_(—)1 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 18 kDa was detected inmembrane fractions using SDS polyacrylamide gel electrophoresis.

[3763] Clone “fx317_(—)11”

[3764] A polynucleotide of the present invention has been identified asclone “fx317_(—)11”. fx317_(—)11 was isolated from a human fetal braincDNA library using methods which are selective for cDNAs encodingsecreted proteins (see U.S. Pat. No. 5,536,637), or was identified asencoding a secreted or transmembrane protein on the basis of computeranalysis of the amino acid sequence of the encoded protein. fx317_(—)11is a full-length clone, including the entire coding sequence of asecreted protein (also referred to herein as “fx317_(—)11 protein”).

[3765] The nucleotide sequence of fx317_(—)11 as presently determined isreported in SEQ ID NO:171, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the fx317_(—)11 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:172. Amino acids 229 to 241of SEQ ID NO:172 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 242. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thefx317_(—)11 protein.

[3766] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone fx317_(—)11 should be approximately 1900 bp.

[3767] The nucleotide sequence disclosed herein for fx317_(—)11 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. fx317_(—)11 demonstratedat least some similarity with sequences identified as AA505600(nh93h11.s1 NCI_CGAP_Br2 Homo sapiens cDNA clone IMAGE:966117), N47450(yy89c09.r1 Homo sapiens cDNA clone 280720 5′ similar to containselement PTR5 repetitive element), T64549 (Human activated plateletprotein-2 APP-2 cDNA), and W52611 (zc49e02.r1 Soares senescentfibroblasts NbHSF Homo sapiens cDNA clone 325658 5′). The predictedamino acid sequence disclosed herein for fx317_(—)11 was searchedagainst the GenPept and GeneSeq amino acid sequence databases using theBLASTX search protocol. The predicted fx317_(—)11 protein demonstratedat least some similarity to sequences identified as W15413 (Humanactivated platelet protein-2 APP-2) and W15414 (Human activated plateletprotein-2 APP-2 alternatively spliced variant). APP-2 protein isexpressed on activated human platelets. Based upon sequence similarity,fx317_(—)11 proteins and each sirnilar protein or peptide may share atleast some activity.

[3768] Clone “lp547_(—)4”

[3769] A polynucleotide of the present invention has been identified asclone “lp547_(—)4”. lp547_(—)4 was isolated from a human adult blood(peripheral blood mononuclear cells treated in vivo withgranulocyte-colony stimulating factor) cDNA library using methods whichare selective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. lp547_(—)4 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“lp547_(—)4 protein”).

[3770] The nucleotide sequence of lp547_(—)4 as presently determined isreported in SEQ ID NO:173, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the lp547_(—)4 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:174.

[3771] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone lp547_(—)4 should be approximately 1800 bp.

[3772] The nucleotide sequence disclosed herein for lp547_(—)4 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. lp547_(—)4 demonstratedat least some similarity with sequences identified as AA442560(zv75g07.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 7595165′ similar to TR:G436941 G436941 PHORBOLIN I). The predicted amino acidsequence disclosed herein for lp547_(—)4 was searched against theGenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted lp547_(—)4 protein demonstrated at leastsome similarity to sequences identified as R58704 (Apo-B RNA editingprotein), U03891 (phorbolin I [Homo sapiens]), and U21951(apolipoprotein B mRNA-editing component 1 [Mus musculus]). U03891protein (phorbolin I) is upregulated in psoriatic keratinocytes. Thepredicted lp547_(—)4 protein also contains a cytidine anddeoxycytidylate deaminases zinc-binding region signature. Based uponsequence similarity, lp547_(—)4 proteins and each similar protein orpeptide may share at least some activity. The TopPredII computer programpredicts a potential transmembrane domain within the lp547_(—)4 proteinsequence, centered around amino acid 290 of SEQ ID NO:174; amino acids278 to 290 are also a possible leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 291.

[3773] lp547_(—)4 protein was expressed in a COS cell expression system,and an expressed protein band of approximately 41 kDa was detected inconditioned medium and membrane fractions using SDS polyacrylamide gelelectrophoresis.

[3774] Clone “lv310_(—)7”

[3775] A polynucleotide of the present invention has been identified asclone “lv310_(—)7”. Clones were first isolated from a human adultthyroid cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wereidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.Probes derived from these cDNAs were then used to isolate lv310_(—)7from a human adult brain cDNA library. lv310_(—)7 is a full-lengthclone, including the entire coding sequence of a secreted protein (alsoreferred to herein as “lv310_(—)7 protein”).

[3776] The nucleotide sequence of lv3107 as presently determined isreported in SEQ ID NO:175, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the lv31l_(—)7 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:176. Amino acids 269 to 281of SEQ ID NO:176 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 282. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thelv310l7 protein.

[3777] Another possible lv310_(—)7 reading frame and predicted aminoacid sequence, encoded by base pairs 1619 to 2188 of SEQ ID NO:175, isreported in SEQ ID NO:283.

[3778] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone lv310_(—)7 should be approximately 3650 bp.

[3779] The nucleotide sequence disclosed herein for lv310_(—)7 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. lv310_(—)7 demonstratedat least some similarity with sequences identified as N37001 (yy40a01.s1Homo sapiens cDNA clone 273672 3′), R56228 (yg90d01.s1 Homo sapiens cDNAclone 40958 3′), and R56310 (yg90d01.r1 Homo sapiens cDNA clone 409585′). The predicted amino acid sequence disclosed herein for lv310_(—)7was searched against the GenPept and GeneSeq amino acid sequencedatabases using the BLASTX search protocol. The predicted lv310_(—)7protein demonstrated at least some similarity to sequences identified asU24223 (alpha-CPl [Homo sapiens]). Based upon sequence similarity,lv310_(—)7 proteins and each similar protein or peptide may share atleast some activity. The TopPredII computer program predicts 10potential transmembrane domains within the lv310_(—)7 protein sequence,centered around amino acids 100, 130, 160, 210, 280, 490, 520, 600, 690,and 750 of SEQ ID NO:176, respectively.

[3780] Clone “nq34_(—)12”

[3781] A polynucleotide of the present invention has been identified asclone “nq34_(—)12”. nq34_(—)12 was isolated from a human adult blood(erythroleukemia TF-1) cDNA library using methods which are selectivefor cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), orwas identified as encoding a secreted or transmembrane protein on thebasis of computer analysis of the amino acid sequence of the encodedprotein. nq34_(—)12 is a full-length clone, including the entire codingsequence of a secreted protein (also referred to herein as “nq34_(—)12protein”).

[3782] The nucleotide sequence of nq34_(—)12 as presently determined isreported in SEQ ID NO:177, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the nq34_(—)12 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:178. Amino acids 287 to 299of SEQ ID NO:178 are a predicted leader/signal sequence, with —thepredicted mature amino acid sequence beginning at amino acid 300. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thenq34_(—)12 protein.

[3783] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone nq34 12 should be approximately 1700 bp.

[3784] The nucleotide sequence disclosed herein for nq34_(—)12 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. nq34_(—)12 demonstratedat least some similarity with sequences identified as AA126375(zl86c06.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 5114985′), AA446675 (zw84a08.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 783638 5′), AA448974 (zx07d05.r1 Soares total fetus Nb2HF8 9w Homosapiens cDNA clone 785769 5′ similar to SW YNDO_YEAST P40344HYPOTHETICAL 35.9 KD PROTEIN IN RPC34-CSE2 INTERGENIC REGION), R57902(F6699 Fetal heart Homo sapiens cDNA clone F6699 5′ end), and X07453(Plasmodium falciparum 11_(—)1 gene part 1). The predicted amino acidsequence disclosed herein for nq34_(—)12 was searched against theGenPept and GeneSeq amino acid sequence databases using the BLASTXsearch protocol. The predicted nq34_(—)12 protein demonstrated at leastsome similarity to sequences identified as X77395 (N2040 gene product[Saccharomyces cerevisiae]). Based upon sequence similarity, nq34_(—)12proteins and each similar protein or peptide may share at least someactivity. nq34_(—)12 protein was expressed in a COS cell expressionsystem, and an expressed protein band of approximately 34 kDa wasdetected in membrane fractions using SDS polyacrylamide gelelectrophoresis.

[3785] Clone “pj154_(—)1”

[3786] A polynucleotide of the present invention has been identified asclone “pj154_(—)1”. pj154_(—)1 was isolated from a human fetal carcinoma(NTD2 cells treated with retinoic acid for 23 days) cDNA library usingmethods which are selective for cDNAs encoding secreted proteins (seeU.S. Pat. No.5,536,637), or was identified as encoding a secreted ortransmembrane protein on the basis of computer analysis of the aminoacid sequence of the encoded protein. pj154_(—)1 is a full-length clone,including the entire coding sequence of a secreted protein (alsoreferred to herein as “pj154 1 protein”).

[3787] The nucleotide sequence of pj154_(—)1 as presently determined isreported in SEQ ID NO:179, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pj154_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:180. Amino acids 13 to 25of SEQ ID NO:180 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amnino acid 26. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thepj154_(—)1 protein.

[3788] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pj154_(—)1 should be approximately 2300 bp.

[3789] The nucleotide sequence disclosed herein for pj154_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. pj154_(—)1 demonstratedat least some similarity with sequences identified as AA223153(zr07g12.r1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNAclone 650854 5′), AA223170 (zr07g12.s1 Stratagene NT2 neuronal precursor937230 Homo sapiens cDNA clone 650854 3′ similar to contains Alurepetitive element), H16627 (ym26d04.r1 Homo sapiens cDNA clone 494695′), and Z44660 (H. sapiens partial cDNA sequence; clone c-26d11). Basedupon sequence similarity, pj154_(—)1 proteins and each similar proteinor peptide may share at least some activity. The nucleotide sequence ofpj154_(—)1 indicates that it may contain an Alu repetitive element.

[3790] Clone “pk147_(—)1”

[3791] A polynucleotide of the present invention has been identified asclone “pk147_(—)1”. pk147_(—)1 was isolated from a human fetal kidney(293 cell line) cDNA library using methods which are selective for cDNAsencoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.pk147_(—)1 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “pk147_(—)1 protein”).

[3792] The nucleotide sequence of pk147_(—)1 as presently determined isreported in SEQ ID NO:181, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pk147_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:182. Amino acids 16 to 28of SEQ ID NO:182 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 29. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thepk147_(—)1 protein.

[3793] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pk147_(—)1 should be approximately 1600 bp.

[3794] The nucleotide sequence disclosed herein for pk147_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. pk147_(—)1 demonstratedat least some similarity with sequences identified as AA126920(z123h01.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 5028013′), AA406448 (zv12f07.r1 Soares NhHMPu S1 Homo sapiens cDNA clone753445 5′), and R51886 (yg78c03.s1 Homo sapiens cDNA clone 39574 3′).Based upon sequence similarity, pk147_(—)1 proteins and each similarprotein or peptide may share at least some activity. The TopPredIIcomputer program predicts an additional potential transmembrane domainwithin the pk147_(—)1 protein sequence centered around amino acid 37 ofSEQ ID NC:182.

[3795] Clone “pt127_(—)1”

[3796] A polynucleotide of the present invention has been identified asclone “pt127_(—)1”. pt127_(—)1 was isolated from a human adultblood(lymphoblastic leukemia MOLT-4) cDNA library using methods which areselective for cDNAs encoding secreted proteins (see U.S. Pat. No.5,536,637), or was identified as encoding a secreted or transmembraneprotein on the basis of computer analysis of the amino acid sequence ofthe encoded protein. pt127_(—)1 is a full-length clone, including theentire coding sequence of a secreted protein (also referred to herein as“pt127_(—)1 protein”).

[3797] The nudeotide sequence of pt127_(—)1 as presently determined isreported in SEQ ID NO:183, and includes a poly(A) tail. What applicantspresently believe to be the proper reading frame and the predicted aminoacid sequence of the pt127_(—)1 protein corresponding to the foregoingnucleotide sequence is reported in SEQ ID NO:184. Amnino acids 8 to 20of SEQ ID NO:184 are a predicted leader/signal sequence, with thepredicted mature amino acid sequence beginning at amino acid 21. Due tothe hydrophobic nature of the predicted leader/signal sequence, it islikely to act as a transmembrane domain should the predictedleader/signal sequence not be separated from the remainder of thept127_(—)1 protein.

[3798] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone pt127_(—)1 should be approximately 2600 bp.

[3799] The nucleotide sequence disclosed herein for pt127_(—)1 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. pt127_(—)1 demonstratedat least some similarity with sequences identified as AA081843(zn19g10.r1 Stratagene neuroepitheliumNT2RAMI 937234 Homo sapiens cDNAclone 547938 5′) and R39258 (yc91h08.s1 Homo sapiens cDNA clone 235143′). Based upon sequence similarity, pt127_(—)1 proteins and eachsimilar protein or peptide may share at least some activity. TheTopPredII computer program predicts five additional potentialtransmembrane domains within the pt127_(—)1 protein sequence centeredaround amino acids 60, 100, 130, 190, and 240 of SEQ ID NO:184.

[3800] Clone “qo115_(—)13”

[3801] A polynucleotide of the present invention has been identified asclone “qo115_(—)13”. qo115_(—)13 was isolated from a human adult brain(corpus callosum) cDNA library using methods which are selective forcDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or wasidentified as encoding a secreted or transmembrane protein on the basisof computer analysis of the amino acid sequence of the encoded protein.qo115_(—)13 is a full-length clone, including the entire coding sequenceof a secreted protein (also referred to herein as “qo115_(—)13protein”). The nucleotide sequence of qo115_(—)13 as presentlydetermined is reported in SEQ ID NO:185, and includes a poly(A) tail.What applicants presently believe to be the proper reading frame and thepredicted amino acid sequence of the qo115_(—)13 protein correspondingto the foregoing nucleotide sequence is reported in SEQ ID NO:186. Aminoacids 29 to 41 of SEQ ID NO:186 are a predicted leader/signal sequence,with the predicted mature amino acid sequence beginning at amino acid42. Due to the hydrophobic nature of the predicted leader/signalsequence, it is likely to act as a transmembrane domain should thepredicted leader/signal sequence not be separated from the remainder ofthe qo115_(—)3 protein.

[3802] The EcoRI/NotI restriction fragment obtainable from the depositcontaining clone qo115_(—)13 should be approximately 1200 bp.

[3803] The nucleotide sequence disclosed herein for qo115_(—)13 wassearched against the GenBank and GeneSeq nucleotide sequence databasesusing BLASTN/BLASTX and FASTA search protocols. No significant hits werefound in the database. The nucleotide sequence of qo115_(—)13 indicatesthat it may contain repetitive elements.

[3804] Deposit of Clones

[3805] Clones bd306_(—)7, fj283_(—)11, fk317_(—)3, k213_(—)2x,na316_(—)1, nf93_(—)20, np164_(—)1, pe204_(—)1, ya1_(—)1, and yb8_(—)1were deposited on Nov. 26,1997 with the ATCC (American Type CultureCollection, 10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.)as an original deposit under the Budapest Treaty and were given theaccession number 98599, fromwhich each clone comprising a particularpolynucleotide is obtainable. Clone fj283_(—)6 was deposited on Nov. 17,1998 with the ATCC (American Type Culture Collection, 10801 UniversityBoulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit underthe Budapest Treaty and was given the accession number 98988.

[3806] Clones am856_(—)3, am996_(—)12, cc69_(—)1, cc162_(—)1, if87_(—)1,nn103_(—)4, np206_(—)8, nt746_(—)4, pe286_(—)1, and yb7_(—)1 weredeposited on Dec. 4,1997 with the ATCC (American Type CultureCollection, 10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.)as an original deposit under the Budapest Treaty and were given theaccession number 98600, from which each clone comprising a particularpolynucleotide is obtainable.

[3807] Clones am728_(—)60, bf377_(—)1, cw354_(—)1, nml34_(—)4,yb11_(—)1,and yc2_(—)1 were deposited on Dec. 19, 1997 with the ATCC (AmericanType Culture Collection, 10801 University Boulevard, Manassas, Va.20110-2209 U.S.A.) as an original deposit under the Budapest Treaty andwere given the accession number 98621, from which each clone comprisinga particular polynucleotide is obtainable.

[3808] Clones ff168_(—)12, ls9_(—)1, na1010_(—)1, nf87_(—)1, nh796_(—)1,nn229_(—)1, and np156_(—)1 were deposited on Dec. 31, 1997 with the ATCC(American Type Culture Collection, 10801 University Boulevard, Manassas,Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treatyand were given the accession number 98623, from which each clonecomprising a particular polynucleotide is obtainable.

[3809] Clones bg570_(—)1,bi120_(—)2,bn594_(—)1, en554_(—)1, na474_(—)10,nn16_(—)10, np189_(—)9, ny226_(—)1, pe159_(—)1, and pj314_(—)8 weredeposited on Jan. 7,1998 with the ATCC (American Type CultureCollection, 10801 University Boulevard, Manassas, Virginia 20110_(—)2209U.S.A.) as an original deposit under the Budapest Treaty and were giventhe accession number 98629, from which each clone comprising aparticular polynucleotide is obtainable.

[3810] Clones bp870 2, bx141l2, cw272_(—)7, nh328 5, nnn214 3, nn320 2,pp392 3, yal31, yb37_(—)1, and yb39_(—)1 were deposited on Jan. 8, 1998with the American Type Culture Collection, 10801 University Boulevard,Manassas, Va. 20110_(—)2209 U.S.A.) as an original deposit under theBudapest Treaty and were given the accession number 98630, from whicheach clone comprising a particular polynucleotide is obtainable. Clonebp870_(—)1 was deposited on Apr. 7, 1998 with the ATCC (American TypeCulture Collection, 10801 University Boulevard, Manassas, Virginia20110-2209 U.S.A.) as an original deposit under the Budapest Treaty andwas given the accession number 98724, from which deposit the bp870_(—)1clone comprising a particular polynucleotide is obtainable.

[3811] Clones bd577_(—)1, bv280_(—)3, co315_(—)3, ij226_(—)6,nf443_(—)1, nt429_(—)1, pe503_(—)1, pe834_(—)6, ya10_(—)1l, andyb40_(—)1 were deposited on Jan. 13, 1998 with the ATCC (American TypeCulture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209U.S.A.) as an original deposit under the Budapest Treaty and were giventhe accession number 98631, from which each clone comprising aparticular polynucleotide is obtainable.

[3812] Clones cs756_(—)2, ew150_(—)1, gg894_(—)13, it217_(—)2,ml235_(—)2, mt24_(—)2, pe584_(—)2, pj323_(—)2, yb24_(—)1, and yb44_(—)1were deposited on Jan. 22,1998 with the ATCC (American Type CultureCollection, 10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.)as an original deposit under the Budapest Treaty and were given theaccession number 98636, from which each clone comprising a particularpolynucleotide is obtainable.

[3813] Clones bn69_(—)15, cb110_(—)1, ch4_(—)11, cn621_(—)8, gy621_(—)1,hb104_(—)2, mh703_(—)1, na461_(—)19, na492_(—)2, and na669_(—)10 weredeposited on Jan. 30, 1998 with the ATCC (American Type CultureCollection, 10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.)as an original deposit under the Budapest Treaty and were given theaccession number 98647, from which each clone comprising a particularpolynucleotide is obtainable.

[3814] Clones co821_(—)31, dk329_(—)1, fx317_(—)11, lp547_(—)4,lv310_(—)7, nq34_(—)12, pj154_(—)1, pk147_(—)1, pt127_(—)1, andqo115_(—)13 were deposited on Feb. 18, 1998 with the American TypeCulture Collection (10801 University Boulevard, Manassas, Va. 20110-2209U.S.A.) as an original deposit under the Budapest Treaty and were giventhe accession number ATCC 98663, from which each clone comprising aparticular polynucleotide is obtainable.

[3815] All restrictions on the availability to the public of thedeposited material will be irrevocably removed upon the granting of thepatent, except for the requirements specified in 37 C.F.R. § 1.808(b),and the term of the deposit will comply with 37 C.F.R. § 1.806.

[3816] Each clone has been transfected into separate bacterial cells (E.coli) in these composite deposits. Each clone can be removed from thevector in which it was deposited by performing an EcoRI/NotI digestion(5′ site, EcoRI; 3′ site, NotI) to produce the appropriate fragment forsuch clone. Each clone was deposited in either the pED6 or pNOTs vectordepicted in FIGS. 1A and 1B, respectively. The pED6dpc2 vector (“pED6”)was derived from pED6dpcl by insertion of a new polylinker to facilitatecDNA cloning (Kaufman et al., 1991, Nucleic Acids Res. 19:4485_(—)4490); the pNOTs vector was derived from pMT2 (Kaufman et al.,1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences,insertion of a new polylinker, and insertion of the M13 origin ofreplication in the Clal site. In some instances, the deposited clone canbecome “flipped” (i.e., in the reverse orientation) in the depositedisolate. In such instances, the cDNA insert can still be isolated bydigestion with EcoRI and NotI. However, NotI will then produce the 5′site and EcoR will produce the 3′ site for placement of the cDNA inproper orientation for expression in a suitable vector. The cDNA mayalso be expressed from the vectors in which they were deposited.

[3817] Bacterial cells containing a particular clone can be obtainedfrom the composite deposit as follows:

[3818] An oligonucleotide probe or probes should be designed to thesequence that is known for that particular clone. This sequence can bederived from the sequences provided herein, or from a combination ofthose sequences. The sequence of an oligonucleotide probe that was usedto isolate or to sequence each full-length clone is identified below,and should be most reliable in isolating the clone of interest. CloneProbe Sequence bd306_7 SEQ ID NO: 187 fj283_11 SEQ ID NO: 188 p283_6 SEQID NO: 197 fk317_3 SEQ ID NO: 189 k213_2x SEQ ID NO: 190 na316_1 SEQ IDNO: 191 nf93_20 SEQ ID NO: 192 np164_1 SEQ ID NO: 193 pe204_1 SEQ ID NO:194 ya1_1 SEQ ID NO: 195 yb8_1 SEQ ID NO: 196 am856_3 SEQ ID NO: 199am996_12 SEQ ID NO: 200 cc69_1 SEQ ID NO: 201 cc162_1 SEQ ID NO: 202if87_1 SEQ ID NO: 203 nnlO3_4 SEQ ID NO: 204 np206_8 SEQ ID NO: 205nt746_4 SEQ ID NO: 206 pe286_1 SEQ ID NO: 207 yb7_1 SEQ ID NO: 208am728_60 SEQ ID NO: 209 cw354_1 SEQ ID NO: 210 nm134_4 SEQ ID NO: 211yb11_1 SEQ ID NO: 212 yc2_1 SEQ ID NO: 213 ff168_12 SEQ ID NO: 214 1s9_1SEQ ID NO: 215 na1010_1 SEQ ID NO: 216 nf87_1 SEQ ID NO: 217 nh796_1 SEQID NO: 218 nn229_1 SEQ ID NO: 219 np156_1 SEQ ID NO: 220 bi120_2 SEQ IDNO: 221 na474_10 SEQ ID NO: 222 nnl6_10 SEQ ID NO: 223 np189_9 SEQ IDNO: 224 ny226_1 SEQ ID NO: 225 pe159_1 SEQ ID NO: 226 pj314_8 SEQ ID NO:227 bp870_1 SEQ ID NO: 228 bx141_2 SEQ ID NO: 229 cw272_7 SEQ ID NO: 230nh328_5 SEQ ID NO: 231 nm214_3 SEQ ID NO: 232 nn320_2 SEQ ID NO: 233pp392_3 SEQ ID NO: 234 yb37_1 SEQ ID NO: 235 bd577_1 SEQ ID NO: 236bv280_3 SEQ ID NO: 237 co315_3 SEQ ID NO: 238 ij226_6 SEQ ID NO: 239nf443_1 SEQ ID NO: 240 nt429_1 SEQ ID NO: 241 pe503_1 SEQ ID NO: 242pe834_6 SEQ ID NO: 243 yb40_1 SEQ ID NO: 244 cs756_2 SEQ ID NO: 245ew150_1 SEQ ID NO: 246 gg894_13 SEQ ID NO: 247 it217_2 SEQ ID NO: 248ml235_2 SEQ ID NO: 249 mt24_2 SEQ ID NO: 250 pe584_2 SEQ ID NO: 251pj323_2 SEQ ID NO: 252 yb24_1 SEQ ID NO: 253 bn69_15 SEQ ID NO: 254cb110_1 SEQ ID NO: 255 ch4_11 SEQ ID NO: 256 cn621_8 SEQ ID NO: 257gy621_1 SEQ ID NO: 258 hb1041_2 SEQ ID NO: 259 mh703_1 SEQ ID NO: 260na461_19 SEQ ID NO: 261 na492_2 SEQ ID NO: 262 na669_10 SEQ ID NO: 263co821_31 SEQ ID NO: 264 dk329_1 SEQ ID NO: 265 fx317_11 SEQ ID NO: 266lp547_4 SEQ ID NO: 267 lv310_7 SEQ ID NO: 268 nq342_12 SEQ ID NO: 269pj154_1 SEQ ID NO: 270 pk147_1 SEQ ID NO: 271 pt127_1 SEQ ID NO: 272qo115_13 SEQ ID NO: 273

[3819] In the sequences listed above which include an N at position 2,that position is occupied in preferred probes/primers by a biotinylatedphosphoaramidite residue rather than a nucleotide (such as, for example,that produced by use of biotin phosphoramidite(1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramadite)(Glen Research, cat. no. 10-1953)).

[3820] The design of the oligonucleotide probe should preferably followthese parameters:

[3821] (a) It should be designed to an area of the sequence which hasthe fewest ambiguous bases (“N's”), if any;

[3822] (b) It should be designed to have a T_(m) of approx. 80 C(assuming 2 for each A or T and 4 degrees for each G or C).

[3823] The oligonucleotide should preferably be labeled with γ-³²P ATP(specific activity 6000 Ci/mmole) and T4 polynucleotide kinase usingcommonly employed techniques for labeling oligonucleotides. Otherlabeling techniques can also be used. Unincorporated label shouldpreferably be removed by gel filtration chromatography or otherestablished methods. The amount of radioactivity incorporated into theprobe should be quantitated by measurement in a scintillation counter.Preferably, specific activity of the resulting probe should beapproximately 4e+6 dpm/pmole.

[3824] The bacterial culture containing the pool of full-length clonesshould preferably be thawed and 100 μl of the stock used to inoculate asterile culture flask containing 25 ml of sterile L-broth containingampicillin at 100 μg/ml. The culture should preferably be grown tosaturation at 37° C., and the saturated culture should preferably bediluted in fresh L-broth. Aliquots of these dilutions should preferablybe plated to determine the dilution and volume which will yieldapproximately 5000 distinct and well-separated colonies on solidbacteriological media containing L-broth containing ampicillin at 100μg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at37° C. Other known methods of obtaining distinct, well-separatedcolonies can also be employed.

[3825] Standard colony hybridization procedures should then be used totransfer the colonies to nitrocellulose filters and lyse, denature andbake them.

[3826] The filter is then preferably incubated at 65° C. for 1 hour withgentle agitation in 6×SSC (20×stock is 175.3 g NaCl/liter, 88.2 g Nacitrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100μg/ml of yeast RNA, and 10 mM EDTA (approximately mL per 150 mm filter).Preferably, the probe is then added to the hybridization mix at aconcentration greater than or equal to le+6 dpm/mL. The filter is thenpreferably incubated at 65° C. with gentle agitation overnight. Thefilter is then preferably washed in 500 mL of 2)(SSC/0.5% SDS at roomtemperature without agitation, preferably followed by 500 mL of2×SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. Athird wash with 0.1×SSC/0.5% SDS at 65° C. for 30 minutes to 1 hour isoptional. The filter is then preferably dried and subjected toautoradiography for sufficient time to visualize the positives on theX-ray film. Other known hybridization methods can also be employed.

[3827] The positive colonies are picked, grown in culture, and plasmidDNA isolated using standard procedures. The clones can then be verifiedby restriction analysis, hybridization analysis, or DNA sequencing.

[3828] Fragments of the proteins of the present invention which arecapable of exhibiting biological activity are also encompassed by thepresent invention. Fragments of the protein maybe in linear form or theymay be cyclized using known methods, for example, as described in H. U.Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R. S.McDowell, et al., J. Amer. Chem. Soc. 11.4 9245-9253 (1992), both ofwhich are incorporated herein by reference. Such fragments maybe fusedto carrier molecules such as immunoglobulins for many purposes,including increasing the valency of protein binding sites. For example,fragments of the protein may be fused through “linker” sequences to theFc portion of an immunoglobulin. For a bivalent form of the protein,such a fusion could be to the Fc portion of an IgG molecule. Otherimmunoglobulin isotypes may also be used to generate such fusions. Forexample, a protein-IgM fusion would generate a decavalent form of theprotein of the invention.

[3829] The present invention also provides both full-length and matureforms of the disclosed proteins. The full-length form of the suchproteins is identified in the sequence listing by translation of thenucleotide sequence of each disclosed clone. The mature form(s) of suchprotein may be obtained by expression of the disclosed full-lengthpolynucleotide (preferably those deposited with ATCC) in a suitablemammalian cell or other host cell. The sequence(s) of the mature form(s)of the protein may also be determinable from the amino acid sequence ofthe full-length form.

[3830] The present invention also provides genes corresponding to thepolynucleotide sequences disclosed herein. “Corresponding genes” are theregions of the genome that are transcribed to produce the mRNAs fromwhich cDNA polynucleotide sequences are derived and may includecontiguous regions of the genome necessary for the regulated expressionof such genes. Corresponding genes may therefore include but are notlimited to coding sequences, 5′ and 3′ untranslated regions,alternatively spliced exons, introns, promoters, enhancers, and silenceror suppressor elements. The corresponding genes can be isolated inaccordance with known methods using the sequence information disclosedherein. Such methods include the preparation of probes or primers fromthe disclosed sequence information for identification and/oramplification of genes in appropriate genomic libraries or other sourcesof genomic materials. An “isolated gene” is a gene that has beenseparated from the adjacent coding sequences, if any, present in thegenome of the organism from which the gene was isolated.

[3831] The chromosomal location corresponding to the polynucleotidesequences disclosed herein may also be determined, for example byhybridizing appropriately labeled polynucleotides of the presentinvention to chromosomes in situ. It may also be possible to determinethe corresponding chromosomal location for a disclosed polynucleotide byidentifying significantly similar nucleotide sequences in publicdatabases, such as expressed sequence tags (ESTs), that have alreadybeen mapped to particular chromosomal locations. For at least some ofthe polynucleotide sequences disclosed herein, public database sequenceshaving at least some similarity to the polynucleotide of the presentinvention have been listed by database accession number. Searches usingthe GenBank accession numbers of these public database sequences canthen be performed at an Internet site provided by the National Centerfor Biotechnology Information having the addresshttp://www.ncbi.nlm.nih.gov/UniGene/, in order to identify “UniGeneclusters” of overlapping sequences. Many of the “UniGene clusters” soidentified will already have been mapped to particular chromosomalsites.

[3832] Organisms that have enhanced, reduced, or modified expression ofthe gene(s) corresponding to the polynucleotide sequences disclosedherein are provided. The desired change in gene expression can beachieved through the use of antisense polynucleotides or ribozymes thatbind and/or cleave the mRNA transcribed from the gene (Albert andMorris, 1994, Trends Pharmacol. Sci. 15(7): 250-254; Lavarosky et al.,1997, Biochem. Mol. Med. 62(1): 11_(—)22; and Hampel, 1998, Prog.Nucleic Acid Res. Mol. Biol. 58: 1-39; all of which are incorporated byreference herein). Transgenic animals that have multiple copies of thegene(s) corresponding to the polynucleotide sequences disclosed herein,preferably produced by transformation of cells with genetic constructsthat are stably maintained within the transformed cells and theirprogeny, are provided. Transgenic animals that have modified geneticcontrol regions that increase or reduce gene expression levels, or thatchange temporal or spatial patterns of gene expression, are alsoprovided (see European Patent No. 0 649 464 B1, incorporated byreference herein). In addition, organisms are provided in which thegene(s) corresponding to the polynucleotide sequences disclosed hereinhave been partially or completely inactivated, through insertion ofextraneous sequences into the corresponding gene(s) or through deletionof all or part of the corresponding gene(s). Partial or complete geneinactivation can be accomplished through insertion, preferably followedby imprecise excision, of transposable elements (Plasterk, 1992,Bioessays 14(9): 629_(—)633; Zwaal et al., 1993, Proc. Natl. Acad. Sci.USA 90(16): 7431_(—)7435; Clark et al., 1994, Proc. Natl. Acad. Sci. USA91(2): 719-722; all of which are incorporated by reference herein), orthrough homologous recombination, preferably detected bypositive/negative genetic selection strategies (Mansour et al., 1988,Nature 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059;5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which areincorporated by reference herein). These organisms with altered geneexpression are preferably eukaryotes and more preferably are mammals.Such organisms are useful for the development of non-human models forthe study of disorders involving the corresponding gene(s), and for thedevelopment of assay systems for the identification of molecules thatinteract with the protein product(s) of the corresponding gene(s).

[3833] Where the protein of the presentinvention is membrane-bound(e.g., is a receptor), the present invention also provides for solubleforms of such protein. In such forms, part or all of the intracellularand transmembrane domains of the protein are deleted such that theprotein is fully secreted from the cell in which it is expressed. Theintracellular and transmembrane domains of proteins of the invention canbe identified in accordance with known techniques for determination ofsuch domains from sequence information. For example, the TopPredIHcomputer program can be used to predict the location of transmembranedomains in an amino acid sequence, domains which are described by thelocation of the center of the transmsmbrane domain, with at least tentransmembrane amino acids on each side of the reported centralresidue(s).

[3834] Proteins and protein fragments of the present invention includeproteins with amino acid sequence lengths that are at least 25%(morepreferably at least 50%, and most preferably at least 75%) of the lengthof a disclosed protein and have at least 60% sequence identity (morepreferably, at least 75% identity; most preferably at least 90% or 95%identity) with that disclosed protein, where sequence identity isdetermined by comparing the amino acid sequences of the proteins whenaligned so as to maximize overlap and identity while minimizing sequencegaps. Also included in the present invention are proteins and proteinfragments that contain a segment preferably comprising 8 or more (morepreferably 20 or more, most preferably 30 or more) contiguous aminoacids that shares at least 75% sequence identity (more preferably, atleast 85% identity; most preferably at least 95% identity) with any suchsegment of any of the disclosed proteins.

[3835] In particular, sequence identity may be determined using WU-BLAST(Washington University BLAST) version 2.0 software, which builds uponWU-BLAST version 1.4, which in turn is based on the public domainNCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignmentstatistics, Doolittle ed., Methods in Enzymology 266: 460-480; Altschulet al., 1990, Basic local alignment search tool, Journal of MolecularBiology 215: 403-410; Gish and States, 1993, Identification of proteincoding regions by database similarity search, Nature Genetics 3:266-272; Karlin and Altschul, 1993, Applications and statistics formultiple high-scoring segments in molecular sequences, Proc. Natl. Acad.Sci. USA 90: 5873_(—)5877; all of which are incorporated by referenceherein). WU-BLAST version 2.0 executable programs for several UNIXplatforms can be downloaded from ftp:/blast.wustl.edu/blastlexecutables.The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN,and TBLASTX) is provided at that site, in addition to several supportprograms. WU-BLAST 2.0 is copyrighted and may not be sold orredistributed in any form or manner without the express written consentof the author; but the posted executables may otherwise be freely usedfor commercial, nonprofit, or academic purposes. In all search programsin the suite —BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX—the gappedalignment routines are integral to the database search itself, and thusyield much better sensitivity and selectivity while producing the moreeasily interpreted output. Gapping can optionally be turned off in allof these programs, if desired. The default penalty (Q) for a gap oflength one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but maybe changed to any integer value including zero, one through eight, nine,ten, eleven, twelve through twenty, twenty-one through fifty, fifty-onethrough one hundred, etc. The default per-residue penalty for extendinga gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but maybe changed to any integer value including zero, one, two, three, four,five, six, seven, eight, nine, ten, eleven, twelve through twenty,twenty-one through fifty, fifty-one through one hundred, etc. Anycombination of values for Q and R can be used in order to alignsequences so as to maximize overlap and identity while minimizingsequence gaps. The default amino acid comparison matrix is BLOSUM62, butother amino acid comparison matrices such as PAM can be utilized.

[3836] Species homologues of the disclosed polynucleotides and proteinsare also provided by the present invention. As used herein, a “specieshomologue” is a protein or polynucleotide with a different species oforigin from that of a given protein or polynucleotide, but withsignificant sequence similarity to the given protein or polynucleotide.Preferably, polynucleotide species homologues have at least 60% sequenceidentity (more preferably, at least 75% identity; most preferably atleast 90% identity) with the given polynucleotide, and protein specieshomologues have at least 30% sequence identity (more preferably, atleast 45% identity; most preferably at least 60% identity) with thegiven protein, where sequence identity is determined by comparing thenucleotide sequences of the polynucleotides or the amino acid sequencesof the proteins when aligned so as to maximize overlap and identitywhile minimizing sequence gaps. Species homologues may be isolated andidentified by making suitable probes or primers from the sequencesprovided herein and screening a suitable nucleic acid source from thedesired species. Preferably, species homologues are those isolated fromma:malian species. Most p referably, species homologues are thoseisolated from certain mammalian species such as, for example, Pantroglodytes, Gorilla gorilla, Pongo pygmaeus, Hylobates concolor, MacacamuZatta, Papio papio, Papio hamadryas, Cercopithecus aethiops, Cebuscapucinus, Aotus trivirgatus, Sanguinus oedipus, Microcebus murinus, Musmusculus, Rattus norvegicus, Cricetulusgriseus,Felis catus,Mustelavison, Canisfamiliaris, Oryctolagus cuniculus, Bos taurus, Ovis aries,Sus scrofa, and Equus caballus, for which genetic maps have been createdallowing the identification of syntenic relationships between thegenomic organization of genes in one species and the genomicorganization of the related genes in another species (O'Brien andSeuanez, 1988, Ann. Rev. Genet. 22: 323351; O'Brien et al., 1993, NatureGenetics 3:103-112; Johansson et al., 1995, Genomics 25: 682-690; Lyonset al., 1997, Nature Genetics 15: 47-56; O'Brien et al., 1997, Trends inGenetics 13(10):393-399; Carver and Stubbs, 1997, Genome Research7:1123-1137; all of which are incorporated by reference herein).

[3837] The invention also encompasses allelic variants of the disclosedpolynucleotides or proteins; that is, naturally-occurring alternativeforms of the isolated polynucleotides which also encode proteins whichare identical or have significantly similar sequences to those encodedby the disclosed polynucleotides. Preferably, allelic variants have atleast 60% sequence identity (more preferably, at least 75% identity;most preferably at least 90% identity) with the given polynucleotide,where sequence identity is determined by comparing the nucleotidesequences of the polynucleotides when aligned so as to maximize overlapand identity while minimizing sequence gaps. Allelic variants may beisolated and identified by making suitable probes or primers from thesequences provided herein and screening a suitable nucleic acid sourcefrom individuals of the appropriate species.

[3838] The invention also includes polynucleotides with sequencescomplementary to those of the polynucleotides disclosed herein.

[3839] The present invention also includes polynucleotides thathybridize under reduced stringency conditions, more preferably stringentconditions, and most preferably highly stringent conditions, topolynucleotides described herein. Examples of stringency conditions areshown in the table below: highly stringent conditions are those that areat least as stringent as, for example, conditions A-F; stringentconditions are at least as stringent as, for example, conditions G-L;and reduced stringency conditions are at least as stringent as, forexample, conditions M-R. Strin- gency Poly- Hybrid Hybridization WashCon- nucleotide Length Temperature and Temperature dition Hybrid(bp)^(‡) Buffer^(†) and Buffer^(†) A DNA:DNA ≧50 65° C.; 1 × SSC 65° C.;0.3 × SSC -or- 42° C.; 1 × SSC, 50% formamide B DNA:DNA <50 T_(B)*; 1 ×SSC T_(B)*;   1 × SSC C DNA:RNA ≧50 67° C.; 1 × SSC 67° C.; 0.3 × SSC-or- 45° C.; 1 × SSC, 50% formamide D DNA:RNA <50 T_(D)*; 1 × SSCT_(D)*;   1 × SSC E RNA:RNA ≧50 70° C.; 1 × SSC 70° C.; 0.3 × SSC -or-50° C.; 1 × SSC, 50% formamide F RNA:RNA <50 T_(G)*; 1 × SSC T_(F)*;   1× SSC G DNA:DNA ≧50 65° C.; 4 × SSC 65° C.;   1 × SSC -or- 42° C.; 4 ×SSC, 50% formamide H DNA:DNA <50 T_(H)*; 4 × SSC T_(H)*;   4 × SSC IDNA:RNA ≧50 67° C.; 4 × SSC 67° C.;   1 × SSC -or- 45° C.; 4 × SSC, 50%formamide J DNA:RNA <50 T_(J)*; 4 × SSC T_(J)*;   4 × SSC K RNA:RNA ≧5070° C.; 4 × SSC 67° C.;   1 × SSC -or- 50° C.; 4 × SSC, 50% formamide LRNA:RNA <50 T_(L)*; 2 × SSC M DNA:DNA ≧50 50° C.; 4 × SSC 50° C.;   2 ×SSC -or- 40° C.; 6 × SSC, 50% formamide N DNA:DNA <50 T_(N)*; 6 × SSCT_(N)*;   6 × SSC O DNA:RNA ≧50 55° C.; 4 × SSC 55° C.;   2 × SSC -or-42° C.; 6 × SSC, 50% formamide P DNA:RNA <50 T_(P)*; 6 × SSC T_(P)*;   6× SSC Q RNA:RNA ≧50 60° C.; 4 × SSC 60° C.;   2 × SSC -or- 45° C.; 6 ×SSC, 50% formamide R RNA:RNA <50 T_(R)*; 4 × SSC T_(R)*;   4 × SSC #bases). For hybrids between 18 and 49 base pairs in length, T_(m)(° C.)81.5 + 16.6(log₁₀[Na⁺]) + 0.41(% G + C) − (600/N), where N is the numberof bases in the hybrid, and [Na⁺] is the concentration of sodium ions inthe hybridization buffer ([Na⁺] for 1 × SSC = 0.165M).

[3840] Additional examples of stringency conditions for polynucleotidehybridization are provided in Sambrook, J., E. F. Fritsch, and T.Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Cold SpringHarbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 9 and 11,and Current Protocols in Molecular Biology, 1995, F.M. Ausubel et al.,eds., John Wiley & Sons, Inc., sections 2.10 and 6.3_(—)6.4,incorporated herein by reference.

[3841] Preferably, each such hybridizing polynucleotide has a lengththat is at least 25%(more preferably at least 50%, and most preferablyat least 75%) of the length of the polynucleotide of the presentinvention to which it hybridizes, and has at least 60% sequence identity(more preferably, at least 75% identity; most preferably at least 90% or95% identity) with the polynucleotide of the present invention to whichit hybridizes, where sequence identity is determined by comparing thesequences of the hybridizing polynucleotides when aligned so as tomaximize overlap and identity while minimizing sequence gaps.

[3842] The isolated polynucleotide of the invention may be operablylinked to an expression control sequence such as the pMT2 or pEDexpression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19,4485-4490 (1991), in order to produce the protein recombinantly. Manysuitable expression control sequences are known in the art. Generalmethods of expressing recombinant proteins are also known and areexemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). Asdefined herein “operably linked” means that the isolated polynucleotideof the invention and an expression control sequence are situated withina vector or cell in such a way that the protein is expressed by a hostcell which has been transformed (transfected) with the ligatedpolynucleotide/expression control sequence.

[3843] A number of types of cells may act as suitable host cells forexpression of the protein. Mammalian host cells include, for example,monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1cells, other transformed primate cell lines, normal diploid cells, cellstrains derived from in vitro culture of primary tissue, primaryexplants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkatcells.

[3844] Alternatively, it may be possible to produce the protein in lowereukaryotes such as yeast or in prokaryotes such as bacteria. Potentiallysuitable yeast strains include Saccharomyces cerevisiae,Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeaststrain capable of expressing heterologous proteins. Potentially suitablebacterial strains include Escherichia coli, Bacillus subtilis,Salmonella typhimurium, or any bacterial strain capable of expressingheterologous proteins. If the protein is made in yeast or bacteria, itmay be necessary to modify the protein produced therein, for example byphosphorylation or glycosylation of the appropriate sites, in order toobtain the functional protein. Such covalent attachments may beaccomplished using known chemical or enzymatic methods.

[3845] The protein may also be produced by operably linking the isolatedpolynucleotide of the invention to suitable control sequences in one ormore insect expression vectors, and employing an insect expressionsystem. Materials and methods for baculovirus/insect cell expressionsystems are commercially available in kit form from, e.g., Invitrogen,San Diego, Calif., U.S.A. (the MaxBac® kit), and such methods are wellknown in the art, as described in Summers and Smith, Texas AgriculturalExperiment Station Bulletin No. 1555 (1987), incorporated herein byreference. As used herein, an insect cell capable of expressing apolynucleotide of the present invention is “transformed.”

[3846] The protein of the invention may be prepared by culturingtransformed host cells under culture conditions suitable to express therecombinant protein. The resulting expressed protein may then bepurified from such culture (i.e., from culture medium or cell extracts)using known purification processes, such as gel filtration and ionexchange chromatography. The purification of the protein may alsoinclude an affinity column containing agents which will bind to theprotein; one or more column steps over such affinity resins asconcanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GASepharose®; one or more steps involving hydrophobic interactionchromatography using such resins as phenyl ether, butyl ether, or propylether; or immunoaffinity chromatography.

[3847] Alternatively, the protein of the invention may also be expressedin a form which will facilitate purification. For example, it may beexpressed as a fusion protein, such as those of maltose binding protein(MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits forexpression and purification of such fusion proteins are commerciallyavailable from New England BioLabs (Beverly, Mass.), Pharmacia(Piscataway, N.J.) and Invitrogen Corporation (Carlsbad, Calif.),respectively. The protein can also be tagged with an epitope andsubsequently purified by using a specific antibody directed to suchepitope. One such epitope (“Flag”) is commercially available from theEastman Kodak Company (New Haven, Conn.).

[3848] Finally, one or more reverse-phase high performance liquidchromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media,e.g., silica gel having pendant methyl or other aliphatic groups, can beemployed to further purify the protein. Some or all of the foregoingpurification steps, in various combinations, can also be employed toprovide a substantially homogeneous isolated recombinant protein. Theprotein thus purified is substantially free of other mammalian proteinsand is defined in accordance with the present invention as an “isolatedprotein.”

[3849] The protein of the invention may also be expressed as a productof transgenic animals, e.g., as a component of the milk of transgeniccows, goats, pigs, or sheep which are characterized by somatic or germcells containing a nucleotide sequence encoding the protein.

[3850] The protein may also be produced by known conventional chemicalsynthesis. Methods for constructing the proteins of the presentinvention by synthetic means are known to those skilled in the art. Thesynthetically-constructed protein sequences, by virtue of sharingprimary, secondary or tertiary structural and/or conformationalcharacteristics with proteins may possess biological properties incommon therewith, including protein activity. Thus, they may be employedas biologically active or immunological substitutes for natural,purified proteins in screening of therapeutic compounds and inimmunological processes for the development of antibodies.

[3851] The proteins provided herein also include proteins characterizedby amino acid sequences similar to those of purified proteins but intowhich modification are naturally provided or deliberately engineered.For example, modifications in the peptide or DNA sequences can be madeby those skilled in the art using known techniques. Modifications ofinterest in the protein sequences may include the alteration,substitution, replacement, insertion or deletion of a selected aminoacid residue in the coding sequence. For example, one or more of thecysteine residues may be deleted or replaced with another amino acid toalter the conformation of the molecule. Techniques for such alteration,substitution, replacement, insertion or deletion are well known to thoseskilled in the art (see, e.g., U.S. Pat. No. 4,518,584). Preferably,such alteration, substitution, replacement, insertion or deletionretains the desired activity of the protein.

[3852] Other fragments and derivatives of the sequences of proteinswhich would be expected to retain protein activity in whole or in partand may thus be useful for screening or other immunologicalmethodologies may also be easily made by those skilled in the art giventhe disclosures herein. Such modifications are believed to beencompassed by the present invention.

[3853] Uses and Biological Activity

[3854] The polynucleotides and proteins of the present invention areexpected to exhibit one or more of the uses or biological activities(including those associated with assays cited herein) identified below.Uses or activities described for proteins of the present invention maybe provided by administration or use of such proteins or byadministration or use of polynucleotides encoding such proteins (suchas, for example, in gene therapies or vectors suitable for introductionof DNA).

[3855] Research Uses and Utilities

[3856] The polynucleotides provided by the present invention can be usedby the research community for various purposes. The polynucleotides canbe used to express recombinant protein for analysis, characterization ortherapeutic use; as markers for tissues in which the correspondingprotein is preferentially expressed (either constitutively or at aparticular stage of tissue differentiation or development or in diseasestates); as molecular weight markers on Southern gels; as chromosomemarkers or tags (when labeled) to identify chromosomes or to map relatedgene positions; to compare with endogenous DNA sequences in patients toidentify potential genetic disorders; as probes to hybridize and thusdiscover novel, related DNA sequences; as a source of information toderive PCR primers for genetic fingerprinting; as a probe to“subtract-out” known sequences in the process of discovering other novelpolynucleotides; for selecting and making oligomers for attachment to a“gene chip” or other support, including for examination of expressionpatterns; to raise anti-protein antibodies using DNA immunizationtechniques; and as an antigen to raise anti-DNA antibodies or elicitanother immune response. Where the polynucleotide encodes a proteinwhichbinds or potentially binds to another protein (such as, forexample, in a receptor-ligand interaction), the polynucleotide can alsobe used in interaction trap assays (such as, for example, thosedescribed in Gyuris et al., 1993, Cell 75: 791_(—)803 and in Rossi etal., 1997, Proc. Natl. Acad. Sci. USA 94: 8405_(—)8410, all of which areincorporated by reference herein) to identify polynucleotides encodingthe other protein with which binding occurs or to identify inhibitors ofthe binding interaction.

[3857] The proteins provided by the present invention can similarly beused in assay to determine biological activity, including in a panel ofmultiple proteins for high-throughput screening; to raise antibodies orto elicit another immune response; as a reagent (including the labeledreagent) in assays designed to quantitatively determine levels of theprotein (or its receptor) in biological fluids; as markers for tissuesin which the corresponding protein is preferentially expressed (eitherconstitutively or at a particular stage of tissue differentiation ordevelopment or in a disease state); and, of course, to isolatecorrelative receptors or ligands. Where the protein binds or potentiallybinds to another protein (such as, for example, in a receptor-ligandinteraction), the protein can be used to identify the other protein withwhich binding occurs or to identify inhibitors of the bindinginteraction. Proteins involved in these binding interactions can also beused to screen for peptide or small molecule inhibitors or agonists ofthe binding interaction.

[3858] Any or all of these research utilities are capable of beingdeveloped into reagent grade or kit format for commercialization asresearch products.

[3859] Methods for performing the uses listed above are well known tothose skilled in the art. References disclosing such methods includewithout limitation “Molecular Cloning: A Laboratory Manual”, 2d ed.,Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T.Maniatis eds., 1989, and “Methods in Enzymology: Guide to MolecularCloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmeleds., 1987.

[3860] Nutritional Uses

[3861] Polynucleotides and proteins of the present invention can also beused as nutritional sources or supplements. Such uses include withoutlimitation use as a protein or amino acid supplement, use as a carbonsource, use as a nitrogen source and use as a source of carbohydrate. Insuch cases the protein or polynucleotide of the invention can be addedto the feed of a particular organism or can be administered as aseparate solid or liquid preparation, such as in the form of powder,pills, solutions, suspensions or capsules. In the case ofmicroorganisms, the protein or polynucleotide of the invention can beadded to the medium in or on which the microorganism is cultured.

[3862] Cytokine and Cell Proliferation/Differentiation Activity

[3863] A protein of the present invention may exhibit cytokine, cellproliferation (either inducing or inhibiting) or cell differentiation(either inducing or inhibiting) activity or may induce production ofother cytokines in certain cell populations. Many protein factorsdiscovered to date, including all known cytokines, have exhibitedactivity in one or more factor-dependent cell proliferation assays, andhence the assays serve as a convenient confirmation of cytokineactivity. The activity of a protein of the present invention isevidenced by any one of a number of routine factor dependent cellproliferation assays for cell lines including, without limitation, 32D,DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1, 123,T1165, HT2, CTLL2, TF-1, Mo7e and CMK. The activity of a protein of theinvention may, among other means, be measured by the following methods:Assays for T-cell or thymocyte proliferation include without limitationthose described in: Current Protocols in Immunology, Ed by J. E.Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober,Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, InVitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7,Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500,1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolliet al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J.Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761,1994.

[3864] Assays for cytokine production and/or proliferation of spleencells, lymph node cells or thymocytes include, without limitation, thosedescribed in: Polyclonal T cell stimulation, Kruisbeek, A. M. andShevach, E. M. In Current Protocols in Immunology. J. E. e.a. Coliganeds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; andMeasurement of mouse and human Interferon γ, Schreiber, R. D. In CurrentProtocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8,John Wiley and Sons, Toronto. 1994.

[3865] Assays for proliferation and differentiation of hematopoietic andlymphopoietic cells include, without limitation, those described in:Measurement of Human and Murine Interleukin 2 and Interleukin 4,Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols inImmunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wileyand Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211,1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc.Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse andhuman interleukin 6- Nordan, R. In Current Protocols in Immunology. J.E. e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons,Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861,1986; Measurement of human Interleukin 11- Bennett, F., Giannotti, J.,Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991;Measurement of mouse and human Interleukin 9- Ciarletta, A., Giannotti,J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology.J. E. e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto.1991. Assays for T-cell clone responses to antigens (which willidentify, among others, proteins that affect APC-T cell interactions aswell as direct T-cell effects by measuring proliferation and cytokineproduction) include, without limitation, those described in: CurrentProtocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H.Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associatesand Wiley-Interscience (Chapter 3, In Vitro assays for Mouse LymphocyteFunction; Chapter 6, Cytokines and their cellular receptors; Chapter 7,Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad.Sci. USA 77:6091-6095,1980; Weinberger et al., Eur. J. Immun.11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takaiet al., J. Immunol. 140:508-512, 1988.

[3866] Immune Stimulating or Suppressing Activitv

[3867] A protein of the present invention may also exhibit immunestimulating or immune suppressing activity, including without limitationthe activities for which assays are described herein. A protein may beuseful in the treatment of various immune deficiencies and disorders(including severe combined immnunodeficiency (SCID)), e.g., inregulating (up or down) growth and proliferation of T and/or Blymphocytes, as well as effecting the cytolytic activity of NK cells andother cell populations. These immune deficiencies may be genetic or becaused by viral (e.g., HIV) as well as bacterial or fungal infections,or may result from autoimmune disorders. More specifically, infectiousdiseases causes by viral, bacterial, fungal or other infection may betreatable using a protein of the present invention, including infectionsby HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp.,malaria spp. and various fungal infections such as candidiasis. Ofcourse, in this regard, a protein of the present invention may also beuseful where a boost to the immune system generally may be desirable,i.e., in the treatment of cancer. Autoimmune disorders which may betreated using a protein of the present invention include, for example,connective tissue disease, multiple sclerosis, systemic lupuserythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation,Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependentdiabetes mellitis, myasthenia gravis, graft-versus-host disease andautoimmune inflammatory eye disease.

[3868] Such a protein of the present invention may also to be useful inthe treatment of allergic reactions and conditions, such as asthma(particularly allergic asthma) or other respiratory problems. Otherconditions, in which immune suppression is desired (including, forexample, organ transplantation), may also be treatable using a proteinof the present invention.

[3869] Using the proteins of the invention it may also be possible toregulate immune responses in a number of ways. Down regulation may be inthe form of inhibiting or blocking an immune response already inprogress or may involve preventing the induction of an immune response.The functions of activated T cells may be inhibited by suppressing Tcell responses or by inducing specific tolerance in T cells, or both.Immunosuppression of T cell responses is generally an active,non-antigen-specific, process which requires continuous exposure of theT cells to the suppressive agent. Tolerance, which involves inducingnon-responsiveness or anergy in T cells, is distinguishable fromimmunosuppression in that it is generally antigen-specific and persistsafter exposure to the tolerizing agent has ceased. Operationally,tolerance can be demonstrated by the lack of a T cell response uponreexposure to specific antigen in the absence of the tolerizing agent.

[3870] Down regulating or preventing one or more antigen functions(including without limitation B lymphocyte antigen functions (such as,for example, B7)), e.g., preventing high level lymphokine synthesis byactivated T cells, will be useful in situations of tissue, skin andorgan transplantation and in graft-versus-host disease (GVHD). Forexample, blockage of T cell function should result in reduced tissuedestruction in tissue transplantation. Typically, in tissue transplants,rejection of the transplant is initiated through its recognition asforeign by T cells, followed by an immune reaction that destroys thetransplant. The administration of a molecule which inhibits or blocksinteraction of a B7 lymphocyte antigen with its natural ligand(s) onimmune cells (such as a soluble, monomeric form of a peptide having B7-2activity alone or in conjunction with a monomeric form of a peptidehaving an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) orblocking antibody), prior to transplantation can lead to the binding ofthe molecule to the natural ligand(s) on the immune cells withouttransmitting the corresponding costimulatory signal. Blocking Blymphocyte antigen function in this matter prevents cytokine synthesisby immune cells, such as T cells, and thus acts as an immunosuppressant.Moreover, the lack of costirnulation may also be sufficient to anergizethe T cells, thereby inducing tolerance in a subject. Induction oflong-term tolerance by B lymphocyte antigen-blocking reagents may avoidthe necessity of repeated administration of these blocking reagents. Toachieve sufficient immunosuppression or tolerance in a subject, it mayalso be necessary to block the function of a combination of B lymphocyteantigens.

[3871] The efficacy of particular blocking reagents in preventing organtransplant rejection or GVHD can be assessed using animal models thatare predictive of efficacy in humans. Examples of appropriate systemswhich can be used include allogeneic cardiac grafts in rats andxenogeneic pancreatic islet cell grafts in mice, both of which have beenused to examine the immunosuppressive effects of CTLA4Ig fusion proteinsin vivo as described in Lenschow et al., Science 257:789-792 (1992) andTurka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). Inaddition, murine models of GVHD (see Paul ed., Fundamental Immunology,Raven Press, New York, 1989, pp. 846-847) can be used to determine theeffect of blocking B lymphocyte antigen function in vivo on thedevelopment of that disease.

[3872] Blocking antigen function may also be therapeutically useful fortreating autoimmune diseases. Many autoimnuune disorders are the resultof inappropriate activation of T cells that are reactive against selftissue and which promote the production of cytokines and autoantibodiesinvolved in the pathology of the diseases. Preventing the activation ofautoreactive T cells may reduce or eliminate disease symptoms.Administration of reagents which block costimulation of T cells bydisrupting receptor:ligand interactions of B lymphocyte antigens can beused to inhibit T cell activation and prevent production ofautoantibodies or T cell-derived cytokines which may be involved in thedisease process. Additionally, blocking reagents may induceantigen-specific tolerance of autoreactive T cells which could lead tolong-term relief from the disease. The efficacy of blocking reagents inpreventing or alleviating autoimmune disorders can be determined using anumber of well-characterized animal models of human autoimmune diseases.Examples include murine experimental autoimmune encephalitis, systemiclupus erythmatosis in MRL/lpr/Zpr mice or NZB hybrid mice, murineautoimmune collagen arthritis, diabetes mellitus in NOD mice and BBrats, and murine experimental myasthenia gravis (see Paul ed.,Fundamental Immunology, Raven Press, New York, 1989, pp. 840856).

[3873] Upregulation of an antigen function (preferably a B lymphocyteantigen function), as a means of up regulating immune responses, mayalso be useful in therapy. Upregulation of immune responses may be inthe form of enhancing an existing immune response or eliciting aninitial immune response. For example, enhancing an immune responsethrough stimulating B lymphocyte antigen function may be useful in casesof viral infection. In addition, systemic viral diseases such asinfluenza, the common cold, and encephalitis might be alleviated by theadministration of stimulatory forms of B lymphocyte antigenssystemically.

[3874] Alternatively, anti-viral immune responses maybe enhanced in aninfected patient by removing T cells from the patient, costimulating theT cells in vitro with viral antigen-pulsed APCs either expressing apeptide of the present invention or together with a stimulatory form ofa soluble peptide of the present invention and reintroducing the invitro activated T cells into the patient. Another method of enhancinganti-viral immune responses would be to isolate infected cells from apatient, transfect them with a nucleic acid encoding a protein of thepresent invention as described herein such that the cells express all ora portion of the protein on their surface, and reintroduce thetransfected cells into the patient. The infected cells would now becapable of delivering a costimulatory signal to, and thereby activate, Tcells in vivo.

[3875] In another application, up regulation or enhancement of antigenfunction (preferably B lymphocyte antigen function) may be useful in theinduction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma,lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleicacid encoding at least one peptide of the present invention can beadministered to a subject to overcome tumor-specific tolerance in thesubject. If desired, the tumor cell can be transfected to express acombination of peptides. For example, tumor cells obtained from apatient can be transfected ex vivo with an expression vector directingthe expression of a peptide having B7-2-like activity alone, or inconjunction with a peptide having B7-1-like activity and/or B7-3-likeactivity. The transfected tumor cells are returned to the patient toresult in expression of the peptides on the surface of the transfectedcell. Alternatively, gene therapy techniques can be used to target atumor cell for transfection in vivo.

[3876] The presence of the peptide of the present invention having theactivity of a B lymphocyte antigen(s) on the surface of the tumor cellprovides the necessary costimulation signal to T cells to induce a Tcell mediated immune response against the transfected tumor cells. Inaddition, tumor cells which lack MHC class I or MHC class II molecules,or which fail to reexpress sufficient amounts of MHC class I or MHCclass II molecules, can be transfected with nucleic acid encoding all ora portion of (e.g., a cytoplasmic-domain truncated portion) of an MHCclass I α chain protein and β₂ microglobulin protein or an MHC class IIα chain protein and an MHC class II β chain protein to thereby expressMHC class I or MHC class II proteins on the cell surface. Expression ofthe appropriate class I or class II MHC in conjunction with a peptidehaving the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3)induces a T cell mediated immune response against the transfected tumorcell. Optionally, a gene encoding an antisense construct which blocksexpression of an MHC class II associated protein, such as the invariantchain, can also be cotransfected with a DNA encoding a peptide havingthe activity of a B lymphocyte antigen to promote presentation of tumorassociated antigens and induce tumor specific immunity. Thus, theinduction of a T cell mediated immune response in a human subject may besufficient to overcome tumor-specific tolerance in the subject.

[3877] The activity of a protein of the invention may, among othermeans, be measured by the following methods:

[3878] Suitable assays for thymocyte or splenocyte cytotoxicity include,without limitation, those described in: Current Protocols in Immunology,Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, WStrober, Pub. Greene Publishing Associates and Wiley-Interscience(Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19;Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl.Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol.128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985;Takai et al., J. Immunol. 137:3494-3500,1986; Takai et al., J. Immunol.140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982;Handa et al., J. Immunol. 135:1564-1572,1985; Takai et al., J. Immunol.137:3494-3500,1986; Bowmanet al., J. Virology 61:1992-1998; Takai etal., J. Immunol. 140:508-512, 1988; Bertagnolli et al., CellularImmunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092,1994.

[3879] Assays for T-cell-dependent immunoglobulin responses and isotypeswitching (which will identify, among others, proteins that modulateT-cell dependent antibody responses and that affect Thl/Th2 profiles)include, without limitation, those described in: Maliszewski, J.Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitroantibody production, Mond, J. J. and Brunswick, M. In Current Protocolsin Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, JohnWiley and Sons, Toronto. 1994.

[3880] Mixed lymphocyte reaction (MLR) assays (which will identify,among others, proteins that generate predominantly Thl and CTLresponses) include, without limitation, those described in: CurrentProtocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H.Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associatesand Wiley-Interscience (Chapter 3, In Vitro assays for Mouse LymphocyteFunction 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai etal., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol.140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.Dendritic cell-dependent assays (which will identify, among others,proteins expressed by dendritic cells that activate naive T-cells)include, without limitation, those described in: Guery et al., J.Immunol. 134:536-544, 1995; Inaba et al., Journal of ExperimentalMedicine 173:549-559, 1991; Macatonia et al., Journal of Immunology154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069,1993;Huang et al., Science 264:961-965,1994; Macatonia et al., Journal ofExperimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal ofClinical Investigation 94:797-807,1994; and Inaba et al., Journal ofExperimental Medicine 172:631-640, 1990.

[3881] Assays for lymphocyte survival/apoptosis (which will identify,among others, proteins that prevent apoptosis after superantigeninduction and proteins that regulate lymphocyte homeostasis) include,without limitation, those described in: Darzynkiewicz et al., Cytometry13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca etal., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243,1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai etal., Cytometry 14:891-897, 1993; Gorczyca et al., International Journalof Oncology 1:639648, 1992.

[3882] Assays for proteins that influence early steps of T-cellcommitment and development include, without limitation, those describedin: Antica et al., Blood 84:111-117, 1994; Fine et al., CellularImmunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995;Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

[3883] Hematopoiesis Regulating Activity

[3884] A protein of the present invention may be useful in regulation ofhematopoiesis and, consequently, in the treatment of myeloid or lymphoidcell deficiencies. Even marginal biological activity in support ofcolony forming cells or of factor-dependent cell lines indicatesinvolvement in regulating hematopoiesis, e.g. in supporting the growthand proliferation of erythroid progenitor cells alone or in combinationwith other cytokines, thereby indicating utility, for example, intreating various anemias or for use in conjunction withirradiation/chemotherapy to stimulate the production of erythroidprecursors and/or erythroid cells; in supporting the growth andproliferation of myeloid cells such as granulocytes andmonocytes/macrophages (i.e., traditional CSF activity) useful, forexample, in conjunction with chemotherapy to prevent or treat consequentmyelo-suppression; in supporting the growth and proliferation ofmegakaryocytes and consequently of platelets thereby allowing preventionor treatment of various platelet disorders such as thrombocytopenia, andgenerally for use in place of or complimentary to platelet transfusions;and/or in supporting the growth and proliferation of hematopoietic stemcells which are capable of maturing to any and all of theabove-mentioned hematopoietic cells and therefore find therapeuticutility in various stem cell disorders (such as those usually treatedwith transplantation, including, without limitation, aplastic anemia andparoxysmal nocturnal hemoglobinuria), as well as in repopulating thestem cell compartment post irradiation/chemotherapy, either in-vivo orex-vivo (i.e., in conjunction with bone marrow transplantation or withperipheral progenitor cell transplantation (homologous or heterologous))as normal cells or genetically manipulated for gene therapy.

[3885] The activity of a protein of the invention may, among othermeans, be measured by the following methods:

[3886] Suitable assays for proliferation and differentiation of varioushematopoietic lines are cited above.

[3887] Assays for embryonic stem cell differentiation (which willidentify, among others, proteins that influence embryonicdifferentiation hematopoiesis) include, without limitation, thosedescribed in: Johansson et al. Cellular Biology 15:141-151, 1995; Kelleret al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan etal., Blood 81:2903-2915, 1993.

[3888] Assays for stem cell survival and differentiation (which willidentify, among others, proteins that regulate lympho-hematopoiesis)include, without limitation, those described in: Methylcellulose colonyforming assays, Freshney, M. G. In Culture ofHematopoietic Cells. R. I.Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY.1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992;Primitive hematopoietic colony forming cells with high proliferativepotential, McNiece, I. K. and Briddell, R. A. In Culture ofHematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 23-39,Wiley-Liss, Inc., New York, NY. 1994; Neben et al., ExperimentalHematology 22:353-359, 1994; Cobblestone area forming cell assay,Ploemacher, R. E. In Culture of Hematopoietic Cells. R. I. Freshney, etal. eds. Vol pp.1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long termbone marrow cultures in the presence of stromal cells, Spooncer, E.,Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R. I.Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y.1994; Long term culture initiating cell assay, Sutherland, H.J. InCulture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp.139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

[3889] Tissue Growth Activity A protein of the present invention alsomay have utility in compositions used for bone, cartilage, tendon,ligament and/or nerve tissue growth or regeneration, as well as forwound healing and tissue repair and replacement, and in the treatment ofburns, incisions and ulcers.

[3890] A protein of the present invention, which induces cartilageand/or bone growth in circumstances where bone is not normally formed,has application in the healing of bone fractures and cartilage damage ordefects in humans and other animals. Such a preparation employing aprotein of the invention may have prophylactic use in closed as well asopen fracture reduction and also in the improved fixation of artificialjoints. De novo bone formation induced by an osteogenic agentcontributes to the repair of congenital, trauma induced, or oncologicresection induced craniofacial defects, and also is useful in cosmeticplastic surgery.

[3891] A protein of this invention may also be used in the treatment ofperiodontal disease, and in other tooth repair processes. Such agentsmay provide an environment to attract bone-forming cells, stimulategrowth of bone-forming cells or induce differentiation of progenitors ofbone-forming cells. A protein of the invention may also be useful in thetreatment of osteoporosis or osteoarthritis, such as through stimulationof bone and/or cartilage repair orbyblocking inflammation or processesof tissue destruction (collagenase activity, osteoclast activity, etc.)mediated by inflammatory processes.

[3892] Another category of tissue regeneration activity that may beattributable to the protein of the present invention is tendon/ligamentformation. A protein of the present invention, which inducestendon/ligament-like tissue or other tissue formation in circumstanceswhere such tissue is not normally formed, has application in the healingof tendon or ligament tears, deformities and other tendon or ligamentdefects in humans and other animals. Such a preparation employing atendon/ligament-like tissue inducing protein may have prophylactic usein preventing damage to tendon or ligament tissue, as well as use in theimproved fixation of tendon or ligament to bone or other tissues, and inrepairing defects to tendon or ligament tissue. De novotendon/ligament-like tissue formation induced by a composition of thepresent invention contributes to the repair of congenital, traumainduced, or other tendon or ligament defects of other origin, and isalso useful in cosmetic plastic surgery for attachment or repair oftendons or ligaments. The compositions of the present invention mayprovide an environment to attract tendon- or ligament-forming cells,stimulate growth of tendon- or ligament-forming cells, inducedifferentiation of progenitors of tendon- or ligament-forming cells, orinduce growth of tendon/ligament cells or progenitors ex vivo for returnin vivo to effect tissue repair. The compositions of the invention mayalso be useful in the treatment of tendinitis, carpal tunnel syndromeand other tendon or ligament defects. The compositions may also includean appropriate matrix and/or sequestering agent as a carrier as is wellknown in the art.

[3893] The protein of the present invention may also be useful forproliferation of neural cells and for regeneration of nerve and braintissue, i.e. for the treatment of central and peripheral nervous systemdiseases and neuropathies, as well as mechanical and traumaticdisorders, which involve degeneration, death or trauma to neural cellsor nerve tissue. More specifically, a protein may be used in thetreatment of diseases of the peripheral nervous system, such asperipheral nerve injuries, peripheral neuropathy and localizedneuropathies, and central nervous system diseases, such as Alzheimer's,Parkinson's disease, Huntington's disease, amyotrophic lateralsclerosis, and Shy-Drager syndrome. Further conditions which may betreated in accordance with the present invention include mechanical andtraumatic disorders, such as spinal cord disorders, head trauma andcerebrovascular diseases such as stroke. Peripheral neuropathiesresulting from chemotherapy or other medical therapies may also betreatable using a protein of the invention.

[3894] Proteins of the invention may also be useful to promote better orfaster closure of non-healing wounds, including without limitationpressure ulcers, ulcers associated with vascular insufficiency, surgicaland traumatic wounds, and the like.

[3895] It is expected that a protein of the present invention may alsoexhibit activity for generation or regeneration of other tissues, suchas organs (including, for example, pancreas, liver, intestine, kidney,skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular(including vascular endothelium) tissue, or for promoting the growth ofcells comprising such tissues. Part of the desired effects may be byinhibition or modulation of fibrotic scarring to allow normal tissue toregenerate. A protein of the invention may also exhibit angiogenicactivity.

[3896] A protein of the present invention may also be useful for gutprotection or regeneration and treatment of lung or liver fibrosis,reperfusion injury in various tissues, and conditions resulting fromsystemic cytokine damage.

[3897] A protein of the present invention may also be useful forpromoting or inhibiting differentiation of tissues described above fromprecursor tissues or cells; or for inhibiting the growth of tissuesdescribed above.

[3898] The activity of a protein of the invention may, among othermeans, be measured by the following methods:

[3899] Assays for tissue generation activity include, withoutlimitation, those described in: International Patent Publication No.WO95/16035 (bone, cartilage, tendon);

[3900] International Patent Publication No. WO95/05846 (nerve,neuronal); International Patent Publication No. WO91/07491 (skin,endothelium).

[3901] Assays for wound healing activity include, without limitation,those described in: Winter, Epidermal Wound Healing, pps. 71-112(Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc.,Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol71:382-84 (1978).

[3902] Activin/Inhibin Activity

[3903] A protein of the present invention may also exhibit activin- orinhibin-related activities. Inhibins are characterized by their abilityto inhibit the release of follicle stimulating hormone (FSH), whileactivins and are characterized by their ability to stimulate the releaseof follicle stimulating hormone (FSH). Thus, a protein of the presentinvention, alone or in heterodimers with a member of the inhibin ccfamily, may be useful as a contraceptive based on the ability ofinhibins to decrease fertility in female mammals and decreasespermatogenesis in male mammals. Administration of sufficient amounts ofother inhibins can induce infertility in these mammals. Alternatively,the protein of the invention, as a homodimer or as a heterodimer withother protein subunits of the inhibin-P group, may be useful as afertility inducing therapeutic, based upon the ability of activinmolecules in stimulating PSH release from cells of the anteriorpituitary. See, for example, U.S. Pat. No. 4,798,885. A protein of theinvention may also be useful for advancement of the onset of fertilityin sexually immature mammals, so as to increase the lifetimereproductive performance of domestic animals such as cows, sheep andpigs. The activity of a protein of the invention may, among other means,be measured by the following methods:

[3904] Assays for activin/inhibin activity include, without limitation,those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling etal., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986;Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad.Sci. USA 83:3091-3095, 1986.

[3905] Chemotactic/Chemokinetic Activitv

[3906] A protein of the present invention may have chemotactic orchemokinetic activity (e.g., act as a chemokine) for mammalian cells,including, for example, monocytes, fibroblasts, neutrophils, T-cells,mast cells, eosinophils, epithelial and/or endothelial cells.Chemotactic and chemokinetic proteins can be used to mobilize or attracta desired cell population to a desired site of action. Chemotactic orchemokinetic proteins provide particular advantages in treatment ofwounds and other trauma to tissues, as well as in treatment of localizedinfections. For example, attraction of lymphocytes, monocytes orneutrophils to tumors or sites of infection may result in improvedimmune responses against the tumor or infecting agent.

[3907] A protein or peptide has chemotactic activity for a particularcell population if it can stimulate, directly or indirectly, thedirected orientation or movement of such cell population. Preferably,the protein or peptide has the ability to directly stimulate directedmovement of cells. Whether a particular protein has chemotactic activityfor a population of cells can be readily determined by employing suchprotein or peptide in any known assay for cell chemotaxis.

[3908] The activity of a protein of the invention may, among othermeans, be measured by the following methods:

[3909] Assays for chemotactic activity (which will identify proteinsthat induce or prevent chemotaxis) consist of assays that measure theability of a protein to induce the migration of cells across a membraneas well as the ability of a protein to induce the adhesion of one cellpopulation to another cell population. Suitable assays for movement andadhesion include, without limitation, those described in: CurrentProtocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H.Margulies, E. M. Shevach, W.Strober, Pub. Greene Publishing Associatesand Wiley-Interscience (Chapter 6.12, Measurement of alpha and betaChemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376,1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol.25: 17441748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnstonet al. J. of Immunol. 153: 1762-1768, 1994.

[3910] Hemostatic and Thrombolvtic Activitv

[3911] A protein of the invention may also exhibit hemostatic orthrombolytic activity. As a result, such a protein is expected to beuseful in treatment of various coagulation disorders (includinghereditary disorders, such as hemophilias) or to enhance coagulation andother hemostatic events in treating wounds resulting from trauma,surgery or other causes. A protein of the invention may also be usefulfor dissolving or inhibiting formation of thromboses and for treatmentand prevention of conditions resulting therefrom (such as, for example,infarction of cardiac and central nervous system vessels (e.g., stroke).

[3912] The activity of a protein of the invention may, among othermeans, be measured by the following methods: Assay for hemostatic andthrombolytic activity include, without limitation, those described in:Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al.,Thrombosis Res. 45:413-419,1987; Humphrey et al., Fibrinolysis 5:71-79(1991); Schaub, Prostaglandins 35:467-474, 1988.

[3913] Receptor/Ligand Activity

[3914] A protein of the present invention may also demonstrate activityas receptors, receptor ligands or inhibitors or agonists ofreceptor/ligand interactions. Examples of such receptors and ligandsinclude, without limitation, cytokine receptors and their ligands,receptor kinases and their ligands, receptor phosphatases and theirligands, receptors involved in cell-cell interactions and their ligands(including without limitation, cellular adhesion molecules (such asselecting, integrins and their ligands) and receptor/ligand pairsinvolved in antigen presentation, antigen recognition and development ofcellular and humoral immune responses). Receptors and ligands are alsouseful for screening of potential peptide or small molecule inhibitorsof the relevant receptor/ligand interaction. A protein of the presentinvention (including, without limitation, fragments of receptors andligands) may themselves be useful as inhibitors of receptor/ligandinteractions.

[3915] The activity of a protein of the invention may, among othermeans, be measured by the following methods:

[3916] Suitable assays for receptor-ligand activity include withoutlimitation those described in:Current Protocols in Inmunology, Ed by J.E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W.Strober,Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28,Measurement of Cellular Adhesion under static conditions7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA84:6864-6868,1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988;Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J.Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

[3917] Anti-Inflammatory Activitv

[3918] Proteins of the present invention may also exhibitanti-inflammatory activity. The anti-inflammatory activity may beachieved by providing a stimulus to cells involved in the inflammatoryresponse, by inhibiting or promoting cell-cell interactions (such as,for example, cell adhesion), by inhibiting or promoting chemotaxis ofcells involved in the inflammatory process, inhibiting or promoting cellextravasation, or by stimulating or suppressing production of otherfactors which more directly inhibit or promote an inflammatory response.Proteins exhibiting such activities can be used to treat inflammatoryconditions including chronic or acute conditions), including withoutlimitation inflammation associated with infection (such as septic shock,sepsis or systemic inflammatory response syndrome (SIRS)),ischemia-reperfusion injury, endotoxin lethality, arthritis,complement-mediated hyperacute rejection, nephritis, cytokine orchemokine-induced lung injury, inflammatory bowel disease, Crohn'sdisease or resulting from over production of cytokines such as TNF orIL-1. Proteins of the invention may also be useful to treat anaphylaxisand hypersensitivity to an antigenic substance or material.

[3919] Cadherin/Tumor Invasion Suppressor Activity

[3920] Cadherins are calcium-dependent adhesion molecules that appear toplay major roles during development, particularly in defining specificcell types. Loss or alteration of normal cadherin expression can lead tochanges in cell adhesion properties linked to tumor growth andmetastasis. Cadherin malfunction is also implicated in other humandiseases, such as pemphigus vulgaris and pemphigus foliaceus(auto-immune blistering skin diseases), Crohn's disease, and somedevelopmental abnormalities.

[3921] The cadherin superfamily includes well over forty members, eachwith a distinct pattern of expression. All members of the superfamilyhave in common conserved extracellular repeats (cadherin domains), butstructural differences are found in other parts of the molecule. Thecadherin domains bind calcium to form their tertiary structure and thuscalcium is required to mediate their adhesion. Only a few amino acids inthe first cadherin domain provide the basis for homophilic adhesion;modification of this recognition site can change the specificity of acadherin so that instead of recognizing only itself, the mutant moleculecan now also bind to a different cadherin. In addition, some cadherinsengage in heterophilic adhesion with other cadherins.

[3922] E-cadherin, one member of the cadherin superfamily, is expressedin epithelial cell types. Pathologically, if E-cadherin expression islost in a tumor, the malignant cells become invasive and the cancermetastasizes. Transfection of cancer cell lines with polynucleotidesexpressing E-cadherin has reversed cancer-associated changes byreturning altered cell shapes to normal, restoring cells' adhesivenessto each other and to their substrate, decreasing the cell growth rate,and drastically reducing anchorage-independent cell growth. Thus,reintroducing E-cadherin expression reverts carcinomas to a lessadvanced stage. It is likely that other cadherins have the same invasionsuppressor role in carcinomas derived from other tissue types.Therefore, proteins of the present invention with cadherin activity, andpolynucleotides of the present invention encoding such proteins, can beused to treat cancer. Introducing such proteins or polynucleotides intocancer cells can reduce or eliminate the cancerous changes observed inthese cells by providing normal cadherin expression.

[3923] Cancer cells have also been shown to express cadherins of adifferent tissue type than their origin, thus allowing these cells toinvade and metastasize in a different tissue in the body. Proteins ofthe present invention with cadherin activity, and polynucleotides of thepresent invention encoding such proteins, can be substituted in thesecells for the inappropriately expressed cadherins, restoring normal celladhesive properties and reducing or eliminating the tendency of thecells to metastasize.

[3924] Additionally, proteins of the present invention with cadherinactivity, and polynucleotides of the present invention encoding suchproteins, can used to generate antibodies recognizing and binding tocadherins. Such antibodies can be used to block the adhesion ofinappropriately expressed tumor-cell cadherins, preventing the cellsfrom forming a tumor elsewhere. Such an anti-cadherin antibody can alsobe used as a marker for the grade, pathological type, and prognosis of acancer, i.e. the more progressed the cancer, the less cadherinexpression there will be, and this decrease in cadherin expression canbe detected by the use of a cadherin-binding antibody.

[3925] Fragments of proteins of the present invention with cadherinactivity, preferably a polypeptide comprising a decapeptide of thecadherin recognition site, and poly-nucleotides of the present inventionencoding such protein fragments, can also be used to block cadherinfunction by binding to cadherins and preventing them from binding inways that produce undesirable effects. Additionally, fragments ofproteins of the present invention with cadherin activity, preferablytruncated soluble cadherin fragments which have been found to be stablein the circulation of cancer patients, and polynucleotides encoding suchprotein fragments, can be used to disturb proper cell-cell adhesion.

[3926] Assays for cadherin adhesive and invasive suppressor activityinclude, without limitation, those described in: Hortsch et al. J BiolChem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552,1995; Ozawa et al. Cell 63: 1033-1038, 1990.

[3927] Tumor Inhibition Activity

[3928] In addition to the activities described above for immunologicaltreatment or prevention of tumors, a protein of the invention mayexhibit other anti-tumor activities. A protein may inhibit tumor growthdirectly or indirectly (such as, for example, via antibody-dependentcell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumorinhibitory activity by acting on tumor tissue or tumor precursor tissue,by inhibiting formation of tissues necessary to support tumor growth(such as, for example, by inhibiting angiogenesis), by causingproduction of other factors, agents or cell types which inhibit tumorgrowth, or by suppressing, eliminating or inhibiting factors, agents orcell types which promote tumor growth.

[3929] Other Activities

[3930] A protein of the invention may also exhibit one or more of thefollowing additional activities or effects: inhibiting the growth,infection or function of, or killing, infectious agents, including,without limitation, bacteria, viruses, fungi and other parasites;effecting (suppressing or enhancing) bodily characteristics, including,without limitation, height, weight, hair color, eye color, skin, fat tolean ratio or other tissue pigmentation, or organ or body part size orshape (such as, for example, breast augmentation or diminution, changein bone form or shape); effecting biorhythms or caricadic cycles orrhythms; effecting the fertility of male or female subjects; effectingthe metabolism, catabolism, anabolism, processing, utilization, storageor elimination of dietary fat, lipid, protein, carbohydrate, vitamins,minerals, cofactors or other nutritional factors or component(s);effecting behavioral characteristics, including, without limitation,appetite, libido, stress, cognition (including cognitive disorders),depression (including depressive disorders) and violent behaviors;providing analgesic effects or other pain reducing effects; promotingdifferentiation and growth of embryonic stem cells in lineages otherthan hematopoietic lineages; hormonal or endocrine activity; in the caseof enzymes, correcting deficiencies of the enzyme and treatingdeficiency-related diseases; treatment of hyperproliferative disorders(such as, for example, psoriasis); immunoglobulin-like activity (suchas, for example, the ability to bind antigens or complement); and theability to act as an antigen in a vaccine composition to raise an immuneresponse against such protein or another material or entity which iscross-reactive with such protein.

[3931] Administration and Dosing

[3932] A protein of the present invention (from whatever source derived,including without limitation from recombinant and non-recombinantsources) may be used in a pharmaceutical composition when combined witha pharmaceutically acceptable carrier. Such a composition may alsocontain (in addition to protein and a carrier) diluents, fillers, salts,buffers, stabilizers, solubilizers, and other materials well known inthe art. The term “pharmaceutically acceptable” means a non-toxicmaterial that does not interfere with the effectiveness of thebiological activity of the active ingredient(s). The characteristics ofthe carrier will depend on the route of administration. Thepharmaceutical composition of the invention may also contain cytokines,lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF,IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,IL-12,IL-13, IL-14, IL-15, IFN, TNFO, TNFi, TNF2, GCSF, Meg-CSF,thrombopoietin, stem cell factor, and erythropoietin. The pharmaceuticalcomposition may further contain other agents which either enhance theactivity of the protein or compliment its activity or use in treatment.Such additional factors and/or agents may be included in thepharmaceutical composition to produce a synergistic effect with proteinof the invention, or to minimize side effects. Conversely, protein ofthe present invention may be included in formulations of the particularcytokine, lymphokine, other hematopoietic factor, thrombolytic oranti-thrombotic factor, or anti-inflammatory agent to minimize sideeffects of the cytokine, lymphokine, other hematopoietic factor,thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

[3933] A protein of the present invention may be active in multimers(e.g., heterodimers or homodimers) or complexes with itself or otherproteins. As a result, pharmaceutical compositions of the invention maycomprise a protein of the invention in such multimeric or complexedform.

[3934] The pharmaceutical composition of the invention may be in theform of a complex of the protein(s) of present invention along withprotein or peptide antigens. The protein and/or peptide antigen willdeliver a stimulatory signal to both B and T lymphocytes. B lymphocyteswill respond to antigen through their surface immunoglobulin receptor. Tlymphocytes will respond to antigen through the T cell receptor (TCR)following presentation of the antigen by MHC proteins. MHC andstructurally related proteins including those encoded by class I andclass II MHC genes on host cells will serve to present the peptideantigen(s) to T lymphocytes. The antigen components could also besupplied as purified MHC-peptide complexes alone or with co-stimulatorymolecules that can directly signal T cells. Alternatively antibodiesable to bind surface immunolgobulin and other molecules on B cells aswell as antibodies able to bind the TCR and other molecules on T cellscan be combined with the pharmaceutical composition of the invention.

[3935] The pharmaceutical composition of the invention may be in theform of a liposome in which protein of the present invention iscombined, in addition to other pharmaceutically acceptable carriers,with amphipathic agents such as lipids which exist in aggregated form asmicelles, insoluble monolayers, liquid crystals, or lamellar layers inaqueous solution. Suitable lipids for liposomal formulation include,without limitation, monoglycerides, diglycerides, sulfatides,lysolecithin, phospholipids, saponin, bile acids, and the like.Preparation of such liposomal formulations is within the level of skillin the art, as disclosed, for example, in U.S. Pat. No. 4,235,871; U.S.Pat. No. 4,501,728; U.S.

[3936] Pat. No. 4,837,028; and U.S. Pat. No. 4,737,323, all of which areincorporated herein by reference.

[3937] As used herein, the term “therapeutically effective amount” meansthe total amount of each active component of the pharmaceuticalcomposition or method that is sufficient to show a meaningful patientbenefit, i.e., treatment, healing, prevention or amelioration of therelevant medical condition, or an increase in rate of treatment,healing, prevention or amelioration of such conditions. When applied toan individual active ingredient, administered alone, the term refers tothat ingredient alone. When applied to a combination, the term refers tocombined amounts of the active ingredients that result in thetherapeutic effect, whether administered in combination, serially orsimultaneously.

[3938] In practicing the method of treatment or use of the presentinvention, a therapeutically effective amount of protein of the presentinvention is administered to a mammal having a condition to be treated.Protein of the present invention may be administered in accordance withthe method of the invention either alone or in combination with othertherapies such as treatments employing cytokines, lymphokines or otherhematopoietic factors. When co-administered with one or more cytokines,lymphokines or other hematopoietic factors, protein of the presentinvention may be administered either simultaneously with thecytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolyticor anti-thrombotic factors, or sequentially. If administeredsequentially, the attending physician will decide on the appropriatesequence of administering protein of the present invention incombination with cytokine(s), lymphokine(s), other hematopoieticfactor(s), thrombolytic or anti-thrombotic factors.

[3939] Administration of protein of the present invention used in thepharmaceutical composition or to practice the method of the presentinvention can be carried out in a variety of conventional ways, such asoral ingestion, inhalation, topical application or cutaneous,subcutaneous, intraperitoneal, parenteral or intravenous injection.Intravenous administration to the patient is preferred.

[3940] When a therapeutically effective amount of protein of the presentinvention is administered orally, protein of the present invention willbe in the form of a tablet, capsule, powder, solution or elixir. Whenadministered in tablet form, the pharmaceutical composition of theinvention may additionally contain a solid carrier such as a gelatin oran adjuvant. The tablet, capsule, and powder contain from about 5 to 95%protein of the present invention, and preferably from about 25 to 90%protein of the present invention. When administered in liquid form, aliquid carrier such as water, petroleum, oils of animal or plant originsuch as peanut oil, mineral oil, soybean oil, or sesame oil, orsynthetic oils may be added. The liquid form of the pharmaceuticalcomposition may further contain physiological saline solution, dextroseor other saccharide solution, or glycols such as ethylene glycol,propylene glycol or polyethylene glycol. When administered in liquidform, the pharmaceutical composition contains from about 0.5 to 90% byweight of protein of the present invention, and preferably from about 1to 50% protein of the present invention.

[3941] When a therapeutically effective amount of protein of the presentinvention is administered by intravenous, cutaneous or subcutaneousinjection, protein of the present invention will be in the form of apyrogen-free, parenterally acceptable aqueous solution. The preparationof such parenterally acceptable protein solutions, having due regard topH, isotonicity, stability, and the like, is within the skill in theart. A preferred pharmaceutical composition for intravenous, cutaneous,or subcutaneous injection should contain, in addition to protein of thepresent invention, an isotonic vehicle such as Sodium ChlorideInjection, Ringer's Injection, Dextrose Injection, Dextrose and SodiumChloride Injection, Lactated Ringer's Injection, or other vehicle asknown in the art. The pharmaceutical composition of the presentinvention may also contain stabilizers, preservatives, buffers,antioxidants, or other additives known to those of skill in the art.

[3942] The amount of protein of the present invention in thepharmaceutical composition of the present invention will depend upon thenature and severity of the condition being treated, and on the nature ofprior treatments which the patient has undergone. Ultimately, theattending physician will decide the amount of protein of the presentinvention with which to treat each individual patient. Initially, theattending physician will administer low doses of protein of the presentinvention and observe the patient's response. Larger doses of protein ofthe present invention may be administered until the optimal therapeuticeffect is obtained for the patient, and at that point the dosage is notincreased further. It is contemplated that the various pharmaceuticalcompositions used to practice the method of the present invention shouldcontain about 0.01 μg to about 100 mg (preferably about 0.1μg to about10 mg, more preferably about 0.1 μg to about 1 mg) of protein of thepresent invention per kg body weight.

[3943] The duration of intravenous therapy using the pharmaceuticalcomposition of the present invention will vary, depending on theseverity of the disease being treated and the condition and potentialidiosyncratic response of each individual patient. It is contemplatedthat the duration of each application of the protein of the presentinvention will be in the range of 12 to 24 hours of continuousintravenous administration. Ultimately the attending physician willdecide on the appropriate duration of intravenous therapy using thepharmaceutical composition of the present invention.

[3944] Protein of the invention may also be used to immunize animals toobtain polyclonal and monoclonal antibodies which specifically reactwith the protein. Such antibodies may be obtained using either theentire protein or fragments thereof as an immunogen. The peptideimnunogens additionally may contain a cysteine residue at the carboxylterminus, and are conjugated to a hapten such as keyhole limpethemocyanin (KLH). Methods for synthesizing such peptides are known inthe art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85,2149-2154 (1963); J. L. Krstenansky, et al., FEBS Lett. 211, 10 (1987).Monoclonal antibodies binding to the protein of the invention may beuseful diagnostic agents for the immunodetection of the protein.Neutralizing monoclonal antibodies binding to the protein may also beuseful therapeutics for both conditions associated with the protein andalso in the treatment of some forms of cancer where abnormal expressionof the protein is involved. In the case of cancerous cells or leukemiccells, neutralizing monoclonal antibodies against the protein may beuseful in detecting and preventing the metastatic spread of thecancerous cells, which may be mediated by the protein.

[3945] For compositions of the present invention which are useful forbone, cartilage, tendon or ligament regeneration, the therapeutic methodincludes administering the composition topically, systematically, orlocally as an implant or device. When administered, the therapeuticcomposition for use in this invention is, of course, in a pyrogen-free,physiologically acceptable form. Further, the composition may desirablybe encapsulated or injected in a viscous form for delivery to the siteof bone, cartilage or tissue damage. Topical administration may besuitable for wound healing and tissue repair. Therapeutically usefulagents other than a protein of the invention which may also optionallybe included in the composition as described above, may alternatively oradditionally, be administered simultaneously or sequentially with thecomposition in the methods of the invention. Preferably for bone and/orcartilage formation, the composition would include a matrix capable ofdelivering the protein-containing composition to the site of bone and/orcartilage damage, providing a structure for the developing bone andcartilage and optimally capable of being resorbed into the body. Suchmatrices may be formed of materials presently in use for other implantedmedical applications.

[3946] The choice of matrix material is based on biocompatibility,biodegradability, mechanical properties, cosmetic appearance andinterface properties. The particular application of the compositionswill define the appropriate formulation. Potential matrices for thecompositions may be biodegradable and chemically defined calciumsulfate, tricalciumphosphate, hydroxyapatite, polylactic acid,polyglycolic acid and polyanhydrides. Other potential materials arebiodegradable and biologically well-defined, such as bone or dermalcollagen. Further matrices are comprised of pure proteins orextracellular matrix components. Other potential matrices arenonbiodegradable and chemically defined, such as sintered hydroxapatite,bioglass, aluminates, or other ceramics. Matrices may be comprised ofcombinations of any of the above mentioned types of material, such aspolylactic acid and hydroxyapatite or collagen and tricalciumphosphate.The bioceramics may be altered in composition, such as incalcium-aluminate-phosphate and processing to alter pore size, particlesize, particle shape, and biodegradability.

[3947] Presently preferred is a 50:50 (mole weight) copolymer of lacticacid and glycolic acid in the form of porous particles having diametersranging from 150 to 800 microns. In some applications, it will be usefulto utilize a sequestering agent, such as carboxymethyl cellulose orautologous blood clot, to prevent the protein compositions fromdisassociating from the matrix.

[3948] A preferred family of sequestering agents is cellulosic materialssuch as alkylcelluloses (including hydroxyalkylcelluloses), includingmethylcellulose, ethylcellulose, hydroxyethylcellulose,hydroxypropylcellulose, hydroxypropyl-methylcellulose, andcarboxymethylcellulose, the most preferred being cationic salts ofcarboxymethylcellulose (CMC). Other preferred sequestering agentsinclude hyaluronic acid, sodium alginate, poly(ethylene glycol),polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). Theamount of sequestering agent useful herein is 0.5-20 wt %, preferably1-10 wt % based on total formulation weight, which represents the amountnecessary to prevent desorbtion of the protein from the polymer matrixand to provide appropriate handling of the composition, yet not so muchthat the progenitor cells are prevented from infiltrating the matrix,thereby providing the protein the opportunity to assist the osteogenicactivity of the progenitor cells.

[3949] In further compositions, proteins of the invention may becombined with other agents beneficial to the treatment of the boneand/or cartilage defect, wound, or tissue in question. These agentsinclude various growth factors such as epidermal growth factor (EGF),platelet derived growth factor (PDGF), transforming growth factors(TGF-α and TGF-β), and insulin-like growth factor aGF).

[3950] The therapeutic compositions are also presently valuable forveterinary applications. Particularly domestic animals and thoroughbredhorses, in addition to humans, are desired patients for such treatmentwith proteins of the present invention.

[3951] The dosage regimen of a protein-containing pharmaceuticalcomposition to be used in tissue regeneration will be determined by theattending physician considering various factors which modify the actionof the proteins, e.g., amount of tissue weight desired to be formed, thesite of damage, the condition of the damaged tissue, the size of awound, type of damaged tissue (e.g., bone), the patient's age, sex, anddiet, the severity of any infection, time of administration and otherclinical factors. The dosage may vary with the type of matrix used inthe reconstitution and with inclusion of other proteins in thepharmaceutical composition. For example, the addition of other knowngrowth factors, such as IGF I (insulin like growth factor I), to thefinal composition, may also effect the dosage. Progress can be monitoredby periodic assessment of tissue/bone growth and/or repair, for example,X-rays, histomorphometric determinations and tetracycline labeling.

[3952] Polynucleotides of the present invention can also be used forgene therapy. Such polynucleotides can be introduced either in vivo orex vivo into cells for expression in a mammalian subject.Polynucleotides of the invention may also be administered by other knownmethods for introduction of nucleic acid into a cell or organism(including, without limitation, in the form of viral vectors or nakedDNA).

[3953] Cells may also be cultured ex vivo in the presence of proteins ofthe present invention in order to proliferate or to produce a desiredeffect on or activity in such cells.

[3954] Treated cells can then be introduced in vivo for therapeuticpurposes.

[3955] Patent and literature references cited herein are incorporated byreference as if fully set forth.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 283 <210> SEQ ID NO 1<211> LENGTH: 3871 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 1 tttccttctc cctccccttt tcccttcctt cgtcccttcc ttccttcctttcgccgggcg 60 cgatggagcc ggggcgccgg ggggccgcgg cgctgctagc gctgctgtgcgtggcctgcg 120 cgctgcgcgc cgggcgcgcc caatacgaac gctacagctt ccgcagcttcccacgggacg 180 agctgatgcc gctcgagtcg gcctaccggc acgcgctgga caagtacagcggcgagcact 240 gggccgagag cstkggctac ctggagatca gcctgcggct gcaccgcttgctgcgcgaca 300 gcgaggcctt ctgccaccgc aactgcagcg ccgcgccgca gcccgagcccgccgccggcc 360 tcgccagcta tcccgagctg cgcctcttcg ggggcctgct gcgccgcgcgcactgcctca 420 agcgctgcaa gcagggcctg ccagccttcc gccagtccca gcccagccgcgaggtgctgg 480 cggacttcca gcgccgcgag ccctacaagt tcctgcagtt cgcttacttcaaggcaaata 540 atctccccaa agccatcgcc gctgctcaca cctttctact gaagcatcctgatgacgaaa 600 tgatgaagag gaacatggca tattataaga gcctgcctgg tgccgaggactacattaaag 660 acctggaaac caagtcatat gaaagcctgt tcatccgagc agtgcgggcatacaacggtg 720 agaactggag aacatccatc acagacatgg agctggccct tcccgacttcttcaaagcct 780 tttacgagtg tctcgcagcc tgcgagggtt ccagggagat caaggacttcaaggatttct 840 acctttccat agcagatcat tatgtagaag ttctggaatg caaaatacagtgtgaagaga 900 acctcacccc agttatagga ggctatccgg ttgagaaatt tgtggctaccatgtatcatt 960 acttgcagtt tgcctattat aagttgaacg acctgaagaa tgcagccccctgtgcagtca 1020 gctatctgct ctttgatcag aatgacaagg tcatgcagca gaacctggtgtattaccagt 1080 accacaggga cacttggggc ctctcggatg agcacttcca gcccagacctgaagcagttc 1140 agttctttaa tgtgaccaca ctccagaagg agctgtatga ctttgctaaggaaaatataa 1200 tggatgatga tgagggagaa gttgtggaat atgtggatga cctcttggaactggaggaga 1260 ccagctagcc cacagcaacc aaagagactt cctcttggcg ttcaggaaacacagattctt 1320 tgtccttttc ccaacagccc aggctgttga tacctcagag ccttctctttactctccaaa 1380 gtgaaaggga agcccccgtc tctctaactg catgtcatca ggggtgagcctgcctttcct 1440 atcttcacac ctgccacctc atgttcacac ctatctttct caccttttttttgagatgga 1500 gtctcgctct cttgcccagg ctggagtgca atggcacgtt ctcagctcactgcaacctcc 1560 gcctcttggg ttcaagcaat tctgctgcat cagcctcccg agtacctgggattacaggca 1620 tgtgccacca cgcccggcta attttgtatt tttagtagag acggggttttgccatgttgg 1680 ccaggctggt ctcgaactct tgacttcaga tgatccatct gccttggcctcccacagtgc 1740 tgggattaca ggcgtgagcc accatgcccg gcctctttct cacctttacacctgtcttct 1800 tatcctcaca tctgttttca caccttcatc cctgtcttcc tcatgttcacacttgtcttc 1860 cccatgttca tagctgcctt tcttaccatt ttggtttgaa gggcagtcttctctggcttg 1920 tttttttgtt tttcccagaa aatcagtatt attttttaaa taagaaaaacattcctagaa 1980 gatgataatt gtgaaaacct cctttggctt atttgctttt ccagattttagtctcctttc 2040 tccccatccg ggaaagatgg tggaagacat aggctaaatt tctccagcctcacaatggtc 2100 ttcacttggt ctgacttgta ccaattctag cacccactga aaaacaagttgagtagagag 2160 tgtagagtgc agaaatgtgg cttttgcccc actttgcatc tccaaaattacaacggttgg 2220 ccgatcccat ttgaggacaa tgcttagtta taagtctccg agttggaaaaggaagaaagc 2280 cagagctgtc tagtttcatt cattctttca gtaaatattt attgagtacctactgtgtgc 2340 taggcattga cctgggaact agagatactt cacagaataa cagggaaagttccctgtgct 2400 catggagctt acattctaca gggagaaaga gatagccaat acataggaataaatatatac 2460 aaggtatcat gtagtgataa ttgctgtgga gaaaaataaa gcaggggagggagtaagaaa 2520 tcctggagat gaggctgcag ttttaaatgg ggcctcactg ggaatgtgacgttgagcaga 2580 gacgttaggg aagtggatcc tggacaaggc attccaggca gaggaacaagatgtgcactg 2640 ccccaaagtg agaacttgct ctacgtggtc aggaaagagc agggagaccaagcagagtcg 2700 tgggcagggg tagaatggaa ggagaggcgg ctggggagga caggtggtggagggccttgg 2760 cttctgctaa gtgagatggg aaccactgga gggtttgaac agaggagtgccttgattgat 2820 ttatattttg caagggtcat tctagctgca atattgtgaa aaactttagtggacaagggc 2880 agaaggaaga gggaagacct gttaggaagc tactgcaagg ttccaggcttgggcctgggc 2940 cacagcaaca gcagtggtca aatatctaga tttattttga aaagagccaataggatttgc 3000 tgagagtttg aatgtggagt gtaagagaag gaagagttaa tgatgacattaaggtttttg 3060 gcctgaatag caggaaagat ggagttacca gttactgaaa tagggaaggatgggctgggt 3120 aagtaaggaa tttggtgcaa agcaggctgt ctgtggttgg aatgggaggttctggctgca 3180 aatcaaagtg gagattctct caggtcaggt ctgcagcaga gctcgagacagggatctgaa 3240 tgcacttggt ttattgttgg gggtgctctc agaaggaacc tgtgaaagcctttatcagtc 3300 atttattggc tgtgagaagt tctctgggag tgtgggtaca tttgaaggcaagtgacttca 3360 gttgagggca agtctctgga aaagaggctg taggcatctg gcagctaccatgcgtggtag 3420 tgtgttgggg gtgggggtcc tgggcactgg ctgtgtgaag ggatctggcagggcaccaca 3480 gcgcccccta ctgaaccatc agcatgtcag tggcatttaa agccatgcagctggaggggc 3540 cactgagatt gtctctgagt attactgaga agcaacagaa aagagccatggatggagccc 3600 ttgggctctc tgggaaatgg gaaatcagcc aaaggactga gaaggagttaccttaaggtc 3660 agagaaaacc aagagagtgt ggtgttctgg aagctgagct ttctttattcaacctcattc 3720 ccttctccaa ataagccact tgtgtagttg ggcccctcca gggttgaaggcaagaggaga 3780 aaggcacagc gtttgggaaa caagactttt cctgcaatag cctgggaaggaataaaagga 3840 tagagtgtta aaataaaaaa aaaaaaaaaa a 3871 <210> SEQ ID NO2 <211> LENGTH: 401 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220>FEATURE: <221> NAME/KEY: UNSURE <222> LOCATION: (64) <400> SEQUENCE: 2Met Glu Pro Gly Arg Arg Gly Ala Ala Ala Leu Leu Ala Leu Leu Cys 1 5 1015 Val Ala Cys Ala Leu Arg Ala Gly Arg Ala Gln Tyr Glu Arg Tyr Ser 20 2530 Phe Arg Ser Phe Pro Arg Asp Glu Leu Met Pro Leu Glu Ser Ala Tyr 35 4045 Arg His Ala Leu Asp Lys Tyr Ser Gly Glu His Trp Ala Glu Ser Xaa 50 5560 Gly Tyr Leu Glu Ile Ser Leu Arg Leu His Arg Leu Leu Arg Asp Ser 65 7075 80 Glu Ala Phe Cys His Arg Asn Cys Ser Ala Ala Pro Gln Pro Glu Pro 8590 95 Ala Ala Gly Leu Ala Ser Tyr Pro Glu Leu Arg Leu Phe Gly Gly Leu100 105 110 Leu Arg Arg Ala His Cys Leu Lys Arg Cys Lys Gln Gly Leu ProAla 115 120 125 Phe Arg Gln Ser Gln Pro Ser Arg Glu Val Leu Ala Asp PheGln Arg 130 135 140 Arg Glu Pro Tyr Lys Phe Leu Gln Phe Ala Tyr Phe LysAla Asn Asn 145 150 155 160 Leu Pro Lys Ala Ile Ala Ala Ala His Thr PheLeu Leu Lys His Pro 165 170 175 Asp Asp Glu Met Met Lys Arg Asn Met AlaTyr Tyr Lys Ser Leu Pro 180 185 190 Gly Ala Glu Asp Tyr Ile Lys Asp LeuGlu Thr Lys Ser Tyr Glu Ser 195 200 205 Leu Phe Ile Arg Ala Val Arg AlaTyr Asn Gly Glu Asn Trp Arg Thr 210 215 220 Ser Ile Thr Asp Met Glu LeuAla Leu Pro Asp Phe Phe Lys Ala Phe 225 230 235 240 Tyr Glu Cys Leu AlaAla Cys Glu Gly Ser Arg Glu Ile Lys Asp Phe 245 250 255 Lys Asp Phe TyrLeu Ser Ile Ala Asp His Tyr Val Glu Val Leu Glu 260 265 270 Cys Lys IleGln Cys Glu Glu Asn Leu Thr Pro Val Ile Gly Gly Tyr 275 280 285 Pro ValGlu Lys Phe Val Ala Thr Met Tyr His Tyr Leu Gln Phe Ala 290 295 300 TyrTyr Lys Leu Asn Asp Leu Lys Asn Ala Ala Pro Cys Ala Val Ser 305 310 315320 Tyr Leu Leu Phe Asp Gln Asn Asp Lys Val Met Gln Gln Asn Leu Val 325330 335 Tyr Tyr Gln Tyr His Arg Asp Thr Trp Gly Leu Ser Asp Glu His Phe340 345 350 Gln Pro Arg Pro Glu Ala Val Gln Phe Phe Asn Val Thr Thr LeuGln 355 360 365 Lys Glu Leu Tyr Asp Phe Ala Lys Glu Asn Ile Met Asp AspAsp Glu 370 375 380 Gly Glu Val Val Glu Tyr Val Asp Asp Leu Leu Glu LeuGlu Glu Thr 385 390 395 400 Ser <210> SEQ ID NO 3 <211> LENGTH: 3637<212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221>NAME/KEY: unsure <222> LOCATION: (1582) <400> SEQUENCE: 3 ttttttttttttttttttta agaagaaggt ccaaatcaat aggtctttta ttgcatcatt 60 taaatatcacaagtaggtct taagtgtcat ctggcatctt ctttctgtag ccaggtaact 120 cttagatcttattcatcagc ctgctgaaca gttccttttt cagagacata gataccatcc 180 aaaaatttcctgatatcctt gtttttaact gttgtggctt gctgaatcaa agccgctgaa 240 tttgaaacaagctcaatgtc atcccgattg agtaccagct ccccactgcc ctgagggcgg 300 gccggcctgcggcggaggga aaaaggaaga ggagaaggaa attgtcccga atccctgcag 360 tctttctgtaggttgcggca caacgccagg caaaagaaga ggaaggaatt taatcctaat 420 cggtggaggtcgatttgagg gtctgctgta gcaggtggct ccgcttgaag cgagggagga 480 agtttcctccgatcagtaga gattggaaag attgttggga gtggcacacc actagggaaa 540 agaagaaggggcgaactgct tgtcttgagg aggtcaaccc ccagaatcag ctcttgtggc 600 cttgaagtggctgaagacga tcaccctcca caggcttgag cccagtccca cagccttcct 660 cccccagcctgagtgactac tctattcctt ggtccctgct attgtcgggg acgattgcat 720 gggctacgccaggaaagtag gctgggtgac cgcaggcctg gtgattgggg ctggcgcctg 780 ctattgcatttatagactga ctaggggaag aaaacagaac aaggaaaaaa tggctgaggg 840 tggatctggggatgtggatg atgctgggga ctgttctggg gccaggtata atgactggtc 900 tgatgatgatgatgacagca atgagagcaa gagtatagta tggtacccac cttgggctcg 960 gattgggactgaagctggaa ccagaactag ggccagggca agggccaggg ctacccgggc 1020 acgtctggctgtccagaaac gggcttcccc caattcagat gataccgttt tgtcccctca 1080 agagctacaaaaggttcttt gcttggttga gatgtctgaa aagccttata ttcttgaagc 1140 agctttaattgctctgggta acaatgctgc ttatgcattt aacagagata ttattcgtga 1200 tctgggtggtctcccaattg tcgcaaagat tctcaatact cgggatccca tagttaagga 1260 aaaggctttaattgtcctga ataacttgag tgtgaatgct gaaaatcagc gcaggcttaa 1320 agtatacatgaatcaagtgt gtgatgacac aatcacttct cgcttgaact catctgtgca 1380 gcttgctggactgagattgc ttacaaatat gactgttact aatgagtatc agcacatgct 1440 tgctaattccatttctgact tttttcgttt attttcagcg ggaaatgaag aaaccaaact 1500 tcaggttctgaaactccttt tgaatttggc tgaaaatcca gccatgacta gggaactgct 1560 cagggcccaagtaccatctt cnctgggctc cctctttaat aagaaggaga acaaagaagt 1620 tattcttaaacttctggtca tatttgagaa cataaatgat aatttcaaat gggaagaaaa 1680 tgaacctactcagaatcaat tcggtgaagg ttcacttttt ttctttttaa aagaatttca 1740 agtgtgtgctgataaggttc tgggaataga aagtcaccat gattttttgg tgaaagtaaa 1800 agttggaaaattcatggcca aacttgctga acatatgttc ccaaagagcc aggaataaca 1860 ccttgattttgtaatttaga agcaacacac attgtaaact attcattttc tccaccttgt 1920 ttatatggtaaaggaatcct ttcagctgcc agttttgaat aatgaatatc atattgtatc 1980 atcaatgctgatatttaact gagttggtct ttaggtttaa gatggataaa tgaatatcac 2040 tacttgttctgaaaacatgt ttgttgcttt ttatctcgct gcctagattg aaatattttg 2100 ctatttcttctgcataagtg acagtgaacc aattcatcat gagtaagctc ccttctgtca 2160 ttttcattgatttaatttgt gtatcatcaa taaaattgta tgttaatgct ggaaagaaaa 2220 aaagaagaaagaaagaaacc atccctgtcc ttcagtttat aatctagttg gagagataag 2280 aaacgtacaaaccaaaagat aacagaatat ctgaagcatg tactcattgt cagatgttcc 2340 ctctgagagcacagaggagg caaaagcttc tgtgggatgt gctagtcggc taaagcttca 2400 cagaggaggtggcaattgaa aatgagtcct gaatggggta gggtggttag ggaattccat 2460 gagacaagacaaggggggca tggtgtgaga aaggcatgga agtaggaacc ctcttcctat 2520 gacaggagatcattctgctt agagtggaga gtgtggagag tgggagtaga taattttgga 2580 aagctgggtgaagccagttg tggagaattg tttgaatatt atcccattga atacccagag 2640 ccactaaatctttttttact agaaaataat tggggtccat atgaaagtct ctattactga 2700 gtagtgtcaatgagggtgtg gcaaaatgga gcctttcaca tcctagtggt ggccatttgg 2760 taatacagatataagcctta aactatgtaa acccttgtcc taaggaagta attgaataat 2820 tgcccaaagattgtatgtat gaggctgttc atcccagcac tgtctaagct agtaaaaatt 2880 ggaaacaatttaagtatcta gcacattgga ttggttataa agcaaggaat gttcacacag 2940 taggatattataagtatgct gatggaaatc tatattgcca ggaaaagcta ttcattatgc 3000 gttgtgaagtcagaaagtaa aaaagggtag atagaagtat tcgaagtata gttccatttt 3060 ttgagactaataaaacatat gtttaaaagg acactaaaaa ctggagttat agatatccag 3120 atagaaacagtagttatctt tgggtagaag aataatgagt gatctttact tttttacttt 3180 ttattcatctttgtgttttt atttatctaa aatgggtatt gatttttagg acggttttga 3240 aaaagaaaagtgttgggaat gaagcaagtg attgattgga aaacatactg aatggaagaa 3300 atatttagattaaaaatgag gtaggttgaa gtttcttctc tgaaatgata gataaatggt 3360 gaagataaggcttattgtga ggattcagtg aggtaatata tgcaaagtac ttacaatgtt 3420 ctggcacatagtaattaatt aagaaaatcg agcaccctta attacctaga atgcagggtt 3480 gttagttttttggttgactt ttgttttgct ggggcattct gccatgtttt agtgtcattt 3540 aataaataatagtaacaata aaggttaaca tttattaagt gaaaaaaaaa aaaaaaaaaa 3600 aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa aaaaaaa 3637 <210> SEQ ID NO 4 <211> LENGTH: 379<212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4 Met GlyTyr Ala Arg Lys Val Gly Trp Val Thr Ala Gly Leu Val Ile 1 5 10 15 GlyAla Gly Ala Cys Tyr Cys Ile Tyr Arg Leu Thr Arg Gly Arg Lys 20 25 30 GlnAsn Lys Glu Lys Met Ala Glu Gly Gly Ser Gly Asp Val Asp Asp 35 40 45 AlaGly Asp Cys Ser Gly Ala Arg Tyr Asn Asp Trp Ser Asp Asp Asp 50 55 60 AspAsp Ser Asn Glu Ser Lys Ser Ile Val Trp Tyr Pro Pro Trp Ala 65 70 75 80Arg Ile Gly Thr Glu Ala Gly Thr Arg Thr Arg Ala Arg Ala Arg Ala 85 90 95Arg Ala Thr Arg Ala Arg Leu Ala Val Gln Lys Arg Ala Ser Pro Asn 100 105110 Ser Asp Asp Thr Val Leu Ser Pro Gln Glu Leu Gln Lys Val Leu Cys 115120 125 Leu Val Glu Met Ser Glu Lys Pro Tyr Ile Leu Glu Ala Ala Leu Ile130 135 140 Ala Leu Gly Asn Asn Ala Ala Tyr Ala Phe Asn Arg Asp Ile IleArg 145 150 155 160 Asp Leu Gly Gly Leu Pro Ile Val Ala Lys Ile Leu AsnThr Arg Asp 165 170 175 Pro Ile Val Lys Glu Lys Ala Leu Ile Val Leu AsnAsn Leu Ser Val 180 185 190 Asn Ala Glu Asn Gln Arg Arg Leu Lys Val TyrMet Asn Gln Val Cys 195 200 205 Asp Asp Thr Ile Thr Ser Arg Leu Asn SerSer Val Gln Leu Ala Gly 210 215 220 Leu Arg Leu Leu Thr Asn Met Thr ValThr Asn Glu Tyr Gln His Met 225 230 235 240 Leu Ala Asn Ser Ile Ser AspPhe Phe Arg Leu Phe Ser Ala Gly Asn 245 250 255 Glu Glu Thr Lys Leu GlnVal Leu Lys Leu Leu Leu Asn Leu Ala Glu 260 265 270 Asn Pro Ala Met ThrArg Glu Leu Leu Arg Ala Gln Val Pro Ser Ser 275 280 285 Leu Gly Ser LeuPhe Asn Lys Lys Glu Asn Lys Glu Val Ile Leu Lys 290 295 300 Leu Leu ValIle Phe Glu Asn Ile Asn Asp Asn Phe Lys Trp Glu Glu 305 310 315 320 AsnGlu Pro Thr Gln Asn Gln Phe Gly Glu Gly Ser Leu Phe Phe Phe 325 330 335Leu Lys Glu Phe Gln Val Cys Ala Asp Lys Val Leu Gly Ile Glu Ser 340 345350 His His Asp Phe Leu Val Lys Val Lys Val Gly Lys Phe Met Ala Lys 355360 365 Leu Ala Glu His Met Phe Pro Lys Ser Gln Glu 370 375 <210> SEQ IDNO 5 <211> LENGTH: 1608 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 5 gtatcctggt gcatagactt aacactgtat tttaactcag gtaatgtatggcctttttgt 60 ttattttttt cctgcatttt tggggggtgt tgaaataagt aaactgggaaggtgcagggg 120 aattcttaaa ttcaatgcaa ggagtttttg ctgagtatct gcagcattcaaggaattaat 180 attagtcact gagaacaaaa agcgaaatta gaaaatttca agtcacttctaggcttgtag 240 gggagaagac gtgtagtgat gaattctatc atttatgaag tacccactggatcccacaca 300 ctgtgcaaga cctttagatc aggcgcctcc ctcggttttc ttcaccctgtgcagcaggtg 360 ctgttatttc cttttttaaa ttattattta ttattattat tttttgagacaggatctccc 420 tttgtcactc aggctggaat gcagaggcat gatcactgct cactgcagcttcgaccaccc 480 aggctcaaag gagtctccca cctcgggtgc tgccacacct ggccaacttttttgtatttt 540 tttggtagag accggggttt caccatgttg cccaggctgg tcttgaacttttggactcca 600 gcgatctgcc tgcctccgcc tccctaagtg ctgggattac agacatgagccattgtgccc 660 gtcctgttgt ttcctgttta gctgaggagg aagggttaga taacttggccagtcggttgt 720 aggaccagca ctagtacagt gttgggcacg tagtaggtgt ttaatacatgaccgatgagc 780 aaatggctcc agatgtctct ggttccatag gcagccttga atagggctttacacacctga 840 tgagaatgac agcctgtgtt gactgagccc tgacttgtgt ccaaccctgccatagtgcca 900 gtgccttgca tgaattcaat aatttgagcc tagcagcaac cttaagaggtaggtactgtt 960 acctccccgt ttataaatga gaagacaggc gcagtgaggc ccaagattgaagagcttgtg 1020 gccaagaaga tggagttgca ggtggtttgg ccatagagct gatgcttgctaaatgtgtta 1080 tatctgtgat ggtcatttta ggttaataaa agctctgttt ttagattgataattctaagg 1140 gtttatcatc aaggtgtatg agaaggtgag ggagcccctg tgtgtagcgcagcaactctg 1200 gccttctgga cagtaggtag gcatgtgatc actgttgtca ctaaacctgggaaatgattc 1260 ctgggtcagg gttcattaat tgccaaatga ttaaagtaat aaagctgacactggaaactt 1320 atctaacttc atttcttttc cttgatttac aaagatagtc aatacattttcctaccaaaa 1380 agaactggcc agccgtggtg gctcatgcct gtaatcctag cagtttaggaagccgaggtg 1440 ggcggatcgc ttgaggtcag gagttcgaga ccagtctggc caacatggttgaaatcctgt 1500 ctctactgaa aatacaaaaa ttatctgggc atagtggtgt gtgcctgtaattgcagcctg 1560 ggcaacggag tgagagactg tctcaggaaa aaaaaaaaaa aaaaaaaa1608 <210> SEQ ID NO 6 <211> LENGTH: 122 <212> TYPE: PRT <213> ORGANISM:Homo sapiens <400> SEQUENCE: 6 Met Asn Ser Ile Ile Tyr Glu Val Pro ThrGly Ser His Thr Leu Cys 1 5 10 15 Lys Thr Phe Arg Ser Gly Ala Ser LeuGly Phe Leu His Pro Val Gln 20 25 30 Gln Val Leu Leu Phe Pro Phe Leu AsnTyr Tyr Leu Leu Leu Leu Phe 35 40 45 Phe Glu Thr Gly Ser Pro Phe Val ThrGln Ala Gly Met Gln Arg His 50 55 60 Asp His Cys Ser Leu Gln Leu Arg ProPro Arg Leu Lys Gly Val Ser 65 70 75 80 His Leu Gly Cys Cys His Thr TrpPro Thr Phe Leu Tyr Phe Phe Gly 85 90 95 Arg Asp Arg Gly Phe Thr Met LeuPro Arg Leu Val Leu Asn Phe Trp 100 105 110 Thr Pro Ala Ile Cys Leu ProPro Pro Pro 115 120 <210> SEQ ID NO 7 <211> LENGTH: 1969 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 7 ggaagttggt ggctgcagctgccgtggttt tctcctggtg tccagcagaa acggcggcgg 60 cgcaaggtgt ggctgggccaacccaggatc tcccaggacc ctccgctctg cgcgacaagg 120 ggcccgcgct tgccaaggccgacgggcagg agtgaacgtg gcctccgtgg gtctgcagcc 180 ccgataggcc aattgtacagaatttaaacc gtctctcaga tgtgtacagt agaactcaag 240 aagacagact accaagggtcatctgaagtc gtgattgggt cactaataac accaggacaa 300 agttaaggga tcactactcaagcataagcc ccagttttca taagactgct gtgaagatgt 360 ttgatataaa ggcttgggctgagtatgttg tggaatgggc tgcaaaggac ccctatggct 420 tccttacaac cgttattttggcccttactc cactgttcct agcaagtgct gtactgtctt 480 ggaaattggc caagatgattgaggccaggg agaaggagca aaagaagaag caaaaacgcc 540 aagaaaacat tgcaaaagctaaacgactaa aaaaggattg aaggactgaa caggctttgc 600 aaccagagga aaatcatttggaaaattaca cagctttgga agaatccact aaagtttctt 660 ctttggattt cttgacagtatgatttagta aatgaaattt gaccaaatgg aagaatcatg 720 ttagttctga cctcaatactatagtaactt ttaggcgtgg gtgtagaagt ttataggttt 780 ctattgacag ttattgtaaattagcattta ctgtggtaca aattctttat aactgactta 840 gtcatttgcc gcttagcagtttatatactg aaatgaaaac atcttgtggg gaaaagtgac 900 tttagattat gaactcaattcaaatgaact ctatttaaaa tggggtccta ttttggacaa 960 aggaaattaa gaatgttaaagtcagaacag tcttgaggta aaaagtgtgc tttggcttaa 1020 aagggataca gtatattaattacatctttt attattattg tttatttctt agaatcattt 1080 ctggctttct caaaacaaaataatattaat gagtacttct atttgctgca tttttcttat 1140 tacagccttt gagacagctggtaattataa gtcattttcc attttttaaa acataatttt 1200 ataaagaatt ctcttatctcgactatgtag aataccacct actggacaga acaatttttg 1260 tactcacaaa cactgccattttcttagaga tggcttgaga ggagtaacac tatggtttaa 1320 agcttgcagt aaaaatgccaaacactgtag taccttggaa cccagtttat tcttgtgcta 1380 agcagaactg taaaatagttaaaatgtctt atcaagtaat tcgccgatta caaagacacc 1440 atttgttttt tatttcattctttgttttaa ctcatgtggt agtgatattt aatactttct 1500 gatcaaacag gttcaaagtaaaacgttaaa tttcacattt cttttaaaga actcttaaag 1560 tgtaacagtt acgccatacttcataagtgg taaagaaagg tataaaattt ggaaacattt 1620 tgttgggcat agtagtgattgggtgaaaag gataaattat atcaaaatga gaatgtgctg 1680 taattggaag tagggagctaaaggatgttt ctttcagttt agtagaactg gaacgtttta 1740 ctattaaaca tggcttttataaatgcatgg tccaataatt ttattcactg ttagtattta 1800 attcactgtc agcttattaatgttttctgt acccattaat gaattttaaa ttacmaaaaa 1860 ttgtctwgca gctacagtttaaaaatgaaa ctagacatta aaataaattt gataattttt 1920 ttttaaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa aaaaaaaaa 1969 <210> SEQ ID NO 8 <211> LENGTH: 74<212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 8 Met PheAsp Ile Lys Ala Trp Ala Glu Tyr Val Val Glu Trp Ala Ala 1 5 10 15 LysAsp Pro Tyr Gly Phe Leu Thr Thr Val Ile Leu Ala Leu Thr Pro 20 25 30 LeuPhe Leu Ala Ser Ala Val Leu Ser Trp Lys Leu Ala Lys Met Ile 35 40 45 GluAla Arg Glu Lys Glu Gln Lys Lys Lys Gln Lys Arg Gln Glu Asn 50 55 60 IleAla Lys Ala Lys Arg Leu Lys Lys Asp 65 70 <210> SEQ ID NO 9 <211>LENGTH: 819 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE:9 tgacttttta tatatatctc agaggcaaac attcctagtg aagggttgtt ttcttcttgc 60accttggagg ggtcttttca tctgctcagg caccttcgca tccccgtgga tcagggctca 120gagcagagga gagtcagcag tctctaaatt atcatcatct cctacctgca catgtacaca 180aaaataagcc tgaatgcttt ttcttagtat gcaatttgct gtctattttt aacttgtaca 240cagagggcca aaaagaaaat tccatgagga catgagagtg cattgaggtt gcaggtatac 300agtcaccaaa gaacctgaaa taattgccgg aatgatatcc tctaaaagat gtgagcctct 360cagagagaga gagagagggt tcctcttgca acaggcatcg tgtgtgtgtt ttatgtccct 420tctcttctgc tgctgtgcac ttaattcggt tccagccgtg tcagggagac tcgagaaaaa 480aatcccacca ttaaagacat gctctttgtt ttttcaatct gtgaccccag caatctcttt 540agcaagccat ggttcagtga actggcacac agcagccgtt cggcagtgga aaaaatcata 600aaacagatgg aagctttaca tttttgttta gtttttaaga gcagttttta taacatcgct 660taagaccatt ctgatgcatc atactgttta cactcaaagc tttgtagcta agatgtttac 720agtatggaga atgttttaag atattttata gttttgatat ttagataatt ggcaaaaaaa 780aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 819 <210> SEQ ID NO 10 <211>LENGTH: 89 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:10 Met Ile Ser Ser Lys Arg Cys Glu Pro Leu Arg Glu Arg Glu Arg Gly 1 510 15 Phe Leu Leu Gln Gln Ala Ser Cys Val Cys Phe Met Ser Leu Leu Phe 2025 30 Cys Cys Cys Ala Leu Asn Ser Val Pro Ala Val Ser Gly Arg Leu Glu 3540 45 Lys Lys Ile Pro Pro Leu Lys Thr Cys Ser Leu Phe Phe Gln Ser Val 5055 60 Thr Pro Ala Ile Ser Leu Ala Ser His Gly Ser Val Asn Trp His Thr 6570 75 80 Ala Ala Val Arg Gln Trp Lys Lys Ser 85 <210> SEQ ID NO 11 <211>LENGTH: 1969 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 11 acactccatc tcccgggagc aaggggaaac tccgagagga gggcaacagagccagcatct 60 tgccagggcc ccggaggagg ggttccccgc tacgcctgtg ccggaggagttccagtcacc 120 gagcgagggg cgcaagggtg ggtgcatcct gcgctgcggc gggcgcgctacccagacgct 180 ggtgtgcaga gccacatgaa gcctgctggg gactgggggc cagggagcagcaagccagct 240 gggactgagg cggacgctgt ctcagggaga cgctgactcg caaagacactcccttccttg 300 tgcctgggta aaaagtctcc tcctggggtc cctggccatc ctgaatatccagaatggtgt 360 ttctgaagtt cttctgcatg agtttcttct gccacctgtg tcaaggctacttcgatggcc 420 ccctctaccc agagatgtcc aatgggactc tgcaccacta cttcgtgcccgatggggact 480 atgaggagaa cgatgacccc gagaagtgcc agctgctctt cagggtgagtgaccacaggc 540 gctgctccca gggggagggg agccaggttg gcagcctgct gagcctcaccctgcgggagg 600 agttcaccgt gctgggccgc caggtggagg atgctgggcg cgtgctggagggcatcagca 660 aaagcatctc ctacgaccta gacggggaag agagctatgg caagtacctgcggcgggagt 720 cccaccagat cggggatgcc tactccaact cggacaaatc cctcactgagctggagagca 780 agttcaagca gggccaggaa caggacagcc ggcaggagag caggctcaacgaggactttc 840 tgggaatgct ggtccacacc aggtccctgc tgaaggagac actggacatctctgtggggc 900 tcagggacaa atacgagctg ctggccctca ccattaggag ccatgggacccgactaggtc 960 ggctgaaaaa tgattatctt aaagtatagg tggaaggata caaatgctagaaagagggaa 1020 tcaaatcagc cccgttttgg agggtggggg acagaagatg gggctacatttcccccatac 1080 ctactatttt tttatatccc gatttgcact ttgagaatac atctaaggtcatctttcaaa 1140 agagaaaaat tggacacttg agtgactttg tttttagttt tgtttttgtacattatttat 1200 gtgattgtta tggaattgtc acctggaaag aacaatttta agcaatgtcatttctagatg 1260 ggtttctaat tctgcagaga cacccgtttc agccacatct aaaagagcacagtttatgtg 1320 gtgcggaatt aaacttcccc atcctgcaga ttatgtggaa atacccaaagataatagtgc 1380 atagctcctt tcagcctcta gccttcactc ctgggctcca aaagctatcccagttgcctg 1440 tttttcaaat gaggttcaag gtgctgcttt gcatgcctgc caacccatggaagttgtttc 1500 ttacttcttt tctctcttat ttattaacca tggtctgaga gttgtttttgttctatgtaa 1560 cagtattgcc acaaaactat aggcaaatcg tgtttgcagg gagatttctgatgcctctgt 1620 gggtgtgtgt aagttaaagt ggccacattt aagaaggcca agctttgtagtggttgcaca 1680 gtcacactga tatgctgatt tgctctttct cattgtatgt ctatgctttgtcatcagtgc 1740 tatagtaaat tacaaagaaa taggtagatt gtatgaacat acccacaaatgcctatgatt 1800 taggttacca atgtattctt tctcatttgg ggttttgctt ctgtctgtctgtttattgga 1860 aacttgtact tcaagtaggg ggaatcctaa ttctaataac tccttagctaagttttatta 1920 ttcaggcaat aaacatgttt tcatgtaaaa aaaaaaaaaa aaaaaaaaa1969 <210> SEQ ID NO 12 <211> LENGTH: 211 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 12 Met Val Phe Leu Lys Phe PheCys Met Ser Phe Phe Cys His Leu Cys 1 5 10 15 Gln Gly Tyr Phe Asp GlyPro Leu Tyr Pro Glu Met Ser Asn Gly Thr 20 25 30 Leu His His Tyr Phe ValPro Asp Gly Asp Tyr Glu Glu Asn Asp Asp 35 40 45 Pro Glu Lys Cys Gln LeuLeu Phe Arg Val Ser Asp His Arg Arg Cys 50 55 60 Ser Gln Gly Glu Gly SerGln Val Gly Ser Leu Leu Ser Leu Thr Leu 65 70 75 80 Arg Glu Glu Phe ThrVal Leu Gly Arg Gln Val Glu Asp Ala Gly Arg 85 90 95 Val Leu Glu Gly IleSer Lys Ser Ile Ser Tyr Asp Leu Asp Gly Glu 100 105 110 Glu Ser Tyr GlyLys Tyr Leu Arg Arg Glu Ser His Gln Ile Gly Asp 115 120 125 Ala Tyr SerAsn Ser Asp Lys Ser Leu Thr Glu Leu Glu Ser Lys Phe 130 135 140 Lys GlnGly Gln Glu Gln Asp Ser Arg Gln Glu Ser Arg Leu Asn Glu 145 150 155 160Asp Phe Leu Gly Met Leu Val His Thr Arg Ser Leu Leu Lys Glu Thr 165 170175 Leu Asp Ile Ser Val Gly Leu Arg Asp Lys Tyr Glu Leu Leu Ala Leu 180185 190 Thr Ile Arg Ser His Gly Thr Arg Leu Gly Arg Leu Lys Asn Asp Tyr195 200 205 Leu Lys Val 210 <210> SEQ ID NO 13 <211> LENGTH: 2020 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 13 ggccggaggggcagtccgcc gcgggggcga gcgcgcatgc gccttcctgg gacccacggc 60 aggcgcgaatcccaacggcc ggcgggcggc ggggatactt ctacatagac ataatcaagt 120 tttgactatttggaaaccaa gcatcattaa aattctctca aactcctaat tgcgaagaat 180 ccataacatttcaagaagtg ataacatttc tctgaacaag aaaagaagtg attgaccacg 240 ttttaaaagtactctggcac tggtgctgtg ttttcttccc ctccctaaat ttgaagaact 300 atggagaaatggtacttgat gacagtagtg gttttaatag gactaacagt acgatggaca 360 gtgtctcttaattcttattc aggtgctggt aaaccgccta tgtttggtga ttatgaagct 420 cagagacactggcaagaaat aacttttaat ttaccggtca aacaatggta ttttaacagc 480 agtgataacaatttacagta ttggggattg gattacccac ctcttacagc ttatcatagt 540 ctcctatgtgcatatgtggc aaagtttata aatccagact ggattgctct ccatacatca 600 cgtggatatgagagtcaggc acataagctc ttcatgcgta caacagtttt aattgctgat 660 ctgctgatttacatacctgc agtggttttg tactgttgtt gcttaaaaga aatctcaact 720 aagaaaaagattgctaatgc attatgcatc ttgctgtatc caggccttat tcttatagac 780 tatggacattttcaatataa ttctgtgagt cttggctttg ctttgtgggg tgttcttgga 840 atatcttgtgactgcgacct cctagggtca ctggcatttt gcttagctat aaattataaa 900 cagatggaactttaccacgc cttgccattt ttttgctttt tacttggcaa gtgttttaaa 960 aaaggcctcaaaggaaaggg gtttgtgtkg ctagttaagc tagctkgtat tgttgtggct 1020 tccttcgttctctgctggct gccattcttt acagaaaggg aacaaaccct gcaggttcta 1080 agaagactcttcccggttga tcgtggatta tttgaggata aagtagccaa tatttggtgc 1140 agcttcaatgtctttctgaa gattaaggat attttgccac gtcacatcca attaataatg 1200 agcttttgttttacgttttt gagcctgctt cctgcatgca taaaattaat acttcagccc 1260 tcttccaaaggattcaaatt tacactggtt agctgtgcgc tatcattctt tttattttct 1320 ttccaagtacatgaaaaatc cattctcttg gtgtcactac cagtctgctt agttttaagt 1380 gaaattccttttatgtctac ttggttttta cttgtgtcaa catttagtat gctacctctt 1440 ctattgaaggatgaactcct aatgccctct gttgtgacaa caatggcatt ttttatagct 1500 tgtgtaacttccttttcaat atttgaaaag acttctgaag aagaactgca gttgaaatcc 1560 ttttccatttctgtgaggaa atatcttcca tgtttwacat ttctttccag aattawacaa 1620 tatttgtttcttatctcagt catcactatg gtgcttctga cgttgatgac tgtcacactg 1680 gatcctcctcagaaactacc ggacttgttt tctgtattgg tgtgtttkgt atcttgcttg 1740 aacttcctgttcttcttggt atactttaac attattatta tgtgggattc caaaagtgga 1800 agaaatcagaagaaaatcag ctagctgtat tcctaaacaa attgtttcct aaacaaatgt 1860 gaaaatgtgaacagtgctga aaggttttgt gaactttttg ctatgtataa atgaaattac 1920 cattttgagaaccatggaac cacaggaaag gaaatggtga aaagtcattg ttgtctacac 1980 maaataaatgtatatggaga ccaaaaaaaa aaaaaaaaaa 2020 <210> SEQ ID NO 14 <211> LENGTH:507 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221>NAME/KEY: UNSURE <222> LOCATION: (230) <221> NAME/KEY: UNSURE <222>LOCATION: (236) <221> NAME/KEY: UNSURE <222> LOCATION: (432) <221>NAME/KEY: UNSURE <222> LOCATION: (439) <221> NAME/KEY: UNSURE <222>LOCATION: (476) <400> SEQUENCE: 14 Met Glu Lys Trp Tyr Leu Met Thr ValVal Val Leu Ile Gly Leu Thr 1 5 10 15 Val Arg Trp Thr Val Ser Leu AsnSer Tyr Ser Gly Ala Gly Lys Pro 20 25 30 Pro Met Phe Gly Asp Tyr Glu AlaGln Arg His Trp Gln Glu Ile Thr 35 40 45 Phe Asn Leu Pro Val Lys Gln TrpTyr Phe Asn Ser Ser Asp Asn Asn 50 55 60 Leu Gln Tyr Trp Gly Leu Asp TyrPro Pro Leu Thr Ala Tyr His Ser 65 70 75 80 Leu Leu Cys Ala Tyr Val AlaLys Phe Ile Asn Pro Asp Trp Ile Ala 85 90 95 Leu His Thr Ser Arg Gly TyrGlu Ser Gln Ala His Lys Leu Phe Met 100 105 110 Arg Thr Thr Val Leu IleAla Asp Leu Leu Ile Tyr Ile Pro Ala Val 115 120 125 Val Leu Tyr Cys CysCys Leu Lys Glu Ile Ser Thr Lys Lys Lys Ile 130 135 140 Ala Asn Ala LeuCys Ile Leu Leu Tyr Pro Gly Leu Ile Leu Ile Asp 145 150 155 160 Tyr GlyHis Phe Gln Tyr Asn Ser Val Ser Leu Gly Phe Ala Leu Trp 165 170 175 GlyVal Leu Gly Ile Ser Cys Asp Cys Asp Leu Leu Gly Ser Leu Ala 180 185 190Phe Cys Leu Ala Ile Asn Tyr Lys Gln Met Glu Leu Tyr His Ala Leu 195 200205 Pro Phe Phe Cys Phe Leu Leu Gly Lys Cys Phe Lys Lys Gly Leu Lys 210215 220 Gly Lys Gly Phe Val Xaa Leu Val Lys Leu Ala Xaa Ile Val Val Ala225 230 235 240 Ser Phe Val Leu Cys Trp Leu Pro Phe Phe Thr Glu Arg GluGln Thr 245 250 255 Leu Gln Val Leu Arg Arg Leu Phe Pro Val Asp Arg GlyLeu Phe Glu 260 265 270 Asp Lys Val Ala Asn Ile Trp Cys Ser Phe Asn ValPhe Leu Lys Ile 275 280 285 Lys Asp Ile Leu Pro Arg His Ile Gln Leu IleMet Ser Phe Cys Phe 290 295 300 Thr Phe Leu Ser Leu Leu Pro Ala Cys IleLys Leu Ile Leu Gln Pro 305 310 315 320 Ser Ser Lys Gly Phe Lys Phe ThrLeu Val Ser Cys Ala Leu Ser Phe 325 330 335 Phe Leu Phe Ser Phe Gln ValHis Glu Lys Ser Ile Leu Leu Val Ser 340 345 350 Leu Pro Val Cys Leu ValLeu Ser Glu Ile Pro Phe Met Ser Thr Trp 355 360 365 Phe Leu Leu Val SerThr Phe Ser Met Leu Pro Leu Leu Leu Lys Asp 370 375 380 Glu Leu Leu MetPro Ser Val Val Thr Thr Met Ala Phe Phe Ile Ala 385 390 395 400 Cys ValThr Ser Phe Ser Ile Phe Glu Lys Thr Ser Glu Glu Glu Leu 405 410 415 GlnLeu Lys Ser Phe Ser Ile Ser Val Arg Lys Tyr Leu Pro Cys Xaa 420 425 430Thr Phe Leu Ser Arg Ile Xaa Gln Tyr Leu Phe Leu Ile Ser Val Ile 435 440445 Thr Met Val Leu Leu Thr Leu Met Thr Val Thr Leu Asp Pro Pro Gln 450455 460 Lys Leu Pro Asp Leu Phe Ser Val Leu Val Cys Xaa Val Ser Cys Leu465 470 475 480 Asn Phe Leu Phe Phe Leu Val Tyr Phe Asn Ile Ile Ile MetTrp Asp 485 490 495 Ser Lys Ser Gly Arg Asn Gln Lys Lys Ile Ser 500 505<210> SEQ ID NO 15 <211> LENGTH: 940 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 15 gtttggaggt gcttgcctta gagcaagggaaacagctctc attcaaagga actagaagcc 60 tctccctcag tggtagggag acagccaggagcggttttct gggaactgtg ggatgtgccc 120 ttgggggccc gagaaaacag aaggaagatgctccagacca gtaactacag cctggtgctc 180 tctctgcagt tcctgctgct gtcctatgacctctttgtca attccttctc agaactgctc 240 caaaagactc ctgtcatcca gcttgtgctcttcatcatcc aggatattgc agtcctcttc 300 aacatcatca tcattttcct catgttcttcaacaccttcg tcttccaggc tggcctggtc 360 aacctcctat tccataagtt caaagggaccatcatcctga cagctgtgta ctttgccctc 420 agcatctccc ttcatgtctg ggtcatgaacttacgctgga aaaactccaa cagcttcata 480 tggacagatg gacttcaaat gctgtttgtattccagagac tagtttggac cgaattctaa 540 tttttcttga ctacaagtct tcaaaataatgttttcattt ttttcttctt ttttccattt 600 ttttccaatt tggagtcact gaaaactaagctgtgctttc ataaagccct gcaaactgaa 660 tctagacaac ttcagaagaa aaataacagcaacctattta catacataag ccactttcat 720 acctgcctac cgatgtatgg acttcagagtaatgtggctt atagcaattt tccaggattg 780 ttcttttgtt tgttgttgtt ctcccttcctccccctattt tgtctttatg ggacatgaca 840 cttcacaacc ttctaaaaat gagttttcctaataactcag gacctactcg tctagaaata 900 aaccatccta gccatgagag ataagataaaaaaaaaaaaa 940 <210> SEQ ID NO 16 <211> LENGTH: 130 <212> TYPE: PRT<213> ORGANISM: Homo sapiens <400> SEQUENCE: 16 Met Leu Gln Thr Ser AsnTyr Ser Leu Val Leu Ser Leu Gln Phe Leu 1 5 10 15 Leu Leu Ser Tyr AspLeu Phe Val Asn Ser Phe Ser Glu Leu Leu Gln 20 25 30 Lys Thr Pro Val IleGln Leu Val Leu Phe Ile Ile Gln Asp Ile Ala 35 40 45 Val Leu Phe Asn IleIle Ile Ile Phe Leu Met Phe Phe Asn Thr Phe 50 55 60 Val Phe Gln Ala GlyLeu Val Asn Leu Leu Phe His Lys Phe Lys Gly 65 70 75 80 Thr Ile Ile LeuThr Ala Val Tyr Phe Ala Leu Ser Ile Ser Leu His 85 90 95 Val Trp Val MetAsn Leu Arg Trp Lys Asn Ser Asn Ser Phe Ile Trp 100 105 110 Thr Asp GlyLeu Gln Met Leu Phe Val Phe Gln Arg Leu Val Trp Thr 115 120 125 Glu Phe130 <210> SEQ ID NO 17 <211> LENGTH: 1348 <212> TYPE: DNA <213>ORGANISM: Homo sapiens <400> SEQUENCE: 17 gctgcttgca ggaattcaacatcatggaaa agaataaagg atgggctctc ctgggaggaa 60 aagatggcca tcttcagggactatttctcc ttgccaacgc attgctggaa agaaatcagc 120 tccttgcaca gaaggtcatgtacttattag tccctcttct taaccgaggg aatgataaac 180 ataaactcac atctgcaggcttttttgtgg agcttctccg gagtccagtg gccaagagac 240 tgcccagcat atactctgttgcccgcttta aagactggct acaagatgga aatcatctct 300 ttagaattct cggcctgaggggactgtaca atcttgttgg acaccaggag atgagagaag 360 acatcaagag cctgttgccatacattgtag acagcttgcg tgaaaccgat gagaagatcg 420 ttctgtcagc catccagatactcctgcaac ttgttagaac aatggatttc actaccctgg 480 ctgccatgat gaggaccctgttctccttat ttggtgatgt gagatctgat gttcatcgtt 540 tctccgtgac tctctttggagccgccataa agtctgtaaa aaacccagat aagaagagta 600 tagagaacca agtcctggacagcttggtcc cactacttct gtattctcag gatgaaaatg 660 atgcagtagc tgaggagagcaggcaagtcc taactatatg tgcccagttc ctgaagtgga 720 agctgcccca agaagtgtactccaaagatc cctggcacat caaacctact gaagcaggaa 780 caatctgcag attctttgaaaaaaagtgca aggggaaaat taacatccta gaacaaacac 840 tgatgtactc caagaacccaaaacttccca tcagaagatc agcagtcttg tttgtaggcc 900 ttttatcgaa gtacatggatcacaatgagc tcaggaggat gggtactgac tggatagagg 960 acgatctgag agacctgctgtgtgaccctg agccctcgct gtgcatcatc gcttcccaga 1020 ctctgttact agtccagatggcgagggccg aaccaaaacc taagcagaga gtgaactggt 1080 tgcagaagct catgggcaggtcctctgcct agaaacacaa ggcaagcaac atcagagaca 1140 gaatcttgct atgttgtgcggcaagctagt cttgaactca tggcctcaag tcatcctcct 1200 gtgtcagcct cccaaagtgctgggattaca agcatgcacc acggcaccca gcagaattcc 1260 agtcttgaga aacaggtcaaggacagcttc aaaagagatt ctaaataaat gttaatgtta 1320 caatgttaaa aaaaaaaaaaaaaaaaaa 1348 <210> SEQ ID NO 18 <211> LENGTH: 362 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 18 Met Glu Lys Asn Lys Gly TrpAla Leu Leu Gly Gly Lys Asp Gly His 1 5 10 15 Leu Gln Gly Leu Phe LeuLeu Ala Asn Ala Leu Leu Glu Arg Asn Gln 20 25 30 Leu Leu Ala Gln Lys ValMet Tyr Leu Leu Val Pro Leu Leu Asn Arg 35 40 45 Gly Asn Asp Lys His LysLeu Thr Ser Ala Gly Phe Phe Val Glu Leu 50 55 60 Leu Arg Ser Pro Val AlaLys Arg Leu Pro Ser Ile Tyr Ser Val Ala 65 70 75 80 Arg Phe Lys Asp TrpLeu Gln Asp Gly Asn His Leu Phe Arg Ile Leu 85 90 95 Gly Leu Arg Gly LeuTyr Asn Leu Val Gly His Gln Glu Met Arg Glu 100 105 110 Asp Ile Lys SerLeu Leu Pro Tyr Ile Val Asp Ser Leu Arg Glu Thr 115 120 125 Asp Glu LysIle Val Leu Ser Ala Ile Gln Ile Leu Leu Gln Leu Val 130 135 140 Arg ThrMet Asp Phe Thr Thr Leu Ala Ala Met Met Arg Thr Leu Phe 145 150 155 160Ser Leu Phe Gly Asp Val Arg Ser Asp Val His Arg Phe Ser Val Thr 165 170175 Leu Phe Gly Ala Ala Ile Lys Ser Val Lys Asn Pro Asp Lys Lys Ser 180185 190 Ile Glu Asn Gln Val Leu Asp Ser Leu Val Pro Leu Leu Leu Tyr Ser195 200 205 Gln Asp Glu Asn Asp Ala Val Ala Glu Glu Ser Arg Gln Val LeuThr 210 215 220 Ile Cys Ala Gln Phe Leu Lys Trp Lys Leu Pro Gln Glu ValTyr Ser 225 230 235 240 Lys Asp Pro Trp His Ile Lys Pro Thr Glu Ala GlyThr Ile Cys Arg 245 250 255 Phe Phe Glu Lys Lys Cys Lys Gly Lys Ile AsnIle Leu Glu Gln Thr 260 265 270 Leu Met Tyr Ser Lys Asn Pro Lys Leu ProIle Arg Arg Ser Ala Val 275 280 285 Leu Phe Val Gly Leu Leu Ser Lys TyrMet Asp His Asn Glu Leu Arg 290 295 300 Arg Met Gly Thr Asp Trp Ile GluAsp Asp Leu Arg Asp Leu Leu Cys 305 310 315 320 Asp Pro Glu Pro Ser LeuCys Ile Ile Ala Ser Gln Thr Leu Leu Leu 325 330 335 Val Gln Met Ala ArgAla Glu Pro Lys Pro Lys Gln Arg Val Asn Trp 340 345 350 Leu Gln Lys LeuMet Gly Arg Ser Ser Ala 355 360 <210> SEQ ID NO 19 <211> LENGTH: 1656<212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 19cttctcccac cctcgctcgc gtagccatgg cggagccgtc ggcggccact cagtcccatt 60ccatctcctc gtcgtccttc ggagccgagc cgtccgcgcc cggcggcggc gggagcccag 120gagcctgccc cgccctgggg acgaagagct gcagctcctc ctgtgcggtg cacgatctga 180ttttctggag agatgtgaag aagactgggt ttgtctttgg caccacgctg atcatgctgc 240tttccctggc agctttcagt gtcatcagtg tggtttctta cctcatcctg gctcttctct 300ctgtcaccat cagcttcagg atctacaagt ccgtcatcca agctgtacag aagtcagaag 360aaggccatcc attcaaagcc tacctggacg tagacattac tctgtcctca gaagctttcc 420ataattacat gaatgctgcc atggtgcaca tcaacagggc cctgaaactc attattcgtc 480tctttctggt agaagatctg gttgactcct tgaagctggc tgtcttcatg tggctgatga 540cctatgttgg tgctgttttt aacggaatca cccttctaat tcttgctgaa ctgctcattt 600tcagtgtccc gattgtctat gagaagtaca agacccagat tgatcactat gttggcatcg 660cccgagatca gaccaagtca attgttgaaa agatccaagc aaaactccct ggaatcgcca 720aaaaaaaggc agaataagta catggaaacc agaaatgcaa cagttactaa aacaccattt 780aatagttata acgtcgttac ttgtactatg aaggaaaata ctcagtgtca gcttgagcct 840gcattccaag cttttttttt taatttggtg ttttctccca tcctttccct ttaaccctca 900gtatcaagca caaaaattga tggactgata aaagaactat cttagaactc agaagaagaa 960agaatcaaat tcataggata agtcaatacc ttaatggtgg tagagccttt acctgtagct 1020tgaaagggga aagattggag gtaagagaga aaatgaaaga acacctctgg gtccttctgt 1080ccagttttca gcactagtct tactcagcta tccattatag ttttgccctt aagaagtcat 1140gattaactta tgaaaaaatt atttggggac aggagtgtga taccttcctt ggtttttttt 1200tgcagccctc aaatcctatc ttcctgcccc acaatgtgag cagctacccc tgatactcct 1260tttctttaat gatttaacta tcaacttgat aaataactta taggtgatag tgataattcc 1320tgattccaag aatgccatct gataaaaaag aatagaaatg gaaagtggga ctgagaggga 1380gtcagcaggc atgctgcggt ggcggtcact ccctctgcca ctatccccag ggaaggaaag 1440gctccgccat ttgggaaagt ggtttctacg tcactggaca ccggttctga gcattagttt 1500gagaactcgt tcccgaatgt gctttcctcc ctctcccctg cccacctcaa gtttaataaa 1560taaggttgta cttttcttac tataaaataa atgtctgtaa ctgcaaaaaa aaaaaaaaaa 1620aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1656 <210> SEQ ID NO 20 <211>LENGTH: 236 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:20 Met Ala Glu Pro Ser Ala Ala Thr Gln Ser His Ser Ile Ser Ser Ser 1 510 15 Ser Phe Gly Ala Glu Pro Ser Ala Pro Gly Gly Gly Gly Ser Pro Gly 2025 30 Ala Cys Pro Ala Leu Gly Thr Lys Ser Cys Ser Ser Ser Cys Ala Val 3540 45 His Asp Leu Ile Phe Trp Arg Asp Val Lys Lys Thr Gly Phe Val Phe 5055 60 Gly Thr Thr Leu Ile Met Leu Leu Ser Leu Ala Ala Phe Ser Val Ile 6570 75 80 Ser Val Val Ser Tyr Leu Ile Leu Ala Leu Leu Ser Val Thr Ile Ser85 90 95 Phe Arg Ile Tyr Lys Ser Val Ile Gln Ala Val Gln Lys Ser Glu Glu100 105 110 Gly His Pro Phe Lys Ala Tyr Leu Asp Val Asp Ile Thr Leu SerSer 115 120 125 Glu Ala Phe His Asn Tyr Met Asn Ala Ala Met Val His IleAsn Arg 130 135 140 Ala Leu Lys Leu Ile Ile Arg Leu Phe Leu Val Glu AspLeu Val Asp 145 150 155 160 Ser Leu Lys Leu Ala Val Phe Met Trp Leu MetThr Tyr Val Gly Ala 165 170 175 Val Phe Asn Gly Ile Thr Leu Leu Ile LeuAla Glu Leu Leu Ile Phe 180 185 190 Ser Val Pro Ile Val Tyr Glu Lys TyrLys Thr Gln Ile Asp His Tyr 195 200 205 Val Gly Ile Ala Arg Asp Gln ThrLys Ser Ile Val Glu Lys Ile Gln 210 215 220 Ala Lys Leu Pro Gly Ile AlaLys Lys Lys Ala Glu 225 230 235 <210> SEQ ID NO 21 <211> LENGTH: 2439<212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 21cgcttttttt ttttttttaa attctctttc aatccattat ccattttata gctacagtgt 60ttttttcctt aacttgcagt tggttacaat gcgtttatta aattcctatt gtcctgactt 120ctgtagcaca tcaattccat gtgatctgat gtttgctcct ctttagcctt ctccattata 180tttccttcct tcgtacattt ttgtttgtcc atcatggttt tgtttttttt ttttttttct 240ttggctgttc catgctctct gccatctcta gacgtttgta caaactattc ccttgagtta 300ttttctctgg ctcttcagct ccttcctccc acctcctccc ctgcaccacc aatccattct 360tttgcttaat ttctctccat ccttcaggtt tcagctttaa gaggtcactt cttttaggag 420acattccctg aatcctctca cctccaccca caaaaaaggc ctctccagat gcccttcttt 480tctgctcaaa cctcatctgc ttcctttatc atatgcttat cgttttggat tgtaattatt 540tatttaattg catgtctttc tgctagtttt tgtgttagca acaacaagga tcatattttt 600cttgttaact aatgtataac actgggtgcc taccagtaag tatttgttga atgactaaat 660gagtgaaatg agttaaatga gtagaaaata tccaggaaag tagctgtttt tttttttttt 720acagtacctt tgctgttgat tccctgcccc actttttttg gtagaagtga taagctaaaa 780tctattttca tgaatcattg tatatgttgt tgtaagttgg gattcatatt cattccagtc 840cattatttat atttttcagg ctggcttatt tattgacaaa ggtgtcaaaa caaccaactc 900tagtgctgct gacccaaggg aatacctctg tttggacaat aatgcaaggt aaagctggct 960cttttaagtc acactcaagc tatactttgc caaagcaaaa ctttctaact ggagtttatt 1020gtgctctttc tgtggtaata catttaaaat aaagttttag aagttcgtaa aagggttttt 1080ggaaaaccac ttattctgtt gtcccaggtc ctgtgactgg tcttttatct tattgaaata 1140ctaaagaggt tgatgttttt ctcctttttc attggctata aatagatgct agagagagtt 1200gcagaaagag aaagaaaaaa gaggagatat gttgagaaag tttccaaatt tggtgtgcag 1260tatgattcat tgaaaaataa gttaaactaa gatgtttagt ctcatccttg aaaaaccaaa 1320ccatatagaa tttattcttt gtggtcaaaa tgaatactgc atttaatatt tcaaaaggaa 1380tgatcccaaa tttgatgagc aacctggttc tggttcagcc ctttgtagcc tcagatttac 1440atcatagcca ggctctaggt tactttcttt tgtaatcaca aaatgcatta ggtatggatc 1500agcatttcag cagagttctc taacatgcta tatatgagcc aaaataaaga aaatgtccca 1560gatgaaaata aacttttctg gaaaagatgg tgacttaaag tcatattcag tagaacctgt 1620gtacatatta ttattttcca tactttcaaa ttgattgacc agtttatgga gttgatagag 1680tgctagattt aataggcttt gttgacagac acttaggaaa agaataccag gcctgattgt 1740tcttcaaaga atcaagtagg aagcacacca taggttggtg agcctgactt cagggtgagg 1800cagattctca caacacttta ataagacatg aggtcagaag aaaactgggg aaagtctagt 1860ttgtcttgag gattcctcaa acatcaagtt gagcctgaaa tatgttgatg caatgatcag 1920atagcatttg agaaacccag aaactgtggg cgttttaaaa aataaaacac aaagaactgg 1980atacctaaaa gctgatcaac aaatgaagtg aaaaaataga agagataaac ttaagaagaa 2040aaaagagtat atagatgaca ataaattatg aactaagagg agaatattag ctggcaaata 2100aagaattcta tctagaaggt tactgctgct tttttagctt tgaagagttt attataattg 2160gtagaactaa tataatttat tataattggt agaaagtaat gtgttctttg cttagcattg 2220ccaaaaaatc cataaacaca attggttctc ttccctgcct taaaaactta tttatgtata 2280tatatttatg tatatttata gtaatgtgta tgtgtatata tgtgaatata tgtgtgtata 2340tatatgaata gagtaaatat atttgagttc attgatgttt taattagact tgacaataaa 2400acaatttact cataaaaaaa aaaaaaaaaa aaaaaaaaa 2439 <210> SEQ ID NO 22 <211>LENGTH: 47 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:22 Met Pro Phe Phe Ser Ala Gln Thr Ser Ser Ala Ser Phe Ile Ile Cys 1 510 15 Leu Ser Phe Trp Ile Val Ile Ile Tyr Leu Ile Ala Cys Leu Ser Ala 2025 30 Ser Phe Cys Val Ser Asn Asn Lys Asp His Ile Phe Leu Val Asn 35 4045 <210> SEQ ID NO 23 <211> LENGTH: 1132 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <220> FEATURE: <221> NAME/KEY: unsure <222> LOCATION:(1009) <400> SEQUENCE: 23 attctagacc tgcggccttg aaaagacagt agtggggaaaaaaagtacca ttttaccatg 60 tgcctcaagt ttgtaatact ggttgcttaa acacccttcccttccacggt gggattttct 120 cttcactttc ccttgggagt ctcaaatgaa taagttacagtttgacagca gcagcagagc 180 ataagatttt atgaatgtga aaccattatg atctttttatttacttagaa aatttaagtg 240 tgtgataatc tttttaatag ttcatttttc tacatctatttctgatttca tgttgcaact 300 atgtcatgca aaaagacagt agatattgta agattgtcttcaacagttga aattcaggct 360 tgccttttta cagtagattt catttatagt ttatacagataaatgagaac taatataaaa 420 tagtaatttt gttatggcat tatggtatat tttaaattcatcaagctcat ctgtatgtgt 480 ctttttgtcc ttttactact gagaggattg gggctgggatcatggcagcc tgctctgatg 540 tatttctctc cactctattt tattattttt ttaaagagttctaacttaaa tacgtggacc 600 agctattgga taactttaat tcatatattt atcattctttctattcactt tgccacatac 660 acaccatgtg atgattttaa acccgatttc tgtatagagaatgttaaaag gatggcgttt 720 ttcagaggtt ccaaataggt agacattgac aatatagttgcacagtatat ggaatacgta 780 tatgtataga catatataca cacatataca tacagatatacatatatatt tctatgtata 840 cacatataca tatatcatat atgtacacat atgcatattgcatatactgt gcaatatata 900 tatacacaca caatttccca gttcgtattt ttcattatgtcatgtacctt attgatagct 960 attattatat ggcttatgca tactgatttg aaataaacaattttacttng aaaaaaaaaa 1020 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa 1080 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa aa 1132 <210> SEQ ID NO 24 <211> LENGTH: 98 <212> TYPE: PRT<213> ORGANISM: Homo sapiens <400> SEQUENCE: 24 Met Val Tyr Phe Lys PheIle Lys Leu Ile Cys Met Cys Leu Phe Val 1 5 10 15 Leu Leu Leu Leu ArgGly Leu Gly Leu Gly Ser Trp Gln Pro Ala Leu 20 25 30 Met Tyr Phe Ser ProLeu Tyr Phe Ile Ile Phe Leu Lys Ser Ser Asn 35 40 45 Leu Asn Thr Trp ThrSer Tyr Trp Ile Thr Leu Ile His Ile Phe Ile 50 55 60 Ile Leu Ser Ile HisPhe Ala Thr Tyr Thr Pro Cys Asp Asp Phe Lys 65 70 75 80 Pro Asp Phe CysIle Glu Asn Val Lys Arg Met Ala Phe Phe Arg Gly 85 90 95 Ser Lys <210>SEQ ID NO 25 <211> LENGTH: 401 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 25 gaatcatagt gattaaaata gttggggtaa agttgtagcttatatgcaat actacttgga 60 ggaattcttc tactaatttg tatttaatgt ggaaattgtatagtttcatt gatttaatca 120 taaataatgg aaatggtctc caagaagttt tatttttcatttttttgctt atacactctg 180 attcctataa tacagtgcta taagctatgc acagaaaataaaatgtttga aatccaagaa 240 taatggttct tactgctaag agggagtaat agttattactaatgattttg attgggttgc 300 atttttgttg caatgtttat tccacttgca gttagaatatgaatatgttt tatcactagt 360 gtggctaaat aaccaaacat ttgtgtaaaa aaaaaaaaaa a401 <210> SEQ ID NO 26 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM:Homo sapiens <400> SEQUENCE: 26 Met Glu Met Val Ser Lys Lys Phe Tyr PheSer Phe Phe Cys Leu Tyr 1 5 10 15 Thr Leu Ile Pro Ile Ile Gln Cys TyrLys Leu Cys Thr Glu Asn Lys 20 25 30 Met Phe Glu Ile Gln Glu 35 <210>SEQ ID NO 27 <211> LENGTH: 755 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 27 aaccgccacc ttctaacatt taaggtagta gacagtatatacagatttga accttgcttt 60 ttcacataat agatagttga ggtcattcca tagcagtacacagaaactca tctttggtct 120 taaaactgca taggtacttt agtcctcttt gacaaatgttgggttgtttc agtcttctgc 180 tatcacaaat aatgctgcaa agaatacatt tgttcatatgtcatttcatc cttggcaatt 240 ttgcctctgg aaagttccta gaagtcagat tcccaggtcaaaggttaaat gcgcatgtaa 300 ttttgctgga tattgttaaa tccccctaca gagcatgcaccactcagcat tcccctcagc 360 gttgtatgag agggaccatt tctccatggc ctcaccagcagatttggtta ttgtagctct 420 gggcttttac caatttcaca ggttaaaaat agtatctaagacaggcgtgg cggctcatgc 480 ctgtaatccc agcactttga gaggccgagg aaggcagatcactggaggtc aggagttcga 540 gatcatccta gccaacatgg tgaaatcctg tctctactaaaaacataaaa attagctggg 600 catggtggca catgcctgta atcccagcta ctcaggaggctgaggaagga gaatatcagg 660 aacctgggag gcaggggttg cagtgagcag agatagcgccactccactcc agcctgggcg 720 acagagtgag actctgtctc aaaaaaaaaa aaaaa 755<210> SEQ ID NO 28 <211> LENGTH: 86 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 28 Met Leu Gly Cys Phe Ser Leu Leu Leu Ser GlnIle Met Leu Gln Arg 1 5 10 15 Ile His Leu Phe Ile Cys His Phe Ile LeuGly Asn Phe Ala Ser Gly 20 25 30 Lys Phe Leu Glu Val Arg Phe Pro Gly GlnArg Leu Asn Ala His Val 35 40 45 Ile Leu Leu Asp Ile Val Lys Ser Pro TyrArg Ala Cys Thr Thr Gln 50 55 60 His Ser Pro Gln Arg Cys Met Arg Gly ThrIle Ser Pro Trp Pro His 65 70 75 80 Gln Gln Ile Trp Leu Leu 85 <210> SEQID NO 29 <211> LENGTH: 885 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 29 cgcccgagtc caagattctt cccaggaaca caaacgtaggagacccacgc tcctggaagc 60 accagccttt atctcttcac cttcaagtcc cctttctcaagaatcctctg ttctttgccc 120 tctaaagtct tggtacatct aggacccagg catcttgctttccagccaca aagagacaga 180 tgaagatgca gaaaggaaat gttctcctta tgtttggtctactattgcat ttagaagctg 240 caacaaattc caatgagact agcacctctg ccaacactggatccagtgtg atctccagtg 300 gagccagcac agccaccaac tctgggtcca gtgtgacctccagtggggtc agcacagcca 360 ccatctcagg gtccagcgtg acctccaatg gggtcagcatagtcaccaac tctgagttcc 420 atacaacctc cagtgggatc agcacagcca ccaactctgagttcagcaca gcgtccagtg 480 ggatcagcat agccaccaac tctgagtcca gcacaacctccagtggggcc agcacagcca 540 ccaactctga gtccagcaca ccctccagtg gggccagcacagccaccaac tctgactcca 600 gcacaacctc cagtggggct agcacagcca ccaactctgactccagcctg ggcaacaaga 660 gtggaactct gtttcaaaaa agaaagaaag aaattcagctcccacttaaa gttcagttgt 720 actctgttat tgacaagtaa agtcgattga agcccagtcatctcctgtat gttgtgtgac 780 ttctcataat tatctgatca agagtcttga agaaacatttacaatttgat gggcaataaa 840 ataatttgaa agcaagaaaa aaaaaaaaaa aaaaaaaaaaaaaaa 885 <210> SEQ ID NO 30 <211> LENGTH: 186 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 30 Met Lys Met Gln Lys Gly AsnVal Leu Leu Met Phe Gly Leu Leu Leu 1 5 10 15 His Leu Glu Ala Ala ThrAsn Ser Asn Glu Thr Ser Thr Ser Ala Asn 20 25 30 Thr Gly Ser Ser Val IleSer Ser Gly Ala Ser Thr Ala Thr Asn Ser 35 40 45 Gly Ser Ser Val Thr SerSer Gly Val Ser Thr Ala Thr Ile Ser Gly 50 55 60 Ser Ser Val Thr Ser AsnGly Val Ser Ile Val Thr Asn Ser Glu Phe 65 70 75 80 His Thr Thr Ser SerGly Ile Ser Thr Ala Thr Asn Ser Glu Phe Ser 85 90 95 Thr Ala Ser Ser GlyIle Ser Ile Ala Thr Asn Ser Glu Ser Ser Thr 100 105 110 Thr Ser Ser GlyAla Ser Thr Ala Thr Asn Ser Glu Ser Ser Thr Pro 115 120 125 Ser Ser GlyAla Ser Thr Ala Thr Asn Ser Asp Ser Ser Thr Thr Ser 130 135 140 Ser GlyAla Ser Thr Ala Thr Asn Ser Asp Ser Ser Leu Gly Asn Lys 145 150 155 160Ser Gly Thr Leu Phe Gln Lys Arg Lys Lys Glu Ile Gln Leu Pro Leu 165 170175 Lys Val Gln Leu Tyr Ser Val Ile Asp Lys 180 185 <210> SEQ ID NO 31<211> LENGTH: 3285 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 31 gcaggtggct aaccccattt agcatctcca ggccctgcca tggtgtctcatcttgctgtt 60 atctctagct ctttccctcc tcccatttcc tttagtagtt gaattttgcaaagcttgtag 120 cagtagctca gttgcctgca gcatccttgt gtgtagataa attagtcgacagaaactcag 180 cactggggac aggattgcaa agtcggggac atagatgcag acagttgttgagatttgggg 240 atagccgggc ttgtgagcgg tgcccatttc cagatgaagc ctttcagcccttctgagtcc 300 ccggcccttg gtgcgatgtc tgtgagtttg acctgcccag cgtgtgggctggctcaatgc 360 tgaataaagt gggtttgtgt cagctcgttt gcttcgtctc cgtgtgtccacctggcctct 420 tccccctgcc ctggccaccc tccagtgtca aaggaaactt cctcgtgacacgtgctaaag 480 catggtgagg aggactttga ttgggaccat tgagatgggt gtgggaccctttccttgggg 540 cctgggggga gatggggctc caccccgacg tagcagggca ggggttggaggagcgaggag 600 cagtataggg tccatgggtg ggaatgactg tgaggagaca tcagggctgagggggctctg 660 gctaaaccca cctcacagag tccttgctgc aggcaggcag ggcgatcagacattggctgc 720 aaacggtcag agaggaaccc agtcaggtac cattgagggt ggtcagatattatggttaac 780 caaattaggg ttcttgctaa aactggattt cataagaaag ggcaaagagggccctaggag 840 aagattccag agcctggcca gagtttggcc aagtagagaa tctttgtcagcacgccaaca 900 acatcccgac cctgagacct ccagtttgtc tttctcactg tctccgcctgctgcagtctg 960 ctgtcatccc tgagcatccc tgcccctgcc ctgcacacct gtgatgcttgcccggacagg 1020 tcctgatggc agagtctccc acaacatcag tgtctccaca tcaccaggtccgacagtggc 1080 ttcaccatcc tcacctaacc tagctgacca gcaacatccc accctgtcaatcacaacctc 1140 tttctattta agaaaattat atatttatgg ggcacagtgt gatgttttgatatctatgta 1200 cattgtggag tgacagatta atgtatccat ctcatgtttt tttttggtggtgagaatatt 1260 tgaaatctac actcagcaat ttcaaataca gtcatccctc tgtgcctaagggggattggt 1320 tccaggaccc cctcatggat accaaaatct gcagatactc aagtaccctgcagtcagccc 1380 tccctctgca catatgtggg acagtcagat acagagggcc aactgcgtacagtacacggt 1440 tatcagctga agtcaccatg ctgtgcaata gaccttgagt ttattcttgtatagcaggga 1500 ctctgtaccc tctgactaga atttccccaa atcctcttgt ctcagcccctgctaaccacc 1560 gttctactct ctaattctat aaatcaacat tttgattcca catataagtgagatcatgtg 1620 atatttgtcc tgttcctggc ttatttcact taatataaat gtcctgtaaattcacccatg 1680 ttgcaaatgg cagggtttcc ttttttatgg ccaaatagta ttccatgatgtgtatacacc 1740 acattttctt aagccattta tccactttat ccctttatca ctttgcttctagaccacgta 1800 ggttgattcc gtatcttgac tgttgtaaaa gtgctcttaa gaaacacaggagtgtgggta 1860 tctcttccat atattcatgt cgtttccttt gggaaaatac ttagcagtaggattgctggg 1920 tcacggtact ctttttaagt ttttgaataa cctccatatg cttctccataatggctataa 1980 taatttacat actcaccaac atttattttc tttgaaatta gtcattctaagaagtgtgag 2040 ataatctcat tgtgatttgg tttacgtttc cctgatgatt aatgatgttgagcatttttt 2100 tatatacctg ttggccattg gtatgtcttc ttttgagaag tgtctcttcaggttctttgc 2160 tcatttttta gtcgtttatt tgctttcctg ctattgagtt tgagttccatgtatattttg 2220 gatattaacc ccctacttaa tgtatggttt gcaaatactc tatcccaatttgtgagttgt 2280 cttcactctg tttatgattt cctttgctgt gcagaagctt tttagctctatgcaatcatg 2340 tatgtttatt tttcttttgt tgcttgtgct tttagggtca tatgcaagaagtgatacaac 2400 cctgaaacct aggccagtgt catggagttt ttcacctgtg ttttcttctactggctttac 2460 agtttcaggc cttacaatta agcccttgtc tattttgaat ggatttttgtgtagggacat 2520 tccctccaca agggcttcct ctggccttgc tgatgctcct ccgtctcccttgtgtcctct 2580 ccactccacc ctcttcatgt ggaagaaccc ttggcatcct cgtgtggcctctctgtccta 2640 tccagccccc catggtgacc tcacacttgc ctctctgacg tgggtctctctcccaaaccc 2700 tcttccaggt ccaaccactg cctccatccc agacttgccc aggggcccaatccctgcagt 2760 cctcagacat ctcagagctg tctctgagtt gttttctcta acagtccacaataggtctgc 2820 aaaggaatcc tgcaggctct tcctgtagcc aaagaccttg acctcatcttacctgctccc 2880 cgccagtccc ccaccgtggc ccactggcac tgtcctcttc tgcccaggagacctggggac 2940 ctcatctcct cccgctgctc caacaatgca ttctcaaccc agcaggtagatgggtttcta 3000 ctttaaaata tgtaggatga accagtctgg tgatccgatg tacaacaggaggaatgtagg 3060 taataaaatt gcactgtttt gggagttcct gctaaatgac tagacttcagctgctcttgc 3120 cacaaaatcc taaaagtggt tgactctggg aggtgatggg aatgttaattgctcccctgt 3180 agtgaccatt ttgctatctg tttgtacttt gtaacatcac gttgcataccttaaatatac 3240 acaatgaaat ttattaaaac aatgaaaata aaaaaaaaaa aaaaa 3285<210> SEQ ID NO 32 <211> LENGTH: 184 <212> TYPE: PRT <213> ORGANISM:Homo sapiens <400> SEQUENCE: 32 Met Ile Ser Phe Ala Val Gln Lys Leu PheSer Ser Met Gln Ser Cys 1 5 10 15 Met Phe Ile Phe Leu Leu Leu Leu ValLeu Leu Gly Ser Tyr Ala Arg 20 25 30 Ser Asp Thr Thr Leu Lys Pro Arg ProVal Ser Trp Ser Phe Ser Pro 35 40 45 Val Phe Ser Ser Thr Gly Phe Thr ValSer Gly Leu Thr Ile Lys Pro 50 55 60 Leu Ser Ile Leu Asn Gly Phe Leu CysArg Asp Ile Pro Ser Thr Arg 65 70 75 80 Ala Ser Ser Gly Leu Ala Asp AlaPro Pro Ser Pro Leu Cys Pro Leu 85 90 95 His Ser Thr Leu Phe Met Trp LysAsn Pro Trp His Pro Arg Val Ala 100 105 110 Ser Leu Ser Tyr Pro Ala ProHis Gly Asp Leu Thr Leu Ala Ser Leu 115 120 125 Thr Trp Val Ser Leu ProAsn Pro Leu Pro Gly Pro Thr Thr Ala Ser 130 135 140 Ile Pro Asp Leu ProArg Gly Pro Ile Pro Ala Val Leu Arg His Leu 145 150 155 160 Arg Ala ValSer Glu Leu Phe Ser Leu Thr Val His Asn Arg Ser Ala 165 170 175 Lys GluSer Cys Arg Leu Phe Leu 180 <210> SEQ ID NO 33 <211> LENGTH: 1819 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 33 aaactatatttcaagacaac caaaagttgg tgaaggaaag ttgttgatta gagaattcca 60 actggttaaaaggtcaaagg aggccaggcg cggtggctca agcctgtaat cccagcactt 120 tgggaggccgaggcaggtgg atcgtgaggt caggagatca agaccatcct ggctaacacg 180 gtgaaaccccatctctacta aaaatacaaa aaattcgccg ggcgtggtgg caggcgcctg 240 tagtcccagctactcaggag gctgaggcag gagaatggct tgaacccggg aggcggagct 300 tgcagtgagccgagatcgcg ccactgcact ccagcctggg tgacagaccg agactctgtc 360 tcaaacaaaaaacaaaaaac aaaacaaaac aaagatcaaa tgaatgatag aatttgaaaa 420 ctacgctctttaattttaca aaatcatgga ttttcgtggt gatagcaatg gatgcgaaga 480 ccattaggtgaaaaatggat aggaagctta taatgcatgg agcagaatga caggacacta 540 atctatattaacatctctaa atgagatcag ccagatgaac ttgatgtgat gaaatggata 600 cacacagtggacacctgtga agttttcttg gctcccccaa aactgagaag tacaagttag 660 tctccaaacctaattaccag tttacaggaa acatggggaa taaaagaaca aattaacaac 720 acaaagaagcaaacaaccaa atgcacaatt tgggaaattc tgcagaagta atggcctagt 780 tttttaaccaatacatgtca aaaaaaaaaa aaaaaaagac aaaaatggaa tcctacactt 840 taaaggagactaagaaacgt atccttcaaa tacagtgtat ggagcatttt aggatccttg 900 tgttaaaatgcgcttgggat ttgttttaat caatcatggt gagacaggca gacatggaaa 960 ttattgtcatgaaggaagaa gtttatacgc agatcccaca aacgggaggc atggcatggc 1020 atgcagggtcacgtaaagaa gcacctgggt gtatcaggag gcagagggtg agagcacagc 1080 atggcccagagcttttattg ggggttttca tgggaaggaa tggacaaggc aggggtaggc 1140 acactggtaagcttaggatt gaatagtttg agtaattttg ttggtctctg ggatctaggg 1200 gggattcgtaattgtctagt tagggcaggg gaatattgaa ttggtgtatg agagtttggt 1260 aaaggagatagttgggagta tgggctctgg attggttggt ttgtatatga aaggcatgct 1320 tgcagtggagtttatcatct atgcattagc ttgccctggg aggggcagcc tatccaggat 1380 caaggccccaagtggccaga gcatcaggaa tacagaaaat aaagaaaaca tagtcaatac 1440 aagatttgaaggaataaaat gtctctacat attgtacaaa tgtaaacatg gattggttac 1500 taaatgatacgaaataattt attgttcata tgttaggcat gactatggca ttatgggtat 1560 atgtgtatgagtccttaagt gttagagatt catactgagg tatttaaggc tgaaatgtta 1620 tgcctgtgatttacttttaa atacttaaaa acaaaaggtg ggagggatag atgaaacaag 1680 attagcaaaatgttggtaaa tgtttaatct ggatcattag gtacacaggg ttcattgtgc 1740 cgttcttactatctttacat atattttaaa ttttccataa taaagttttt taaagtagaa 1800 aatcaaaaaaaaaaaaaaa 1819 <210> SEQ ID NO 34 <211> LENGTH: 75 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 34 Met Gly Ser Gly Leu Val GlyLeu Tyr Met Lys Gly Met Leu Ala Val 1 5 10 15 Glu Phe Ile Ile Tyr AlaLeu Ala Cys Pro Gly Arg Gly Ser Leu Ser 20 25 30 Arg Ile Lys Ala Pro SerGly Gln Ser Ile Arg Asn Thr Glu Asn Lys 35 40 45 Glu Asn Ile Val Asn ThrArg Phe Glu Gly Ile Lys Cys Leu Tyr Ile 50 55 60 Leu Tyr Lys Cys Lys HisGly Leu Val Thr Lys 65 70 75 <210> SEQ ID NO 35 <211> LENGTH: 1269 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 35 gcggaggcggcgcggtggct gatcagagcg cgtagggctt cgccggggcc gggagctggg 60 cgcggtcctgctcagcccag ctcaccgcgc gccggccctc ggcgccctgg ttctgcggat 120 caggagaaaataatgaatgt caaaggaaaa gtaattctgt caatgctggt tgtctcaact 180 gtgatcattgtgttttggga atttatcaac agcacagaag gctctttctt gtggatatat 240 cactcaaaaaacccagaagt tgatgacagc agtgctcaga agggctggtg gtttctgagc 300 tggtttaacaatgggatcca caattatcaa caaggggaag aagacataga caaagaaaaa 360 ggaagagaggagaccaaagg aaggaaaatg acacaacaga gcttcggcta tgggactggt 420 ttaatccaaacttgaaggaa tccgaataac taaactggac tctggttttc tgactcagtc 480 cttctagaagacctggactg agagatcatg cggttaagga gtgtgtaaca ggcggaccac 540 ctgttgggactgcgagattc tcaaggggaa ggactgggtc tcatttctcc catctcagcg 600 cttagcaggatgacctggta tagagcaggg aactgggaaa tgtgggtcag gggatcagac 660 actccagttgggtcttttat ataaattaaa tggcaaaagg ctccataccc ttctccttct 720 ttcctaccctccactttatc tgcaaaatgg gaatgatgat aacacccact tcatagaatg 780 gtcatgaagatcaaatgaga gaataaaagt caagcactta gcctctggtg cacaataagt 840 attaaataagtatacctatt cctccttttc cttttttaaa aataatatta ccaaatgtcc 900 agcttatacacatttacaag acttagctag tgggctatgt tagagctact aaaagatctt 960 tgacaagctaaaactaagat gcaatgaatg aggtgtaacg aacaagagag ttttaagttc 1020 agaaatggttacagaagtat aagacagctg tgtgggtgtt ttttggtttt tggtttctgg 1080 tttacaatctcgtcattcaa caaagatggg agttttatag aactaaaagc accatgtaag 1140 ctactaaaaacaacaacaaa aaaggctcat catttctcag tctgaattga caaaaatgcc 1200 aatgcaaataaaaatgatta ctttttattt taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260 aaaaaaaaa1269 <210> SEQ ID NO 36 <211> LENGTH: 100 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 36 Met Asn Val Lys Gly Lys ValIle Leu Ser Met Leu Val Val Ser Thr 1 5 10 15 Val Ile Ile Val Phe TrpGlu Phe Ile Asn Ser Thr Glu Gly Ser Phe 20 25 30 Leu Trp Ile Tyr His SerLys Asn Pro Glu Val Asp Asp Ser Ser Ala 35 40 45 Gln Lys Gly Trp Trp PheLeu Ser Trp Phe Asn Asn Gly Ile His Asn 50 55 60 Tyr Gln Gln Gly Glu GluAsp Ile Asp Lys Glu Lys Gly Arg Glu Glu 65 70 75 80 Thr Lys Gly Arg LysMet Thr Gln Gln Ser Phe Gly Tyr Gly Thr Gly 85 90 95 Leu Ile Gln Thr 100<210> SEQ ID NO 37 <211> LENGTH: 232 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 37 aaaaaaaaga tacttctcca aagtgttctcatgtggcctc acccaggtct tgtgtattat 60 ttggtaatta atttatggat cttaaaaactgcagtattcc cccattttgt gatgagagtg 120 tggggctggc aggggttggt tggagggaggagagaagaca gaggagcact taaggtgcaa 180 agcagcctat tttttcttca ataaaaattgttaagagaaa aaaaaaaaaa aa 232 <210> SEQ ID NO 38 <211> LENGTH: 57 <212>TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 38 Met Trp ProHis Pro Gly Leu Val Tyr Tyr Leu Val Ile Asn Leu Trp 1 5 10 15 Ile LeuLys Thr Ala Val Phe Pro His Phe Val Met Arg Val Trp Gly 20 25 30 Trp GlnGly Leu Val Gly Gly Arg Arg Glu Asp Arg Gly Ala Leu Lys 35 40 45 Val GlnSer Ser Leu Phe Phe Leu Gln 50 55 <210> SEQ ID NO 39 <211> LENGTH: 1135<212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 39ctcaaggcct ggggcagggg cgtttaattg atgatgacag aggacacagg tttttgccag 60caaaaaggaa aaccaargct tggtggaagg gaaaggtggt gtgtcccctg ttccctattc 120catctccctg ggacttcctg ctcatcatag tacccagtga gcccagagat cctactagac 180tgggtcagca attctagaga accttccgga atagtctggg aacatggtca aggtggaagg 240ggctccccta gagagggtgg gggtgtagtt acttcccagt tggccagaaa actgggcctt 300gcagaccccc ttagcatttt ttcccttttt ttccttccct gctttctact tctttgggga 360gccccttgtg ttttggagtc tgactggagt ctcgcatcct ggggcctgct ccatccatcc 420ctcctgggcg ccagaccctc catccaagcc ctgtgtcttt ccatagtcag ggtcaggccc 480tgcatctatt ccaaggggca ctcagtacac attccataaa ttagctgggt gtccctgcac 540gcccacccca tgaaactcga gcaggtctct ggaagccatt tgttaaaaaa aaaaaaaaaa 600gttttaaaaa taccttttaa ttttctggta attccagttc tttgaagcat cctctgctgg 660gtcttggggt gtgtggatgg attggctgtc tgatgggatt ggtaacccct cgctactcaa 720gatgggggga tacaaacacc ttcagggaag gggagcctgg ttcttctcgt tttccttttt 780tttttttttt ttaaaaaaaa actatttaat tttttaattt atttttggtt gttttttgca 840caatgaagtt tcagcttctc aaccttctcc cctacccagg gctgtggacc cagactggcc 900ttgagccaca gtccctcttt ccctcctcac cctcttcccc ctgcgggctc ccgggtctgt 960ccatttgtta ctgtgctgtg ctggggattg gcgccgaggt ggcgtgagat tccacttgtg 1020tagaactttg ttgagtaaag atcagtttct tgtgaaaaaa aaaaaaaaaa aaaaaaaaaa 1080aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 1135 <210>SEQ ID NO 40 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 40 Met Lys Phe Gln Leu Leu Asn Leu Leu Pro TyrPro Gly Leu Trp Thr 1 5 10 15 Gln Thr Gly Leu Glu Pro Gln Ser Leu PhePro Ser Ser Pro Ser Ser 20 25 30 Pro Cys Gly Leu Pro Gly Leu Ser Ile CysTyr Cys Ala Val Leu Gly 35 40 45 Ile Gly Ala Glu Val Ala 50 <210> SEQ IDNO 41 <211> LENGTH: 4292 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 41 ctcaagttaa accaacaagc cgatagaaaa aggtagttatcaagagattt taaaacttca 60 accctttttc tcttatagtt agtgaagaga gtagaatatctccagttttg gctgacatct 120 ctacaacctg aacaattggc ttaaacttca cttgggattcccggttgctt gttttagcat 180 ggcaaaattt ggcgttcaca gaatccttct tctggctatttctctgacaa agtgtctgga 240 gagtacaaaa ctgctggcag accttaaaaa atgtggtgacttggaatgtg aagctttaat 300 aaacagagtc tcagccatga gagattatag aggacctgactgccgatacc tgaacttcac 360 taagggagaa gagatatctg tttatgttaa acttgcaggagaaagggaag atttgtgggc 420 aggaagtaaa ggaaaggagt ttggatattt tcccagagatgcagtccaga ttgaagaggt 480 gttcatatct gaggaaattc agatgtcaac gaaagaatctgactttcttt gtcttcttgg 540 agtaagttac acatttgaca atgaagatag tgaattaaacggtgattatg gtgaaaatat 600 atatccttat gaagaagata aagatgaaaa atctagtatatatgaaagtg attttcagat 660 agaacctgga ttttatgcaa cttatgaaag tactttgtttgaagaccaag ttccagcatt 720 agaggctcct gaagatatcg gaagtaccag tgaatcaaaagactgggaag aagtagttgt 780 tgaaagtatg gaacaggatc gtattccaga agtgcatgtcccaccatctt cagctgtgtc 840 tggagtcaaa gaatggtttg gattgggagg agaacaagctgaagagaagg cttttgaatc 900 agttattgaa cctgtacaag aaagctcatt tcggagtagaaaaatagcag tggaagatga 960 gaatgaccta gaggaattaa ataatggtga gcctcaaacagaacatcagc aagaatctga 1020 atcagaaatt gattcagtgc caaagacaca gtctgaactagcatctgagt cagagcacat 1080 tcccaaacct caatccactg gttggtttgg tggaggatttacaagttatt taggttttgg 1140 agatgaggat acagggcttg aattaatagc tgaagaaagcaatccaccac tacaagattt 1200 tcccaatccc atatcatctg ataaagaagc cacagttccatgtacagaaa tattaacaga 1260 aaaaaaagac acaatcacta atgatagctt gagtctcaagccaagttggt ttgattttgg 1320 ttttgctata ctaggctttg catatgccaa ggaagataaaattatgttag atgacaggaa 1380 aaatgaagaa gatggtgggg cagatgaaca tgaacatcctctaacaagtg aattagaccc 1440 tgaaaaagaa caagaaatag aaacgataaa aattatagaaacagaagatc aaatagacaa 1500 gaaaccagtc tcagaaaaaa cagacgaatc tgatactataccatatttga aaaagttctt 1560 gtataatttt gacaaccctt ggaacttcca gaacattccaaaggaaacag aattgccatt 1620 tcccaaacag atactggatc aaaataatgt aattgaaaatgaagaaactg gagaattttc 1680 cattgataat tatcccacag ataatacaaa agttatgatattcaaaagtt catacagtct 1740 gtcagatatg gtctctaaca tagagttacc tacgagaattcacgaagaag tatattttga 1800 accctcatct tctaaagata gtgatgaaaa ttcgaaaccatcagtagaca ccgaagggcc 1860 tgctctggtg gagatagaca gatctgtgga aaataccctgctaaatagtc agatggtttc 1920 aactgataac tctttgtctt ctcaaaatta tatttctcagaaagaagatg cttctgagtt 1980 tcagattctg aaatacttat tccaaattga tgtttatgatttcatgaatt ctgcattttc 2040 accaattgta attcttacag aaagggttgt ggcagcactgcctgaaggta tgagaccaga 2100 ttctaatctt tatggttttc catgggaatt ggtgatatgtgcagctgttg ttggattttt 2160 tgctgttctc ttttttttgt ggagaagttt tagatcggttaggagtcggc tttatgtggg 2220 acgagagaaa aagcttgctc taatgctttc tggactaattgaagaaaaaa gtaaactact 2280 tgaaaaattt agccttgttc aaaaagagta tgaaggctatgaagtagagt catctttaaa 2340 ggatgccagc tttgagaagg aggcaacaga agcacaaagtttggaggcaa cctgtgaaaa 2400 gctgaacagg tccaattctg aacttgagga tgaaatactctgtctagaaa aagagttaaa 2460 agaagagaaa tccaaacatt ctgaacaaga tgaattgatggcggatattt caaaaaggat 2520 acagtctcta gaagatgagt caaaatccct caaatcacaagtagctgaag ccaaaatgac 2580 cttcaagata tttcaaatga atgaagaacg actgaagatagcaataaaag atgctttgaa 2640 tgaaaattct caacttcagg aaagccagaa acagcttttgcaagaagctg aagtatggaa 2700 agaacaagtg agtgaactta ataaacagaa agtaacatttgaagactcca aagtacatgc 2760 agaacaagtt ctaaatgata aagaaagtca catcaagactctgactgaac gcttgttaaa 2820 gatgaaagat tgggctgcta tgcttggaga agacataacggatgatgata acttggaatt 2880 agaaatgaac agtgaatcgg aaaatggtgc ttacttagataatcctccaa aaggagcttt 2940 gaagaaactg attcatgctg ctaagttaaa tgcttctttaaaaaccttag aaggagaaag 3000 aaaccaaatt tatattcagt tgtctgaagt tgataaaacaaaggaagagc ttacagagca 3060 tattaaaaat cttcagactc aacaagcatc tttgcagtcagaaaacacac attttgaaaa 3120 tgagaatcag aagcttcaac agaaacttaa agtaatgactgaattatatc aagaaaatga 3180 aatgaaactc caccggaaat taacagtaga ggaaaattatcggttagaga aagaagagaa 3240 actttctaaa gtcgacgaaa agatcagcca tgccactgaagagctggaga cctatagaaa 3300 gcgagccaaa gatcttgaag aagaattgga gagaactattcattcttatc aagggcagat 3360 tatttcccat gagaaaaaag cacatgataa ttggttggcagctcggaatg ctgaaagaaa 3420 cctcaatgat ttaaggaaag aaaatgctca caacagacaaaaattaactg aaacagagct 3480 taaatttgaa cttttagaaa aagatcctta tgcactcgatgttccaaata cagcatttgg 3540 cagaggctca cgaggcccag ggaatcctct ggaccatcagattaccaatg aaagaggaga 3600 atcaagctgt gataggttaa ccgatcctca tagggctccctctgacactg ggtctctgtc 3660 acctccatgg gaccaggacc gtaggatgat gtttcctccgccaggacaat catatcctga 3720 ttcagccctt cctccacaaa ggcaagacag attttgttctaattctggta gactgtctgg 3780 accagcagaa ctcagaagtt ttaatatgcc ttctttggataaaatggatg ggtcaatgcc 3840 ttcagaaatg gaatccagta gaaatgatac caaagatgatcttggtaatt taaatgtgcc 3900 tgattcatct ctccctgctg aaaatgaagc cactggccctggctttgttc ctccacctct 3960 tgctccaatc agaggtccat tgtttccagt ggatgcaagaggcccattct tgagaagagg 4020 acctcctttc cccccacctc ctccaggagc catgtttggagcttctcgag attattttcc 4080 accaagggat ttcccaggtc caccacctgc tccatttgcaatgagaaatg tctatccacc 4140 gaggggtttt cctccttacc ttcccccaag acctggatttttccccccac ccccacattc 4200 tgaaggtaga agtgagttcc cctcaggttt gattccaccttcaaatgagc ctgctactga 4260 acatccagaa ccacagcaag aaacctgaca at 4292<210> SEQ ID NO 42 <211> LENGTH: 1369 <212> TYPE: PRT <213> ORGANISM:Homo sapiens <400> SEQUENCE: 42 Met Ala Lys Phe Gly Val His Arg Ile LeuLeu Leu Ala Ile Ser Leu 1 5 10 15 Thr Lys Cys Leu Glu Ser Thr Lys LeuLeu Ala Asp Leu Lys Lys Cys 20 25 30 Gly Asp Leu Glu Cys Glu Ala Leu IleAsn Arg Val Ser Ala Met Arg 35 40 45 Asp Tyr Arg Gly Pro Asp Cys Arg TyrLeu Asn Phe Thr Lys Gly Glu 50 55 60 Glu Ile Ser Val Tyr Val Lys Leu AlaGly Glu Arg Glu Asp Leu Trp 65 70 75 80 Ala Gly Ser Lys Gly Lys Glu PheGly Tyr Phe Pro Arg Asp Ala Val 85 90 95 Gln Ile Glu Glu Val Phe Ile SerGlu Glu Ile Gln Met Ser Thr Lys 100 105 110 Glu Ser Asp Phe Leu Cys LeuLeu Gly Val Ser Tyr Thr Phe Asp Asn 115 120 125 Glu Asp Ser Glu Leu AsnGly Asp Tyr Gly Glu Asn Ile Tyr Pro Tyr 130 135 140 Glu Glu Asp Lys AspGlu Lys Ser Ser Ile Tyr Glu Ser Asp Phe Gln 145 150 155 160 Ile Glu ProGly Phe Tyr Ala Thr Tyr Glu Ser Thr Leu Phe Glu Asp 165 170 175 Gln ValPro Ala Leu Glu Ala Pro Glu Asp Ile Gly Ser Thr Ser Glu 180 185 190 SerLys Asp Trp Glu Glu Val Val Val Glu Ser Met Glu Gln Asp Arg 195 200 205Ile Pro Glu Val His Val Pro Pro Ser Ser Ala Val Ser Gly Val Lys 210 215220 Glu Trp Phe Gly Leu Gly Gly Glu Gln Ala Glu Glu Lys Ala Phe Glu 225230 235 240 Ser Val Ile Glu Pro Val Gln Glu Ser Ser Phe Arg Ser Arg LysIle 245 250 255 Ala Val Glu Asp Glu Asn Asp Leu Glu Glu Leu Asn Asn GlyGlu Pro 260 265 270 Gln Thr Glu His Gln Gln Glu Ser Glu Ser Glu Ile AspSer Val Pro 275 280 285 Lys Thr Gln Ser Glu Leu Ala Ser Glu Ser Glu HisIle Pro Lys Pro 290 295 300 Gln Ser Thr Gly Trp Phe Gly Gly Gly Phe ThrSer Tyr Leu Gly Phe 305 310 315 320 Gly Asp Glu Asp Thr Gly Leu Glu LeuIle Ala Glu Glu Ser Asn Pro 325 330 335 Pro Leu Gln Asp Phe Pro Asn ProIle Ser Ser Asp Lys Glu Ala Thr 340 345 350 Val Pro Cys Thr Glu Ile LeuThr Glu Lys Lys Asp Thr Ile Thr Asn 355 360 365 Asp Ser Leu Ser Leu LysPro Ser Trp Phe Asp Phe Gly Phe Ala Ile 370 375 380 Leu Gly Phe Ala TyrAla Lys Glu Asp Lys Ile Met Leu Asp Asp Arg 385 390 395 400 Lys Asn GluGlu Asp Gly Gly Ala Asp Glu His Glu His Pro Leu Thr 405 410 415 Ser GluLeu Asp Pro Glu Lys Glu Gln Glu Ile Glu Thr Ile Lys Ile 420 425 430 IleGlu Thr Glu Asp Gln Ile Asp Lys Lys Pro Val Ser Glu Lys Thr 435 440 445Asp Glu Ser Asp Thr Ile Pro Tyr Leu Lys Lys Phe Leu Tyr Asn Phe 450 455460 Asp Asn Pro Trp Asn Phe Gln Asn Ile Pro Lys Glu Thr Glu Leu Pro 465470 475 480 Phe Pro Lys Gln Ile Leu Asp Gln Asn Asn Val Ile Glu Asn GluGlu 485 490 495 Thr Gly Glu Phe Ser Ile Asp Asn Tyr Pro Thr Asp Asn ThrLys Val 500 505 510 Met Ile Phe Lys Ser Ser Tyr Ser Leu Ser Asp Met ValSer Asn Ile 515 520 525 Glu Leu Pro Thr Arg Ile His Glu Glu Val Tyr PheGlu Pro Ser Ser 530 535 540 Ser Lys Asp Ser Asp Glu Asn Ser Lys Pro SerVal Asp Thr Glu Gly 545 550 555 560 Pro Ala Leu Val Glu Ile Asp Arg SerVal Glu Asn Thr Leu Leu Asn 565 570 575 Ser Gln Met Val Ser Thr Asp AsnSer Leu Ser Ser Gln Asn Tyr Ile 580 585 590 Ser Gln Lys Glu Asp Ala SerGlu Phe Gln Ile Leu Lys Tyr Leu Phe 595 600 605 Gln Ile Asp Val Tyr AspPhe Met Asn Ser Ala Phe Ser Pro Ile Val 610 615 620 Ile Leu Thr Glu ArgVal Val Ala Ala Leu Pro Glu Gly Met Arg Pro 625 630 635 640 Asp Ser AsnLeu Tyr Gly Phe Pro Trp Glu Leu Val Ile Cys Ala Ala 645 650 655 Val ValGly Phe Phe Ala Val Leu Phe Phe Leu Trp Arg Ser Phe Arg 660 665 670 SerVal Arg Ser Arg Leu Tyr Val Gly Arg Glu Lys Lys Leu Ala Leu 675 680 685Met Leu Ser Gly Leu Ile Glu Glu Lys Ser Lys Leu Leu Glu Lys Phe 690 695700 Ser Leu Val Gln Lys Glu Tyr Glu Gly Tyr Glu Val Glu Ser Ser Leu 705710 715 720 Lys Asp Ala Ser Phe Glu Lys Glu Ala Thr Glu Ala Gln Ser LeuGlu 725 730 735 Ala Thr Cys Glu Lys Leu Asn Arg Ser Asn Ser Glu Leu GluAsp Glu 740 745 750 Ile Leu Cys Leu Glu Lys Glu Leu Lys Glu Glu Lys SerLys His Ser 755 760 765 Glu Gln Asp Glu Leu Met Ala Asp Ile Ser Lys ArgIle Gln Ser Leu 770 775 780 Glu Asp Glu Ser Lys Ser Leu Lys Ser Gln ValAla Glu Ala Lys Met 785 790 795 800 Thr Phe Lys Ile Phe Gln Met Asn GluGlu Arg Leu Lys Ile Ala Ile 805 810 815 Lys Asp Ala Leu Asn Glu Asn SerGln Leu Gln Glu Ser Gln Lys Gln 820 825 830 Leu Leu Gln Glu Ala Glu ValTrp Lys Glu Gln Val Ser Glu Leu Asn 835 840 845 Lys Gln Lys Val Thr PheGlu Asp Ser Lys Val His Ala Glu Gln Val 850 855 860 Leu Asn Asp Lys GluSer His Ile Lys Thr Leu Thr Glu Arg Leu Leu 865 870 875 880 Lys Met LysAsp Trp Ala Ala Met Leu Gly Glu Asp Ile Thr Asp Asp 885 890 895 Asp AsnLeu Glu Leu Glu Met Asn Ser Glu Ser Glu Asn Gly Ala Tyr 900 905 910 LeuAsp Asn Pro Pro Lys Gly Ala Leu Lys Lys Leu Ile His Ala Ala 915 920 925Lys Leu Asn Ala Ser Leu Lys Thr Leu Glu Gly Glu Arg Asn Gln Ile 930 935940 Tyr Ile Gln Leu Ser Glu Val Asp Lys Thr Lys Glu Glu Leu Thr Glu 945950 955 960 His Ile Lys Asn Leu Gln Thr Gln Gln Ala Ser Leu Gln Ser GluAsn 965 970 975 Thr His Phe Glu Asn Glu Asn Gln Lys Leu Gln Gln Lys LeuLys Val 980 985 990 Met Thr Glu Leu Tyr Gln Glu Asn Glu Met Lys Leu HisArg Lys Leu 995 1000 1005 Thr Val Glu Glu Asn Tyr Arg Leu Glu Lys GluGlu Lys Leu Ser Lys 1010 1015 1020 Val Asp Glu Lys Ile Ser His Ala ThrGlu Glu Leu Glu Thr Tyr Arg 1025 1030 1035 1040 Lys Arg Ala Lys Asp LeuGlu Glu Glu Leu Glu Arg Thr Ile His Ser 1045 1050 1055 Tyr Gln Gly GlnIle Ile Ser His Glu Lys Lys Ala His Asp Asn Trp 1060 1065 1070 Leu AlaAla Arg Asn Ala Glu Arg Asn Leu Asn Asp Leu Arg Lys Glu 1075 1080 1085Asn Ala His Asn Arg Gln Lys Leu Thr Glu Thr Glu Leu Lys Phe Glu 10901095 1100 Leu Leu Glu Lys Asp Pro Tyr Ala Leu Asp Val Pro Asn Thr AlaPhe 1105 1110 1115 1120 Gly Arg Gly Ser Arg Gly Pro Gly Asn Pro Leu AspHis Gln Ile Thr 1125 1130 1135 Asn Glu Arg Gly Glu Ser Ser Cys Asp ArgLeu Thr Asp Pro His Arg 1140 1145 1150 Ala Pro Ser Asp Thr Gly Ser LeuSer Pro Pro Trp Asp Gln Asp Arg 1155 1160 1165 Arg Met Met Phe Pro ProPro Gly Gln Ser Tyr Pro Asp Ser Ala Leu 1170 1175 1180 Pro Pro Gln ArgGln Asp Arg Phe Cys Ser Asn Ser Gly Arg Leu Ser 1185 1190 1195 1200 GlyPro Ala Glu Leu Arg Ser Phe Asn Met Pro Ser Leu Asp Lys Met 1205 12101215 Asp Gly Ser Met Pro Ser Glu Met Glu Ser Ser Arg Asn Asp Thr Lys1220 1225 1230 Asp Asp Leu Gly Asn Leu Asn Val Pro Asp Ser Ser Leu ProAla Glu 1235 1240 1245 Asn Glu Ala Thr Gly Pro Gly Phe Val Pro Pro ProLeu Ala Pro Ile 1250 1255 1260 Arg Gly Pro Leu Phe Pro Val Asp Ala ArgGly Pro Phe Leu Arg Arg 1265 1270 1275 1280 Gly Pro Pro Phe Pro Pro ProPro Pro Gly Ala Met Phe Gly Ala Ser 1285 1290 1295 Arg Asp Tyr Phe ProPro Arg Asp Phe Pro Gly Pro Pro Pro Ala Pro 1300 1305 1310 Phe Ala MetArg Asn Val Tyr Pro Pro Arg Gly Phe Pro Pro Tyr Leu 1315 1320 1325 ProPro Arg Pro Gly Phe Phe Pro Pro Pro Pro His Ser Glu Gly Arg 1330 13351340 Ser Glu Phe Pro Ser Gly Leu Ile Pro Pro Ser Asn Glu Pro Ala Thr1345 1350 1355 1360 Glu His Pro Glu Pro Gln Gln Glu Thr 1365 <210> SEQID NO 43 <211> LENGTH: 412 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 43 ttactttatg ccagatccag tacatgccat tgttatcctctgtttacagg tggggaagct 60 gaggcaggaa gccctttagt cacttgccga aggccacgctgttacccatg ggaccggttt 120 tgggcggccg aagagcactc atggggccgg attcacgccccgggcccgtt ccctcctgct 180 ctctggtgct cctcacgcca ttggccccac tgcctctcactgcccgtgag tccctgtgcc 240 cgtgtcctcc ttcttgaacc cctcagccct cagttaaccctcagaaagct ggctcggaga 300 agtccttgtg tggtatctgg gaggcagagt ttgccgtgagccgagattgt gccactgcac 360 gcactccagc ctgggcgaca gagcgagacc ccatctcaaaaaaaaaaaaa aa 412 <210> SEQ ID NO 44 <211> LENGTH: 49 <212> TYPE: PRT<213> ORGANISM: Homo sapiens <400> SEQUENCE: 44 Met Gly Pro Val Leu GlyGly Arg Arg Ala Leu Met Gly Pro Asp Ser 1 5 10 15 Arg Pro Gly Pro ValPro Ser Cys Ser Leu Val Leu Leu Thr Pro Leu 20 25 30 Ala Pro Leu Pro LeuThr Ala Arg Glu Ser Leu Cys Pro Cys Pro Pro 35 40 45 Ser <210> SEQ ID NO45 <211> LENGTH: 1317 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 45 gtctgtgaga gtcaattcag gggaaagata caagattgat ttgtaaaacccttgaaatgt 60 agatttcttg tagatgtatc cttcacgttg taaatatgtt ttgtagagtgaagccatggg 120 aagccatgtg taacagagct tagacatcca aaactaatca atgctgaggtggctaaatac 180 ctagcctttt acatgtaaac ctgtctgcaa aattagcttt tttaaaaaaaaaaaaaaaaa 240 aaaattgggg gggttaattt atcattcaga aatcttgcat tttcaaaaattcagtgcaag 300 cgccaggcga tttgtgtcta aggatacgat tttgaaccat atgggcagtgtacaaaatat 360 gaaacaactg tttccacact tgcacctgat caagagcagt gcttctccatttgttttgca 420 gagaaatgtt tttcatttcc cgtgtgtttc catttccttc tgaaattctgattttatcca 480 tttttttaag gctcctcttt atctcctttc ttaaggcact gttgctatggcacttttcta 540 taaccttttc attcctgtgt acagtagctt aaaattgcag tgattgagcataacctactt 600 gtttgtataa attattgaaa tccatttgca ccctgtaaga atggacttaaaagtactgct 660 ggacaggcat gtgtgctcaa agtacattga ttgctcaaat ataaggaaatggcccaatga 720 acgtggttgt gggaggggaa agaggaaaca gagctagtca gatgtgaattgtatctgttg 780 taataaacat gttaaaacaa acaaaaattg ttatttttct tttccttcggtcagtgcaca 840 ttagcatttg aactacctgg ggattcttta tcagaactgt tcttgttgaatatttatact 900 taattgaaat aattccttaa gggaggtttt gtttaaaacg tattaacaggaaattgtgta 960 tgagatattt aatgaaataa gaaattcaac aagaatgatt aagtcacttcccaagtggtt 1020 gtcatttgtt aaaccctggt ttacctgtct tgctattatg acatttcatttggaaggatg 1080 tttgtgttgt agctaactgt tcaagtctgg tgctgactgc tgttcttagccatcacaaaa 1140 cgctaaattt gtgtaattgg agcttcctgc tgttatctgg aaatagcaggaaagcgcagc 1200 tttgtatatt gtttcctaaa gtatattaaa ataaaaaaag aaactattgctactaaaaaa 1260 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaaaaaaaaa 1317 <210> SEQ ID NO 46 <211> LENGTH: 48 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 46 Met Phe Phe Ile Ser Arg ValPhe Pro Phe Pro Ser Glu Ile Leu Ile 1 5 10 15 Leu Ser Ile Phe Leu ArgLeu Leu Phe Ile Ser Phe Leu Lys Ala Leu 20 25 30 Leu Leu Trp His Phe SerIle Thr Phe Ser Phe Leu Cys Thr Val Ala 35 40 45 <210> SEQ ID NO 47<211> LENGTH: 1442 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 47 tgcggttgtt ttccttctct ccgtgcaacg ctggcaagtc tcaaagtcgccacagaaaca 60 tgcccctgat tcagtgcctc tgcttagctg taacatgtta atcagaactacctggcatct 120 tcctgaacaa gactttcaat aggggccagt atgcttcgct tcatccagaagttttctcaa 180 gcatcttcaa agatactgaa gtactctttc ccagtgggac taagaaccagcagaacagat 240 atactttctc tcaagatgtc tctccagcaa aacttttccc catgtccaaggccttggctt 300 tcctcatcat ttccagcgta tatgagcaag acacagtgct atcatacatccccctgcagc 360 tttaaaaagc agcagaagca agcacttcta gccagaccct caagcaccatcacttaccta 420 actgacagcc caaagccagc attatgtgta actctggcag gactaatccccttcgttgct 480 ccaccactgg tcatgctgat gacaaaaact tatattccca tattagcttttactcagatg 540 gcttatggag ccagtttcct atctttcttg ggtgggatca gatggggttttgctctacca 600 gaaggtagtc cagccaaacc agactacctt aatttagcta gcagtgcagctcctcttttc 660 ttttcatggt ttgccttcct tatttctgaa agacttagtg aagccatagtcacagtaata 720 atgggtatgg gagtagcatt ccaccttgaa ctttttctct taccacattatcccaactgg 780 tttaaagccc tgaggatagt agtcacttta ttggccactt tttcatttataatcacttta 840 gtagttaaaa gtagttttcc agaaaaagga cataagagac ctggtcaagtataaaaaata 900 taaaagtctg ggaagtgagg agcacctctg cccagctgct gccccgtctgggaagtgagg 960 agcgcctctg cctggccgcc tgaccatctg ggaagtgtga caagcgcctctgcccggccg 1020 ctgtgcaacc ttccacgtgt gaagtgacag ccttgtgtgt gatcttttctgtcttcccca 1080 agtttgcatt ttcgacatta aagtttactt tttagttaaa agttttaaaaatatatatat 1140 ataaatacac tgtagataac atttgtatgc cagctacacc tttttctacttctgtttggc 1200 tttttttccc cacaccaatg gtaatttatc ttcacagatt gttcttcatttctagaaatt 1260 gttacttcat ggtaattact tgagcaaaag cttgaaaatc cctgacaagtacttttcatc 1320 tcatagtata ttagttttca ctcagtcatt ttatgaataa tatagttatccacttaaaca 1380 tttcaatatt ttaaccatct tgaaaattaa agattaaaaa tccccttaaaaaaaaaaaaa 1440 aa 1442 <210> SEQ ID NO 48 <211> LENGTH: 247 <212> TYPE:PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 48 Met Leu Arg Phe IleGln Lys Phe Ser Gln Ala Ser Ser Lys Ile Leu 1 5 10 15 Lys Tyr Ser PhePro Val Gly Leu Arg Thr Ser Arg Thr Asp Ile Leu 20 25 30 Ser Leu Lys MetSer Leu Gln Gln Asn Phe Ser Pro Cys Pro Arg Pro 35 40 45 Trp Leu Ser SerSer Phe Pro Ala Tyr Met Ser Lys Thr Gln Cys Tyr 50 55 60 His Thr Ser ProCys Ser Phe Lys Lys Gln Gln Lys Gln Ala Leu Leu 65 70 75 80 Ala Arg ProSer Ser Thr Ile Thr Tyr Leu Thr Asp Ser Pro Lys Pro 85 90 95 Ala Leu CysVal Thr Leu Ala Gly Leu Ile Pro Phe Val Ala Pro Pro 100 105 110 Leu ValMet Leu Met Thr Lys Thr Tyr Ile Pro Ile Leu Ala Phe Thr 115 120 125 GlnMet Ala Tyr Gly Ala Ser Phe Leu Ser Phe Leu Gly Gly Ile Arg 130 135 140Trp Gly Phe Ala Leu Pro Glu Gly Ser Pro Ala Lys Pro Asp Tyr Leu 145 150155 160 Asn Leu Ala Ser Ser Ala Ala Pro Leu Phe Phe Ser Trp Phe Ala Phe165 170 175 Leu Ile Ser Glu Arg Leu Ser Glu Ala Ile Val Thr Val Ile MetGly 180 185 190 Met Gly Val Ala Phe His Leu Glu Leu Phe Leu Leu Pro HisTyr Pro 195 200 205 Asn Trp Phe Lys Ala Leu Arg Ile Val Val Thr Leu LeuAla Thr Phe 210 215 220 Ser Phe Ile Ile Thr Leu Val Val Lys Ser Ser PhePro Glu Lys Gly 225 230 235 240 His Lys Arg Pro Gly Gln Val 245 <210>SEQ ID NO 49 <211> LENGTH: 2696 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 49 taggcctctt tggccgtgga gctgtccctc ctaggtgggaatgttcactc ttttgttgtc 60 aggttgtatg ggggggcagg gacagtgctg ctgggaaggatgccagctct gggattgggc 120 cagtcctgtg ggcaagactt gcaagaggct ggatcaacttggtgtggtat ctctgatggc 180 ttagagtaat ggcaatgagg gtctctgttg tgatgtcactgagtactttc tggggtgctt 240 ctgggcaccc cttatgatgt cacaggaagc agttcctcagaggttacttc ctgtgaacat 300 aagggagcag gtacttcctg tgatgtctca atgagttcttccttgaaggt cactttggtg 360 atatcatggg aaggtgtact tccggtgatg cctagaggtcacgtcctgtg atgtcattag 420 gctgaagcat gtacttcctg tattggacag tgaccagtctctgacctgcc ttctccctcc 480 acacccttct ttggtgggtg ttggcctggg ggtcttcctaggaagagaat aaggcacggg 540 acttggatcc aatctggagg actctaacgg aaaaaaaccaatattgtcag ggtcatctcc 600 attcaaacac gtcaagtctg cgaactcgcc ctggagggaggggtgggaga tggacctagt 660 gcaaactact gttaaagacc tcccttccca cccctgccttttgtgtgcat gcctgtgtct 720 gcgtggcttt gtttcattga atcgggtgag ccaagtgtgtggtggctctg tcaggccagt 780 atggccaggt gtagagttca gtgagccata gtagggtcccttgggccaga atgcttcgtg 840 tggtctgata ggttagattg gtttggtggc ttccaccaagctggcatact tcggtgatgt 900 ctgatggatc agaatgtttt ggtgtgctca ccaggggctctggagaacta gaatgttctg 960 atggagtctg acaagccagg cggccttgag agttggtttaggagtggctc cctgagtgct 1020 gtggctgtgg tcagctctaa ggacctgttg gcagactgagatttcagggc ctgacaacca 1080 tgtagactag gatagctgag acctccctct acccccacccatctccctct cttccttgga 1140 gaccacctcc actttctcca acccaaagca gggcgcccagtgccctggtt ccatcatcag 1200 catctctggg ggaggggcgc cccatgccca ccctctcccccatttgtccg cctcctaggt 1260 cttccaaacc cttttcttct ctatgacttt gggggaaatccagcctcctt gtctctctcc 1320 taaaaaagga gggaagaaaa gccacagaga caattcctgcccctaaagcc taggagatcc 1380 ctctcccttg ctagagagcc acccccaaat caaaatgtgaaaatccctag aaagcaatag 1440 ccttcgaggt accttgcact gaatttccca ccccagcccttccacccgat gggaggctgt 1500 aacttgggca ctggggtgac tttttccatg cccttgtcatctccagggtg ggaggcaggc 1560 cccacttccc ctcccctatc ccccacttcc cattgttgttgccccacccc taatctccag 1620 actgaaccca gatggagatc tgagtgccaa aacaattcttgatgtaactt tgtacatatc 1680 ttctactacc gttgggggct cttggggtta gaggtgggggcggctctgtg ggccattgct 1740 cccctccacc tctcaaaaga ccttacagta tttcacagtatctctacccg cacgcgagta 1800 ttacagtatc tagctggaat atccccctac agccccccaggaccctatga ggaagggaag 1860 gagccaggga gagtgaagta aggtctggga ctggggaggtgggatctgat gaactcattt 1920 gcatatcatt cgcatcctcc gcttggcagc cgctttctacaaactcattc actggagtct 1980 gggtcccaat cagccgggtc caggactcct ctcacacagacacatctccg gaggctgggc 2040 ctcctgaaaa gtgtttgctt ggggtgtctg tgtaacaacccctccctatt catatttctt 2100 ggggaccccc tacccagcca gccagggtga tctgaaaggtatactttgct agctcagtga 2160 gctagttcac tcaccatgtt ggtgagcaga gagccacacctttccccatt ttaccttggg 2220 aaactcactc caccatcttt gccatctctt gaaagtcccttctgcaatct gacctcaatc 2280 ttttgtgctg cagtttgtcc agaggggaca cagatgtggggtcagggatg aggattattg 2340 aaaaacccat catctctttt ttttttcccc gtctccctattagccaatcc gatctcagag 2400 tctctgagtg gcctccttgc accttctctt cagcacccagtaggtgctta ataagtgttt 2460 gctgcattga attatctccc tattccttct catttgccctctagcttccc ataccttctc 2520 caagtgtctt cctccctttc tttgtctggc tccctatgactttctatttt tttttcctcc 2580 gtgtggttcc cattgttttc tgtcctgtct ctatcttagtctttgtctgt cttcctcctt 2640 tcctcaaatg tctcaactct ctctccccaa tttccccatttaaaaaaaaa aaaaaa 2696 <210> SEQ ID NO 50 <211> LENGTH: 73 <212> TYPE:PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 50 Met Asn Ser Phe AlaTyr His Ser His Pro Pro Leu Gly Ser Arg Phe 1 5 10 15 Leu Gln Thr HisSer Leu Glu Ser Gly Ser Gln Ser Ala Gly Ser Arg 20 25 30 Thr Pro Leu ThrGln Thr His Leu Arg Arg Leu Gly Leu Leu Lys Ser 35 40 45 Val Cys Leu GlyCys Leu Cys Asn Asn Pro Ser Leu Phe Ile Phe Leu 50 55 60 Gly Asp Pro LeuPro Ser Gln Pro Gly 65 70 <210> SEQ ID NO 51 <211> LENGTH: 2791 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 51 tttttttagagtggtaacat ttattaggaa ggagagactt cagttagact cccatgtctc 60 acacagaagaaacagatggt aactgccatt tctttctttc tttctttctt tttttttttg 120 agatggagtttcgctcttat tgcccaggct ggagtgcaat ggtgcaattt cggctcacct 180 caacctccgcctcccggttt caagagattc tcctgcctca gcctcctaag tagctgggat 240 tacaggcatacgccaccatg cctggctaat tctgtatttt tagtagacac ggggtttctc 300 catgttggtcaggctggtct tgaactcccg acctcaggtg atccgcccac ctcggcttcc 360 caaagtgctgggattacaag cgtgagccac tgcgcccagc cagtaactgc catttctaaa 420 gaggaaagagagcaggcaga gggtcctgac tcccagggga caggtagttc agctggacaa 480 tgagggagtatgagattagg gtggataagg acactgctca ccaccctcca ctgaagttca 540 gtggctaaaatactgctaca ccagccaatc agtggaaggc tatcttgctc tccaggggac 600 acttgggatgtggttggtgg caggaagaaa gaatgtcatg ctatctcttg ctgctcctcc 660 gggtttctttgccgttacta acagggttgc tggaagggcc aggcgggcct gcaggtgtgt 720 ggttgggctggcttcgagtg attcgggtgc tgggtgggtg ggagggagta tgagggggat 780 gtgggccaccaccgggacct ggtggggcac tcagtccatt cccattctgg ttctcagagg 840 ctggagaggcagcagagggt ccagtggtag gctgggaagc tgaagggttg ctgtcgttct 900 gcaccgccttgttgggtgcc tgctgggtgc tgtactctgg gtttggctca ctgaagttag 960 gaacctcagaataaaccata cagaattctc caatcttctg cagatcaccc ccacggccag 1020 tatatagtgtcagacaacct ttgaaaactg aagcgtaccc tttggtgagc cggataatgt 1080 ccccaggctggatcagattg ccaacatcgt cccagacaga gatattgatg ctgcctgttt 1140 tgtccgccactttgcaggtc cgaacctcat gcccgtcctt tgtcttggtc actcggcctg 1200 tctccagcacaatgaagata aggttcagat tcttgagccc aggcttgata tccttcacaa 1260 aggtctccgtcgtcatgctg cctgagcctc ggcaccccac tggatgggga atagaggatg 1320 aaggctcaatgcttggatcc tttgccccca tgctccactt cccaaggcct acctacccca 1380 ttaggatggggtcaggcagc ctcaacccct ctaacccttc taaaagatta aaaaagaaca 1440 tccccggaggcctccaactt caggatcaga atttgggggt ctctggacag gctgctttgg 1500 ggctggaaggccccctgccg ggatgctctt ttagtctcaa gccgcgaagt ggcggagccg 1560 acgtagacaggggtagggaa cccggtgcac agccagggag tagaatctta ctggccagat 1620 cttccggaaccctcatcccg acaagccggg actcggtcca tcccctcccc taccggcagc 1680 ccaccacccacccaagccag ccggcaggac tgtgccgtgg ctggaagtta ctgtgaggcg 1740 gcggctaagaaggcggttct ggtggcggcg gtggaggctg aggcggcggc cgaggcggcg 1800 acggaggaaacagaagatgg cagatttttt gaaaggactg cctgtctaca acaaaagcaa 1860 ttttagtcgatttcacgcgg actccgtgtg caaagcctcg aaccgacggc cctcagtcta 1920 cctgcctacccgcgagtacc cgtctgaaca gatcatcgtg acagaaaaga caaacatcct 1980 cctgcgctacctgcatcagc aatgggacaa aaagaacgct gccaagaaga gagaccagga 2040 gcaagtggagctcgaaggcg agagctccgc acctccccgc aaggtggcgc ggaccgacag 2100 cccagacatgcacgaggaca cttaagactc tcaactccac aggcgcctcc tgccaggtct 2160 gctcctcggtcgcccacccg cctgcccgcc atgtgtaagc accccgcccg cccgcctccc 2220 tgccggcccatccacaccct gcgtccacac cacttccaac ctcataggag ccgatgtatt 2280 tattttccttgagtttttat ttatgctgta acctgtatca agcgttggtt aaaggggaca 2340 tcagacccagtagtgtgatg ttggtagatg ctttttaaaa aaaacaacat tgtccccccg 2400 acccccgccttccatcgggc cagttccccg attcctgccc ccagttctcc agagaaccag 2460 agtgtgtctgtgagagtctc tagcgggggc tttactgtgg ccgggcgaca ggggcgggcc 2520 cggggtggcctgacctacca ggacagccga gtggccttct cccccccaac accgatccag 2580 gccattgagactcggtcttg tcccacgttc gcccggaact ttcccatgcc cagacctcac 2640 tcagcgtgcacgcacgttgg ggagaagtcg gcccttggga tctttctctt gagtcatttt 2700 atttttatcatggactagtg cgtgctccgt gtccacccca ataaaagggt ctttcctaaa 2760 aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa a 2791 <210> SEQ ID NO 52 <211> LENGTH: 219 <212>TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 52 Met Ser ProGly Trp Ile Arg Leu Pro Thr Ser Ser Gln Thr Glu Ile 1 5 10 15 Leu MetLeu Pro Val Leu Ser Ala Thr Leu Gln Val Arg Thr Ser Cys 20 25 30 Pro SerPhe Val Leu Val Thr Arg Pro Val Ser Ser Thr Met Lys Ile 35 40 45 Arg PheArg Phe Leu Ser Pro Gly Leu Ile Ser Phe Thr Lys Val Ser 50 55 60 Val ValMet Leu Pro Glu Pro Arg His Pro Thr Gly Trp Gly Ile Glu 65 70 75 80 AspGlu Gly Ser Met Leu Gly Ser Phe Ala Pro Met Leu His Phe Pro 85 90 95 ArgPro Thr Tyr Pro Ile Arg Met Gly Ser Gly Ser Leu Asn Pro Ser 100 105 110Asn Pro Ser Lys Arg Leu Lys Lys Asn Ile Pro Gly Gly Leu Gln Leu 115 120125 Gln Asp Gln Asn Leu Gly Val Ser Gly Gln Ala Ala Leu Gly Leu Glu 130135 140 Gly Pro Leu Pro Gly Cys Ser Phe Ser Leu Lys Pro Arg Ser Gly Gly145 150 155 160 Ala Asp Val Asp Arg Gly Arg Glu Pro Gly Ala Gln Pro GlySer Arg 165 170 175 Ile Leu Leu Ala Arg Ser Ser Gly Thr Leu Ile Pro ThrSer Arg Asp 180 185 190 Ser Val His Pro Leu Pro Tyr Arg Gln Pro Thr ThrHis Pro Ser Gln 195 200 205 Pro Ala Gly Leu Cys Arg Gly Trp Lys Leu Leu210 215 <210> SEQ ID NO 53 <211> LENGTH: 1527 <212> TYPE: DNA <213>ORGANISM: Homo sapiens <400> SEQUENCE: 53 tgaacaacaa gctaaaatggaatagcacag aatggctgag gagccactgt gaagaaaggc 60 atgcagccat gaaactgcagtgtcccttgc tgttagtggg gtggctctga ccaatctgga 120 agatacagaa aatgccaagagagcctacgc agaagcagtc cacctggata agtgtaaccc 180 tttagtaaac ctgaactatgctgtgctgct gtacaaccag ggcgagaaga agaacgccct 240 ggcccaatat caggagatggagaagaaagt cagcctactc aaggacaata gctctctgga 300 atttgactct gagatggtggagatggctca gaagttggga gctgctctcc aggttgggga 360 ggcactggtc tggaccaaaccagttaaaga tcccaaatca aagcaccaga ccacttcaac 420 cagcaaacct gccagtttccagcagcctct gggctctaat caagctctag gacaggcaat 480 gtcttcagca gctgcatacaggacgctccc ctcaggtgct ggaggaacat cccagttcac 540 aaagccccca tctcttcctctggagccaga gcctgcggtg gaatcaagtc caactgaaac 600 atcagaacaa ataagagagaaataagaata gaatgaatga ccccaaaata gggttttctt 660 gggcgaggat gtgctggattaggaaaggtg acatgacaca ggcagagcag agtggcaccc 720 accacagaat acagtgtgtgttattacgag gagccagcag ttgagcctaa ggtccttcta 780 cctacctggt attggcatttgaggtcggaa accctctact gccccataag ccaggaaaag 840 tgaaaagaga acacagttcctttaagaact ggcagcaagg cttgaggcct tatgtatgta 900 gctgagtcag caaggtacatgatgctgtct gctttcaaaa ggacttttct ctcctagctg 960 actgactcct tccttagttcaaggaacagc tgagacagac ctctgctgag tagctctgtg 1020 atgacaaagc cttggtttaactgaggtgat cctcaggttg tgaggtttat tagtccccaa 1080 ggcaaacaca aatattagattaataatcca actttaatag tatacattta aaagaaaaaa 1140 aacaaaagcc ctggaagttgaggccaagcc tgctgagtat tgcagctgca tttgcccaaa 1200 gggaatccag aacaagtccctccmtgtatt ttgttcttga gaggggtcag tctagaagct 1260 agatcctatc aggatgaggagcagcagccc agggcttgtc tggatmagca ccaacgattt 1320 taaagaaaaa aggaagagtttcttagatga gtaattgtta ttgaagatag tcagtgataa 1380 ccactgacca gatgctatcaatacastatg tgtccttttt agaataaaga ttacatatca 1440 tcatttcctt tggggaaaattgttattcag gtataaaaac aagagatcat aataaaaacc 1500 taaaagaacc taaaaaaaaaaaaaaaa 1527 <210> SEQ ID NO 54 <211> LENGTH: 122 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 54 Met Glu Lys Lys Val Ser LeuLeu Lys Asp Asn Ser Ser Leu Glu Phe 1 5 10 15 Asp Ser Glu Met Val GluMet Ala Gln Lys Leu Gly Ala Ala Leu Gln 20 25 30 Val Gly Glu Ala Leu ValTrp Thr Lys Pro Val Lys Asp Pro Lys Ser 35 40 45 Lys His Gln Thr Thr SerThr Ser Lys Pro Ala Ser Phe Gln Gln Pro 50 55 60 Leu Gly Ser Asn Gln AlaLeu Gly Gln Ala Met Ser Ser Ala Ala Ala 65 70 75 80 Tyr Arg Thr Leu ProSer Gly Ala Gly Gly Thr Ser Gln Phe Thr Lys 85 90 95 Pro Pro Ser Leu ProLeu Glu Pro Glu Pro Ala Val Glu Ser Ser Pro 100 105 110 Thr Glu Thr SerGlu Gln Ile Arg Glu Lys 115 120 <210> SEQ ID NO 55 <211> LENGTH: 2352<212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 55agcagagtga gctgaagctc ctgaggaggg ttcccgaagg ggggcgctca gagatggggg 60cagggggcgg ggagaggaga gtctgcctta tgtcccttcc ttgtggactt cacatggtca 120tgcaggaagt gaggatgggt gtccagcggg ggccgaggcc actagtatcc tcctgcttcc 180ccctgccatt ctccagggct ggactgaccc tatggactgg gagagagtgc ctgaggccac 240catgccacag tcaaaggggg tcctatctca gaaggtggca gcatccactg agatatcctc 300acccgaaggg aaggaggctg ctgggtagca aataagcccc ttcttttctt ggtgagttga 360tgacctccaa tagctcccag tgtcatgggt acccagtacg cattagctgg tgttgggttg 420attgagacct ggggcagttc ctggggcaag aagccagatg ggagatgaga tagaaagtgt 480taggagttat cctctttgcc tggcctttga gaataactta ctgtgtgact ttgggcaagt 540tccttcccca ctctgggcct cagtttctca cttgggaaag caaggagttt gaccagatga 600tcacaatggg ccttcctagc tctggccacc aagaatttgt gaacattaga gctcctggtc 660tggtgggtag agccagagct gctgactggt ctctctgcct ccagagggga tttattggac 720ctcagaggtg gcagggccct atggagcacc aactgccctc aaccccaccc tgtgcccaag 780actgggaagg gattgatgtc aggctgtggc cataggtagc atgagttgcc caaggaggga 840cagagcatat ctttgctgag gcttggctga ggggcttatg atagggcttg cagtacctca 900cagccccctg tgggcacaga caccctgagg tttacccagg caaatatatt gattagcagg 960acaagggctc tctcctcagt ttctgctccc ttccatctct ctcccatact tgtctgaaaa 1020gggagacaaa aaatcttata caagtggcat ctcaatcctt tccagtccag cacctcctgg 1080ggcaggcagt gtgacttatt tcctgtggtg aaatcacctg tttcacaagc ctggcagcgc 1140gacttctgag tctcatgacc actcaaccca agggacccct ccccagacca gaaccaagtc 1200agctgggggc tgtcgtacta ccctgtccag tcttgagggc ctagttgcag gtcccccagg 1260catccagccc ctcctagagc ttgctgggca ggctgcacct catctgggca ggcgcagagc 1320tgatgaaatg ctggagcaat gcatggcaaa catatgccct ccagtgtctt ctgaaacctt 1380tggggctgac acaagatcct ttagtgtttg ggatgacctc tttcctgcag acttcttccc 1440ctatccctaa ctcatgcatg gaaaacgttt gtcaggctgg tttcccgagc ctcctgcacc 1500tcaacatcac gctcaccctt ttgggtttag cccagtgtta tttagcaaat ttctccagct 1560gcagggaagg atcagagcac tatctttttt tttttttttt ctcctggagc caggactgca 1620caaggcaatg gccaaattta gttgaattca gcctaccatc ctttgctgat gactcagctc 1680tatgccaagt actggagcca cagagatggg tcagtcccag cccctgtcct caggaagccc 1740atggtcaggg aaacgttgta gggataagta atagagggca gttgccttca gggctcctgg 1800tggctgctgg tccctatggt gccttgatgt gaattagaag acggtgccct ttccaggtgg 1860attcagacct acactagaac gcacagcttt gggagtgaca cacaggttgg attttagcac 1920cccttgcccc ttggccagag gtgccctgct gcacggccat acgctgcagc ctcgagggac 1980acacaggcca aagtgtttcc ttcagcctct tcctggagag gaagccgcag gtcatgtttc 2040caagcttctg gtctcaaact cttggcctca agggatcctc ctacctcggc ctccgaaagt 2100gctgggatta caggtgtgag ccaccatgcc tggcctcact gtgtagttgt gaatagctta 2160atagtttgca atgtggtgct tctcacagct cttctctgta atgggaacat gaaaaattac 2220ctggtacagt tttatgcttt gtggtgtggc ttttaatttt tataaacatg tcttactgct 2280attgccaggg atttagattt ttaataaact tccagataca acagtaaaaa aaaaaaaaaa 2340aaaaaaaaaa aa 2352 <210> SEQ ID NO 56 <211> LENGTH: 169 <212> TYPE: PRT<213> ORGANISM: Homo sapiens <400> SEQUENCE: 56 Met Lys Cys Trp Ser AsnAla Trp Gln Thr Tyr Ala Leu Gln Cys Leu 1 5 10 15 Leu Lys Pro Leu GlyLeu Thr Gln Asp Pro Leu Val Phe Gly Met Thr 20 25 30 Ser Phe Leu Gln ThrSer Ser Pro Ile Pro Asn Ser Cys Met Glu Asn 35 40 45 Val Cys Gln Ala GlyPhe Pro Ser Leu Leu His Leu Asn Ile Thr Leu 50 55 60 Thr Leu Leu Gly LeuAla Gln Cys Tyr Leu Ala Asn Phe Ser Ser Cys 65 70 75 80 Arg Glu Gly SerGlu His Tyr Leu Phe Phe Phe Phe Phe Ser Trp Ser 85 90 95 Gln Asp Cys ThrArg Gln Trp Pro Asn Leu Val Glu Phe Ser Leu Pro 100 105 110 Ser Phe AlaAsp Asp Ser Ala Leu Cys Gln Val Leu Glu Pro Gln Arg 115 120 125 Trp ValSer Pro Ser Pro Cys Pro Gln Glu Ala His Gly Gln Gly Asn 130 135 140 ValVal Gly Ile Ser Asn Arg Gly Gln Leu Pro Ser Gly Leu Leu Val 145 150 155160 Ala Ala Gly Pro Tyr Gly Ala Leu Met 165 <210> SEQ ID NO 57 <211>LENGTH: 995 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE:<221> NAME/KEY: unsure <222> LOCATION: (852) <400> SEQUENCE: 57ctaaaccctt cctccagcct ctacctcctg caaaccatcg tccatattgc aagcaatcag 60atttatttat ttattttttg aggcaggaga atggcgtgaa cccgggaggc aaagcttgca 120gtgagccaag atcgcaccac tgcactccag cctgggtgac agagcgagac tctgtctcaa 180aaaaaaaaaa aaaaaagaaa agaaaaaaac ctattgccta cctcccaagg gcaaatgcag 240cctggtgttt ggctccaagt ctgcttcagc tttggctccc atcactccgc tttccttttg 300cctcaactta agatcttgcc acatgtacac ttcccataac attccagctg agaggctttt 360gtatacgagg ggtttttttt tgtttgtttt gccwagaatg atcctccctg gtgaatctta 420gcttaaatca ccaggcagtt aagcaggctt ttctctatga tttcaccccc actttgtata 480tttctgtgat tagtcctgaa catcccatgt tgtactgttt acctctctca ctggacttag 540aaattctgaa gaacagaaac aaaaagtttt ctctttctct gtatgttctt tttttgttgt 600tattattatt gacttggtat atcttctttc agatgtattt tcttttattc tcaacacaaa 660gtaattttaa catgatcttt ctgggccaaa attttcttat ctgtaaaatg aagatgttgg 720actaggattc agggcttctt aactaaagaa ttcaatagat gatgctggga caagtgtata 780tctacctgta aaggaatgaa gttggacccc ttcctcatac tatacacaaa aattaactca 840aaatggatca tngacctaaa cataagagct aaaactataa gactttcaga agaaaacaca 900ggagtaagtc ttcatgacct tggattaagg aatggttgct tagatatgac acccaaaaaa 960aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 995 <210> SEQ ID NO 58 <211>LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:58 Met Leu Tyr Cys Leu Pro Leu Ser Leu Asp Leu Glu Ile Leu Lys Asn 1 510 15 Arg Asn Lys Lys Phe Ser Leu Ser Leu Tyr Val Leu Phe Leu Leu Leu 2025 30 Leu Leu Leu Thr Trp Tyr Ile Phe Phe Gln Met Tyr Phe Leu Leu Phe 3540 45 Ser Thr Gln Ser Asn Phe Asn Met Ile Phe Leu Gly Gln Asn Phe Leu 5055 60 Ile Cys Lys Met Lys Met Leu Asp 65 70 <210> SEQ ID NO 59 <211>LENGTH: 1038 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 59 gacggcctca ccatgatgaa acgggcagct gctgctgcag tgggaggaggtaagttaccc 60 ggatcgcctg tctccaggcc ctcacctagc ctggtccccg ggctgctgggagaacgcaga 120 gatgaggcgc tgggctggct ctcaccctcc acttccgaag ctgcccgagtagcctgagtg 180 agccacagca tcaaaatact ccagggaaaa gctcactccc attcctgacccagcttctct 240 tctagtcctt atgtcgaata agcataggag gaagatcgtt tgaaagargatttgcagcta 300 aactccacgt ggcttatttc acatttatgc gtggacacac acacacacacacacacacac 360 acacaaattt gagaccaatg aagggtattg acttcctcag catcacacagcaagttagag 420 acaaaccagg gccatggctg gtccttctat gacatctttg cttcacctggctccacactc 480 caccttttct tcaccagaag accactaagt tgccatctct gtattgctcaagctgacagt 540 ctccggaaac tgtcaaggaa ttcctaagcg gggggcgggg ggaagggtcccttctcctga 600 gcccacctct gcactcagct tctctctccc acagccctgg cagtgggggctgtgcccgtg 660 gtgctcagtg ccatgggctt cactggggca ggaatcgccg cgtcctccatagcagccaag 720 atgatgtccg cagcagccat tgccaacggg ggtggtgttt ctgcggggagcctggtggct 780 actctgcagt ccgtgggggc agctggactc tccacatcat ccaacatcctcctggcctct 840 gttgggtcag tgtkgggggc ctgctkgggg aattcacctt cttcttctctcccagctgaa 900 cccgaggcta aagaagatga ggcaagagaa aatgtacccc aaggtgaacctccaaaaccc 960 ccactcaagt cagagaaaca tgaggaataa aggtcacatg cagatgcataaaaaaaaaaa 1020 aaaaaaaaaa aaaaaaaa 1038 <210> SEQ ID NO 60 <211>LENGTH: 105 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE:<221> NAME/KEY: UNSURE <222> LOCATION: (61) <221> NAME/KEY: UNSURE <222>LOCATION: (65) <400> SEQUENCE: 60 Met Gly Phe Thr Gly Ala Gly Ile AlaAla Ser Ser Ile Ala Ala Lys 1 5 10 15 Met Met Ser Ala Ala Ala Ile AlaAsn Gly Gly Gly Val Ser Ala Gly 20 25 30 Ser Leu Val Ala Thr Leu Gln SerVal Gly Ala Ala Gly Leu Ser Thr 35 40 45 Ser Ser Asn Ile Leu Leu Ala SerVal Gly Ser Val Xaa Gly Ala Cys 50 55 60 Xaa Gly Asn Ser Pro Ser Ser SerLeu Pro Ala Glu Pro Glu Ala Lys 65 70 75 80 Glu Asp Glu Ala Arg Glu AsnVal Pro Gln Gly Glu Pro Pro Lys Pro 85 90 95 Pro Leu Lys Ser Glu Lys HisGlu Glu 100 105 <210> SEQ ID NO 61 <211> LENGTH: 1060 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 61 gaggagacca ggacagctgctgagacctct aagaagtcca gatactaaga gcaaagatgt 60 ttcaaactgg gggcctcattgtcttctacg ggctgttagc ccagaccatg gcccagtttg 120 gaggcctgcc cgtgcccctggaccagaccc tgcccttgaa tgtgaatcca gccctgccct 180 tgagtcccac aggtcttgcaggaagcttga caaatgccct cagcaatggc ctgctgtctg 240 ggggcctgtt gggcattctggaaaaccttc cgctcctgga catcctgaag cctggaggag 300 gtacttctgg tggcctccttgggggactgc ttggaaaagt gacgtcagtg attcctggcc 360 tgaacaacat cattgacataaaggtcactg acccccagct gctggaactt ggccttgtgc 420 agagccctga tggccaccgtctctatgtca ccatccctct cggcataaag ctccaagtga 480 atacgcccct ggtcggtgcaagtctgttga ggctggctgt gaagctggac atcactgcag 540 aaatcttagc tgtgagagataagcaggaga ggatccacct ggtccttggt gactgcaccc 600 attcccctgg aagcctgcaaatttctctgc ttgatggact tggccccctc cccattcaag 660 gtcttctgga cagcctcacagggatcttga ataaagtcct gcctgagttg gttcagggca 720 acgtgtgccc tctggtcaatgaggttctca gaggcttgga catcaccctg gtgcatgaca 780 ttgttaacat gctgatccacggactacagt ttgtcatcaa ggtctaagcc ttccaggaag 840 gggctggcct ctgctgagctgaactatttc ttgctgctca atccatttcc tctggcccag 900 cttcccagtg ctcacagatggctggcccat gtgctggaag atgacacagt tgccttctct 960 ccgaggaacc tgccccctctcctttcccac caggcgtgtg taacatccca tgtgcctcac 1020 ctaataaaat ggctcttcttctgcaaaaaa aaaaaaaaaa 1060 <210> SEQ ID NO 62 <211> LENGTH: 256 <212>TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 62 Met Phe GlnThr Gly Gly Leu Ile Val Phe Tyr Gly Leu Leu Ala Gln 1 5 10 15 Thr MetAla Gln Phe Gly Gly Leu Pro Val Pro Leu Asp Gln Thr Leu 20 25 30 Pro LeuAsn Val Asn Pro Ala Leu Pro Leu Ser Pro Thr Gly Leu Ala 35 40 45 Gly SerLeu Thr Asn Ala Leu Ser Asn Gly Leu Leu Ser Gly Gly Leu 50 55 60 Leu GlyIle Leu Glu Asn Leu Pro Leu Leu Asp Ile Leu Lys Pro Gly 65 70 75 80 GlyGly Thr Ser Gly Gly Leu Leu Gly Gly Leu Leu Gly Lys Val Thr 85 90 95 SerVal Ile Pro Gly Leu Asn Asn Ile Ile Asp Ile Lys Val Thr Asp 100 105 110Pro Gln Leu Leu Glu Leu Gly Leu Val Gln Ser Pro Asp Gly His Arg 115 120125 Leu Tyr Val Thr Ile Pro Leu Gly Ile Lys Leu Gln Val Asn Thr Pro 130135 140 Leu Val Gly Ala Ser Leu Leu Arg Leu Ala Val Lys Leu Asp Ile Thr145 150 155 160 Ala Glu Ile Leu Ala Val Arg Asp Lys Gln Glu Arg Ile HisLeu Val 165 170 175 Leu Gly Asp Cys Thr His Ser Pro Gly Ser Leu Gln IleSer Leu Leu 180 185 190 Asp Gly Leu Gly Pro Leu Pro Ile Gln Gly Leu LeuAsp Ser Leu Thr 195 200 205 Gly Ile Leu Asn Lys Val Leu Pro Glu Leu ValGln Gly Asn Val Cys 210 215 220 Pro Leu Val Asn Glu Val Leu Arg Gly LeuAsp Ile Thr Leu Val His 225 230 235 240 Asp Ile Val Asn Met Leu Ile HisGly Leu Gln Phe Val Ile Lys Val 245 250 255 <210> SEQ ID NO 63 <211>LENGTH: 992 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE:63 gcagaatggg gctctggtct ctgggcattc atttccctca tagaggctga gaataaaaca 60aggacttatt cacacatgtt ctagaacccc agaatggccc aagttacctg agaccagggt 120ttctcaacct tgacaccatt gacattttgg actgggtaat tctttgttct gcagagctgt 180cctttgcact gtaggagatt tactaatatc cctggcctct acccagtagt accactagca 240cctattcccc acccagcgtg tctccagata ttgtcaaata tcccatcggg tgcaaaatga 300tccctggtca agatctgttg cccaagatgt tacaggtcac aatgaccaca tttgaaattg 360ttttcccttt cattttaccc tgtgaaagca tctctcctag agccttgcaa gaggcaggtg 420acattgtgtc catatttctt cctgtttcag aacttctgtt tcacaacaat ttctctctcg 480ctacaagtat tctttcactc agcactgggg aagttgggaa cagctggtca ccatcatccc 540tttaatcaac tcacacctgt ttaaagagtg tttctgattt gaccttcatc ccttagttta 600ctggggttaa aaaaagtctc agcaattttc attatttctc gtgggtctca ttatcaaacc 660tttacttatt tcggcatatt tcctctgggc ttcttctagt ttctgcctta caagcaatgc 720tgttctgtaa atttattgaa aactctggaa catttcacct ttagagatgg aggatggaag 780gattggtacc agaagagggc taagatacgt tttctgtctt gagctgaaag cacagtctac 840tctccttcgt tttgtcgatg agaaagttga ggccagaggg gaggtgacat gtttagagtc 900acccagctgg ttagtgacag aaaaagcgtg agagttgtct aggattcctg ccactttcaa 960taaagacctg acttggaaaa aaaaaaaaaa aa 992 <210> SEQ ID NO 64 <211> LENGTH:82 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 64 MetIle Pro Gly Gln Asp Leu Leu Pro Lys Met Leu Gln Val Thr Met 1 5 10 15Thr Thr Phe Glu Ile Val Phe Pro Phe Ile Leu Pro Cys Glu Ser Ile 20 25 30Ser Pro Arg Ala Leu Gln Glu Ala Gly Asp Ile Val Ser Ile Phe Leu 35 40 45Pro Val Ser Glu Leu Leu Phe His Asn Asn Phe Ser Leu Ala Thr Ser 50 55 60Ile Leu Ser Leu Ser Thr Gly Glu Val Gly Asn Ser Trp Ser Pro Ser 65 70 7580 Ser Leu <210> SEQ ID NO 65 <211> LENGTH: 1095 <212> TYPE: DNA <213>ORGANISM: Homo sapiens <400> SEQUENCE: 65 gtcttaatga gcaacagcaacagcagtctc cagttaagaa agagagaatt aaatacagca 60 gagatttcct gttgaagctctcaagtgttt ccatctgcag aaaaaaacca gactttctgc 120 ctgatcatcc cattgtactgcaaaaaccag aaaacaacca aagttttaag tagcatttta 180 agaacagatg aatttaagtttggacatctg caaatgaggt ggatctagca acaataactg 240 taatggactg tgacaattcaatttattctt aattttgatg gttggctatt tgacttctct 300 aaaaatgaga aagagctattttaaaatata aagaattttc taatcagttt cagctttgca 360 ggaggtttcc tgcataaattgggaagtaac actggaaagt aggaatttgg ttagtgaagt 420 gggaagactg tatatttataatttgcatac tacttgcaat tttttgtttt tcatcacttg 480 taataatgga atggaaatgtaagctgtaaa gactctcaaa tataaaatat ttgctacagt 540 gtatatatgg tacataattgcttgttgctt ttaaagttcc ttctgttgtt ctgcttccca 600 ctgatttcat accagctcatgaatggatca ttacagtctc tccagaggct tagaatgatt 660 cagaatgttc aatgcatagttctcaataaa caggaggcag aatttttaat gggtatttct 720 tttcagatat atgattggtctctaggtttt tgataataat atggtcttaa attcataatt 780 actagcagag attgataatttggaaacaat ggtagtgaat gaaactgaag ttgaaaaacg 840 gctgctactt atgtcactaatcagaccata tgaatagcag aagttgagca atttcaaagt 900 aaaactgata tttttatttccaaaggaatt tagacatttg aaaataattg acatacatta 960 agttttaatt cgataatttcttatatatgg atgaacaatt tttgggttta agcttttaat 1020 tcctagaaat tttatacattaaatctcctg caatttgtca ctctggatgt tactgtttaa 1080 aaaaaaaaaa aaaaa 1095<210> SEQ ID NO 66 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 66 Met Val His Asn Cys Leu Leu Leu Leu Lys PheLeu Leu Leu Phe Cys 1 5 10 15 Phe Pro Leu Ile Ser Tyr Gln Leu Met AsnGly Ser Leu Gln Ser Leu 20 25 30 Gln Arg Leu Arg Met Ile Gln Asn Val GlnCys Ile Val Leu Asn Lys 35 40 45 Gln Glu Ala Glu Phe Leu Met Gly Ile SerPhe Gln Ile Tyr Asp Trp 50 55 60 Ser Leu Gly Phe 65 <210> SEQ ID NO 67<211> LENGTH: 831 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 67 ggctctgtgg gcccagccct acccctgaag cacagttaac tggttctggggtaggaactg 60 ggggccggag ggacagggtt ctggttctgg ctcaaccttg gctgctggtgagatccaggg 120 cctgggaaag aggggctgag gcctgaactg ggcctaagga gagtgcagctcagttcgcac 180 acaacagcac ccagccctgt ccccttgctg cctctaccca gccctgggcagttccctcaa 240 cagagctctg cagccccaag tggcagctgc tggctcaaag ctgggactacatgaaagtct 300 gaaaagagaa tgagaaggag gtggcgcaag agcctggacg cacgtgtgggaggccgtttt 360 gtgcagcgct attgtgctcc ccgggcgggc atgtkctcgc gctccgtggctctgttggtg 420 cccarcgtgc gggggtgtgc tkgtggccct gtgggcctgt agggcaacccatgccaactg 480 cggaaaagta accagcacca tacacccccc ccaacacaaa actggtcatttatttttttt 540 gttgtcattg ttattaggaa gcaaaaaaat gtacagttac aagaatcattttccaaacag 600 aggttaaata tgagctgaaa agtgtaaaaa aggaagagga acatcactttacaaatcatt 660 aaattaaaca aataaacaaa cagaacccaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa 720 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa 780 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a831 <210> SEQ ID NO 68 <211> LENGTH: 50 <212> TYPE: PRT <213> ORGANISM:Homo sapiens <220> FEATURE: <221> NAME/KEY: UNSURE <222> LOCATION: (29)<221> NAME/KEY: UNSURE <222> LOCATION: (39) <221> NAME/KEY: UNSURE <222>LOCATION: (45) <400> SEQUENCE: 68 Met Arg Arg Arg Trp Arg Lys Ser LeuAsp Ala Arg Val Gly Gly Arg 1 5 10 15 Phe Val Gln Arg Tyr Cys Ala ProArg Ala Gly Met Xaa Ser Arg Ser 20 25 30 Val Ala Leu Leu Val Pro Xaa ValArg Gly Cys Ala Xaa Gly Pro Val 35 40 45 Gly Leu 50 <210> SEQ ID NO 69<211> LENGTH: 1893 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 69 ggcaraccgt gtgagggggc ctgtggcccc agcgtgctgt ggcctcggggagtgggaagt 60 ggaggcagga gccttcctta cacttcgcca tgagtttcct catcgactccagcatcatga 120 ttacctccca ratactattt tttggatttg ggtggctttt cttcatgcgccaattgttta 180 aagactatga ratacgtcag tatgttgtac aggtgatctt ctccgtgacgtttgcatttt 240 cttgcaccat gtttgagctc atcatctttg aaatcttagg agtattgaatagcagctccc 300 gttattttca ctggaaaatg aacctgtgtg taattctgct gatcctggttttcatggtgc 360 ctttttacat tggctatttt attgtgagca atatccgact actgcataaacaacgactgc 420 ttttttcctg tctcttatgg ctgaccttta tgtatttctt ctggaaactaggagatccct 480 ttcccattct cagcccaaaa catgggatct tatccataga acagctcatcagccgggttg 540 gtgtgattgg agtgactctc atggctcttc tttctggatt tggtgctgtcaactgcccat 600 acacttacat gtcttacttc ctcaggaatg tgactgacac ggatattctagccctggaac 660 ggcgactgct gcaaaccatg gatatgatca taagcaaaaa gaaaaggatggcaatggcac 720 ggagaacaat gttccagaag ggggaagtgc ataacaaacc atcaggtttctggggaatga 780 taaaaagtgt taccacttca gcatcaggaa gtgaaaatct tactcttattcaacaggaag 840 tggatgcttt ggaagaatta agcaggcagc tttttctgga aacagctgatctatatgcta 900 ccaaggagag aatagaatac tccaaaacct tcaaggggaa atatttaatttcttggttac 960 tttttctcta tctactgtgt ttggaaaatt ttcatgaata ccatcaatattgtatttgat 1020 cgagttggga aaacggatcc tgtcacaaga ggcattgaga tcactgtgaattatctggga 1080 atccaatttg atgtgaagtt ttggtcccaa cacatttcct tcattcttgttggaataatc 1140 atcgtcacat ccatcagagg attgctgatc actcttacca agttcttttatgccatctct 1200 agcagtaagt cctccaatgt cattgtcctg ctattagcac agataatgggcatgtacttt 1260 gtctcctctg tgctgctgat ccgaatgagt atgcctttag aataccgcaccataatcact 1320 gaagtccttg gagaactgca gttcaacttc tatcaccgtt ggtttgatgtgatcttcctg 1380 gtcagcgctc tctctagcat actcttcctc tatttggctc acaaacaggcaccagagaag 1440 caaatggcac cttgaactta agcctactac agactgttag aggccagtggtttcaaaatt 1500 tagatataag aggggggaaa aatggaacca gggcctgaca ttttataaacaaacaaaatg 1560 ctatggtagc atttttcacc ttcatagcat actccttccc cgtcaggtgatactatgacc 1620 atgagtagca tcagccagaa catgagaggg agaactaact caagacaatactcagcagag 1680 agcatcccgt gtggatatga ggctggtgta gaggcggaga ggagccaagaaactaaaggt 1740 gaaaaataca ctggaactct ggggcaagac atgtctatgg tagctgagccaaacacgtag 1800 gatttccgtt ttaaggttca catggaaaag gttatagctt tgccttgagattgactcatt 1860 aaaatcagag actgtaacaa aaaaaaaaaa aaa 1893 <210> SEQ IDNO 70 <211> LENGTH: 309 <212> TYPE: PRT <213> ORGANISM: Homo sapiens<400> SEQUENCE: 70 Met Ser Phe Leu Ile Asp Ser Ser Ile Met Ile Thr SerGln Ile Leu 1 5 10 15 Phe Phe Gly Phe Gly Trp Leu Phe Phe Met Arg GlnLeu Phe Lys Asp 20 25 30 Tyr Glu Ile Arg Gln Tyr Val Val Gln Val Ile PheSer Val Thr Phe 35 40 45 Ala Phe Ser Cys Thr Met Phe Glu Leu Ile Ile PheGlu Ile Leu Gly 50 55 60 Val Leu Asn Ser Ser Ser Arg Tyr Phe His Trp LysMet Asn Leu Cys 65 70 75 80 Val Ile Leu Leu Ile Leu Val Phe Met Val ProPhe Tyr Ile Gly Tyr 85 90 95 Phe Ile Val Ser Asn Ile Arg Leu Leu His LysGln Arg Leu Leu Phe 100 105 110 Ser Cys Leu Leu Trp Leu Thr Phe Met TyrPhe Phe Trp Lys Leu Gly 115 120 125 Asp Pro Phe Pro Ile Leu Ser Pro LysHis Gly Ile Leu Ser Ile Glu 130 135 140 Gln Leu Ile Ser Arg Val Gly ValIle Gly Val Thr Leu Met Ala Leu 145 150 155 160 Leu Ser Gly Phe Gly AlaVal Asn Cys Pro Tyr Thr Tyr Met Ser Tyr 165 170 175 Phe Leu Arg Asn ValThr Asp Thr Asp Ile Leu Ala Leu Glu Arg Arg 180 185 190 Leu Leu Gln ThrMet Asp Met Ile Ile Ser Lys Lys Lys Arg Met Ala 195 200 205 Met Ala ArgArg Thr Met Phe Gln Lys Gly Glu Val His Asn Lys Pro 210 215 220 Ser GlyPhe Trp Gly Met Ile Lys Ser Val Thr Thr Ser Ala Ser Gly 225 230 235 240Ser Glu Asn Leu Thr Leu Ile Gln Gln Glu Val Asp Ala Leu Glu Glu 245 250255 Leu Ser Arg Gln Leu Phe Leu Glu Thr Ala Asp Leu Tyr Ala Thr Lys 260265 270 Glu Arg Ile Glu Tyr Ser Lys Thr Phe Lys Gly Lys Tyr Leu Ile Ser275 280 285 Trp Leu Leu Phe Leu Tyr Leu Leu Cys Leu Glu Asn Phe His GluTyr 290 295 300 His Gln Tyr Cys Ile 305 <210> SEQ ID NO 71 <211> LENGTH:1424 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 71cttggctgac ggattgcctt agaagacttc atgttattga ataacgtgaa tactgtgatg 60atggccaatt ccaggtgcgc atgaagatcg tgaaaataac agctatttcc agtgtttaca 120tctacttaat attctcgtgc tcagagctaa cgaggctggc gttaggcggt gacgtgggcc 180tgtttgaagg atgctggaag tcgcgggcct aggttgcatg gtgtgtgtct gggctgcctc 240ccaaaccgag gtatgtggcc cagatctggc taatggacag tttcacccaa gctctgtcct 300gtttccagct gacagctgct acctgcaggt gctgctcgag tctgtctctg gttcaccata 360agccaaggtt gggtcttctc ccccaagggc tcctccattc cctgagacct ccctgtctgg 420gggtcctggc agcatgctat gggaggagtc ctccagacat ttccctcacc ctcacccctc 480atacccctga ctcaccaaac cctctagccc tctggctttg ttgttctgca aaatccaaca 540tttccttttc ctacccccgc ccaacctgcc taagttcaga tgtccccact cctcacctcc 600atcataaggt aagaacctga atttgttttc ccacttcctt ttgggcctca ctcttctcca 660agttccccag tcacctccag aatgacttct gaacatgcaa ccctcaggag tctctccgcc 720ctccccactt tccccaaccc tgcagtcagc accccagggc tctggaggct gtacaggtat 780gagatgcaaa gggcctgtgg tttaggtgtg agtgtggtat gggggtgtgg aggcagcccc 840gtctggcatg gctgtgaggg ggcagtggaa gacaggctgt ctgtgctccc atgatggtct 900ggggcccccc tggtcagccc acatggccct gtgggggctc ctgctgctac agggtgctgg 960gctgggcgga ggaagagctg gccattcagg atgggcgcag tggctcatgc ctgtaatccc 1020agcactttgg gaggcccagg caggtggatt gcttgagccc aggagttcaa gaccagcctg 1080ggcaacatag taaaaccccg tctttactga aaacacaaaa tttagccagg tgtggtggcg 1140cacgcctgyt actctggagg ctgaggcatg agaatcgctt gaaccaggag gtggaggttg 1200cagtgagcca aaaccatgcc actgcactcc agcctgggca acagagtgag acgcggtctc 1260aaaaaaagaa gaaagaaaga aagaaagaaa gaaagaaaga aataaagaaa gagagagaga 1320gagagagaga gagagagaga aagaaagaaa gaaagawaga aagaaagaaa gaaagaaaga 1380aagaaagaaa gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1424 <210> SEQ ID NO 72<211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 72 Met Thr Ser Glu His Ala Thr Leu Arg Ser Leu Ser Ala Leu ProThr 1 5 10 15 Phe Pro Asn Pro Ala Val Ser Thr Pro Gly Leu Trp Arg LeuTyr Arg 20 25 30 Tyr Glu Met Gln Arg Ala Cys Gly Leu Gly Val Ser Val ValTrp Gly 35 40 45 Cys Gly Gly Ser Pro Val Trp His Gly Cys Glu Gly Ala ValGlu Asp 50 55 60 Arg Leu Ser Val Leu Pro 65 70 <210> SEQ ID NO 73 <211>LENGTH: 1726 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 73 agctggggag aaggaagaaa actgggccgg gaacccctcc cctcagtgtcccccagttct 60 ccatctccat aaggagccat caggctgtca ttaaggaaca gagtgtcactcagggggcac 120 tgtcacaaag cagcacccat ggcacatggg ccgggggtgc agaagcctggcttatttcag 180 gctgacagct ggaccctctg ggtgcagggg ctcaggcagt ggccaagagcccaaagggct 240 aaggcccgtg acgaccaccc agcccgtcac cccaggtaca aacactgaccccaaagcaag 300 agcagggact gtccctcagc cctcagggcc ttcatgcagg gtgcagaatctcatgtccac 360 atggaggtca cccctcaggt cacacccact cccagagcaa ccctgggcarggaggggcac 420 cctggggttg tgttgaccac ctccccttca ggtgaggccc ttttctgccttctttctagc 480 cccctgcatg gggcacctgc tattgctggg gctctggggt ggaccctgtgtgatttctgt 540 cagggagctt gtgctgtgca tggccagagg tgtttacatc cagaagggcccagcacggcc 600 ctgtggggtg tggggggaat atggtagatc attgtgatgt gcctcggggccctcttgcct 660 tggagccagc tttgtttcag aatctgctac ttgggccctc ttcagggttttgaggctgga 720 gaagtgagtt gggacagtca ctgtcatcac cacccaccct gtcacccacctggaaaacat 780 tcttgatata ctggccatgc tgggccgggc tcacatccac tgagggtatagtgaccaagc 840 atctaaacca gtcgttctca aacttcggtg agtatcagaa tcacctggaagggcttttac 900 agattgctgg ccccaccccc cagaatttct catcaggagt gggcaagaccaatcatttgc 960 atttctaaca agttcctagg agctgcagct gctggccctg gaaccacactttgagaacca 1020 ctgctttaga ccaaacacca aaggaagatg cagccaccct cctttacatgtcacaacgct 1080 cagggtccat gagtacctca ggctgtccag ctgagctcca cctgcagcagccgagattcc 1140 cgactcgctc caccattggg ggctaggagt gaagcgtgtc accatggtcagctcatggcc 1200 agccaggaaa gcctctctgc tgtgcgtctg tgcagttctt gttcttccctggaggactct 1260 tggatcgcct gtgatcttgg ccaggagacc aggtgcctgg gtcccttcctggaaggggac 1320 aagttacaca ccccagcccc attttcccac caacttctac atgccttgggagaacctgct 1380 acatgttggc tgcccccttc ccctatttca gcagtgccca gtcctgcttataaacctgag 1440 gcctgctccc cataccctgc cctgtgcaag tgccagccgt tattccaggcagcccaatgt 1500 tgttgaggcc agatggattc ctggaagcag ctggcccatg gatgtgagtcatcacagtat 1560 tctagaaaca gagaagaggt cttaacctaa tgcgcataga gaaattgttctcattgtaaa 1620 catacccctg tccttagctg atctaggtgg aagcccagct tcatgtgctagggggcatga 1680 taatgataat aaaggaattg tatctaggaa aaaaaaaaaa aaaaaa 1726<210> SEQ ID NO 74 <211> LENGTH: 133 <212> TYPE: PRT <213> ORGANISM:Homo sapiens <400> SEQUENCE: 74 Met Val Ser Ser Trp Pro Ala Arg Lys AlaSer Leu Leu Cys Val Cys 1 5 10 15 Ala Val Leu Val Leu Pro Trp Arg ThrLeu Gly Ser Pro Val Ile Leu 20 25 30 Ala Arg Arg Pro Gly Ala Trp Val ProSer Trp Lys Gly Thr Ser Tyr 35 40 45 Thr Pro Gln Pro His Phe Pro Thr AsnPhe Tyr Met Pro Trp Glu Asn 50 55 60 Leu Leu His Val Gly Cys Pro Leu ProLeu Phe Gln Gln Cys Pro Val 65 70 75 80 Leu Leu Ile Asn Leu Arg Pro AlaPro His Thr Leu Pro Cys Ala Ser 85 90 95 Ala Ser Arg Tyr Ser Arg Gln ProAsn Val Val Glu Ala Arg Trp Ile 100 105 110 Pro Gly Ser Ser Trp Pro MetAsp Val Ser His His Ser Ile Leu Glu 115 120 125 Thr Glu Lys Arg Ser 130<210> SEQ ID NO 75 <211> LENGTH: 927 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 75 cagacggcgg agcctggagg agcccacgcagtctgttcct ggcacccggt gcgtgtgaag 60 ggacttgagg gcagcgagat ggaatcagcaagagaaaaca tcgaccttca acctggaagc 120 tccgacccca ggagccagcc catcaacctgaaccattacg ccaccaagaa gagcgtggcg 180 gagagcatgc tggacgtggc cctgttcatgtccaacgcca tgcggctgaa ggcggtgctg 240 gagcagggac catcctctca ctactacaccaccctggtca ccctcatcag cctctctctg 300 ctcctgcagg tggtcatcgg tgtcctgctcgtggtcattg cacggctgaa cctgaatgag 360 gtagaaaagc agtggcgact caaccagctcaacaacgcag ccaccatctt ggtcttcttc 420 actgtggtca tcaatgtttt cattacagccttcggggcac ataaaacagg gttcctggct 480 gccagggcct caaggaatcc tctctgaatgcagcctggga cccaggttct ggggcctgga 540 acttctgcct ccttcctccg tgatctgccaggctcggtgg gcactttcca cagcccagga 600 gagcttctga aaggacagta tagctgcccttgctccctac ccacagcacc tgagttaaaa 660 agtgattttt akgttattgg tctaagggacttccatcttg gtctgaagtc ctgagctcag 720 acgcaggtac tgccagccat accttcctggtagcatctgc tggacctaag taaggcatgt 780 ctgtctaagg ccaagtctgc ccggcttaaggatgctggtt ctgactctac cccactgctt 840 ccttctgctc caggcctcaa ttttcccttcttgtaaaatg gaatctatat ctataaaggt 900 ttcttcaaat ccaaaaaaaa aaaaaaa 927<210> SEQ ID NO 76 <211> LENGTH: 142 <212> TYPE: PRT <213> ORGANISM:Homo sapiens <400> SEQUENCE: 76 Met Glu Ser Ala Arg Glu Asn Ile Asp LeuGln Pro Gly Ser Ser Asp 1 5 10 15 Pro Arg Ser Gln Pro Ile Asn Leu AsnHis Tyr Ala Thr Lys Lys Ser 20 25 30 Val Ala Glu Ser Met Leu Asp Val AlaLeu Phe Met Ser Asn Ala Met 35 40 45 Arg Leu Lys Ala Val Leu Glu Gln GlyPro Ser Ser His Tyr Tyr Thr 50 55 60 Thr Leu Val Thr Leu Ile Ser Leu SerLeu Leu Leu Gln Val Val Ile 65 70 75 80 Gly Val Leu Leu Val Val Ile AlaArg Leu Asn Leu Asn Glu Val Glu 85 90 95 Lys Gln Trp Arg Leu Asn Gln LeuAsn Asn Ala Ala Thr Ile Leu Val 100 105 110 Phe Phe Thr Val Val Ile AsnVal Phe Ile Thr Ala Phe Gly Ala His 115 120 125 Lys Thr Gly Phe Leu AlaAla Arg Ala Ser Arg Asn Pro Leu 130 135 140 <210> SEQ ID NO 77 <211>LENGTH: 1660 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 77 gcaagtccca cgcacagtcc tgaaaaaaat tttaatcttc ttttcttagaactatcttgg 60 ttggcatcat caggccctga gagcacagtg catgtcagca tctaagattccacttttcaa 120 aatgaaggac ctgatactga tcctatgcct cctggaaatg agttttgcagtgccgttctt 180 tcctcagcaa tctggaacac cgggtatggc tagtttgagc cttgagacaatgagacagtt 240 gggaagtctg cagagattaa acacactttc tcagtattct agatacggctttggaaaatc 300 atttaattct ttgtggatgc acggtctcct cccaccacat tcctctcttccatggatgag 360 gccaagagaa catgaaactc aacagtatga atattctttg cctgtgcatcccccacctct 420 cccatcacag ccatccttga agcctcaaca gccaggactg aaaccttttctccagtctgc 480 tgctgcaacc accaaccagg ccacagcact gaaagaagca cttcagcctccaattcacct 540 gggacatctg cccttgcagg aaggagaact gcctctggtt cagcagcaggtggcaccatc 600 agataagcca ccaaagcctg agctcccagg agtagatttt gctgatccacaaggtccatc 660 actcccagga atggattttc ctgatccaca aggtccatca ctcccaggattggattttgc 720 tgatccacaa ggttcaacaa ttttccagat agcccgtttg atttctcacggaccaatgcc 780 acaaaataaa caatctccac tttatccagg aatgttgtac gtgccttttggagcaaatca 840 attgaatgcc cctgccagac ttggcatcat gagttcagaa gaagtggcaggcgggagaga 900 agacccaatg gcctatggag ccatgtttcc aggatttgga ggcatgaggcccggctttga 960 gggaatgccc cacaacccag ctatgggcgg tgacttcact ctggaatttgactccccagt 1020 ggctgccacc aaaggccctg agaacgaaga aggaggtgca caaggctcccctatgccgga 1080 ggccaaccca gacaatctag aaaacccagc tttccttaca gagctagaacctgctcccca 1140 cgcagggctc cttgctctcc ctaaggatga cattcccggc ctgccaaggagcccttcagg 1200 gaagatgaag ggactcccca gygtcacccc agcagctgct gacccactgatgacccctga 1260 attagctgat gtttatagga cctacgatgc tgacatgacc acatccgtggatttccagga 1320 agaagcaacc atggatacca cgatggcccc aaactctctg caaacatccatgccaggaaa 1380 caaagcccag gagcccgaga tgatgcatga cgcatggcat ttccaagagccctgacagct 1440 ctaagatatt agctactttc tgtatgcaca agcttcccag ctttgtccccacagtgtacc 1500 tttttgctaa aacacttatt acccttctgc agcaaaggca ttaaaagcgctaagcatata 1560 ttaataaatg caagtggcta gaaatagtgt aggtcccctt cttgctttcaatatcttgtt 1620 gaaataaaat gtgtcaattg tcaaaaaaaa aaaaaaaaaa 1660 <210>SEQ ID NO 78 <211> LENGTH: 447 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 78 Met Ser Ala Ser Lys Ile Pro Leu Phe Lys MetLys Asp Leu Ile Leu 1 5 10 15 Ile Leu Cys Leu Leu Glu Met Ser Phe AlaVal Pro Phe Phe Pro Gln 20 25 30 Gln Ser Gly Thr Pro Gly Met Ala Ser LeuSer Leu Glu Thr Met Arg 35 40 45 Gln Leu Gly Ser Leu Gln Arg Leu Asn ThrLeu Ser Gln Tyr Ser Arg 50 55 60 Tyr Gly Phe Gly Lys Ser Phe Asn Ser LeuTrp Met His Gly Leu Leu 65 70 75 80 Pro Pro His Ser Ser Leu Pro Trp MetArg Pro Arg Glu His Glu Thr 85 90 95 Gln Gln Tyr Glu Tyr Ser Leu Pro ValHis Pro Pro Pro Leu Pro Ser 100 105 110 Gln Pro Ser Leu Lys Pro Gln GlnPro Gly Leu Lys Pro Phe Leu Gln 115 120 125 Ser Ala Ala Ala Thr Thr AsnGln Ala Thr Ala Leu Lys Glu Ala Leu 130 135 140 Gln Pro Pro Ile His LeuGly His Leu Pro Leu Gln Glu Gly Glu Leu 145 150 155 160 Pro Leu Val GlnGln Gln Val Ala Pro Ser Asp Lys Pro Pro Lys Pro 165 170 175 Glu Leu ProGly Val Asp Phe Ala Asp Pro Gln Gly Pro Ser Leu Pro 180 185 190 Gly MetAsp Phe Pro Asp Pro Gln Gly Pro Ser Leu Pro Gly Leu Asp 195 200 205 PheAla Asp Pro Gln Gly Ser Thr Ile Phe Gln Ile Ala Arg Leu Ile 210 215 220Ser His Gly Pro Met Pro Gln Asn Lys Gln Ser Pro Leu Tyr Pro Gly 225 230235 240 Met Leu Tyr Val Pro Phe Gly Ala Asn Gln Leu Asn Ala Pro Ala Arg245 250 255 Leu Gly Ile Met Ser Ser Glu Glu Val Ala Gly Gly Arg Glu AspPro 260 265 270 Met Ala Tyr Gly Ala Met Phe Pro Gly Phe Gly Gly Met ArgPro Gly 275 280 285 Phe Glu Gly Met Pro His Asn Pro Ala Met Gly Gly AspPhe Thr Leu 290 295 300 Glu Phe Asp Ser Pro Val Ala Ala Thr Lys Gly ProGlu Asn Glu Glu 305 310 315 320 Gly Gly Ala Gln Gly Ser Pro Met Pro GluAla Asn Pro Asp Asn Leu 325 330 335 Glu Asn Pro Ala Phe Leu Thr Glu LeuGlu Pro Ala Pro His Ala Gly 340 345 350 Leu Leu Ala Leu Pro Lys Asp AspIle Pro Gly Leu Pro Arg Ser Pro 355 360 365 Ser Gly Lys Met Lys Gly LeuPro Ser Val Thr Pro Ala Ala Ala Asp 370 375 380 Pro Leu Met Thr Pro GluLeu Ala Asp Val Tyr Arg Thr Tyr Asp Ala 385 390 395 400 Asp Met Thr ThrSer Val Asp Phe Gln Glu Glu Ala Thr Met Asp Thr 405 410 415 Thr Met AlaPro Asn Ser Leu Gln Thr Ser Met Pro Gly Asn Lys Ala 420 425 430 Gln GluPro Glu Met Met His Asp Ala Trp His Phe Gln Glu Pro 435 440 445 <210>SEQ ID NO 79 <211> LENGTH: 2036 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 79 gacaaatacc aagaattttt gcgtatgttt atattgtattgttctaaata atgggtagcc 60 tgtgaaataa gatcttgcca cccatgtaat aatagtagtaatactatagt taaaatggct 120 gtaagaatag ttttataaaa gtgaatacac agatctattgtatttgaaac ataactttga 180 caattattag tgtgaccaaa gtattaggcg gttttcatacatttttcacc ttgtacaaaa 240 ttatgaattc atttttcctc caggccgaca aggagttgtagaatgaaaat gccctctaag 300 tgttattttg gttgttctaa cttacaaaag tgattttgaataagaaatat ttggtgttct 360 ttttataacc agtttttgat tggtaattgt tttctgtattgtttaaaacg gatcaaaaat 420 gtwagtctat tggtagagat taagtattta ttgctacmtcatagttgawa aattgatgtt 480 atcgtaaagc catatgttct gtycaagtct tgtttgccttgaaatgawta ttcctacaag 540 tgaaacacta gactatttgg gagtgtatat ggcttgtgttttgggatttt tttttttttt 600 ttttggcttt tgtttttgtt tgtttttttg tttcgtttggtagttcatct gccttttaac 660 ccattcacca aaatttacct tgttaacaag catcaccaatgaacatttca gagcaatctg 720 catatttaac agacctaaaa taaatcctat taggcaagtcagttgaaaat gctcgtgctg 780 ctaatggaat tagagtgcgt tcattttaca ggctagtattttaaaaatag aaatcaaaat 840 ctggcaccga agcatgctaa ttgtttactg taccttgtgaggttttcact cataaattta 900 aaccagtgta tttttttaga actggtttgt gtatatatatagtgattatg gatactaatt 960 caatgtaatt tataattttc tatgtcaata caaaaatacatcacagcctt ctcaaacagc 1020 tcaagcaata tattgtatat tgccatatcg tctggtgaaagggttaaatt acttcacctc 1080 ttgcactttt agatgcaaat cagtttttca tttctgtaatagaaaattat tcacgtattt 1140 ttacatcatt tgtttttcct gaccagtatt taaaaccaaaaggatattct gaaaaatggc 1200 caacaatttt tttagaagta gcatcccaag cagcgtgcctaaacattaca ttgcatatgg 1260 aaataaaaga atcaaacgtc taatgcctta tttctgatttcctttttcat tttaagtggt 1320 gtggagattc cagcactccc aggacagtgg agtcagcagtaagccctggg acaggtggca 1380 agggtgggtc ccttgacctt tgcacgcctt ctcaggaaccccctttcccg ggtgagcccc 1440 tctctgaaga gactgtcctt gggcctcctc tggaagcagcacccccagag gacagggctc 1500 ctcctgcttg cctcagggct gcctgacttg aatggcgttggacctcgggg attactggta 1560 gataatatgc tctggtctcg cctggtggtg agttttgccagccatggcca gggtttggct 1620 ccactggtgg cacacgtggc ctccgtggta tggacctggtggcttctcca tcccactgtg 1680 gcctctgtgg tatggacctg gtggcttctc catcctacccaaggtaacag tgtcttgctt 1740 catcccactg actgctggga gagagcctct gggacttttctttggggcat cattttgttt 1800 tgtcttttgt agcagggaaa ggatatgaca atggggaggacagttctttt ggaggttgga 1860 ggggccaagc caaggacagg agcaagtgtg ccctcattttgtttctactt ttaatttctg 1920 tgtgttggcc atactgaatt atgagactaa cagatgtctacaatacaata cctgtattca 1980 aaataacaaa aataaagcct gattctttgt ttctagaaaaaaaaaaaaaa aaaaaa 2036 <210> SEQ ID NO 80 <211> LENGTH: 81 <212> TYPE:PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 80 Met Leu Trp Ser ArgLeu Val Val Ser Phe Ala Ser His Gly Gln Gly 1 5 10 15 Leu Ala Pro LeuVal Ala His Val Ala Ser Val Val Trp Thr Trp Trp 20 25 30 Leu Leu His ProThr Val Ala Ser Val Val Trp Thr Trp Trp Leu Leu 35 40 45 His Pro Thr GlnGly Asn Ser Val Leu Leu His Pro Thr Asp Cys Trp 50 55 60 Glu Arg Ala SerGly Thr Phe Leu Trp Gly Ile Ile Leu Phe Cys Leu 65 70 75 80 Leu <210>SEQ ID NO 81 <211> LENGTH: 3465 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 81 attttttcaa atgtaaaaat aatattttta taggtatgtttgaataaaaa atgcataatc 60 ctgcctttct gttacagctt ttaaaaatca gctatgtattcctttctgtt tttcgtatat 120 gtacatataa aaaaagactt ttcttgttaa attctataagtaaatttctc tgaaatgtca 180 aaaatatgag gagaagacct ttcagacata tgaccttcatcaaatggtcc cagtggaaga 240 agagtaataa atgaaattaa tcaagaccaa gaaactaggagggcagcggg aggtagggga 300 ataagggaaa aactattttc tagttttctt acttttatgaatttaacatt tttctgtaat 360 aaatgattgt taccttttca tttggtgcta gaagtgggtggagtatgact gacccaagct 420 ttaaaaaaag tcaaaacaaa gtagctagga attttttttttttttttgag acagggtctc 480 gggtgcagtg gtacagtcac ggctcactgc agcctggacctcctgggccc aagcaatttt 540 cccacctcag ccttggcctc ccaagtaggt gggactacaggtgctcacca ccatgcccag 600 ccaatgtttt tattgtgtag agatggggtc ttgccatgttgccaggctgg tcccaaactc 660 ctgggcgcaa gcagtcctcc cactttggcc tcccaaagtgttggaattac aggcatgagc 720 caccacaccc agcctcagag tatgttctcc aacatgaccttcacctttgt tttctgggaa 780 atgtccacct cacctctggt ctttcctttg ttttcatactctttaaaata tccttttgtt 840 cctacagact agaggtggtg aagcagttta gtgttggccattcctctccc tgccttcttt 900 agtcacagac aaggtacaga tcactgaagt ggagtgctagcacagacagg gtgtcactca 960 ggctaaacac ttacatgtca acctctatgg cagactttacgtctcagacc ctcccttctg 1020 ttcatttgcc tgttctttct ttcttggcat tggtgtgcctgtgctgtgct tgatgctgag 1080 gaagaaggac tgcttttgtc ccccacagtc atactgtattaatctgtttt catgctgcta 1140 tgaggaactg cctgagactg ggtaatttat aaaggaaagaggtttaattg actcacagtt 1200 cctcagggct ggggaggcct caggaaactc agtcatggcagaaggtgaaa caaacacatc 1260 cttcttcacg tggtggcagg agaaagaagt gctgagcaaaagggggaagc ctcttataaa 1320 accatcagat ctcgtgagaa ctcactcact atcatgagaagagcatggag gtaaccgccc 1380 ccatgatcct attacctcct actgtgtccc tcccacaacatacagggatt atgggaacta 1440 caattcaaga tgagatttgg gtggggacac agccaaaccatatcacatgc ctatagaaca 1500 tggtccagct gctactctca gggataggtc agggatccagcagacaaagc agcattcgct 1560 ggacattctc tgaaatgtac ttcttcttgs ttagacaaagccttctgctc agtatcttgc 1620 tttggttctg cattttgcta ctgttgtcca cttcacttctctctccattt cttttttttt 1680 tttttttttt tttttgagat ggagtttcgc tccagcctgggtgacagagt gagactctgt 1740 atataaaaca gcgatatctc aaaatgacac ctaaaaatttgatgaatttt aaataattgg 1800 agtcatagag acacagggaa atgagaagag gaaacctggagtgaaatcca tcagactgtt 1860 ttttgaggac actcttggca ctgacctaag gtagatgacttttgcattta cctggaagga 1920 tggtcttgaa ttcatcattc agtatttatc catatcctgtggaatgatat agcaattgtg 1980 gaggattatc cgaagggtct gaaacccaca cattcgtcttaaattttctg aaatttattt 2040 acttgtttta aatatgatga taagagccgc ccacctgcatgggcttgtgt ccctgctttt 2100 aatgtggatt tatgccactg atctgcattt tggacatcataagaaatact gctgtgcttc 2160 ccctacaccc acccctaccc cacttgttta ttctttgaaatggtactgag aggacttcct 2220 tctcttatag gagcctttgg gaaaaatgga attcagtagttcaaatgtct gggcttctac 2280 tgagcagata atttgtttct aacttagggc actgtcaatcctgtaattga ttttttttcc 2340 ccctttttaa gttgattcac aacaatatgt gtatcctctaaacatttttt aacagcttta 2400 tttagggtta ttaacatact ataaatggta tgtttaatgtgaacaatttg ataagttttg 2460 acatgtttat ccctgtataa atcatcacta caatcaagatactgtgtata tccatcaacc 2520 cccaacattg tctgtgctct ttggcaattc ctcttttctacctctccctt tcccctcctg 2580 cctccatccc taggaaacca cttgtctgct ttttgtcatgatagagtagt ttacattttc 2640 taaaattgta tataaatagg atcatgtaag tatgtacttttttggttttg cttctttctt 2700 tcatcataat tgtttgagat ttatccatgt ttttgcatgcatcagtagtt catgccttct 2760 taatgctgag tagttttact ttgtacagat gtaccaccatttgttgatcc attcacttat 2820 taatggacat ttgggttgtt ttccagtttt gggcttttactcatggtaca gttatgaaaa 2880 tttatgtaca aatctttgca tggatatatg ctttcattctcttgagtaca tatctgtgag 2940 tggaattgcc ggatggtatg gtagatatat atttaaaattttaagacaat tgacatgctg 3000 tgttccgcag tggttataca tttttgcagc agtgtattagatttccagtt gctgtgcacc 3060 ctcaccagca cttagtatca gtctttttaa ctttaaccgttctagtaagt gtgtagcagc 3120 tcattatggc tgtgatttat atttctctaa tgatattaagcatcttttca tgtgctaatt 3180 tttatccata tgaaaatatg gtgaaactat tcaaatcttttgcccattta tttattagat 3240 tgttttctta ctgagttttg aaaagttttt aaagttttttttatagattt aggggtacaa 3300 gtgcaactgt gttacatgga tatattgtgt cttgttgaactctggatttt agcataccca 3360 tcagctgaat agtatacctt gtaccttgag tatttcattcctcaacccct gacccccakg 3420 taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaaaaaaa 3465 <210> SEQ ID NO 82 <211> LENGTH: 51 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 82 Met Met Ile Arg Ala Ala HisLeu His Gly Leu Val Ser Leu Leu Leu 1 5 10 15 Met Trp Ile Tyr Ala ThrAsp Leu His Phe Gly His His Lys Lys Tyr 20 25 30 Cys Cys Ala Ser Pro ThrPro Thr Pro Thr Pro Leu Val Tyr Ser Leu 35 40 45 Lys Trp Tyr 50 <210>SEQ ID NO 83 <211> LENGTH: 808 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 83 gtatgggaag aagacccttt ctgagggtca caaagggaggacctaaagct gagcagggag 60 cacacatgga aggagaaaat ccctctggca ggccagcctgcaccctcagt ccaaggtgtc 120 attggaggaa ctggaagctg ctgcattggg ggtaaccatagcaacaataa acctcaaacc 180 tagcccaact ctttttttta tttacttttt agagacaaggtcttgctctg ttgcccaggc 240 tgaagtgcag tggtgtgatc gcagctcact gcagcctcaaactcctgggc tcaagcaatc 300 ctcctgcttc agcctttgta ggagattggt cagggtggtgggagaaatta taggaaagac 360 acaaaccttc ttggaaggcc gagaggtttt gcaaaagcttcagaaagaaa ttatggctga 420 aggcagccaa attcttatct gaagcctgag agcaaagggcagataacagg ggagttgtat 480 aggaacttac ctagataaat ttgtttattc ctgtgtccagaaaccaacct ttgatcattc 540 acacacagga ctgctgtcta cttgggatgt tgacaatgtttattgcccac aaattgtgtt 600 tgctccaagc ctttgtcatt aaatttgtgc taaataaatgtgagggccac cagcttaagg 660 ggactgctaa ctctcttcgg cccctagtgc tggcagtcccctagcctgct ctctcactga 720 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa 780 aaaaaaaaaa aaaaaaaaaa aaaaaaaa 808 <210> SEQID NO 84 <211> LENGTH: 45 <212> TYPE: PRT <213> ORGANISM: Homo sapiens<400> SEQUENCE: 84 Met Leu Thr Met Phe Ile Ala His Lys Leu Cys Leu LeuGln Ala Phe 1 5 10 15 Val Ile Lys Phe Val Leu Asn Lys Cys Glu Gly HisGln Leu Lys Gly 20 25 30 Thr Ala Asn Ser Leu Arg Pro Leu Val Leu Ala ValPro 35 40 45 <210> SEQ ID NO 85 <211> LENGTH: 1024 <212> TYPE: DNA <213>ORGANISM: Homo sapiens <400> SEQUENCE: 85 gaagacgcat tcctttcctgccaacctctt tccagataag cccttgaggt ctcgggctga 60 cctacacaca cacacacacacacacacaca cacaccccca cacacacaca cgacagagaa 120 catgccataa acatccttgaacccatgcag gaaagcccat cccatattct gaaaaaatgc 180 caaattaggt ttttctttctttttggaaat cagtcattac agtaaccgaa accattgggt 240 tcagcgaaaa tggaaagatttagctgaatg tagtcagtcc aattaagttg gatgcaactg 300 agtgatttag ttgcttgggtaacccagtgc ttgcttgctt tcttcattct ctgggtggaa 360 actaagatca agacacatgtttggggataa gttaaatgtc tgagctattt tgctcggttt 420 atcctaagag aactttattatgggatgagg aggtgaccca agatgagaag tggaggggga 480 cagcgatgtt ttctaaacatcgtccagtgt tgactggctt ccttactttg cacagtgaac 540 acaactaacc acattaattcagctttgtga agtccctgct ctctgtgggt ctatgagtca 600 gcagcaacat tggcctaacctccgtcccag cctcctggct caccacatgt gtacagtgct 660 gtttgcagtt gtactcattatccatccatc tctctgccat ccccaagcat cgctgggtgt 720 aaaacgcaaa ctctccaccgacactgccat gcgtagtcat gtcttgatgc cttcaggggc 780 tcagtagcta tcaaagaggcctggagggcc tgggcaggct tgacgatgcc tgaccgagtt 840 caagacccac accctgtagcaataccaagt gctattacat aatcaatgga cgatttatac 900 ttttattttt tatgattatttgtttctata ttgctgttag aaaaagtgaa ataaaaatac 960 ttcaaaagaa gatatccatataaaaataaa aggagagaaa aaaaaaaaaa aaaaaaaaaa 1020 aaaa 1024 <210> SEQ IDNO 86 <211> LENGTH: 64 <212> TYPE: PRT <213> ORGANISM: Homo sapiens<400> SEQUENCE: 86 Met Ser Gln Gln Gln His Trp Pro Asn Leu Arg Pro SerLeu Leu Ala 1 5 10 15 His His Met Cys Thr Val Leu Phe Ala Val Val LeuIle Ile His Pro 20 25 30 Ser Leu Cys His Pro Gln Ala Ser Leu Gly Val LysArg Lys Leu Ser 35 40 45 Thr Asp Thr Ala Met Arg Ser His Val Leu Met ProSer Gly Ala Gln 50 55 60 <210> SEQ ID NO 87 <211> LENGTH: 867 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 87 ctctgttggctgaaggaggt aactcaaacc tcagggtttg tttttcccgg gacagatagt 60 agtgatagtgcattatattt gaataagaaa aacaaaccag tataccttga gaaattttaa 120 aaagcatagttgaggcatat tttttcataa ttatatactt atctgtttat tgcccatgga 180 aaatatatgtgtagaagtat ttcttctgtt atttgttact atcttcttaa tttgttccaa 240 agaaaatgctgccatactgc attccctctg gaaggaaaca aaacaaaaca aaactcactc 300 aaaaccagcagtgctgctat cagataagta gatgtcaatg tatacttaca aggaaaaact 360 aaaaaatgtaatgtgttaat tcagcctttt tctatgtaat atttccaagt cagactttct 420 tacattcctggaatttactt tgatatacca agaataataa tgataaaatg tttgctttga 480 ttactgtggggggaaagatg aaatgttcaa ttatattaaa acaaacaagc ttttcagaga 540 tactggtttcctgcccttga agggtataaa gaatttagat catgcctgta atcccagtac 600 tttgggaggccgaggcaggt ggatcacctg agatcaggag ttcgagacca gcctggccaa 660 catggcaaaaccctgtctct actaaaaata caataattag ccaggcatgg tggcgggcac 720 ctgtcatcccagctacttgg gaggctgagg caggagaatc gcttgaaccc aggaggcagt 780 gattgcagtgagctgagata gcaccactgc atgcaagcct gggcaataga gcgagactcc 840 gtctcaaaaaaaaaaaaaaa aaaaaaa 867 <210> SEQ ID NO 88 <211> LENGTH: 51 <212> TYPE:PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 88 Met Glu Asn Ile CysVal Glu Val Phe Leu Leu Leu Phe Val Thr Ile 1 5 10 15 Phe Leu Ile CysSer Lys Glu Asn Ala Ala Ile Leu His Ser Leu Trp 20 25 30 Lys Glu Thr LysGln Asn Lys Thr His Ser Lys Pro Ala Val Leu Leu 35 40 45 Ser Asp Lys 50<210> SEQ ID NO 89 <211> LENGTH: 1797 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 89 gtctcgggct agtcatggcg tccccgtctcggagactgca gactaaacca gtcattactt 60 gtttcaagag cgttctgcta atctacacttttattttctg gatcactggc gttatccttc 120 ttgcagttgg catttggggc aaggtgagcctggagaatta cttttctctt ttaaatgaga 180 aggccaccaa tgtccccttc gtgctcattgctactggtac cgtcattatt cttttgggca 240 cctttggttg ttttgctacc tgccgagcttctgcatggat gctaaaactg tatgcaatgt 300 ttctgactct cgtttttttg gtcgaactggtcgctgccat cgtaggattt gttttcagac 360 atgagattaa gaacagcttt aagaataattatgagaaggc tttgaagcag tataactcta 420 caggagatta tagaagccat gcagtagacaagatccaaaa tacgttgcat tgttgtggtg 480 tcaccgatta tagagattgg acagatactaattattactc agaaaaagga tttcctaaga 540 gttgctgtaa acttgaagat tgtactccacagagagatgc agacaaagta aacaatgaag 600 gttgttttat aaaggtgatg accattatagagtcagaaat gggagtcgtt gcaggaattt 660 cctttggagt tgcttgcttc caactgattggaatctttct cgcctactgc ctctctcgtg 720 ccataacaaa taaccagtat gagatagtgtaacccaatgt atctgtgggc ctattcctct 780 ctacctttaa ggacatttag ggtcccccctgtgaattaga aagttgcttg gctggagaac 840 tgacaacact acttactgat agaccaaaaaactacaccag taggttgatt caatcaagat 900 gtatgtagac ctaaaactac accaataggctgattcaatc aagatccgtg ctcgcagtgg 960 gctgattcaa tcaagatgta tgtttgctatgttctaagtc caccttctat cccattcatg 1020 ttagatcgtt gaaaccctgt atccctctgaaacactggaa gagctagtaa attgtaaatg 1080 aagtaatact gtgttcctct tgactgttatttttcttagt agggggcctt tggaaggcac 1140 tgtgaatttg ctattttgat gtagtgttacaagatggaaa attgattcct ctgactttgc 1200 tattgatgta gtgtgataga aaattcacccctctgaactg gctccttccc agtcaaggtt 1260 atctggtttg attgtataat ttgcaccaagaagttaaaat gttttatgac tctctgttct 1320 gctgacaggc agagagtcac attgtgtaatttaatttcag tcagtcaata gatggcatcc 1380 ctcatcaggg ttgccagatg gtgataacagtgtaaggcct tgggtctaag gcatccacga 1440 ctggaaggga ctactgatgt tctgtgatacatcaggtttc agcacacaac ttacatttct 1500 ttgcctccaa attgaggcat ttattatgatgttcatactt tccctcttgt ttgaaagttt 1560 ctaattatta aatggtgtcg gaattgttgtattttcctta ggaattcagt ggaacttatc 1620 ttcattaaat ttagctggta ccaggttgatatgacttgtc aatattatgg tcaactttaa 1680 gtcttagttt tcgtttgtgc ctttgattaataagtataac tcttatacaa taaatactgc 1740 tttcctctaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa aaaaaaa 1797 <210> SEQ ID NO 90 <211> LENGTH: 245<212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 90 Met AlaSer Pro Ser Arg Arg Leu Gln Thr Lys Pro Val Ile Thr Cys 1 5 10 15 PheLys Ser Val Leu Leu Ile Tyr Thr Phe Ile Phe Trp Ile Thr Gly 20 25 30 ValIle Leu Leu Ala Val Gly Ile Trp Gly Lys Val Ser Leu Glu Asn 35 40 45 TyrPhe Ser Leu Leu Asn Glu Lys Ala Thr Asn Val Pro Phe Val Leu 50 55 60 IleAla Thr Gly Thr Val Ile Ile Leu Leu Gly Thr Phe Gly Cys Phe 65 70 75 80Ala Thr Cys Arg Ala Ser Ala Trp Met Leu Lys Leu Tyr Ala Met Phe 85 90 95Leu Thr Leu Val Phe Leu Val Glu Leu Val Ala Ala Ile Val Gly Phe 100 105110 Val Phe Arg His Glu Ile Lys Asn Ser Phe Lys Asn Asn Tyr Glu Lys 115120 125 Ala Leu Lys Gln Tyr Asn Ser Thr Gly Asp Tyr Arg Ser His Ala Val130 135 140 Asp Lys Ile Gln Asn Thr Leu His Cys Cys Gly Val Thr Asp TyrArg 145 150 155 160 Asp Trp Thr Asp Thr Asn Tyr Tyr Ser Glu Lys Gly PhePro Lys Ser 165 170 175 Cys Cys Lys Leu Glu Asp Cys Thr Pro Gln Arg AspAla Asp Lys Val 180 185 190 Asn Asn Glu Gly Cys Phe Ile Lys Val Met ThrIle Ile Glu Ser Glu 195 200 205 Met Gly Val Val Ala Gly Ile Ser Phe GlyVal Ala Cys Phe Gln Leu 210 215 220 Ile Gly Ile Phe Leu Ala Tyr Cys LeuSer Arg Ala Ile Thr Asn Asn 225 230 235 240 Gln Tyr Glu Ile Val 245<210> SEQ ID NO 91 <211> LENGTH: 1992 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 91 cagaaacacc attcactccg agctgtgaccgcgcaccaac aacagcaaca actccactgc 60 gccgggctga ggagcaggaa ttaggagctcgcgaataata tgaaagggat ccgcaaaggg 120 gaaagccgag caaaggaatc caaaccctgggagcctggca agcgaagatg cgctaaatgt 180 ggccgcctag acttcatcct gatgaagaaaatggggatta aaagtggatt tacgttttgg 240 aacctcgtct ttttattgac ggtgtcttgtgtgaaaggat ttatttatac atgtggtgga 300 actttaaaag gacttaatgg cactatagaaagccctggtt ttccatatgg atatccaaat 360 ggtgcaaact gcacatgggt aataatagcagaagaacgaa atagaataca aattgttttt 420 cagtcatttg ctctagaaga agaatacgactacttatcat tatatgatgg acatcctcat 480 cctacaaact ttaggacaag gttaacaggattccatctgc cacctccagt gacaagtacc 540 aaatctgtgt tctcactacg tttgaccagtgattttgcag ttagtgctca tggatttaag 600 gtatattacg aagaattgca gagtagctcttgtggaaatc ctggtgttcc acccaaaggt 660 gtattatatg gcacaagatt cgacgtcggggacaagatcc gctacagctg tgtaactgga 720 tacatccttg atggccaccc tcagctcacctgcatagcca attcagttaa tacagcttcg 780 tgggattttc ctgttcctat ctgtagagctgaagatgctt gtggaggaac aatgagagga 840 tccagtggca tcatatccag ccctagttttcctaatgagt accataacaa tgctgattgc 900 acttggacca ttgtagcaga gcctggggacacaatttcac tcatatttac tgattttcaa 960 atggaagaga aatatgatta cttagaaatagaaggttctg agccacctac catatggtta 1020 tctggaatga atataccacc accaattatcagcaacaaaa actggctcag actgcatttt 1080 gttacagaca gcaatcatcg ataccgtggatttagtgctc cctatcaagt gaaaaaggcc 1140 atagatttta aatctagagg atttaaattgtttccaggga aagacaacag caacaagttt 1200 tctatcttaa atgagggagg tattaaaacagcttccaatt tatgcccaga tccaggagaa 1260 ccagaaaatg ggaagagaat cggatcagattttagccttg gatcaactgt gcagttctct 1320 tgtgatgaag attatgtcct acagggcgcaaagagcatca cctgtcaacg gatagctgaa 1380 gtttttgctg cttggagtga tcacaggcctgtgtgtaaag tgaaaacgtg tggctctaat 1440 cttcaaggac caagtggtac ctttacatctcccaactttc cgttccagta tgacagcaat 1500 gcacaatgtg tctgggtcat cacagcagtgaatacaaata aggttatcca gataaatttt 1560 gaagaatttg atctggagat tggctatgataccttgacaa ttggcgatgg gggcgaagtt 1620 ggagatccta ggacagtgct ccaagtgctgactggaagct ttgtaccaga cttgatagtg 1680 agcatgagta gccaaatgtg gctgcaccttcaaacggacg aaagtgttgg atctgttggt 1740 ttcaaggtta actacaaagg taatgattaatttctacata ggaaatgtta tcttaatacc 1800 accagagaat atttttaaat tcacgtttaattgcatctac aaaattaaaa gttttgcaga 1860 acacatgcta catttcaaca aagatcatttcctccttaat ttaactacaa atgttaatta 1920 cacttatctt taaataaaat gagtttttcctttaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980 aaaaaaaaaa aa 1992 <210> SEQ ID NO92 <211> LENGTH: 556 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 92 Met Lys Gly Ile Arg Lys Gly Glu Ser Arg Ala Lys Glu Ser LysPro 1 5 10 15 Trp Glu Pro Gly Lys Arg Arg Cys Ala Lys Cys Gly Arg LeuAsp Phe 20 25 30 Ile Leu Met Lys Lys Met Gly Ile Lys Ser Gly Phe Thr PheTrp Asn 35 40 45 Leu Val Phe Leu Leu Thr Val Ser Cys Val Lys Gly Phe IleTyr Thr 50 55 60 Cys Gly Gly Thr Leu Lys Gly Leu Asn Gly Thr Ile Glu SerPro Gly 65 70 75 80 Phe Pro Tyr Gly Tyr Pro Asn Gly Ala Asn Cys Thr TrpVal Ile Ile 85 90 95 Ala Glu Glu Arg Asn Arg Ile Gln Ile Val Phe Gln SerPhe Ala Leu 100 105 110 Glu Glu Glu Tyr Asp Tyr Leu Ser Leu Tyr Asp GlyHis Pro His Pro 115 120 125 Thr Asn Phe Arg Thr Arg Leu Thr Gly Phe HisLeu Pro Pro Pro Val 130 135 140 Thr Ser Thr Lys Ser Val Phe Ser Leu ArgLeu Thr Ser Asp Phe Ala 145 150 155 160 Val Ser Ala His Gly Phe Lys ValTyr Tyr Glu Glu Leu Gln Ser Ser 165 170 175 Ser Cys Gly Asn Pro Gly ValPro Pro Lys Gly Val Leu Tyr Gly Thr 180 185 190 Arg Phe Asp Val Gly AspLys Ile Arg Tyr Ser Cys Val Thr Gly Tyr 195 200 205 Ile Leu Asp Gly HisPro Gln Leu Thr Cys Ile Ala Asn Ser Val Asn 210 215 220 Thr Ala Ser TrpAsp Phe Pro Val Pro Ile Cys Arg Ala Glu Asp Ala 225 230 235 240 Cys GlyGly Thr Met Arg Gly Ser Ser Gly Ile Ile Ser Ser Pro Ser 245 250 255 PhePro Asn Glu Tyr His Asn Asn Ala Asp Cys Thr Trp Thr Ile Val 260 265 270Ala Glu Pro Gly Asp Thr Ile Ser Leu Ile Phe Thr Asp Phe Gln Met 275 280285 Glu Glu Lys Tyr Asp Tyr Leu Glu Ile Glu Gly Ser Glu Pro Pro Thr 290295 300 Ile Trp Leu Ser Gly Met Asn Ile Pro Pro Pro Ile Ile Ser Asn Lys305 310 315 320 Asn Trp Leu Arg Leu His Phe Val Thr Asp Ser Asn His ArgTyr Arg 325 330 335 Gly Phe Ser Ala Pro Tyr Gln Val Lys Lys Ala Ile AspPhe Lys Ser 340 345 350 Arg Gly Phe Lys Leu Phe Pro Gly Lys Asp Asn SerAsn Lys Phe Ser 355 360 365 Ile Leu Asn Glu Gly Gly Ile Lys Thr Ala SerAsn Leu Cys Pro Asp 370 375 380 Pro Gly Glu Pro Glu Asn Gly Lys Arg IleGly Ser Asp Phe Ser Leu 385 390 395 400 Gly Ser Thr Val Gln Phe Ser CysAsp Glu Asp Tyr Val Leu Gln Gly 405 410 415 Ala Lys Ser Ile Thr Cys GlnArg Ile Ala Glu Val Phe Ala Ala Trp 420 425 430 Ser Asp His Arg Pro ValCys Lys Val Lys Thr Cys Gly Ser Asn Leu 435 440 445 Gln Gly Pro Ser GlyThr Phe Thr Ser Pro Asn Phe Pro Phe Gln Tyr 450 455 460 Asp Ser Asn AlaGln Cys Val Trp Val Ile Thr Ala Val Asn Thr Asn 465 470 475 480 Lys ValIle Gln Ile Asn Phe Glu Glu Phe Asp Leu Glu Ile Gly Tyr 485 490 495 AspThr Leu Thr Ile Gly Asp Gly Gly Glu Val Gly Asp Pro Arg Thr 500 505 510Val Leu Gln Val Leu Thr Gly Ser Phe Val Pro Asp Leu Ile Val Ser 515 520525 Met Ser Ser Gln Met Trp Leu His Leu Gln Thr Asp Glu Ser Val Gly 530535 540 Ser Val Gly Phe Lys Val Asn Tyr Lys Gly Asn Asp 545 550 555<210> SEQ ID NO 93 <211> LENGTH: 2085 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 93 caggcgctcg cgagggggta gctcttctagtagtgctcgg cgtcagacat ggcggaggcg 60 atggatttgg gcaaagaccc caacgggcccacccattcct cgactctgtt cgtgagggac 120 gacggcagct ccatgtcctt ctacgtgcggcccagcccgg ccaagcgtcg gctgtcgacg 180 ctcatcctgc acggcggcgg caccgtgtgccgagtgcagg agcccggggc cgtgctgctg 240 gcccagcccg gggaggcgct ggccgaggcctcgggtgatt tcatctccac gcagtacatc 300 ctggactgcg tggagcgcaa cgagaggctggagctggagg cctatcggct gggccccgcc 360 tcggcggcgg acaccggctc ggaagcaaagcccggggccc tggccgaggg cgccgcggag 420 ccggagccgc agcggcacgc cgggcggatcgccttcacgg atgcggacga cgtagccatc 480 cttacctacg tgaaggaaaa tgcccgctcgcccagctccg tcaccggtaa cgccttgtgg 540 aaagcgatgg agaagagctc gctcacgcagcactcgtggc agtccctgaa ggaccgctac 600 ctcaagcacc tgcggggcca ggagcataagtacctgctgg gggacgcgcc ggtgagcccc 660 tcctcccaga agctcaagcg gaaggcggaggaggacccgg aggccgcgga tagcggggaa 720 ccacagaata agagaactcc agatttgcctgaagaagagt atgtgaagga agaaatccag 780 gagaatgaag aagcagtcaa aaagatgcttgtggaagcca cccgggagtt tgaggaggtt 840 gtggtggatg agagccctcc tgattttgaaatacatataa ctatgtgtga tgatgatcca 900 cccacacctg aggaagactc agaaacacagcctgatgagg aggaagaaga agaagaagaa 960 aaagtttctc aaccagaggt gggagctgccattaagatca ttcggcagtt aatggagaag 1020 tttaacttgg atctatcaac agttacacaggccttcctaa aaaatagtgg tgagctggag 1080 gctacttccg ccttcttagc gtctggtcagagagctgatg gatatcccat ttggtcccga 1140 caagatgaca tagatttgca aaaagatgatgaggatacca gagaggcatt ggtcaaaaaa 1200 tttggtgctc agaatgtagc tcggaggattgaatttcgaa agaaataatt ggcaagataa 1260 tgagaaaaga aaaaagtcat ggtaggtgaggtggttaaaa aaaattgtga ccaatgaact 1320 ttagagagtt cttgcattgg aactggcacttattttctga ccatcgctgc tgttgctctg 1380 tgagtcctag atttttgtag ccaagcagagttgtagaggg ggataaaaag aaaagaaatt 1440 ggatgtattt acagctgtcc ttgaacaagtatcaatgtgt ttatgaaagg aagatctaaa 1500 tcagacagga gttggtctac atagtagtaatccattgttg gaatggaacc cttgctatag 1560 tagtgacaaa gtgaaaggaa atttaggaggcataggccat ttcaggcagc ataagtaatc 1620 tcctgtcctt tggcagaagc tcctttagattgggatagat tccaaataaa gaatctagaa 1680 ataggagaag atttaattat gaggccttgaacacggatta tccccaaacc cttgtcattt 1740 cccccagtga gctctgattt ctagactgctttgaaaatgc tgtattcatt ttgctaactt 1800 agtatttggg taccctgctc tttggctgttctttttttgg agcccttctc agtcaagtct 1860 gccggatgtc tttctttacc tacccctcagttttccttaa aacgcgcaca caactctaga 1920 gagtgttaag aataatgtta cttggttaatgtgttattta ttgagtattg tttgtgctaa 1980 gcattgtgtt agatttaaaa aattagtggattgactccac tttgttgtgt tgttttcatt 2040 gttgaaaata aatataactt tgtattcgaaaaaaaaaaaa aaaaa 2085 <210> SEQ ID NO 94 <211> LENGTH: 399 <212> TYPE:PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 94 Met Ala Glu Ala MetAsp Leu Gly Lys Asp Pro Asn Gly Pro Thr His 1 5 10 15 Ser Ser Thr LeuPhe Val Arg Asp Asp Gly Ser Ser Met Ser Phe Tyr 20 25 30 Val Arg Pro SerPro Ala Lys Arg Arg Leu Ser Thr Leu Ile Leu His 35 40 45 Gly Gly Gly ThrVal Cys Arg Val Gln Glu Pro Gly Ala Val Leu Leu 50 55 60 Ala Gln Pro GlyGlu Ala Leu Ala Glu Ala Ser Gly Asp Phe Ile Ser 65 70 75 80 Thr Gln TyrIle Leu Asp Cys Val Glu Arg Asn Glu Arg Leu Glu Leu 85 90 95 Glu Ala TyrArg Leu Gly Pro Ala Ser Ala Ala Asp Thr Gly Ser Glu 100 105 110 Ala LysPro Gly Ala Leu Ala Glu Gly Ala Ala Glu Pro Glu Pro Gln 115 120 125 ArgHis Ala Gly Arg Ile Ala Phe Thr Asp Ala Asp Asp Val Ala Ile 130 135 140Leu Thr Tyr Val Lys Glu Asn Ala Arg Ser Pro Ser Ser Val Thr Gly 145 150155 160 Asn Ala Leu Trp Lys Ala Met Glu Lys Ser Ser Leu Thr Gln His Ser165 170 175 Trp Gln Ser Leu Lys Asp Arg Tyr Leu Lys His Leu Arg Gly GlnGlu 180 185 190 His Lys Tyr Leu Leu Gly Asp Ala Pro Val Ser Pro Ser SerGln Lys 195 200 205 Leu Lys Arg Lys Ala Glu Glu Asp Pro Glu Ala Ala AspSer Gly Glu 210 215 220 Pro Gln Asn Lys Arg Thr Pro Asp Leu Pro Glu GluGlu Tyr Val Lys 225 230 235 240 Glu Glu Ile Gln Glu Asn Glu Glu Ala ValLys Lys Met Leu Val Glu 245 250 255 Ala Thr Arg Glu Phe Glu Glu Val ValVal Asp Glu Ser Pro Pro Asp 260 265 270 Phe Glu Ile His Ile Thr Met CysAsp Asp Asp Pro Pro Thr Pro Glu 275 280 285 Glu Asp Ser Glu Thr Gln ProAsp Glu Glu Glu Glu Glu Glu Glu Glu 290 295 300 Lys Val Ser Gln Pro GluVal Gly Ala Ala Ile Lys Ile Ile Arg Gln 305 310 315 320 Leu Met Glu LysPhe Asn Leu Asp Leu Ser Thr Val Thr Gln Ala Phe 325 330 335 Leu Lys AsnSer Gly Glu Leu Glu Ala Thr Ser Ala Phe Leu Ala Ser 340 345 350 Gly GlnArg Ala Asp Gly Tyr Pro Ile Trp Ser Arg Gln Asp Asp Ile 355 360 365 AspLeu Gln Lys Asp Asp Glu Asp Thr Arg Glu Ala Leu Val Lys Lys 370 375 380Phe Gly Ala Gln Asn Val Ala Arg Arg Ile Glu Phe Arg Lys Lys 385 390 395<210> SEQ ID NO 95 <211> LENGTH: 1427 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 95 ggaagtcaca agtactctct cctacttcccttaaacttac ccgcattcct gaaaaagaac 60 aataaccctg tatacctttt atttacagtagacctttaca cagtcacccc actatttaaa 120 ctctgtctac ttatgcccct aatcaccattctcacctact tctaaatgcc ctgcttttgt 180 ctatactgcc agttcacgct tttcctccagaccattgtag ctgatacctc atggagtcac 240 cctccagctg ctacccttaa ctctctcttagagtggatag atgaccttct gtggcaaagt 300 actctccaat tcttccatcc tgatgaagttcttttctttt atacttactc tttgtcttac 360 tcccgttctc ctgccaccct ctatccctccctaattatct csagaatacc atcaacctca 420 cccactccct cttcaccatc tccaatccttcctatgcatt tccctctctt cctcmtacta 480 tacaggtgtc cctgccctgc cagcccastgggcaacttcc cccatctccc tatacctcca 540 aacctctttc agtgaccccc aactttaccctcctgaacaa cttctttact tcctagaaaa 600 attcagcaaa aactcccctg atacctcataccaacaagct gctgctctcc tccataccta 660 cctacgaaat ctatctccct acgtcacttccacacctcct gttcttggac ccctcactat 720 acaaacaact atccccattg ctgcccccttatgcatctcc ctacaattac ctgctggaat 780 tcccttgggt tacctcccat cttccttatgttcctttact ctttacctcc aaggccctgc 840 cacccacatt aaccaaaata ttggagcattccagcttcgt attacagaaa agccctccct 900 catcactaac actcttaaaa acatcagtagcaacttttgc ctaggaagac atttaccctg 960 gctctcactc catccttggc tatccttcccctgttcaatg gattcccctc caaggccttc 1020 tgcctgcctg tttataccta gtcttataaataacagtgaa tggctactta cagataccaa 1080 attctttttt tcacaccatt aaaacagaacctctccctct acacagttat cctaccaaac 1140 cccactacaa cctctaatag ccgctgcccttgctggatcc ctagggctct gggtgcagga 1200 ctctgcttcc agaacacact ctcattttttttactctcca cttccagtta tgcctgcctc 1260 atggactctt tttgtttctg ttggtttttccgcatacatg tgcctccctg ccaattggac 1320 aggcaccttc actttaatct tccttactcccaagatcgag tttacaaatg gaaacaaaca 1380 actccccatt cccctcataa ctccaacatgacaaaaaaaa aaaaaaa 1427 <210> SEQ ID NO 96 <211> LENGTH: 129 <212> TYPE:PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: UNSURE<222> LOCATION: (104) <221> NAME/KEY: UNSURE <222> LOCATION: (115) <400>SEQUENCE: 96 Met Pro Cys Phe Cys Leu Tyr Cys Gln Phe Thr Leu Phe Leu GlnThr 1 5 10 15 Ile Val Ala Asp Thr Ser Trp Ser His Pro Pro Ala Ala ThrLeu Asn 20 25 30 Ser Leu Leu Glu Trp Ile Asp Asp Leu Leu Trp Gln Ser ThrLeu Gln 35 40 45 Phe Phe His Pro Asp Glu Val Leu Phe Phe Tyr Thr Tyr SerLeu Ser 50 55 60 Tyr Ser Arg Ser Pro Ala Thr Leu Tyr Pro Ser Leu Ile IleSer Arg 65 70 75 80 Ile Pro Ser Thr Ser Pro Thr Pro Ser Ser Pro Ser ProIle Leu Pro 85 90 95 Met His Phe Pro Leu Phe Leu Xaa Leu Tyr Arg Cys ProCys Pro Ala 100 105 110 Ser Pro Xaa Gly Asn Phe Pro His Leu Pro Ile ProPro Asn Leu Phe 115 120 125 Gln <210> SEQ ID NO 97 <211> LENGTH: 2482<212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221>NAME/KEY: unsure <222> LOCATION: (1663) <400> SEQUENCE: 97 ggcgcagctctctccccctc cgcagtctca gtggcgagct ccgggtgctg tggcccggcc 60 ttggcggggcggcctccggc tcaggctggc tgagaggctc ccagctgcag cgtccccgcc 120 cgcctcctcgggagctctga tctcagctga cagtgccctc ggggaccaaa caagcctggc 180 aggacaaaattagaagatca aaatggaaaa tatgctgctt tggttgatat ttttcacccc 240 tgggtggaccctcattgatg gatctgaaat ggaatgggat tttatgtggc acttgagaaa 300 ggtaccccggattgtcagtg aaaggacttt ccatctcacc agccccgcat ttgaggcaga 360 tgctaagatgatggtaaata cagtgtgtgg catcgaatgc cagaaagaac tcccaactcc 420 cagcctttctgaattggagg attatctttc ctatgagact gtctttgaga atggcacccg 480 aaccttaaccagggtgaaag ttcaagattt ggttcttgag ccgactcaaa atatcaccac 540 aaagggagtatctgttagga gaaagagaca ggtgtatggc accgacagca ggttcagcat 600 cttggacaaaaggttcttaa ccaatttccc tttcagcaca gctgtgaagc tttccacggg 660 ctgtagtggcattctcattt cccctcagca tgttctaact gctgcccact gtgttcatga 720 tggaaaggactatgtcaaag ggagtaaaaa gctaagggta gggttgttga agatgaggaa 780 taaaagtggaggcaagaaac gtcgaggttc taagaggagc aggagagaag ctagtggtgg 840 tgaccaaagagagggtacca gagagcatct gcaggagaga gcgaagggtg ggagaagaag 900 aaaaaaatctggccggggtc agaagattgc cgaagggagg ccttcctttc agtggacccg 960 ggtcaagaatacccacattc cgaagggctg ggcacgagga ggcatggggg acgctacctt 1020 ggactatgactatgctcttc tggagctgaa gcgtgctcac aaaaagaaat acatggaact 1080 tggaatcagcccaacgatca agaaaatgcc tggtggaatg atccacttct caggatttga 1140 taacgatagggctgatcagt tggtctatcg gttttgcagt gtgtccgacg aatccaatga 1200 tctcctttaccaatactgcg atgctgagtc gggctccacc ggttcggggg tctatctgcg 1260 tctgaaagatccagacaaaa agaattggaa gcgcaaaatc attgcggtct actcagggca 1320 ccagtgggtggatgtccacg gggttcagaa ggactacaac gttgctgttc gcatcactcc 1380 cctaaaatacgcccagattt gcctctggat tcacgggaac gatgccaatt gtgcttacgg 1440 ctaacagagacctgaaacag ggcggtgtat catctaaatc acagagaaaa ccagctctgc 1500 ttaccgtagtgagatcactt cataggttat gcctggactt gaactctgtc aatagcattt 1560 caacatttttcaaaatcagg agattttcgt ccatttaaaa aatgtatagg tgcagatatt 1620 gaaactaggtgggcacttca atgccaagta tatactcttc ttnacatggt gatgagtttc 1680 atttgtagaaaaattttgtt gccttcttaa aaattagaca cactttaaac cttcaaacag 1740 gtattataaataacatgtga ctccttaatg gacttattct cagggtccta ctctaagaag 1800 aatctaataggatgctggtt gtgtattaaa tgtgaaattg catagataaa ggtagatggt 1860 aaagcaattagtatcagaat agagacagaa agttacaaca cagtttgtac tactctgaga 1920 tggatccattcagctcatgc cctcaatgtt tatattgtgt tatctgttgg gtctgggaca 1980 tttagtttagtttttttgaa gaattacaaa tcagaagaaa aagcaagcat tataaacaaa 2040 actaataactgttttactgc tttaagaaat aacaattaca atgtgtatta tttaaaaatg 2100 ggagaaatagtttgttctat gaaataaacc tagtttagaa atagggaagc tgagacattt 2160 taagatctcaagtttttatt taactaatac tcaaaatatg gacttttcat gtatgcatag 2220 ggaagacacttcacaaatta tgaatgatca tgtgttgaaa gccacattat tttatgctat 2280 acattctatgtatgaggtgc tacattttta ggacaaagaa ttctgtaatc tttttcaaga 2340 aagagtctttttctccttga caaaatccag cttttgtatg aggactatag ggtgaattct 2400 ctgattagtaattttagata tgtcctttcc taaaaatgaa taaaatttat gaatatgact 2460 taaaaaaaaaaaaaaaaaaa aa 2482 <210> SEQ ID NO 98 <211> LENGTH: 413 <212> TYPE: PRT<213> ORGANISM: Homo sapiens <400> SEQUENCE: 98 Met Glu Asn Met Leu LeuTrp Leu Ile Phe Phe Thr Pro Gly Trp Thr 1 5 10 15 Leu Ile Asp Gly SerGlu Met Glu Trp Asp Phe Met Trp His Leu Arg 20 25 30 Lys Val Pro Arg IleVal Ser Glu Arg Thr Phe His Leu Thr Ser Pro 35 40 45 Ala Phe Glu Ala AspAla Lys Met Met Val Asn Thr Val Cys Gly Ile 50 55 60 Glu Cys Gln Lys GluLeu Pro Thr Pro Ser Leu Ser Glu Leu Glu Asp 65 70 75 80 Tyr Leu Ser TyrGlu Thr Val Phe Glu Asn Gly Thr Arg Thr Leu Thr 85 90 95 Arg Val Lys ValGln Asp Leu Val Leu Glu Pro Thr Gln Asn Ile Thr 100 105 110 Thr Lys GlyVal Ser Val Arg Arg Lys Arg Gln Val Tyr Gly Thr Asp 115 120 125 Ser ArgPhe Ser Ile Leu Asp Lys Arg Phe Leu Thr Asn Phe Pro Phe 130 135 140 SerThr Ala Val Lys Leu Ser Thr Gly Cys Ser Gly Ile Leu Ile Ser 145 150 155160 Pro Gln His Val Leu Thr Ala Ala His Cys Val His Asp Gly Lys Asp 165170 175 Tyr Val Lys Gly Ser Lys Lys Leu Arg Val Gly Leu Leu Lys Met Arg180 185 190 Asn Lys Ser Gly Gly Lys Lys Arg Arg Gly Ser Lys Arg Ser ArgArg 195 200 205 Glu Ala Ser Gly Gly Asp Gln Arg Glu Gly Thr Arg Glu HisLeu Gln 210 215 220 Glu Arg Ala Lys Gly Gly Arg Arg Arg Lys Lys Ser GlyArg Gly Gln 225 230 235 240 Lys Ile Ala Glu Gly Arg Pro Ser Phe Gln TrpThr Arg Val Lys Asn 245 250 255 Thr His Ile Pro Lys Gly Trp Ala Arg GlyGly Met Gly Asp Ala Thr 260 265 270 Leu Asp Tyr Asp Tyr Ala Leu Leu GluLeu Lys Arg Ala His Lys Lys 275 280 285 Lys Tyr Met Glu Leu Gly Ile SerPro Thr Ile Lys Lys Met Pro Gly 290 295 300 Gly Met Ile His Phe Ser GlyPhe Asp Asn Asp Arg Ala Asp Gln Leu 305 310 315 320 Val Tyr Arg Phe CysSer Val Ser Asp Glu Ser Asn Asp Leu Leu Tyr 325 330 335 Gln Tyr Cys AspAla Glu Ser Gly Ser Thr Gly Ser Gly Val Tyr Leu 340 345 350 Arg Leu LysAsp Pro Asp Lys Lys Asn Trp Lys Arg Lys Ile Ile Ala 355 360 365 Val TyrSer Gly His Gln Trp Val Asp Val His Gly Val Gln Lys Asp 370 375 380 TyrAsn Val Ala Val Arg Ile Thr Pro Leu Lys Tyr Ala Gln Ile Cys 385 390 395400 Leu Trp Ile His Gly Asn Asp Ala Asn Cys Ala Tyr Gly 405 410 <210>SEQ ID NO 99 <211> LENGTH: 2054 <212> TYPE: DNA <213> ORGANISM: Homosapiens <220> FEATURE: <221> NAME/KEY: unsure <222> LOCATION: (650)<400> SEQUENCE: 99 agcctggctg tgggcccatc tttggaaaaa agatctgggaatgattgtct agcctccagc 60 ctcaacttac ttgatgcttg agagactcaa agccccgtggtcagctgccc tgcaaagaaa 120 gtattttgac cttggcattt ggacarctcc catctctcccatkgccctka caatgctgaa 180 tgggctcctg attaaggact caagcccwcc tatgctgctgcwccaggttw acaagactgc 240 ccwgttmgat wccttcwact accagakctg ctttatgcmaagtgtctttg accatttccc 300 tgagatctta tttatccacc sgacctataa cccaaggggtaaggtcttat atwccttcct 360 ggtggatgga cctcsggtgc agctggaggg tcwtcttgcccgagcagtct actttgccat 420 ccctgccaag gaggacactg aaggcctggc ccagatgttccaagtattca agaagtttaa 480 tccagcatgg gagagagtct gtaccatcct ggtggatcctcatttccttc cactgcctat 540 cctagctatg gagttcccca cagctgaggt ccttctctcagccttccaca tttgtaagtt 600 cctccaggcc aagttctatc agctgtccct tgaacggcccgtggaaaggn tgctcctgac 660 ctccctgcag agcacaatgt gctcagccac agcaggcaacctgagaaagt tgtatacact 720 cctgagcaac tgcatccctc cagccaagct gcccgagcttcactcacact ggctgctcaa 780 cgaccgcatc tggctggctc accgctggag aagccgagctgagagcagcc actacttcca 840 gagcctcgag gtcaccaccc acatcctcag ccagttctttggtaccaccc catctgagaa 900 acaaggtatg gcttctctgt tccgttacat gcagcagaactctgcagaca aggcaaactt 960 caaccagggc ctgtgtgccc agaacaatca tgctcccccagacatcatcc ccgaaagccc 1020 caaactggag cagctggtag aatcccacat ccagcactccctcaatgcca tctgcacagg 1080 gccagcagcc caactgtgcc tgggcgagct tgctgtggtccagaaatcca cacacctcat 1140 tggctctggc tcagaaaaga tgaacataca gatcctggaagatacccata aggtgcagcc 1200 ccakccccct gccagctgca kctgctactt taaccaggccttccacctgc cctgccgcca 1260 catcctagcc atgctcagtg cccgccgcca ggtgctccagcccgacatgc tgccggctca 1320 gtggacggca ggctgtgcta ccagtctaga cagcatcctgggcagcaagt ggagtgagac 1380 cctggataag cacctggcag tgactcacct caccgaggaggtgggtcagc tgttgcagca 1440 ctgcaccaag gaggagtttg agcggaggta tagcaccctgcgggaactgg ccgacagctg 1500 gattgggcct tatgagcagg tccaactctg attattctcgatgcccagag atgctcatgc 1560 acctgtgcac actcacatcc acccatacac acacacacacacacacacac acacacacac 1620 tcccttacac ttgtacttcc gtgggccctc cttccagaacaaggacaaca aggacaaggt 1680 tgaagggtct tctcatctac catggcctgc actccagcctgggagggtga gactccatct 1740 aaaaaaaata aaataaatgg caacccctgg tctaagataagagataaaac atcaggtggt 1800 gaggttgagg tttggggctt ggtagcagtt gccccagtcatgagatgact cacttaaccc 1860 gtctccttta agtgagctgg gctgggaggc ttcctacaggggaagaggcc cctctgggga 1920 gctgactcag ccaggctccc tgaacttttt tccttgtcccatcctggggt caataaaact 1980 gaatgttgca tattctaaaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa 2040 aaaaaaaaaa aaaa 2054 <210> SEQ ID NO 100<211> LENGTH: 485 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220>FEATURE: <221> NAME/KEY: UNSURE <222> LOCATION: (25) <221> NAME/KEY:UNSURE <222> LOCATION: (30) <221> NAME/KEY: UNSURE <222> LOCATION: (50)<221> NAME/KEY: UNSURE <222> LOCATION: (53) <221> NAME/KEY: UNSURE <222>LOCATION: (57)..(58) <221> NAME/KEY: UNSURE <222> LOCATION: (60) <221>NAME/KEY: UNSURE <222> LOCATION: (62) <221> NAME/KEY: UNSURE <222>LOCATION: (65) <221> NAME/KEY: UNSURE <222> LOCATION: (69) <221>NAME/KEY: UNSURE <222> LOCATION: (83) <221> NAME/KEY: UNSURE <222>LOCATION: (94) <221> NAME/KEY: UNSURE <222> LOCATION: (101) <221>NAME/KEY: UNSURE <222> LOCATION: (107) <221> NAME/KEY: UNSURE <222>LOCATION: (193) <221> NAME/KEY: UNSURE <222> LOCATION: (377) <221>NAME/KEY: UNSURE <222> LOCATION: (383) <400> SEQUENCE: 100 Met Leu GluArg Leu Lys Ala Pro Trp Ser Ala Ala Leu Gln Arg Lys 1 5 10 15 Tyr PheAsp Leu Gly Ile Trp Thr Xaa Pro Ile Ser Pro Xaa Ala Leu 20 25 30 Thr MetLeu Asn Gly Leu Leu Ile Lys Asp Ser Ser Pro Pro Met Leu 35 40 45 Leu XaaGln Val Xaa Lys Thr Ala Xaa Xaa Asp Xaa Phe Xaa Tyr Gln 50 55 60 Xaa CysPhe Met Xaa Ser Val Phe Asp His Phe Pro Glu Ile Leu Phe 65 70 75 80 IleHis Xaa Thr Tyr Asn Pro Arg Gly Lys Val Leu Tyr Xaa Phe Leu 85 90 95 ValAsp Gly Pro Xaa Val Gln Leu Glu Gly Xaa Leu Ala Arg Ala Val 100 105 110Tyr Phe Ala Ile Pro Ala Lys Glu Asp Thr Glu Gly Leu Ala Gln Met 115 120125 Phe Gln Val Phe Lys Lys Phe Asn Pro Ala Trp Glu Arg Val Cys Thr 130135 140 Ile Leu Val Asp Pro His Phe Leu Pro Leu Pro Ile Leu Ala Met Glu145 150 155 160 Phe Pro Thr Ala Glu Val Leu Leu Ser Ala Phe His Ile CysLys Phe 165 170 175 Leu Gln Ala Lys Phe Tyr Gln Leu Ser Leu Glu Arg ProVal Glu Arg 180 185 190 Xaa Leu Leu Thr Ser Leu Gln Ser Thr Met Cys SerAla Thr Ala Gly 195 200 205 Asn Leu Arg Lys Leu Tyr Thr Leu Leu Ser AsnCys Ile Pro Pro Ala 210 215 220 Lys Leu Pro Glu Leu His Ser His Trp LeuLeu Asn Asp Arg Ile Trp 225 230 235 240 Leu Ala His Arg Trp Arg Ser ArgAla Glu Ser Ser His Tyr Phe Gln 245 250 255 Ser Leu Glu Val Thr Thr HisIle Leu Ser Gln Phe Phe Gly Thr Thr 260 265 270 Pro Ser Glu Lys Gln GlyMet Ala Ser Leu Phe Arg Tyr Met Gln Gln 275 280 285 Asn Ser Ala Asp LysAla Asn Phe Asn Gln Gly Leu Cys Ala Gln Asn 290 295 300 Asn His Ala ProPro Asp Ile Ile Pro Glu Ser Pro Lys Leu Glu Gln 305 310 315 320 Leu ValGlu Ser His Ile Gln His Ser Leu Asn Ala Ile Cys Thr Gly 325 330 335 ProAla Ala Gln Leu Cys Leu Gly Glu Leu Ala Val Val Gln Lys Ser 340 345 350Thr His Leu Ile Gly Ser Gly Ser Glu Lys Met Asn Ile Gln Ile Leu 355 360365 Glu Asp Thr His Lys Val Gln Pro Xaa Pro Pro Ala Ser Cys Xaa Cys 370375 380 Tyr Phe Asn Gln Ala Phe His Leu Pro Cys Arg His Ile Leu Ala Met385 390 395 400 Leu Ser Ala Arg Arg Gln Val Leu Gln Pro Asp Met Leu ProAla Gln 405 410 415 Trp Thr Ala Gly Cys Ala Thr Ser Leu Asp Ser Ile LeuGly Ser Lys 420 425 430 Trp Ser Glu Thr Leu Asp Lys His Leu Ala Val ThrHis Leu Thr Glu 435 440 445 Glu Val Gly Gln Leu Leu Gln His Cys Thr LysGlu Glu Phe Glu Arg 450 455 460 Arg Tyr Ser Thr Leu Arg Glu Leu Ala AspSer Trp Ile Gly Pro Tyr 465 470 475 480 Glu Gln Val Gln Leu 485 <210>SEQ ID NO 101 <211> LENGTH: 700 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 101 gggggtttga aaggagctgc tcttgctggc tccggtgcaggggatgaatg ccagtgaatg 60 ccagtgttca gcagggctcc tgccaggcgg cactccagggtccggcccaa ggtgactgtc 120 ctgaactatg cctccccgat aaccgcagtc agccggccactgaatgagat ggtcttgacc 180 ccactgacag agcaggaggg ggaagcctac ctggagaagtgtggcagcgt gcggcggcac 240 acggtggcca atgcccactc ggacatccag ctgctggccatggccaccat gatgcactcs 300 ggcctggggg aggaggccar cagtgagaac aagtkcctgctcctgccacc carcttcccc 360 ccgccccacc sgcagtgctc cagtkagccc aacatcaccgacaaccctga cggactggag 420 gagggggcca ggggcagcca ggagggctcg gagctgaactgtgcttccct cagctgagtc 480 gccacccctg ggcctttcca tctcctgttt tgcaaccaggatgrggaccc ctccatctcc 540 gtggattact gaggggggct cttgctttat gcgatgctgccttatttcct ttagggtact 600 gtcctggtca aaatgaccta aggggaaacc gttgttgtaaacctttttat tttggaaaaa 660 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa700 <210> SEQ ID NO 102 <211> LENGTH: 139 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: UNSURE <222>LOCATION: (88) <221> NAME/KEY: UNSURE <222> LOCATION: (93) <221>NAME/KEY: UNSURE <222> LOCATION: (99) <221> NAME/KEY: UNSURE <222>LOCATION: (105) <221> NAME/KEY: UNSURE <222> LOCATION: (110) <400>SEQUENCE: 102 Met Pro Val Phe Ser Arg Ala Pro Ala Arg Arg His Ser ArgVal Arg 1 5 10 15 Pro Lys Val Thr Val Leu Asn Tyr Ala Ser Pro Ile ThrAla Val Ser 20 25 30 Arg Pro Leu Asn Glu Met Val Leu Thr Pro Leu Thr GluGln Glu Gly 35 40 45 Glu Ala Tyr Leu Glu Lys Cys Gly Ser Val Arg Arg HisThr Val Ala 50 55 60 Asn Ala His Ser Asp Ile Gln Leu Leu Ala Met Ala ThrMet Met His 65 70 75 80 Ser Gly Leu Gly Glu Glu Ala Xaa Ser Glu Asn LysXaa Leu Leu Leu 85 90 95 Pro Pro Xaa Phe Pro Pro Pro His Xaa Gln Cys SerSer Xaa Pro Asn 100 105 110 Ile Thr Asp Asn Pro Asp Gly Leu Glu Glu GlyAla Arg Gly Ser Gln 115 120 125 Glu Gly Ser Glu Leu Asn Cys Ala Ser LeuSer 130 135 <210> SEQ ID NO 103 <211> LENGTH: 658 <212> TYPE: DNA <213>ORGANISM: Homo sapiens <400> SEQUENCE: 103 cccgtcagtt ctgctcacgtgaggtgcttc atgaaccctc tctctgctca ctacctgtaa 60 cagtggtgca aatgaatgtttatacccatt ttcgaggatc ccatcaggga caagtgcagg 120 gcagtggccc atcagggtggtgtctacaag ggaactttgg tccatctctc ttcagtgact 180 ggaggagccc ctggccagcatccttccaca castgctgct tgcaggcaca ggactggccc 240 ccaccttccc ggcctccagcgtggtggcaa gcctgcctga acctgggagt tcctcagggc 300 ccacttccaa atgccactgagccacagcag ggaacaagaa tcaaagagca ccccacccgc 360 cacccatgcc tatggccccctccaagggtg tcagtggggt tcagtgggcc ctacaggccc 420 tcctcgaatc cagccccatctgcaagtccc aaagaaactt ttctaaagtt tctggaatgc 480 gggtgcaacc ctcactggtttttgccccat ttttatgttc cattcatttc actgggattc 540 tgagaggggg aagataaacttgggttcaag ctaccctagc tgacccagga gttccatgga 600 aacagaattc tgaaaaaaaaaaaaaataaa taaataaata attaaaaaaa aaaaaaaa 658 <210> SEQ ID NO 104 <211>LENGTH: 155 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE:<221> NAME/KEY: UNSURE <222> LOCATION: (46) <400> SEQUENCE: 104 Met PheIle Pro Ile Phe Glu Asp Pro Ile Arg Asp Lys Cys Arg Ala 1 5 10 15 ValAla His Gln Gly Gly Val Tyr Lys Gly Thr Leu Val His Leu Ser 20 25 30 SerVal Thr Gly Gly Ala Pro Gly Gln His Pro Ser Thr Xaa Cys Cys 35 40 45 LeuGln Ala Gln Asp Trp Pro Pro Pro Ser Arg Pro Pro Ala Trp Trp 50 55 60 GlnAla Cys Leu Asn Leu Gly Val Pro Gln Gly Pro Leu Pro Asn Ala 65 70 75 80Thr Glu Pro Gln Gln Gly Thr Arg Ile Lys Glu His Pro Thr Arg His 85 90 95Pro Cys Leu Trp Pro Pro Pro Arg Val Ser Val Gly Phe Ser Gly Pro 100 105110 Tyr Arg Pro Ser Ser Asn Pro Ala Pro Ser Ala Ser Pro Lys Glu Thr 115120 125 Phe Leu Lys Phe Leu Glu Cys Gly Cys Asn Pro His Trp Phe Leu Pro130 135 140 His Phe Tyr Val Pro Phe Ile Ser Leu Gly Phe 145 150 155<210> SEQ ID NO 105 <211> LENGTH: 836 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 105 atatctttat gattttctcc ttttctagtttgggattgac ttaagcaaat tagattttaa 60 ggaccaagca actaacagaa aatacatcatggctgtacat ttggagggga aaaaaatagt 120 gtatcataga ataattcatc tcttgtcatatactttctcc cagttttgac ccagcaaaac 180 aaagagaagc ctcactagac aaaatgcaccttattcttac aagggtggaa acaatacatt 240 gaaatagcca ggtacttgaa atgggagaaggataatgaac agcgaggaca agacagttgg 300 ccatttttcc gcgtctattg ctctctttcttatttctgca cctttattgc ttctaatggg 360 ttcaactatg tgtgtttata tttttaggaatggaggaaat accttaggaa gcagatgaat 420 tattgatcat atacagaaat gatagagacagtaggaaata tgtttgatgg aagccctgtg 480 tatatatttt tggggggagg ggcttgaagtcacttggtac acaggttttt gggtaaggat 540 tggagaaaat gggaataaat ttttctagaagcagaactat gttctgaatt ggcatctttg 600 aaagggggaa taaaccctta agtgggtgggactgtaactt tgtttgggga gacaaagagg 660 agactctctt gagaccttta ttatcaggatgaggtttaaa gtcagatccc aaggaaaaaa 720 cagccctagt gaaacttcca agctctttgagagttgactt tttggtttgg atagaaaatg 780 gaagtaagga taatagattt gactgtgtgccatggtagtg gaaaaaaaaa aaaaaa 836 <210> SEQ ID NO 106 <211> LENGTH: 47<212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 106 Met AsnSer Glu Asp Lys Thr Val Gly His Phe Ser Ala Ser Ile Ala 1 5 10 15 LeuPhe Leu Ile Ser Ala Pro Leu Leu Leu Leu Met Gly Ser Thr Met 20 25 30 CysVal Tyr Ile Phe Arg Asn Gly Gly Asn Thr Leu Gly Ser Arg 35 40 45 <210>SEQ ID NO 107 <211> LENGTH: 1581 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 107 agaaaaacgg atcacagcca ctatggatga catgttgtctactcggtcta gcaccttgac 60 cgaggatgga gctaagagtt cagaggccat caaggagagcagcaagtttc catttggcat 120 tagcccagca cagagccacc ggaacatcaa gatcctagaggacgaacccc acagtaagga 180 tgagacccca ctgtgtaccc ttctggactg gcaggattctcttgccaagc gctgcgtctg 240 tgtgtccaat accattcgaa gcctgtcatt tgtgccaggcaatgactttg agatgtccaa 300 acacccaggg ctgctgctca tcctgggcaa gctgatcctgctgcaccaca agcacccaga 360 acggaagcag gcaccactaa cttatgaaaa ggaggaggaacaggaccaag ggtgagctgc 420 aacaaaatgg agtggtggtg ggactgcttg gagatgctccgggaaaacac cttggttaca 480 ctcgccaaca tctcggggca gttggaccta tctccataccccgagagcat ttgcctgcct 540 gtcctggacg gactcctaca ctgggcagtt tgcccttcagctgaagccca ggaccccttt 600 tccaccctgg gccccaatgc cgtcctttcc ccgcagagactggtcttgga aaccctcagc 660 aaactcagca tccaggacaa caatgtggac ctgattctggccacaccccc cttcagccgc 720 ctggagaagt tgtatagcac tatggtgcgc ttcctcagtgaccgaaagaa cccggtgtgc 780 cgggagatgg ctgtggtact gctggccaac ctggctcagggggacagcct ggcagctcgt 840 gccattgcag tgcagaaggg cagtatcggc aacctcctgggcttcctaga ggacagcctt 900 gccgccacac agttccagca gagccaggcc agcctcctccacatgcagaa cccacccttt 960 gagccaacta gtgtggacat gatgcggcgg gctgcccgcgcgctgcttgc cttggccaag 1020 gtggacgaga accactcaga gtttactctg tacgaatcacggctgttgga catctcggta 1080 tcaccgttga tgaactcatt ggtttcacaa gtcatttgtgatgtactgtt tttgattggc 1140 cagtcatgac agccgtggga cacctccccc cccccgtgtgtgtgtgcgtg tgtggagaac 1200 ttagaaactg actgttgccc tttatttatg caaaaccacctcagaatcca gtttaccctg 1260 tgctgtccag cttctccctt gggaaaaagt ctctcctgtttctctctcct ccttccacct 1320 cccctccctc catcacctca cgcctttctg ttccttgtcctcaccttact cccctcagga 1380 ccctacccca ccctctttga aaagacaaag ctctgcctacatagaagact ttttttattt 1440 taaccaaagt tactgttgtt tacagtgagt ttggggaaaaaaaataaaat aaaaatggct 1500 ttcccagtcc ttgcatcaac gggatgccac atttcataactgtttttaat ggtaaaaaaa 1560 aaaaaaaaaa aaaaaaaaaa a 1581 <210> SEQ ID NO108 <211> LENGTH: 240 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 108 Met Glu Trp Trp Trp Asp Cys Leu Glu Met Leu Arg Glu AsnThr Leu 1 5 10 15 Val Thr Leu Ala Asn Ile Ser Gly Gln Leu Asp Leu SerPro Tyr Pro 20 25 30 Glu Ser Ile Cys Leu Pro Val Leu Asp Gly Leu Leu HisTrp Ala Val 35 40 45 Cys Pro Ser Ala Glu Ala Gln Asp Pro Phe Ser Thr LeuGly Pro Asn 50 55 60 Ala Val Leu Ser Pro Gln Arg Leu Val Leu Glu Thr LeuSer Lys Leu 65 70 75 80 Ser Ile Gln Asp Asn Asn Val Asp Leu Ile Leu AlaThr Pro Pro Phe 85 90 95 Ser Arg Leu Glu Lys Leu Tyr Ser Thr Met Val ArgPhe Leu Ser Asp 100 105 110 Arg Lys Asn Pro Val Cys Arg Glu Met Ala ValVal Leu Leu Ala Asn 115 120 125 Leu Ala Gln Gly Asp Ser Leu Ala Ala ArgAla Ile Ala Val Gln Lys 130 135 140 Gly Ser Ile Gly Asn Leu Leu Gly PheLeu Glu Asp Ser Leu Ala Ala 145 150 155 160 Thr Gln Phe Gln Gln Ser GlnAla Ser Leu Leu His Met Gln Asn Pro 165 170 175 Pro Phe Glu Pro Thr SerVal Asp Met Met Arg Arg Ala Ala Arg Ala 180 185 190 Leu Leu Ala Leu AlaLys Val Asp Glu Asn His Ser Glu Phe Thr Leu 195 200 205 Tyr Glu Ser ArgLeu Leu Asp Ile Ser Val Ser Pro Leu Met Asn Ser 210 215 220 Leu Val SerGln Val Ile Cys Asp Val Leu Phe Leu Ile Gly Gln Ser 225 230 235 240<210> SEQ ID NO 109 <211> LENGTH: 1684 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 109 ctgcctgatt tgggaagcgc tgcaaggacaaccggctggg gtccttgcgc gccgcggctc 60 agggaggagc accgactgcg ccgcaccctgagagatggtt ggtgccatgt ggaaggtgat 120 tgtttcgctg gtcctgttga tgcctggcccctgtgatggg ctgtttcact ccctatacag 180 aagtgtttcc atgccaccta agggagactcaggacagcca ttatttctca ccccttacat 240 tgaagctggg aagatccaaa aaggaagagaattgagtttg gtcggtcctt tcccaggact 300 gaacatgaag agttatgccg gcttcctcaccgtgaataag acttacaaca gcaacctctt 360 cttctggttc ttcccagctc agatacagccagaagatgcc ccagtagttc tctggctaca 420 gggtgggccg ggaggttcat ccatgtttggactctttgtg gaacatgggc cttatgttgt 480 cacaagtaac atgaccttgc gtgacagagacttcccctgg accacaacgc tctccatgct 540 ttacattgac aatccagtgg gcacaggcttcagttttact gatgataccc acggatatgc 600 agtcaatgag gacgatgtag cacgggatttatacagtgca ctaattcagt ttttccagat 660 atttcctgaa tataaaaata atgacttttatgtcactggg gagtcttatg cagggaaata 720 tgtgccagcc attgcacacc tcatccattccctcaaccct gtgagagagg tgaagatcaa 780 cctgaacgga attgctattg gagatggatattctgatccc gaatcaatta tagggggcta 840 tgcagaattc ctgtacctaa ttggcttgttggatgagaag caaaaaaagt acttccagaa 900 gcagtgccat gaatgcatag aacacatcaggaagcagaac tggtttgagg cctttgaaat 960 actggataaa ctactagatg gcgacttaacaagtgatcct tcttacttcc agaatgttac 1020 aggatgtagt aattactata actttttgcggtgcacggaa cctgaggatc agctttacta 1080 tgtgaaattt ttgtcactcc cagaggtgagacaagccatc cacgtgggga atcagacttt 1140 taatgatgga actatagttg aaaagtacttgcgagaagat acagtacagt cagttaagcc 1200 atggttaact gaaatcatga ataattataaggttctgatc tacaatggcc aactggacat 1260 catcgtggca gctgccctga cagagcgctccttgatgggc atggactgga aaggatccca 1320 ggaatacaag aaggcagaaa aaaaagtttggaagatcttt aaatctgaca gtgaagtggc 1380 tggttacatc cggcaagcgg gtgacttccatcaggtaatt attcgaggtg gaggacatat 1440 tttaccctat gaccagcctc tgagagcttttgacatgatt aatcgattca tttatggaaa 1500 aggatgggat ccttatgttg gataaactaccttcccaaaa gagaacatca gaggttttca 1560 ttgctgaaaa gaaaatcgta aaaacagaaaatgtcatagg aataaaaaaa ttatcttttc 1620 atatctgcaa gatttttttc atcaataaaaattatccttg raaaaaaaaa aaaaaaaaaa 1680 aaaa 1684 <210> SEQ ID NO 110<211> LENGTH: 476 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 110 Met Val Gly Ala Met Trp Lys Val Ile Val Ser Leu Val LeuLeu Met 1 5 10 15 Pro Gly Pro Cys Asp Gly Leu Phe His Ser Leu Tyr ArgSer Val Ser 20 25 30 Met Pro Pro Lys Gly Asp Ser Gly Gln Pro Leu Phe LeuThr Pro Tyr 35 40 45 Ile Glu Ala Gly Lys Ile Gln Lys Gly Arg Glu Leu SerLeu Val Gly 50 55 60 Pro Phe Pro Gly Leu Asn Met Lys Ser Tyr Ala Gly PheLeu Thr Val 65 70 75 80 Asn Lys Thr Tyr Asn Ser Asn Leu Phe Phe Trp PhePhe Pro Ala Gln 85 90 95 Ile Gln Pro Glu Asp Ala Pro Val Val Leu Trp LeuGln Gly Gly Pro 100 105 110 Gly Gly Ser Ser Met Phe Gly Leu Phe Val GluHis Gly Pro Tyr Val 115 120 125 Val Thr Ser Asn Met Thr Leu Arg Asp ArgAsp Phe Pro Trp Thr Thr 130 135 140 Thr Leu Ser Met Leu Tyr Ile Asp AsnPro Val Gly Thr Gly Phe Ser 145 150 155 160 Phe Thr Asp Asp Thr His GlyTyr Ala Val Asn Glu Asp Asp Val Ala 165 170 175 Arg Asp Leu Tyr Ser AlaLeu Ile Gln Phe Phe Gln Ile Phe Pro Glu 180 185 190 Tyr Lys Asn Asn AspPhe Tyr Val Thr Gly Glu Ser Tyr Ala Gly Lys 195 200 205 Tyr Val Pro AlaIle Ala His Leu Ile His Ser Leu Asn Pro Val Arg 210 215 220 Glu Val LysIle Asn Leu Asn Gly Ile Ala Ile Gly Asp Gly Tyr Ser 225 230 235 240 AspPro Glu Ser Ile Ile Gly Gly Tyr Ala Glu Phe Leu Tyr Leu Ile 245 250 255Gly Leu Leu Asp Glu Lys Gln Lys Lys Tyr Phe Gln Lys Gln Cys His 260 265270 Glu Cys Ile Glu His Ile Arg Lys Gln Asn Trp Phe Glu Ala Phe Glu 275280 285 Ile Leu Asp Lys Leu Leu Asp Gly Asp Leu Thr Ser Asp Pro Ser Tyr290 295 300 Phe Gln Asn Val Thr Gly Cys Ser Asn Tyr Tyr Asn Phe Leu ArgCys 305 310 315 320 Thr Glu Pro Glu Asp Gln Leu Tyr Tyr Val Lys Phe LeuSer Leu Pro 325 330 335 Glu Val Arg Gln Ala Ile His Val Gly Asn Gln ThrPhe Asn Asp Gly 340 345 350 Thr Ile Val Glu Lys Tyr Leu Arg Glu Asp ThrVal Gln Ser Val Lys 355 360 365 Pro Trp Leu Thr Glu Ile Met Asn Asn TyrLys Val Leu Ile Tyr Asn 370 375 380 Gly Gln Leu Asp Ile Ile Val Ala AlaAla Leu Thr Glu Arg Ser Leu 385 390 395 400 Met Gly Met Asp Trp Lys GlySer Gln Glu Tyr Lys Lys Ala Glu Lys 405 410 415 Lys Val Trp Lys Ile PheLys Ser Asp Ser Glu Val Ala Gly Tyr Ile 420 425 430 Arg Gln Ala Gly AspPhe His Gln Val Ile Ile Arg Gly Gly Gly His 435 440 445 Ile Leu Pro TyrAsp Gln Pro Leu Arg Ala Phe Asp Met Ile Asn Arg 450 455 460 Phe Ile TyrGly Lys Gly Trp Asp Pro Tyr Val Gly 465 470 475 <210> SEQ ID NO 111<211> LENGTH: 750 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 111 acgatgtgtt gaccggctgc cgtttgagga ctttggtcac ccagactagacaccttctgt 60 gctcatgttt ggaaagctga aagggaagga cagctgtgcc ctcctgggagctcatgtgtc 120 cctggcgctg tgctagcttt cctttacagc tgtttacaga caaggcaggcctgaggcaga 180 tggccactgc tcttgtgatg tttgctcaga ggaatatgaa cattttatttttgaaaaggg 240 atgatgtggt ttttgccagg tgtttataat taatccttta atattatggttattaacctc 300 ttaaacatga atgaattctt gattgtttta acacagtacc taagactaatgctttctgtg 360 gacaccactg agctctgcct caactccacc ctctgcgacc ggaggactatgcccctagta 420 actgctgtcg gtgtggacgc tgtgctggtt ctgttttcta aaggagcagaaggacaggtc 480 tctgagacag gatcgttgtc cctacaggag gaacagtggc cttgcttcttagacggtctt 540 cactgtgtgt tttaaaacaa caacaacaac aacaacaaca taaaactcttttgacctgta 600 acttaaagat cataaacttc aggcaataat attttctgtg taagcttttaaaattatttt 660 tggggatcat agcttgtttt attttgtgct ataaaattaa cagtattaaatgacttatat 720 tcttagaata aaaaaaaaaa aaaaaaaaaa 750 <210> SEQ ID NO 112<211> LENGTH: 89 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 112 Met Val Ile Asn Leu Leu Asn Met Asn Glu Phe Leu Ile ValLeu Thr 1 5 10 15 Gln Tyr Leu Arg Leu Met Leu Ser Val Asp Thr Thr GluLeu Cys Leu 20 25 30 Asn Ser Thr Leu Cys Asp Arg Arg Thr Met Pro Leu ValThr Ala Val 35 40 45 Gly Val Asp Ala Val Leu Val Leu Phe Ser Lys Gly AlaGlu Gly Gln 50 55 60 Val Ser Glu Thr Gly Ser Leu Ser Leu Gln Glu Glu GlnTrp Pro Cys 65 70 75 80 Phe Leu Asp Gly Leu His Cys Val Phe 85 <210> SEQID NO 113 <211> LENGTH: 2156 <212> TYPE: DNA <213> ORGANISM: Homosapiens <220> FEATURE: <221> NAME/KEY: unsure <222> LOCATION: (1353)<400> SEQUENCE: 113 aagtgatcta cctgcctggg cctcccaagg tgctgggattacgggtgtga gccaccgcgc 60 ccagcctatt cttttttgtt tgtgataatg gtcatcctaatggacatgag gtagtgtcat 120 gtggttttga tttgcatgtc cctgataaat aatgatgttgaccatctact catgtgcttg 180 ttggctattt gcatggcgtg tttggagaaa cgtctgttcaagggctttgc cttttttttt 240 tgagacagar tcttactccg ttgccccarg ctggagtkcggtggtgaggg gtgcactgca 300 acatccgcct tccaggttca agcgattctt gtgcctcagcctcccaaaga gctgggatta 360 caaaagtgca gtttgcccat ttttaatcga ttttgttcctgagttggagt tttttgtata 420 ttcaggctgt taacccctta tgagatagat ggtttgcacatagtctcttc cattctatag 480 gatatcattt ctgttaatag attcctttgc tgtgcagaaactttttagtt tgaggtcatc 540 ccatttgtct atttttactt tcgttgccct tgctgttggtgtcatgttca agaaatcatt 600 gccaagacca atgtcgtgaa gtctttccct ttgttttcttctaagggttt tacagtttca 660 agtctgtgtt tgggtcttgc atcggttttg agttagtttttgtgtatgat gtaaggtaag 720 ggtctatctt tatttgcaag tggatatcca gttttcccagcgctgcatat tgaagagacc 780 atcctttccc cattgtgcaa gaagttcttg tcacccttgttgaaggtcat ctgtctgtca 840 ttgtcatttc tggccctgtg ctgtcctgtc ctgtcctgtcctgtcctgtt ctgttctgtt 900 ggtctgtagg tctgtcttta tgtcagcacc atactggctgttggactttt taattctttt 960 cttgacagtg gtaatttatt tgcttctttt tcttattagtccctttgcct actttaaata 1020 attaattttg ttaattttta gttttctgtt attttagttcattaatttca ttgcttcctt 1080 tatttattta tttatttttt ttgagatgga gtcttgctctgtcactcagg ctggagtgca 1140 gtggcacgat ctcagctcac tgcaacctcc acctcccaggttcaagtgat tctcctgtct 1200 cagtctcctg agtagctggg attacaggca cttgccaccatgcccggcta attttttgta 1260 ttttttagta gagacggggt ttcgctgtgt tgcccgggctggtttcaaac ttctgagctc 1320 aggcaatcca cctgcctcgg cctcccaaag tgntaggattacaggtgtga gccaccacgc 1380 ctgacccatt gctgccttaa atacacaaag cgcttgagttaataaagtta cctgaaggat 1440 tgaactttaa tttctaacag cgtttggagg tgaggggactacttgttttt gctcattttt 1500 agtttttttt tttttgcact tggggtcaaa tggcatgtcatatgtgctgt tacctgaaat 1560 atattgaggg tttctttgtt ctatcatacm tggtcattttcataactgtc ccacagacac 1620 tggagaagca tgatgactcc atggggtaca gaatttagaacatccttgtc agattgagtc 1680 tatggtgatg tgtcttaagt cgtcccttag tcttttttttcctaatcagt ctgtcaaatt 1740 tcagagaacc atgttaaaat cccctattat tgtggttttgaaggttgttt ccagtgtttt 1800 tccttcattt aattcttcct ctgtcgctgt gcgcctgcagattccaggct gcttgacatg 1860 ggttcctttc catatgggag tgagccagca gacagccctacagatcgtac acacgttttc 1920 caaaactaac aatggaacag gcggcaaacc tatgccaatatactagaaat tgcagattaa 1980 atagatgaaa tattctaaac tggagtttac ataatgaacataagagtaat cagagaatct 2040 gactcatttt agatgtgtgt gtgtgtgtat atatatgtgtgtgtgtgtga aaaacattga 2100 ctataataaa aataatctcg agttcaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaa 2156 <210> SEQ ID NO 114 <211> LENGTH: 94 <212> TYPE:PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 114 Met Val Met Cys LeuLys Ser Ser Leu Ser Leu Phe Phe Pro Asn Gln 1 5 10 15 Ser Val Lys PheGln Arg Thr Met Leu Lys Ser Pro Ile Ile Val Val 20 25 30 Leu Lys Val ValSer Ser Val Phe Pro Ser Phe Asn Ser Ser Ser Val 35 40 45 Ala Val Arg LeuGln Ile Pro Gly Cys Leu Thr Trp Val Pro Phe His 50 55 60 Met Gly Val SerGln Gln Thr Ala Leu Gln Ile Val His Thr Phe Ser 65 70 75 80 Lys Thr AsnAsn Gly Thr Gly Gly Lys Pro Met Pro Ile Tyr 85 90 <210> SEQ ID NO 115<211> LENGTH: 3941 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220>FEATURE: <221> NAME/KEY: unsure <222> LOCATION: (2895) <400> SEQUENCE:115 cagacacaga gatcagaatt ccaggaaatg atcttccagt gcgttctggg tcagttatgg 60tgactgtaaa taccgtcatc acagctggcc ctcaaaataa cgcaataata acatatttac 120ataatgacat attatgactg taagtgcagt cagccccatc tggggctgag gcgggggccc 180tgctgtgcac tctcccccca gctatcccac cgggccaggg gtgggcctca gggttgtgct 240gggagccgca gggcctgaag gggcctcggc tgtacgggga tgagactcgc aggggagagg 300gcagaggccg gtgacctggc gaggacttgc ccaggagatt ggagctcctt gcttctgcgc 360cacgcggatg ccccacgctg gtctcagctg ggttgttggc tctgagtggt catctcgttg 420ctgccatatt ttcttgcttc attgaatttc actgtgctcc agcctgggca acacagccgg 480actctgtttc aaaaaaaaaa attttttttt tccaagatag gatggtagag aaaatacctc 540ctgccatgtc ctgctatgaa tacagctttg tatttctctc tctagttttg tcagttttgg 600cttttcagat tttgaagcgt gtttgtgggc tgaatcttgc ccttatcacc catttctagg 660atgctttttg ctccactcat tctttgtctt gcttcacttg actttgaact gtatactttt 720ttccatcgtt ttactttcag tatcttcata catgtatgtt tttgtacgcc tctcttagaa 780cagtgtatgg ttttgtaaaa attcagcctg tagcttttac ctgcctcctt catgaccttt 840ataatcccct tggttctcag cctgccactc acaggacttt tccctgtgct gcgttccmag 900tgccccctcc ccgcccccac ctgtgctttt tgttggatta gtagaattgc ttttgtcatt 960ccattgtttt catatatttg tttgggacat tttacttttt tctgttaacg cttaccctag 1020aaattagaaa tgacaccacg tattcttagc gaagtccagt tttcagcatt ttgtccttat 1080tggacaatag caaggatatt agaacgtgtt ggttccgcgt gcttccgtct tgagttatgt 1140gctgctattg tcggatattt tgtcttagat gtacgtactt tcctgttcat tgtggtatgt 1200gtaatttgcg ttactttgaa ttttccacgt ttttactttc tttgtctctc atcacttact 1260gcttttggga ccccccccat cggggttcac attccctctc cctagagcac actcccttgg 1320atttcctcga gtggggtctg ctgcggtgaa gctttcccat tttatgtgca gattattttc 1380agagggtata tagaattcag gcagctgttt cgttgtagca cattaaaaat attttcccac 1440ttcctccttg cttctgttgt tgcttttgag tgttacctct gagtctgcct gtgctccctg 1500gaaacggccc gggtttccca ccccctgccc aggtttgctc cttccgtggt ttttctgtca 1560ttatcacgct cacgtgtttc cctcggtcac cccctctgca attttcacac gtcttttccc 1620tctctctttg cttcattacc tttggcccgc ctgccagctg ctgattctct ctgaagatgt 1680ctctaaatga cttttaactg tgatttgtgg aattcttatt gtggagtttt gcgtcttttc 1740aggtgtaggt tttttgtctc gcgtgtttcc acgtctgctt gtagcgcttt ccgcttcgcc 1800gttccctgcg gcccttcctt ccgtgcccgg tgttcatcct cttgaatgct cttttcctgc 1860ctgtttggct gggtgtgtct gagttgcaac ctgagcgggt ttctttgtct tcttacttgt 1920ctggtattgt gttctctcgg gacgttgcgt ttgaggggtc gcacctcaga gcaagccgag 1980gtctgggcta agcctgtgct ttggcaggca ggaccttagt ttgccttttc tgggcacctg 2040aggagagggt agcagcagcc tggggtctcc ttgactcacg gtcagcagtg agggtttcct 2100ggcctgttgg gtggctggag cttggctgca ttccccactg agagagggag gtgcgcacct 2160tctcctccct ggagtggcct tccaggtgcc ctctcagagc tgctcatcag ggctgtgcct 2220ttgtcagcac caagcctcag cccttgtccc tgctgccact gaaggctcaa aacaacactg 2280cacagccttg tgtgtcctct gtgtgtcggc agtttccccc ggctctgcag cagcccaggc 2340caggtagcct ctggagggag tggtggagga gcacgggcat cctggccgcc gctgtgttgg 2400ggacagaccc tggggcctgg aaagggaggt gaggccccgt gggggctgct gcaccacagg 2460caagagagca agagacagca gaggccggcc aggtggtggc acagccgcta gggaccaggc 2520cggcctgtgg aggtattggg atggggacca gcggacttgc tggcagaggg gcctcagggc 2580tgcaggcttc ttggactgag ccactgggag gacggagttg accttctttg agacagaaaa 2640agtgtgcatc ccggggctgc ctgtgaaagc tcatctctaa agtgtgtgtt gttcttccag 2700ccaccccttt gctgtgaagt tgcttgcgct ctgtaagaaa gaaatcaaga attcaaaaga 2760tatccagaag ctcctgtcag gcatcgcagt gtgagtttca agtgctactg gccttagacg 2820gaatggcagg gcgcagcctc ccttggctga gggcaggagt ccacggctcc aggcgggaga 2880ggagcagtta gtgtnactcc tcaagctaac ctaagatcgt gcattccaat gttcaaagca 2940gtcgcaatgg gaggtgaggc agcccaggtg ctggtggagg gagttcccgc gggaacaggc 3000gagctctgcc tctgctgccc tcgcgctctg ccctggcggg aggggaggct ccggaaagga 3060gctgcgtggt caggggctgc ctccccgatt ctcctgtgtg ccctgggggt cgctgttgag 3120tgccttgctc tgcggcgctc aggtggacac tgggcaggtg cgccagccag cgataggcac 3180cttggctgct ctgtggctcc ttgaggtggg ggtcctcatg gcagggcgag cggccctgca 3240ggagatcctc tgtgaggcgt cctcacttcc cacagtgact ttccaagtgc gacactcgcg 3300tgtgtaggca cagtgcagat gtgcgcacac acacacctcc ggcttggggc cccaggcccg 3360cactgtgctc acggatctgc tctgcccagg ttctgcggga tggtgcagtt ccccggcgaa 3420cgtgaggagg caggccctcc tgcagctgtg tctgctcctc tgccaccgtt tccsgctgat 3480ccggaagacc acggccagcc aggtgtacga gacattgctc acctacagtg acktcgtggg 3540cgcggatgtg ctggacgagg tggtgactgt gctcagtgac actgsgtgga cgcagagctt 3600gcagtggtga gagagcagcg caaccgtctg tgtgaccttc tgggcgtacc caggccccag 3660ytggtgcccc agcctggtgc ctgctgaagc cagtcctgga gcccatacct cacccctgcc 3720tggtgaggat gtcttgttcc tgagggaggc cggtgtggaa agcctcgcac agtggtgcct 3780ccagctgttg aagggtagcg ctggcccttg gaggctggca ctagctgaca gcttttcctc 3840tctgcacctg cgctctggtg acttggggtg gacgcctctg ccttcacttg aacacaaatg 3900tgcttcctat aaaatcatgt accaagaaaa aaaaaaaaaa a 3941 <210> SEQ ID NO 116<211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 116 Met Cys Cys Tyr Cys Arg Ile Phe Cys Leu Arg Cys Thr TyrPhe Pro 1 5 10 15 Val His Cys Gly Met Cys Asn Leu Arg Tyr Phe Glu PheSer Thr Phe 20 25 30 Leu Leu Ser Leu Ser Leu Ile Thr Tyr Cys Phe Trp AspPro Pro His 35 40 45 Arg Gly Ser His Ser Leu Ser Leu Glu His Thr Pro LeuAsp Phe Leu 50 55 60 Glu Trp Gly Leu Leu Arg 65 70 <210> SEQ ID NO 117<211> LENGTH: 1779 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 117 ccaagttcca ggtctagaat tcaaattact aatttactgc ttctctctctctaagcctca 60 gctccctgat ctagaccatg agatttacag taggagagta ccatgtttatccccaaatac 120 ttaacagcta gggttttccc agactgaata ataataataa cttttttaaaattcagaagg 180 tatcttcaag ttcttggctt gcttcttgta cattcaatat caaagaagagaaaacacact 240 atctgagagt acttcccatg cacctaataa gtgccaaagc cacctggtgctagagccctt 300 caccaaaatg agcatcagcc ttgctttcag aaagcaggga ccacatatatatgatttaaa 360 aaaaatctgc gatcaacttt tctctaaaaa acccaaatat gctggggtacagaaagatca 420 atgcaaaagc aaaacatcct gtgcctgtcc tagaggtccc cagaggcaggatgccccgac 480 tcagaaagaa actcctaagc tggcctggcc aaagggagga agaacccagggtgggtgtcg 540 taactcatct aaaaataacg atgtcatcag gcagatgtgc cattgtgctggggctgggtg 600 ggtgtggcag gcccaccttg ggtatgcaaa gctctgacag tgtttcacttgctaccctcg 660 gtctgcttac cacactccca gttctgctga ccttacggga aggctcatgctgggttgact 720 cacggcaggc ctagagcact gtgagggatg tgtgaggaca agggtcacaccccagggtgg 780 catttccaag ccccatgcct ctggccatat cccatagggg ctctaggcctctgttttccc 840 atctttaaaa taattggggg caatacctcc tatgatcttt ctgagaattaatagagattt 900 catggcaatt gcttagccct gcccagcaga gatagcaaat aatcaatcagctccctttct 960 cctctgtctc ttgggtgttt tctactcctg gaaccccaga gcaagagaggaccctgaaac 1020 atggcctaca tccaattctt tcattttgca tttgaggaaa tcgaggcacatggctgcggt 1080 tctactctta ccaacccata tcaggtcatt gctctaacga ggcttaaggagcaataaccc 1140 gcctttcacg tggttcttac ggatacccag aaagatgact cagcttctccagatttctga 1200 gaagactaag cataagtcag agagagtata gacaaaggaa aagggggcataactgcaagg 1260 accccctcaa atgtgtgctg tggcagcatt ggtgggacag gggctgaaagagcaaaacag 1320 tagggatcac atcttggaga gtactcggga aggagtccaa aaacgaccatggatcctgga 1380 gctacaggtt gcaaccaaac tacaatcatt ccatttggcc tcaggatgtggaagcacccc 1440 aaatgtgttt gcctcaaaaa gcaaagagga tgaggcccgg catggtagctcaggcctgta 1500 atcccagcac tttgggaggc cgaggtgggc ggatcacttg agtccaggagttcgagatca 1560 gcctgggcaa tgtagcaaca ccgcacctct acaaaaaata aaagaattaactgggcgtgg 1620 tggcgcatgc ctgtagtccc agctactctg gaggctgagg tgggaggatcccttgagccc 1680 aggagatgga ggttgcagtg agctgagatg gcaccactgc actccagtctgggtgacaga 1740 gcaagaccca gactcaaaaa aaaaaaaaaa aaaaaaaaa 1779 <210>SEQ ID NO 118 <211> LENGTH: 109 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 118 Met Ser Ile Ser Leu Ala Phe Arg Lys Gln GlyPro His Ile Tyr Asp 1 5 10 15 Leu Lys Lys Ile Cys Asp Gln Leu Phe SerLys Lys Pro Lys Tyr Ala 20 25 30 Gly Val Gln Lys Asp Gln Cys Lys Ser LysThr Ser Cys Ala Cys Pro 35 40 45 Arg Gly Pro Gln Arg Gln Asp Ala Pro ThrGln Lys Glu Thr Pro Lys 50 55 60 Leu Ala Trp Pro Lys Gly Gly Arg Thr GlnGly Gly Cys Arg Asn Ser 65 70 75 80 Ser Lys Asn Asn Asp Val Ile Arg GlnMet Cys His Cys Ala Gly Ala 85 90 95 Gly Trp Val Trp Gln Ala His Leu GlyTyr Ala Lys Leu 100 105 <210> SEQ ID NO 119 <211> LENGTH: 1170 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 119 agccgcgcggctgcgggggc gcaaataggg tcactgggcc gcttggcggt gtcgttgcgg 60 taccaggtccgcgtgagggg ttcgggggtt ctgggcaggc acaatggcgt ctcgagcagg 120 cccgcgagcggccggcaccg acggcagcga ctttcagcac cgggagcgcg tcgccatgca 180 ctaccagatgagtgtgaccc tcaagtatga aatcaagaag ctgatctacg tacatctggt 240 catatggctgctgctggttg ctaagatgag cgtgggacac ctgaggctct tgtcacatga 300 tcaggtggccatgccctatc agtgggaata cccgtatttg ctgagcattt tgccctctct 360 cttgggccttctctcctttc cccgcaacaa cattagctac ctggtgctct ccatgatcag 420 catgggactcttttccatcg ctccactcat ttatggcagc atggagatgt tccctgctgc 480 acagcagctctaccgccatg gcaaggccta ccgtttcctc tttggttttt ctgccgtttc 540 catcatgtacctggtgttgg tgttggcagt gcaagtgcat gcctggcagt tgtactacag 600 caagaagctcctagactctt ggttcaccag cacacaggag aagaagcata aatgaagcct 660 ctttggggtgaagcctggac atcccatcga atgaaaggac actagtacag cggttccaaa 720 atcccttctggtgattttag cagctgtgat gttggtacct ggtgcagacc aggccaaagt 780 tctggaaagctccttttgcc atctgctgag gtggcaaaac tataatttat tcctggttgg 840 ctagaactgggtgaccgaca gctatgaaac aaatttcagc tgtttgaagt tgaactttga 900 ggtttttctttaagaatgag cttcgtcctt gcctctactc ggtcattctc cccatttcca 960 tccattaccccttagccatt gagactaaag gaaataggga ataaatcaaa ttacttcatc 1020 tctaggtcacgggtcaggaa acatttgggc agctgctccc ttggcagctg tggtctcctc 1080 tgcaaagcattttaattaaa aacctcaata aagatggccc tgcccacaaa aaaaaaaaaa 1140 aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa 1170 <210> SEQ ID NO 120 <211> LENGTH: 183 <212>TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 120 Met Ala SerArg Ala Gly Pro Arg Ala Ala Gly Thr Asp Gly Ser Asp 1 5 10 15 Phe GlnHis Arg Glu Arg Val Ala Met His Tyr Gln Met Ser Val Thr 20 25 30 Leu LysTyr Glu Ile Lys Lys Leu Ile Tyr Val His Leu Val Ile Trp 35 40 45 Leu LeuLeu Val Ala Lys Met Ser Val Gly His Leu Arg Leu Leu Ser 50 55 60 His AspGln Val Ala Met Pro Tyr Gln Trp Glu Tyr Pro Tyr Leu Leu 65 70 75 80 SerIle Leu Pro Ser Leu Leu Gly Leu Leu Ser Phe Pro Arg Asn Asn 85 90 95 IleSer Tyr Leu Val Leu Ser Met Ile Ser Met Gly Leu Phe Ser Ile 100 105 110Ala Pro Leu Ile Tyr Gly Ser Met Glu Met Phe Pro Ala Ala Gln Gln 115 120125 Leu Tyr Arg His Gly Lys Ala Tyr Arg Phe Leu Phe Gly Phe Ser Ala 130135 140 Val Ser Ile Met Tyr Leu Val Leu Val Leu Ala Val Gln Val His Ala145 150 155 160 Trp Gln Leu Tyr Tyr Ser Lys Lys Leu Leu Asp Ser Trp PheThr Ser 165 170 175 Thr Gln Glu Lys Lys His Lys 180 <210> SEQ ID NO 121<211> LENGTH: 1127 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 121 ctcgccgcag aagtatctcc gaatggagcc atcccccttc ggcgacgtctcctcccgcct 60 caccacagaa caaattctgt acaacataaa acaagagtat aaacgaatgcagaagagaag 120 acatttagaa acgagtttcc aacagacaga tccgtgttgt acttctgatgcacagccaca 180 tgcatttctc ctcagtggac cagcttcacc agggacttca tctgcagcatcctcaccatt 240 aaaaaaagaa cagcccttat ttactctacg gcaggttggg atgatctgtgaacgtttgtt 300 gaaagaacgt gaagagaaag ttcgagaaga atatgaagaa atattgaacacaaaacttgc 360 agaacaatat gatgcgtttg tgaagtttac gcatgatcaa ataatgcgacgatatggaga 420 acagcctgct agctatgttt catgaatcac gtatcctgca tttgtgggctgccttgttcc 480 ttgttgagtt gttgcaagag gtcccaatta tgacatgcag caatgccaataccccttctg 540 tgaatacagg ttatttcaag ctttcgtcag tggcaaccac tcttaggcagcagcaactgg 600 ttttggaaat ttccctgatg tcagtaccac ctggatgtgg acctttgctacctgtattaa 660 taccagtggc ctcattttgc tgtatcatta caatttggct tcttatattaatgtttgaaa 720 aggattaaag ctggtattct agaacatgcc cttcactggt tgtgtaaataaaactgtaga 780 atgacacttc agatgaagtt agtgtgattt taattgtgca ctacaaccgagctgtaacca 840 gttactaatt ttagaatgta atcccaggac aatattaagc aaatagcctgcagtgcttcc 900 tgtgaaatag tgaaggagga gggcatttct gtattccagg acttcttggggtttcagaat 960 gggtttgtat gatttttttt tttttgtagt tttatttatt ctatcagtctttttaacaaa 1020 tgtttattgc tgcatttttt tttttccagt gtatcattgt tttactgcccttgtagtact 1080 ggaatttagt tggaagaata aaacatttac ttctaaaaaa aaaaaaa 1127<210> SEQ ID NO 122 <211> LENGTH: 140 <212> TYPE: PRT <213> ORGANISM:Homo sapiens <400> SEQUENCE: 122 Met Glu Pro Ser Pro Phe Gly Asp Val SerSer Arg Leu Thr Thr Glu 1 5 10 15 Gln Ile Leu Tyr Asn Ile Lys Gln GluTyr Lys Arg Met Gln Lys Arg 20 25 30 Arg His Leu Glu Thr Ser Phe Gln GlnThr Asp Pro Cys Cys Thr Ser 35 40 45 Asp Ala Gln Pro His Ala Phe Leu LeuSer Gly Pro Ala Ser Pro Gly 50 55 60 Thr Ser Ser Ala Ala Ser Ser Pro LeuLys Lys Glu Gln Pro Leu Phe 65 70 75 80 Thr Leu Arg Gln Val Gly Met IleCys Glu Arg Leu Leu Lys Glu Arg 85 90 95 Glu Glu Lys Val Arg Glu Glu TyrGlu Glu Ile Leu Asn Thr Lys Leu 100 105 110 Ala Glu Gln Tyr Asp Ala PheVal Lys Phe Thr His Asp Gln Ile Met 115 120 125 Arg Arg Tyr Gly Glu GlnPro Ala Ser Tyr Val Ser 130 135 140 <210> SEQ ID NO 123 <211> LENGTH:806 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 123gtgtatcttc agaggcagca ggggccagtg tgccacatct tgccccagtc ctgaaaggat 60agatggtatt tggcctgtga cccttggctg aggagccatg gtccggctct gccaggccct 120gctgctgtta gtggccactg tggcccttgc atccagaaga ttccaagcct ggggctcaac 180aaargtggtg aggacattcc aagatatccc tcaaaactac gtctatgtkc arcakgcact 240ctggttcgcc atagaaggag tataacaagg ccagctttag tataacaagt tcagctttag 300ggtgctgaag gttctgaaga gccasgarca ggtgacagat agtttggagt actatattga 360ggtcaaaatt gcccgaacar tttgcaagaa aatttcagaa gatgaaaact gtgcatttca 420agaggatccc aaaatgcaaa aggtggtttt ttgtaytttt attgttgcat ctaaaccatg 480gaaatttgaa ctcaccatgy tgraaacaat gcaaagatat gtagttatct tctmgtgtgt 540tctgccacac tcatttccat tttaaagaag aagcaaagac ayttgcaaga aytagaacaa 600cacagttaac ccattaactt catttgtttg gcctttttgc atttttgtgt gttcttcatg 660ggctgatgtt gaaaatccat gatgtgtttt gacagcattg catagcctat tcttgctgga 720tacttcccct actagctggg ataatctgyt gcaataaatg gaagtggttt cttacacstc 780aaaaaaaaaa aaaaaaaaaa aaaaaa 806 <210> SEQ ID NO 124 <211> LENGTH: 55<212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221>NAME/KEY: UNSURE <222> LOCATION: (46) <400> SEQUENCE: 124 Met Val ArgLeu Cys Gln Ala Leu Leu Leu Leu Val Ala Thr Val Ala 1 5 10 15 Leu AlaSer Arg Arg Phe Gln Ala Trp Gly Ser Thr Lys Val Val Arg 20 25 30 Thr PheGln Asp Ile Pro Gln Asn Tyr Val Tyr Val Gln Xaa Ala Leu 35 40 45 Trp PheAla Ile Glu Gly Val 50 55 <210> SEQ ID NO 125 <211> LENGTH: 1783 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 125 tccccaccccccttatgtct cagccgaacc taccctaatc cagcccacgc cacaatggtg 60 ggacaggttccccagtccct atgtggtctt atttttaccc ttgcactccc tgtagaccat 120 caattctacaccctaattac aaaatcatat ccacctctgc ctggcagaag gtgttatgct 180 tttctggctcgcctaccatc cacacatccc tacacctcac caccggatcc tcttttcttt 240 ccttccatccaattcctggc ttccccgctg ccaactctgc tctctatgtc tccagtttaa 300 aggtgccccctggaaaaaat gtaacaattc cctcacctgt gactggtacc tgacagccac 360 cacaccggggcagcaatggc taacggttga caaagacaat ttctttctct ctccaaaacc 420 aaacagccttcatcaactcc ctagccaaga ctccctatca ggcccttaca ggtgccgctc 480 tggctggcagttacccmatt tgggaaaacg aaaataccct atcatggcta cctaccttca 540 cctacaacttctgcctgtcc acccccagtc tcttcttttt gtgtgataca aactgatatc 600 tttgcctaccagccaactgg tcaggaactt gcaccctggt ctttcaggct ccaaccatca 660 acatcctaccccctaaccaa actattctaa tttctgtaga agcctctatc tcctcttcac 720 ccataagaaataaatgggct ctacatctca tcaccctgct aacaggatta ggcatcactg 780 ctgcacttggcactggaata gcaggcataa ccacctcaat cacctcatac caaacactat 840 tcacaaccctttctaacacc gtagaagata tgcacacttc cattaccagt ctccaacgac 900 aattagacttcctcgtggga gtcatccttc aaaactggag agtcctggac ctcctaacca 960 ctgagaaagggggtacctgc atatacctcc aggaagaatg ctgtttctgt gttaatgaat 1020 ctggcattgttcatatcgca gttcgtaggc ttcatgacag ggctgcagag ctttgacatc 1080 aagtcgctgactcctggtgg caaggatcat cccttctaag atggataccc tgggttgccc 1140 ccttcctaggacccctgatc ttcctcttcc tgttactaat gattgggcca tgcatattta 1200 accttgtatcccgcttcatt tcccaaaggc tgaattgttt tatccaggca agcatgcaaa 1260 aacacattgataatatattt cacctttgcc acgtctaata ccagagccta cgaggaaacc 1320 attcggaagctccagaaccc aggccctaat cacaacgccc ctatccagca ggaagcagcc 1380 agatgatyaamgacgccctt tttccttttt atactaaagt aagaaataag aatgttagcc 1440 caaactgcaytattttgcag acccctacca ttttacaaac tggtcagagt ggaaaattcc 1500 accagggcctgagctgtgag aaacatcctg tcaggcaggt cccaggccta acccctggst 1560 gcactaaattccttcattat cagcagccaa acacaccgcc cccaccccat tttcacaaca 1620 atcccagacctctcctgccc gggactgtaa ctggtccagc ctgtaagcgg gaagggggct 1680 ctggcactagstggtacccc ctctccgcag gtctttctcc caataaatct gtgttgccct 1740 tgraaaaaaaaaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1783 <210> SEQ ID NO 126 <211>LENGTH: 136 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE:<221> NAME/KEY: UNSURE <222> LOCATION: (108) <400> SEQUENCE: 126 Met LeuPhe Trp Leu Ala Tyr His Pro His Ile Pro Thr Pro His His 1 5 10 15 ArgIle Leu Phe Ser Phe Leu Pro Ser Asn Ser Trp Leu Pro Arg Cys 20 25 30 GlnLeu Cys Ser Leu Cys Leu Gln Phe Lys Gly Ala Pro Trp Lys Lys 35 40 45 CysAsn Asn Ser Leu Thr Cys Asp Trp Tyr Leu Thr Ala Thr Thr Pro 50 55 60 GlyGln Gln Trp Leu Thr Val Asp Lys Asp Asn Phe Phe Leu Ser Pro 65 70 75 80Lys Pro Asn Ser Leu His Gln Leu Pro Ser Gln Asp Ser Leu Ser Gly 85 90 95Pro Tyr Arg Cys Arg Ser Gly Trp Gln Leu Pro Xaa Leu Gly Lys Arg 100 105110 Lys Tyr Pro Ile Met Ala Thr Tyr Leu His Leu Gln Leu Leu Pro Val 115120 125 His Pro Gln Ser Leu Leu Phe Val 130 135 <210> SEQ ID NO 127<211> LENGTH: 3149 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 127 ggtctttaac gtgagcccgc tgcaggtgtg cggcccagtc cgagacagcagatgaggaga 60 ctgtccttcc tgtttcgcag atgaggaaac tgaggcttag agaagtttggcaaattggct 120 aagttcctac agctaccaca gcagaaagtg ctgggcagta gagagctgccccctccagaa 180 gatgatcagc tgcactccag tgcccccaga tcctcgtgga aggaacggatccttaaagca 240 aaggtggtga cggtgtctca ggaggcagar tgggatcaaa tcgagcccttgcttagaagt 300 gaattagaag attttccagt acttggaatt gactgtgagt gggtaaatttggaaggcaaa 360 gcctgccctc tgtcacttct acaaatggcc tccccaagtg gcctgtgtgtcttggttcgc 420 ctgcccaagc taatctgtgg aggaaaaaca ctaccaagaa cgttattggatattttggca 480 gatggcacca ttttgaaagt tggagtggga tgctcagaag atgccagcaagcttctgcag 540 gattatggcc tcgttgttag ggggtgcctg gacctccgat acctagccatgcggcagaga 600 aacaatttgc tctgtaatgg gcttagcctg aagtccctcg ctgagactgttttgaacttt 660 ccccttgaca agtcccttct acttcgttgc agcaactggg atgctgagactctcacagag 720 gaccaggtaa tttatgctgc cagggatgcc cagatttcag tggctctctttcttcatctt 780 cttggatacc ctttctctag gaattcacct ggagaaaaaa aacgatgaccacagtagctg 840 gagaaaagtc ttggaaaaat gccagggtgt ggtcgacatc ccatttcgaagcaaaggaat 900 gagcagattg ggagaagagg ttaatgggga agcaacagaa tctcagcagaagccaagaaa 960 taagaagtct aagatggatg ggatggtgcc aggcaaccac caagggagagaccccagaaa 1020 acataaaaga aagcctctgg gggtgggcta ttctgccaga aaatcacctctttatgataa 1080 ctgctttctc catgctcctg atggacagcc cctctgcact tgtgatagaagaaaagctca 1140 gtggtacctg gacaaaggca ttggtgagct ggtgagtgaa gagccctttgtggtgaagct 1200 gcggtttgaa cctgcaggaa ggcccgaatc tcctggagac tattacttgatggttaaaga 1260 gaacctgtgt gtagtgtgtg gcaagagaga ctcctacatt cggaagaacgtgattccaca 1320 tgagtaccgg aagcacttcc ccatcgagat gaaggaccac aactcccacgatgtgctgct 1380 gctctgcacc tcctgccatg ccatttccaa ctactatgac aaccatctgaagcagcagct 1440 ggccaaggag ttccaggccc ccatcggctc tgaggagggc ttgcgcctgctggaagatcc 1500 tgagcgccgg caggtgcgtt ctggggccag ggccctgctc aacgcggagagcctgcctac 1560 tcatcgaaag gaggagctgc tgcaagcact cagagagttt tataacacagacgtggtcac 1620 agaggagatg cttcaagagg ctgccagcct ggagaccaga atctccaatgaaaactatgt 1680 tcctcacggg ctgaaggtgg tgcagtgtca cagccagggt ggcctgcgctccctcatgca 1740 gctggagagc cgctggcgtc agcacttcct ggactccatg cagcccaagcacctgcccca 1800 gcagtggtca gtggaccaca accatcagaa gctgctccgg aaattcggggaagatcttcc 1860 catccagctg tcttgatagc tgctttcctc ccagttagga caagtgggaagctggagcca 1920 aggttgaaga gtcacctctt cccattttag tacatcatta attgtcaaagcctgtgtgac 1980 acaactcaga atactaacct agactaatcc caggatgctt ctgctggagcaaagatattg 2040 tttgaaggag agtttatggt tttggatttt aaacgggcag ggtcttttttcctctcattt 2100 ttgtggacaa gagaggcctt cgcctttatt tttactctcc ctcttctgctgtccctgtgc 2160 agaggaaaaa tgaagaattc tcccagaagt gacttgtcaa gacttaaaaaaaatgttttt 2220 aatgcatttc ttccttgtct agtgcctcgg tttatctcta acaggggctgtccagtatat 2280 cggtcctgtt aggaggggag aaaaagttct tccaaaggct ggagaagtgaacaaggagtc 2340 aaatttattt tcccaattca acttcataat tatcatttct ttggcttcatgctctcccgt 2400 aactcatgtg gttgggatcc atcccatctg ggtcacttca gtctacttcacgtacttgaa 2460 aaggctttcc tttacacttc caggaccaaa cagcaacttc ctgccacacacttccaccct 2520 atcactggga gaaatccttt tctggacatg agcctttgac ctgggtggggcagaaagaac 2580 cacaaactcc atctcccaat agaactttga aattcactca gcttttcctttcatgctgtt 2640 tgttgcctgc ttgttgcact cctcctgccc cagaactgca agatttttagcttcacccct 2700 ttctgagagt aatgttatct tttatcagaa tcagtatcag ttcccctgtattctgtgctt 2760 catcgaattt gcaagactga cctcttttaa gcatttaatt cactcccagagtcatctggt 2820 caggttgcaa tatgaggact tctctgtctc ctctgaagcc tgggacactgagcttactta 2880 atacattaga tgttcaaaag aggagcgttg tttcatcttt caaaatgttaggccattact 2940 ttgagtataa aatcgactta ttaatgatta gtaatttttc taaagtattgggaaaacttt 3000 cttattttat aagatcttaa caagcttaaa aaagaatttt atgaccagaatccaacaaga 3060 gctctatttt ggaattgtgc ccaagttggt gatgtttact ctaaaattaataataaaact 3120 acttgtaagc aaaaaaaaaa aaaaaaaaa 3149 <210> SEQ ID NO 128<211> LENGTH: 380 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 128 Met Leu Pro Gly Met Pro Arg Phe Gln Trp Leu Ser Phe PheIle Phe 1 5 10 15 Leu Asp Thr Leu Ser Leu Gly Ile His Leu Glu Lys LysAsn Asp Asp 20 25 30 His Ser Ser Trp Arg Lys Val Leu Glu Lys Cys Gln GlyVal Val Asp 35 40 45 Ile Pro Phe Arg Ser Lys Gly Met Ser Arg Leu Gly GluGlu Val Asn 50 55 60 Gly Glu Ala Thr Glu Ser Gln Gln Lys Pro Arg Asn LysLys Ser Lys 65 70 75 80 Met Asp Gly Met Val Pro Gly Asn His Gln Gly ArgAsp Pro Arg Lys 85 90 95 His Lys Arg Lys Pro Leu Gly Val Gly Tyr Ser AlaArg Lys Ser Pro 100 105 110 Leu Tyr Asp Asn Cys Phe Leu His Ala Pro AspGly Gln Pro Leu Cys 115 120 125 Thr Cys Asp Arg Arg Lys Ala Gln Trp TyrLeu Asp Lys Gly Ile Gly 130 135 140 Glu Leu Val Ser Glu Glu Pro Phe ValVal Lys Leu Arg Phe Glu Pro 145 150 155 160 Ala Gly Arg Pro Glu Ser ProGly Asp Tyr Tyr Leu Met Val Lys Glu 165 170 175 Asn Leu Cys Val Val CysGly Lys Arg Asp Ser Tyr Ile Arg Lys Asn 180 185 190 Val Ile Pro His GluTyr Arg Lys His Phe Pro Ile Glu Met Lys Asp 195 200 205 His Asn Ser HisAsp Val Leu Leu Leu Cys Thr Ser Cys His Ala Ile 210 215 220 Ser Asn TyrTyr Asp Asn His Leu Lys Gln Gln Leu Ala Lys Glu Phe 225 230 235 240 GlnAla Pro Ile Gly Ser Glu Glu Gly Leu Arg Leu Leu Glu Asp Pro 245 250 255Glu Arg Arg Gln Val Arg Ser Gly Ala Arg Ala Leu Leu Asn Ala Glu 260 265270 Ser Leu Pro Thr His Arg Lys Glu Glu Leu Leu Gln Ala Leu Arg Glu 275280 285 Phe Tyr Asn Thr Asp Val Val Thr Glu Glu Met Leu Gln Glu Ala Ala290 295 300 Ser Leu Glu Thr Arg Ile Ser Asn Glu Asn Tyr Val Pro His GlyLeu 305 310 315 320 Lys Val Val Gln Cys His Ser Gln Gly Gly Leu Arg SerLeu Met Gln 325 330 335 Leu Glu Ser Arg Trp Arg Gln His Phe Leu Asp SerMet Gln Pro Lys 340 345 350 His Leu Pro Gln Gln Trp Ser Val Asp His AsnHis Gln Lys Leu Leu 355 360 365 Arg Lys Phe Gly Glu Asp Leu Pro Ile GlnLeu Ser 370 375 380 <210> SEQ ID NO 129 <211> LENGTH: 1861 <212> TYPE:DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 129 agagccaggggggtcgcgta gtgtcatgac cagggcggga gatcacaacc gccagagagg 60 atgctgtggatccttggcgg actacctgac ctctgcaaaa ttccttctct accttggtca 120 ttctctctctacttggggag atcggatgtg gcactttgcg gtgtctgtgt ttctggtaga 180 gctctatggaaacagcctcc ttttgacagc agtctacggg ctggtggtgg cagggtctgt 240 tctggtcctgggagccatca tcggtgactg ggtggacaag aatgctagac ttaaagtggc 300 ccagacctcgctggtggtac agaatgtttc agtcatcctg tgtggaatca tcctgatgat 360 ggttttcttacataaacatg agcttctgac catgtaccat ggatgggttc tcacttcctg 420 ctatatcctgatcatcacta ttgcaaatat tgcaaatttg gccagtactg ctactgcaat 480 cacaatccaaagggattgga ttgttgttgt tgcaggagaa gacagaagca aactagcaaa 540 tatgaatgccacaatacgaa ggattgacca gttaaccaac atcttagccc ccatggctgt 600 tggccagattatgacatttg gctccccart catcggctgt ggctttattt cgggatggaa 660 cttggtatccatgtgcgtgg agtacgttct gctctggaag gtttaccaga aaaccccagc 720 tctagctgtgaaagctggtc ttaaagaaga ggaaactgaa ttgaaacagc tgaatttaca 780 caaagatactgagccaaaac ccctggaggg aactcatcta atgggtgtga aagactctaa 840 catccatgagcttgaacatg agcaagagcc tacttgtgcc tcccagatgg ctgagccctt 900 ccgtaccttccgagatggat gggtctccta ctacaaccag cctgtgtttc tggctggcat 960 gggtcttgctttcctttata tgactgtcct gggctttgac tgcatcacca cagggtacgc 1020 ctacactcagggactgagtg gttccatcct cagtattttg atgggagcat cagctataac 1080 tggaataatgggaactgtag cttttacttg gctacgtcga aaatgtggtt tggttcggac 1140 aggtctgatctcaggattgg cacagctttc ctgtttgatc ttgtgtgtga tctctgtatt 1200 catgcctggaagccccctgg acttgtccgt ttctcctttt gaagatatcc gatcaaggtt 1260 cattcaaggagagtcaatta cacctaccaa gatacctgaa attacaactg aaatatacat 1320 gtctaatgggtctaattctg ctaatattgt cccggagaca agtcctgaat ctgtgcccat 1380 aatctctgtcagtctgctgt ttgcaggcgt cattgctgct agaatcggtc tttggtcctt 1440 tgatttaactgtgacacagt tgctgcaaga aaatgtaatt gaatctgaaa gaggcattat 1500 aaatggtgtacagaactcca tgaactatct tcttratctt ctgcatttca tcatggtcat 1560 cctggctccaaatcctgaag cttttggctt gctcgtattg atttcagtct cctttgtggc 1620 aatgggccacattatgtatt tccgatttgc ccaaaatact ctgggaaaca agctctttgc 1680 ttgcggtcctgatgcaaaag aagttaggaa ggaaaatcaa gcaaatacat ctgttgtttg 1740 agacagtttaactgttgcta tcctgttact agattatata gagcacatgt gcttattttg 1800 tactgcagaattccaataaa tggctgggtg ttttgctctg tttttaaaaa aaaaaaaaaa 1860 a 1861 <210>SEQ ID NO 130 <211> LENGTH: 571 <212> TYPE: PRT <213> ORGANISM: Homosapiens <220> FEATURE: <221> NAME/KEY: UNSURE <222> LOCATION: (202)<221> NAME/KEY: UNSURE <222> LOCATION: (504) <400> SEQUENCE: 130 Met ThrArg Ala Gly Asp His Asn Arg Gln Arg Gly Cys Cys Gly Ser 1 5 10 15 LeuAla Asp Tyr Leu Thr Ser Ala Lys Phe Leu Leu Tyr Leu Gly His 20 25 30 SerLeu Ser Thr Trp Gly Asp Arg Met Trp His Phe Ala Val Ser Val 35 40 45 PheLeu Val Glu Leu Tyr Gly Asn Ser Leu Leu Leu Thr Ala Val Tyr 50 55 60 GlyLeu Val Val Ala Gly Ser Val Leu Val Leu Gly Ala Ile Ile Gly 65 70 75 80Asp Trp Val Asp Lys Asn Ala Arg Leu Lys Val Ala Gln Thr Ser Leu 85 90 95Val Val Gln Asn Val Ser Val Ile Leu Cys Gly Ile Ile Leu Met Met 100 105110 Val Phe Leu His Lys His Glu Leu Leu Thr Met Tyr His Gly Trp Val 115120 125 Leu Thr Ser Cys Tyr Ile Leu Ile Ile Thr Ile Ala Asn Ile Ala Asn130 135 140 Leu Ala Ser Thr Ala Thr Ala Ile Thr Ile Gln Arg Asp Trp IleVal 145 150 155 160 Val Val Ala Gly Glu Asp Arg Ser Lys Leu Ala Asn MetAsn Ala Thr 165 170 175 Ile Arg Arg Ile Asp Gln Leu Thr Asn Ile Leu AlaPro Met Ala Val 180 185 190 Gly Gln Ile Met Thr Phe Gly Ser Pro Xaa IleGly Cys Gly Phe Ile 195 200 205 Ser Gly Trp Asn Leu Val Ser Met Cys ValGlu Tyr Val Leu Leu Trp 210 215 220 Lys Val Tyr Gln Lys Thr Pro Ala LeuAla Val Lys Ala Gly Leu Lys 225 230 235 240 Glu Glu Glu Thr Glu Leu LysGln Leu Asn Leu His Lys Asp Thr Glu 245 250 255 Pro Lys Pro Leu Glu GlyThr His Leu Met Gly Val Lys Asp Ser Asn 260 265 270 Ile His Glu Leu GluHis Glu Gln Glu Pro Thr Cys Ala Ser Gln Met 275 280 285 Ala Glu Pro PheArg Thr Phe Arg Asp Gly Trp Val Ser Tyr Tyr Asn 290 295 300 Gln Pro ValPhe Leu Ala Gly Met Gly Leu Ala Phe Leu Tyr Met Thr 305 310 315 320 ValLeu Gly Phe Asp Cys Ile Thr Thr Gly Tyr Ala Tyr Thr Gln Gly 325 330 335Leu Ser Gly Ser Ile Leu Ser Ile Leu Met Gly Ala Ser Ala Ile Thr 340 345350 Gly Ile Met Gly Thr Val Ala Phe Thr Trp Leu Arg Arg Lys Cys Gly 355360 365 Leu Val Arg Thr Gly Leu Ile Ser Gly Leu Ala Gln Leu Ser Cys Leu370 375 380 Ile Leu Cys Val Ile Ser Val Phe Met Pro Gly Ser Pro Leu AspLeu 385 390 395 400 Ser Val Ser Pro Phe Glu Asp Ile Arg Ser Arg Phe IleGln Gly Glu 405 410 415 Ser Ile Thr Pro Thr Lys Ile Pro Glu Ile Thr ThrGlu Ile Tyr Met 420 425 430 Ser Asn Gly Ser Asn Ser Ala Asn Ile Val ProGlu Thr Ser Pro Glu 435 440 445 Ser Val Pro Ile Ile Ser Val Ser Leu LeuPhe Ala Gly Val Ile Ala 450 455 460 Ala Arg Ile Gly Leu Trp Ser Phe AspLeu Thr Val Thr Gln Leu Leu 465 470 475 480 Gln Glu Asn Val Ile Glu SerGlu Arg Gly Ile Ile Asn Gly Val Gln 485 490 495 Asn Ser Met Asn Tyr LeuLeu Xaa Leu Leu His Phe Ile Met Val Ile 500 505 510 Leu Ala Pro Asn ProGlu Ala Phe Gly Leu Leu Val Leu Ile Ser Val 515 520 525 Ser Phe Val AlaMet Gly His Ile Met Tyr Phe Arg Phe Ala Gln Asn 530 535 540 Thr Leu GlyAsn Lys Leu Phe Ala Cys Gly Pro Asp Ala Lys Glu Val 545 550 555 560 ArgLys Glu Asn Gln Ala Asn Thr Ser Val Val 565 570 <210> SEQ ID NO 131<211> LENGTH: 2157 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 131 ctctctttaa tatcttcacc tctaccatgt gtctttcttt taatatagttataattttcc 60 aaccacgtag atcaatattt actcatcatg accataaaat gcagtttagccatatagaaa 120 actatgatta cttttcttta taatttccct tcagttaata cttattttattttctgtttt 180 tatcatctag tcaactcgca aacttccagc atttgtctaa atctactcaatatattccag 240 tacatcagat aatatatcag tttcatcctc ctgaaaaact cttttccagtgtatcctgac 300 ctgctctaat tttgacttga tgctttctgt atctggtgca cagctgttaccttggaatct 360 tcccttcatc attattcaga gtgtttctgt agtttttctc ttgcattggattttgtgctt 420 cctgaatccc tctctctctt tttttttttt tttttacttg gcttactccttgctttgatg 480 gatctcaggc tccagtagct tccttggaaa gagtgtttgg aagttgcttctgcaggaagc 540 ctttttggtg gcatggtcct caagaagttc ctaaaaggtt gatgaaaagcccagaacctt 600 gatgacagat tgtctggtta taaagcattt tttacgtaaa atcatcatggtgcaccctaa 660 ggtcagattt catttcagtg taaaggtaaa tggaatcctc tccacagagatctttggggt 720 ggagaatgaa cccactttga accttgggaa tggaattgct cttttggtcgactcccagca 780 ttatgtgagt agaccaaatt ttggtacaat tgaatcacac tgcagcagaattcaccctgt 840 gctaggacat ccagtaatgc ttttcatccc tgaagacgtg gctggcatggacttgttggg 900 agaactgata ctgactccag cagctgcact gtgccccagc ccaaaggtttcttccaacca 960 gcttaacagg atttcttcag tttccatatt tctatatgga cctttgggtctgcctctgat 1020 attgtcaact tgggagcagc cgatgactac tttcttcaaa gatacctcttctttagttga 1080 ctggaaaata ccatttgtgt atgataccca atttggatct caatttggatagagatttgg 1140 tgcttccaga tgtgagttat caggtggaat ccagtgagga ggatcagtctcagactatgg 1200 atcctcaagg acaaactctg ctgctttttc tctttgtgga tttccacagtgcatttccag 1260 tccagcaaat ggaaatctgg ggagtctata ctttgctcac aactcatctcaatgccatcc 1320 ttgtggagag ccacagtgta gtgcaaggtt ccatccaatt cactgtggacaaggtcttgg 1380 agcaacatca ccaggctgcc aaggctcagc agaaactaca ggcctcactctcagtggctg 1440 tgaactccat catgagtatt ctgactggaa gcactaggag cagcttccgaaagatgtgtc 1500 tccagaccct tcaagcagct gacacacaag agttcaggac caaactgcacaaagtatttc 1560 gtgagatcac ccaacaccaa tttcttcacc actgctcatg tgaggtgaagcagctaaccc 1620 tagaaaaaaa ggactcagcc cagggcactg aggacgcacc tgataacagcagcctggagc 1680 tcctagcagt gcttaaacag ccttcccagc ccacagcagc aggggtacagcagctctcac 1740 attcagtcac tagcagagat gccagatacc agcgggcaag cagaaaacaagaggctcaag 1800 aggggcagcc cccgcataga ggagatgcga gctctgcgct ctgccagggccccgagcccg 1860 tcagaggccg ccccgcgccg cccggaagcc accgcggccc ccctcactcytagaggaagg 1920 gagcaccgcg aggctcacgg cagggccctg gcgccgggca gggcgagcctcggaagccgc 1980 ctggaggacg tcctgtggct gcaggaggtc tccaacctgt cagagtggctgagtcccagc 2040 cctgggccct gagccgggtc cccttccgca agcgcccacc gatccggaggctgcgggcag 2100 ccgttatccc gtggtttaat aaagctgccg cgcgctcacc aaaaaaaaaaaaaaaaa 2157 <210> SEQ ID NO 132 <211> LENGTH: 270 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 132 Met Ile Pro Asn Leu Asp LeuAsn Leu Asp Arg Asp Leu Val Leu Pro 1 5 10 15 Asp Val Ser Tyr Gln ValGlu Ser Ser Glu Glu Asp Gln Ser Gln Thr 20 25 30 Met Asp Pro Gln Gly GlnThr Leu Leu Leu Phe Leu Phe Val Asp Phe 35 40 45 His Ser Ala Phe Pro ValGln Gln Met Glu Ile Trp Gly Val Tyr Thr 50 55 60 Leu Leu Thr Thr His LeuAsn Ala Ile Leu Val Glu Ser His Ser Val 65 70 75 80 Val Gln Gly Ser IleGln Phe Thr Val Asp Lys Val Leu Glu Gln His 85 90 95 His Gln Ala Ala LysAla Gln Gln Lys Leu Gln Ala Ser Leu Ser Val 100 105 110 Ala Val Asn SerIle Met Ser Ile Leu Thr Gly Ser Thr Arg Ser Ser 115 120 125 Phe Arg LysMet Cys Leu Gln Thr Leu Gln Ala Ala Asp Thr Gln Glu 130 135 140 Phe ArgThr Lys Leu His Lys Val Phe Arg Glu Ile Thr Gln His Gln 145 150 155 160Phe Leu His His Cys Ser Cys Glu Val Lys Gln Leu Thr Leu Glu Lys 165 170175 Lys Asp Ser Ala Gln Gly Thr Glu Asp Ala Pro Asp Asn Ser Ser Leu 180185 190 Glu Leu Leu Ala Val Leu Lys Gln Pro Ser Gln Pro Thr Ala Ala Gly195 200 205 Val Gln Gln Leu Ser His Ser Val Thr Ser Arg Asp Ala Arg TyrGln 210 215 220 Arg Ala Ser Arg Lys Gln Glu Ala Gln Glu Gly Gln Pro ProHis Arg 225 230 235 240 Gly Asp Ala Ser Ser Ala Leu Cys Gln Gly Pro GluPro Val Arg Gly 245 250 255 Arg Pro Ala Pro Pro Gly Ser His Arg Gly ProPro His Ser 260 265 270 <210> SEQ ID NO 133 <211> LENGTH: 1607 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 133 gtgaacttcactactggaaa gcaacaaagg cagtcggcat aaaaatgggt tctctcagca 60 cagctaacgttgaattttgc cttgatgtgt tcaaagagct gaacagtaac aacataggag 120 ataacatcttcttttcttcg ctgagtctgc tttatgctct aagcatggtc ctccttggtg 180 ccaggggagagactgcagag caattggaga aggtgcttca ttttagtcat actgtagact 240 cattaaaaccagggttcaag gactcaccta agtgcagcca agctggaaga attcattccg 300 agtttggtgtctaattctct caaatcaacc agccagactc taactgtacc ctcagcattg 360 ccaacaggctctacgggaca aagacgatgg catttcatca ggaaaagtcg caaatctctt 420 tggaaagagcacaattgacc cttcatctgt aatggtcctg gtgaatacca tatatttcaa 480 aggacaatggcaaaataaat ttcaagtaag agagacagtt aaaagtcctt ttcagctaag 540 tgagggtaaaaatgtaactg tggaaatgat gtatcaaatt ggaacattta aactggcctt 600 tgtaaaggagccgcagatgc aagttcttga gctgccctac gttaacaaca aattaagcat 660 gattattctgcttccagtag gcatagctaa tctgaaacag atagaaaagc agctgaattc 720 ggggacgtttcatgagtgga caagctcttc taacatgatg gaaagagaag ttgaagtaca 780 cctccccagattcaaacttg aaattaagta tgagctaaat tccctgttaa aacctctagg 840 ggtgacagatctcttcaacc aggtcaaagc tgatctttct ggaatgtcac caaccaaggg 900 cctatatttatcaaaagcca tccacaagtc atacctggat gtcagcgaag agggcacgga 960 ggcagcagcagccactgggg acagcatcgc tgtaaaaagc ctaccaatga gagctcagtt 1020 caaggcgaaccaccccttcc tgttctttat aaggcacact cataccaaca cgatcctatt 1080 ctgtggcaagcttgcctctc cctaatcaga tggggttgag taaggctcag agttgcagat 1140 gaggtgcagagacaatcctg tgactttccc acggccaaaa agctgttcac acctcacaca 1200 cctctgtgcctcagtttgct catctgcaaa ataggtctag gatttcttcc aaccatttca 1260 tgagttgtgaagctaaggct ttgttaatca tggaaaaagg tagacttatg cagaaagcct 1320 ttctggctttcttatctgtg gtgtctcatt tgagtgctgt ccagtgacat gatcaagtca 1380 atgagtaaaattttaaggga ttagattttc ttgacttgta kgtatctgtg agatcttgaa 1440 taagtgacctgacatctctg cttaaagaaa accagctgaa gggcttcaac tttgcttgga 1500 tttttaaatattttccttgc atatgtaaat agaatgtggt gagttttagt tcaaaattct 1560 ctgttgagaataataaatgc atgaaatacc ttaaaaaaaa aaaaaaa 1607 <210> SEQ ID NO 134 <211>LENGTH: 217 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:134 Met Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Gln Trp Gln Asn Lys 1 510 15 Phe Gln Val Arg Glu Thr Val Lys Ser Pro Phe Gln Leu Ser Glu Gly 2025 30 Lys Asn Val Thr Val Glu Met Met Tyr Gln Ile Gly Thr Phe Lys Leu 3540 45 Ala Phe Val Lys Glu Pro Gln Met Gln Val Leu Glu Leu Pro Tyr Val 5055 60 Asn Asn Lys Leu Ser Met Ile Ile Leu Leu Pro Val Gly Ile Ala Asn 6570 75 80 Leu Lys Gln Ile Glu Lys Gln Leu Asn Ser Gly Thr Phe His Glu Trp85 90 95 Thr Ser Ser Ser Asn Met Met Glu Arg Glu Val Glu Val His Leu Pro100 105 110 Arg Phe Lys Leu Glu Ile Lys Tyr Glu Leu Asn Ser Leu Leu LysPro 115 120 125 Leu Gly Val Thr Asp Leu Phe Asn Gln Val Lys Ala Asp LeuSer Gly 130 135 140 Met Ser Pro Thr Lys Gly Leu Tyr Leu Ser Lys Ala IleHis Lys Ser 145 150 155 160 Tyr Leu Asp Val Ser Glu Glu Gly Thr Glu AlaAla Ala Ala Thr Gly 165 170 175 Asp Ser Ile Ala Val Lys Ser Leu Pro MetArg Ala Gln Phe Lys Ala 180 185 190 Asn His Pro Phe Leu Phe Phe Ile ArgHis Thr His Thr Asn Thr Ile 195 200 205 Leu Phe Cys Gly Lys Leu Ala SerPro 210 215 <210> SEQ ID NO 135 <211> LENGTH: 1537 <212> TYPE: DNA <213>ORGANISM: Homo sapiens <400> SEQUENCE: 135 gtaggatttg gggatgtggatatttaagac aatttctttt ttcttttggt ttaatagggg 60 cgggtatagg gaccaactgggaccgagtgc ccagggggcc gagcacggtc atgctggccg 120 gcctgcatgc atgcgtgtgccgggctgggc tgggcggccg gcggtcgtgg ggcagggttg 180 ggggtctgtg ctcagctgataactgccatg cactgtactg cacacgtccc tagagcctac 240 cgggacccga cgcttttcagggcatttctc cctccagcca gggcccaact cccacctgcc 300 tgggcgaatc tcctccaaggaagtcccagg aggatgggga ccaggaaggc tgtggacccc 360 catctccagg gggccttcccagcctgatcc ctgtcctcca agttctggag gaggccgctg 420 tagggtctgg ctgagcttcccacccacttt ccctggtccc aatcctttct tgtcctatac 480 ccagctgggg ttgctgccctgaacgaactg cgtgtggggc cggcacatcc tagcaggcag 540 cccctggcgc ctgctgcctcagggatgctc caaccaccct cgttctcctc gcagtggccc 600 tggctcccac ctcccgccccagcctgccgt ggggcccgtc agcctggtcc cacccccatg 660 gagaacccaa agtcttactgtatataactc caggtgacgt ttctatattt atagcagtgt 720 tgaaaaccca cgtgttttacacagaaccac cctctccaac ccctcccttc ccgaccccaa 780 caaaacgttt tcaaaccccttacagttcct ggggcaggcg gaaacaggct cacagattgt 840 gtgtcggctg cagcagtgattccaacaagc agctattggg ggggaaacac agcatttaaa 900 aagatcatca ttaaaaaacaagatttatac aacaattact taggatgttt gtgatctgcc 960 gaccttgcta tagatgccatgttaccaatg atttcctgtg gtgggggctt gccattgttt 1020 actctcttat ttaccaacttctggcctagg catgacagtg ggcaccttcc cccagccctg 1080 gctgggccca gcgcctgtgttytgtgttag aaaggtttta tatatatata aaattacata 1140 tatakgtaga aatatatgtaattttggggg ccctgttcct tgcacatttt acagttacct 1200 catttttccc atgtatgtatttgagaaaat gctaatatat agagaaaaaa atggttctta 1260 aaacttaaat gtgtggttttttccattcca tgggattcac attggtttgt agcatttaac 1320 ataactagta tgttgtattatatatatgtg tatactgatt gaaattttta acagatttgt 1380 acttttttta aaatgaaagttgctagttct gcttgaccaa gtagtgcaat cattattttt 1440 tttaatattg ttgctgatttcagagggata ttcactaata aatgtatgat gtatacccac 1500 graaaaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaaa 1537 <210> SEQ ID NO 136 <211> LENGTH: 86 <212> TYPE:PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 136 Met His Ala Cys AlaGly Leu Gly Trp Ala Ala Gly Gly Arg Gly Ala 1 5 10 15 Gly Leu Gly ValCys Ala Gln Leu Ile Thr Ala Met His Cys Thr Ala 20 25 30 His Val Pro ArgAla Tyr Arg Asp Pro Thr Leu Phe Arg Ala Phe Leu 35 40 45 Pro Pro Ala ArgAla Gln Leu Pro Pro Ala Trp Ala Asn Leu Leu Gln 50 55 60 Gly Ser Pro ArgArg Met Gly Thr Arg Lys Ala Val Asp Pro His Leu 65 70 75 80 Gln Gly AlaPhe Pro Ala 85 <210> SEQ ID NO 137 <211> LENGTH: 1302 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 137 cttcatggcc tacacacaccaccttacccc tctgctggca agaggggacc tgattcatcc 60 tcacgctaaa cactcattctacccaactga ttgagacaga acagaagata aactgaaact 120 tctctgcctt cccgctgcaagagtgaatga gcgatccctc tcaactgact caaaatgttt 180 gcctcaccca ggagatggagctctcgaagg ccttctctgg ccagcggaca ctcctatctg 240 ccatcctcag catgctatcactcagcttct ccacaacatc cctgctcagc aactactggt 300 ttgtgggcac acagaaggtgcccaagcccc tgtgcgagaa aggtctggca gccaagtgct 360 ttgacatgcc agtgtccctggatggagata ccaacacatc cacccaggag gtggtacaat 420 acaactggga gactggggatgaccggttct ccttccggag cttccggagt ggcatgtggc 480 tatcctgtga ggaaactgtggaagaaccag gggagaggtg ccgaagtttc attgaactta 540 caccaccagc caagagagaaatcctatggt tatccctggg aacgcagatc acctacatcg 600 gacttcaatt catcagcttcctcctgctac taacagactt gctactcact gggaaccctg 660 cctgtgggct caaactgagcgcctttgctg ctgtttcctc tgtcctgtca ggtctcctgg 720 ggatggtggc ccacatgatgtattcacaag tcttccaagc gactgtcaac ttgggtccag 780 aagactggag accacatgtttggaattatg gctgggcctt ctacatggcc tggctctcct 840 tcacctgctg catggcgtcggctgtcacca ccttcaacac gtacaccagg atggtgctgg 900 agttcaagtg caagcatagtaagagcttca aggaaaaccc gaactgccta ccacatcacc 960 atcagtgttt ccctcggcggctgtcaagtg cagcccccac cgtgggtcct ttgaccagct 1020 accaccagta tcataatcagcccatccact ctgtctctga gggagtcgac ttctactccg 1080 agctgcggaa caagggatttcaaagagggg ccagccagga gctgaaagaa gcagttaggt 1140 catctgtaga ggaagagcagtgttaggagt taagcgggtt tggggagtag gcttgagccc 1200 taccttacac gtctgctgattatcaacatg tgcttaagcc aaaaaaaaaa aaaaaaaaaa 1260 aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa aa 1302 <210> SEQ ID NO 138 <211> LENGTH: 339<212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 138 Met SerAsp Pro Ser Gln Leu Thr Gln Asn Val Cys Leu Thr Gln Glu 1 5 10 15 MetGlu Leu Ser Lys Ala Phe Ser Gly Gln Arg Thr Leu Leu Ser Ala 20 25 30 IleLeu Ser Met Leu Ser Leu Ser Phe Ser Thr Thr Ser Leu Leu Ser 35 40 45 AsnTyr Trp Phe Val Gly Thr Gln Lys Val Pro Lys Pro Leu Cys Glu 50 55 60 LysGly Leu Ala Ala Lys Cys Phe Asp Met Pro Val Ser Leu Asp Gly 65 70 75 80Asp Thr Asn Thr Ser Thr Gln Glu Val Val Gln Tyr Asn Trp Glu Thr 85 90 95Gly Asp Asp Arg Phe Ser Phe Arg Ser Phe Arg Ser Gly Met Trp Leu 100 105110 Ser Cys Glu Glu Thr Val Glu Glu Pro Gly Glu Arg Cys Arg Ser Phe 115120 125 Ile Glu Leu Thr Pro Pro Ala Lys Arg Glu Ile Leu Trp Leu Ser Leu130 135 140 Gly Thr Gln Ile Thr Tyr Ile Gly Leu Gln Phe Ile Ser Phe LeuLeu 145 150 155 160 Leu Leu Thr Asp Leu Leu Leu Thr Gly Asn Pro Ala CysGly Leu Lys 165 170 175 Leu Ser Ala Phe Ala Ala Val Ser Ser Val Leu SerGly Leu Leu Gly 180 185 190 Met Val Ala His Met Met Tyr Ser Gln Val PheGln Ala Thr Val Asn 195 200 205 Leu Gly Pro Glu Asp Trp Arg Pro His ValTrp Asn Tyr Gly Trp Ala 210 215 220 Phe Tyr Met Ala Trp Leu Ser Phe ThrCys Cys Met Ala Ser Ala Val 225 230 235 240 Thr Thr Phe Asn Thr Tyr ThrArg Met Val Leu Glu Phe Lys Cys Lys 245 250 255 His Ser Lys Ser Phe LysGlu Asn Pro Asn Cys Leu Pro His His His 260 265 270 Gln Cys Phe Pro ArgArg Leu Ser Ser Ala Ala Pro Thr Val Gly Pro 275 280 285 Leu Thr Ser TyrHis Gln Tyr His Asn Gln Pro Ile His Ser Val Ser 290 295 300 Glu Gly ValAsp Phe Tyr Ser Glu Leu Arg Asn Lys Gly Phe Gln Arg 305 310 315 320 GlyAla Ser Gln Glu Leu Lys Glu Ala Val Arg Ser Ser Val Glu Glu 325 330 335Glu Gln Cys <210> SEQ ID NO 139 <211> LENGTH: 3184 <212> TYPE: DNA <213>ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: unsure <222>LOCATION: (1644) <400> SEQUENCE: 139 gtgcatgctt gtaatcgcag ctacttcggagcctgagaga ctccttcagg gtgagcaaag 60 gcctggaaaa acctgtatgc agataaagaaaaggaaagaa agagataatc agtgcatgca 120 gttgtcagct ggctgggacc tgaggagagtcacttgtgga ggcaactggt ctttatcccc 180 attgtccggt acaaggcagg cattaatcctgtgatcctta tctgaagctc agctacaagg 240 ctttggccga ccaagtgtgt accatgctgctattgtcatc ttccttgaat tctttgcgtg 300 gggcctgttg acaactccaa tgttgactgttctacatgaa acattttctc aacacacatt 360 cctcatgaat ggtctcattc aaggtgtaaagggcctgctc tcttttttga gtgccccact 420 cattggtgcc ctgtctgatg tgtgggggaggaagcccttt ctcctcggca ctgtattctt 480 tacctgcttc ccaatcccac tgatgaggatcagcccatgg tggtattttg cgatgatttc 540 tgtgtctgga gtcttctcgg tcacgttttctgttatattt gcctatgtag ctgatgtcac 600 tcaggagcac gagcgaagta cagcttatggatgggtctca gccacctttg cggctagtct 660 tgtcagcagc ccggccattg gagcatatctttctgccagt tacggagaca gcctcgttgt 720 gctggtggcc acagtggtgg ctcttctggacatctgcttc atcttagtgg ctgttccaga 780 atctctgcct gagaaaatga gaccggtttcctggggagct cagatttctt ggaaacaagc 840 agaccctttt gcgtcgttga agaaagttggaaaagattct actgtcttac taatctgcat 900 caccgtgttt ctttcatacc ttcctgaagctggacagtat tcaagttttt ttctctatct 960 caggcaggtc ataggttttg gatctgttaaaattgcagca ttcatagcta tggtaggaat 1020 tctgtctatt gtggctcaga cggcctttcttagcatcttg atgagatcat taggaaataa 1080 gaatactgtc ctccttggct tgggcttccagatgctccag ttagcctggt acggttttgg 1140 atcacaggcc tggatgatgt gggcagcagggaccgtggct gccatgtcca gcatcacgtt 1200 tccggcaatc agtgccctcg tctctcggaatgcagagtca gatcagcaag gagttgccca 1260 ggggatcata actggaataa gaggactatgcaatggcctg gggccagcac tgtatggctt 1320 catattctac atgttccatg tggaactgactgagttgggc ccgaaattga attctaacaa 1380 cgttcccctg cagggagctg tcatcccaggcccgccgttt ttatttgggg catgtatagt 1440 ccttatgtct tttctggttg ccttattcattcctgaatac agtaaagcca gtggagttca 1500 aaaacacagt aacagcagca gcggcagcctgaccaacacc ccagaacggg gcagtgatga 1560 ggacattgag ccactactgc aagacagcagcatctgggag ctctcttcat ttgaggagcc 1620 tgggaatcag tgcactgagc tgtnaactcggcagaaagtg ggattctgca tacgccatct 1680 ctgagagcca tggagggagc cacacccctggtgacttcat ggtgctggat gggagacgct 1740 agcggcatcc ttcagggcca agtttgataaataccaccgc catcattctg ctcatcctcc 1800 tcctgttttt tttttttctc ttacattctttttttttttc ctgtttatac attagaacaa 1860 gataagattt gaaatacttc cttgcaaataatgtgcaact cccaaggtga aactcaaata 1920 gaaaaagtca tctctctggt agaaaggatggctttcctgt aatgactata gagtaagagt 1980 ggcagcaatc tttccatgcc cttttcagcagaaggcacag aacagtagcg ggactgccat 2040 ctctggcaag atttcaggta aagaatctcttcttaatttc taccttcctg tttctctgaa 2100 tcagcccata ggtgttgatg agtggccactcttaaagagt cactcagtat cagggatcta 2160 ctgtctttgt tcaaaggtca aataaaaacctagtctcctt ttattctact ttctattctt 2220 agctagaatg aaactcagca tatatacacttctggacata ataatattga atagtaatta 2280 cctttactag atgaaagaaa ttttcattacaaacttaaat catgtaaaac tcaacaactc 2340 agattcctgg acctggtgtc ctggttgggtccaaggtgat tttacagaag aaaaaaacaa 2400 ctcaagcatt ctggtggcaa catagagattgtaggctgct tctaagaaag ttattaacaa 2460 tttggaaatt cctaagtagg atgagagttagtaactggat acgagtgaag tttatatcca 2520 agttcagact caaaggcatt attatgatttgcttcttccc atgtcttcca tgtcctgctt 2580 ctcaaagttt ttctcatcca tcacactcctgccttaactg ctctgagtat gcatttgttt 2640 tcaattcatc tttatttcaa tctgtttaacttttgaatcg catgggaata cgcacattaa 2700 gttcctttct aaaataaggt tttatgaagctgagtttcac gataagtgtc ttgctatttt 2760 ttgagatgtt ttatggacaa agaaaactttacagatttat atgtattttg ctgcaccagt 2820 aaatggacca ttaactaggg cccacctttaacagagcacc cctttgaaag ttttataggt 2880 atgaaatata tgtagatatt tgtaaagggttttaattttt tttttttgat ggggtgctgt 2940 gtaaatcttg tatttataaa tgtaatgaaggtattgacag aaaaaaatat atacaacttt 3000 tataaaggat tgtgtactga ctgaatacatttaaaagaaa atatattttg aaacctgttc 3060 tgctatgaac agagataaca tatctttttactatgctatt ggtttttagg ttaagcttcc 3120 taatgcataa taaatttaca gtggttaaaaaaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3180 aaaa 3184 <210> SEQ ID NO 140<211> LENGTH: 454 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220>FEATURE: <221> NAME/KEY: UNSURE <222> LOCATION: (442) <400> SEQUENCE:140 Met Leu Thr Val Leu His Glu Thr Phe Ser Gln His Thr Phe Leu Met 1 510 15 Asn Gly Leu Ile Gln Gly Val Lys Gly Leu Leu Ser Phe Leu Ser Ala 2025 30 Pro Leu Ile Gly Ala Leu Ser Asp Val Trp Gly Arg Lys Pro Phe Leu 3540 45 Leu Gly Thr Val Phe Phe Thr Cys Phe Pro Ile Pro Leu Met Arg Ile 5055 60 Ser Pro Trp Trp Tyr Phe Ala Met Ile Ser Val Ser Gly Val Phe Ser 6570 75 80 Val Thr Phe Ser Val Ile Phe Ala Tyr Val Ala Asp Val Thr Gln Glu85 90 95 His Glu Arg Ser Thr Ala Tyr Gly Trp Val Ser Ala Thr Phe Ala Ala100 105 110 Ser Leu Val Ser Ser Pro Ala Ile Gly Ala Tyr Leu Ser Ala SerTyr 115 120 125 Gly Asp Ser Leu Val Val Leu Val Ala Thr Val Val Ala LeuLeu Asp 130 135 140 Ile Cys Phe Ile Leu Val Ala Val Pro Glu Ser Leu ProGlu Lys Met 145 150 155 160 Arg Pro Val Ser Trp Gly Ala Gln Ile Ser TrpLys Gln Ala Asp Pro 165 170 175 Phe Ala Ser Leu Lys Lys Val Gly Lys AspSer Thr Val Leu Leu Ile 180 185 190 Cys Ile Thr Val Phe Leu Ser Tyr LeuPro Glu Ala Gly Gln Tyr Ser 195 200 205 Ser Phe Phe Leu Tyr Leu Arg GlnVal Ile Gly Phe Gly Ser Val Lys 210 215 220 Ile Ala Ala Phe Ile Ala MetVal Gly Ile Leu Ser Ile Val Ala Gln 225 230 235 240 Thr Ala Phe Leu SerIle Leu Met Arg Ser Leu Gly Asn Lys Asn Thr 245 250 255 Val Leu Leu GlyLeu Gly Phe Gln Met Leu Gln Leu Ala Trp Tyr Gly 260 265 270 Phe Gly SerGln Ala Trp Met Met Trp Ala Ala Gly Thr Val Ala Ala 275 280 285 Met SerSer Ile Thr Phe Pro Ala Ile Ser Ala Leu Val Ser Arg Asn 290 295 300 AlaGlu Ser Asp Gln Gln Gly Val Ala Gln Gly Ile Ile Thr Gly Ile 305 310 315320 Arg Gly Leu Cys Asn Gly Leu Gly Pro Ala Leu Tyr Gly Phe Ile Phe 325330 335 Tyr Met Phe His Val Glu Leu Thr Glu Leu Gly Pro Lys Leu Asn Ser340 345 350 Asn Asn Val Pro Leu Gln Gly Ala Val Ile Pro Gly Pro Pro PheLeu 355 360 365 Phe Gly Ala Cys Ile Val Leu Met Ser Phe Leu Val Ala LeuPhe Ile 370 375 380 Pro Glu Tyr Ser Lys Ala Ser Gly Val Gln Lys His SerAsn Ser Ser 385 390 395 400 Ser Gly Ser Leu Thr Asn Thr Pro Glu Arg GlySer Asp Glu Asp Ile 405 410 415 Glu Pro Leu Leu Gln Asp Ser Ser Ile TrpGlu Leu Ser Ser Phe Glu 420 425 430 Glu Pro Gly Asn Gln Cys Thr Glu LeuXaa Thr Arg Gln Lys Val Gly 435 440 445 Phe Cys Ile Arg His Leu 450<210> SEQ ID NO 141 <211> LENGTH: 2481 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 141 aggtctagaa ttcaatcggg aagaaggaaaagttcccttc tgctgtgaaa ctatttggca 60 agaggctgga gggcccaatg gctgcaaaatcgcaacccaa cattcccaaa gccaagagtc 120 tagatggcgt caccaatgac agaaccgcatctcaagggca gtggggccgt gcctgggagg 180 tggactggtt ttcactggcg agcgtcatcttcctactgct gttcgccccc ttcatcgtct 240 actacttcat catggcttgt gaccaatacagctgcgccct gaccggccct gtggtggaca 300 tcgtcaccgg acatgctcgg ctctcggacatctgggccaa gactccacct ataacgagga 360 aagccgccca gctctatacc ttgtgggtcaccttccaggt gcttctgtac acgtctctcc 420 ctgacttctg ccataagttt ctacccggctacgtaggagg catccaggag ggggccgtga 480 ctcctgcagg ggttgtgaac aagtatcagatcaacggcct gcaagcctgg ctcctcacgc 540 acctgctctg gtttgcaaac gctcatctcctgtcctggtt ctcgcccacc atcatcttcg 600 acaactggat cccactgctg tggtgcgccaacatccttgg ctatgccgtc tccaccttcg 660 ccatggtcaa gggctacttc ttccccaccagcgccagaga ctgcaaattc acaggcaatt 720 tcttttacaa ctacatgatg ggcatcgagtttaaccctcg gatcgggaag tggtttgact 780 tcaagctgtt cttcaatggg cgccccgggatcgtcgcctg gaccctcatc aacctgtcct 840 tcgcagcgaa gcagcgggag ctccacagccatgtgaccaa tgccatggtc ctggtcaacg 900 tcctgcaggc catctacgtg attgacttcttctggaacga aacctggtac ctgaagacca 960 ttgacatctg ccatgaccac ttcgggtggtacctgggctg gggcgactgt gtctggctgc 1020 cttatcttta cacgctgcag ggtctgtacttggtgtacca ccccgtgcag ctgtccaccc 1080 cgcacgccgt gggcgtcctg ctgctgggcctggtgggcta ctacatcttc cgggtggcca 1140 accaccagaa ggacctgttc cgccgcacggatgggcgctg cctcatctgg ggcaggaagc 1200 ccaaggtcat cgagtgctcc tacacatccgccgacgggca gaggcaccac agcaagctgc 1260 tggtgtcggg cttctggggc gtggcccgccacttcaacta cgtcggcgac ctgatgggca 1320 gcctggccta ctgcctggcc tgtggcggtggccacctgct gccctacttc tacatcatct 1380 acatggccat cctgctgacc caccgctgcctccgggacga gcaccgctgc gccagcaagt 1440 acggccggga ctgggagcgc tacaccgccgcagtgcctta ccgcctgctg cctggaatct 1500 tctaagggca cgccctaggg agaagccctgtggggctgtc aagagcgtgt tctgccaggt 1560 ccatgggggc tggcatccca gctccaactcgaggagcctc agtttcctca tctgtaaact 1620 ggagagagcc cagcacttgg caggtgtccagtacctaatc acgctctgtt ccttgctttt 1680 gccttcaagg gaattccgag tgtccagcactgccgtattg ccagcacaga cggattttct 1740 ctaatcagtg tccctggggc aggaggatgacccagtcacc tttactagtc ctttggagac 1800 aatttacctg tattaggagc ccaggccacgctacactctg cccacactgg tgagcaggag 1860 gtcttcccac gccctgtcat taggctgcatttactcttgc taaataaaag tgggagtggg 1920 gcgtgcgcgt tatccatgta ttgcctttcagctctagatc cccctcccct gcctgctctg 1980 cagtcgtggg tggggcccgt gcgccgtttctccttggtag cgtgcacggt gttgaactgg 2040 gacactgggg agaaaggggc tttcatgtcgtttccttcct gctcctgctg macagctgcc 2100 aggagtgctc tgcctggagt ctgcagacctcagagaggtc ccagcactgg ctgtggcctt 2160 tcaggtgtag gcaggtgggc tctgcttcccgattccctgt gagcgcccac cctctcgaaa 2220 gaattttctg cttgccctgt gactgtgcagactctggctc gagcaacccg gggaacttca 2280 ccctcagggg cctcccacac cttctccagcgaggaggtyt cagtcccagc ctcgggaggg 2340 cacctccttt tctgtgcttt cttccctgaggcattcttcc tcatccctag ggtgttgtgt 2400 agaactcttt ttaaactcta tgctccgagtagagttcatc tttatattaa acttcccctg 2460 ttcaaataaa aaaaaaaaaa a 2481 <210>SEQ ID NO 142 <211> LENGTH: 475 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 142 Met Ala Ala Lys Ser Gln Pro Asn Ile Pro LysAla Lys Ser Leu Asp 1 5 10 15 Gly Val Thr Asn Asp Arg Thr Ala Ser GlnGly Gln Trp Gly Arg Ala 20 25 30 Trp Glu Val Asp Trp Phe Ser Leu Ala SerVal Ile Phe Leu Leu Leu 35 40 45 Phe Ala Pro Phe Ile Val Tyr Tyr Phe IleMet Ala Cys Asp Gln Tyr 50 55 60 Ser Cys Ala Leu Thr Gly Pro Val Val AspIle Val Thr Gly His Ala 65 70 75 80 Arg Leu Ser Asp Ile Trp Ala Lys ThrPro Pro Ile Thr Arg Lys Ala 85 90 95 Ala Gln Leu Tyr Thr Leu Trp Val ThrPhe Gln Val Leu Leu Tyr Thr 100 105 110 Ser Leu Pro Asp Phe Cys His LysPhe Leu Pro Gly Tyr Val Gly Gly 115 120 125 Ile Gln Glu Gly Ala Val ThrPro Ala Gly Val Val Asn Lys Tyr Gln 130 135 140 Ile Asn Gly Leu Gln AlaTrp Leu Leu Thr His Leu Leu Trp Phe Ala 145 150 155 160 Asn Ala His LeuLeu Ser Trp Phe Ser Pro Thr Ile Ile Phe Asp Asn 165 170 175 Trp Ile ProLeu Leu Trp Cys Ala Asn Ile Leu Gly Tyr Ala Val Ser 180 185 190 Thr PheAla Met Val Lys Gly Tyr Phe Phe Pro Thr Ser Ala Arg Asp 195 200 205 CysLys Phe Thr Gly Asn Phe Phe Tyr Asn Tyr Met Met Gly Ile Glu 210 215 220Phe Asn Pro Arg Ile Gly Lys Trp Phe Asp Phe Lys Leu Phe Phe Asn 225 230235 240 Gly Arg Pro Gly Ile Val Ala Trp Thr Leu Ile Asn Leu Ser Phe Ala245 250 255 Ala Lys Gln Arg Glu Leu His Ser His Val Thr Asn Ala Met ValLeu 260 265 270 Val Asn Val Leu Gln Ala Ile Tyr Val Ile Asp Phe Phe TrpAsn Glu 275 280 285 Thr Trp Tyr Leu Lys Thr Ile Asp Ile Cys His Asp HisPhe Gly Trp 290 295 300 Tyr Leu Gly Trp Gly Asp Cys Val Trp Leu Pro TyrLeu Tyr Thr Leu 305 310 315 320 Gln Gly Leu Tyr Leu Val Tyr His Pro ValGln Leu Ser Thr Pro His 325 330 335 Ala Val Gly Val Leu Leu Leu Gly LeuVal Gly Tyr Tyr Ile Phe Arg 340 345 350 Val Ala Asn His Gln Lys Asp LeuPhe Arg Arg Thr Asp Gly Arg Cys 355 360 365 Leu Ile Trp Gly Arg Lys ProLys Val Ile Glu Cys Ser Tyr Thr Ser 370 375 380 Ala Asp Gly Gln Arg HisHis Ser Lys Leu Leu Val Ser Gly Phe Trp 385 390 395 400 Gly Val Ala ArgHis Phe Asn Tyr Val Gly Asp Leu Met Gly Ser Leu 405 410 415 Ala Tyr CysLeu Ala Cys Gly Gly Gly His Leu Leu Pro Tyr Phe Tyr 420 425 430 Ile IleTyr Met Ala Ile Leu Leu Thr His Arg Cys Leu Arg Asp Glu 435 440 445 HisArg Cys Ala Ser Lys Tyr Gly Arg Asp Trp Glu Arg Tyr Thr Ala 450 455 460Ala Val Pro Tyr Arg Leu Leu Pro Gly Ile Phe 465 470 475 <210> SEQ ID NO143 <211> LENGTH: 1518 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 143 cttccccact ggctcttggt ttatgagttc cccttttaaggatctgttgt gacttaccta 60 tctgggctag tgacctcaga tgtctcagac tgagcatcttaccactgttt ctggttgatc 120 ccttcactca tggtcttaac acatttgcac ttcctctcatctcagagagt acagtcacgg 180 ggcagagctt gcatagggat ccaggtgtta ctagtcttactctggagctg gtccaactca 240 gtttcatggc acagaactag attaggtctc cactgcgcagtctgttttac tgcttaggga 300 aagccagctt ttctacccac acacgtttag tttgaagagtatctattttt ggagggttct 360 ttgggaggtt gggcaggctt ctttggatcc cagatacatttagagctttt tgcattaagt 420 gtgaggaaaa taacttctct ttgatgatgt tgatacaccatgtkggcacc ytggggcaca 480 gcggtttagc tggggagatt ccatgagaat gaacccaaactactcttctt tgctagggtc 540 ctttacccac acagaggtga gcctttcagg ttcttcattttgcttagttt cttcccttgt 600 ccttggcatt taagaggcat ccatgtgtta gccagccaaagccccctgaa ggagctggct 660 gctttaaagg atttacttgg gaggatgtca aatggctttgccttctgcag acttcattta 720 ttttaatctt tttatggctc ctttctcttg ctttaaaacaggattataag cacacagcag 780 gtactgacac ctgaagtctt actaaattcc tgtcctcaggccatcctttt tctcctgaaa 840 cctggactcc aattttcaat gacgtttttg tttttctctttcaagcctaa ctatgggaca 900 gctttacgag aaggaaaaag atgaagatgg attcttatatgtggcctaca gcggagagaa 960 cacttttggc ttctgagggc cattgctggg ctaggtgcaccgtaactgct tgtgtatctt 1020 gtaaatagcc asccattttc agttattawa ccagaacctcttmacataga cctattagtg 1080 catttgtaac tggatttatt tcttaatata tkggaaggttttgtttcctt agactagtaa 1140 attatcatac agagttttat tttgagtttt tctttttgtgcattgtcctc atgcctgtat 1200 tctccaggaa acttgtcctt ctggaaatca tatkgaatgatatttctata tcgaagtgag 1260 gtaggtgcgg tattaaagtg aaagggaagg tgatgcatttattctgggtt atgcttgaag 1320 tgttagatgg ctaagtatta aaattatcca aattaaatccttagcagtca gaacacttgc 1380 ttcactagaa tatgccaact gccaatcatg ttggactgagctaatttgtt cctctttctg 1440 aaactattaa ggtaaataat taacaataaa aattctcttataaaggcaaa aaaaaaaaaa 1500 aaaaaaaaaa aaaaaaaa 1518 <210> SEQ ID NO 144<211> LENGTH: 55 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 144 Met Val Leu Thr His Leu His Phe Leu Ser Ser Gln Arg ValGln Ser 1 5 10 15 Arg Gly Arg Ala Cys Ile Gly Ile Gln Val Leu Leu ValLeu Leu Trp 20 25 30 Ser Trp Ser Asn Ser Val Ser Trp His Arg Thr Arg LeuGly Leu His 35 40 45 Cys Ala Val Cys Phe Thr Ala 50 55 <210> SEQ ID NO145 <211> LENGTH: 2097 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 145 ctcttgagta cctggggctt gcagatgcat gccaccacacccggctaatt tttttttttt 60 ttaaatagag atggggtctt gttctgttgc ccargctggtctggaactcc tggcttcaat 120 cagtcctccc acctcagctt cccaaagctc tgggattataggcatgagcc actgtacctg 180 tccacctgag aaattttcta agcctggatt cagtcttatgaaatataata ctttgaaatg 240 cacaataact ttgaaaatga aactcattgc ttttcatttcaccaggagtt actaactata 300 ataagcttta gagcaaattc tccttagata tgatttttgttattattaga aacacatact 360 atcttgataa ctaaattttg ccaatcattc ttcttgactagtggtcttta tatatacata 420 catatatata tatatataca tatatatata tatgaggaattttccataag tgacttgaaa 480 aatacagaat gcactccatg gtaggtctgt tcagtgttatcaggaatact gtttctcatc 540 ttcctttctt ggtgtccctt tgcaggggtt gtgtttgcacattatggtcc cgtctggaga 600 caacaaagga agttctctca ttcaactctt cgtcattttgggttgggaaa acttagcttg 660 gagcccaaga ttattgagga gttcaaatat gtgaaagcagaaatgcaaaa gcacggagaa 720 gaccccttct gccctttctc catcatcagc aatgccgtctctaacatcat ttgctccttg 780 tgctttggcc agcgctttga ttacactaat agtgagttcaagaaaatgct tggttttatg 840 tcacgaggcc tagaaatctg tctgaacagt caagtcctcctggtcaacat atgcccttgg 900 ctttattacc ttccctttgg accatttaag gaattaagacaaattgaaaa ggatataacc 960 agtttcctta aaaaaatcat caaagaccat caagagtctctggatagaga gaaccctcag 1020 gacttcatag acatgtacct tctccacatg gaagaggagaggaaaaataa tagtaacagc 1080 agttttgatg aagagtactt attttatatc attggggatctctttattgc tgggactgat 1140 accacaacta actctttgct ctggtgcctg ctgtatatgtcgctgaaccc cgatgtacaa 1200 gaaaaggttc atgaagaaat tgaaagagtc attggcgccaaccgagctcc ttccctcaca 1260 gacaaggccc agatgcccta cacagaagcc accatcatggaagtgcagag gctaactgtg 1320 gtggtgccgc ttgccattcc tcatatgacc tcagagaacacagtgctcca agggtatacc 1380 attcctaaag gcacattgat cttacccaac ctgtggtcagtacatagaga cccagccatt 1440 tgggagaaac cggaggattt ctaccctaat cgatttctggatgaccaagg acaactaatt 1500 aaaaaagaaa cctttattcc ttttgggata gggaagcgggtgtgtatggg agaacaactg 1560 gcaaagatgg aattattcct aatgtttgtg agcctaatgcagagtttcgc atttgcttta 1620 cctgaggatt ctaagaagcc cctcctgast ggaagatttggtctaacttt agccccacat 1680 ccatttaata taactatttc aaggagatga agagcatctccaagaagaga tggtaaaaag 1740 atatataaat acatatcctt ctaagcagat tcttcctactgcaaaggaca gtgaatccag 1800 caactcagtg gatccaagct gggctcagag gtcggaaggagggtagagca cactgggagg 1860 tttcatcttg gaggattcct cagcaggata cttcagccattttagtaatg caggtctgtg 1920 atttggggga tagaaaacaa agtacctatg aaacgggatatctggatttt acttgcagtg 1980 gcttccaccg atgggccaat cttctcattt cttagtgcctcagacatccc atatgtaaaa 2040 tgagagtaat aaaacttggc ttctctctac ctctcagcactaaaaaaaaa aaaaaaa 2097 <210> SEQ ID NO 146 <211> LENGTH: 398 <212>TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY:UNSURE <222> LOCATION: (379) <400> SEQUENCE: 146 Val Leu Ser Gly Ile LeuPhe Leu Ile Phe Leu Ser Trp Cys Pro Phe 1 5 10 15 Ala Gly Val Val PheAla His Tyr Gly Pro Val Trp Arg Gln Gln Arg 20 25 30 Lys Phe Ser His SerThr Leu Arg His Phe Gly Leu Gly Lys Leu Ser 35 40 45 Leu Glu Pro Lys IleIle Glu Glu Phe Lys Tyr Val Lys Ala Glu Met 50 55 60 Gln Lys His Gly GluAsp Pro Phe Cys Pro Phe Ser Ile Ile Ser Asn 65 70 75 80 Ala Val Ser AsnIle Ile Cys Ser Leu Cys Phe Gly Gln Arg Phe Asp 85 90 95 Tyr Thr Asn SerGlu Phe Lys Lys Met Leu Gly Phe Met Ser Arg Gly 100 105 110 Leu Glu IleCys Leu Asn Ser Gln Val Leu Leu Val Asn Ile Cys Pro 115 120 125 Trp LeuTyr Tyr Leu Pro Phe Gly Pro Phe Lys Glu Leu Arg Gln Ile 130 135 140 GluLys Asp Ile Thr Ser Phe Leu Lys Lys Ile Ile Lys Asp His Gln 145 150 155160 Glu Ser Leu Asp Arg Glu Asn Pro Gln Asp Phe Ile Asp Met Tyr Leu 165170 175 Leu His Met Glu Glu Glu Arg Lys Asn Asn Ser Asn Ser Ser Phe Asp180 185 190 Glu Glu Tyr Leu Phe Tyr Ile Ile Gly Asp Leu Phe Ile Ala GlyThr 195 200 205 Asp Thr Thr Thr Asn Ser Leu Leu Trp Cys Leu Leu Tyr MetSer Leu 210 215 220 Asn Pro Asp Val Gln Glu Lys Val His Glu Glu Ile GluArg Val Ile 225 230 235 240 Gly Ala Asn Arg Ala Pro Ser Leu Thr Asp LysAla Gln Met Pro Tyr 245 250 255 Thr Glu Ala Thr Ile Met Glu Val Gln ArgLeu Thr Val Val Val Pro 260 265 270 Leu Ala Ile Pro His Met Thr Ser GluAsn Thr Val Leu Gln Gly Tyr 275 280 285 Thr Ile Pro Lys Gly Thr Leu IleLeu Pro Asn Leu Trp Ser Val His 290 295 300 Arg Asp Pro Ala Ile Trp GluLys Pro Glu Asp Phe Tyr Pro Asn Arg 305 310 315 320 Phe Leu Asp Asp GlnGly Gln Leu Ile Lys Lys Glu Thr Phe Ile Pro 325 330 335 Phe Gly Ile GlyLys Arg Val Cys Met Gly Glu Gln Leu Ala Lys Met 340 345 350 Glu Leu PheLeu Met Phe Val Ser Leu Met Gln Ser Phe Ala Phe Ala 355 360 365 Leu ProGlu Asp Ser Lys Lys Pro Leu Leu Xaa Gly Arg Phe Gly Leu 370 375 380 ThrLeu Ala Pro His Pro Phe Asn Ile Thr Ile Ser Arg Arg 385 390 395 <210>SEQ ID NO 147 <211> LENGTH: 2504 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 147 gtcactgtga gtggagccca tgctgggctc tgtgccctctgtgtctgtgc atgcgcgtgt 60 gtgtgtgggc gtgtgtgcat tgctgggcca gcttgaagggaaggcccgtc atgtccctgc 120 actctgtttt gcaagatgcc aaaccccagt tctgatggggctccaacagc caggctgtgg 180 tcctttgacg ttcctcacct gttgccaacc tatcccgtagtgaactgaaa ccccaatgaa 240 gacagaactg tgcctgggga gatgcaatga ggtgagggctgaactcatcc ttttatattt 300 cttttcaaga ttggatcaga gctcatctcc atccagtcttgtttctatga aggcttcaat 360 ctgtttccat gcaaatttgc taatcagagc ccagagctgctgggtccctc atctccctca 420 tctattatag attgacttac agcagggaga gaatctctttagctcattcc taatggggtt 480 gggatcacaa tatggtctgg tccaatctgc atcttgttgtgtcccaagac cctatctcct 540 ccccaacatt cttattgcct ttggctccca gtaaggaacgaattgggggc cagggaggag 600 aacagggggg atcaagaagg gaaacccaat tccccctttgaaagtgggtt ctttgaacta 660 tgtgtttggg ggaagttcct ctggatacta atttgaatttatatacctca tgttttgggg 720 gtttgaccta tatatatata tatatatata tatgcatatatatttcataa tatttggaag 780 gtttttgatg ctagaaaaat ggaaacaaga gaaccttcaaaaatggtact tagatgggaa 840 ctggaggcca atctttcata aagccagccc catagctgcttgctgttagg cctccagcca 900 ttttgacatt ggggtggata gtcgattcac ctgcctgtcagtcgattcac ctgcctgtca 960 cccagttctg tggatgtgct ggtgctgagc ctttgctctctttccaaatg gttacaggga 1020 tgttgatcag ctccaccaga gggagctctg atgggaggaattgctctgcc atccttgtcc 1080 ctgtgtctcc tgtcggcagg cagccattgt atctcaccagcagaccagga gactggtccc 1140 aaggttactg caccacaggg caatttcctg ccatagttaggaaggaaaca cctgaactaa 1200 atggaagaga catccctgcg gtgtttaata tcacacccatgccctttgtc aggttaccat 1260 gtacagagat tacttggaga gcctcatgcc gtctctaccttcgcacactg gtcaagtatc 1320 tgctgagctt cttggccgca aggatgcaga aataggctgagggtccatgg gaagaaagac 1380 acaatgaggc agtaggaggt gggaagaaaa gaagacagactttcaaaatg gaattaggca 1440 ctggggagag atcagtttcc ccacatcagg gagaagaaggtataggtggg gaagggggtg 1500 gccaggagca gaaggaagaa gactcaagat ggaaagggagccgctgtgcc tgtggcaata 1560 ccacttggag aggtcgactt cataccttca agccttttcccctgggcttt tgattgtgtc 1620 tgtgccccct ttcttgtcct ctctgcagat gcccagtaggggctacctca tcctcgtgct 1680 gttcttgtgt ggctttctgg gcagtaggga tcttgaatttcctttctaac actgtgcccg 1740 gcaaggcggg gagcattcct ctgccctttg tcttgtgccaacctggaaag gtgcagtcta 1800 gatttcagtg agaaccctgc cagctgagcc ctgtgcatctactaccttga cacagagtgt 1860 tttcccacta gaagctctgc tctgctctcc tggcccaagtaggggattcc atgccttccc 1920 tttcatggtc ttagcaccag cagcctagtt tctcccttccagagtctcca gggatgacaa 1980 attggattgg agacaaacct cgtcagatgc tcatcccctaaaaggttaat tgtgtatttg 2040 tggctgcgtg tgcctttgtg ttttcattct cttcccatttttgtacattt tggtcttctc 2100 tgtggtttta tacttggtca aaagtactcg tcttggtattgcactgttgt gtgcatgaga 2160 aaactggggg aaggctcact ggtacaagaa aggacccctgacccctttcc ttctctgtgg 2220 tccccggcat tagattgggg gttctgggag aggcaggtgaatgtcctaag tgaattgttc 2280 tgtttgtaac tggaatgttt ttgaagtctt tggtgttgctccgtgaaagg acatcgccac 2340 ctggtgctca tgaggtgtct ttgcagaaca ataaatggcaaatgaacaac cccccccaaa 2400 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa 2460 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaaaaaa 2504 <210> SEQ ID NO 148 <211> LENGTH: 66 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 148 Met Glu Arg Glu Pro Leu CysLeu Trp Gln Tyr His Leu Glu Arg Ser 1 5 10 15 Thr Ser Tyr Leu Gln AlaPhe Ser Pro Gly Leu Leu Ile Val Ser Val 20 25 30 Pro Pro Phe Leu Ser SerLeu Gln Met Pro Ser Arg Gly Tyr Leu Ile 35 40 45 Leu Val Leu Phe Leu CysGly Phe Leu Gly Ser Arg Asp Leu Glu Phe 50 55 60 Pro Phe 65 <210> SEQ IDNO 149 <211> LENGTH: 928 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 149 caagaccagt cttgccaaca taacaagaat ctgtctctatataagaagat taagaattgg 60 ctgggcatgg tggcatgtgc ttgtggccct agctacttgggaggctgcgg tggaaggatc 120 acttgggccc aggcattcca gcttatgatt tcagtgagttatgatcacaa cactgaattc 180 caacctaatg gatggagaga gactatgtct ctaaaaataaaaaataaaga gattaggaac 240 tgtctgcact aagatgactt tactattcca agaaatccttgcctaagaaa gtaaagttga 300 aattactttt ttgtcctgga aactttccga tctatgtatctgtactcata cagcctcatc 360 gggctaaaca gccttctttt cagaacagta gatcactcaactgggttttc aagtgactgt 420 ttacctttca aggctggctt tataggtctt gcctcactgtatccagcaat ccaaacttta 480 ccctatccca gtcaggactg cacacctcat gttgaaagacataccttaga accagactcc 540 ccaaagctta caaatatccc acccttgact cccttttctgaggctactaa gattatgtga 600 agacagtcat cttccttact gcagtgagca ataaacttggtttttgttca tcagtaaacc 660 attttggtgg tttctggagg agccagcagt tggcaatggttataaatcta aatctaaaag 720 ccatttataa aagactgatg aatctagtaa cataaaaataaactgcatga taaatatcat 780 aaacaaagtc aaaagacaac tgacaaccag gttaaaaacatgctttcaac atatattaca 840 ggaaaagggc taatattcct aatatgtaaa taattgttagaaattaagag atcaagcacc 900 aagcacccat tagaaaaaaa aaaaaaaa 928 <210> SEQID NO 150 <211> LENGTH: 88 <212> TYPE: PRT <213> ORGANISM: Homo sapiens<400> SEQUENCE: 150 Met Tyr Leu Tyr Ser Tyr Ser Leu Ile Gly Leu Asn SerLeu Leu Phe 1 5 10 15 Arg Thr Val Asp His Ser Thr Gly Phe Ser Ser AspCys Leu Pro Phe 20 25 30 Lys Ala Gly Phe Ile Gly Leu Ala Ser Leu Tyr ProAla Ile Gln Thr 35 40 45 Leu Pro Tyr Pro Ser Gln Asp Cys Thr Pro His ValGlu Arg His Thr 50 55 60 Leu Glu Pro Asp Ser Pro Lys Leu Thr Asn Ile ProPro Leu Thr Pro 65 70 75 80 Phe Ser Glu Ala Thr Lys Ile Met 85 <210> SEQID NO 151 <211> LENGTH: 1343 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 151 ccgagccagg gttccctgcc ggccttggag atggcgggacttcccacgtc tggagccgag 60 gcctggataa ttcggatttg gcacgggaaa catcttggtcgtttgccatt tttcggcttt 120 ggggagtgtt tgcgtttctt ctccgtttgg cagtgaaacacatctcagaa aggtggagct 180 gatcagaata atgttcagca tcaaccccct ggagaacctgaaggtgtaca tcagcagtcg 240 gcctcccctg gtggtcttca tgatcagcgt aagcgccatggccatagctt tcctgaccct 300 gggctacttc ttcaaaatca aggagattaa atccccagaaatggcagagg attggaatac 360 ttttctgcta cggttcaatg atttggactt gtgtgtatcagagaatgaaa ccctcaagca 420 tctcacaaac gacaccacaa ctccggaaag tacaatgaccagcgggcagg cccgagcttc 480 cacccagtcc ccccaggccc tggaggactc gggcccggtgaatatctcag tctcaatcac 540 cctaaccctg gacccactga aacccttcgg agggtattcccgcaacgtca cccatctgta 600 ctcaaccatc ttagggcatc agattggact ttcaggcagggaagcccacg aggagataaa 660 catcaccttc accctgccta cagcgtggag ctcagatgactgcgccctcc acggtcactg 720 tgagcaggtg gtattcacag cctgcatgac cctcacggccagccctgggg tgttccccgt 780 cactgtacag ccaccgcact gtgttcctga cacgtacagcaacgccacgc tctggtacaa 840 gatcttcaca actgccagag atgccaacac aaaatacgcccaagattaca atcctttctg 900 gtgttataag ggggccattg gaaaagtcta tcatgctttaaatcccaagc ttacagtgat 960 tgttccagat gatgaccgtt cattaataaa tttgcatctcatgcacacca gttacttcct 1020 ctttgtgatg gtgataacaa tgttttgcta tgctgttatcaagggcagac ctagcaaatt 1080 gcgtcagagc aatcctgaat tttgtcccga gaaggtggctttggctgaag cctaattcca 1140 cagctccttg ttttttgaga gagactgaga gaaccataatccttgcctgc tgaacccagc 1200 ctgggcctgg atgctctgtg aatacattat cttgcgatgttgggttattc cagccaaaga 1260 catttcaagt gcctgtaact gatttgtaca tatttataaaaatctattcg gaaaaaaaaa 1320 aaaaaaaaaa aaaaaaaaaa aaa 1343 <210> SEQ IDNO 152 <211> LENGTH: 314 <212> TYPE: PRT <213> ORGANISM: Homo sapiens<400> SEQUENCE: 152 Met Phe Ser Ile Asn Pro Leu Glu Asn Leu Lys Val TyrIle Ser Ser 1 5 10 15 Arg Pro Pro Leu Val Val Phe Met Ile Ser Val SerAla Met Ala Ile 20 25 30 Ala Phe Leu Thr Leu Gly Tyr Phe Phe Lys Ile LysGlu Ile Lys Ser 35 40 45 Pro Glu Met Ala Glu Asp Trp Asn Thr Phe Leu LeuArg Phe Asn Asp 50 55 60 Leu Asp Leu Cys Val Ser Glu Asn Glu Thr Leu LysHis Leu Thr Asn 65 70 75 80 Asp Thr Thr Thr Pro Glu Ser Thr Met Thr SerGly Gln Ala Arg Ala 85 90 95 Ser Thr Gln Ser Pro Gln Ala Leu Glu Asp SerGly Pro Val Asn Ile 100 105 110 Ser Val Ser Ile Thr Leu Thr Leu Asp ProLeu Lys Pro Phe Gly Gly 115 120 125 Tyr Ser Arg Asn Val Thr His Leu TyrSer Thr Ile Leu Gly His Gln 130 135 140 Ile Gly Leu Ser Gly Arg Glu AlaHis Glu Glu Ile Asn Ile Thr Phe 145 150 155 160 Thr Leu Pro Thr Ala TrpSer Ser Asp Asp Cys Ala Leu His Gly His 165 170 175 Cys Glu Gln Val ValPhe Thr Ala Cys Met Thr Leu Thr Ala Ser Pro 180 185 190 Gly Val Phe ProVal Thr Val Gln Pro Pro His Cys Val Pro Asp Thr 195 200 205 Tyr Ser AsnAla Thr Leu Trp Tyr Lys Ile Phe Thr Thr Ala Arg Asp 210 215 220 Ala AsnThr Lys Tyr Ala Gln Asp Tyr Asn Pro Phe Trp Cys Tyr Lys 225 230 235 240Gly Ala Ile Gly Lys Val Tyr His Ala Leu Asn Pro Lys Leu Thr Val 245 250255 Ile Val Pro Asp Asp Asp Arg Ser Leu Ile Asn Leu His Leu Met His 260265 270 Thr Ser Tyr Phe Leu Phe Val Met Val Ile Thr Met Phe Cys Tyr Ala275 280 285 Val Ile Lys Gly Arg Pro Ser Lys Leu Arg Gln Ser Asn Pro GluPhe 290 295 300 Cys Pro Glu Lys Val Ala Leu Ala Glu Ala 305 310 <210>SEQ ID NO 153 <211> LENGTH: 3343 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 153 tcccgcgccg gggccgcggg cggagctgcc tgccggtcccgcgccgcgcg tccgcactcc 60 tcggccctcg ggcggtcgat gggacggggc gccgcggagcaggaggcggc gcccgtcggg 120 gtgctcgggc cgcgcgggag cccactgtgg ggctcgggcatggcgggccg caggacctga 180 gctctcctca ggggagcggg gaggcagctg ctggccggcgatggggacgg agtggggccg 240 tcgccgccgc gccgagccgt gagcgccgag ccaccgccgccgctacctca gcccttcgcg 300 aagcgccggg cagctcggga acatggccct ggagcggctctgctcggtcc tcaaagtgtt 360 gttaataaca gtactggtag tggaagggat tgccgtggcccaaaaaaacc caagatggac 420 aaaatattgg aatcaagcat attcctgcaa cccagtgtggcatttgggtt cgaaccagca 480 atggaggtca ttttgcttcg ccaaattatc ctgactcatatccaccaaac aaggagtgta 540 tctacatttt ggaagctgct ccacgtcaaa gaatagagttgacctttgat gaacattatt 600 atatagaacc atcatttgag tgtcggtttg atcacttggaagttcgagat gggccatttg 660 gtttctctcc tcttatagat cgttactgtg gcgtgaaaagccctccatta attagatcaa 720 cagggagatt catgtggatt aagtttagtt ctgatgaagagcttgaagga ctgggatttc 780 gagcaaaata ttcatttatt ccagatccag actttacttacctaggaggt attttaaatc 840 ccattccaga ttgtcagttc gagctctcgg gagctgatggaatagtgcgc tctagtcagg 900 tagaacaaga ggagaaaaca aaaccaggcc aagccgttgattgcatctgg accattaaag 960 ccactccaaa agctaagatt tatttgaggt tcctagattatcaaatggag cactcaaatg 1020 aatgcaagag aaacttcgtt gcagtctatg atggaagcagttctattgaa aacctgaagg 1080 ccaagttttg cagcactgtg gccaatgatg taatgcttaaaacaggaatt ggagtgattc 1140 gaatgtgggc agatgaaggt agtcggctta gcaggtttcgaatgctcttt acttcctttg 1200 tggagcctcc ctgcacaagc agcactttct tttgccatagcaacatgtgc atcaataatt 1260 ctttagtctg taatggtgtc caaaattgtg catacccttgggatgaaaat cattgtaaag 1320 aaaagaaaaa agcaggagta tttgaacaaa tcactaagactcatggaaca attattggca 1380 ttacttcagg gattgtcttg gtccttctca ttatttctattttagtacaa gtgaaacagc 1440 ctcgaaaaaa ggtcatggct tgcaaaaccg cttttaataaaaccgggttc caagaagtgt 1500 ttgatcctcc tcattatgaa ctgttttcac taagggacaaagagatttct gcagacctgg 1560 cagacttgtc ggaagaattg gacaactacc agaagatgcggcgctcctcc accgcctccc 1620 gctgcatcca cgaccaccac tgtgggtcgc aggcctccagcgtcaaacaa agcaggacca 1680 acctcagttc catggaactt cctttccgaa atgactttgcacaaccacag ccaatgaaaa 1740 catttaatag caccttcaag aaaagtagtt acactttcaaacagggacat gagtgccctg 1800 agcaggccct ggaagaccga gtaatggagg agattccctgtgaaatttat gtcagggggc 1860 gagaagattc tgcacaagca tccatatcca ttgacttctaatcttctgct aatggtgatg 1920 tgaattctta gggtgtgtac gtacgcagcc tccagggcaccatactgttt ccagcagcca 1980 acccttttct cccatcacaa ctacgaagac cttgatttaccgttaaccta ttgtatggtg 2040 atgtttttat tctctcaggc agtctatata tgttaaaccaatcaaggaac ttactctatt 2100 cagtggaaac aataatcatc tctattgctt ggtgtcatttataggaagca ctgccagtta 2160 aagagcatta gaagaggtgg ttggatggag ccaggctcaggctgcctctt cgttttagca 2220 acaagaagac tgctcttgac tgataacagc tctgtcaatattttgatgcc acaataaact 2280 tgatttttct ttacattcct tttatttttc ctttctctaaatttaatttg ttttataagc 2340 ctatcgtttt accatttcat tttcttacat aagtacaagtggttaatgta ccacatactt 2400 cagtataggc atttgttctt gagtgtgtca aaatacagctagttactgtg ccaattaaga 2460 cccagttgta tttcacccat ctgtttcttc ttggctaatctctgtacttc tgccttttaa 2520 ttactgggcc cttattcctt attttctgtg agaaataatagatgatatga tttattacct 2580 ttcaattata tttttctcag ttatactaga aaatttcataatcctgggat atatgtacca 2640 ttgtcagcta tgactaaaaa tttgaaaaag ataaaaatttctagcaagcc tttgaagttt 2700 accaagtata gtcacattca gtgacagccc attcattccagtaaagaatc atttcattca 2760 ctttgggaga ggcctataat wacatttatt tgcaatgtttctcttcgcta gattgtwaca 2820 tagctcccat tctgttggtt ttgcttacag catatggtaaccaaggttag atgccagtta 2880 aaattcctta gaaattggat gagccttgag attgcttcttaactgggaca tgacattttt 2940 ctagctctta tcaagaataa caacttccac ttttttttaaactgcacttt tgactttttt 3000 tatggtataa aaacaataat ttataaacat aaaagctcattgtgtttttt agacttttga 3060 tattatttga tactgtacaa actttattaa atcaagatgaaagacctaca ggacagattc 3120 ctttcagtgt tcacatcagt ggctttgtat gcaaatatgctgtgttggac ctggacgcta 3180 taacttattg taaagacctt ggaaatgtgg acataagctctttctttcct tttgttactg 3240 tatttagttt gtgataaatt tttcactgtg tgatatttatgctctaaatc actacacaaa 3300 tcccatatta aaatatacat tgtacctgaa aaaaaaaaaaaaa 3343 <210> SEQ ID NO 154 <211> LENGTH: 389 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 154 Met Trp Ile Lys Phe Ser SerAsp Glu Glu Leu Glu Gly Leu Gly Phe 1 5 10 15 Arg Ala Lys Tyr Ser PheIle Pro Asp Pro Asp Phe Thr Tyr Leu Gly 20 25 30 Gly Ile Leu Asn Pro IlePro Asp Cys Gln Phe Glu Leu Ser Gly Ala 35 40 45 Asp Gly Ile Val Arg SerSer Gln Val Glu Gln Glu Glu Lys Thr Lys 50 55 60 Pro Gly Gln Ala Val AspCys Ile Trp Thr Ile Lys Ala Thr Pro Lys 65 70 75 80 Ala Lys Ile Tyr LeuArg Phe Leu Asp Tyr Gln Met Glu His Ser Asn 85 90 95 Glu Cys Lys Arg AsnPhe Val Ala Val Tyr Asp Gly Ser Ser Ser Ile 100 105 110 Glu Asn Leu LysAla Lys Phe Cys Ser Thr Val Ala Asn Asp Val Met 115 120 125 Leu Lys ThrGly Ile Gly Val Ile Arg Met Trp Ala Asp Glu Gly Ser 130 135 140 Arg LeuSer Arg Phe Arg Met Leu Phe Thr Ser Phe Val Glu Pro Pro 145 150 155 160Cys Thr Ser Ser Thr Phe Phe Cys His Ser Asn Met Cys Ile Asn Asn 165 170175 Ser Leu Val Cys Asn Gly Val Gln Asn Cys Ala Tyr Pro Trp Asp Glu 180185 190 Asn His Cys Lys Glu Lys Lys Lys Ala Gly Val Phe Glu Gln Ile Thr195 200 205 Lys Thr His Gly Thr Ile Ile Gly Ile Thr Ser Gly Ile Val LeuVal 210 215 220 Leu Leu Ile Ile Ser Ile Leu Val Gln Val Lys Gln Pro ArgLys Lys 225 230 235 240 Val Met Ala Cys Lys Thr Ala Phe Asn Lys Thr GlyPhe Gln Glu Val 245 250 255 Phe Asp Pro Pro His Tyr Glu Leu Phe Ser LeuArg Asp Lys Glu Ile 260 265 270 Ser Ala Asp Leu Ala Asp Leu Ser Glu GluLeu Asp Asn Tyr Gln Lys 275 280 285 Met Arg Arg Ser Ser Thr Ala Ser ArgCys Ile His Asp His His Cys 290 295 300 Gly Ser Gln Ala Ser Ser Val LysGln Ser Arg Thr Asn Leu Ser Ser 305 310 315 320 Met Glu Leu Pro Phe ArgAsn Asp Phe Ala Gln Pro Gln Pro Met Lys 325 330 335 Thr Phe Asn Ser ThrPhe Lys Lys Ser Ser Tyr Thr Phe Lys Gln Gly 340 345 350 His Glu Cys ProGlu Gln Ala Leu Glu Asp Arg Val Met Glu Glu Ile 355 360 365 Pro Cys GluIle Tyr Val Arg Gly Arg Glu Asp Ser Ala Gln Ala Ser 370 375 380 Ile SerIle Asp Phe 385 <210> SEQ ID NO 155 <211> LENGTH: 2991 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: unsure <222>LOCATION: (1270) <221> NAME/KEY: unsure <222> LOCATION: (2613) <400>SEQUENCE: 155 ggcatggcta ttgcaccttg ggagaagcct ttaatcggtt agacttctcaagtgcaattc 60 aagatatccg aaggttcaat tatgtggtca aactgttgca gctaattgcaaaatcccagt 120 taacttcatt gagtggcgtg gcacagaaga attacttcaa cattttggataaaatcgttc 180 aaaaggttct ttgattaagc gaggattgtg gtggtcatca agaaccttttcccgattgaa 240 ttctagacct gcggggtagt tgcctttggc caaaccaagg acatcatcaggcagatcctg 300 caggctgatg gacttcgcgg cttctatcga ggctatgtgg cttcactgcttacctatatc 360 ccaaacagtg ctgtctggtg gcccttctat cacttctatg caggttgagggcaagaactc 420 catcatcctg accttcagac agctgatggc agaagaaggg ccttggggcctcatgaaagg 480 cctctcggcc agaatcatct cagccacacc ttccaccatt gtcattgtggtgggctatga 540 gagcctcaag aaactcagcc tccgacctga gctggtggac tcgagacactggtaaccagt 600 ggtggggaga gaagcctgct gttttccaca ctaccgtggg tcaggggcagagtggagagg 660 acagcaccct ctccaggtgc tcccaccaca cacccagccc tgccctgggccaagtggcct 720 atctgggata gggatagaga ctttgaactg ctcttgctga agaggctccacgcctggatc 780 ccttgccccc actatttaaa attctcttct gagctgggct ccctcactcagtccctgtat 840 ttgatactgg cctaaagacc ccacccccca ccctgccagc ccttcttctggcttcccctt 900 ccatctgtgt ccctgagacc ctgagaagag ctgtacatag agcttgcttactaccactgg 960 ttcttcctct tgggctttca gcccagactc caagcagctg ctatcaaccctctctccctt 1020 catctcttag ccttgcttat ttttattttg ggaccgagct gcccactagatgactctgct 1080 tttccctgca tttggggcta aggtgccagg tacttatttg cacagggagcaggagcagca 1140 aaaaatctct ggttctccag agcactcgtc ctctctttgg aggggttattaggttgggag 1200 aaatgttgat acttttgttt tgtgtgtgtg tgtgtgtgtg tgtgtgtgtgtgtgtgtgtg 1260 tgtgtgtttn aacatctgtg aaccaggcta ttagtcctgc taaagcgccaatcctgctgt 1320 cagagctcac ccccttccta agacaggtag aaaaatgtaa tgtagctttttccacaagcc 1380 acttccctgt cccttcagtc tcaggagccc taggagagtc taagctggggcatcccctgg 1440 cccagaggac tcccgtggtg ggcacagttc taagtggatc aggctgtcttgggtgcactg 1500 gacttggagc actaccttga gaagtcaggt tgagaaagta gttgatctagaaggcaacaa 1560 gtgggcatgt gttccccagc acattaccca ggccagcaga gccaaacctaggagagggca 1620 gtgggtagat tctctgcccc aggcagccat gacatacaca taaataccccaatcactcag 1680 acttacggca acaagtgttg tctcactatg gtgatctcta agatccacatcactggatgc 1740 gtagtcatcc cagtcatggt accctgtgga ggaatgctgg aagaacataaagagcagttc 1800 agaaagtcac ccaataccag gaccactgca tttaccagcc tgatactgccaagattatct 1860 gatgctctcc tcaggagcta ggagaggagt gctccttcct ccctaccgctactctcccca 1920 agcctgtgtt gcaggtagag aggtgcagca aatagagaag gcatgtcaaaccctgcattt 1980 ctacctgaga cgtgtgacct ggatgatcct ccaaacccta ttggtcccaccccctgggaa 2040 aggccatggt gccagtttga aaggtgctag ctacctgaag ccttgatatttcttcatggg 2100 tgccgcacat tcttccacct tggccagaac aggttctgaa aaccacttctctaccttcac 2160 caccaccact gcccatcttg atctctttga gggttttccc atttcacttgatcttatttt 2220 ggtttatccc ttcctgcact ttgtcaagag agtcctccag tttctatccaggaatgttca 2280 catccaaagg gttggaccca cggatcattc tgaatcttcc tgcccctcctcagtgcttaa 2340 ccctgagaac cacaaatata atggaagcag ttccccccac cctcaccccatctctttaag 2400 ctcatcctag caagacctct agagacccta gagactcgac tttagtccttccccgccatg 2460 gcacagtggg gaaggtgtca atggggagtg tcacggacag gaggtaggatcctgccgctc 2520 gcgtcttagt gtttctccct caagactttc cttctgtttt gttgtcttgtgtagtatttt 2580 acagcccctc ttgtgttttt ctttatttct cgnacacaca cgcagttttaagggtgatgt 2640 gtgtataatt aaaaggaccc ttggcccata ctttcctaat tctttagggactgggattgg 2700 gtttgactga aatatgtttt ggtggggatg ggacggtgga cttccattctccctaaactg 2760 gagttttggt cggtaatcaa aactaaaaga aacctctggg agactggaaacctgattgga 2820 gcactgagga acaagggaat gaaaaggcag actctctgaa cgtttgatgaaatggactct 2880 tgtgaaaatt aacagtgaat attcactgtt gcactgtacg aagtctctgaaatgtaatta 2940 aaagttttta ttgagccccc gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a2991 <210> SEQ ID NO 156 <211> LENGTH: 95 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 156 Met Asp Phe Ala Ala Ser IleGlu Ala Met Trp Leu His Cys Leu Pro 1 5 10 15 Ile Ser Gln Thr Val LeuSer Gly Gly Pro Ser Ile Thr Ser Met Gln 20 25 30 Val Glu Gly Lys Asn SerIle Ile Leu Thr Phe Arg Gln Leu Met Ala 35 40 45 Glu Glu Gly Pro Trp GlyLeu Met Lys Gly Leu Ser Ala Arg Ile Ile 50 55 60 Ser Ala Thr Pro Ser ThrIle Val Ile Val Val Gly Tyr Glu Ser Leu 65 70 75 80 Lys Lys Leu Ser LeuArg Pro Glu Leu Val Asp Ser Arg His Trp 85 90 95 <210> SEQ ID NO 157<211> LENGTH: 2293 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 157 cacctgctgc ccaccacccc ggcagcacct ttccctgccc aggcttcagagtgccctgtt 60 gctgctgcca ctgcccccca cactccaggg ccatgtcaga gctcccatctaccctccacc 120 agcatgccgc tcctgaagat gcccccacca ttctcggggt gcagccacccctgcagcggg 180 cactgtggtg ggcactgcag tgggcctctc ctcccacccc cgagctctcagccactccct 240 agcactcaca gggatcccgg gtgcaagggg cacaagtttg cacacagtggcctggcttgc 300 cagctgcccc agccctgcga ggcagatgag gggctgggtg aggaagaggatagcagctct 360 gagcgaagct cctgcacctc atcctccacc caccagagag atgggaagttctgtgactgc 420 tgctactgtg agttcttcgg ccacaatgcg ccacccgctg ccccgacgagtcggaactat 480 accgagatcc gggagaagct ccgctcgagg ctgaccaggc ggaaagaggagctgcccatg 540 aaggggggca ccctgggcgg gatccctggg gagcccgccg tggaccaccgagatgtggat 600 gagctgctgg aattcatcaa cagcacggag cccaaagtcc ccaacagcgccagggccgcc 660 aagcgggccc ggcacaagct gaaaaagaag gaaaaggaga aggcccagttggcagcagaa 720 gctctaaagc aggcaaatcg tgtttctgga agccgggagc caaggcctgccagggagagg 780 ctcttggagt ggcccgaccg ggaactggat cgggtcaaca gcttcctgagcagccgtctg 840 caggagatca aaaacactgt caaagactcc atccgtgcca gcttcagtgtgtgtgagctc 900 agcatggaca gcaatggctt ctctaaggag ggggctgctg agcctgagcctcagagtcta 960 cccccctcaa acctcagtkg ctcctcagag cagcagcctg acatcaaccttgacctgtcc 1020 cctttgactt tgggctcccc tcagaaccac acgttacaag ctccaggcgagccagcccca 1080 ccatgggcag aaatgagagg cccccaccca ccatggacag aggtgagggggccccctccc 1140 ggtatcgtcc ccgagaacgg gctcgtgagg agactcaaca ccgtgcccaacctatcccgg 1200 gtgatctggg tcaagacacc caagccgggc taccccagct ccgaggagccaagctcaaag 1260 gaagttccca gttgcaagca ggagctgcct gagcctgtgt cctcaggtgggaagccacag 1320 aagggcaaga ggcagggcag tcaggccaag aagagcgagg caagcccagccccccggccc 1380 ccagccagcc tagaggttcc cagtgccaag ggccaggtcg ctggccccaagcagccaggc 1440 agggtcctag agcttcccaa agtaggcagc tgtgctgagg ctggagaggggagccggggg 1500 agccggccag gaccaggttg ggctggcagt cccaaaactg agaaggagaagggcagctcc 1560 tggcgaaact ggccaggcga ggccaaggca cggcctcagg agcaggagtctgtgcagccc 1620 ccaggcccag caaggccaca gagcttgccc cagggcaagg gccgcagccgccggagccgc 1680 aacaagcagg agaagccagc ctcctccttg gacgatgtgt tcctgcccaaggacatggac 1740 ggggtggaga tggatgagac tgaccgagag gtggagtact ttaagaggttctgtttggat 1800 tctgcaaagc agactcgtca gaaagttgct gtgaactgga ccaacttcagcctcaagaaa 1860 accactccta gcacagctca gtgaggccct gcccaggctg agctgcttcagggcatcctg 1920 aggccctgac tgccagctga aggcgtataa tttttccctc cgtgtgccccacmtacccgt 1980 ccaagaccct ctgtgctccc caccatcctg gaccaaccaa aagctgaacggatgccacac 2040 tgtgctgggg ccccttgacc tcagcagagc cgcttcctgg tgctacgcagcctccacact 2100 cagagcccgt ggactgggct ggcctaaggg ccagggctga tggtactgctggcccaacac 2160 tgctctcttt gtgtttggtt tttttgtttt tgtttttatt ttgtttttttccaattcttt 2220 acttttgata ctgtgaagat ctttcgtgcc gaaagataaa gcaacatttggacacagaaa 2280 aaaaaaaaaa aaa 2293 <210> SEQ ID NO 158 <211> LENGTH:586 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221>NAME/KEY: UNSURE <222> LOCATION: (286) <400> SEQUENCE: 158 Met Pro LeuLeu Lys Met Pro Pro Pro Phe Ser Gly Cys Ser His Pro 1 5 10 15 Cys SerGly His Cys Gly Gly His Cys Ser Gly Pro Leu Leu Pro Pro 20 25 30 Pro SerSer Gln Pro Leu Pro Ser Thr His Arg Asp Pro Gly Cys Lys 35 40 45 Gly HisLys Phe Ala His Ser Gly Leu Ala Cys Gln Leu Pro Gln Pro 50 55 60 Cys GluAla Asp Glu Gly Leu Gly Glu Glu Glu Asp Ser Ser Ser Glu 65 70 75 80 ArgSer Ser Cys Thr Ser Ser Ser Thr His Gln Arg Asp Gly Lys Phe 85 90 95 CysAsp Cys Cys Tyr Cys Glu Phe Phe Gly His Asn Ala Pro Pro Ala 100 105 110Ala Pro Thr Ser Arg Asn Tyr Thr Glu Ile Arg Glu Lys Leu Arg Ser 115 120125 Arg Leu Thr Arg Arg Lys Glu Glu Leu Pro Met Lys Gly Gly Thr Leu 130135 140 Gly Gly Ile Pro Gly Glu Pro Ala Val Asp His Arg Asp Val Asp Glu145 150 155 160 Leu Leu Glu Phe Ile Asn Ser Thr Glu Pro Lys Val Pro AsnSer Ala 165 170 175 Arg Ala Ala Lys Arg Ala Arg His Lys Leu Lys Lys LysGlu Lys Glu 180 185 190 Lys Ala Gln Leu Ala Ala Glu Ala Leu Lys Gln AlaAsn Arg Val Ser 195 200 205 Gly Ser Arg Glu Pro Arg Pro Ala Arg Glu ArgLeu Leu Glu Trp Pro 210 215 220 Asp Arg Glu Leu Asp Arg Val Asn Ser PheLeu Ser Ser Arg Leu Gln 225 230 235 240 Glu Ile Lys Asn Thr Val Lys AspSer Ile Arg Ala Ser Phe Ser Val 245 250 255 Cys Glu Leu Ser Met Asp SerAsn Gly Phe Ser Lys Glu Gly Ala Ala 260 265 270 Glu Pro Glu Pro Gln SerLeu Pro Pro Ser Asn Leu Ser Xaa Ser Ser 275 280 285 Glu Gln Gln Pro AspIle Asn Leu Asp Leu Ser Pro Leu Thr Leu Gly 290 295 300 Ser Pro Gln AsnHis Thr Leu Gln Ala Pro Gly Glu Pro Ala Pro Pro 305 310 315 320 Trp AlaGlu Met Arg Gly Pro His Pro Pro Trp Thr Glu Val Arg Gly 325 330 335 ProPro Pro Gly Ile Val Pro Glu Asn Gly Leu Val Arg Arg Leu Asn 340 345 350Thr Val Pro Asn Leu Ser Arg Val Ile Trp Val Lys Thr Pro Lys Pro 355 360365 Gly Tyr Pro Ser Ser Glu Glu Pro Ser Ser Lys Glu Val Pro Ser Cys 370375 380 Lys Gln Glu Leu Pro Glu Pro Val Ser Ser Gly Gly Lys Pro Gln Lys385 390 395 400 Gly Lys Arg Gln Gly Ser Gln Ala Lys Lys Ser Glu Ala SerPro Ala 405 410 415 Pro Arg Pro Pro Ala Ser Leu Glu Val Pro Ser Ala LysGly Gln Val 420 425 430 Ala Gly Pro Lys Gln Pro Gly Arg Val Leu Glu LeuPro Lys Val Gly 435 440 445 Ser Cys Ala Glu Ala Gly Glu Gly Ser Arg GlySer Arg Pro Gly Pro 450 455 460 Gly Trp Ala Gly Ser Pro Lys Thr Glu LysGlu Lys Gly Ser Ser Trp 465 470 475 480 Arg Asn Trp Pro Gly Glu Ala LysAla Arg Pro Gln Glu Gln Glu Ser 485 490 495 Val Gln Pro Pro Gly Pro AlaArg Pro Gln Ser Leu Pro Gln Gly Lys 500 505 510 Gly Arg Ser Arg Arg SerArg Asn Lys Gln Glu Lys Pro Ala Ser Ser 515 520 525 Leu Asp Asp Val PheLeu Pro Lys Asp Met Asp Gly Val Glu Met Asp 530 535 540 Glu Thr Asp ArgGlu Val Glu Tyr Phe Lys Arg Phe Cys Leu Asp Ser 545 550 555 560 Ala LysGln Thr Arg Gln Lys Val Ala Val Asn Trp Thr Asn Phe Ser 565 570 575 LeuLys Lys Thr Thr Pro Ser Thr Ala Gln 580 585 <210> SEQ ID NO 159 <211>LENGTH: 1704 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 159 ccggagggca gaaggcagar tccaggctta gactgcagtt cctcgcttacctgtgcagtc 60 taattttgag ctgcctcttt gtagtcttaa aaggcaggag cttcgtgttgtgggtctgct 120 aacccgtacg tttccgtggg caagtcgtgt gtactcctcg ccatggctcagctccaaaca 180 cgcttctaca ctgataacaa gaaatatgcc gtagatgatg ttcccttctcaatccctgct 240 gcctctgaaa ttgccgacct tagtaacatc atcaataaac tactaaaggacaaaaatgag 300 ttccacaaac atgtggagtt tgatttcctt attaagggcc agtttctgcgaatgcccttg 360 gacaaacaca tggaaatgga gaacatctca tcagaagaag ttgtggaaatagaatacgtg 420 gagaagtata ctgcacccca gccagagcaa tgcatgttcc atgatgactggatcagttca 480 attaaagggg cagaggaatg gatcttgact ggttcttatg ataagacttctcggatctgg 540 tccttggaag gaaagtcaat aatgacaatt gtgggacata cggatgttgtaaaagatgtg 600 gcctgggtga aaaaagatag tttgtcctgc ttattattga gtgcttctatggatcagact 660 attctcttat gggagtggaa tgtagagaga aacaaagtga aagccctacactgctgtaga 720 ggtcatgctg gaagtgtaga ttctatagct gttgatggct caggaactaaattttgcagt 780 ggctcctggg ataagatgct aaagatctgg tctacagtcc ctacagatgaagaagatgaa 840 atggaggagt ccacaaatcg accaagaaag aaacagaaga cagaacagttgggactaaca 900 aggactccca tagtgaccct ctctggccac atggaggcag tttcctcagttctgtggtca 960 gatgctgaag aaatctgcag tgcatcttgg gaccatacaa ttagagtgtgggatgttgag 1020 tctggcagtc ttaagtcaac tttgacagga aataaagtgt ttaattgtatttcctattct 1080 ccactttgta aacgtttagc atctggaagc acagataggc atatcagactgtgggatccc 1140 cgaactaaag atggttcttt ggtgtcgctg tccctaacgt cacatactggttgggtgaca 1200 tcagtaaaat ggtctcctac ccatgaacag cagctgattt caggatctttagataacatt 1260 gttaagctgt gggatacaag aagttgtaag gctcctctct atgatctggctgctcatgaa 1320 gacaaagttc tgagtgtaga ctggacagac acagggctac ttctgagtggaggagcagac 1380 aataaattgt attcctacag atattcacct accacttccc atgttggggcatgaaagtga 1440 acaataattt gactatagag attatttctg taaatgaaat tggtagagaaccatgaaatt 1500 acatagatgc agatgcagaa agcagccttt tgaagtttat ataatgttttcacccttcat 1560 aacagctaac gtatcacttt ttcttatttk gtatttataa taagataggtkgtgtttata 1620 aaatacaaac tgtggcatac attctctata caaacttgaa attaaactgagttttacatt 1680 tcttctttaa aaaaaaaaaa aaaa 1704 <210> SEQ ID NO 160<211> LENGTH: 423 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 160 Met Ala Gln Leu Gln Thr Arg Phe Tyr Thr Asp Asn Lys LysTyr Ala 1 5 10 15 Val Asp Asp Val Pro Phe Ser Ile Pro Ala Ala Ser GluIle Ala Asp 20 25 30 Leu Ser Asn Ile Ile Asn Lys Leu Leu Lys Asp Lys AsnGlu Phe His 35 40 45 Lys His Val Glu Phe Asp Phe Leu Ile Lys Gly Gln PheLeu Arg Met 50 55 60 Pro Leu Asp Lys His Met Glu Met Glu Asn Ile Ser SerGlu Glu Val 65 70 75 80 Val Glu Ile Glu Tyr Val Glu Lys Tyr Thr Ala ProGln Pro Glu Gln 85 90 95 Cys Met Phe His Asp Asp Trp Ile Ser Ser Ile LysGly Ala Glu Glu 100 105 110 Trp Ile Leu Thr Gly Ser Tyr Asp Lys Thr SerArg Ile Trp Ser Leu 115 120 125 Glu Gly Lys Ser Ile Met Thr Ile Val GlyHis Thr Asp Val Val Lys 130 135 140 Asp Val Ala Trp Val Lys Lys Asp SerLeu Ser Cys Leu Leu Leu Ser 145 150 155 160 Ala Ser Met Asp Gln Thr IleLeu Leu Trp Glu Trp Asn Val Glu Arg 165 170 175 Asn Lys Val Lys Ala LeuHis Cys Cys Arg Gly His Ala Gly Ser Val 180 185 190 Asp Ser Ile Ala ValAsp Gly Ser Gly Thr Lys Phe Cys Ser Gly Ser 195 200 205 Trp Asp Lys MetLeu Lys Ile Trp Ser Thr Val Pro Thr Asp Glu Glu 210 215 220 Asp Glu MetGlu Glu Ser Thr Asn Arg Pro Arg Lys Lys Gln Lys Thr 225 230 235 240 GluGln Leu Gly Leu Thr Arg Thr Pro Ile Val Thr Leu Ser Gly His 245 250 255Met Glu Ala Val Ser Ser Val Leu Trp Ser Asp Ala Glu Glu Ile Cys 260 265270 Ser Ala Ser Trp Asp His Thr Ile Arg Val Trp Asp Val Glu Ser Gly 275280 285 Ser Leu Lys Ser Thr Leu Thr Gly Asn Lys Val Phe Asn Cys Ile Ser290 295 300 Tyr Ser Pro Leu Cys Lys Arg Leu Ala Ser Gly Ser Thr Asp ArgHis 305 310 315 320 Ile Arg Leu Trp Asp Pro Arg Thr Lys Asp Gly Ser LeuVal Ser Leu 325 330 335 Ser Leu Thr Ser His Thr Gly Trp Val Thr Ser ValLys Trp Ser Pro 340 345 350 Thr His Glu Gln Gln Leu Ile Ser Gly Ser LeuAsp Asn Ile Val Lys 355 360 365 Leu Trp Asp Thr Arg Ser Cys Lys Ala ProLeu Tyr Asp Leu Ala Ala 370 375 380 His Glu Asp Lys Val Leu Ser Val AspTrp Thr Asp Thr Gly Leu Leu 385 390 395 400 Leu Ser Gly Gly Ala Asp AsnLys Leu Tyr Ser Tyr Arg Tyr Ser Pro 405 410 415 Thr Thr Ser His Val GlyAla 420 <210> SEQ ID NO 161 <211> LENGTH: 2302 <212> TYPE: DNA <213>ORGANISM: Homo sapiens <400> SEQUENCE: 161 cgttggcaag caattcacaaggtggggaca gacttgtact ttaacatgta gtccattcaa 60 gcaaacaact ttggactctactgatagatg aaagagcaaa tgatgactag tttagcctct 120 gcatatcaac aatataatgcagatcaagta taatgctcaa tattagtgac atgagtatca 180 ctaaattaca tagaaccctgatggggtttc ctgtgtcgta atccattaaa tcggtggcca 240 gtgcttgctg ccgtggtttagtgattgggt gttagaaata aaaactcagg tctatttctt 300 accagtcagt aacaatttttagagaatgta cttggtatat aatatatgga cttcaggaac 360 tttattgggg tggggggttaattttgcctt accctgttca ctttcagatg awtaggcttt 420 tgcactttag aatgagaaacttgtgacgtt agtgtgttct tactagcttt aatttgtatg 480 ttagcaatga attgtgaatcttagtgcagt gggttttttt aaaaaactca aaaagctggg 540 aattaagtgg tttcagtaataatgctatac cgaggtgctt gcattgtatt tcataatttt 600 gttacaaacc aaaattatttttaatgagaa cagtcttggg ttcagaggtg tgatgccaga 660 atgtattttc gtactgttaggcccttggaa cagataccgg tgctttctga aagatgaaag 720 aaatgcaatg ggtgctcttcatgcaaggtt gcaaacctac caagaatgca taatagtctc 780 acttttcccc aataaagagatgcgtgtgac tagttttgga cttttaacct taatgggggt 840 tgcatgtctc ctattgttaatcattgtcag ctgcagtgac atgatccaca gtcctgcatt 900 tactgccttt cacttaatgattttggacag gttttagaga gccaggatgt tggtctgggc 960 ctttatttgg ttttggctttagctgataat gttttagtga tgtcagctag tgcagttctc 1020 aaatggctgc ctattagggaaagaattcag aggatttgac tgctcctaat catctgtcat 1080 tgctgctaga taatgattggcaatttttaa gactcaactg gaaatctcaa cagttgctgg 1140 taaaccatta accataaaaacgttgctttt gaacaccagt gctgaaaaaa atattttttt 1200 tttttttttt gagagtgaaaagggcttgga cttaagatag gacaatgtgg agaatggggg 1260 gaagaatgca aaacgatatagtatccctta tggatggtac atgtgcaaca gggaactctt 1320 acttcatata ccytttgcagtaatcattca gggaggaaga aaaacstgga acttgaatga 1380 aggctgatct ttgttttgtgcactgtggcc ctgccaggca tatagtgaag gtgaatgtct 1440 tctccctcag aaaaaaattggttccttgct gtcccagtaa ggcatagctt ttccagccct 1500 aactttaaaa ctcagtgaggacttagatgg gaaagaatga ggtaaataca aaggattgca 1560 ggacaacaac tacagcgttgtgtactgtgg gaaggggagt tgggcactct tgggaggact 1620 cctgctgaag gtggtcagcctgcctgacaa tggaagacat acttgaatgg ggagcagggt 1680 atgtgctttc atatgaaaaaagagctgatg ttaaaactca tttggtgagg tcaacgttgt 1740 cacatacctt cacataagggatagtwtatt ttgggttgca gtcaaacttg tgctcagact 1800 ggtgaaactg agagtcaggcttttacattt taaagaaaat acagtattca ttctaattca 1860 ggtgtctact tattttatgtaagaataatt ttagatttcc cccccaccat gaagtttctt 1920 cctattttct tatgctgtaacttaccccca atctttatct ctggattttt actctttaaa 1980 ttttgaagtt gactagcattttcaaacctt tattttatac ccttgtcttt tatatwaact 2040 ttttcttatt attctttaggtaagaatgat tgatgttggc tgatattgga gtgctcattc 2100 acatgaagtg gatagatacttctcaagaca tcacacagcg tgagtcaatc aaggagggaa 2160 gccacaagca gactgacaacgtttctagca ggatcaggtg agctgtgtcc agaaaaccaa 2220 cgagaaggag tggaaggaggaatgaacgtt tcattctcgt taataaaggc attatcctaa 2280 ttaaaaaaaa aaaaaaaaaaaa 2302 <210> SEQ ID NO 162 <211> LENGTH: 94 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 162 Met Pro Glu Cys Ile Phe ValLeu Leu Gly Pro Trp Asn Arg Tyr Arg 1 5 10 15 Cys Phe Leu Lys Asp GluArg Asn Ala Met Gly Ala Leu His Ala Arg 20 25 30 Leu Gln Thr Tyr Gln GluCys Ile Ile Val Ser Leu Phe Pro Asn Lys 35 40 45 Glu Met Arg Val Thr SerPhe Gly Leu Leu Thr Leu Met Gly Val Ala 50 55 60 Cys Leu Leu Leu Leu IleIle Val Ser Cys Ser Asp Met Ile His Ser 65 70 75 80 Pro Ala Phe Thr AlaPhe His Leu Met Ile Leu Asp Arg Phe 85 90 <210> SEQ ID NO 163 <211>LENGTH: 1538 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 163 rcagcctgct gcgcgcccag gggtcccgcg ggttttcggg cgcagggtggcscccgcggc 60 aggcggcggc catgaacttc tccgaggtat tcaagctctc cagcttactctgcaagttct 120 ccccggacrg caagtacctg gcttcctgtg tccagtaccg gttagtggtccgggatgtga 180 acacccttca gatccttcag ctgtacacgt gcctagacca gatccagcacatcgagtggt 240 cggcagactc gctcttcatc ctgtkcgcca tgtacaarcg agggctggtgcaggtctggt 300 ctttagagca gcccgaatgg cactgcaaaa tagacgaggg ctcagccgggctggtggcct 360 cgtgctggag cccggacggg cgccacattc tcaacaccac ggaattccatctgcggataa 420 ccgtctggtc cttgtgcaca aaatccgtgt cttacatcaa atacccgaaagcttgtctgc 480 agggaatcac cttcaccagg gacggccgct acatggcgct ggcagaacggcgcgactgca 540 aagattacgt gagcatcttc gtctgcagtg attggcagct cctgcggcattttgatacgg 600 acacccagga tctcacaggg attgagtggg ccccaaacgg ctgtgtgctggcagtgtggg 660 acacctgctt ggaggtgcgc atccttaatc acgtgacttg gaaaatgatcacggagtttg 720 ggcatcctgc agccattaat gatcccaaga tagtggtgta taaggaggccgagaagagcc 780 cacagctggg actgggctgc ctctccttcc cgccgccccg ggccggggccggccctctcc 840 cgagctcaga gagtaaatat gagatcgcct ctgtcccagt ctccttacagacactgaaac 900 ctgttaccga cagagcaaac ccgaaaatgg gcataggaat gctggcatttagtcctgaca 960 gctacttcct ggcgacaagg aacgacaaca ttcccaatgc cgtctgggtctgggacattc 1020 agaagctgag gctgttcgcg gtgctcgagc agctgtcccc agtgcgcgcgtttcagtggg 1080 acccgcagca gccgcggctg gccatctgca cgggaggcag caggctctacctgtggtccc 1140 cagcgggctg catgtcggtg caggtgcctg gggaaggcga ctttgcagtgctctctctgt 1200 gctggcattt aagcggagac tcgatggccc tcctcagcaa ggatcacttctgcctctgct 1260 tcctggagac agaggcagtg gtcggcacag cctgcagaca gctgggcggccacacgtagc 1320 agcggtgcac taacgtgtgc agaaacaggg ctactctgtg tttccagtgtgggaaaaaac 1380 acagcttcac caggaggttc tccactgtgg tggtctggat tcagtgattgattctatttt 1440 tctatagcaa agcatttttg taaatatgta tggtataaaa ctgtagttttattatttaaa 1500 ataaatactt gctgatttat aaaaaaaaaa aaaaaaaa 1538 <210> SEQID NO 164 <211> LENGTH: 415 <212> TYPE: PRT <213> ORGANISM: Homo sapiens<220> FEATURE: <221> NAME/KEY: UNSURE <222> LOCATION: (20) <221>NAME/KEY: UNSURE <222> LOCATION: (65) <400> SEQUENCE: 164 Met Asn PheSer Glu Val Phe Lys Leu Ser Ser Leu Leu Cys Lys Phe 1 5 10 15 Ser ProAsp Xaa Lys Tyr Leu Ala Ser Cys Val Gln Tyr Arg Leu Val 20 25 30 Val ArgAsp Val Asn Thr Leu Gln Ile Leu Gln Leu Tyr Thr Cys Leu 35 40 45 Asp GlnIle Gln His Ile Glu Trp Ser Ala Asp Ser Leu Phe Ile Leu 50 55 60 Xaa AlaMet Tyr Lys Arg Gly Leu Val Gln Val Trp Ser Leu Glu Gln 65 70 75 80 ProGlu Trp His Cys Lys Ile Asp Glu Gly Ser Ala Gly Leu Val Ala 85 90 95 SerCys Trp Ser Pro Asp Gly Arg His Ile Leu Asn Thr Thr Glu Phe 100 105 110His Leu Arg Ile Thr Val Trp Ser Leu Cys Thr Lys Ser Val Ser Tyr 115 120125 Ile Lys Tyr Pro Lys Ala Cys Leu Gln Gly Ile Thr Phe Thr Arg Asp 130135 140 Gly Arg Tyr Met Ala Leu Ala Glu Arg Arg Asp Cys Lys Asp Tyr Val145 150 155 160 Ser Ile Phe Val Cys Ser Asp Trp Gln Leu Leu Arg His PheAsp Thr 165 170 175 Asp Thr Gln Asp Leu Thr Gly Ile Glu Trp Ala Pro AsnGly Cys Val 180 185 190 Leu Ala Val Trp Asp Thr Cys Leu Glu Val Arg IleLeu Asn His Val 195 200 205 Thr Trp Lys Met Ile Thr Glu Phe Gly His ProAla Ala Ile Asn Asp 210 215 220 Pro Lys Ile Val Val Tyr Lys Glu Ala GluLys Ser Pro Gln Leu Gly 225 230 235 240 Leu Gly Cys Leu Ser Phe Pro ProPro Arg Ala Gly Ala Gly Pro Leu 245 250 255 Pro Ser Ser Glu Ser Lys TyrGlu Ile Ala Ser Val Pro Val Ser Leu 260 265 270 Gln Thr Leu Lys Pro ValThr Asp Arg Ala Asn Pro Lys Met Gly Ile 275 280 285 Gly Met Leu Ala PheSer Pro Asp Ser Tyr Phe Leu Ala Thr Arg Asn 290 295 300 Asp Asn Ile ProAsn Ala Val Trp Val Trp Asp Ile Gln Lys Leu Arg 305 310 315 320 Leu PheAla Val Leu Glu Gln Leu Ser Pro Val Arg Ala Phe Gln Trp 325 330 335 AspPro Gln Gln Pro Arg Leu Ala Ile Cys Thr Gly Gly Ser Arg Leu 340 345 350Tyr Leu Trp Ser Pro Ala Gly Cys Met Ser Val Gln Val Pro Gly Glu 355 360365 Gly Asp Phe Ala Val Leu Ser Leu Cys Trp His Leu Ser Gly Asp Ser 370375 380 Met Ala Leu Leu Ser Lys Asp His Phe Cys Leu Cys Phe Leu Glu Thr385 390 395 400 Glu Ala Val Val Gly Thr Ala Cys Arg Gln Leu Gly Gly HisThr 405 410 415 <210> SEQ ID NO 165 <211> LENGTH: 3178 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: unsure <222>LOCATION: (1653) <221> NAME/KEY: unsure <222> LOCATION: (1767) <400>SEQUENCE: 165 atttcttttg ccacttaaaa ttaactgtgg gctactcagc cagggtacagtgggagcctc 60 aggaaggtca gaggcaacct cctcccctgt tctatcaata gaaacccaacgttgaggcaa 120 ttcctaaaca gacgcacctc gtagcttgct gtatgtgttt attctttattgctttcagct 180 ttggggctgt aacaggtaca aatatttggt ttccctatga tttatagagaagaagaagaa 240 acccagcttt ctatcagagc actgcaagag aagagtctta cacctgccctcagtgggaga 300 tgagaatggt cattatgact tagagaatgc tacacgtgta ggttgctggtgtgtcctgaa 360 tccacaggca taaagcactc cccattttcc tactgtaatg cagattctccggctcaaggt 420 ctagaatatt tgatcctaag atcaagacat catgcccttc gaatagtactgctctttgtt 480 ttcaggagtc acgtgaacac acaactctcc tatattcctc acgaacctcaggattgagca 540 aggtctttgt aatttttttg gttcacttta ttgacctggg agcaaggtgctaattctgtg 600 gtcagtattc aatgtttttt tcagtggagc tttttctttg ggccatatttgccttctaat 660 acattcctgc aatatgtagt ggtgatttcc cttagcttcc tcctactacctcttatactc 720 atctccccaa attatttgcc tcccttaaat aagttttcct agaaggtaagctggtcaggc 780 aatttgaaaa atattagatc ccaagaaatc tattccgttt gcattggacttctcggattc 840 catgtgtttg cagcaggact acatcgaact ctgatgtgcc ggattgtggcatgtctgcat 900 gtctcatcca tctattgttt ttggtaactc agtttggaat ttcagtgtctgtcttccctg 960 ggttgacatt ggaatcagcc tctcctttga gcttatttta actcttgagcaacataacat 1020 agatttaatg tgaacagttt ataccaaagg gcagcctgtg cctgtttatggatcctctct 1080 gcctttgtac ttgaagagcg cattttacat ttccagtcct ttcacagacaggagctccaa 1140 ccttacgatg gagaattaaa cttgcttgta tttccacttt gtggatgaggaactatgaga 1200 ggtggagtga cttcctgggt ccccgctgag acttagtgac agatcccagacaagaacttc 1260 atctctgact ccaggtctag tcctcttccc cctgtctctt gccaactccagccctgacac 1320 cgtgggcgtc tcccctgaga gcagatatat ttcaattgtc caggccaaaagaggggcgag 1380 gcggcataaa cacccaaatt aggtggagga tccaaaagtc attttcatttggctgtggaa 1440 tatgtttttt gtatttcaat cagctagggg tgtgttcact gtttttggaaattcacagcg 1500 cttgagcctc cataatgaag ctgggctgca gagcacctgg cacgtgctccaggctcccag 1560 ctcccaacct aggacctctc cctgccctcc actctggttg gtttgtggttccctcgaccg 1620 agggtttcta gaatcaggga ccttgtctaa gtnttgtttg cccagagcccagcgaagtgt 1680 gtgatacacc ttgggagttt aggagatcac aaaagggatg aaaacacctttagaaaacat 1740 ttcattggtg gggcgtggtg gcttatncct gtgatcccag cctcctgagtagctgggatc 1800 acaggcgtac accaccacac ccagctaagt ttttgtactt ttagtggagacggggtttca 1860 ccatgttggc caggctggtc acggactcct gacctcagat gatctgcccgcctgagcctc 1920 cgaaagtgct gggattacag gcgtgagcca ctgcgcccgg catggagctgctattgatgg 1980 gtgagctcca cagcttttgc agaagcagag gatatgactt gagagcagtgctgtcacctc 2040 tcagcatgtc cccaagccca actggggcct cctggagatg cctcagtcggcactggcccc 2100 aagggaatcg tggggaacag ttgcacaatt tgcaagtttc tgagtgcagcttttcccatc 2160 cttgggatca gcagataagt tgtaaacaca gggaggtact gcttattggatatacttttc 2220 ataagtagga cagaattctt ttgggactct agagttggga actaccacttactagcggcg 2280 tggctgaggc agtcttcctc ctctgtggct caggcccttc atctgtgaaatggggtcaca 2340 gcatctgcct ctcagggtca ctgtgaggtg tcgatgtgag caaggcctgaggcttggcaa 2400 gaagtcaatg tctgcaactc agcagggagc aatggcaggg gcagtcaggggtcggctcgg 2460 ataggggtgg gtgggctcct gaggttggaa gggtaggaat tacagagctcttgttactat 2520 tgttgttact gtttttaaag atacgatatt tcagataatt caggagcacgtaaggatgaa 2580 acttaggata acctaaaatc acacaaccta gagagaagcg catttttgtcttcccccatt 2640 ttctaggcaa aaatgaaagt actttgtcct cttgaaaaac aattctctaatgaatatcct 2700 atgttacata gaggcctgtg taatgcattt gtgtggccac atggtgtcaatttcatgaat 2760 atacaataat attattaatt ccctgctgag gacattaact ggtttccaaggctgcttgtt 2820 gtttttgcta ctacaaataa tgcattgatg ataaatactt ttacatacatggttgtatgt 2880 ttatctgaac tattttcacc aatatattca cctagtgtgt atggaagtgtccatttttgt 2940 catacccctg gtaaccctgt gatattattt ttaaacattt tgctaatggatctctgttct 3000 tgtttgaatg tatttaattt ccagcagaat gagccccatt ccttattttgattggccatt 3060 tatcatgtac atatggtgaa atgcctattc gtgacttagc caatgttgtttctttttctt 3120 actgattact acagtacatt tttatatgaa aaaaaaaaaa aaaaaaaaaaaaaaaaaa 3178 <210> SEQ ID NO 166 <211> LENGTH: 67 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 166 Met Ile Asn Thr Phe Thr TyrMet Val Val Cys Leu Ser Glu Leu Phe 1 5 10 15 Ser Pro Ile Tyr Ser ProSer Val Tyr Gly Ser Val His Phe Cys His 20 25 30 Thr Pro Gly Asn Pro ValIle Leu Phe Leu Asn Ile Leu Leu Met Asp 35 40 45 Leu Cys Ser Cys Leu AsnVal Phe Asn Phe Gln Gln Asn Glu Pro His 50 55 60 Ser Leu Phe 65 <210>SEQ ID NO 167 <211> LENGTH: 2401 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 167 cgcatcctca gccaccgtcg cagctgcctc cgccaccaccgccgcctcct cttccttggc 60 caccccagaa ctgggcagca gcctcaagaa gaagaagcggctctcccagt cagatgagga 120 tgtcattagg ctaataggac agcacttgaa tggcttagggctcaaccaga ctgttgatct 180 cctcatgcaa gagtcaggat gtcgtttaga acatccttctgctaccaaat tccgaaatca 240 tgtcatggaa ggagactggg ataaggcaga aaatgacctgaatgaactaa agcctttagt 300 gcattctcct catgctattg tgaggatgaa gtttttgctgctgcagcaga agtacctaga 360 atacctggag gatggcaagg tcctggaggc acttcaagttctacgctgtg aattgacgcc 420 gctgaaatac aatacagagc gcattcatgt tcttagtgggtatctgatgt gtagccatgc 480 agaagaccta cgtgcaaaag cagaatggga aggcaaagggacagcttccc gatctaaact 540 attggataaa cttcagacct atttaccacc atcagtgatgcttcccccac ggcgtttaca 600 gactctcctg cggcaggcgg tggaactaca aagggatcggtgcctatatc acaataccaa 660 acttgataat aatctagatt ctgtgtctct gcttatagaccatgtttgta gtaggaggca 720 gttcccatgt tatacgcagc agatacttac ggagcattgtaatgaagtgt ggttctgtaa 780 attctctaat gatggcacta aactagcaac aggatcaaaagatacaacag ttatcatatg 840 gcaagttgat ccggatacac acctgctaaa actgcttaaaacattagaag gacatgctta 900 tggcgtttct tatattgcat ggagtccaga tgacaactatcttgttgctt gtggcccaga 960 tgactgctct gagctttggc tttggaatgt acaaacaggagaactaagga caaaaatgag 1020 ccagtctcat gaagacagtt tgacaagtgt ggcttggaatccagatggga agcgctttgt 1080 gactggaggt cagcgtgggc agttctatca gtgtgacttagatggtaatc tccttgactc 1140 ctgggaaggg gtaagagtgc aatgcctttg gtgcttgagtgatggaaaga ctgttctggc 1200 atcagataca caccagcgaa ttcggggcta taacttcgaggaccttacag ataggaacat 1260 agtacaagaa gatcatccta ttatgtcttt tactatttcaaaaaatggcc gattagcttt 1320 gttaaatgta gcaactcagg gagttcattt atgggacttgcaagacagag ttttagtaag 1380 aaagtatcaa ggtgttacac aagggtttta tacaattcattcatgttttg gaggccataa 1440 tgaagacttc atcgctagtg gcagtgaaga tcacaaggtttacatctggc acaaacgtag 1500 tgaactgcca attgcggagc tgacagggca cacacgtacagtaaactgtg tgagctggaa 1560 cccacagatt ccatccatga tggccagcgc ctcagatgatggcactgtta gaatatgggg 1620 accagcacct tttatagacc accagaatat tgaagaggaatgcagtagca tggatagttg 1680 atggtgaatt tggagcagac gacttctgtt taacttaaaattagtcgtat tttaatggct 1740 tgggatttgg tgcaaacaaa catgattgat agctggacagacatgctcgt catgaaaaaa 1800 gaaccatttc tgaagcccga ttggggccaa acatttacaccttgcttcat agtaaccagt 1860 tgagatgaag cacgtcgtta gaacgttgtt ggacaccatgttgaattatt cccccatcgg 1920 ttgtgaagaa ctgtgctaca ttcaggctta cccattgaactcagtatata tatttttttc 1980 cttcctgtct tttgtctggc aggataccat tcttgttgctcttctgtgta atgaagttta 2040 aatgcttgtt tggaaaactt tatttaacag tttagaaggcttgatagaaa gagtgcatta 2100 gtctgaagag tatacattgg ataggaaaga atttccttcttttgtttctc caaatctttc 2160 cgccttattt agcttgagat ctttgcagct tggttcatggattctagcct tgcccgttgc 2220 gcagtatata ctgatccaga tgataaacca gtgaactatgtcaaaagcac tctcaatatt 2280 acatttgaca aaaagttttg tacttttcac atagcttgttgccccgtaaa agggttaaca 2340 gcacaatttt ttaaaaataa attaagaagt atttataggattaaaaaaaa aaaaaaaaaa 2400 a 2401 <210> SEQ ID NO 168 <211> LENGTH: 498<212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 168 Met GlnGlu Ser Gly Cys Arg Leu Glu His Pro Ser Ala Thr Lys Phe 1 5 10 15 ArgAsn His Val Met Glu Gly Asp Trp Asp Lys Ala Glu Asn Asp Leu 20 25 30 AsnGlu Leu Lys Pro Leu Val His Ser Pro His Ala Ile Val Arg Met 35 40 45 LysPhe Leu Leu Leu Gln Gln Lys Tyr Leu Glu Tyr Leu Glu Asp Gly 50 55 60 LysVal Leu Glu Ala Leu Gln Val Leu Arg Cys Glu Leu Thr Pro Leu 65 70 75 80Lys Tyr Asn Thr Glu Arg Ile His Val Leu Ser Gly Tyr Leu Met Cys 85 90 95Ser His Ala Glu Asp Leu Arg Ala Lys Ala Glu Trp Glu Gly Lys Gly 100 105110 Thr Ala Ser Arg Ser Lys Leu Leu Asp Lys Leu Gln Thr Tyr Leu Pro 115120 125 Pro Ser Val Met Leu Pro Pro Arg Arg Leu Gln Thr Leu Leu Arg Gln130 135 140 Ala Val Glu Leu Gln Arg Asp Arg Cys Leu Tyr His Asn Thr LysLeu 145 150 155 160 Asp Asn Asn Leu Asp Ser Val Ser Leu Leu Ile Asp HisVal Cys Ser 165 170 175 Arg Arg Gln Phe Pro Cys Tyr Thr Gln Gln Ile LeuThr Glu His Cys 180 185 190 Asn Glu Val Trp Phe Cys Lys Phe Ser Asn AspGly Thr Lys Leu Ala 195 200 205 Thr Gly Ser Lys Asp Thr Thr Val Ile IleTrp Gln Val Asp Pro Asp 210 215 220 Thr His Leu Leu Lys Leu Leu Lys ThrLeu Glu Gly His Ala Tyr Gly 225 230 235 240 Val Ser Tyr Ile Ala Trp SerPro Asp Asp Asn Tyr Leu Val Ala Cys 245 250 255 Gly Pro Asp Asp Cys SerGlu Leu Trp Leu Trp Asn Val Gln Thr Gly 260 265 270 Glu Leu Arg Thr LysMet Ser Gln Ser His Glu Asp Ser Leu Thr Ser 275 280 285 Val Ala Trp AsnPro Asp Gly Lys Arg Phe Val Thr Gly Gly Gln Arg 290 295 300 Gly Gln PheTyr Gln Cys Asp Leu Asp Gly Asn Leu Leu Asp Ser Trp 305 310 315 320 GluGly Val Arg Val Gln Cys Leu Trp Cys Leu Ser Asp Gly Lys Thr 325 330 335Val Leu Ala Ser Asp Thr His Gln Arg Ile Arg Gly Tyr Asn Phe Glu 340 345350 Asp Leu Thr Asp Arg Asn Ile Val Gln Glu Asp His Pro Ile Met Ser 355360 365 Phe Thr Ile Ser Lys Asn Gly Arg Leu Ala Leu Leu Asn Val Ala Thr370 375 380 Gln Gly Val His Leu Trp Asp Leu Gln Asp Arg Val Leu Val ArgLys 385 390 395 400 Tyr Gln Gly Val Thr Gln Gly Phe Tyr Thr Ile His SerCys Phe Gly 405 410 415 Gly His Asn Glu Asp Phe Ile Ala Ser Gly Ser GluAsp His Lys Val 420 425 430 Tyr Ile Trp His Lys Arg Ser Glu Leu Pro IleAla Glu Leu Thr Gly 435 440 445 His Thr Arg Thr Val Asn Cys Val Ser TrpAsn Pro Gln Ile Pro Ser 450 455 460 Met Met Ala Ser Ala Ser Asp Asp GlyThr Val Arg Ile Trp Gly Pro 465 470 475 480 Ala Pro Phe Ile Asp His GlnAsn Ile Glu Glu Glu Cys Ser Ser Met 485 490 495 Asp Ser <210> SEQ ID NO169 <211> LENGTH: 1110 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 169 ggtgcgggag ccgctctccg ccggtcggtc cccgcgcggctgagcccagg ccgccagcgc 60 cgcggccccg tgcggtgtcc ctgagctcct gctccccgccgggctgctcc gagcaacggt 120 gcttcggagc tccaaactcg ggctgccggg gcaagtgtcttcatgaaccc agaggatgtc 180 cgggaagcac tacaagggtc ctgaagtcag ttgttgcatcaaatacttca tatttggctt 240 caatgtcata ttttggtttt tgggaataac atttcttggaattggactgt gggcatggaa 300 tgaaaaagga gttctgtcca acatctcttc catcaccgatctcggcggct ttgacccagt 360 ttggctcttc cttgtggtgg gaggagtgat gttcattttgggatttgcag ggtgcattgg 420 agcgctacgg gaaaacactt tccttctcaa gtttttttctgtgttcctgg gaattatttt 480 cttcctggag ctcactgccg gagttctagc atttgttttcaaagactgga tcaaagacca 540 gctgtatttc tttataaaca acaacatcag agcatatcgggatgacattg atttgcaaaa 600 cctcatagac ttcacccagg aatatattcc aatgcaagtcgagagcgatg tggcgttcca 660 ttctcctgct gcactaaaga tcccgcagaa gatgtcatcaacactcagtg tggctatgat 720 gccaggcaaa aaccagaagt tgaccagcag attgtaatctacacgaaagg ctgtgtgccc 780 cagtttgaga agtggttgca ggacaattta accwtcgttgctggtatttt cataggcatt 840 gcattgctgc agatatttgg gatmtgcctg gcccagaatttggttagcga tatcgawgct 900 gtcagggcga gctggtagac cccctgcaac cgctgctgcaagacactgga cagacccagc 960 tttcgggacc ctcccgcgtg ccgaactgat cttcgagctgcatggaccta atcacagatg 1020 cagcctgcag tctcgcctaa tggagctgcc attaggggagtgtaaaactg ggaaatgctg 1080 ctcactgaca gaattaaaaa aaaaaaaaaa 1110 <210>SEQ ID NO 170 <211> LENGTH: 193 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 170 Met Ser Gly Lys His Tyr Lys Gly Pro Glu ValSer Cys Cys Ile Lys 1 5 10 15 Tyr Phe Ile Phe Gly Phe Asn Val Ile PheTrp Phe Leu Gly Ile Thr 20 25 30 Phe Leu Gly Ile Gly Leu Trp Ala Trp AsnGlu Lys Gly Val Leu Ser 35 40 45 Asn Ile Ser Ser Ile Thr Asp Leu Gly GlyPhe Asp Pro Val Trp Leu 50 55 60 Phe Leu Val Val Gly Gly Val Met Phe IleLeu Gly Phe Ala Gly Cys 65 70 75 80 Ile Gly Ala Leu Arg Glu Asn Thr PheLeu Leu Lys Phe Phe Ser Val 85 90 95 Phe Leu Gly Ile Ile Phe Phe Leu GluLeu Thr Ala Gly Val Leu Ala 100 105 110 Phe Val Phe Lys Asp Trp Ile LysAsp Gln Leu Tyr Phe Phe Ile Asn 115 120 125 Asn Asn Ile Arg Ala Tyr ArgAsp Asp Ile Asp Leu Gln Asn Leu Ile 130 135 140 Asp Phe Thr Gln Glu TyrIle Pro Met Gln Val Glu Ser Asp Val Ala 145 150 155 160 Phe His Ser ProAla Ala Leu Lys Ile Pro Gln Lys Met Ser Ser Thr 165 170 175 Leu Ser ValAla Met Met Pro Gly Lys Asn Gln Lys Leu Thr Ser Arg 180 185 190 Leu<210> SEQ ID NO 171 <211> LENGTH: 1621 <212> TYPE: DNA <213> ORGANISM:Homo sapiens <400> SEQUENCE: 171 ctttaaaatg tggctaatgc ctgccttagggaaccgttgt gaggattaag tgagacatgg 60 tatataaaac gacctccttc tggcataaacttgaggtgga agataccttg aggatgcttg 120 aaggtctgct aggcagcttc acagccttttctttcctctt ctctatcaga ggtctctttg 180 gaagcaataa tgatgactat aacaagaacttatcttgctt tgcaagattc ttccgccgtc 240 agagtttctg atttattttc tggggttccatgtatgccag ggagaaagag agagcgcgaa 300 agagagagga tgtctctctc agactggcacctggcggtga agctggctga ccagccactt 360 actccaaagt ctattcttcg gttgccagagacagaactgg gagaatactc gctagggggc 420 tatagtattt catttctgaa gcagcttattgctggcaaac tccaggagtc tgttccagac 480 cctgagctga ttgatctgat ctactgtggtcggaagctaa aagatgacca gacacttgac 540 ttctatggca ttcaacctgg gtccactgtccatgttctgc gaaagtcctg gcctgaacct 600 gatcagaaac cggaacctgt ggacaaagtggctgccatga gagagttccg ggtgttgcac 660 actgccctgc acagcagctc ctcttacagggaggcggtct ttaagatgct cagcaataag 720 gagtctctgg atcagatcat tgtggccaccccaggcctca gcagtgaccc tattgctctt 780 ggggttctcc aggacaagga cctcttctctgtcttcgctg atcccaatat gcttgatacg 840 ttggtgcctg ctcacccagc cctcgtcaatgccattgtcc tggttctgca ctccgtagca 900 ggcagtgccc caatgcctgg gactgactcctcttcccgga gcatgccctc cagctcatac 960 cgggatatgc caggtggctt cctgtttgaagggctctcag atgatgagga tgactttcac 1020 ccaaacacca ggtccacacc ctctagcagtactcccagct cccgcccagc ctccctgggg 1080 tacagtggag ctgctgggcc ccggcccatcacccagagtg agctggccac cgccttggcc 1140 ctggccagca ctccggagag cagctctcacacaccgactc ctggcaccca gggtcattcc 1200 tcagggacct caccaatgtc ctctggtgtccagtcaggga cgcccatcac caatgatctc 1260 ttcagccaag ccctacagca tgcccttcaggcctctgggc agcccagcct tcagagccag 1320 tggcagcccc agctgcagca gctacgtgacatgggcatcc aggacgatga gctgagcctg 1380 cgggccctgc aggccaccgg tggggacatccaagcagccc tggagctcat ctttgctgga 1440 ggagccccat gaactccctg cttcccctgaacccccagca agttgcagag gctactgccc 1500 ttgggaggca ctcatgaagg tgcctccatctctcccttcc ccaatatacc tgatggtcaa 1560 ctctaaaaaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1620 a 1621 <210> SEQ ID NO 172 <211>LENGTH: 420 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:172 Met Met Thr Ile Thr Arg Thr Tyr Leu Ala Leu Gln Asp Ser Ser Ala 1 510 15 Val Arg Val Ser Asp Leu Phe Ser Gly Val Pro Cys Met Pro Gly Arg 2025 30 Lys Arg Glu Arg Glu Arg Glu Arg Met Ser Leu Ser Asp Trp His Leu 3540 45 Ala Val Lys Leu Ala Asp Gln Pro Leu Thr Pro Lys Ser Ile Leu Arg 5055 60 Leu Pro Glu Thr Glu Leu Gly Glu Tyr Ser Leu Gly Gly Tyr Ser Ile 6570 75 80 Ser Phe Leu Lys Gln Leu Ile Ala Gly Lys Leu Gln Glu Ser Val Pro85 90 95 Asp Pro Glu Leu Ile Asp Leu Ile Tyr Cys Gly Arg Lys Leu Lys Asp100 105 110 Asp Gln Thr Leu Asp Phe Tyr Gly Ile Gln Pro Gly Ser Thr ValHis 115 120 125 Val Leu Arg Lys Ser Trp Pro Glu Pro Asp Gln Lys Pro GluPro Val 130 135 140 Asp Lys Val Ala Ala Met Arg Glu Phe Arg Val Leu HisThr Ala Leu 145 150 155 160 His Ser Ser Ser Ser Tyr Arg Glu Ala Val PheLys Met Leu Ser Asn 165 170 175 Lys Glu Ser Leu Asp Gln Ile Ile Val AlaThr Pro Gly Leu Ser Ser 180 185 190 Asp Pro Ile Ala Leu Gly Val Leu GlnAsp Lys Asp Leu Phe Ser Val 195 200 205 Phe Ala Asp Pro Asn Met Leu AspThr Leu Val Pro Ala His Pro Ala 210 215 220 Leu Val Asn Ala Ile Val LeuVal Leu His Ser Val Ala Gly Ser Ala 225 230 235 240 Pro Met Pro Gly ThrAsp Ser Ser Ser Arg Ser Met Pro Ser Ser Ser 245 250 255 Tyr Arg Asp MetPro Gly Gly Phe Leu Phe Glu Gly Leu Ser Asp Asp 260 265 270 Glu Asp AspPhe His Pro Asn Thr Arg Ser Thr Pro Ser Ser Ser Thr 275 280 285 Pro SerSer Arg Pro Ala Ser Leu Gly Tyr Ser Gly Ala Ala Gly Pro 290 295 300 ArgPro Ile Thr Gln Ser Glu Leu Ala Thr Ala Leu Ala Leu Ala Ser 305 310 315320 Thr Pro Glu Ser Ser Ser His Thr Pro Thr Pro Gly Thr Gln Gly His 325330 335 Ser Ser Gly Thr Ser Pro Met Ser Ser Gly Val Gln Ser Gly Thr Pro340 345 350 Ile Thr Asn Asp Leu Phe Ser Gln Ala Leu Gln His Ala Leu GlnAla 355 360 365 Ser Gly Gln Pro Ser Leu Gln Ser Gln Trp Gln Pro Gln LeuGln Gln 370 375 380 Leu Arg Asp Met Gly Ile Gln Asp Asp Glu Leu Ser LeuArg Ala Leu 385 390 395 400 Gln Ala Thr Gly Gly Asp Ile Gln Ala Ala LeuGlu Leu Ile Phe Ala 405 410 415 Gly Gly Ala Pro 420 <210> SEQ ID NO 173<211> LENGTH: 1534 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400>SEQUENCE: 173 aaaccctggt gctccagaca aagatcttag tcgggactag ccggccaaggatgaagcctc 60 acttcagaaa cacagtggag cgaatgtatc gagacacatt ctcctacaacttttataata 120 gacccatcct ttctcgtcgg aataccgtct ggctgtgcta cgaagtgaaaacaaagggtc 180 cctcaaggcc ccctttggac gcaaagatct ttcgaggcca ggtgtattccgaacttaagt 240 accacccaga gatgagattc ttccactggt tcagcaagtg gaggaagctgcatcgtgacc 300 aggagtatga ggtcacctgg tacatatcct ggagcccctg cacaaagtgtacaagggata 360 tggccacgtt cctggccgag gacccgaagg ttaccctgac catcttcgttgcccgcctct 420 actacttctg ggacccagat taccaggagg cgcttcgcag cctgtgtcagaaaagagacg 480 gtccgcgtgc caccatgaag atcatgaatt atgacgaatt tcagcactgttggagcaagt 540 tcgtgtacag ccaaagagag ctatttgagc cttggaataa tctgcctaaatattatatat 600 tactgcacat catgctgggg gagattctca gacactcgat ggatccacccacattcactt 660 tcaactttaa caatgaacct tgggtcagag gacggcatga gacttacctgtgttatgagg 720 tggagcgcat gcacaatgac acctgggtcc tgctgaacca gcgcaggggctttctatgca 780 accaggctcc acataaacac ggtttccttg aaggccgcca tgcagagctgtgcttcctgg 840 acgtgattcc cttttggaag ctggacctgg accaggacta cagggttacctgcttcacct 900 cctggagccc ctgcttcagc tgtgcccagg aaatggctaa attcatttcaaaaaacaaac 960 acgtgagcct gtgcatcttc actgcccgca tctatgatga tcaaggaagatgtcaggagg 1020 ggctgcgcac cctggccgag gctggggcca aaatttcaat aatgacatacagtgaattta 1080 agcactgctg ggacaccttt gtggaccacc agggatgtcc cttccagccctgggatggac 1140 tagatgagca cagccaagac ctgagtggga ggctgcgggc cattctccagaatcaggaaa 1200 actgaaggat gggcctcagt ctctaaggaa ggcagagacc tgggttgagcctcagaataa 1260 aagatcttct tccaagaaat gcaaacaggc tgttcaccac catctccagctgatcacaga 1320 caccagcaaa gcaatgcact cctgaccaag tagattcttt taaaaattagagtgcattac 1380 tttgaatcaa aaatttattt atatttcaag aataaagtac taagattgtgctcaaaaaaa 1440 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaaaaaaaaaaaa 1500 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1534 <210> SEQ IDNO 174 <211> LENGTH: 384 <212> TYPE: PRT <213> ORGANISM: Homo sapiens<400> SEQUENCE: 174 Met Lys Pro His Phe Arg Asn Thr Val Glu Arg Met TyrArg Asp Thr 1 5 10 15 Phe Ser Tyr Asn Phe Tyr Asn Arg Pro Ile Leu SerArg Arg Asn Thr 20 25 30 Val Trp Leu Cys Tyr Glu Val Lys Thr Lys Gly ProSer Arg Pro Pro 35 40 45 Leu Asp Ala Lys Ile Phe Arg Gly Gln Val Tyr SerGlu Leu Lys Tyr 50 55 60 His Pro Glu Met Arg Phe Phe His Trp Phe Ser LysTrp Arg Lys Leu 65 70 75 80 His Arg Asp Gln Glu Tyr Glu Val Thr Trp TyrIle Ser Trp Ser Pro 85 90 95 Cys Thr Lys Cys Thr Arg Asp Met Ala Thr PheLeu Ala Glu Asp Pro 100 105 110 Lys Val Thr Leu Thr Ile Phe Val Ala ArgLeu Tyr Tyr Phe Trp Asp 115 120 125 Pro Asp Tyr Gln Glu Ala Leu Arg SerLeu Cys Gln Lys Arg Asp Gly 130 135 140 Pro Arg Ala Thr Met Lys Ile MetAsn Tyr Asp Glu Phe Gln His Cys 145 150 155 160 Trp Ser Lys Phe Val TyrSer Gln Arg Glu Leu Phe Glu Pro Trp Asn 165 170 175 Asn Leu Pro Lys TyrTyr Ile Leu Leu His Ile Met Leu Gly Glu Ile 180 185 190 Leu Arg His SerMet Asp Pro Pro Thr Phe Thr Phe Asn Phe Asn Asn 195 200 205 Glu Pro TrpVal Arg Gly Arg His Glu Thr Tyr Leu Cys Tyr Glu Val 210 215 220 Glu ArgMet His Asn Asp Thr Trp Val Leu Leu Asn Gln Arg Arg Gly 225 230 235 240Phe Leu Cys Asn Gln Ala Pro His Lys His Gly Phe Leu Glu Gly Arg 245 250255 His Ala Glu Leu Cys Phe Leu Asp Val Ile Pro Phe Trp Lys Leu Asp 260265 270 Leu Asp Gln Asp Tyr Arg Val Thr Cys Phe Thr Ser Trp Ser Pro Cys275 280 285 Phe Ser Cys Ala Gln Glu Met Ala Lys Phe Ile Ser Lys Asn LysHis 290 295 300 Val Ser Leu Cys Ile Phe Thr Ala Arg Ile Tyr Asp Asp GlnGly Arg 305 310 315 320 Cys Gln Glu Gly Leu Arg Thr Leu Ala Glu Ala GlyAla Lys Ile Ser 325 330 335 Ile Met Thr Tyr Ser Glu Phe Lys His Cys TrpAsp Thr Phe Val Asp 340 345 350 His Gln Gly Cys Pro Phe Gln Pro Trp AspGly Leu Asp Glu His Ser 355 360 365 Gln Asp Leu Ser Gly Arg Leu Arg AlaIle Leu Gln Asn Gln Glu Asn 370 375 380 <210> SEQ ID NO 175 <211>LENGTH: 3005 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE:<221> NAME/KEY: unsure <222> LOCATION: (1407) <400> SEQUENCE: 175aaagaagttg tacgaaggtc aaagaaattg tctgttccag cctcagtggt gtcgaggata 60atgggaagag gaggatgcaa catcactgca atacrkgatg ttactggtgc ccatattgat 120gtggataaac aaaaagataa gaatggcgag agaatgatca caataagggg tggcacagaa 180tcaacaagat atgcagttca actaatcaat gcactcattc aagatcctgc taaggaactg 240gaagacttga ttcctaaaaa tcatatcaga acacctgcca gcaccaaatc aattcatgct 300aacttctcat ctggagtagg taccacagca gcttccagta aaaatgcatt tcctttgggt 360gctccaactc ttgtaacttc acaggcaaca acgttatcta cgttccagcc cgctaataaa 420cttaataaga atgttccaac aaatgtacgt tcttctttcc cagtttctct acccttagct 480tatcctcacc ctcattttgc cctgctggct gctcaaacta tgcaacagat tcggcatcct 540cgcttaccca tggcccagtt tggaggaacc ttctcacctt ctcctaacac atggggacca 600ttcccagtga gacctgtgaa tcctggcaac acaaatagct ctccaaagca taataacaca 660agccgtctac ctaaccagaa cgggactgtt ttaccctcag agtctgctgg actagctact 720gccagttgtc ctatcactgt ctcttctgta gttgctgcca gtcagcaact gtgtgtcact 780aatacccgga ctccttcatc agtcagaaag cagttgtttg cctgtgtgcc taagacaagt 840cctccagcaa cagtgatttc ttctgtgaca agcacttgta gttccctgcc ttctgtctcc 900tctgcaccta tcactagcgg gcaagctccc accacatttc tacctgcaag tacttctcaa 960gcacagcttt cttcacaaaa gatggagtct ttctctgctg tgccacccac caaagagaaa 1020gtgtccacac aggaccagcc catggcaaac ctatgtaccc catcttcaac tgcaaacagt 1080tgcagtagct ctgccagcaa caccccggga gctccagaaa ctcacccatc cagtagtccc 1140actcctactt ccagtaacac acaagaggag gcacagccat ccagtgtgtc tgatttaagt 1200cctatgtcaa tgccttttgc atctaactca gaacctgctc cattgacttt gacatcaccc 1260agaatggttg ctgctgataa tcaggacacc agtaatttac ctcagttagc tgtaccagca 1320cctcgagttt ctcatcgaat gcagcccaga ggttcttttt actccatggt accaaatgca 1380actattcacc aggatcccca gtctatnttt gttacgaatc cagttacttt aacaccacct 1440caaggcccac cagctgcagt gcagctttct tcagctgtga acattatgaa tggttctcag 1500atgcacataa acccagcaaa taagtctttg ccacctacat ttggcccagc cacacttttc 1560aatcacttca gcagtctttt tgatagtagt caggtgccag ctaaccaggg ctggggagat 1620ggtccactgt cctcacgagt tgctacagat gcctctttca ctgttcagtc agcgttcctg 1680ggtaactcag tgcttggaca cttggaaaac atgcaccctg ataactcaaa ggcacctggc 1740ttcagaccac cttcccagcg agtttctact agtccagttg ggttaccatc cattgaccca 1800tcaggcagct ccccatcttc ctcttctgct cctctggcaa gtttttccgg cataccagga 1860acaagggttt tcctgcaagg gccagctcct gttgggactc ctagtttcaa cagacaacat 1920ttttctcccc atccttggac aagcgcctca aactcatcca cttctgcccc accaacgttg 1980ggccaaccaa aaggagtcag tgccagtcaa gatcgaaaga tacctccccc aattggaaca 2040gagagactgg cccgaattcg gcaaggaggg tctgttgcac aagccccggc ggggaccagt 2100tttgtcgctc ccgttggaca cagtggaatc tggtcatttg gtgtcaatgc tgtgtcagaa 2160ggcttatcag gttggtcgca atctgtgatg gggaaccatc caatgcatca acaattatca 2220gacccaagca cattctccca acatcagcca atggagagag atgattctgg aatggtagcc 2280ccctctaaca tttttcatca gcctatggca agtggttttg tggatttttc taaaggtctg 2340ccaatttcca tgtatggagg caccataata ccctctcatc ctcagcttgc tgatgttcca 2400ggaggccctc tgtttaatgg acttcacaat ccagatcctg cttggaaccc tatgataaaa 2460gttatccaaa attcaactga atgcactgat gcccagcaga tttggcctgg cacgtgggca 2520cctcatattg gaaacatgca tctcaaatat gtcaactaag ttagaaggtc tttactcttt 2580agccttgttt aagaaaccta tgaccttgga agaaccatgg ggattttttt ttaatgtgcc 2640taagaaattt tctctgaggc tttagcaatg gaaatttgat tgcccattgt ataagaacaa 2700attgatttcc tatccacctg attatgttct ctggttagtt tagccatttt gaacttaaga 2760tcatatgacc ttagtgcttt tggctaaaca tacagaatac tacttgtatg cagaagagaa 2820ttagttgatt acatgtttca accttttagg gtgataaata catgtataat tgtttacata 2880cttaaaagga aaaagttgag taaatttctt gtcatatagt ggctctacgt aatgtagcct 2940gtattaatgt gaaatattta ccagaatatt caataaaaag atgaacagtc aaaaaaaaaa 3000aaaaa 3005 <210> SEQ ID NO 176 <211> LENGTH: 832 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: UNSURE <222>LOCATION: (12) <221> NAME/KEY: UNSURE <222> LOCATION: (449) <400>SEQUENCE: 176 Met Gly Arg Gly Gly Cys Asn Ile Thr Ala Ile Xaa Asp ValThr Gly 1 5 10 15 Ala His Ile Asp Val Asp Lys Gln Lys Asp Lys Asn GlyGlu Arg Met 20 25 30 Ile Thr Ile Arg Gly Gly Thr Glu Ser Thr Arg Tyr AlaVal Gln Leu 35 40 45 Ile Asn Ala Leu Ile Gln Asp Pro Ala Lys Glu Leu GluAsp Leu Ile 50 55 60 Pro Lys Asn His Ile Arg Thr Pro Ala Ser Thr Lys SerIle His Ala 65 70 75 80 Asn Phe Ser Ser Gly Val Gly Thr Thr Ala Ala SerSer Lys Asn Ala 85 90 95 Phe Pro Leu Gly Ala Pro Thr Leu Val Thr Ser GlnAla Thr Thr Leu 100 105 110 Ser Thr Phe Gln Pro Ala Asn Lys Leu Asn LysAsn Val Pro Thr Asn 115 120 125 Val Arg Ser Ser Phe Pro Val Ser Leu ProLeu Ala Tyr Pro His Pro 130 135 140 His Phe Ala Leu Leu Ala Ala Gln ThrMet Gln Gln Ile Arg His Pro 145 150 155 160 Arg Leu Pro Met Ala Gln PheGly Gly Thr Phe Ser Pro Ser Pro Asn 165 170 175 Thr Trp Gly Pro Phe ProVal Arg Pro Val Asn Pro Gly Asn Thr Asn 180 185 190 Ser Ser Pro Lys HisAsn Asn Thr Ser Arg Leu Pro Asn Gln Asn Gly 195 200 205 Thr Val Leu ProSer Glu Ser Ala Gly Leu Ala Thr Ala Ser Cys Pro 210 215 220 Ile Thr ValSer Ser Val Val Ala Ala Ser Gln Gln Leu Cys Val Thr 225 230 235 240 AsnThr Arg Thr Pro Ser Ser Val Arg Lys Gln Leu Phe Ala Cys Val 245 250 255Pro Lys Thr Ser Pro Pro Ala Thr Val Ile Ser Ser Val Thr Ser Thr 260 265270 Cys Ser Ser Leu Pro Ser Val Ser Ser Ala Pro Ile Thr Ser Gly Gln 275280 285 Ala Pro Thr Thr Phe Leu Pro Ala Ser Thr Ser Gln Ala Gln Leu Ser290 295 300 Ser Gln Lys Met Glu Ser Phe Ser Ala Val Pro Pro Thr Lys GluLys 305 310 315 320 Val Ser Thr Gln Asp Gln Pro Met Ala Asn Leu Cys ThrPro Ser Ser 325 330 335 Thr Ala Asn Ser Cys Ser Ser Ser Ala Ser Asn ThrPro Gly Ala Pro 340 345 350 Glu Thr His Pro Ser Ser Ser Pro Thr Pro ThrSer Ser Asn Thr Gln 355 360 365 Glu Glu Ala Gln Pro Ser Ser Val Ser AspLeu Ser Pro Met Ser Met 370 375 380 Pro Phe Ala Ser Asn Ser Glu Pro AlaPro Leu Thr Leu Thr Ser Pro 385 390 395 400 Arg Met Val Ala Ala Asp AsnGln Asp Thr Ser Asn Leu Pro Gln Leu 405 410 415 Ala Val Pro Ala Pro ArgVal Ser His Arg Met Gln Pro Arg Gly Ser 420 425 430 Phe Tyr Ser Met ValPro Asn Ala Thr Ile His Gln Asp Pro Gln Ser 435 440 445 Xaa Phe Val ThrAsn Pro Val Thr Leu Thr Pro Pro Gln Gly Pro Pro 450 455 460 Ala Ala ValGln Leu Ser Ser Ala Val Asn Ile Met Asn Gly Ser Gln 465 470 475 480 MetHis Ile Asn Pro Ala Asn Lys Ser Leu Pro Pro Thr Phe Gly Pro 485 490 495Ala Thr Leu Phe Asn His Phe Ser Ser Leu Phe Asp Ser Ser Gln Val 500 505510 Pro Ala Asn Gln Gly Trp Gly Asp Gly Pro Leu Ser Ser Arg Val Ala 515520 525 Thr Asp Ala Ser Phe Thr Val Gln Ser Ala Phe Leu Gly Asn Ser Val530 535 540 Leu Gly His Leu Glu Asn Met His Pro Asp Asn Ser Lys Ala ProGly 545 550 555 560 Phe Arg Pro Pro Ser Gln Arg Val Ser Thr Ser Pro ValGly Leu Pro 565 570 575 Ser Ile Asp Pro Ser Gly Ser Ser Pro Ser Ser SerSer Ala Pro Leu 580 585 590 Ala Ser Phe Ser Gly Ile Pro Gly Thr Arg ValPhe Leu Gln Gly Pro 595 600 605 Ala Pro Val Gly Thr Pro Ser Phe Asn ArgGln His Phe Ser Pro His 610 615 620 Pro Trp Thr Ser Ala Ser Asn Ser SerThr Ser Ala Pro Pro Thr Leu 625 630 635 640 Gly Gln Pro Lys Gly Val SerAla Ser Gln Asp Arg Lys Ile Pro Pro 645 650 655 Pro Ile Gly Thr Glu ArgLeu Ala Arg Ile Arg Gln Gly Gly Ser Val 660 665 670 Ala Gln Ala Pro AlaGly Thr Ser Phe Val Ala Pro Val Gly His Ser 675 680 685 Gly Ile Trp SerPhe Gly Val Asn Ala Val Ser Glu Gly Leu Ser Gly 690 695 700 Trp Ser GlnSer Val Met Gly Asn His Pro Met His Gln Gln Leu Ser 705 710 715 720 AspPro Ser Thr Phe Ser Gln His Gln Pro Met Glu Arg Asp Asp Ser 725 730 735Gly Met Val Ala Pro Ser Asn Ile Phe His Gln Pro Met Ala Ser Gly 740 745750 Phe Val Asp Phe Ser Lys Gly Leu Pro Ile Ser Met Tyr Gly Gly Thr 755760 765 Ile Ile Pro Ser His Pro Gln Leu Ala Asp Val Pro Gly Gly Pro Leu770 775 780 Phe Asn Gly Leu His Asn Pro Asp Pro Ala Trp Asn Pro Met IleLys 785 790 795 800 Val Ile Gln Asn Ser Thr Glu Cys Thr Asp Ala Gln GlnIle Trp Pro 805 810 815 Gly Thr Trp Ala Pro His Ile Gly Asn Met His LeuLys Tyr Val Asn 820 825 830 <210> SEQ ID NO 177 <211> LENGTH: 1561 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY:unsure <222> LOCATION: (1150) <400> SEQUENCE: 177 gagaaggaag ggaagccggaaggggcgcga gtgaagcaaa gcgaggacag acagctccca 60 gagggcgagg ggtgcgtgtgcgtccgcttc tcacctcagg tctcccttcg gccccgctgc 120 cctccctcgc ggctgggtgacagctgggtc cggtccgtcg cgggctgcct ggggtgcgag 180 gatcgcgcac cccgtcttcgcgcgctgtgc ctgccgcccc gccccctcgt cccgcccgtc 240 ccgtcgcgtc gcgtcccgtcccctcgggtg ctgccagccg ggtgctgatg cgagtcggtg 300 gcagcgagga cattttctgactccctggcc cctgacacgg ctgcactttc catcccgtcg 360 cggggccggc cgctactccggccccaggat gcagaatgtg attaatactg tgaagggaaa 420 ggcactggaa gtggctgagtacctgacccc ggtcctcaag gaatcaaagt ttaaggaaac 480 aggtgtaatt accccagaagagtttgtggc agctggagat cacctagtcc accactgtcc 540 aacatggcaa tgggctacaggggaagaatt gaaagtgaag gcatacctac caacaggcaa 600 acaatttttg gtaaccaaaaatgtgccgtg ctataagcgg tgcaaacaga tggaatattc 660 agatgaattg gaagctatcagtgaagaaga tgatggtgat ggcggatggg tagatacata 720 tcacaacaca ggtattacaggaataacgga agccgttaaa gagatcacac tggaaaataa 780 ggacaatata aggcttcaagattgctcagc actatgtgaa gaggaagaag atgaagatga 840 aggagaagct gcagatatggaagaatatga agagagtgga ttgttggaaa cagatgaggc 900 taccctagat acaaggaaaatagtagaagc ttgtaaagcc aaaactgatg ctggcggtga 960 agatgctatt ttgcaaaccagaacttatga cctttacatc acttatgata aatattacca 1020 gactccacga ttatggttgtttggctatga tgagcaacgg cagcctttaa cagttgagca 1080 catgtatgaa gacatcagtcaggatcatgt gaagaaaaca gtgaccattg aaaatcaccc 1140 tcatctgccn ccacctcccatgtgttcagt tcacccatgc aggcatgctg aggtgatgaa 1200 gaaaatcatt gagactgttgcagaaggagg gggagaactt ggagttcata tgtatcttct 1260 tattttcttg aaatttgtacaagctgtcat tccaacaata gaatatgact acacaagaca 1320 cttcacaatg taatgaagagagcataaaat ctatcctaat tattggttct gatttttaaa 1380 gaattaaccc atagatgtgaccattgacca tattcatcaa tatatacagt ttctctaata 1440 agggacttat atgtttatgcattaaataaa aatatgttcc actaccagcc ttatttgttt 1500 aataaaaatc agtgcaaagagaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1560 a 1561 <210> SEQ ID NO178 <211> LENGTH: 314 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 178 Met Gln Asn Val Ile Asn Thr Val Lys Gly Lys Ala Leu GluVal Ala 1 5 10 15 Glu Tyr Leu Thr Pro Val Leu Lys Glu Ser Lys Phe LysGlu Thr Gly 20 25 30 Val Ile Thr Pro Glu Glu Phe Val Ala Ala Gly Asp HisLeu Val His 35 40 45 His Cys Pro Thr Trp Gln Trp Ala Thr Gly Glu Glu LeuLys Val Lys 50 55 60 Ala Tyr Leu Pro Thr Gly Lys Gln Phe Leu Val Thr LysAsn Val Pro 65 70 75 80 Cys Tyr Lys Arg Cys Lys Gln Met Glu Tyr Ser AspGlu Leu Glu Ala 85 90 95 Ile Ser Glu Glu Asp Asp Gly Asp Gly Gly Trp ValAsp Thr Tyr His 100 105 110 Asn Thr Gly Ile Thr Gly Ile Thr Glu Ala ValLys Glu Ile Thr Leu 115 120 125 Glu Asn Lys Asp Asn Ile Arg Leu Gln AspCys Ser Ala Leu Cys Glu 130 135 140 Glu Glu Glu Asp Glu Asp Glu Gly GluAla Ala Asp Met Glu Glu Tyr 145 150 155 160 Glu Glu Ser Gly Leu Leu GluThr Asp Glu Ala Thr Leu Asp Thr Arg 165 170 175 Lys Ile Val Glu Ala CysLys Ala Lys Thr Asp Ala Gly Gly Glu Asp 180 185 190 Ala Ile Leu Gln ThrArg Thr Tyr Asp Leu Tyr Ile Thr Tyr Asp Lys 195 200 205 Tyr Tyr Gln ThrPro Arg Leu Trp Leu Phe Gly Tyr Asp Glu Gln Arg 210 215 220 Gln Pro LeuThr Val Glu His Met Tyr Glu Asp Ile Ser Gln Asp His 225 230 235 240 ValLys Lys Thr Val Thr Ile Glu Asn His Pro His Leu Pro Pro Pro 245 250 255Pro Met Cys Ser Val His Pro Cys Arg His Ala Glu Val Met Lys Lys 260 265270 Ile Ile Glu Thr Val Ala Glu Gly Gly Gly Glu Leu Gly Val His Met 275280 285 Tyr Leu Leu Ile Phe Leu Lys Phe Val Gln Ala Val Ile Pro Thr Ile290 295 300 Glu Tyr Asp Tyr Thr Arg His Phe Thr Met 305 310 <210> SEQ IDNO 179 <211> LENGTH: 2379 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 179 atttagttac acatagacat aactcttcaa ccttaactatggcaatacat ttgtgcttta 60 actgttacat agcagtatca ccacttacca ggatccaaatcgaaataata aaagctgtct 120 ccatagttta aaatcgaata gtgccatcat cacagtatattagtcaaata gaagcttcat 180 cagaaatgta tcccacatag agttttaaga cttggattctcttctgccct tgttaatctc 240 caactaatta ctacagattg acacgttttt aattagctgtcctttgtaag aagtcaggaa 300 atctgatgct gtgtccaaaa ttatgcactg tttgttgaagtagaaccaga aatcctgacc 360 tcctgttaaa tgacatcagt ttccccctct gagcaacagactgcttgtct tgctaggaga 420 ggaggatggg gggctgagca ctcaggctgt ccattgaaaccccttgtcca tgaatagggt 480 catactccta agactgatgg ggtgttgatc ttctaggacatcacttgttt attcagtgcc 540 ccaaacacag atttctcttc tagcacttta gaattgatccttgaagtctc tcctggttca 600 ttcaaataca agctgtgtga gtctggtggt tttctgtgattggtctaatg tgagctcttt 660 gaacagacag atctgacagt ggaatgactc tcccctgcttctggcataac tgctttgcct 720 ctgtctagtg tccaagcatc ttagctgttc aagaggagagggcagcataa cttcctgacc 780 actggtgtca gatatcagag cattctggac tcctgagaggcagtggcctc ttgagtgaac 840 aggggaggcc agtagatgcc ccagatccag agccgtggctgcaaatccag caggaataag 900 gagggacaac cacagcctcc tcatccatgt gtcatttccaagggtttgcc ttgtgtctca 960 gctcattctg ggcagcacgt ttgtcttctg tccctagagatttgaaggat tttggactct 1020 tgtgaatggg tgactggact tggctttaca gagttgggtgcttttttctc tctgcaatta 1080 cctgtcatag cattttgtgc tcaccacgaa ggatggtctctgccttctct tgtcggtgta 1140 tgccatctga acctaggaac acaaagtata ttggcctcaaacgggagacc cagggttgcc 1200 agttttccgt gggccttccc ctcccttgaa atgtctttaattacctcccc ttcatcgtca 1260 ggccacgtgt gacttctgtt cttagcactg ccagggtcattgacttccat ctaagcttgc 1320 atcaggaaga tgttccttct gtgatcattg gtactgaagccagaaaagct ctcattcagg 1380 aactctgaag agcaaaaagg gacaaacact aactgctgagctgggccatt tgatctcctt 1440 tcaccttgca ttgctgtcac agcaccttgt atgatggcaggacaggctcc agcagagaga 1500 actgcacagt gaccactgta tttttcacgc tcttccagggatccctgtcc cccgacattg 1560 aagagatctc attcaggcca gagacacaga gaccacatagcccagtgatt aaaccccggt 1620 ttcactctgg ccccaggagt ggagcctggc cactcctgtttggttctcac tgggaggccc 1680 actggccttg gatcatctcc tcatgcacac ccggagttttacctgcttgc ttgctttcct 1740 ggactgctgt ttgcaagaaa gtaactaaaa catgaaaagtaaacctccag cttccacagt 1800 atattacctg ccgttgcatg catttgaaag ttagcctcctcccttgccac cgtcttggtg 1860 gcagtagcga tgcaagaatg atgggagctt tccgagagcgttcagtgttt cactgaagac 1920 aggacccata gccttcattt ctggctctgt gtctcctctggcatatggac acatttcctg 1980 gcatttgcct gagtctacac cactttttga gaacctgaaatagaagggaa tcttctgtgg 2040 cccacagtct ccatattggc cctagaagac tggcctggcggaggaatttg cgttggcttg 2100 ctttcagggg ttagctacaa gattcagctt tatatctctgttgcttcttg gccagtgtag 2160 tcaataaggg tcttctttaa catctaagat agaggtttggttggccgggc gtggtcgctw 2220 actcctgtaa tcccagcact ttgggaggcc cagtgaggtgggagaattgc ttgaacccag 2280 gaggcagagg ttgcagtgag ctgagattgc accattgcattccagcctgg gtaacagagt 2340 gagactcttg tctcaaaaaa aaaaaaaaaa aaaaaaaaa2379 <210> SEQ ID NO 180 <211> LENGTH: 67 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 180 Met Gly Asp Trp Thr Trp LeuTyr Arg Val Gly Cys Phe Phe Leu Ser 1 5 10 15 Ala Ile Thr Cys His SerIle Leu Cys Ser Pro Arg Arg Met Val Ser 20 25 30 Ala Phe Ser Cys Arg CysMet Pro Ser Glu Pro Arg Asn Thr Lys Tyr 35 40 45 Ile Gly Leu Lys Arg GluThr Gln Gly Cys Gln Phe Ser Val Gly Leu 50 55 60 Pro Leu Pro 65 <210>SEQ ID NO 181 <211> LENGTH: 1607 <212> TYPE: DNA <213> ORGANISM: Homosapiens <400> SEQUENCE: 181 atacaagtca agatgctacc catgtagaca cactgtatttttaaggtggg caagtgcgat 60 taacgatgaa ccattttaaa ggggaggtta tttgaaacctctaatttgat tattgggagg 120 attttcatgc tttctttagt atttattacc atcataccgattcaaactat tttattgtct 180 aatacattag cattttgtat tttgatggaa attgttacagaatttaaaga tttgatgaaa 240 taagatgtag cagatttttt gtagcaagtt tctggtaaaagggttttttg caagtctcag 300 gttcttgctg cactattttt ttttaaatat ttattccagttattctaatt cagaagcatt 360 cttttcaagt aacagcagca cttgtgaaag gaaaaaaaaatgcacatgtt tcttagtagg 420 ttactaaatt tgtacaatta attaagattt tagccatcagtgagtttgaa aagggaaatg 480 tatttatttt cagcattaaa atgcttccaa aagatcaagttgcttttgtt tgtttgtttt 540 tttaaccgta atgtagatgg agaaattgga ggcaacctcagtataggaac tgccactttg 600 agcagtttag gtcttaaaga gaaagtcaat ctaatgccaaggggagaaca atgagctgaa 660 attgtaccaa ctcctctggc cctccttccc tcaattaaaaaaacacactt accagttttg 720 cttattttac agatatctgg tggttctata gtttaaagcagcttgtgaaa ttaaaaaagt 780 ggactcaatt ttgtttacct ttctgtaagt ttttcatttttgctgtatag cattggcaaa 840 aatatgtaca aattgacctc tgttcttatt tcctattgtgagcattataa agataagctc 900 ctatgtaaaa ccttgctctc agatgagtaa aatatgtatcacagcatagc tcagcaataa 960 ttcatgctca gctgtgggga ccctgggggc tttttgaagatgatggaacc gcactagggt 1020 tgaaactgat ggctgtggag ttaattgtgt tttcgagcttgaatctcacc tgtgattttt 1080 tttttttaat gttgtttcat gacttgattt ttctcataagccaatgtatt tgtaggttta 1140 ctggatttta tttttaggga gtgggtaatt tcttcccttttttgattaag ttggttcagc 1200 tatggtgcta ttcagtaggt atcttcagtg tcaggtcccgtagctgaatg ccattgttat 1260 tataattatt atttgtaatc acattgtaag cttgaatttgggcttgwacc tgcatctttt 1320 gtattctgta catctggtta cttagacttt gggagtccaatttggtttca gtcatgtatg 1380 tctactttgt agtttaagta gacttcatca actatggtctattttgggtt tgtagtttta 1440 atttagaatt gtgttaaatt gatgttttgc atttgacttcatttgacatt agttgaagta 1500 aattatttaa tttttgaatt ctggaatttg aacatttactgtaatttgta atataactgc 1560 tgtgaaatac ttgaataaag atgacaagaa aaaaaaaaaaaaaaaaa 1607 <210> SEQ ID NO 182 <211> LENGTH: 58 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 182 Met Tyr Leu Phe Ser Ala LeuLys Cys Phe Gln Lys Ile Lys Leu Leu 1 5 10 15 Leu Phe Val Cys Phe PheAsn Arg Asn Val Asp Gly Glu Ile Gly Gly 20 25 30 Asn Leu Ser Ile Gly ThrAla Thr Leu Ser Ser Leu Gly Leu Lys Glu 35 40 45 Lys Val Asn Leu Met ProArg Gly Glu Gln 50 55 <210> SEQ ID NO 183 <211> LENGTH: 2695 <212> TYPE:DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 183 gaacagagtagtagccaggc aatgttctca taataaacag aaaaggaaaa gaaactccaa 60 tgtggaaaccatctcaaacc tctgtgtgaa gtctaccaat tttctgttaa tcaaagcaag 120 ctatgtgagtgtactcagag tccaggggca aggtagtcac cctgtgtgtg gtgggaaaat 180 actgcaagattatatgtcaa ataatgggat actcaggaat atttacaaaa atgttgaata 240 ttttaatgaaataacaaata tttagacatt caatagactt gagagtaact ttaccaaggg 300 tctaagtatgagagatatgt ttaatatatt tttatgggct gaaaaccctg agtgggaaaa 360 taggactaatttcaccagga tgacctcctg gaaatgcatt ttccattttg gaaattattt 420 taaaagttcattttttctgg atgggtatgt gtatgtgtgt gtgtctgtcy aygtgtgtat 480 gttttatgagcttgttaaca ctaatgtcat acaaaagtac tggttagcag gaataagatt 540 ttaaggtgtattggcattcc catggttccc aagaaaattt tagatgactt tgattaaaaa 600 gtttggattttgtctattta aatctagcat aaaaattggt catggtgatg atcctagtta 660 tgactaatctccctttaaga tttaggcatt tactgtgtga aatatgtggc acattttcca 720 taacaaacagctaaagttac tgaacacaaa ttatggaaag gtgaaatgag gaaaacattg 780 caaaacactgaaagagaata tgtctttatt tgcatgctgg caaatgaaaa ttccggtttc 840 acttctacttcagtatctaa caagtctcta acaagaacag acattgaatg aatgaattaa 900 gttgagctgtttgaaaatta gaatgttttc cataaataca ttattgaact atcaattagc 960 ataaactgctactttcttgt ttgacactgg tcacagtatt tgaaagtaaa aagaatgtta 1020 ctgcacattcagaaatcagg tccacataaa atttaaggtc aggatattaa aggatcacag 1080 ccagtgctgttaggccttca tttattctat ctttttgtct gttcagacat gataactttt 1140 ctacccatcattttttccat tctagtagtg gttacatttg ttcttgggaa ttttgctaat 1200 ggcttcatagtgttggtaaa ttccattgag tgggtcaaga gacaaaagat ctcctttgct 1260 gaccaaattctcactgctct ggcagtctcc agagttggtt tgctctgggt aatattatwa 1320 cattggtatgcaactgtttt gaatccaggt tcatatagtt taggagtaag aattactact 1380 attaatgcctgggctgtaac caaccatttc agcatctggg ttgctactag cctcagcata 1440 ttttatttgctcaagattgc caatttctcc aactttattt ttcttcactt aaaaaggaga 1500 attaagagtgtcattccagt gatactattg gggtctttgt tatttttggt ttgtcatctt 1560 gttgtggtaaacatggatga gagtatgtgg acaaaagaat atgaaggaaa cgtgagttgg 1620 gagatcaaattgagtgatcc gacgcacctt tcagatatga ctgtaaccac gcttgcaaac 1680 ttaataccctttactctgtc cctgttatct tttctgctct taatctgttc tttgtgtaaa 1740 catctcaagaagatgcagtt ccatggcaaa ggatctccag attccaacac caaggtccac 1800 ataaaagctttgcaaacggt gacctccttc ctcttgttat ttgctgttta ctttctgtcc 1860 ctaatcacatcgatttggaa ttttaggagg aggctgtaga acgaacctgt cctcatgctc 1920 agccaaactactgcaattat atacccttca tttcattcat tcatcctaat ttggggaagc 1980 aagaagctgaaacagacctt tcttttgatt ttgtgtcaga ttaagtgctg agtaaaagac 2040 ctgaaactctcaaatttcta gattcacaag tgggacatcg tgtgtctcca agagaaaaca 2100 aactgatgttgtctggaaca ttttatactt tccactggtt tttctgtatt gtatgttttt 2160 gagtaatttccaaaagtata tctagaaaag tcttttaccc taaagttagt ctaaaaaggt 2220 atctatatakgcatgtgtat ggtgtatatg aaacacttaa gagagagtgg caataacata 2280 atcatttttwacaaactgcc aaattataga aaatattgta agaaattttt cagaatcatg 2340 aagccatgtgtattcacaat acagttcata ttatcatgtt tcatttgaaa aatttatgat 2400 ctctatttataattgttaag aacttacagc ttatttcaca aaatcattgc tcttttccac 2460 tgttatttgtaccatacgta tgtaccatag tgtgcttaaa cgtgattatt tgaacgtcta 2520 gttttttggatggtatgcgc attctaatct aaatcaataa tgaagtttta tctttggggt 2580 agtttttgttgcataatgaa ttctaatttt atgtttaatt taaagcaaac aattattgtt 2640 agaaaactatgcacaaaata aaattcaagg atgaaaaata aaaaaaaaaa aaaaa 2695 <210> SEQ ID NO184 <211> LENGTH: 256 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220>FEATURE: <221> NAME/KEY: UNSURE <222> LOCATION: (64) <400> SEQUENCE: 184Met Ile Thr Phe Leu Pro Ile Ile Phe Ser Ile Leu Val Val Val Thr 1 5 1015 Phe Val Leu Gly Asn Phe Ala Asn Gly Phe Ile Val Leu Val Asn Ser 20 2530 Ile Glu Trp Val Lys Arg Gln Lys Ile Ser Phe Ala Asp Gln Ile Leu 35 4045 Thr Ala Leu Ala Val Ser Arg Val Gly Leu Leu Trp Val Ile Leu Xaa 50 5560 His Trp Tyr Ala Thr Val Leu Asn Pro Gly Ser Tyr Ser Leu Gly Val 65 7075 80 Arg Ile Thr Thr Ile Asn Ala Trp Ala Val Thr Asn His Phe Ser Ile 8590 95 Trp Val Ala Thr Ser Leu Ser Ile Phe Tyr Leu Leu Lys Ile Ala Asn100 105 110 Phe Ser Asn Phe Ile Phe Leu His Leu Lys Arg Arg Ile Lys SerVal 115 120 125 Ile Pro Val Ile Leu Leu Gly Ser Leu Leu Phe Leu Val CysHis Leu 130 135 140 Val Val Val Asn Met Asp Glu Ser Met Trp Thr Lys GluTyr Glu Gly 145 150 155 160 Asn Val Ser Trp Glu Ile Lys Leu Ser Asp ProThr His Leu Ser Asp 165 170 175 Met Thr Val Thr Thr Leu Ala Asn Leu IlePro Phe Thr Leu Ser Leu 180 185 190 Leu Ser Phe Leu Leu Leu Ile Cys SerLeu Cys Lys His Leu Lys Lys 195 200 205 Met Gln Phe His Gly Lys Gly SerPro Asp Ser Asn Thr Lys Val His 210 215 220 Ile Lys Ala Leu Gln Thr ValThr Ser Phe Leu Leu Leu Phe Ala Val 225 230 235 240 Tyr Phe Leu Ser LeuIle Thr Ser Ile Trp Asn Phe Arg Arg Arg Leu 245 250 255 <210> SEQ ID NO185 <211> LENGTH: 1111 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 185 gccgagcgcc gccgccgaag cttccgtctc gctcgctcgcgcagcggcgg cagcagaggt 60 cgcgcacaga tgcgggttag actggcgggg ggaggaggcggaggagggaa ggaagctgca 120 tgcatgagac ccacagactc ttgcaagctg gatgccctctgtggatgaaa gatgtatcat 180 ggaatgaacc cgagcaatgg agatggattt ctagagcagcagcagcagca gcagcaacct 240 cagtcccccc agagactctt ggccgtgatc ctgtggtttcagctggcgct gtgcttcggc 300 cctgcacagc tcacgggcgg gttcgatgac cttcaagtgtgtgctgaccc cggcattccc 360 gagaatggct tcaggacccc cagcggaggg gttttctttgaaggctctgt agcccgattt 420 cactgccaag acggattcaa gctgaagggc gctacaaagagactgtgttt gaagcatttt 480 aatggaaccc taggctggat cccaagtgat aattccatctgtgtgcaaga agattgccgt 540 atccctcaaa tcgaagatgc tgagattcat aacaagacatatagacatgg agagaagcta 600 atcatcactt gtcatgaagg attcaagatc cggtaccccgacctacacaa tatggtttca 660 ttatgtcgcg atgatggaac gtggaataat ctgcccatctgtcaaggctg cctgagacct 720 ctagcctctt ctaatggcta tgtaaacatc tctgagctccagacctcctt cccggtgggg 780 actgtgatct cctatcgctg ctttcccgga tttaaacttgatgggtctgc gtatcttgag 840 tgcttacaaa accttatctg gtcgtccagc ccaccccggtgccttgctct ggaaggagga 900 agacctgaac atcttttccc tgtcctttat ttcccacacatcaggttggc agctgctgtg 960 ctttattttt gccctgtgtt aaagtcctct cccaccccagcacctacctg ttcctcaact 1020 agcaccacca catctctgtt ctaaatgttg ttctcctgcaataaaggacg tttgaattta 1080 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a 1111 <210>SEQ ID NO 186 <211> LENGTH: 290 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 186 Met Tyr His Gly Met Asn Pro Ser Asn Gly AspGly Phe Leu Glu Gln 1 5 10 15 Gln Gln Gln Gln Gln Gln Pro Gln Ser ProGln Arg Leu Leu Ala Val 20 25 30 Ile Leu Trp Phe Gln Leu Ala Leu Cys PheGly Pro Ala Gln Leu Thr 35 40 45 Gly Gly Phe Asp Asp Leu Gln Val Cys AlaAsp Pro Gly Ile Pro Glu 50 55 60 Asn Gly Phe Arg Thr Pro Ser Gly Gly ValPhe Phe Glu Gly Ser Val 65 70 75 80 Ala Arg Phe His Cys Gln Asp Gly PheLys Leu Lys Gly Ala Thr Lys 85 90 95 Arg Leu Cys Leu Lys His Phe Asn GlyThr Leu Gly Trp Ile Pro Ser 100 105 110 Asp Asn Ser Ile Cys Val Gln GluAsp Cys Arg Ile Pro Gln Ile Glu 115 120 125 Asp Ala Glu Ile His Asn LysThr Tyr Arg His Gly Glu Lys Leu Ile 130 135 140 Ile Thr Cys His Glu GlyPhe Lys Ile Arg Tyr Pro Asp Leu His Asn 145 150 155 160 Met Val Ser LeuCys Arg Asp Asp Gly Thr Trp Asn Asn Leu Pro Ile 165 170 175 Cys Gln GlyCys Leu Arg Pro Leu Ala Ser Ser Asn Gly Tyr Val Asn 180 185 190 Ile SerGlu Leu Gln Thr Ser Phe Pro Val Gly Thr Val Ile Ser Tyr 195 200 205 ArgCys Phe Pro Gly Phe Lys Leu Asp Gly Ser Ala Tyr Leu Glu Cys 210 215 220Leu Gln Asn Leu Ile Trp Ser Ser Ser Pro Pro Arg Cys Leu Ala Leu 225 230235 240 Glu Gly Gly Arg Pro Glu His Leu Phe Pro Val Leu Tyr Phe Pro His245 250 255 Ile Arg Leu Ala Ala Ala Val Leu Tyr Phe Cys Pro Val Leu LysSer 260 265 270 Ser Pro Thr Pro Ala Pro Thr Cys Ser Ser Thr Ser Thr ThrThr Ser 275 280 285 Leu Phe 290 <210> SEQ ID NO 187 <211> LENGTH: 29<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223>OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 187 antgacttca gttgagggca agtctctgg 29 <210> SEQID NO 188 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 188 tncagaaagactgcagggat tcgggacaa 29 <210> SEQ ID NO 189 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 189 antcatcact acacgtcttc tcccctaca 29 <210> SEQID NO 190 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 190 gnctgagtatgttgtggaat gggctgcaa 29 <210> SEQ ID NO 191 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 191 tngtgactgt atacctgcaa cctcaatgc 29 <210> SEQID NO 192 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 192 tngccttgacacaggtggca gaagaaact 29 <210> SEQ ID NO 193 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 193 cngactggta gtgacaccaa gagaatgga 29 <210> SEQID NO 194 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 194 anagcacagcttagttttca gtgactcca 29 <210> SEQ ID NO 195 <211> LENGTH: 20 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <400> SEQUENCE: 195 gcatatactc tgttgcccgc20 <210> SEQ ID NO 196 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM:Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <400> SEQUENCE: 196 ctgccactat ccccaggg 18 <210> SEQ IDNO 197 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 197 antggtgtgccactcccaac aatctttcc 29 <210> SEQ ID NO 198 <211> LENGTH: 2505 <212>TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 198 ccagctccccactgccctga gggcgggccg gcctgcggcg gagggaaaaa ggaagaggag 60 aaggaaattgtcccgaatcc ctgcaggtca gtacctggaa gattccataa agtcggggtg 120 cttgagggcgtagggccgag accgtcgcgg gtactgaggc gcctccgtcg tctctcccac 180 tcgccgcccgctttccaaga catatgtccc gcttgcagcc catttcgatg ctgcgaaacg 240 gtgagctgcggggtgtttgg ggaagagctc agagactggg aaatgggaat ctgctgggag 300 cctagggccgcaatccggaa agggagctgt ggcctgggtg ttggccccta gtccaccagg 360 acagtgccggaggggaatgg ctggatatgg gggcgggggt ggtgagatgc aacgcgatat 420 gtcagcagaaccccaagaga ggtaataggg gtgggaaacc tctgacaacc aggcctccga 480 attagaaaagagttttgtgt tctggggact agtccgtcca ccaagcgctc agtggcggca 540 gtttcccgtctttctgcctg tggctgtgtc ttactgacca tggctctgtg tctagtgggt 600 ccaagcctctcccgggtggc cagtctttct gtaggttgcg gcacaacgcc aggcaaaaga 660 agaggaaggaatttaatcct aatcggtgga ggtcgatttg agggtctgct gtagcaggtg 720 gctccgcttgaagcgaggga ggaagtttcc tccgatcagt agagattgga aagattgttg 780 ggagtggcacaccactaggg aaaagaagaa ggggcgaact gcttgtcttg aggaggtcaa 840 cccccagaatcagctcttgt ggccttgaag tggctgaaga cgatcaccct ccacaggctt 900 gagcccagtcccacagcctt cctcccccag cctgagtgac tactctattc cttggtccct 960 gctattgtcggggacgattg catgggctac gccaggaaag taggctgggt gaccgcaggc 1020 ctggtgattggggctggcgc ctgctattgc atttatagac tgactagggg aagaaaacag 1080 aacaaggaaaaaatggctga gggtggatct ggggatgtgg atgatgctgg ggactgttct 1140 ggggccaggtataatgactg gtctgatgat gatgatgaca gcaatgagag caagagtata 1200 gtatggtacccaccttgggc tcggattggg actgaagctg gaaccagagc tagggccagg 1260 gcaagggccagggctacccg ggcacgtcgg gctgtccaga aacgggcttc ccccaattca 1320 gatgataccgttttgtcccc tcaagagcta caaaaggttc tttgcttggt tgagatgtct 1380 gaaaagccttatattcttga agcagcttta attgctctgg gtaacaatgc tgcttatgca 1440 tttaacagagatattattcg tgatctgggt ggtctcccaa ttgtcgcaaa gattctcaat 1500 actcgggatcccatagttaa ggaaaaggct ttaattgtcc tgaataactt gagtgtgaat 1560 gctgaaaatcagcgcaggct taaagtatac atgaatcaag tgtgtgatga cacaatcact 1620 tctcgcttgaactcatctgt gcagcttgct ggactgagat tgcttacaaa tatgactgtt 1680 actaatgagtatcagcacat gcttgctaat tccatttctg acttttttcg tttattttca 1740 gcgggaaatgaagaaaccaa acttcaggtt ctgaaactcc ttttgaattt ggctgaaaat 1800 ccagccatgactagggaact gctcagggcc caagtaccat cttcactggg ctccctcttt 1860 aataagaaggagaacaaaga agttattctt aaacttctgg tcatatttga gaacataaat 1920 gataatttcaaatgggaaga aaatgaacct actcagaatc aattcggtga aggttcactt 1980 tttttctttttaaaagaatt tcaagtgtgt gctgataagg ttctgggaat agaaagtcac 2040 catgattttttggtgaaagt aaaagttgga aaattcatgg ccaaacttgc tgaacatatg 2100 ttcccaaagagccaggaata acaccttgat tttgtaattt agaagcaaca cacattgtaa 2160 actattcattttctccacct tgtttatatg gtaaaggaat cctttcagct gccagttttg 2220 aataatgaatatcatattgt atcatcaatg ctgatattta actgagttgg tctttaggtt 2280 taagatggataaatgaatat cactacttgt tctgaaaaca tgtttgttgc tttttatctc 2340 gctgcctagattgaaatatt ttgctatttc ttctgcataa gtgacagtga accaattcat 2400 catgagtaagctcccttctg tcattttcat tgatttaatt tgtgtatcat caataaaatt 2460 gtatgttaatgctggaaaga aaaaaaaaaa aaaaaaaaaa aaaaa 2505 <210> SEQ ID NO 199 <211>LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220>FEATURE: <223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY:misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 199 gntgaaacct gaaggatggagagaaatta 29 <210> SEQ ID NO 200 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:200 gngagaaata catcagagca ggctgccat 29 <210> SEQ ID NO 201 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 201 tngtattgca tataagctacaactttacc 29 <210> SEQ ID NO 202 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:202 antaaagtac ctatgcagtt ttaagacca 29 <210> SEQ ID NO 203 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 203 gngcaaagaa cagaggattcttgagaaag 29 <210> SEQ ID NO 204 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:204 anactggcct aggtttcagg gttgtatca 29 <210> SEQ ID NO 205 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 205 cntgccctaa ctagacaattacgaatccc 29 <210> SEQ ID NO 206 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:206 angaaagagc cttctgtgct gttgataaa 29 <210> SEQ ID NO 207 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 207 cnctgccagc cccacactctcatcacaaa 29 <210> SEQ ID NO 208 <211> LENGTH: 19 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <400> SEQUENCE: 208 tcctcaccct cttcccttg 19 <210> SEQ IDNO 209 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 209 cnaattgttcaggttgtaga gatgtcagc 29 <210> SEQ ID NO 210 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 210 tnagaaggaa atggaaacac acgggaaat 29 <210> SEQID NO 211 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 211 tnagcatgaccagtggtgga gcaacgaag 29 <210> SEQ ID NO 212 <211> LENGTH: 20 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <400> SEQUENCE: 212 ggtatgggaa gctagagggc20 <210> SEQ ID NO 213 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM:Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <400> SEQUENCE: 213 gtctgggacg atgttggc 18 <210> SEQ IDNO 214 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 214 cngagagctattgtccttga gtaggctga 29 <210> SEQ ID NO 215 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 215 gnatcttgtg tcagccccaa aggtttcag 29 <210> SEQID NO 216 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 216 antacaacatgggatgttca ggactaatc 29 <210> SEQ ID NO 217 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 217 cngcagcagc agctgcccgt ttcatcatg 29 <210> SEQID NO 218 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 218 cngggctaacagcccgtaga agacaatga 29 <210> SEQ ID NO 219 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 219 cnctaggaga gatgctttca cagggtaaa 29 <210> SEQID NO 220 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 220 cngtgggaagcagaacaaca gaaggaact 29 <210> SEQ ID NO 221 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 221 gntcagcagc acagaggaga caaagtaca 29 <210> SEQID NO 222 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 222 angttgaaggtcgatgtttt ctcttgctg 29 <210> SEQ ID NO 223 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 223 gnctgatgat gccaaccaag atagttcta 29 <210> SEQID NO 224 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 224 gngaggacagttcttttgga ggttggagg 29 <210> SEQ ID NO 225 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 225 anttaagacg aatgtgtggg tttcagacc 29 <210> SEQID NO 226 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 226 tntcaacatcccaagtagac agcagtcct 29 <210> SEQ ID NO 227 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 227 tngacccaca gagagcaggg acttcacaa 29 <210> SEQID NO 228 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 228 tngtttccttccagagggaa tgcagtatg 29 <210> SEQ ID NO 229 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 229 gncggtacca gtagcaatga gcacgaagg 29 <210> SEQID NO 230 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 230 tncgcgagctcctaattcct gctcctcag 29 <210> SEQ ID NO 231 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 231 gnaaatctat gtcatcttgt cgggaccaa 29 <210> SEQID NO 232 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 232 tnaggaagatgggaggtaac ccaagggaa 29 <210> SEQ ID NO 233 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 233 tncagatcca tcaatgaggg tccacccag 29 <210> SEQID NO 234 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 234 gncctgtgtgcccagaacaa tcatgctcc 29 <210> SEQ ID NO 235 <211> LENGTH: 18 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <400> SEQUENCE: 235 gtttctggaa tgcgggtg 18<210> SEQ ID NO 236 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <400> SEQUENCE: 236 ccgtgatacc gaaatgtcc 19 <210> SEQ IDNO 237 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 237 gnaacaatcaccttccacat ggcaccaac 29 <210> SEQ ID NO 238 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 238 gngttgaggc agagctcagt ggtgtccac 29 <210> SEQID NO 239 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 239 ancgtgtgtacgatctgtag ggctgtctg 29 <210> SEQ ID NO 240 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 240 gnagcacgcg gaaccaacac gttctaata 29 <210> SEQID NO 241 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 241 anatcagggagctgaggctt agagagaga 29 <210> SEQ ID NO 242 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 242 gngaaaggag agaaggccca agagagagg 29 <210> SEQID NO 243 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 243 gntgccactgacgaaagctt gaaataacc 29 <210> SEQ ID NO 244 <211> LENGTH: 20 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <400> SEQUENCE: 244 ggctctacat ctcatcaccc20 <210> SEQ ID NO 245 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM:Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:245 cnaagttcta ttgggagatg gagtttgtg 29 <210> SEQ ID NO 246 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 246 cnatccatgg tacatggtcagaagctcat 29 <210> SEQ ID NO 247 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:247 tngagcaggt caggatacac tggaaaaga 29 <210> SEQ ID NO 248 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 248 cnactgcctt tgttgctttccagtagtga 29 <210> SEQ ID NO 249 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:249 tnaatatcca catccccaaa tcctacacg 29 <210> SEQ ID NO 250 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 250 cncttgcagc gggaaggcagagaagtttc 29 <210> SEQ ID NO 251 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:251 cntgagccac aatagacaga attcctacc 29 <210> SEQ ID NO 252 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 252 cngtcagggc gcagctgtattggtcacaa 29 <210> SEQ ID NO 253 <211> LENGTH: 19 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <400> SEQUENCE: 253 acccacacag aagtgagcc 19 <210> SEQ IDNO 254 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 254 tnaccagtgtgcgaaggtag agacggcat 29 <210> SEQ ID NO 255 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 255 tntagcccga tgaggctgta tgagtacag 29 <210> SEQID NO 256 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <221>NAME/KEY: misc_feature <222> LOCATION: (2) <223> OTHER INFORMATION:biotinylated phosphoaramidite residue <400> SEQUENCE: 256 tntcactgccaaacggagaa gaaacgcaa 29 <210> SEQ ID NO 257 <211> LENGTH: 29 <212> TYPE:DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHERINFORMATION: oligonucleotide <221> NAME/KEY: misc_feature <222>LOCATION: (2) <223> OTHER INFORMATION: biotinylated phosphoaramiditeresidue <400> SEQUENCE: 257 gngaaggacc aagacaatcc ctgaagtaa 29 <210> SEQID NO 258 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: ArtificialSequence <220> FEATURE: <223> OTHER INFORMATION: oligonucleotide <400>SEQUENCE: 258 ttggagcact gaggaacaag 20 <210> SEQ ID NO 259 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 259 gncgtctgca ggagatcaaaaacactgtc 29 <210> SEQ ID NO 260 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:260 angcagcagg gattgagaag ggaacatca 29 <210> SEQ ID NO 261 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 261 tnagtttcac cagtctgagcacaagtttg 29 <210> SEQ ID NO 262 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:262 anggatcact tctgcctctg cttcctgga 29 <210> SEQ ID NO 263 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 263 antggacact tccatacacactaggtgaa 29 <210> SEQ ID NO 264 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:264 gncatggaag gagactggga taaggcaga 29 <210> SEQ ID NO 265 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 265 tnccaggaac acagaaaaaaacttgagaa 29 <210> SEQ ID NO 266 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:266 gngctgggag tactgctaga gggtgtgga 29 <210> SEQ ID NO 267 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 267 cnctctttgg ctgtacacgaacttgctcc 29 <210> SEQ ID NO 268 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:268 gngggtggca cagcagagaa agactccat 29 <210> SEQ ID NO 269 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 269 tngcatcttc accgccagcatcagttttg 29 <210> SEQ ID NO 270 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:270 cnaactctgt aaagccaagt ccagtcacc 29 <210> SEQ ID NO 271 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 271 tnctgaggtt gcctccaatttctccatct 29 <210> SEQ ID NO 272 <211> LENGTH: 29 <212> TYPE: DNA <213>ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION:oligonucleotide <221> NAME/KEY: misc_feature <222> LOCATION: (2) <223>OTHER INFORMATION: biotinylated phosphoaramidite residue <400> SEQUENCE:272 gntgacaaac caaaaataac aaagacccc 29 <210> SEQ ID NO 273 <211> LENGTH:29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:<223> OTHER INFORMATION: oligonucleotide <221> NAME/KEY: misc_feature<222> LOCATION: (2) <223> OTHER INFORMATION: biotinylatedphosphoaramidite residue <400> SEQUENCE: 273 gntacatctt tcatccacagagggcatcc 29 <210> SEQ ID NO 274 <211> LENGTH: 51 <212> TYPE: PRT <213>ORGANISM: Homo sapiens <400> SEQUENCE: 274 Met Val Leu Phe Phe Phe PhePhe Ser Leu Ala Val Pro Cys Ser Leu 1 5 10 15 Pro Ser Leu Asp Val CysThr Asn Tyr Ser Leu Glu Leu Phe Ser Leu 20 25 30 Ala Leu Gln Leu Leu ProPro Thr Ser Ser Pro Ala Pro Pro Ile His 35 40 45 Ser Phe Ala 50 <210>SEQ ID NO 275 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Homosapiens <220> FEATURE: <221> NAME/KEY: UNSURE <222> LOCATION: (48) <400>SEQUENCE: 275 Met Asn Val Tyr Thr His Phe Arg Gly Ser His Gln Gly GlnVal Gln 1 5 10 15 Gly Ser Gly Pro Ser Gly Trp Cys Leu Gln Gly Asn PheGly Pro Ser 20 25 30 Leu Phe Ser Asp Trp Arg Ser Pro Trp Pro Ala Ser PheHis Thr Xaa 35 40 45 Leu Leu Ala Gly Thr Gly Leu Ala Pro Thr Phe Pro AlaSer Ser Val 50 55 60 Val Ala Ser Leu Pro Glu Pro Gly Ser Ser Ser Gly ProThr Ser Lys 65 70 75 80 Cys His <210> SEQ ID NO 276 <211> LENGTH: 130<212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 276 Met AspAsp Met Leu Ser Thr Arg Ser Ser Thr Leu Thr Glu Asp Gly 1 5 10 15 AlaLys Ser Ser Glu Ala Ile Lys Glu Ser Ser Lys Phe Pro Phe Gly 20 25 30 IleSer Pro Ala Gln Ser His Arg Asn Ile Lys Ile Leu Glu Asp Glu 35 40 45 ProHis Ser Lys Asp Glu Thr Pro Leu Cys Thr Leu Leu Asp Trp Gln 50 55 60 AspSer Leu Ala Lys Arg Cys Val Cys Val Ser Asn Thr Ile Arg Ser 65 70 75 80Leu Ser Phe Val Pro Gly Asn Asp Phe Glu Met Ser Lys His Pro Gly 85 90 95Leu Leu Leu Ile Leu Gly Lys Leu Ile Leu Leu His His Lys His Pro 100 105110 Glu Arg Lys Gln Ala Pro Leu Thr Tyr Glu Lys Glu Glu Glu Gln Asp 115120 125 Gln Gly 130 <210> SEQ ID NO 277 <211> LENGTH: 111 <212> TYPE:PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 277 Met Leu Gly Tyr ArgLys Ile Asn Ala Lys Ala Lys His Pro Val Pro 1 5 10 15 Val Leu Glu ValPro Arg Gly Arg Met Pro Arg Leu Arg Lys Lys Leu 20 25 30 Leu Ser Trp ProGly Gln Arg Glu Glu Glu Pro Arg Val Gly Val Val 35 40 45 Thr His Leu LysIle Thr Met Ser Ser Gly Arg Cys Ala Ile Val Leu 50 55 60 Gly Leu Gly GlyCys Gly Arg Pro Thr Leu Gly Met Gln Ser Ser Asp 65 70 75 80 Ser Val SerLeu Ala Thr Leu Gly Leu Leu Thr Thr Leu Pro Val Leu 85 90 95 Leu Thr LeuArg Glu Gly Ser Cys Trp Val Asp Ser Arg Gln Ala 100 105 110 <210> SEQ IDNO 278 <211> LENGTH: 104 <212> TYPE: PRT <213> ORGANISM: Homo sapiens<400> SEQUENCE: 278 Met Glu Asn Ser Leu Leu Ala Met Phe His Glu Ser ArgIle Leu His 1 5 10 15 Leu Trp Ala Ala Leu Phe Leu Val Glu Leu Leu GlnGlu Val Pro Ile 20 25 30 Met Thr Cys Ser Asn Ala Asn Thr Pro Ser Val AsnThr Gly Tyr Phe 35 40 45 Lys Leu Ser Ser Val Ala Thr Thr Leu Arg Gln GlnGln Leu Val Leu 50 55 60 Glu Ile Ser Leu Met Ser Val Pro Pro Gly Cys GlyPro Leu Leu Pro 65 70 75 80 Val Leu Ile Pro Val Ala Ser Phe Cys Cys IleIle Thr Ile Trp Leu 85 90 95 Leu Ile Leu Met Phe Glu Lys Asp 100 <210>SEQ ID NO 279 <211> LENGTH: 147 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 279 Met Ala Ser Pro Ser Gly Leu Cys Val Leu ValArg Leu Pro Lys Leu 1 5 10 15 Ile Cys Gly Gly Lys Thr Leu Pro Arg ThrLeu Leu Asp Ile Leu Ala 20 25 30 Asp Gly Thr Ile Leu Lys Val Gly Val GlyCys Ser Glu Asp Ala Ser 35 40 45 Lys Leu Leu Gln Asp Tyr Gly Leu Val ValArg Gly Cys Leu Asp Leu 50 55 60 Arg Tyr Leu Ala Met Arg Gln Arg Asn AsnLeu Leu Cys Asn Gly Leu 65 70 75 80 Ser Leu Lys Ser Leu Ala Glu Thr ValLeu Asn Phe Pro Leu Asp Lys 85 90 95 Ser Leu Leu Leu Arg Cys Ser Asn TrpAsp Ala Glu Thr Leu Thr Glu 100 105 110 Asp Gln Val Ile Tyr Ala Ala ArgAsp Ala Gln Ile Ser Val Ala Leu 115 120 125 Phe Leu His Leu Leu Gly TyrPro Phe Ser Arg Asn Ser Pro Gly Glu 130 135 140 Lys Lys Arg 145 <210>SEQ ID NO 280 <211> LENGTH: 176 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 280 Met Thr Asp Cys Leu Val Ile Lys His Phe LeuArg Lys Ile Ile Met 1 5 10 15 Val His Pro Lys Val Arg Phe His Phe SerVal Lys Val Asn Gly Ile 20 25 30 Leu Ser Thr Glu Ile Phe Gly Val Glu AsnGlu Pro Thr Leu Asn Leu 35 40 45 Gly Asn Gly Ile Ala Leu Leu Val Asp SerGln His Tyr Val Ser Arg 50 55 60 Pro Asn Phe Gly Thr Ile Glu Ser His CysSer Arg Ile His Pro Val 65 70 75 80 Leu Gly His Pro Val Met Leu Phe IlePro Glu Asp Val Ala Gly Met 85 90 95 Asp Leu Leu Gly Glu Leu Ile Leu ThrPro Ala Ala Ala Leu Cys Pro 100 105 110 Ser Pro Lys Val Ser Ser Asn GlnLeu Asn Arg Ile Ser Ser Val Ser 115 120 125 Ile Phe Leu Tyr Gly Pro LeuGly Leu Pro Leu Ile Leu Ser Thr Trp 130 135 140 Glu Gln Pro Met Thr ThrPhe Phe Lys Asp Thr Ser Ser Leu Val Asp 145 150 155 160 Trp Lys Ile ProPhe Val Tyr Asp Thr Gln Phe Gly Ser Gln Phe Gly 165 170 175 <210> SEQ IDNO 281 <211> LENGTH: 89 <212> TYPE: PRT <213> ORGANISM: Homo sapiens<400> SEQUENCE: 281 Met Gly Ser Leu Ser Thr Ala Asn Val Glu Phe Cys LeuAsp Val Phe 1 5 10 15 Lys Glu Leu Asn Ser Asn Asn Ile Gly Asp Asn IlePhe Phe Ser Ser 20 25 30 Leu Ser Leu Leu Tyr Ala Leu Ser Met Val Leu LeuGly Ala Arg Gly 35 40 45 Glu Thr Ala Glu Gln Leu Glu Lys Val Leu His PheSer His Thr Val 50 55 60 Asp Ser Leu Lys Pro Gly Phe Lys Asp Ser Pro LysCys Ser Gln Ala 65 70 75 80 Gly Arg Ile His Ser Glu Phe Gly Val 85 <210>SEQ ID NO 282 <211> LENGTH: 115 <212> TYPE: PRT <213> ORGANISM: Homosapiens <400> SEQUENCE: 282 Met Val Thr Gly Met Leu Ile Ser Ser Thr ArgGly Ser Ser Asp Gly 1 5 10 15 Arg Asn Cys Ser Ala Ile Leu Val Pro ValSer Pro Val Gly Arg Gln 20 25 30 Pro Leu Tyr Leu Thr Ser Arg Pro Gly AspTrp Ser Gln Gly Tyr Cys 35 40 45 Thr Thr Gly Gln Phe Pro Ala Ile Val ArgLys Glu Thr Pro Glu Leu 50 55 60 Asn Gly Arg Asp Ile Pro Ala Val Phe AsnIle Thr Pro Met Pro Phe 65 70 75 80 Val Arg Leu Pro Cys Thr Glu Ile ThrTrp Arg Ala Ser Cys Arg Leu 85 90 95 Tyr Leu Arg Thr Leu Val Lys Tyr LeuLeu Ser Phe Leu Ala Ala Arg 100 105 110 Met Gln Lys 115 <210> SEQ ID NO283 <211> LENGTH: 189 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400>SEQUENCE: 283 Met Val His Cys Pro His Glu Leu Leu Gln Met Pro Leu SerLeu Phe 1 5 10 15 Ser Gln Arg Ser Trp Val Thr Gln Cys Leu Asp Thr TrpLys Thr Cys 20 25 30 Thr Leu Ile Thr Gln Arg His Leu Ala Ser Asp His LeuPro Ser Glu 35 40 45 Phe Leu Leu Val Gln Leu Gly Tyr His Pro Leu Thr HisGln Ala Ala 50 55 60 Pro His Leu Pro Leu Leu Leu Leu Trp Gln Val Phe ProAla Tyr Gln 65 70 75 80 Glu Gln Gly Phe Ser Cys Lys Gly Gln Leu Leu LeuGly Leu Leu Val 85 90 95 Ser Thr Asp Asn Ile Phe Leu Pro Ile Leu Gly GlnAla Pro Gln Thr 100 105 110 His Pro Leu Leu Pro His Gln Arg Trp Ala AsnGln Lys Glu Ser Val 115 120 125 Pro Val Lys Ile Glu Arg Tyr Leu Pro GlnLeu Glu Gln Arg Asp Trp 130 135 140 Pro Glu Phe Gly Lys Glu Gly Leu LeuHis Lys Pro Arg Arg Gly Pro 145 150 155 160 Val Leu Ser Leu Pro Leu AspThr Val Glu Ser Gly His Leu Val Ser 165 170 175 Met Leu Cys Gln Lys AlaTyr Gln Val Gly Arg Asn Leu 180 185

What is claimed is:
 1. An isolated polynucleotide selected from thegroup consisting of: (a) a polynucleotide comprising the nucleotidesequence of SEQ ID NO:1; (b) a polynucleotide comprising the nucleotidesequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265; (c) apolynucleotide comprising the nucleotide sequence of SEQ ID NO:1 fromnucleotide 132 to nucleotide 1265; (d) a polynucleotide comprising thenucleotide sequence of the full-length protein coding sequence of clonebd306_(—)7 deposited with the ATCC under accession number 98599; (e) apolynucleotide encoding the full-length protein encoded by the cDNAinsert of clone bd306_(—)7 deposited with the ATCC under accessionnumber 98599; (f) a polynucleotide comprising the nucleotide sequence ofthe mature protein coding sequence of clone bd306_(—)7 deposited withthe ATCC under accession number 98599; (g) a polynucleotide encoding themature protein encoded by the cDNA insert of clone bd306_(—)7 depositedwith the ATCC under accession number 98599; (h) a polynucleotideencoding a protein comprising the amino acid sequence of SEQ ID NO:2;(i) a polynucleotide encoding a protein comprising a fragment of theamino acid sequence of SEQ ID NO:2, the fragment comprising eightconsecutive amino acids of SEQ ID NO:2; and (j) a polynucleotide thathybridizes under stringent conditions to any one of the polynucleotidesspecified in (a)-(i).
 2. The polynucleotide of claim 1 wherein saidpolynucleotide is operably linked to at least one expression controlsequence.
 3. A host cell transformed with the polynucleotide of claim
 2. 4. The host cell of claim 3 , wherein said cell is a mammalian cell.5. A process for producing a protein encoded by the polynucleotide ofclaim 2, which process comprises: (a) growing a culture of the host cellin a suitable culture medium, wherein the host cell has been transformedwith the polynucleotide of claim 2 ; and (b) purifying said protein fromthe culture.
 6. A protein produced according to the process of claim 5 .7. An isolated polynucleotide encoding the protein of claim 6 .
 8. Thepolynucleotide of claim 7 , wherein the polynucleotide comprises thecDNA insert of clone bd306_(—)7 deposited with the ATCC under accessionnumber
 98599. 9. A protein comprising an amino acid sequence selectedfrom the group consisting of: (a) the amino acid sequence of SEQ IDNO:2; (b) the amino acid sequence of SEQ ID NO:2 from amino acid 148 toamino acid 189; (c) fragments of the amino acid sequence of SEQ ID NO:2comprising eight consecutive amino acids of SEQ ID NO:2; and (d) theamino acid sequence encoded by the cDNA insert of clone bd306_(—)7deposited with the ATCC under accession number 98599; the protein beingsubstantially free from other mammalian proteins.
 10. The protein ofclaim 9 , wherein said protein comprises the amino acid sequence of SEQID NO:2.
 11. The protein of claim 9 , wherein said protein comprises theamino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid189.
 12. A composition comprising the protein of claim 9 and apharmaceutically acceptable carrier.
 13. An isolated polynucleotideselected from the group consisting of: (a) a polynucleotide comprisingthe nucleotide sequence of SEQ ID NO:19; (b) a polynucleotide comprisingthe nucleotide sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide734; (c) a polynucleotide comprising the nucleotide sequence of SEQ IDNO:19 from nucleotide 270 to nucleotide 734; (d) a polynucleotidecomprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 85 tonucleotide 1604; (e) a polynucleotide comprising the nucleotide sequenceof the full-length protein coding sequence of clone yb8_(—)1 depositedunder accession number ATCC 98599; (f) a polynucleotide encoding thefull-length protein encoded by the cDNA insert of clone yb8_(—)1deposited under accession number ATCC 98599; (g) a polynucleotidecomprising the nucleotide sequence of the mature protein coding sequenceof clone yb8_(—)1 deposited under accession number ATCC 98599; (h) apolynucleotide encoding the mature protein encoded by the cDNA insert ofclone yb8_(—)1 deposited under accession number ATCC 98599; (i) apolynucleotide encoding a protein comprising the amino acid sequence ofSEQ ID NO:20; (j) a polynucleotide encoding a protein comprising afragment of the amino acid sequence of SEQ ID NO:20, the fragmentcomprising eight consecutive amino acids of SEQ ID NO:20; and (k) apolynucleotide that hybridizes under stringent conditions to any one ofthe polynucleotides specified in (a)-(j).
 14. A protein comprising anamino acid sequence selected from the group consisting of: (a) the aminoacid sequence of SEQ ID NO:20; (b) the amino acid sequence of SEQ IDNO:20 from amino acid 70 to arnino acid 236; (c) fragments of the aninoacid sequence of SEQ ID NO:20 comprising eight consecutive amino acidsof SEQ ID NO:20; and (d) the amino acid sequence encoded by the cDNAinsert of clone yb8_(—)1 deposited under accession number ATCC 98599;the protein being substantially free from other mammalian proteins.